[{"title": "Trial launches exploring combinations of NTD inhibitor and antiandrogens in prostate cancer", "url": "https://www.urologytimes.com/view/trial-exploring-combinations-of-ntd-inhibitor-and-anti-androgens-in-prostate-cancer", "time_published": "20231231T235959", "authors": ["Jordyn Sava"], "summary": "A new phase 1 trial is investigating EPI-7386, an investigational N-terminal domain androgen receptor inhibitor, in combination with either apalutamide or abiraterone acetate for patients with prostate cancer. The study, supported by ESSA Pharma Inc. and Janssen Research & Development, LLC, will assess safety, pharmacokinetics, drug-drug interactions, and preliminary anti-tumor activity across different prostate cancer populations. EPI-7386 previously received FDA fast track designation for metastatic castration-resistant prostate cancer.", "banner_image": null, "source": "Urology Times", "category_within_source": "General", "source_domain": "Urology Times", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.345219, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EPIX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.468416", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.730113", "ticker_sentiment_score": "0.336297", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.647185", "ticker_sentiment_score": "0.225125", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Targets Sales Growth in Years Ahead", "url": "https://www.wsj.com/health/healthcare/johnson-johnson-targets-sales-growth-in-years-ahead-50745d61?gaa_at=eafs&gaa_n=AWEtsqcJhsS0B_l6iWaE9mGEt8PFcolXEabyUnS2AgI86pGp0O09Uz7rmVgo&gaa_ts=6907752e&gaa_sig=pGaVxAZrjwUwS8OlCjO7ARPOD1xHOeGtfDiYkDULdSRP9dQyaSgp7PUMTKgW98ghA4C4i7XdTFo0_WkmW3a6ag%3D%3D", "time_published": "20231231T235959", "authors": ["Robb M. Stewart"], "summary": "Johnson & Johnson is targeting annual sales growth of up to 7% in the coming years, driven by its innovative medicine and MedTech operations. For 2024, the company anticipates operational sales growth of 5% to 6% and adjusted operational per-share earnings of $10.55 to $10.75. This outlook indicates a focus on continued expansion into high-growth markets for its MedTech segment.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "earnings", "relevance_score": "0.947382"}, {"topic": "life_sciences", "relevance_score": "0.825871"}], "overall_sentiment_score": 0.44192, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.432216", "ticker_sentiment_label": "Bullish"}]}, {"title": "Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership", "url": "https://www.businesswire.com/news/home/20230724198201/en/Teva-Pharmaceuticals-and-Alvotech-Provide-Update-on-Strategic-Biosimilars-Partnership", "time_published": "20231231T235959", "authors": [], "summary": "Teva Pharmaceuticals and Alvotech have expanded their existing strategic partnership for biosimilars, with Teva acquiring $40 million in Alvotech's subordinated convertible bonds. The expanded agreement covers exclusive U.S. commercialization of new biosimilar candidates and line extensions, along with increased Teva involvement in Alvotech's manufacturing processes to prepare for FDA inspection. The companies continue to work on pending U.S. approvals for biosimilar candidates like AVT02 (Humira) and AVT04 (Stelara).", "banner_image": null, "source": "Business Wire", "category_within_source": "General", "source_domain": "Business Wire", "topics": [{"topic": "life_sciences", "relevance_score": "0.918239"}, {"topic": "finance", "relevance_score": "0.731246"}], "overall_sentiment_score": 0.370855, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ALVO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.829617", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.646836", "ticker_sentiment_score": "0.128769", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.598047", "ticker_sentiment_score": "0.130027", "ticker_sentiment_label": "Neutral"}]}, {"title": "13 innovations that inspired us in 2023", "url": "https://www.jnj.com/innovation/innovations-that-inspired-us-in-2023", "time_published": "20231220T145943", "authors": ["Johnson & Johnson"], "summary": "Johnson & Johnson highlights 13 healthcare innovations from 2023 that are improving global health. These advancements range from new treatments for incurable cancers and improved surgical tools to AI-driven approaches and personalized medicine, reflecting the company's commitment to patient care as outlined in its Credo.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "technology", "relevance_score": "0.820974"}], "overall_sentiment_score": 0.623401, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.880954", "ticker_sentiment_label": "Bullish"}, {"ticker": "GEHC", "relevance_score": "0.606019", "ticker_sentiment_score": "0.309786", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J Spinoff Kenvue Defeats Suits Alleging Tylenol Causes Autism", "url": "https://www.bloomberg.com/news/articles/2023-12-19/j-j-spinoff-kenvue-defeats-suits-alleging-tylenol-causes-autism", "time_published": "20231219T145900", "authors": ["Jef Feeley"], "summary": "Kenvue Inc. (KVUE, JNJ), a Johnson & Johnson spinoff and maker of Tylenol, has successfully defeated more than 400 lawsuits alleging that prenatal exposure to the painkiller caused autism. A US District Judge in Manhattan ruled that the plaintiffs' scientific evidence demonstrating a link between Tylenol and developmental issues in babies was flawed, effectively ending the consolidated cases.", "banner_image": null, "source": "Bloomberg.com", "category_within_source": "General", "source_domain": "Bloomberg.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.948945"}], "overall_sentiment_score": 0.376387, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.435709", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.740922", "ticker_sentiment_score": "0.332382", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Driving an evidence-rich strategy to strengthen the resilience and well-being of frontline health workers in East Africa", "url": "https://www.jnj.com/global-health-equity/driving-an-evidence-rich-strategy-to-strengthen-the-resilience-and-well-being-of-frontline-health-workers-in-east-africa", "time_published": "20231211T145943", "authors": [], "summary": "Johnson & Johnson, in collaboration with Aga Khan University's Institute for Human Development (IHD) and UNICEF, is implementing a project to strengthen the resilience and well-being of frontline health workers (FHWs) in East Africa. Phase 1 focused on building an evidence base through surveys, synthesizing policy evidence, and increasing immediate psychosocial support via an SMS-based program. The project aims to advance policy changes, build a robust community of practice, and advocate for sustained investment in FHW mental health programs.", "banner_image": "https://jnj-content-lab2.brightspotcdn.com/dims4/default/a36a605/2147483647/strip/true/crop/587x330+0+0/resize/800x450!/quality/90/?url=https%3A%2F%2Fjnj-production-jnj.s3.us-east-1.amazonaws.com%2Fbrightspot%2F7a%2F5c%2F8352676e4d58aebb98fa36a96602%2Fchwi-frontline-health-workers.jpeg", "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "economy_macro", "relevance_score": "0.641431"}], "overall_sentiment_score": 0.426291, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.446135", "ticker_sentiment_label": "Bullish"}]}, {"title": "Edwards to spin off its critical care business", "url": "https://www.medtechdive.com/news/edwards-spinoff-critical-care/701996/", "time_published": "20231208T143537", "authors": ["Ricky Zipp"], "summary": "Edwards Lifesciences plans to spin off its critical care unit as an independent company by the end of next year, allowing Edwards to focus on its cardiac businesses like TAVR and TMTT. This move follows a trend among medtech companies to create spin-offs to concentrate on specific markets. The critical care business generated $855 million in sales in 2022 and is projected to have a 2024 sales range of $900 million to $1 billion.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.934934"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "earnings", "relevance_score": "0.844031"}], "overall_sentiment_score": 0.150583, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EW", "relevance_score": "1.000000", "ticker_sentiment_score": "0.307268", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GE", "relevance_score": "0.743926", "ticker_sentiment_score": "0.121608", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.648199", "ticker_sentiment_score": "0.144881", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMM", "relevance_score": "0.635297", "ticker_sentiment_score": "0.142300", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.562493", "ticker_sentiment_score": "0.105014", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vanda expands commercial presence with $100M deal for US rights to J&J multiple sclerosis drug", "url": "https://www.fiercepharma.com/pharma/vanda-scoops-johnson-johnsons-multiple-sclerosis-med-ponvory-100m", "time_published": "20231207T235700", "authors": ["Zoey Becker"], "summary": "Vanda Pharmaceuticals has acquired U.S. and Canadian rights to Johnson & Johnson's multiple sclerosis drug Ponvory for $100 million, marking a significant expansion of Vanda's commercial portfolio. Ponvory, approved in 2021 for relapsing forms of multiple sclerosis, could also treat other inflammatory and autoimmune disorders. This deal follows J&J's recent layoffs within its MS sales team and adds a new asset to Vanda's pipeline, which also includes potential label expansions for Hetlioz and Fanapt, and a new gastroparesis drug.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.901603"}, {"topic": "life_sciences", "relevance_score": "0.934542"}], "overall_sentiment_score": 0.283714, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VNDA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.402205", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.719186", "ticker_sentiment_score": "0.136210", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sanofi CEO under pressure to woo investors after spending shock", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-ceo-under-pressure-woo-investors-after-spending-shock-2023-12-05/", "time_published": "20231205T073500", "authors": ["Ludwig Burger"], "summary": "Sanofi's CEO, Paul Hudson, is under pressure from investors to provide more details on planned increased R&D spending after shares tumbled 15% following an unexpected abandonment of 2025 margin targets. Investors are seeking clarity on how much will be spent on experimental drugs and their commercial opportunities, especially given the company's reliance on Dupixent and past development setbacks. Hudson is expected to unveil more details and strategies at an investor day on December 7.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.936633"}, {"topic": "earnings", "relevance_score": "0.948074"}, {"topic": "financial_markets", "relevance_score": "0.705397"}], "overall_sentiment_score": 0.018076, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SNY", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.235921", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.627989", "ticker_sentiment_score": "0.137934", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.640227", "ticker_sentiment_score": "0.122783", "ticker_sentiment_label": "Neutral"}]}, {"title": "CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023", "url": "https://www.biospace.com/collplant-biotechnologies-announces-third-quarter-financial-results-for-2023", "time_published": "20231129T052258", "authors": [], "summary": "CollPlant Biotechnologies announced its financial results for the third quarter of 2023, highlighting a $10 million milestone payment from AbbVie for a dermal filler product candidate. The company plans to initiate a large-animal study for commercial-sized breast implants by year-end and reported cash and cash equivalents of $29 million, providing an estimated cash runway of at least two years. The report also detailed revenue of $10.7 million and an operating loss of $2.4 million for the first nine months of 2023.", "banner_image": "https://mma.prnewswire.com/media/2287364/CollPlant.jpg", "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "earnings", "relevance_score": "0.913671"}, {"topic": "life_sciences", "relevance_score": "0.812771"}], "overall_sentiment_score": 0.242935, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CLGN", "relevance_score": "0.982344", "ticker_sentiment_score": "0.301939", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.737928", "ticker_sentiment_score": "0.236206", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.567458", "ticker_sentiment_score": "0.111316", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biopharma\u2019s top 5 IPOs of 2023 (so far)", "url": "https://www.pharmavoice.com/news/biggest-biopharma-ipo-2023-kenvue/700762/", "time_published": "20231128T150106", "authors": ["Alexandra Pecci"], "summary": "This article reviews the top five biopharma IPOs of 2023, highlighting that despite Kenvue's massive $4.24 billion IPO, the biopharma sector saw much smaller IPOs ranging from $192 million to $540 million. It features companies like Acelyrin, Apogee Therapeutics, RayzeBio, Neumora Therapeutics, and Mineralys Therapeutics, detailing their IPO values, areas of focus, and lead programs. Patricia Giglio, director of deals intelligence at Citeline, provides insights into these selections based on value or clinical relevance.", "banner_image": null, "source": "PharmaVoice", "category_within_source": "General", "source_domain": "PharmaVoice", "topics": [{"topic": "ipo", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.742934"}], "overall_sentiment_score": 0.138853, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KVUE-W", "relevance_score": "0.326805", "ticker_sentiment_score": "0.022405", "ticker_sentiment_label": "Neutral"}, {"ticker": "KVUE", "relevance_score": "0.932326", "ticker_sentiment_score": "0.333262", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.719022", "ticker_sentiment_score": "0.237991", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.606482", "ticker_sentiment_score": "0.116888", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.560577", "ticker_sentiment_score": "0.066280", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medtronic to chase Boston Scientific, Abbott in left atrial appendage closure market", "url": "https://www.medtechdive.com/news/medtronic-boston-scientific-abbott-left-atrial-appendage-closu/700802/", "time_published": "20231128T000000", "authors": ["Susan Kelly"], "summary": "Medtronic is entering the fast-growing left atrial appendage closure (LAAC) market with its new Penditure LAA clip, challenging established players like Boston Scientific and Abbott. The company acquired the Penditure system from Syntheon and aims to capture a share of the market, which is projected to quadruple to over $6 billion by 2030. Medtronic's device offers a unique repositioning feature and has received 510(k) clearance from the FDA.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.901460"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.846268"}], "overall_sentiment_score": 0.20039, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.334338", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.959158", "ticker_sentiment_score": "0.267273", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.726604", "ticker_sentiment_score": "0.145911", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.619328", "ticker_sentiment_score": "0.126617", "ticker_sentiment_label": "Neutral"}]}, {"title": "Warren Buffett-Led Berkshire Hathaway Sells Its Entire Procter & Gamble Stake. Should You?", "url": "https://www.fool.com/investing/2023/11/25/buffett-berkshire-sell-procter-gamble-stock/", "time_published": "20231125T054800", "authors": ["Daniel Foelber"], "summary": "Berkshire Hathaway fully exited its small position in Procter & Gamble, likely due to consolidating its portfolio and P&G's premium valuation compared to other opportunities like Apple. Despite Berkshire's sale, P&G is still considered a worthwhile investment for risk-averse individuals due to its strong brand development, pricing power, and commitment to shareholder returns through dividends and buybacks. The article suggests that while P&G's valuation is high, its other characteristics make it a solid choice for passive income and portfolio stability.", "banner_image": null, "source": "The Motley Fool", "category_within_source": "General", "source_domain": "The Motley Fool", "topics": [{"topic": "earnings", "relevance_score": "0.827730"}, {"topic": "financial_markets", "relevance_score": "0.928145"}, {"topic": "economy_macro", "relevance_score": "0.617781"}, {"topic": "finance", "relevance_score": "0.820787"}, {"topic": "retail_wholesale", "relevance_score": "0.746278"}], "overall_sentiment_score": 0.05823, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.111904", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.714084", "ticker_sentiment_score": "0.117544", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.645099", "ticker_sentiment_score": "-0.090891", "ticker_sentiment_label": "Neutral"}]}, {"title": "Legendary value investor's firm launches new fund targeting \u2018quality' stocks", "url": "https://www.nbcdfw.com/news/business/money-report/legendary-value-investors-firm-launches-new-fund-targeting-quality-stocks/3391485/", "time_published": "20231118T200058", "authors": ["Emily Glass"], "summary": "Legendary value investor Jeremy Grantham's firm, GMO, has launched its first active ETF, the GMO U.S. Quality ETF, focusing on \"quality\" stocks. Managed by Tom Hancock, the fund targets companies that can sustainably deploy capital at high rates of return, primarily in technology, healthcare, and consumer staples, offering potential tax advantages and ease of trading for clients. The ETF aims to identify \"battleship companies\" with strong balance sheets and competitive moats.", "banner_image": "https://media.nbcdfw.com/2023/11/104138270-GettyImages-94807551.jpg?quality=85&strip=all&resize=320%2C180", "source": "NBC 5 Dallas-Fort Worth", "category_within_source": "General", "source_domain": "NBC 5 Dallas-Fort Worth", "topics": [{"topic": "financial_markets", "relevance_score": "0.944566"}, {"topic": "finance", "relevance_score": "0.821197"}, {"topic": "technology", "relevance_score": "0.642041"}, {"topic": "life_sciences", "relevance_score": "0.600101"}], "overall_sentiment_score": 0.169283, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QLTY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.420693", "ticker_sentiment_label": "Bullish"}, {"ticker": "MSFT", "relevance_score": "0.808020", "ticker_sentiment_score": "0.525644", "ticker_sentiment_label": "Bullish"}, {"ticker": "UNH", "relevance_score": "0.713345", "ticker_sentiment_score": "0.129085", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.739158", "ticker_sentiment_score": "-0.442285", "ticker_sentiment_label": "Bearish"}]}, {"title": "Buffett\u2019s Berkshire Hathaway Sells Out of GM, P&G, Johnson & Johnson, and Other Longtime Holdings", "url": "https://www.morningstar.com/stocks/buffetts-berkshire-hathaway-sells-out-gm-pg-johnson-johnson-longtime-holdings", "time_published": "20231115T000000", "authors": ["Greggory Warren", "CFA"], "summary": "Berkshire Hathaway (BRK.A, BRK.B) engaged in significant selling activity during the third quarter, offloading $5.7 billion in equities. Notable divestitures included entire stakes in GM, Johnson & Johnson, Procter & Gamble, and Activision Blizzard, alongside reductions in Chevron and HP. The company also acquired new positions primarily due to corporate actions by Liberty Media and continued investments in Japanese trading houses.", "banner_image": null, "source": "Morningstar", "category_within_source": "General", "source_domain": "Morningstar", "topics": [{"topic": "earnings", "relevance_score": "0.924149"}, {"topic": "financial_markets", "relevance_score": "0.809915"}, {"topic": "finance", "relevance_score": "0.731580"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.610499"}], "overall_sentiment_score": -0.164203, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "BATRA", "relevance_score": "0.745570", "ticker_sentiment_score": "0.132869", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.918826", "ticker_sentiment_score": "-0.218666", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PG", "relevance_score": "0.820183", "ticker_sentiment_score": "-0.232158", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.845712", "ticker_sentiment_score": "-0.218489", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson Innovation Launches Singapore QuickFire Challenge with the Singapore Economic Development Board", "url": "https://www.prnewswire.com/apac/news-releases/johnson--johnson-innovation-launches-singapore-quickfire-challenge-with-the-singapore-economic-development-board-301974279.html", "time_published": "20231101T220500", "authors": [], "summary": "Johnson & Johnson Innovation has launched the Singapore QuickFire Challenge, inviting innovators to pitch groundbreaking ideas in healthcare for grant funding totaling $100,000. This initiative follows a new collaboration between Johnson & Johnson Innovation \u2013 JLABS and the Singapore Economic Development Board to accelerate innovation within Singapore's life science ecosystem. The challenge aims to support early-stage discoveries in pharmaceuticals, medical devices, and digital health, fostering scientific progress and healthcare solutions in the region.", "banner_image": "https://mma.prnewswire.com/media/2219093/Johnson_Johnson_Innovation_JLABS_Logo.jpg?w=200", "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.949618"}, {"topic": "technology", "relevance_score": "0.836130"}, {"topic": "finance", "relevance_score": "0.511185"}], "overall_sentiment_score": 0.012904, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.304116", "ticker_sentiment_score": "0.038864", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kenvue tempers annual profit view on soft demand for cold, flu medicines", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/kenvue-reports-higher-q3-revenue-self-care-products-strength-2023-10-26/", "time_published": "20231026T135400", "authors": ["Bhanvi Satija"], "summary": "Kenvue tempered the higher end of its annual profit forecast due to soft demand for cold and flu medicines caused by a delayed flu season in the northern hemisphere and a stronger dollar impact. Despite slightly exceeding Q3 revenue estimates, the company faces headwinds from slower sales in China and an ongoing review of phenylephrine, an ingredient in popular products like Benadryl and Tylenol.", "banner_image": "https://www.reuters.com/resizer/oKzBL0F4JkS_s7h9qXfB87s6o54=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/5M35LSSBBNLTLFOTR2PX3I6G2A.JPG", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "earnings", "relevance_score": "0.934964"}, {"topic": "life_sciences", "relevance_score": "0.840575"}, {"topic": "finance", "relevance_score": "0.746163"}], "overall_sentiment_score": -0.103159, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.998907", "ticker_sentiment_score": "-0.324698", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.704224", "ticker_sentiment_score": "0.116668", "ticker_sentiment_label": "Neutral"}]}, {"title": "Costco class action alleges Kirkland nasal decongestant product ineffective", "url": "https://topclassactions.com/lawsuit-settlements/prescription/costco-class-action-alleges-kirkland-nasal-decongestant-product-ineffective/", "time_published": "20231026T000000", "authors": ["By Top Class Actions"], "summary": "A class action lawsuit has been filed against Costco Wholesale Corp., alleging that its Kirkland-brand Multi-Symptom Cold & Flu Severe is falsely marketed as an effective nasal decongestant. The lawsuit claims the product's active ingredient, phenylephrine, has been deemed ineffective at relieving nasal congestion by an FDA advisory panel. Plaintiff Eduardo Flores seeks to represent a nationwide class of consumers, accusing Costco of unjust enrichment, breach of implied warranty, and violating California consumer protection laws.", "banner_image": "https://topclassactions.com/wp-content/uploads/2023/10/AdobeStock_397941212-e1698305018151.jpeg", "source": "Class Action Lawsuits", "category_within_source": "General", "source_domain": "Class Action Lawsuits", "topics": [{"topic": "life_sciences", "relevance_score": "0.918448"}, {"topic": "retail_wholesale", "relevance_score": "0.800416"}], "overall_sentiment_score": -0.351483, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "COST", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.404525", "ticker_sentiment_label": "Bearish"}, {"ticker": "CVS", "relevance_score": "0.623195", "ticker_sentiment_score": "-0.320032", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.598765", "ticker_sentiment_score": "-0.279280", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Analysts focus on CSX\u2019s new chief operating officer", "url": "https://www.jaxdailyrecord.com/news/2023/oct/26/analysts-focus-on-csxs-new-chief-operating-officer/", "time_published": "20231026T000000", "authors": ["Mark Basch"], "summary": "Analysts are focusing on CSX's new Chief Operating Officer, Mike Cory, who recently joined the company after a long career at Canadian National Railway. Cory's expertise is expected to drive collaboration and growth, leveraging CSX's existing capacity, despite a \"relative non-event\" third-quarter earnings report. The article also touches on other financial news, including Johnson & Johnson's vision sales, FIS's overlooked SunGard acquisition, and growth prospects for Restaurant Brands International's Firehouse Subs.", "banner_image": null, "source": "Jacksonville Daily Record", "category_within_source": "General", "source_domain": "Jacksonville Daily Record", "topics": [{"topic": "earnings", "relevance_score": "0.945078"}, {"topic": "financial_markets", "relevance_score": "0.811397"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.740172"}, {"topic": "energy_transportation", "relevance_score": "0.618320"}, {"topic": "retail_wholesale", "relevance_score": "0.649999"}], "overall_sentiment_score": 0.207628, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CSX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.283195", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.706226", "ticker_sentiment_score": "-0.092942", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIS", "relevance_score": "0.836300", "ticker_sentiment_score": "0.337676", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Myasthenia Gravis Market is Projected to Boost at a", "url": "https://www.globenewswire.com/news-release/2023/10/25/2766854/0/en/Myasthenia-Gravis-Market-is-Projected-to-Boost-at-a-Moderate-Growth-Rate-by-2032-Estimates-DelveInsight-Leading-Companies-DAS-MG-Catalyst-Cabaletta-Bio-Janssen-Argenx-UCB-Pharma-Al.html", "time_published": "20231025T130000", "authors": [], "summary": "The myasthenia gravis market is expected to experience moderate growth through 2032 due to improved diagnosis, increased awareness, higher healthcare spending, and emerging therapies. DelveInsight's report indicates major pharmaceutical companies are developing novel treatments, addressing a significant patient population across the 7MM. The market dynamics are influenced by rising patient numbers, R&D efforts, competition, and patient advocacy, although challenges like the lack of a definitive cure and high development costs persist.", "banner_image": null, "source": "GlobeNewswire", "category_within_source": "General", "source_domain": "GlobeNewswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.946781"}, {"topic": "financial_markets", "relevance_score": "0.620525"}], "overall_sentiment_score": 0.287625, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CABA", "relevance_score": "0.900762", "ticker_sentiment_score": "0.324675", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.736248", "ticker_sentiment_score": "0.276952", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.704727", "ticker_sentiment_score": "0.290442", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Market Leaders Johnson & Johnson Vision, CooperVision, and Alcon Inc Drive Growth in Global Contact Lenses Market", "url": "https://finance.yahoo.com/news/market-leaders-johnson-johnson-vision-085300454.html", "time_published": "20231024T085300", "authors": ["Research and Markets"], "summary": "The global contact lenses market is projected to grow from $9.77 billion in 2023 to $13.57 billion by 2029, driven by factors such as an aging population, increased awareness, and prevalent eye diseases. North America currently holds the largest market share, with the APAC region showing the highest growth potential. The report highlights key players like Johnson & Johnson Vision, CooperVision, and Alcon Inc.", "banner_image": null, "source": "Yahoo Finance", "category_within_source": "General", "source_domain": "Yahoo Finance", "topics": [{"topic": "life_sciences", "relevance_score": "0.911965"}, {"topic": "financial_markets", "relevance_score": "0.840109"}, {"topic": "economy_macro", "relevance_score": "0.720323"}], "overall_sentiment_score": 0.461344, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.492075", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.876144", "ticker_sentiment_score": "0.434102", "ticker_sentiment_label": "Bullish"}, {"ticker": "COO", "relevance_score": "0.878347", "ticker_sentiment_score": "0.439529", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson Considers Ditching Texas Two-Step for Third Talc Bankruptcy", "url": "https://www.wsj.com/articles/johnson-johnson-considers-ditching-texas-two-step-for-third-talc-bankruptcy-99a0cc46?gaa_at=eafs&gaa_n=AWEtsqfXNbOixNPQJJKALePYRKyj8Qo8RTufeXtfpMGkLVffxR852H-docfZ&gaa_ts=69077532&gaa_sig=p2j6T_Nc7H1XOl9wPR7zv3DXmEOkhDTDE1tCvT5oaRBIIJVrI2mE4bW8rprXXwGG4Dv42c_TjW9Jw_6qrTUKlw%3D%3D", "time_published": "20231020T172200", "authors": ["Andrew Scurria"], "summary": "Johnson & Johnson is exploring a third bankruptcy filing for its talc-related liabilities, considering a different corporate structure than its previous failed attempts using the \"Texas Two-Step.\" The healthcare giant aims for a consensual resolution through bankruptcy for tens of thousands of personal-injury lawsuits, following two unsuccessful prior efforts to resolve these mass claims in chapter 11 proceedings. J&J faces numerous lawsuits alleging that talc in its Baby Powder caused various health issues, which the company denies.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.937777"}, {"topic": "finance", "relevance_score": "0.712166"}], "overall_sentiment_score": -0.409004, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.416168", "ticker_sentiment_label": "Bearish"}]}, {"title": "Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myerss-injectable-kindey-cancer-drug-found-non-inferior-iv-form-2023-10-19/", "time_published": "20231019T124200", "authors": ["Reuters"], "summary": "Bristol Myers Squibb announced that the injectable form of its cancer drug Opdivo met its primary goal in a kidney cancer trial, demonstrating non-inferiority to the intravenous version. This new formulation uses Halozyme Therapeutics' technology, allowing for a quicker, subcutaneous administration. The company plans to discuss regulatory submissions for this new treatment option.", "banner_image": "https://www.reuters.com/resizer/lFhJb14mJqG_R-pXv7m1zX4-I5I=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/Y4J7YI2P3ZJIRK6B5I2Z3B6L4Y.jpg", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.272529, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.441702", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.624320", "ticker_sentiment_score": "0.122792", "ticker_sentiment_label": "Neutral"}]}, {"title": "Oversold and Overextended, Abbott Laboratories is a Great Buy", "url": "https://www.entrepreneur.com/finance/oversold-and-overextended-abbott-laboratories-is-a-great/463937", "time_published": "20231018T000000", "authors": ["Thomas Hughes"], "summary": "Abbott Laboratories' stock has been oversold and overextended after a nearly two-year downturn, but recent solid Q3 results and favorable guidance suggest a strong rebound. The company's value and dividend yield are at their best levels in years, with analysts maintaining a Moderate Buy rating and significant upside potential. Technical indicators also confirm support at a critical multi-year low, pointing towards further stock appreciation.", "banner_image": null, "source": "Entrepreneur", "category_within_source": "General", "source_domain": "Entrepreneur", "topics": [{"topic": "earnings", "relevance_score": "0.900341"}, {"topic": "financial_markets", "relevance_score": "0.837302"}, {"topic": "life_sciences", "relevance_score": "0.924052"}], "overall_sentiment_score": 0.307129, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.455533", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.633962", "ticker_sentiment_score": "0.132584", "ticker_sentiment_label": "Neutral"}]}, {"title": "Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics", "url": "https://via.tt.se/pressmeddelande/3381944/thermo-fisher-scientific-to-acquire-olink-a-leader-in-next-generation-proteomics?publisherId=259167", "time_published": "20231017T070947", "authors": [], "summary": "Thermo Fisher Scientific is set to acquire Olink, a leader in next-generation proteomics solutions, for approximately $3.1 billion. This acquisition, approved by both companies' boards, represents a 74% premium to Olink's closing price on October 16, 2023. Thermo Fisher aims to leverage Olink's proprietary technology to advance life science research and precision medicine, expecting the transaction to complete by mid-2024 and contribute significantly to its Life Sciences Solutions segment.", "banner_image": null, "source": "Via TT", "category_within_source": "General", "source_domain": "Via TT", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.944213"}], "overall_sentiment_score": 0.257366, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OLK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.492735", "ticker_sentiment_label": "Bullish"}, {"ticker": "TMO", "relevance_score": "0.988972", "ticker_sentiment_score": "0.405879", "ticker_sentiment_label": "Bullish"}, {"ticker": "JPM", "relevance_score": "0.630303", "ticker_sentiment_score": "0.115544", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.575474", "ticker_sentiment_score": "0.092543", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.629501", "ticker_sentiment_score": "0.142549", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surge", "url": "https://www.cnbc.com/2023/10/17/johnson-johnson-jnj-q3-earnings-report-2023.html", "time_published": "20231017T062500", "authors": ["Annika Kim Constantino"], "summary": "Johnson & Johnson (JNJ) reported adjusted earnings and revenue that surpassed Wall Street's expectations for Q3 2023, driven by strong sales in its pharmaceutical and medical devices divisions. The company raised its full-year guidance and recorded a significant one-time gain from the separation of its consumer health spinoff, Kenvue. J&J's results reflect growth in key pharmaceutical products and medical devices, despite ongoing legal challenges regarding its talc-based products and drug price negotiations with Medicare.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "earnings", "relevance_score": "0.903958"}, {"topic": "life_sciences", "relevance_score": "0.818014"}], "overall_sentiment_score": 0.003582, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.347019", "ticker_sentiment_score": "0.046964", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why You Should Invest In Healthcare Stocks", "url": "https://www.kiplinger.com/investing/healthcare-stocks/why-you-should-invest-in-healthcare-stocks", "time_published": "20231015T153500", "authors": ["James K. Glassman"], "summary": "The article advocates for investing in healthcare stocks, highlighting their stability due to constant demand regardless of economic conditions, and the sector's significant economic contribution. It suggests avoiding pharmaceutical stocks due to regulatory risks and recommends alternative investments like over-the-counter medicine companies (Kenvue), medical device manufacturers (Stryker), hospital networks (HCA Healthcare), health insurers (UnitedHealth Group, Cigna Group), and innovative genetic detection or diagnostics firms (Illumina, Danaher, Augmedix, West Pharmaceutical Services, Intuitive Surgical). The author also suggests an equal-weight healthcare ETF (Invesco S&P 500 Equal Weight Health Care) to diversify away from large drugmakers.", "banner_image": null, "source": "Kiplinger", "category_within_source": "General", "source_domain": "Kiplinger", "topics": [{"topic": "life_sciences", "relevance_score": "0.927869"}, {"topic": "financial_markets", "relevance_score": "0.702758"}, {"topic": "economy_macro", "relevance_score": "0.605870"}, {"topic": "finance", "relevance_score": "0.601753"}], "overall_sentiment_score": 0.107761, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RSPH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.328826", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.742819", "ticker_sentiment_score": "-0.446487", "ticker_sentiment_label": "Bearish"}, {"ticker": "KVUE", "relevance_score": "0.751477", "ticker_sentiment_score": "0.345160", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.609884", "ticker_sentiment_score": "0.134624", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA denies Stelara biosimilar application from Alvotech", "url": "https://www.healio.com/news/rheumatology/20231012/fda-denies-stelara-biosimilar-application-from-alvotech", "time_published": "20231012T000000", "authors": [], "summary": "The FDA has denied Alvotech's biologics license application for AVT04, its biosimilar to ustekinumab (Stelara), due to deficiencies at its Reykjavik facility. Alvotech plans to resubmit the application and aims for U.S. market entry by February 2025, pending a satisfactory reinspection and approval. This marks the second FDA denial for Alvotech stemming from manufacturing issues at the same facility.", "banner_image": null, "source": "Healio", "category_within_source": "General", "source_domain": "Healio", "topics": [{"topic": "life_sciences", "relevance_score": "0.928184"}, {"topic": "manufacturing", "relevance_score": "0.727738"}], "overall_sentiment_score": -0.312475, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "ALVO", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.605915", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.835508", "ticker_sentiment_score": "-0.129467", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.604482", "ticker_sentiment_score": "-0.148182", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medical equipment manufacturers in Chennai: Fact guide", "url": "https://housing.com/news/medical-equipment-manufacturers-in-chennai-fact-guide/", "time_published": "20231009T144512", "authors": ["Housing News Desk"], "summary": "The article provides a guide to the top medical equipment manufacturers in Chennai, highlighting the city's role as a significant business hub in the global healthcare sector. It details key companies like Wipro GE Healthcare, Johnson & Johnson, and Medtronic, along with their specializations and founding dates. The piece also discusses the impact of these manufacturers on Chennai's commercial real estate demand and overall economic growth.", "banner_image": null, "source": "Housing", "category_within_source": "General", "source_domain": "Housing", "topics": [{"topic": "life_sciences", "relevance_score": "0.933895"}, {"topic": "manufacturing", "relevance_score": "0.818948"}, {"topic": "real_estate", "relevance_score": "0.715349"}, {"topic": "finance", "relevance_score": "0.643467"}, {"topic": "economy_macro", "relevance_score": "0.623661"}], "overall_sentiment_score": 0.449876, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GEHC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.477984", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.897186", "ticker_sentiment_score": "0.431261", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.844587", "ticker_sentiment_score": "0.443863", "ticker_sentiment_label": "Bullish"}]}, {"title": "Aid agency urges Johnson & Johnson to improve access to tuberculosis drug", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/unitaid-urges-johnson-johnson-improve-access-tb-drug-bedaquiline-2023-09-29/", "time_published": "20230929T104900", "authors": ["Reuters"], "summary": "Global health aid agency Unitaid has urged Johnson & Johnson (JNJ.N) to expand access to its tuberculosis drug bedaquiline, which is currently protected by patents hindering generic alternatives. While J&J has lowered the price, Unitaid considers this an \"incomplete solution\" and advocates for the removal of all secondary patents to ensure lower prices are available to all countries with high TB cases. J&J has stated its intent not to enforce patents for generic versions of SIRTURO in 134 low- and middle-income countries, provided they are of good quality and medically acceptable.", "banner_image": "https://www.reuters.com/resizer/o-56Z_h_9G_s2-3L-P7uM6t2t1o=/960x0/filters:format(jpg):quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/525U2353J5IC7LGRF3CZX4V6B4.JPG", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.901723"}, {"topic": "finance", "relevance_score": "0.707743"}], "overall_sentiment_score": 0.102368, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.129717", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moldova: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis", "url": "https://msfaccess.org/moldova-open-letter-csos-request-urgent-action-johnson-johnson-improve-equitable-access-bedaquiline", "time_published": "20230921T145943", "authors": [], "summary": "Civil society organizations (CSOs), communities, and partner institutions in Moldova have sent an open letter to Johnson & Johnson (J&J), urging the pharmaceutical company to take immediate action to improve equitable access to bedaquiline, a critical TB drug, in Moldova and other high-burden countries. This appeal follows similar requests from other nations and comes after an announcement by the Stop TB Partnership/Global Drug Facility regarding a deal with J&J for generic bedaquiline, which currently excludes Moldova.", "banner_image": "https://msfaccess.org/sites/default/files/styles/full_default/public/2023-09/IP_Ukraine_Bedaquiline_2018_OksanaParafeniuk_MSF248561_3800px.jpg?itok=NcCGHL0n", "source": "MSF Access", "category_within_source": "General", "source_domain": "MSF Access", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.731152"}], "overall_sentiment_score": -0.31545, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.334006", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "(oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia", "url": "https://www.businesswire.com/news/home/20230919732476/en/Otsuka-and-Astex-announce-that-the-European-Commission-has-approved-INAQOVI-oral-decitabine-and-cedazuridine-for-the-treatment-of-adults-with-newly-diagnosed-acute-myeloid-leukaemia", "time_published": "20230919T000000", "authors": [], "summary": "Otsuka and Astex announced that the European Commission has approved INAQOVI\u00ae (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia who are ineligible for standard induction chemotherapy. This approval makes INAQOVI\u00ae the first and only oral hypomethylating agent licensed in the European Economic Area for this patient population, offering a new oral treatment option. The decision is based on positive results from the Phase 3 ASCERTAIN clinical trial, which demonstrated pharmacokinetic exposure equivalence to intravenous decitabine.", "banner_image": null, "source": "Business Wire", "category_within_source": "General", "source_domain": "Business Wire", "topics": [{"topic": "life_sciences", "relevance_score": "0.920948"}], "overall_sentiment_score": 0.301681, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ASTX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.477621", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.705574", "ticker_sentiment_score": "0.349822", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.628595", "ticker_sentiment_score": "0.276815", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.562258", "ticker_sentiment_score": "0.205968", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's why Johnson & Johnson just ditched one of the world's oldest logos", "url": "https://www.creativebloq.com/news/new-johnson-and-johnson-logo", "time_published": "20230916T145942", "authors": ["Joe Foley"], "summary": "Johnson & Johnson has replaced its iconic 135-year-old cursive logo with a cleaner, sans-serif design. This change reflects the company's shift in focus to innovative pharmaceuticals and medical devices after spinning off its consumer healthcare business. The new logo aims for better legibility and a more modern identity aligned with its updated corporate strategy.", "banner_image": null, "source": "Creative Bloq", "category_within_source": "General", "source_domain": "Creative Bloq", "topics": [{"topic": "life_sciences", "relevance_score": "0.812201"}, {"topic": "finance", "relevance_score": "0.633444"}], "overall_sentiment_score": 0.073534, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.142702", "ticker_sentiment_label": "Neutral"}, {"ticker": "KVUE", "relevance_score": "0.859174", "ticker_sentiment_score": "0.077739", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.712854", "ticker_sentiment_score": "-0.097222", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Daily Scoop: Johnson & Johnson plays it safe with new logo change", "url": "https://www.prdaily.com/johnson-johnson-plays-it-safe-with-new-logo-change/", "time_published": "20230915T145944", "authors": ["Sherri Kolade"], "summary": "Johnson & Johnson is changing its 136-year-old cursive logo to a plainer font in a brighter red, aiming to highlight its focus on medical devices and pharmaceuticals and to modernize its brand for a digital age. This rebrand also helps distance the company from controversies surrounding its talcum-based baby powder. While some marketing professionals praise the change for readability, others criticize it for being generic, demonstrating the challenges of evolving an iconic brand.", "banner_image": null, "source": "PR Daily", "category_within_source": "General", "source_domain": "PR Daily", "topics": [{"topic": "life_sciences", "relevance_score": "0.913444"}, {"topic": "retail_wholesale", "relevance_score": "0.714533"}, {"topic": "finance", "relevance_score": "0.601251"}], "overall_sentiment_score": 0.047044, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.326356", "ticker_sentiment_score": "0.008210", "ticker_sentiment_label": "Neutral"}]}, {"title": "Janssen rebrands its identity", "url": "https://www.europeanpharmaceuticalreview.com/news/186733/janssen-rebrands-its-identity/", "time_published": "20230915T145944", "authors": ["Catherine Eckford (European Pharmaceutical Review)"], "summary": "Johnson & Johnson is rebranding its Janssen pharmaceutical division as Johnson & Johnson Innovative Medicine, aligning it more closely with the overall J&J brand. This move is part of an effort to modernize its pharmaceutical and medtech segments. Simultaneously, the company's medical technology segment will remain as Johnson & Johnson MedTech and Novartis also finalized the spin-off of Sandoz.", "banner_image": null, "source": "European Pharmaceutical Review", "category_within_source": "General", "source_domain": "European Pharmaceutical Review", "topics": [{"topic": "life_sciences", "relevance_score": "0.934620"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.603927"}], "overall_sentiment_score": 0.285291, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.271801", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson's rebrand: Focusing on pharma innovation", "url": "https://www.drugdiscoverytrends.com/johnson-johnson-rebrand-pharma-focus/", "time_published": "20230914T145943", "authors": ["Brian Buntz"], "summary": "Johnson & Johnson has rebranded its Janssen pharma division as Johnson & Johnson Innovative Medicine, signaling a strategic shift to prioritize higher-margin prescription drugs and innovation. This move follows significant legal challenges, including talcum powder lawsuits, and the spin-off of its consumer health division, Kenvue. J&J aims for continued growth in its pharma sector, focusing on key therapeutic areas despite upcoming patent expirations for drugs like Stelara.", "banner_image": null, "source": "www.drugdiscoverytrends.com", "category_within_source": "General", "source_domain": "www.drugdiscoverytrends.com", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "earnings", "relevance_score": "0.819219"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.731445"}], "overall_sentiment_score": 0.009853, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.333515", "ticker_sentiment_score": "0.004502", "ticker_sentiment_label": "Neutral"}]}, {"title": "Are super-personalized solutions the future of healthcare?", "url": "https://www.jnj.com/innovation/are-super-personalized-solutions-the-future-of-healthcare", "time_published": "20230914T145941", "authors": ["Barbara Brody"], "summary": "Johnson & Johnson is pioneering precision medicine, aiming to develop individualized treatments based on a patient\u2019s genetic profile to move beyond the traditional one-size-fits-all approach. The company is actively working on targeted therapies for various diseases, partnering with diagnostic companies, and focusing on educating patients and physicians to overcome barriers to access. This approach promises more effective treatments and better outcomes by ensuring patients receive the right test and the right therapy at the right time.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.944992"}], "overall_sentiment_score": 0.425986, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.527977", "ticker_sentiment_label": "Bullish"}, {"ticker": "UNH", "relevance_score": "0.648580", "ticker_sentiment_score": "0.322306", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson drops 136-year-old logo and renames Janssen", "url": "https://www.medicaldesignandoutsourcing.com/johnson-johnson-new-logo-janssen-renamed-innovative-medicine/", "time_published": "20230914T145941", "authors": ["Jim Hammerand"], "summary": "Johnson & Johnson has unveiled a new logo, replacing its 136-year-old cursive design with a more modern look, and renamed its Janssen pharmaceutical business to Johnson & Johnson Innovative Medicine. These changes follow the recent spin-off of its consumer health business and aim to highlight the company's focus on innovative medicine and medtech. The new branding strategy seeks to unite its pharmaceutical and medical device segments under a single, iconic name to better reflect its commitment to healthcare solutions.", "banner_image": null, "source": "Medical Design & Outsourcing", "category_within_source": "General", "source_domain": "Medical Design & Outsourcing", "topics": [{"topic": "life_sciences", "relevance_score": "0.908956"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.705118"}], "overall_sentiment_score": 0.209494, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.251269", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KVUE", "relevance_score": "0.875348", "ticker_sentiment_score": "0.130097", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Marks New Era as Global Healthcare Company with Updated Visual Identity", "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-marks-new-era-as-global-healthcare-company-with-updated-visual-identity", "time_published": "20230914T145940", "authors": [], "summary": "Johnson & Johnson is updating its brand identity to reflect its exclusive focus on healthcare innovation, uniting its medtech and pharmaceutical segments under a single Johnson & Johnson brand. The company's pharmaceutical segment will now be known as Johnson & Johnson Innovative Medicine, and the medical technology segment as Johnson & Johnson MedTech. This rebranding includes a modernized logo, refreshed color palette, and new art direction, aiming to communicate its bold approach to healthcare innovation while maintaining its caring nature.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.464203, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.454612", "ticker_sentiment_label": "Bullish"}]}, {"title": "Mayo Clinic and GE HealthCare enter strategic collaboration to advance innovation in medical imaging and theranostics", "url": "https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-and-ge-healthcare-enter-strategic-collaboration-to-advance-innovation-in-medical-imaging-and-theranostics/", "time_published": "20230914T144509", "authors": ["Jeanette Caban"], "summary": "Mayo Clinic and GE HealthCare have announced a strategic collaboration to advance innovation in medical imaging and theranostics. This partnership will focus on research and product development to transform patient and clinician experiences in radiology, aiming to accelerate the clinical translation of advanced technologies. The collaboration will concentrate on four core areas, including advanced MR technologies, precise cancer imaging, improved interventional ultrasound, and personalized patient imaging experiences through AI and digital health platforms.", "banner_image": null, "source": "Mayo Clinic News Network", "category_within_source": "General", "source_domain": "Mayo Clinic News Network", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "technology", "relevance_score": "0.833912"}], "overall_sentiment_score": 0.386505, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GEHC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.479668", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.633498", "ticker_sentiment_score": "0.327299", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Active Ingredient in Hundreds of Cold and Flu Meds Is \u2018Entirely Ineffective,\u2019 Class Action Says", "url": "https://www.classaction.org/news/active-ingredient-in-hundreds-of-cold-and-flu-meds-is-entirely-ineffective-class-action-says", "time_published": "20230913T000000", "authors": ["Kelly Mehorter"], "summary": "A class action lawsuit has been filed against fourteen companies for selling over-the-counter cold and flu medicines containing phenylephrine, an active ingredient that an FDA advisory panel deemed \"entirely ineffective\" at treating nasal congestion. The lawsuit claims that these companies, including makers of popular brands like Tylenol and Sudafed, have long marketed their products as effective despite knowing the ingredient works no better than a placebo. This legal action follows a unanimous FDA advisory committee vote that phenylephrine does not work to treat nasal congestion, raising questions about its continued use in numerous products.", "banner_image": null, "source": "ClassAction.org", "category_within_source": "General", "source_domain": "ClassAction.org", "topics": [{"topic": "life_sciences", "relevance_score": "0.909951"}, {"topic": "retail_wholesale", "relevance_score": "0.800643"}], "overall_sentiment_score": -0.313626, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "ACI", "relevance_score": "0.952116", "ticker_sentiment_score": "-0.395680", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.941415", "ticker_sentiment_score": "-0.382844", "ticker_sentiment_label": "Bearish"}, {"ticker": "WMT", "relevance_score": "0.893439", "ticker_sentiment_score": "-0.293098", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TGT", "relevance_score": "0.820335", "ticker_sentiment_score": "-0.287160", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PG", "relevance_score": "0.765452", "ticker_sentiment_score": "-0.288894", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Contact - The Lethbridge Herald - News and Sports from around Lethbridge", "url": "https://markets.financialcontent.com/lethbridgeherald/article/bizwire-2023-9-11-first-trust-advisors-lp-announces-distribution-for-first-trust-income-opportunities-etf", "time_published": "20230911T160500", "authors": ["First Trust Advisors L.P."], "summary": "First Trust Advisors L.P. announced the monthly distribution for the First Trust Income Opportunities ETF (FCEF). The distribution amount is $0.1175 per share, with an expected ex-dividend date of September 12, 2023. The article also details the investment objectives, risks, charges, and expenses associated with investing in the Fund, advising potential investors to read the prospectus carefully.", "banner_image": null, "source": "FinancialContent", "category_within_source": "General", "source_domain": "FinancialContent", "topics": [{"topic": "financial_markets", "relevance_score": "0.927631"}, {"topic": "finance", "relevance_score": "0.742090"}, {"topic": "economy_monetary", "relevance_score": "0.602656"}, {"topic": "economy_macro", "relevance_score": "0.600124"}, {"topic": "life_sciences", "relevance_score": "0.642416"}], "overall_sentiment_score": 0.329317, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FCEF", "relevance_score": "1.000000", "ticker_sentiment_score": "0.283938", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.605004", "ticker_sentiment_score": "0.327863", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.618607", "ticker_sentiment_score": "0.305015", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.600850", "ticker_sentiment_score": "0.349773", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.602697", "ticker_sentiment_score": "0.345445", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "IBM notifies J&J unit Janssen CarePath's customers of unauthorized data access", "url": "https://www.reuters.com/technology/ibm-notifies-jj-unit-janssen-carepaths-customers-unauthorized-data-access-2023-09-06/", "time_published": "20230906T203500", "authors": ["Reuters"], "summary": "IBM has notified customers of Janssen CarePath, a Johnson & Johnson unit, about a \"data incident\" involving unauthorized access to personal information stored in a database managed by IBM. The incident did not involve Social Security numbers or financial account information, but may have exposed names, contact details, and health-related information provided to the Janssen CarePath application. IBM stated it was unable to determine the full extent of the unauthorized access.", "banner_image": "https://www.reuters.com/resizer/P225t6yB86L_n0Xb_E2dM_Fq9P0=/960x0/filters:format(jpg):quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/5M74V4LYC5ID7K3M3X35S35FJM.JPG", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.835060"}, {"topic": "technology", "relevance_score": "0.719642"}, {"topic": "finance", "relevance_score": "0.626978"}], "overall_sentiment_score": -0.211338, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "IBM", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.242123", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.846920", "ticker_sentiment_score": "-0.223226", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson: Updated Guidance Following Kenvue Divestment Consistent With Our Expectations", "url": "https://www.morningstar.com/stocks/johnson-johnson-updated-guidance-following-kenvue-divestment-consistent-with-our-expectations", "time_published": "20230831T145942", "authors": ["Damien Conover", "CFA"], "summary": "Johnson & Johnson's updated 2023 guidance following the Kenvue divestment aligns with analyst expectations, leading to no changes in the firm's fair value estimate or wide moat rating. The reduced share count and significant proceeds from the Kenvue split-off largely offset the lost earnings from the divested consumer business. The remaining J&J business, now more focused on pharmaceuticals and medical devices, maintains its wide moat rating due to strong intangible assets and switching costs.", "banner_image": null, "source": "Morningstar", "category_within_source": "General", "source_domain": "Morningstar", "topics": [{"topic": "earnings", "relevance_score": "0.905030"}, {"topic": "ipo", "relevance_score": "0.803559"}, {"topic": "life_sciences", "relevance_score": "0.940345"}], "overall_sentiment_score": 0.210348, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.226782", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KVUE", "relevance_score": "0.830479", "ticker_sentiment_score": "0.204631", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AmerisourceBergen no more: Company changes name to Cencora", "url": "https://www.mmm-online.com/home/channel/amerisourcebergen-no-more-company-changes-name-to-cencora/", "time_published": "20230830T105300", "authors": ["Jack O'Brien"], "summary": "AmerisourceBergen has officially changed its name to Cencora and will now trade under the ticker symbol \"COR\" on the NYSE. This rebranding aims to emphasize its role in connecting the healthcare supply chain, following two decades as AmerisourceBergen. In conjunction with the name change, Cencora also announced a $5 million donation to its newly rebranded Cencora Impact Foundation to support global healthcare initiatives, including a significant grant to the UNICEF Health Fund.", "banner_image": null, "source": "Medical Marketing and Media", "category_within_source": "General", "source_domain": "Medical Marketing and Media", "topics": [{"topic": "life_sciences", "relevance_score": "0.932227"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.846163"}], "overall_sentiment_score": -0.164438, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "COR", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.063244", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.629396", "ticker_sentiment_score": "-0.185829", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CAH", "relevance_score": "0.643158", "ticker_sentiment_score": "-0.157800", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MCK", "relevance_score": "0.615358", "ticker_sentiment_score": "-0.187092", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Boston Scientific Takes the Lead in Pulsed Field Ablation Race", "url": "https://www.mddionline.com/cardiovascular/boston-scientific-takes-the-lead-in-pulsed-field-ablation-race", "time_published": "20230829T000000", "authors": ["Amanda Pedersen"], "summary": "Boston Scientific has taken a significant lead in the pulsed field ablation (PFA) market with positive 12-month results from its ADVENT trial for the Farapulse PFA system. Although the device showed non-inferiority to thermal ablation, analysts anticipate FDA approval in 2024, giving Boston Scientific a potential marketing advantage over competitors like Medtronic and Johnson & Johnson in the growing AF treatment market.", "banner_image": null, "source": "Medical Device and Diagnostic industry", "category_within_source": "General", "source_domain": "Medical Device and Diagnostic industry", "topics": [{"topic": "life_sciences", "relevance_score": "0.907895"}, {"topic": "financial_markets", "relevance_score": "0.634285"}], "overall_sentiment_score": 0.219143, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.469480", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.711244", "ticker_sentiment_score": "0.144282", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.620599", "ticker_sentiment_score": "0.133783", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.577524", "ticker_sentiment_score": "0.144823", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rapport Therapeutics Snags $150M to Develop Precision Neurology Meds", "url": "https://medcitynews.com/2023/08/neurology-drugs-venture-capital/", "time_published": "20230825T123000", "authors": ["Katie Adams"], "summary": "Rapport Therapeutics, a clinical-stage biotech established last year, successfully raised $150 million in Series B financing, bringing its total funding to $250 million. The company aims to develop precision neurology medicines by leveraging receptor-associated proteins to target specific disease-driving circuits and cell types in the brain, thereby reducing broad-acting side effects. Its lead asset is currently in Phase I testing for drug-resistant seizure disorders, with Phase II trials anticipated next year.", "banner_image": null, "source": "MedCity News", "category_within_source": "General", "source_domain": "MedCity News", "topics": [{"topic": "life_sciences", "relevance_score": "0.924707"}, {"topic": "finance", "relevance_score": "0.715775"}], "overall_sentiment_score": 0.132678, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RAPP", "relevance_score": "0.305976", "ticker_sentiment_score": "0.038444", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.622564", "ticker_sentiment_score": "0.206711", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Kenvue Becomes a Fully Independent Company Following Final Separation from Johnson & Johnson", "url": "https://kommunikasjon.ntb.no/pressemelding/17992905/kenvue-becomes-a-fully-independent-company-following-final-separation-from-johnson-johnson?publisherId=90063", "time_published": "20230823T122500", "authors": ["Business Wire"], "summary": "Kenvue has officially become a fully independent company following its final separation from Johnson & Johnson. Johnson & Johnson accepted 190,955,436 shares of its common stock in exchange for 1,533,830,450 shares of Kenvue common stock, reducing its ownership in Kenvue to 9.5%. Kenvue is also expected to be added to the S&P 500 index prior to August 25, 2023.", "banner_image": "https://kommunikasjon.ntb.no/data/images/00882/6f06de45-59f5-4aee-b44f-47d4467b5ca3-w_300_h_100.jpg", "source": "NTB Kommunikasjon", "category_within_source": "General", "source_domain": "NTB Kommunikasjon", "topics": [{"topic": "life_sciences", "relevance_score": "0.931160"}, {"topic": "ipo", "relevance_score": "0.802506"}, {"topic": "financial_markets", "relevance_score": "0.600156"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.518183"}, {"topic": "retail_wholesale", "relevance_score": "0.344494"}], "overall_sentiment_score": 0.282248, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.495051", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.728868", "ticker_sentiment_score": "0.102464", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lilly Completes Acquisition of DICE Therapeutics | Eli Lilly and Company", "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-dice-therapeutics", "time_published": "20230808T052258", "authors": [], "summary": "Eli Lilly and Company has successfully completed its acquisition of DICE Therapeutics, Inc. This strategic move expands Lilly's immunology portfolio by adding DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development for chronic immunologic diseases. The acquisition, priced at $48 per share, finalized with approximately 88.4% of DICE's shares tendered, leading to DICE's delisting from NASDAQ.", "banner_image": "https://investor.lilly.com/sites/g/files/knoqqb97271/themes/site/nir_pid1228/dist/images/Lilly_Newsroom-Hero-1244x504-_0001_AVID_InVITRO_LAB_035.jpg", "source": "Eli Lilly and Company", "category_within_source": "General", "source_domain": "Eli Lilly and Company", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.910764"}], "overall_sentiment_score": 0.175202, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DICE", "relevance_score": "0.331612", "ticker_sentiment_score": "0.017664", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.497200", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.634035", "ticker_sentiment_score": "0.116840", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.626066", "ticker_sentiment_score": "0.101527", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.646587", "ticker_sentiment_score": "0.107090", "ticker_sentiment_label": "Neutral"}]}, {"title": "Glaucoma Market Size, Share, Growth, Industry Analysis 2023 to 2032", "url": "https://www.biospace.com/glaucoma-market-size-share-growth-industry-analysis-2023-to-2032", "time_published": "20230803T154048", "authors": [], "summary": "The global glaucoma market was valued at USD 8.06 billion in 2022 and is projected to reach USD 12.69 billion by 2032, growing at a CAGR of 4.64%. North America held the largest revenue share in 2022, while open-angle glaucoma and prostaglandin analogs dominated disease type and drug class segments, respectively. The market growth is driven by pipeline drugs, product launches, and the increasing prevalence of age-associated eye disorders.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "economy_macro", "relevance_score": "0.722473"}], "overall_sentiment_score": 0.249041, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SKYE", "relevance_score": "0.944300", "ticker_sentiment_score": "0.345378", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.812611", "ticker_sentiment_score": "0.211209", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.706306", "ticker_sentiment_score": "0.211264", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.642249", "ticker_sentiment_score": "0.219778", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Teva CEO says not too late to launch Humira biosimilar in 2024", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/teva-pharm-ceo-not-too-late-launch-humira-biosimilar-2024-2023-08-02/", "time_published": "20230802T110500", "authors": ["Steven Scheer"], "summary": "Teva Pharmaceutical Industries plans to launch its biosimilar version of AbbVie's Humira in 2024, despite a competitive market that saw eight companies launch similar products in 2023. CEO Richard Francis believes the market still offers opportunities, emphasizing Teva's autoinjector as a competitive advantage and the high quality of their biosimilar. He also noted that while the Humira biosimilar might not achieve initial forecasts, Teva's broader biosimilar pipeline, including a Stelara biosimilar in 2025, remains strong.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FV33F7F7YQBNB3HFWP6K74Y3L5E.JPG?auth=76b4b4b3b2c1f9c0e5d0b9e8c3b7f9a8c0e5a8f7b2c1e5d0b9e8c3b7f9a8c0e5&width=1200&height=1200&quality=85&smart=true", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.948266"}, {"topic": "earnings", "relevance_score": "0.622551"}], "overall_sentiment_score": -0.124079, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.247808", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.738387", "ticker_sentiment_score": "-0.118952", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.609320", "ticker_sentiment_score": "0.100058", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.551548", "ticker_sentiment_score": "-0.103175", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson\u2019s innovation, Irvine roots and credo to give back", "url": "https://www.irvinestandard.com/2023/johnson-johnsons-innovation-irvine-roots-and-credo-to-give-back/", "time_published": "20230801T145941", "authors": ["Tom Berg"], "summary": "Celine Martin, Group Chairman of J&J MedTech, discusses why Irvine has been the company's home base for over 30 years, highlighting its access to world-class talent and its contributions to medical technology innovation, particularly in cardiovascular devices. She emphasizes J&J's \"Our Credo\" which guides their culture to prioritize patient well-being and community giving. The article also showcases specific innovations like the QDOT MICRO for AFib treatment and includes testimonials from other medtech leaders on Irvine's significance as an industry hub.", "banner_image": null, "source": "Irvine Standard", "category_within_source": "General", "source_domain": "Irvine Standard", "topics": [{"topic": "life_sciences", "relevance_score": "0.900684"}], "overall_sentiment_score": 0.358078, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.403338", "ticker_sentiment_label": "Bullish"}, {"ticker": "EW", "relevance_score": "0.608020", "ticker_sentiment_score": "0.307213", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.626050", "ticker_sentiment_score": "0.343828", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alvotech Expands Biosimilar Collaboration with Teva Amid Manufacturing Woes", "url": "https://www.biospace.com/alvotech-expands-biosimilar-collaboration-with-teva-amid-manufacturing-woes", "time_published": "20230725T000000", "authors": ["Tristan Manalac"], "summary": "Alvotech is expanding its biosimilar collaboration with Teva Pharmaceuticals after facing two BLA rejections for its Humira biosimilar due to manufacturing deficiencies at its Iceland facility. Teva will increase its involvement in Alvotech's manufacturing and quality control and has invested $40 million in Alvotech's subordinated convertible bonds. The expanded agreement also grants Teva exclusive U.S. commercialization rights to two new biosimilar candidates and line extensions for two existing ones.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "0.925454"}, {"topic": "manufacturing", "relevance_score": "0.721881"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.640506"}], "overall_sentiment_score": -0.120179, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALVO", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.256246", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABBV", "relevance_score": "0.628316", "ticker_sentiment_score": "0.026605", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.568411", "ticker_sentiment_score": "0.036296", "ticker_sentiment_label": "Neutral"}]}, {"title": "BD Names Joanne Waldstreicher to Board of Directors", "url": "https://www.prnewswire.com/news-releases/bd-names-joanne-waldstreicher-to-board-of-directors-301884244.html", "time_published": "20230724T161500", "authors": [], "summary": "BD (Becton, Dickinson and Company) announced the appointment of Dr. Joanne Waldstreicher, former chief medical officer for Johnson & Johnson, to its board of directors. Her extensive experience in clinical and strategic leadership, particularly in R&D, regulatory affairs, and clinical evidence generation, is expected to support BD's innovation agenda and enhance quality and safety in the MedTech industry. Dr. Waldstreicher brings over 30 years of experience from leading healthcare companies and currently serves on other boards and expert panels.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.930203"}], "overall_sentiment_score": 0.330728, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.460484", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.743747", "ticker_sentiment_score": "0.338353", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.582743", "ticker_sentiment_score": "0.212971", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer", "url": "https://www.cnbc.com/2023/07/24/jj-to-reduce-kenvue-stake-by-80percent-through-stock-exchange-offer.html", "time_published": "20230724T090300", "authors": ["Annika Kim Constantino"], "summary": "Johnson & Johnson announced an exchange offer to reduce its stake in Kenvue by at least 80%, allowing J&J shareholders to swap their shares for Kenvue stock at a 7% discount. This move, expected to close on August 18, 2023, is earlier than anticipated due to a waiver dismissing the share lockup period. The split-off aims to sharpen J&J's focus on its pharmaceutical and medtech businesses.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "ipo", "relevance_score": "0.837048"}, {"topic": "life_sciences", "relevance_score": "0.726520"}, {"topic": "earnings", "relevance_score": "0.708418"}], "overall_sentiment_score": 0.037647, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.299676", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KVUE", "relevance_score": "0.988379", "ticker_sentiment_score": "-0.247411", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "BD Names Joanne Waldstreicher to Board of Directors", "url": "https://news.bd.com/2023-07-24-BD-Names-Joanne-Waldstreicher-to-Board-of-Directors", "time_published": "20230724T000000", "authors": [], "summary": "BD (Becton, Dickinson and Company) has appointed Dr. Joanne Waldstreicher to its board of directors. Dr. Waldstreicher previously served as the chief medical officer for Johnson & Johnson, bringing extensive experience in clinical, strategic, and regulatory leadership within the healthcare industry. Her expertise in R&D, regulatory affairs, clinical evidence generation, and safety aligns with BD's innovation agenda and its commitment to quality and safety in MedTech.", "banner_image": null, "source": "BD Newsroom", "category_within_source": "General", "source_domain": "BD Newsroom", "topics": [{"topic": "life_sciences", "relevance_score": "0.904490"}, {"topic": "finance", "relevance_score": "0.719460"}], "overall_sentiment_score": 0.156591, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.276267", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.736072", "ticker_sentiment_score": "0.127634", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.644336", "ticker_sentiment_score": "0.139873", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kenvue CEO says consumers are spending on brand-name health products even as they pull back in other areas", "url": "https://www.cnbc.com/2023/07/21/kenvue-ceo-consumers-spend-on-health-products-as-they-pull-back-elsewhere.html", "time_published": "20230721T164700", "authors": ["Annika Kim Constantino"], "summary": "Kenvue CEO Thibaut Mongon notes that consumers are prioritizing brand-name health and personal care products like Tylenol and Neutrogena, even as they cut spending in other areas. This trend, driven by a focus on health and trust in established brands, is also benefiting beauty and beverage companies that see less trade-down pressure. Kenvue expects continued strong demand, with 2023 sales projected to increase by 4.5% to 5.5%.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "earnings", "relevance_score": "0.946489"}, {"topic": "life_sciences", "relevance_score": "0.896879"}, {"topic": "retail_wholesale", "relevance_score": "0.838758"}, {"topic": "economy_macro", "relevance_score": "0.759923"}, {"topic": "ipo", "relevance_score": "0.605007"}], "overall_sentiment_score": 0.288077, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.451055", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.719889", "ticker_sentiment_score": "0.110686", "ticker_sentiment_label": "Neutral"}, {"ticker": "ULTA", "relevance_score": "0.609251", "ticker_sentiment_score": "0.310717", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KO", "relevance_score": "0.589194", "ticker_sentiment_score": "0.288477", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "7 Companies With Daycare", "url": "https://builtin.com/company-culture/companies-with-daycare", "time_published": "20230721T155114", "authors": ["Rose Velazquez"], "summary": "This article lists seven companies that offer daycare options to support their employees, recognizing the challenges working parents face in finding reliable childcare. The companies mentioned provide various forms of support, including on-site childcare centers, daycare discounts, or backup solutions. The article details the specific childcare benefits offered by Qualtrics, Trupanion, Johnson & Johnson, Whirlpool Corporation, Aflac, Valero Energy, and Recursion.", "banner_image": null, "source": "Built In", "category_within_source": "General", "source_domain": "Built In", "topics": [{"topic": "life_sciences", "relevance_score": "0.719159"}, {"topic": "manufacturing", "relevance_score": "0.610297"}, {"topic": "technology", "relevance_score": "0.749522"}, {"topic": "energy_transportation", "relevance_score": "0.621239"}], "overall_sentiment_score": 0.518152, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "TRUP", "relevance_score": "0.940146", "ticker_sentiment_score": "0.531071", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.808397", "ticker_sentiment_score": "0.533028", "ticker_sentiment_label": "Bullish"}, {"ticker": "AFL", "relevance_score": "0.722915", "ticker_sentiment_score": "0.541557", "ticker_sentiment_label": "Bullish"}, {"ticker": "VLO", "relevance_score": "0.715841", "ticker_sentiment_score": "0.520065", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson sues US government over Medicare drug price negotiation programme", "url": "https://pmlive.com/pharma_news/johnson_and_johnson_sues_us_government_over_medicare_drug_price_negotiation_programme_1495059/", "time_published": "20230721T145943", "authors": ["Emily Kimber"], "summary": "Johnson & Johnson and its Janssen pharmaceuticals unit are suing the US government over the Medicare drug price negotiation element of President Biden\u2019s Inflation Reduction Act (IRA). J&J argues that the plan would force it to sell patented medicines at prices significantly below market rates, potentially stifling pharmaceutical innovation and impacting the creation of generic drugs. Several other pharmaceutical companies and industry groups have also filed lawsuits, citing similar concerns regarding the IRA's drug pricing provisions.", "banner_image": null, "source": "PMLiVE", "category_within_source": "General", "source_domain": "PMLiVE", "topics": [{"topic": "economy_fiscal", "relevance_score": "0.933435"}, {"topic": "life_sciences", "relevance_score": "0.822670"}], "overall_sentiment_score": 0.048679, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.322018", "ticker_sentiment_score": "0.048526", "ticker_sentiment_label": "Neutral"}]}, {"title": "OraSure Technologies Elects Robert McMahon to the Board of Directors", "url": "https://www.citybiz.co/article/443636/orasure-technologies-elects-robert-mcmahon-to-the-board-of-directors/", "time_published": "20230720T152040", "authors": ["NULL"], "summary": "OraSure Technologies, Inc. announced the election of Robert W. McMahon to its Board of Directors, effective July 31, 2023. Mr. McMahon, Senior Vice President and CFO of Agilent Technologies, brings over 30 years of finance expertise in business growth, M&A, and increasing profitability. His appointment is expected to significantly contribute to OraSure's ongoing transformation.", "banner_image": "NULL", "source": "citybiz", "category_within_source": "General", "source_domain": "citybiz", "topics": [{"topic": "life_sciences", "relevance_score": "0.933352"}], "overall_sentiment_score": 0.275885, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OSUR", "relevance_score": "1.000000", "ticker_sentiment_score": "0.409979", "ticker_sentiment_label": "Bullish"}, {"ticker": "A", "relevance_score": "0.737204", "ticker_sentiment_score": "0.321018", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOLX", "relevance_score": "0.611695", "ticker_sentiment_score": "0.233096", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.601413", "ticker_sentiment_score": "0.116417", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kenvue shares fall even as J&J spinoff beats estimates in first quarterly earnings since IPO", "url": "https://www.cnbc.com/2023/07/20/kenvue-kvue-q2-earnings-report-2023.html", "time_published": "20230720T073200", "authors": ["Annika Kim Constantino"], "summary": "Kenvue (KVUE) shares fell despite beating Q2 revenue and adjusted earnings estimates in its first quarterly report since spinning off from Johnson & Johnson. The consumer health company, with brands like Band-Aid and Tylenol, also issued an upbeat sales outlook for 2023, driven by resilient demand. Johnson & Johnson still maintains a 90% stake in Kenvue but plans to reduce its ownership through an upcoming exchange offer.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "earnings", "relevance_score": "0.900429"}, {"topic": "ipo", "relevance_score": "0.910633"}, {"topic": "life_sciences", "relevance_score": "0.704213"}, {"topic": "finance", "relevance_score": "0.643253"}, {"topic": "retail_wholesale", "relevance_score": "0.635173"}], "overall_sentiment_score": -0.074466, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KVUE-W", "relevance_score": "0.312083", "ticker_sentiment_score": "0.000538", "ticker_sentiment_label": "Neutral"}, {"ticker": "KVUE", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.197157", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.729561", "ticker_sentiment_score": "0.102149", "ticker_sentiment_label": "Neutral"}]}, {"title": "Breakingviews - Post-it maker 3M is in danger of coming unstuck", "url": "https://www.reuters.com/breakingviews/post-it-maker-3m-is-danger-coming-unstuck-2023-07-19/", "time_published": "20230719T080200", "authors": ["Jeffrey Goldfarb"], "summary": "3M, known for Post-it Notes and Scotchgard, faces significant financial liabilities from PFAS \"forever chemicals\" and Combat Arms earplug lawsuits, threatening its sacrosanct dividend. The industrial conglomerate's legal troubles and declining financial performance, coupled with the spinoff of its profitable healthcare division, are causing investor concern and a re-evaluation of its financial stability and dividend sustainability.", "banner_image": "https://www.reuters.com/resizer/l92TjVwD9p4Tf31iL4x3Fw5Gj8E=/960x0/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/53J3Z3W2KRMVXLSPX4T2L43D3I.JPG", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "earnings", "relevance_score": "0.941617"}, {"topic": "manufacturing", "relevance_score": "0.847264"}, {"topic": "finance", "relevance_score": "0.729812"}, {"topic": "life_sciences", "relevance_score": "0.611096"}], "overall_sentiment_score": -0.460329, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "MMM", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.645412", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.731567", "ticker_sentiment_score": "-0.313190", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "2 New Wide-Moat Stocks to Watch", "url": "https://www.morningstar.com/stocks/2-new-wide-moat-stocks-watch-2", "time_published": "20230710T000000", "authors": ["Susan Dziubinski"], "summary": "Morningstar's equity research team has added two new wide-moat stocks to its coverage list: Kenvue (KVUE) and Copart (CPRT). Kenvue, Johnson & Johnson's former consumer segment, is the world's largest pure-play consumer health company, while Copart is a dominant salvage vehicle auctioneer leveraging a strong network effect. Analysts have assigned Kenvue a fair value of $27.50 per share, deeming it fairly valued, and Copart a fair value of $77 per share, considering it overpriced.", "banner_image": null, "source": "Morningstar", "category_within_source": "General", "source_domain": "Morningstar", "topics": [{"topic": "financial_markets", "relevance_score": "0.915811"}, {"topic": "life_sciences", "relevance_score": "0.720196"}, {"topic": "retail_wholesale", "relevance_score": "0.625140"}, {"topic": "finance", "relevance_score": "0.606712"}], "overall_sentiment_score": 0.052695, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CPRT", "relevance_score": "0.942589", "ticker_sentiment_score": "0.113773", "ticker_sentiment_label": "Neutral"}, {"ticker": "KVUE", "relevance_score": "0.901026", "ticker_sentiment_score": "0.028949", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.622689", "ticker_sentiment_score": "0.034870", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.635173", "ticker_sentiment_score": "0.044936", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Commercial Market for Legal Psychedelics: Spravato", "url": "https://microdose.buzz/news/legal-psychedelics-spravato/", "time_published": "20230704T143455", "authors": ["Jason Najum"], "summary": "This article examines the commercial market for legal psychedelics, focusing on Spravato (esketamine), the first FDA-approved psychedelic. It highlights Spravato's impressive sales growth, showing the potential for psychedelics in mainstream pharma. The piece also discusses the future outlook for upcoming psychedelic drugs like those from MAPS and Compass Pathways.", "banner_image": null, "source": "microdose.buzz", "category_within_source": "General", "source_domain": "microdose.buzz", "topics": [{"topic": "life_sciences", "relevance_score": "0.917833"}, {"topic": "earnings", "relevance_score": "0.824435"}], "overall_sentiment_score": 0.282108, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ENVB", "relevance_score": "0.309287", "ticker_sentiment_score": "0.044671", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.998523", "ticker_sentiment_score": "0.638524", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRK", "relevance_score": "0.646612", "ticker_sentiment_score": "0.280275", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.628080", "ticker_sentiment_score": "0.274046", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.620069", "ticker_sentiment_score": "0.276072", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Lilly takes over partner working on cell therapies for diabetes", "url": "https://www.biopharmadive.com/news/lilly-sigilon-acquisition-cell-therapy-diabetes/654277/", "time_published": "20230629T120909", "authors": ["Jacob Bell"], "summary": "Eli Lilly announced plans to acquire Sigilon Therapeutics, a cell therapy developer focused on Type 1 diabetes treatments, for up to $310 million. This acquisition follows an initial partnership in 2018 and includes a cash offer for outstanding shares and contingent value rights based on research and regulatory milestones. The move underscores growing pharmaceutical interest in cell therapies for common diseases like diabetes, evidenced by recent advancements in the field.", "banner_image": "https://imgproxy.divecdn.com/lsfpXuG_vI5xzycERGCz5CT-OprzK2CSHvOG3HEMp4I/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9zaXBhcGhvdG9zZml2ZTYwMTIxMi5qcGc=.webp", "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.939733"}], "overall_sentiment_score": 0.365839, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SGTX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.507752", "ticker_sentiment_label": "Bullish"}, {"ticker": "LLY", "relevance_score": "0.926355", "ticker_sentiment_score": "0.413406", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.834956", "ticker_sentiment_score": "0.308028", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.632561", "ticker_sentiment_score": "0.146401", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intuitive\u2019s Ion platform may provide \u2018most exciting advancements in robotic technology\u2019: analysts", "url": "https://www.medtechdive.com/news/intuitive-ISRG-JNJ-ion-platform-robot-surgery/653750/", "time_published": "20230623T145557", "authors": ["Nick Paul Taylor"], "summary": "Analysts at BTIG believe Intuitive Surgical's Ion robotic bronchoscopy platform could see significant advancements in the coming years, potentially expanding beyond lung biopsy to tumor ablation. Despite only contributing an estimated $115 million to last year's revenue, Ion's install base is growing, and it has already been used in almost 41,000 procedures, with forecasts for further sales growth. The platform is seen as a strategic move to serve as both a diagnostic and therapeutic tool, especially given its potential expansion into treating inoperable lung cancers.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "technology", "relevance_score": "0.836821"}, {"topic": "earnings", "relevance_score": "0.644609"}], "overall_sentiment_score": 0.180403, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.436377", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.720157", "ticker_sentiment_score": "0.110228", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.602249", "ticker_sentiment_score": "0.144452", "ticker_sentiment_label": "Neutral"}, {"ticker": "GEHC", "relevance_score": "0.632795", "ticker_sentiment_score": "0.124571", "ticker_sentiment_label": "Neutral"}]}, {"title": "GE HealthCare and DePuy Synthes are partnering in spine surgery", "url": "https://www.massdevice.com/ge-healthcare-and-depuy-synthes-spine-surgery-partnership/", "time_published": "20230621T144510", "authors": ["Chris Newmarker"], "summary": "GE HealthCare has partnered with Johnson & Johnson\u2019s DePuy Synthes to expand the distribution of GE HealthCare\u2019s OEC 3D Imaging System to spine surgeons and patients across the U.S. This collaboration aims to enhance surgical precision and efficiency through advanced imaging technology. The agreement is part of GE HealthCare's broader strategy of forming partnerships to boost competitiveness in the medical device market.", "banner_image": "https://www.massdevice.com/wp-content/uploads/2023/06/OEC-3D-Imaging-System.jpg", "source": "MassDevice", "category_within_source": "General", "source_domain": "MassDevice", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.902458"}, {"topic": "technology", "relevance_score": "0.801659"}], "overall_sentiment_score": 0.391906, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GEHC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.413408", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.732958", "ticker_sentiment_score": "0.314971", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "FDA Lifts Partial Hold on Arcellx\u2019s Multiple Myeloma Trial After Patient Death", "url": "https://www.biospace.com/fda-hold-on-arcellx-s-multiple-myeloma-cell-therapy-trial-after-patient-death", "time_published": "20230620T000000", "authors": ["Kate Goodwin"], "summary": "The FDA has lifted a partial clinical hold on Arcellx\u2019s iMMagine-1 Phase II trial for its CART-ddBCMA treatment for relapsed or refractory multiple myeloma, a trial conducted in partnership with Gilead\u2019s Kite Pharma. The hold was initially placed following the death of a patient who was later determined to be ineligible for the treatment under the trial protocol. Arcellx has since retrained clinical sites and adjusted procedures to prevent recurrence, and expects preliminary data in the second half of 2024.", "banner_image": "https://cdn.biospace.com/images/resize/900x-1/fdasignsistock-jhvephoto.jpeg", "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "0.919834"}, {"topic": "ipo", "relevance_score": "0.607541"}], "overall_sentiment_score": 0.230697, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.401228", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.913630", "ticker_sentiment_score": "0.237044", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.619232", "ticker_sentiment_score": "0.103020", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.566378", "ticker_sentiment_score": "0.127254", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eye on Pharma: First PBM to Cover Yusimry; Celltrion to Test Ocrevus Biosimilar; Another Stelara Settlement", "url": "https://www.centerforbiosimilars.com/view/eye-on-pharma-first-pbm-to-cover-yusimry-celltrion-to-test-ocrevus-biosimilar-another-stelara-settlement", "time_published": "20230615T000000", "authors": ["Skylar Jeremias"], "summary": "SmithRx is the first PBM to announce coverage of Yusimry, an adalimumab biosimilar, offering it at over a 90% discount. Celltrion Healthcare received FDA approval for a phase 3 study of its ocrelizumab biosimilar, CT-P53, targeting the over $4.7 billion Ocrevus market. Additionally, Alvotech and Teva Pharmaceuticals settled with Johnson & Johnson regarding their Stelara biosimilar, AVT04, setting a US launch date of February 21, 2025.", "banner_image": null, "source": "Center for Biosimilars", "category_within_source": "General", "source_domain": "Center for Biosimilars", "topics": [{"topic": "life_sciences", "relevance_score": "0.934995"}], "overall_sentiment_score": -0.00832, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALVO", "relevance_score": "0.916705", "ticker_sentiment_score": "0.347759", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.747777", "ticker_sentiment_score": "-0.235662", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.629155", "ticker_sentiment_score": "-0.125032", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alkermes To Spin-Off Mural Oncology In 2H23", "url": "https://www.forbes.com/sites/joecornell/2023/06/14/alkermes-to-spin-off-mural-oncology-in-2h23/", "time_published": "20230614T111100", "authors": ["Joe Cornell"], "summary": "Alkermes announced its plan to spin off its oncology business into a new, publicly-traded company called Mural Oncology plc in the second half of 2023. This separation aims to unlock shareholder value by allowing both Alkermes (neuroscience focus) and Mural Oncology (cancer therapies) to pursue distinct strategic goals and attract specialized investor bases. The move follows Alkermes' strategic review and is expected to enhance profitability for the parent company, with Mural Oncology focusing on developing nemvaleukin alfa and other preclinical engineered cytokines.", "banner_image": null, "source": "Forbes", "category_within_source": "General", "source_domain": "Forbes", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "earnings", "relevance_score": "0.920711"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.821624"}], "overall_sentiment_score": 0.237376, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "1.000000", "ticker_sentiment_score": "0.431864", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.666247", "ticker_sentiment_score": "0.215652", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.560774", "ticker_sentiment_score": "0.144302", "ticker_sentiment_label": "Neutral"}]}, {"title": "Built from biotech parts, Beacon launches with $120M to develop eye gene therapies", "url": "https://www.biopharmadive.com/news/beacon-biotech-gene-therapy-eye-launch-agtc/652710/", "time_published": "20230612T000000", "authors": ["Jacob Bell"], "summary": "Beacon Therapeutics, a new biotechnology company, has launched with $120 million in funding to develop gene therapies for eye diseases causing blindness. The company is led by former executives from ocular gene therapy developers Nightstar, Gyroscope, and AGTC, and its most advanced program, acquired from AGTC, is in human testing for X-linked retinitis pigmentosa. Beacon will also pursue treatments for dry AMD and cone-rod dystrophy, leveraging insights from University of Oxford and its investors like Syncona Limited.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.817686"}], "overall_sentiment_score": 0.077316, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AGTC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.288697", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.725339", "ticker_sentiment_score": "-0.240946", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.644486", "ticker_sentiment_score": "0.109388", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.574541", "ticker_sentiment_score": "0.130881", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 keys to Mike Mahoney and Boston Scientific\u2019s success", "url": "https://www.medicaldesignandoutsourcing.com/5-keys-to-mike-mahoney-and-boston-scientifics-success/", "time_published": "20230605T000000", "authors": ["Chris Newmarker"], "summary": "This article details five key leadership principles demonstrated by Mike Mahoney, CEO of Boston Scientific, that have contributed to the company's significant growth since 2011. These principles include courage to take on challenges, fostering a startup mentality, willingness to take risks for innovation, understanding the company's core strengths, and prioritizing local company culture. Mahoney's strategies have led to a nearly tenfold increase in Boston Scientific's market capitalization and strong sales growth, even during a challenging period for the medical device industry.", "banner_image": null, "source": "Medical Design & Outsourcing", "category_within_source": "General", "source_domain": "Medical Design & Outsourcing", "topics": [{"topic": "finance", "relevance_score": "0.818258"}, {"topic": "life_sciences", "relevance_score": "0.932390"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.622229"}, {"topic": "technology", "relevance_score": "0.701091"}], "overall_sentiment_score": 0.051307, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.483102", "ticker_sentiment_label": "Bullish"}, {"ticker": "ISRG", "relevance_score": "0.606510", "ticker_sentiment_score": "0.100085", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.638446", "ticker_sentiment_score": "-0.113322", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.598929", "ticker_sentiment_score": "-0.130800", "ticker_sentiment_label": "Neutral"}, {"ticker": "GEHC", "relevance_score": "0.598071", "ticker_sentiment_score": "-0.132018", "ticker_sentiment_label": "Neutral"}]}, {"title": "Farallon Capital succeeds in refreshing Exelixis board", "url": "https://www.mmm-online.com/home/channel/farallon-capital-succeeds-in-refreshing-exelixis-board/", "time_published": "20230601T152700", "authors": ["Marc Iskowitz"], "summary": "Farallon Capital, an activist hedge fund owning 7.8% of Exelixis stock, successfully refreshed the oncology biotech company's board after a shareholder vote. All three of Farallon's independent candidates were elected, including Tomas Heyman, Robert Oliver, and David Johnson. This move addresses Farallon's concerns over unfocused R&D spending and aims to improve capital allocation and strategic focus at Exelixis.", "banner_image": null, "source": "Medical Marketing and Media", "category_within_source": "General", "source_domain": "Medical Marketing and Media", "topics": [{"topic": "life_sciences", "relevance_score": "0.926907"}, {"topic": "earnings", "relevance_score": "0.812272"}, {"topic": "ipo", "relevance_score": "0.740010"}], "overall_sentiment_score": 0.211413, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EXEL", "relevance_score": "1.000000", "ticker_sentiment_score": "0.255448", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.609824", "ticker_sentiment_score": "0.136349", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cummins Spinoff Atmus Raises $275 Million in IPO", "url": "https://www.ttnews.com/articles/cummins-spinoff-atmus-ipo", "time_published": "20230526T151400", "authors": ["Michael Hytha"], "summary": "Cummins Inc. spinoff Atmus Filtration Technologies Inc. raised $275 million in its initial public offering, with shares rising 11% in their trading debut. The company, which manufactures filters for commercial vehicles and other equipment, has a market value of $1.8 billion and its IPO marks the seventh-biggest on a U.S. exchange this year. Cummins retains an 83% ownership stake in Atmus.", "banner_image": null, "source": "Transport Topics", "category_within_source": "General", "source_domain": "Transport Topics", "topics": [{"topic": "ipo", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.915196"}, {"topic": "manufacturing", "relevance_score": "0.818864"}, {"topic": "earnings", "relevance_score": "0.705225"}, {"topic": "energy_transportation", "relevance_score": "0.609798"}], "overall_sentiment_score": 0.150903, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMI", "relevance_score": "0.986487", "ticker_sentiment_score": "0.251079", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.611913", "ticker_sentiment_score": "0.129888", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.589339", "ticker_sentiment_score": "0.051358", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.564311", "ticker_sentiment_score": "0.098120", "ticker_sentiment_label": "Neutral"}, {"ticker": "KVUE", "relevance_score": "0.557181", "ticker_sentiment_score": "0.224601", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Fast Five: Medtronic\u2019s nearly $740M acquisition, Boston Scientific bows out of an acquisition", "url": "https://www.massdevice.com/fast-five-medtronics-nearly-740m-acquisition-boston-scientific-bows-out-of-an-acquisition/", "time_published": "20230526T000000", "authors": ["Danielle Kirsh"], "summary": "This article covers key developments in the medical technology industry, including Medtronic's acquisition of EOFlow for $738 million and Boston Scientific's decision to withdraw from acquiring a majority stake in M.I. Tech. It also highlights HeartBeam's AI-related patent for a handheld vector ECG device and the FDA's approval of Zoll therapy for sleep apnea patients undergoing MRI scans. The Fast Five hosts discuss the implications of these strategic moves and technological advancements.", "banner_image": null, "source": "MassDevice", "category_within_source": "General", "source_domain": "MassDevice", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.940627"}, {"topic": "technology", "relevance_score": "0.828542"}, {"topic": "earnings", "relevance_score": "0.728126"}], "overall_sentiment_score": 0.16525, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.149263", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.908063", "ticker_sentiment_score": "0.310381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.642378", "ticker_sentiment_score": "0.113511", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.600488", "ticker_sentiment_score": "0.114781", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.630300", "ticker_sentiment_score": "0.132861", "ticker_sentiment_label": "Neutral"}]}, {"title": "Report: Medtronic, Johnson & Johnson consider Shockwave Medical acquisition after Boston Scientific talks stall", "url": "https://cardiovascularbusiness.com/topics/healthcare-management/healthcare-economics/medtronic-johnson-johnson-shockwave-medical", "time_published": "20230511T000000", "authors": ["Michael Walter"], "summary": "Medtronic and Johnson & Johnson are reportedly considering an acquisition of Shockwave Medical, a medical device company known for its intravascular lithotripsy technology. This interest follows stalled talks between Boston Scientific and Shockwave Medical. Shockwave Medical's stock price saw an increase, likely due to strong Q1 performance and the news of potential new suitors, highlighting the company's significant impression on the interventional cardiology space.", "banner_image": null, "source": "Cardiovascular Business", "category_within_source": "General", "source_domain": "Cardiovascular Business", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.902453"}, {"topic": "financial_markets", "relevance_score": "0.824013"}, {"topic": "earnings", "relevance_score": "0.700646"}], "overall_sentiment_score": 0.185936, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "0.928275", "ticker_sentiment_score": "0.139034", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.719251", "ticker_sentiment_score": "0.206475", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.735004", "ticker_sentiment_score": "0.232746", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "How Baxter\u2019s $4B Sale of Biopharma Biz Fits With Broader Life Sciences Trends", "url": "https://medcitynews.com/2023/05/baxter-international-biopharma-private-equity-mergers-acquisitions-outsourcing/", "time_published": "20230509T184300", "authors": ["Frank Vinluan"], "summary": "Baxter International is selling its biopharma solutions business for $4.25 billion cash to private equity firms Advent International and Warburg Pincus. This transaction is part of a broader trend among life science companies to streamline operations by divesting non-core businesses. The move by Baxter, which generated $644 million in biopharma solutions revenue in 2022, aims to focus the company on hospital products and connected care.", "banner_image": null, "source": "MedCity News", "category_within_source": "General", "source_domain": "MedCity News", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.916772"}, {"topic": "life_sciences", "relevance_score": "0.919895"}, {"topic": "finance", "relevance_score": "0.729465"}], "overall_sentiment_score": 0.212121, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.284710", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.602483", "ticker_sentiment_score": "0.183077", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDX", "relevance_score": "0.594955", "ticker_sentiment_score": "0.108316", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kenvue CEO looks to brand, product innovation to drive growth after IPO", "url": "https://www.cnbc.com/2023/05/05/jj-spinoff-kenvue-ceo-looks-to-innovation-after-ipo.html", "time_published": "20230505T093700", "authors": ["Annika Kim Constantino"], "summary": "Kenvue CEO Thibaut Mongon plans to drive growth through continuous brand and product innovation, leveraging the company's strong portfolio and research capabilities. After a successful IPO debut, Kenvue, the J&J consumer health spinoff, aims to develop new solutions and personalized digital experiences for consumers. The company also states that while it primarily focuses on organic growth, it does not rule out strategic mergers and acquisitions.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "ipo", "relevance_score": "0.925823"}, {"topic": "life_sciences", "relevance_score": "0.836733"}, {"topic": "earnings", "relevance_score": "0.745416"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.647798"}, {"topic": "retail_wholesale", "relevance_score": "0.603629"}], "overall_sentiment_score": 0.350999, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.453101", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.702319", "ticker_sentiment_score": "0.282720", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J's consumer-health spinoff Kenvue jumps 22% in public market debut", "url": "https://www.cnbc.com/2023/05/04/jj-kenvue-ipo-kvue-starts-trading-on-nyse.html", "time_published": "20230504T124900", "authors": ["Annika Kim Constantino"], "summary": "Johnson & Johnson's consumer-health spinoff, Kenvue (KVUE), saw its shares jump 22% on its market debut on the New York Stock Exchange, making it the biggest U.S. IPO in over a year and valuing the new company at roughly $50 billion. Kenvue raised $3.8 billion by selling 172.8 million shares, initially priced at $22, and holds well-known brands like Band-Aid and Tylenol. Despite the spinoff, J&J will retain a 90.9% stake initially and Kenvue estimates 2022 sales of $14.95 billion and expects to pay a quarterly cash dividend of about 20 cents per share.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "ipo", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.901768"}, {"topic": "life_sciences", "relevance_score": "0.840508"}, {"topic": "earnings", "relevance_score": "0.702592"}, {"topic": "retail_wholesale", "relevance_score": "0.644382"}], "overall_sentiment_score": 0.391561, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.521509", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.830904", "ticker_sentiment_score": "0.248117", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "16-Acre Commercial Life Science Development on Its Way to the Southwestern Medical District", "url": "https://www.dmagazine.com/commercial-real-estate/2023/05/16-acre-commercial-life-science-development-on-its-way-to-the-southwestern-medical-district/", "time_published": "20230503T100000", "authors": ["Will Maddox"], "summary": "Alexandria Real Estate Equities, a California-based REIT, is acquiring and consolidating 16.5 acres in Dallas's Southwestern Medical District to establish a commercial life science hub. The project aims to bring early-stage commercial life science to Texas, building on the company's track record in other biotech centers. This development contributes to a growing boom in the medical district, which includes other major life science and healthcare projects.", "banner_image": null, "source": "D Magazine", "category_within_source": "General", "source_domain": "D Magazine", "topics": [{"topic": "real_estate", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.927879"}, {"topic": "finance", "relevance_score": "0.629656"}, {"topic": "economy_macro", "relevance_score": "0.610169"}], "overall_sentiment_score": 0.289941, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.409685", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.741422", "ticker_sentiment_score": "0.301309", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.619214", "ticker_sentiment_score": "0.201317", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.739428", "ticker_sentiment_score": "0.322846", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.604745", "ticker_sentiment_score": "0.235923", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pfizer turns focus to new drugs as COVID vaccine revenue falls", "url": "https://www.biopharmadive.com/news/pfizer-q1-earnings-covid-revenue-drug-launches/649167/", "time_published": "20230502T152457", "authors": ["Jonathan Gardner"], "summary": "Pfizer is shifting its focus to new drug launches as revenue from its COVID-19 vaccine declines. The company reported first-quarter revenue that beat expectations despite a significant drop from the previous year due to plummeting vaccine sales, but COVID antiviral Paxlovid sales were unexpectedly high. Pfizer is anticipating key regulatory approvals for several new products, including an RSV vaccine and a multiple myeloma drug, which are crucial for achieving its projected non-COVID revenue growth.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "earnings", "relevance_score": "0.932479"}, {"topic": "life_sciences", "relevance_score": "0.908701"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.847343"}, {"topic": "financial_markets", "relevance_score": "0.626327"}, {"topic": "manufacturing", "relevance_score": "0.628418"}], "overall_sentiment_score": -0.08068, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.146505", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.727291", "ticker_sentiment_score": "-0.145593", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.642462", "ticker_sentiment_score": "-0.136162", "ticker_sentiment_label": "Neutral"}]}, {"title": "Better Growth Stock: Johnson & Johnson vs. Intuitive Surgical", "url": "https://www.fool.com/investing/2023/05/02/better-growth-stock-johnson-johnson-vs-intuitive-s/", "time_published": "20230502T072000", "authors": ["Sushree Mohanty"], "summary": "This article compares Johnson & Johnson (JNJ) and Intuitive Surgical (ISRG) as growth stocks, highlighting J&J's stability and consistent dividends versus Intuitive Surgical's strong growth potential in the minimally invasive surgery market. While J&J offers a solid investment, the author ultimately favors Intuitive Surgical due to its dominance in robotic surgery and significant future expansion opportunities.", "banner_image": null, "source": "The Motley Fool", "category_within_source": "General", "source_domain": "The Motley Fool", "topics": [{"topic": "financial_markets", "relevance_score": "0.919134"}, {"topic": "life_sciences", "relevance_score": "0.949325"}, {"topic": "earnings", "relevance_score": "0.808494"}], "overall_sentiment_score": 0.393086, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.488089", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.903245", "ticker_sentiment_score": "0.303700", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Onyx lands 290,000 sq. ft. lease in Summit for J&J consumer health spinoff headquarters", "url": "https://re-nj.com/onyx-lands-290000-sq-ft-lease-in-summit-for-jj-consumer-health-spinoff-headquarters/", "time_published": "20230501T150105", "authors": ["Joshua Burd"], "summary": "Johnson & Johnson's consumer health spinoff, Kenvue, is leasing 290,000 square feet of office and laboratory space at Onyx Equities' Summit East property in Summit, New Jersey. This deal will establish Kenvue's headquarters, including a new 100,000-square-foot R&D building, leveraging the campus's amenities and proximity to a skilled biomedical workforce. The announcement comes as J&J prepares for Kenvue's initial public offering.", "banner_image": "https://re-nj.com/wp-content/uploads/2022/07/Building-L-Summit_6913-combo-edit.jpg", "source": "Real Estate NJ", "category_within_source": "General", "source_domain": "Real Estate NJ", "topics": [{"topic": "real_estate", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.906566"}, {"topic": "ipo", "relevance_score": "0.843688"}], "overall_sentiment_score": 0.287463, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.414076", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.843156", "ticker_sentiment_score": "0.297869", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.345471", "ticker_sentiment_score": "0.109329", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cue Biopharma Appoints Patrick Verheyen to its Board of Directors", "url": "https://www.citybiz.co/article/403059/cue-biopharma-appoints-patrick-verheyen-to-its-board-of-directors/", "time_published": "20230412T000000", "authors": [], "summary": "Cue Biopharma has appointed Patrick Verheyen, an industry veteran with over 35 years of experience from Janssen Pharmaceutical Companies, to its Board of Directors. Mr. Verheyen's expertise in business development, licensing, and M&A, including significant acquisitions for Janssen, is expected to guide Cue Biopharma's corporate development and strategic initiatives. He will contribute to advancing the company's clinical drug candidates and platform technologies in immunotherapy for cancer and autoimmune diseases.", "banner_image": null, "source": "citybiz", "category_within_source": "General", "source_domain": "citybiz", "topics": [{"topic": "life_sciences", "relevance_score": "0.911084"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.806720"}], "overall_sentiment_score": 0.315716, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.457959", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.729424", "ticker_sentiment_score": "0.344203", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.593013", "ticker_sentiment_score": "0.214634", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.582936", "ticker_sentiment_score": "0.202246", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Big Pharma-partnered Evotec on high alert after cyberattack takes systems offline", "url": "https://www.fiercebiotech.com/biotech/big-pharma-partnered-evotec-closes-down-hatchets-after-cyber-attack", "time_published": "20230410T102400", "authors": ["Max Bayer"], "summary": "German biotech Evotec shut down its network after detecting unusual activity on its IT systems on April 6, prompting a forensic examination. The company, which has lucrative partnerships with major pharmaceutical companies like Bristol Myers Squibb and Johnson & Johnson's Janssen Pharmaceuticals, states that business continuity is being upheld despite potential delays. This incident highlights the increasing vulnerability of the healthcare and biotech sectors to cyberattacks, with previous incidents affecting vaccine manufacturers.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "technology", "relevance_score": "0.839319"}, {"topic": "earnings", "relevance_score": "0.710230"}], "overall_sentiment_score": -0.114887, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EVO", "relevance_score": "0.329152", "ticker_sentiment_score": "0.022649", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.700790", "ticker_sentiment_score": "-0.233550", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.634409", "ticker_sentiment_score": "-0.142196", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top 10 Procter & Gamble Competitors & Alternatives", "url": "https://bstrategyhub.com/procter-gamble-competitors-alternatives/", "time_published": "20230404T152506", "authors": ["Kevin Johnson"], "summary": "This article lists the top 10 competitors and alternatives to Procter & Gamble, a leading consumer goods company. It provides details on each competitor, including their founding year, headquarters, key products, and historical background. The list highlights the diverse range of companies vying for market share in the consumer goods sector against P&G.", "banner_image": null, "source": "Business Strategy Hub", "category_within_source": "General", "source_domain": "Business Strategy Hub", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.815370"}, {"topic": "finance", "relevance_score": "0.742848"}], "overall_sentiment_score": 0.099438, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PG", "relevance_score": "0.971672", "ticker_sentiment_score": "0.015750", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.851195", "ticker_sentiment_score": "0.148485", "ticker_sentiment_label": "Neutral"}, {"ticker": "CL", "relevance_score": "0.829070", "ticker_sentiment_score": "0.106245", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMB", "relevance_score": "0.797555", "ticker_sentiment_score": "0.058130", "ticker_sentiment_label": "Neutral"}, {"ticker": "EL", "relevance_score": "0.734923", "ticker_sentiment_score": "0.149814", "ticker_sentiment_label": "Neutral"}]}, {"title": "United States Condom Market Size to Reach $879.43 Million by 2030 | At 12.79% CAGR", "url": "https://finance.yahoo.com/news/united-states-condom-market-size-095600190.html", "time_published": "20230403T095600", "authors": ["Fortune Business Insights"], "summary": "The United States condom market is projected to reach $879.43 million by 2030, growing at a CAGR of 12.79% from its 2022 value of $437.01 million. This growth is driven by increasing demand for HIV and STI prevention, government initiatives for sexual health education, and the widespread availability of affordable condoms. The COVID-19 pandemic initially caused a decline in sales due to lockdowns, but the market rebounded as restrictions eased.", "banner_image": null, "source": "Yahoo Finance", "category_within_source": "General", "source_domain": "Yahoo Finance", "topics": [{"topic": "life_sciences", "relevance_score": "0.903409"}, {"topic": "retail_wholesale", "relevance_score": "0.715988"}, {"topic": "economy_macro", "relevance_score": "0.634983"}], "overall_sentiment_score": 0.265796, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHD", "relevance_score": "0.901908", "ticker_sentiment_score": "0.334536", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDX", "relevance_score": "0.646914", "ticker_sentiment_score": "0.237372", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.589799", "ticker_sentiment_score": "0.210343", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "iShares Global Healthcare ETF (IXJ) Stock Price, Holdings, Dividend Yield", "url": "https://www.gurufocus.com/etf/IXJ/summary", "time_published": "20230403T040332", "authors": ["NULL"], "summary": "This article provides a comprehensive overview of the iShares Global Healthcare ETF (IXJ), detailing its stock price, holdings, dividend yield, and key statistics. As of September 30, 2025, IXJ holds 114 stocks with a total portfolio value of $3.85 billion, featuring top holdings like Eli Lilly and Co, Johnson & Johnson, and AbbVie Inc. The ETF's current PE Ratio is 26.75 and its dividend yield is 1.43%.", "banner_image": "NULL", "source": "GuruFocus", "category_within_source": "General", "source_domain": "GuruFocus", "topics": [{"topic": "financial_markets", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.915709"}], "overall_sentiment_score": 0.243542, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IXJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.123215", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.801962", "ticker_sentiment_score": "0.304916", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.748140", "ticker_sentiment_score": "0.330249", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.616197", "ticker_sentiment_score": "0.320097", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.629151", "ticker_sentiment_score": "0.232967", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "India rejects Johnson & Johnson\u2019s attempt to extend monopoly on lifesaving TB drug", "url": "https://www.eatg.org/hiv-news/india-rejects-johnson-johnsons-attempt-to-extend-monopoly-on-lifesaving-tb-drug/", "time_published": "20230328T145943", "authors": [], "summary": "India's Patent Office has rejected Johnson & Johnson's attempt to extend its monopoly on the vital tuberculosis (TB) drug bedaquiline through a secondary patent. This decision is expected to pave the way for generic manufacturing, potentially reducing drug prices by 80% and increasing access for patients, particularly in low- and middle-income nations. The ruling is a significant victory for TB-affected communities and advocates against pharmaceutical \"evergreening\" tactics that restrict access to life-saving medications.", "banner_image": "https://www.eatg.org/wp-content/uploads/2025/06/wbst-hiv-and-co-infections-eatg-2-sq-900x500.png.webp", "source": "European AIDS Treatment Group", "category_within_source": "General", "source_domain": "European AIDS Treatment Group", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.721274"}], "overall_sentiment_score": -0.467631, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.476527", "ticker_sentiment_label": "Bearish"}]}, {"title": "Amgen-Sanofi patent case divides makers of antibody drugs", "url": "https://www.reuters.com/legal/amgen-sanofi-patent-case-divides-makers-antibody-drugs-2023-03-27/", "time_published": "20230327T231600", "authors": ["Patrick Wingrove"], "summary": "A U.S. Supreme Court case involving Amgen's cholesterol drug Repatha and Sanofi/Regeneron's Praluent is dividing antibody drugmakers. The ruling will determine how much information companies must disclose in patents and could reshape U.S. patent law, impacting competition in the $181 billion monoclonal antibodies market. Companies on each side are advocating for either broad or narrow patent protection, with significant implications for future drug development and market exclusivity.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.945713"}, {"topic": "finance", "relevance_score": "0.744903"}], "overall_sentiment_score": -0.106923, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.133612", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.848888", "ticker_sentiment_score": "-0.111391", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.705389", "ticker_sentiment_score": "-0.124432", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.639509", "ticker_sentiment_score": "-0.129641", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.640234", "ticker_sentiment_score": "-0.107175", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intuitive\u2019s ecosystem means it will take J&J, Medtronic years to win surgical robot market share: analysts", "url": "https://www.medtechdive.com/news/intuitive-robotic-surgery-market-share-ISRG-MDT-JNJ-/645907/", "time_published": "20230324T145557", "authors": ["Nick Paul Taylor"], "summary": "Analysts from William Blair suggest that Intuitive Surgical's well-established ecosystem of hardware, software, training, and support will allow it to maintain its leading position in the surgical robot market for years. Despite growing competition from companies like Medtronic and Johnson & Johnson, these rivals will struggle to gain significant market share without first replicating Intuitive's comprehensive system. The analysts also noted that increased regulatory scrutiny from the FDA acts as another \"competitive moat\" for Intuitive, as new entrants will face higher barriers to approval.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.934047"}], "overall_sentiment_score": -0.05233, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.419911", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.865687", "ticker_sentiment_score": "-0.280780", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MDT", "relevance_score": "0.886867", "ticker_sentiment_score": "-0.230944", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Rapport Therapeutics Launches with $100 Million to Transform the Treatment of Neurological Disease through the Discovery and Development of Precision Therapies", "url": "https://www.businesswire.com/news/home/20230307005230/en/Rapport-Therapeutics-Launches-with-%24100-Million-to-Transform-the-Treatment-of-Neurological-Disease-through-the-Discovery-and-Development-of-Precision-Therapies", "time_published": "20230307T153026", "authors": [], "summary": "Rapport Therapeutics has launched with $100 million in Series A financing to develop precision medicines for neurological disorders. The company's novel platform targets specific neural circuits using receptor-associated proteins, with its lead asset already in Phase 1 for seizure disorders. Abraham Ceesay has been appointed as CEO to lead the company's mission to transform neuroscience treatment.", "banner_image": null, "source": "Business Wire", "category_within_source": "General", "source_domain": "Business Wire", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.241105, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RAPP", "relevance_score": "0.310676", "ticker_sentiment_score": "0.022568", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.727569", "ticker_sentiment_score": "0.404585", "ticker_sentiment_label": "Bullish"}]}, {"title": "Rapport Therapeutics Snags $100M for Precision Approach to Neurological Diseases", "url": "https://www.biospace.com/rapport-therapeutics-launches-with-100m-for-novel-neurological-approach", "time_published": "20230307T153026", "authors": ["Lisa Munger"], "summary": "Rapport Therapeutics, a clinical-stage biotech focused on precision medicines for neurological disorders, has raised $100 million in Series A financing from Third Rock Ventures, ARCH Venture Partners, and Johnson & Johnson Innovation. The company's platform uses small-molecule drugs to target receptor-associated proteins (RAPs) in specific neuroanatomical regions, aiming for higher efficacy and better-tolerated treatments. Rapport's lead program is currently in Phase I for drug-resistant seizure disorders, with CEO Abe Ceesay emphasizing the platform's potential to address unmet needs with highly specific therapies.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "0.920723"}, {"topic": "finance", "relevance_score": "0.714746"}], "overall_sentiment_score": 0.192344, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RAPP", "relevance_score": "0.323587", "ticker_sentiment_score": "0.037147", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.713268", "ticker_sentiment_score": "0.315527", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J-backed startup launches with $100M to build better brain drugs", "url": "https://www.biopharmadive.com/news/rapport-therapeutics-launch-series-a-johnson-johnson/644298/", "time_published": "20230307T153026", "authors": ["Jacob Bell"], "summary": "Rapport Therapeutics, a neuroscience-focused biotech, has launched with $100 million in Series A funding from venture capital firms and Johnson & Johnson's innovation arm. The company aims to develop more precise treatments for neurological disorders by targeting receptor-associated proteins (RAPs) that are localized to specific brain regions. Its most advanced program is already in early human testing for drug-resistant seizure disorders", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.708749"}], "overall_sentiment_score": 0.182205, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RAPP", "relevance_score": "0.347881", "ticker_sentiment_score": "0.019228", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.810369", "ticker_sentiment_score": "0.319136", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies", "url": "https://www.globenewswire.com/news-release/2023/03/01/2618358/0/en/CARGO-Therapeutics-Raises-200-Million-in-Oversubscribed-Upsized-Series-A-Financing-to-Advance-its-Pipeline-of-Next-Generation-CAR-T-Cell-Therapies.html", "time_published": "20230301T093000", "authors": [], "summary": "CARGO Therapeutics has successfully raised $200 million in an oversubscribed and upsized Series A financing round. This funding will be used to advance their pipeline of next-generation CAR T-cell therapies, including their lead candidate CRG-022 (CD22 CAR) for large B-cell lymphoma (LBCL) patients who have relapsed after CD19 CAR T-cell therapy. The company plans to commence a pivotal Phase 2 trial for CRG-022 in mid-2023, building on promising initial Phase 1 results and a Breakthrough Therapy Designation from the FDA.", "banner_image": null, "source": "GlobeNewswire", "category_within_source": "General", "source_domain": "GlobeNewswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.939289"}], "overall_sentiment_score": 0.150954, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CRGX", "relevance_score": "0.308053", "ticker_sentiment_score": "0.022938", "ticker_sentiment_label": "Neutral"}, {"ticker": "TROW", "relevance_score": "0.603283", "ticker_sentiment_score": "0.257177", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.564254", "ticker_sentiment_score": "0.142252", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.583063", "ticker_sentiment_score": "0.134806", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.598657", "ticker_sentiment_score": "0.111845", "ticker_sentiment_label": "Neutral"}]}, {"title": "Schwab U.S. Large-Cap Value ETF Holdings List (NYSEARCA:SCHV)", "url": "https://www.marketbeat.com/stocks/NYSEARCA/SCHV/holdings/", "time_published": "20230228T130905", "authors": [], "summary": "This article provides a list of the top 25 holdings of the Schwab U.S. Large-Cap Value ETF (NYSEARCA: SCHV). The ETF's holdings include major companies like Berkshire Hathaway, JPMorgan Chase & Co., and Exxon Mobil, detailing their current price, weight within the ETF, and shares held. The data reflects the closing prices as of January 2, 2026.", "banner_image": null, "source": "MarketBeat", "category_within_source": "General", "source_domain": "MarketBeat", "topics": [{"topic": "financial_markets", "relevance_score": "0.912486"}, {"topic": "finance", "relevance_score": "0.702625"}, {"topic": "economy_macro", "relevance_score": "0.631397"}], "overall_sentiment_score": 0.148272, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SCHV", "relevance_score": "1.000000", "ticker_sentiment_score": "0.128433", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.633034", "ticker_sentiment_score": "0.200754", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.642119", "ticker_sentiment_score": "0.246651", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.610143", "ticker_sentiment_score": "0.063534", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alcon and AMO reach global settlement over cataract surgery equipment", "url": "https://www.juve-patent.com/cases/alcon-and-amo-reach-global-settlement-over-cataract-surgery-equipment/", "time_published": "20230222T000000", "authors": ["Amy Sandys"], "summary": "Alcon and Johnson & Johnson subsidiary AMO have reached a global settlement in their patent dispute over ophthalmic surgery technology for cataract treatment, valued at nearly $200 million. The agreement ends litigation in Germany, the US, and the Netherlands, following an earlier settlement in the UK in mid-2022. The settlement includes a one-time payment from Alcon to AMO and cross-licences of certain intellectual property.", "banner_image": null, "source": "JUVE Patent", "category_within_source": "General", "source_domain": "JUVE Patent", "topics": [{"topic": "life_sciences", "relevance_score": "0.901475"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.815050"}], "overall_sentiment_score": 0.08664, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.310180", "ticker_sentiment_score": "0.020574", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.114582", "ticker_sentiment_label": "Neutral"}]}, {"title": "Arrowhead Eager To Take On \u2018Straightforward\u2019 NASH Approach Abandoned By J&J", "url": "https://insights.citeline.com/SC147917/Arrowhead-Eager-To-Take-On-Straightforward-NASH-Approach-Abandoned-By-JJ/", "time_published": "20230215T000000", "authors": ["Joseph Haas"], "summary": "Arrowhead Pharmaceuticals is taking over a NASH (Non-alcoholic steatohepatitis) candidate previously licensed to Johnson & Johnson, following J&J's abandonment of the program. This move positions Arrowhead to pursue an RNAi-based treatment for NASH, a liver disease. The article highlights Arrowhead's continued interest in this \"straightforward\" approach for a significant medical need.", "banner_image": null, "source": "Citeline News & Insights", "category_within_source": "General", "source_domain": "Citeline News & Insights", "topics": [{"topic": "life_sciences", "relevance_score": "0.904944"}], "overall_sentiment_score": 0.272448, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARWR", "relevance_score": "1.000000", "ticker_sentiment_score": "0.429394", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.936109", "ticker_sentiment_score": "0.142392", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alcon pays $199M to settle femtosecond laser cataract surgery claims", "url": "https://optics.org/news/14/2/12", "time_published": "20230214T000000", "authors": [], "summary": "Alcon has agreed to pay Johnson & Johnson (J&J) $199 million to resolve legal disputes regarding the use of femtosecond lasers in cataract surgery. The settlement includes a cross-licensing deal for intellectual property related to their ultrafast laser technologies, which both companies acquired through significant buyouts of other firms. Despite the widespread use of femtosecond laser-assisted cataract surgery (FLACS), reports on its cost-effectiveness compared to traditional methods are mixed, though it may offer benefits in specific patient cases.", "banner_image": null, "source": "Optics.org", "category_within_source": "General", "source_domain": "Optics.org", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.933546"}, {"topic": "life_sciences", "relevance_score": "0.843051"}, {"topic": "finance", "relevance_score": "0.641502"}], "overall_sentiment_score": 0.090653, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.336467", "ticker_sentiment_score": "0.023062", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.821897", "ticker_sentiment_score": "0.117167", "ticker_sentiment_label": "Neutral"}]}, {"title": "Distinguished Alum, Scientist, and CEO Thomas Butler", "url": "https://today.csuchico.edu/distinguished-alum-thomas-butler/", "time_published": "20230210T000000", "authors": ["Luke Reid"], "summary": "Thomas Butler, a distinguished alum of Chico State and now CEO of Biomea Fusion, Inc., discusses his career path from organic chemistry to leading a biopharmaceutical company. He highlights the impact of his foundational experiences at Chico State, especially one-on-one professor interactions and the value of hard work, on his journey to developing treatments for cancer and metabolic diseases. Butler emphasizes the importance of passion, inclusive leadership, and a service-oriented mindset in his work.", "banner_image": null, "source": "Chico State Today", "category_within_source": "General", "source_domain": "Chico State Today", "topics": [{"topic": "life_sciences", "relevance_score": "0.908195"}], "overall_sentiment_score": 0.520317, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "BMEA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.855791", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.729486", "ticker_sentiment_score": "0.421819", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.611320", "ticker_sentiment_score": "0.330645", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aligos' hep B functional cure dream fizzles out as cash crunch and layoffs force focus on NASH, COVID-19", "url": "https://www.fiercebiotech.com/biotech/aligos-hep-b-functional-cure-dream-fizzles-out-cash-crunch-and-layoffs-force-focus-nash", "time_published": "20230209T073000", "authors": ["Nick Paul Taylor"], "summary": "Aligos Therapeutics is significantly scaling back its hepatitis B programs due to a cash crunch, deprioritizing its two remaining assets and laying off staff. The company will now focus its resources on its nonalcoholic steatohepatitis (NASH) and COVID-19 drug candidates, aiming to extend its cash runway to the end of 2024. These strategic shifts come as Aligos faces a legal battle with Johnson & Johnson regarding intellectual property.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "0.949798"}], "overall_sentiment_score": -0.169096, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "ALGS", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.416439", "ticker_sentiment_label": "Bearish"}, {"ticker": "MRK", "relevance_score": "0.601504", "ticker_sentiment_score": "0.136100", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.628146", "ticker_sentiment_score": "-0.145875", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J, Medtronic, Boston Scientific gird for battle over US cardiac ablation market with new trials", "url": "https://www.medtechdive.com/news/JNJ-MDT-BSX-biosense-webster-afib-ablation-studies/642104/", "time_published": "20230208T000000", "authors": ["Elise Reuter"], "summary": "Johnson & Johnson, Medtronic, and Boston Scientific are competing to gain market share in the U.S. cardiac ablation market with pulsed-field ablation (PFA) devices, which they claim are safer and more effective for treating atrial fibrillation. While these devices are approved in Europe, they are awaiting FDA clearance in the U.S., with each company conducting clinical trials and reporting promising early results. Analysts expect PFA technology to disrupt the electrophysiology market, potentially taking share from existing thermal ablation methods.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.945149"}, {"topic": "earnings", "relevance_score": "0.730194"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.638418"}], "overall_sentiment_score": 0.339747, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.433543", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.935399", "ticker_sentiment_score": "0.301397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.810446", "ticker_sentiment_score": "0.327793", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EW", "relevance_score": "0.586996", "ticker_sentiment_score": "0.279066", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Drug wholesaler AmerisourceBergen to change name amid expansion plans", "url": "https://www.phillyvoice.com/amerisourcebergen-name-change-cencora-conshohocken-drug-shipping-opioids/", "time_published": "20230124T000000", "authors": ["Michael Tanenbaum"], "summary": "AmerisourceBergen, a global drug shipping company based in Conshohocken, is changing its name to Cencora to better reflect its expanded global reach and identity as a healthcare company. This rebranding comes as the company continues to grow, having reported $239 billion in revenue last fiscal year and recently acquiring Europe-based Walgreens Boots Alliance Inc. for $6.3 billion, despite facing scrutiny and legal actions related to its opioid distribution practices. The new name is expected to be in use by the second half of 2023.", "banner_image": null, "source": "PhillyVoice", "category_within_source": "General", "source_domain": "PhillyVoice", "topics": [{"topic": "life_sciences", "relevance_score": "0.913668"}, {"topic": "retail_wholesale", "relevance_score": "0.806749"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.709907"}], "overall_sentiment_score": 0.045891, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COR", "relevance_score": "1.000000", "ticker_sentiment_score": "0.002675", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.629470", "ticker_sentiment_score": "0.001282", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.638497", "ticker_sentiment_score": "0.015101", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.607649", "ticker_sentiment_score": "0.046880", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.625663", "ticker_sentiment_score": "0.020998", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biosimilar advances for Alvotech-Teva and setback for Biocon Biologics", "url": "https://gabionline.net/biosimilars/news/biosimilar-advances-for-alvotech-teva-and-setback-for-biocon-biologics", "time_published": "20230120T000000", "authors": [], "summary": "Alvotech and Teva Pharmaceuticals announced that the FDA accepted for review their Biologics License Application (BLA) for AVT04, a proposed biosimilar to Stelara (ustekinumab), indicating positive progress. Meanwhile, Biocon Biologics received a complete response letter (CRL) from the FDA for its insulin aspart biosimilar application, citing additional data requirements and pre-approval inspection issues. This article highlights contrasting developments in the biosimilar landscape for these companies.", "banner_image": null, "source": "Generics and Biosimilars Initiative", "category_within_source": "General", "source_domain": "Generics and Biosimilars Initiative", "topics": [{"topic": "life_sciences", "relevance_score": "0.949105"}], "overall_sentiment_score": 0.059043, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALVO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.429342", "ticker_sentiment_label": "Bullish"}, {"ticker": "VTRS", "relevance_score": "0.808165", "ticker_sentiment_score": "-0.404440", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.632307", "ticker_sentiment_score": "0.109932", "ticker_sentiment_label": "Neutral"}]}, {"title": "Keep a 3D Printing Tech ETF Like PRNT on Your Radar", "url": "https://www.etftrends.com/disruptive-technology-channel/keep-a-3d-printing-tech-etf-like-prnt-on-your-radar/", "time_published": "20230110T045105", "authors": ["Nick Peters-Golden"], "summary": "This article highlights the investment potential of 3D printing technology, accessible through ETFs like the 3D Printing ETF (PRNT). It emphasizes the broad applications of 3D printing, from medicine to manufacturing, and notes PRNT's strong performance against ETF Database Category Averages. The piece suggests PRNT as a worthwhile consideration for investors seeking tech exposure in 2023.", "banner_image": "https://www.etftrends.com/wp-content/uploads/2025/09/Disruptive_Tech_Robo_masthead_foreground_1600x121@2x.png", "source": "ETF Trends", "category_within_source": "General", "source_domain": "ETF Trends", "topics": [{"topic": "technology", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.820658"}, {"topic": "manufacturing", "relevance_score": "0.744528"}, {"topic": "life_sciences", "relevance_score": "0.635240"}], "overall_sentiment_score": 0.267518, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PRNT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.426035", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.615320", "ticker_sentiment_score": "0.128584", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bristol Myers Squibb, Pfizer turned away from SCOTUS in high-profile cases", "url": "https://www.fiercepharma.com/pharma/scotus-denies-bms-final-bid-rehear-appeal-against-gilead", "time_published": "20230109T121200", "authors": ["Kevin Dunleavy"], "summary": "Bristol Myers Squibb and Pfizer both lost their high-profile cases at the U.S. Supreme Court. BMS was denied a rehearing in its patent infringement case against Gilead Sciences for Yescarta, reinforcing an earlier decision against it. Pfizer's attempt to have its program to help Medicare patients with out-of-pocket costs for its tafamidis drugs reviewed was also rejected by the Supreme Court, as it was deemed to violate federal anti-kickback laws.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.920548"}, {"topic": "finance", "relevance_score": "0.641542"}], "overall_sentiment_score": -0.125345, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.913465", "ticker_sentiment_score": "0.329380", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.830174", "ticker_sentiment_score": "-0.448850", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.724445", "ticker_sentiment_score": "-0.304161", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.636984", "ticker_sentiment_score": "-0.111235", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fate, two other cell therapy biotechs lay off staff, restructure research", "url": "https://www.biopharmadive.com/news/fate-century-tcr2-layoffs-cell-therapy-restructuring/639810/", "time_published": "20230106T143559", "authors": ["Christopher Newman"], "summary": "Three cell therapy biotechnology companies, Fate Therapeutics, Century Therapeutics, and TCR2 Therapeutics, are implementing significant staff layoffs and restructuring research efforts. These changes are indicative of a more challenging and prolonged development path for next-generation cancer cell therapies than initially anticipated by the companies and their investors. A key factor for Fate was the termination of a partnership with Johnson & Johnson, leading to a major workforce reduction and the discontinuation of several clinical-stage programs.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.908652"}], "overall_sentiment_score": -0.218013, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "FATE", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.414307", "ticker_sentiment_label": "Bearish"}, {"ticker": "BMY", "relevance_score": "0.711215", "ticker_sentiment_score": "-0.148597", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.736522", "ticker_sentiment_score": "-0.133377", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.626476", "ticker_sentiment_score": "-0.120875", "ticker_sentiment_label": "Neutral"}]}, {"title": "GE HealthCare begins trading as spin-off heralds shift to corporate streamlining", "url": "https://finance.yahoo.com/news/ge-health-care-begins-trading-as-spin-off-heralds-shift-to-corporate-streamlining-194525168.html", "time_published": "20230104T144509", "authors": ["Mike Juang"], "summary": "GE HealthCare has begun trading as an independent company under the ticker GEHC, completing its spin-off from General Electric. This move is part of a broader corporate trend where large conglomerates are streamlining by separating business units to focus on core operations and improve capital allocation. GE HealthCare, with $18 billion in annual revenue and a $26 billion valuation, aims to invest in R&D to leverage medical data for new insights and treatments.", "banner_image": null, "source": "Yahoo Finance", "category_within_source": "General", "source_domain": "Yahoo Finance", "topics": [{"topic": "ipo", "relevance_score": "0.923639"}, {"topic": "life_sciences", "relevance_score": "0.941092"}, {"topic": "financial_markets", "relevance_score": "0.822542"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.737671"}, {"topic": "manufacturing", "relevance_score": "0.646790"}], "overall_sentiment_score": 0.328402, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GEHC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.432483", "ticker_sentiment_label": "Bullish"}, {"ticker": "GE", "relevance_score": "0.946810", "ticker_sentiment_score": "0.328371", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.714415", "ticker_sentiment_score": "0.337094", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.616564", "ticker_sentiment_score": "0.331414", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson, Drug Distributors Agree to Opioid Settlement With States - WSJ", "url": "https://www.wsj.com/health/pharma/amerisourcebergen-cardinal-health-mckesson-agree-to-opioid-settlement-with-46-states-11645792157?gaa_at=eafs&gaa_n=AWEtsqcWfja-c0zlhFC7AR0w6VwSLHpn4aM0QEFt5daUgMviZdLb9-5zEHIr&gaa_ts=690787f6&gaa_sig=xd7QDm1TtvQ0zoEujrEMRtYFDbcz0b3lGCPmGXMSlEtI1xi-yObYXy8HwtdSd0gikeuB6eQFG45jCM2nDPyD_A%3D%3D", "time_published": "20221231T235959", "authors": ["Kris Maher and Will Feuer"], "summary": "Johnson & Johnson and three major drug distributors have finalized a landmark opioid settlement with a majority of U.S. states, aimed at resolving thousands of lawsuits related to the opioid epidemic. The drug distributors \u2014 AmerisourceBergen Corp., Cardinal Health Inc., and McKesson Corp. \u2014 will pay a total of $19.5 billion over 18 years, while Johnson & Johnson will contribute $5 billion to 45 states. The combined proceeds, totaling roughly $25 billion, will be used by state and local governments for healthcare and drug-treatment programs.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.710263"}], "overall_sentiment_score": 0.153145, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "0.956084", "ticker_sentiment_score": "-0.349896", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MCK", "relevance_score": "0.941769", "ticker_sentiment_score": "0.303335", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.911533", "ticker_sentiment_score": "0.331720", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COR", "relevance_score": "0.742445", "ticker_sentiment_score": "0.298218", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Top 3 Government Contracts Won by Merck & Co. Inc", "url": "https://www.executivegov.com/articles/top-3-government-contracts-won-by-merck-co-inc", "time_published": "20221223T174604", "authors": ["Dawn Pamulaya"], "summary": "Merck & Co. Inc. secured several significant government contracts, primarily related to the COVID-19 pandemic. These include a $1.2 billion contract for 1.7 million courses of the COVID-19 drug Molnupiravir and a subsequent $1 billion option for an additional 1.4 million courses. Additionally, Merck received a $136.7 million contract to build a new lateral flow membrane production facility in Germany to enhance pandemic preparedness.", "banner_image": null, "source": "ExecutiveGov", "category_within_source": "General", "source_domain": "ExecutiveGov", "topics": [{"topic": "life_sciences", "relevance_score": "0.946284"}, {"topic": "economy_fiscal", "relevance_score": "0.806136"}, {"topic": "manufacturing", "relevance_score": "0.646634"}], "overall_sentiment_score": 0.234531, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.454078", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.593134", "ticker_sentiment_score": "0.124485", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.590240", "ticker_sentiment_score": "0.103790", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson completes $16.6B Abiomed acquisition", "url": "https://www.massdevice.com/johnson-johnson-completes-16-6b-abiomed-acquisition/", "time_published": "20221222T171641", "authors": ["Sean Whooley"], "summary": "Johnson & Johnson announced the completion of its $16.6 billion acquisition of Abiomed, with Abiomed operating as a standalone business within J&J's MedTech segment. The acquisition aims to expand J&J's presence in high-growth cardiovascular markets, adding heart recovery solutions to its portfolio. The deal involved an upfront payment of $380 per share in cash and a contingent value right for Abiomed shareholders.", "banner_image": null, "source": "MassDevice", "category_within_source": "General", "source_domain": "MassDevice", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.919925"}], "overall_sentiment_score": 0.403996, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.419752", "ticker_sentiment_label": "Bullish"}]}, {"title": "A Deep Dive Into Johnson & Johnson\u2019s Asbestos and Talc Controversy", "url": "https://www.mesotheliomaguide.com/community/johnson-johnson-asbestos-in-baby-powder-summary/", "time_published": "20221220T171642", "authors": ["Camryn Keeble"], "summary": "This article details the decades-long controversy surrounding Johnson & Johnson's talcum powder products, specifically the presence of asbestos. It highlights internal reports, lawsuits, and verdicts against J&J, including claims of unethical testing involving prisoners and alleged cover-ups regarding asbestos contamination. The piece also covers the company's attempts to use bankruptcy filings to avoid liabilities and its eventual decision to cease global sales of talc-based baby powder.", "banner_image": null, "source": "Mesothelioma Guide", "category_within_source": "General", "source_domain": "Mesothelioma Guide", "topics": [{"topic": "life_sciences", "relevance_score": "0.933316"}, {"topic": "finance", "relevance_score": "0.727156"}], "overall_sentiment_score": -0.643354, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.642784", "ticker_sentiment_label": "Bearish"}]}, {"title": "Staar Surgical CEO Caren Mason retires, replacement named", "url": "https://www.massdevice.com/staar-surgical-ceo-caren-mason-retires/", "time_published": "20221219T184621", "authors": ["Sean Whooley"], "summary": "Staar Surgical announced that President and CEO Caren Mason will retire at the end of 2022 after more than seven years, during which she oversaw significant growth and shareholder value increase. Thomas G. Frinzi, a veteran of the ophthalmic industry and current board chair, will succeed her on January 1, 2023. The company also provided its Q4 revenue projection, which analysts viewed positively despite a dip in STAA shares following the announcement.", "banner_image": null, "source": "MassDevice", "category_within_source": "General", "source_domain": "MassDevice", "topics": [{"topic": "earnings", "relevance_score": "0.812011"}, {"topic": "life_sciences", "relevance_score": "0.934841"}], "overall_sentiment_score": -0.01576, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "STAA", "relevance_score": "0.979883", "ticker_sentiment_score": "-0.191225", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.607028", "ticker_sentiment_score": "0.126371", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.574688", "ticker_sentiment_score": "0.090983", "ticker_sentiment_label": "Neutral"}]}, {"title": "Story from Pacira BioScience: Local surgeon enhances mastectomy patients\u2019 recovery with non-opioid options", "url": "https://www.pnj.com/story/sponsor-story/pacira-biosciences/2022/12/19/local-surgeon-enhances-mastectomy-patients-recovery-with-non-opioid-options/69734241007/", "time_published": "20221219T180632", "authors": [], "summary": "This article highlights how Dr. Quintessa Miller in Destin, Florida, is improving mastectomy patients' recovery by using non-opioid pain management options. She incorporates EXPAREL into her Enhanced Recovery After Surgery (ERAS) protocols, significantly reducing the need for opioids post-operatively. The article emphasizes the importance of non-opioid options in mitigating the risks associated with the opioid epidemic while enhancing patient recovery.", "banner_image": null, "source": "Pensacola News Journal", "category_within_source": "General", "source_domain": "Pensacola News Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.937475"}], "overall_sentiment_score": 0.292168, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PCRX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.432484", "ticker_sentiment_label": "Bullish"}, {"ticker": "MCK", "relevance_score": "0.635825", "ticker_sentiment_score": "0.282347", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.642444", "ticker_sentiment_score": "0.248129", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.566320", "ticker_sentiment_score": "0.211842", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Zimmer Biomet Holdings Inc. stock outperforms market despite losses on the day", "url": "https://www.marketwatch.com/data-news/zimmer-biomet-holdings-inc-stock-outperforms-market-despite-losses-on-the-day-01671489290-7974522ce951?gaa_at=eafs&gaa_n=AWEtsqf1Dqhx-zaPwldEV6G8Ftkdl0tHJGWt6Y05IO95thazSsowb8UXvWO_&gaa_ts=6907b37b&gaa_sig=0szrWy0PBPfNgMqHOxd9OdanL7sW-fl5BFJG1GuzfCcxbsTjaHtPzzDWauka-sMO4P61q2GPYuI473gsVfwJvA%3D%3D", "time_published": "20221219T173400", "authors": ["MarketWatch Automation"], "summary": "Zimmer Biomet Holdings Inc. stock (ZBH) fell 0.49% to $124.96 on Monday, experiencing its fourth consecutive day of losses, yet still outperformed the broader market indices like the S&P 500 and Dow Jones Industrial Average. The stock closed $10.09 below its 52-week high but underperformed some competitors, such as Johnson & Johnson, Medtronic PLC, and Stryker Corp., on the same day. Trading volume was below its 50-day average.", "banner_image": "NULL", "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "financial_markets", "relevance_score": "0.904504"}, {"topic": "life_sciences", "relevance_score": "0.710779"}], "overall_sentiment_score": -0.086546, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ZBH", "relevance_score": "0.999794", "ticker_sentiment_score": "-0.213731", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.623162", "ticker_sentiment_score": "0.123806", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.590672", "ticker_sentiment_score": "-0.105552", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson extends tender offer for Abiomed acquisition", "url": "https://www.massdevice.com/johnson-johnson-extends-tender-offer-abiomed-acquisition/", "time_published": "20221214T171642", "authors": ["Sean Whooley"], "summary": "Johnson & Johnson (NYSE:JNJ) announced an extension of its tender offer to acquire Abiomed (Nasdaq:ABMD) for approximately $16.6 billion, pushing the expiration date to December 21, 2022. The deal includes an upfront payment of $380 per share and a contingent value right up to $35 per share based on commercial and clinical milestones. This acquisition aims to bolster J&J's MedTech business and its cardiovascular innovation portfolio.", "banner_image": null, "source": "MassDevice", "category_within_source": "General", "source_domain": "MassDevice", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.943298"}], "overall_sentiment_score": 0.329786, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.344583", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "State Street Health Care Select Sector SPDR ETF (XLV) Stock Price, Holdings, Dividend Yield", "url": "https://www.gurufocus.com/etf/XLV/summary", "time_published": "20221214T051044", "authors": ["NULL"], "summary": "This article provides a detailed overview of the Health Care Select Sector SPDR Fund (XLV), including its current stock price, key statistics, holdings, dividend data, and historical performance. As of Q3 2025, XLV has 60 holdings with a total value of $33.97 billion, with top holdings being Eli Lilly and Co, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Inc, and Abbott Laboratories. The article also provides historical data for Price-to-Earnings, Price-to-Book, and Dividend Yield.", "banner_image": "NULL", "source": "GuruFocus", "category_within_source": "General", "source_domain": "GuruFocus", "topics": [{"topic": "financial_markets", "relevance_score": "0.945137"}, {"topic": "life_sciences", "relevance_score": "0.832342"}, {"topic": "finance", "relevance_score": "0.704583"}], "overall_sentiment_score": 0.126731, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XLV", "relevance_score": "1.000000", "ticker_sentiment_score": "0.121685", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.720791", "ticker_sentiment_score": "0.101722", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.737296", "ticker_sentiment_score": "0.128867", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.728695", "ticker_sentiment_score": "0.122493", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.749157", "ticker_sentiment_score": "0.103754", "ticker_sentiment_label": "Neutral"}]}, {"title": "Edison Electrification Software Health Platform | GE News", "url": "https://www.ge.com/news/taxonomy/term/9093", "time_published": "20221208T164659", "authors": ["Peter C. Beller", "Jodi Helmer"], "summary": "This page compiles articles related to GE HealthCare's Edison Electrification Software Health Platform, highlighting its role in enhancing patient care and data integration. Key themes include GE HealthCare's spin-off from GE, partnerships aimed at improving cardiac care through integrated data, and the broader utility of new digital health platforms for clinicians. The content emphasizes the company's focus on growth and innovation in the healthcare technology sector.", "banner_image": null, "source": "General Electric", "category_within_source": "General", "source_domain": "General Electric", "topics": [{"topic": "life_sciences", "relevance_score": "0.932461"}, {"topic": "technology", "relevance_score": "0.834034"}], "overall_sentiment_score": 0.376304, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GE", "relevance_score": "0.983877", "ticker_sentiment_score": "0.407997", "ticker_sentiment_label": "Bullish"}, {"ticker": "GEHC", "relevance_score": "0.916987", "ticker_sentiment_score": "0.482955", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABT", "relevance_score": "0.612631", "ticker_sentiment_score": "0.344826", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.550790", "ticker_sentiment_score": "0.266515", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.574192", "ticker_sentiment_score": "0.255298", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Palo Alto Networks Unveils Zero Trust Security Solution for Medical Devices", "url": "https://www.msspalert.com/news/palo-alto-networks-unveils-zero-trust-security-solution-for-medical-devices", "time_published": "20221206T180617", "authors": ["Dan Kobialka"], "summary": "Palo Alto Networks has introduced Medical IoT Security, a zero trust solution designed to help healthcare organizations securely deploy and manage connected medical technologies. This solution, available in January 2023, leverages machine learning to offer automated security responses, zero trust policy recommendations, and network segmentation. The news follows Palo Alto Networks' plan to acquire Cider Security for $195 million to enhance its application and supply chain security capabilities.", "banner_image": null, "source": "MSSP Alert", "category_within_source": "General", "source_domain": "MSSP Alert", "topics": [{"topic": "technology", "relevance_score": "0.944537"}, {"topic": "life_sciences", "relevance_score": "0.737057"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.620215"}], "overall_sentiment_score": 0.263772, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PANW", "relevance_score": "0.976849", "ticker_sentiment_score": "0.495753", "ticker_sentiment_label": "Bullish"}, {"ticker": "GEHC", "relevance_score": "0.609769", "ticker_sentiment_score": "0.220387", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.570841", "ticker_sentiment_score": "0.106652", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J\u2019s Duato to replace departing Gorsky as board chair", "url": "https://www.biopharmadive.com/news/johnson-johnson-gorsky-board-chair-duato/637860/", "time_published": "20221202T171643", "authors": ["Delilah Alvarado"], "summary": "Johnson & Johnson CEO Joaquin Duato will assume the role of chairman of the pharmaceutical company's board of directors in January, taking over from Alex Gorsky. Gorsky had served as executive chairman after stepping down as CEO earlier in the year. The leadership change comes amidst broader organizational shifts at J&J, including the planned separation of its consumer health division and the acquisition of Abiomed.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.918608"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.835929"}, {"topic": "finance", "relevance_score": "0.618316"}], "overall_sentiment_score": 0.167268, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.122486", "ticker_sentiment_label": "Neutral"}, {"ticker": "KVUE", "relevance_score": "0.844805", "ticker_sentiment_score": "0.234976", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson CEO Joaquin Duato to take additional role of chairman", "url": "https://www.cnbc.com/2022/12/01/johnson-johnson-ceo-joaquin-duato-to-take-additional-role-of-chairman.html", "time_published": "20221201T040400", "authors": [], "summary": "Johnson & Johnson announced that CEO Joaquin Duato will assume the additional role of chairman, effective January. He will succeed Alex Gorsky, who is stepping down after a transitional period. This appointment comes as J&J undergoes a significant reorganization, including the spin-off of its consumer health business into Kenvue.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.940363"}], "overall_sentiment_score": 0.102213, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.109795", "ticker_sentiment_label": "Neutral"}, {"ticker": "KVUE", "relevance_score": "0.614835", "ticker_sentiment_score": "0.138978", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kimberly-Clark Corp. stock falls Tuesday, still outperforms market", "url": "https://www.marketwatch.com/story/kimberly-clark-corp-stock-falls-tuesday-still-outperforms-market-01669760004-1c8ad3426361?gaa_at=eafs&gaa_n=AWEtsqfaW90lak8AL9K7pjQAxA6WeC1EUx9WQYgPIPkoIbm520jx1NsVirnl&gaa_ts=6907975d&gaa_sig=89mzbyhhf08_956idYtLYKpVzWxjKywRJkjOA8qKbEUFlKid7muDUM1THA3qZvoMBnyDblussCFFenKdhmtykQ%3D%3D", "time_published": "20221129T171300", "authors": ["MarketWatch Automation"], "summary": "Kimberly-Clark Corp. (KMB) stock fell 0.11% on Tuesday, closing at $133.16, marking its second consecutive day of losses. Despite the decline, the stock still outperformed the broader market, with the Dow Jones Industrial Average rising slightly and the S&P 500 Index falling. Kimberly-Clark also outperformed competitors Johnson & Johnson and Procter & Gamble Co., which saw larger percentage drops.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "financial_markets", "relevance_score": "0.929362"}, {"topic": "life_sciences", "relevance_score": "0.639551"}, {"topic": "retail_wholesale", "relevance_score": "0.635233"}], "overall_sentiment_score": -0.153383, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "KMB", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.164997", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.606262", "ticker_sentiment_score": "-0.188584", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PG", "relevance_score": "0.617054", "ticker_sentiment_score": "-0.168872", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Church & Dwight Co. stock rises Wednesday, outperforms market", "url": "https://www.marketwatch.com/story/church-dwight-co-stock-rises-wednesday-outperforms-market-01669239816?gaa_at=eafs&gaa_n=AWEtsqfGv-6yUA1ewN-vaoR-lT0RJxoy-ZBvYSdgbVwfl-c2MkOzQvL9c_kS&gaa_ts=69078847&gaa_sig=yF_tVoHG7958WSE3SR-vHHnKp3AFWy3jINDvOMHWoiqzC7UvnVDKUYTGScgdLuNmaN1dLcn6bNrIv5ynOA3jOA%3D%3D", "time_published": "20221123T164300", "authors": ["MarketWatch Automation"], "summary": "Church & Dwight Co. (CHD) stock increased by 0.61% to $78.57 on Wednesday, outperforming the broader market indexes like the S&P 500 and Dow Jones Industrial Average. This marked the stock's fourth consecutive day of gains, although it remained below its 52-week high. The company's performance was mixed when compared to competitors like Johnson & Johnson, Procter & Gamble Co., and Reckitt Benckiser Group PLC.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "financial_markets", "relevance_score": "0.946871"}, {"topic": "retail_wholesale", "relevance_score": "0.723168"}, {"topic": "life_sciences", "relevance_score": "0.640763"}], "overall_sentiment_score": 0.297674, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHD", "relevance_score": "1.000000", "ticker_sentiment_score": "0.385535", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.693949", "ticker_sentiment_score": "0.243656", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.617904", "ticker_sentiment_score": "0.235868", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pharmacies, drug companies settle lawsuits over U.S. opioid crisis", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pharmacies-drug-companies-settle-lawsuits-over-us-opioid-crisis-2022-11-22/", "time_published": "20221122T172800", "authors": ["Brendan Pierson"], "summary": "Major pharmacy chains like CVS, Walgreens, and Walmart, along with drug distributors and manufacturers, have reached significant settlements in the sprawling U.S. opioid crisis litigation. These agreements, valued in the billions of dollars, aim to resolve claims from state, local, and tribal governments, although some smaller pharmacy operators and individual lawsuits remain ongoing. The article details major companies involved and the status of their settlements, highlighting the substantial financial impact of the crisis.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FVJ47RCNMRZIS5K4W6O3GRLQJQM.JPG?auth=76b4a20b0805c86241a7df38c5324c4fb315264a7873523f53835626a5700201&width=1920&height=1080&smart=true", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "retail_wholesale", "relevance_score": "0.715861"}], "overall_sentiment_score": -0.139803, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.966893", "ticker_sentiment_score": "-0.189828", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WBA", "relevance_score": "0.862054", "ticker_sentiment_score": "-0.220890", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WMT", "relevance_score": "0.819349", "ticker_sentiment_score": "0.078163", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.737359", "ticker_sentiment_score": "-0.243005", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Keurig Dr Pepper Adds Seasoned J&J Executive to Its Board of Directors", "url": "https://dallasinnovates.com/keurig-dr-pepper-adds-seasoned-jj-executive-to-its-board-of-directors/", "time_published": "20221118T172604", "authors": ["Lance Murray"], "summary": "Keurig Dr Pepper announced the election of Oray Boston, a seasoned Johnson & Johnson executive, to its Board of Directors. Boston brings 30 years of leadership experience in operations, sales, and marketing from his tenure at Johnson & Johnson, including his current role as worldwide president of trauma, extremities, craniomaxillofacial, and animal health at DePuy Synthes. KDP Chairman and CEO Bob Gamgort highlighted Boston's extensive experience as a valuable addition to the board.", "banner_image": null, "source": "Dallas Innovates", "category_within_source": "General", "source_domain": "Dallas Innovates", "topics": [{"topic": "life_sciences", "relevance_score": "0.735003"}, {"topic": "retail_wholesale", "relevance_score": "0.608601"}, {"topic": "finance", "relevance_score": "0.716696"}], "overall_sentiment_score": 0.179255, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KDP", "relevance_score": "0.989993", "ticker_sentiment_score": "0.290467", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.740992", "ticker_sentiment_score": "0.105055", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kidney Therapeutics to Halt CKD Progression Make Late-Stage Push Toward NDA", "url": "https://www.biospace.com/kidney-therapeutics-to-halt-disease-progression-make-late-stage-push-toward-nda", "time_published": "20221118T172603", "authors": ["Gail Dutton"], "summary": "Several therapeutics aimed at halting the progression of chronic kidney disease (CKD) are in advanced clinical trials, with potential NDAs as early as 2024. Chinook Therapeutics is advancing atrasentan and BION-1301 for IgA nephropathy, showing significant proteinuria reductions. Boehringer Ingelheim's Jardiance has demonstrated a reduced risk of kidney disease progression and cardiovascular death in CKD patients, while ProKidney's autologous cell therapy, REACT, aims to repair and restore kidney function, with Phase III data expected in 2025.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "0.919224"}], "overall_sentiment_score": 0.21208, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KDNY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.407995", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.739198", "ticker_sentiment_score": "0.212965", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.617545", "ticker_sentiment_score": "0.143190", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.609812", "ticker_sentiment_score": "0.145582", "ticker_sentiment_label": "Neutral"}]}, {"title": "Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial", "url": "https://ascopubs.org/jco/doi/abs/10.1200/JCO.22.00510", "time_published": "20221117T175643", "authors": ["Peter Hillmen", "Barbara Eichhorst", "Jennifer R. Brown", "Nicole Lamanna", "Susan M. O'Brien", "Constantine S. Tam", "Lugui Qiu", "Maciej Kazmierczak", "Keshu Zhou", "Martin \u0160imkovi\u010d", "Ji\u0159\u00ed Mayer", "Amanda Gillespie-Twardy", "Mazyar Shadman", "Alessandra Ferrajoli", "Peter S. Ganly", "Robert Weinkove", "Sebastian Grosicki", "Andrzej Mital", "Tadeusz Robak", "Anders \u00d6sterborg", "Habte A. Yimer", "Tommi Salmi", "Meng Ji", "Jessica Yecies", "Adam Idoine", "Kenneth Wu", "Jane Huang", "Wojciech Jurczak"], "summary": "An interim analysis of the randomized Phase III ALPINE trial compared zanubrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Zanubrutinib demonstrated a significantly higher overall response rate (ORR), improved progression-free survival (PFS), and a lower rate of atrial fibrillation compared to ibrutinib. These results suggest a more favorable efficacy and safety profile for zanubrutinib due to its increased selectivity in BTK inhibition.", "banner_image": null, "source": "ASCO Publications", "category_within_source": "General", "source_domain": "ASCO Publications", "topics": [{"topic": "life_sciences", "relevance_score": "0.902648"}], "overall_sentiment_score": 0.268126, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ONC", "relevance_score": "0.303285", "ticker_sentiment_score": "0.031087", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.749499", "ticker_sentiment_score": "0.428490", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.614510", "ticker_sentiment_score": "0.307903", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.567083", "ticker_sentiment_score": "0.253283", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "[Latest] Global Mosquito Repellent Market Size/Share Worth USD 10.3 Billion by 2030 at a 7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value, Analysis, Outlook)", "url": "https://www.globenewswire.com/news-release/2022/11/17/2558647/0/en/Latest-Global-Mosquito-Repellent-Market-Size-Share-Worth-USD-10-3-Billion-by-2030-at-a-7-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Forecast-Segmentation-Gr.html", "time_published": "20221117T141600", "authors": [], "summary": "The global mosquito repellent market is projected to reach USD 10.3 billion by 2030, growing at a CAGR of 7% from its 2021 valuation of USD 5.1 billion. This growth is driven by increased urbanization, e-commerce adoption, rising awareness of natural products, and outdoor activities. The Asia-Pacific region is expected to dominate the market due to its large population, increasing disposable income, and government initiatives against mosquito-borne diseases.", "banner_image": null, "source": "GlobeNewswire", "category_within_source": "General", "source_domain": "GlobeNewswire", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.885242"}, {"topic": "finance", "relevance_score": "0.770939"}], "overall_sentiment_score": 0.248928, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPB", "relevance_score": "0.928632", "ticker_sentiment_score": "0.339708", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.708392", "ticker_sentiment_score": "0.284228", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.588024", "ticker_sentiment_score": "0.184419", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Walmart to Settle State, Local Opioid Claims for $3.1 Billion", "url": "https://www.investopedia.com/walmart-opioid-settlement-6829203", "time_published": "20221115T191636", "authors": ["Igor Greenwald"], "summary": "Walmart has announced a $3.1 billion settlement with 43 states to resolve claims that its pharmacies contributed to the opioid crisis. This settlement includes the retailer in a larger $54 billion total paid by opioid manufacturers, distributors, and other pharmacy chains like Walgreens and CVS. Despite the settlement, Walmart denies wrongdoing and still faces a federal lawsuit regarding similar claims.", "banner_image": null, "source": "Investopedia", "category_within_source": "General", "source_domain": "Investopedia", "topics": [{"topic": "earnings", "relevance_score": "0.944148"}, {"topic": "life_sciences", "relevance_score": "0.837438"}, {"topic": "retail_wholesale", "relevance_score": "0.824308"}, {"topic": "finance", "relevance_score": "0.712084"}], "overall_sentiment_score": -0.13306, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WMT", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.203188", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WBA", "relevance_score": "0.701205", "ticker_sentiment_score": "-0.224704", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CVS", "relevance_score": "0.733601", "ticker_sentiment_score": "-0.215233", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.603832", "ticker_sentiment_score": "0.135474", "ticker_sentiment_label": "Neutral"}]}, {"title": "Improving access to medicine around the world", "url": "https://www.jnj.com/latest-news/improving-access-to-medicine-around-the-world", "time_published": "20221115T171640", "authors": ["Esther Crain"], "summary": "Johnson & Johnson has secured the #2 spot on the Access to Medicine Index, recognizing its long-standing commitment to making life-saving medicines available and accessible in low- and middle-income nations. The company's efforts include significant investments in addressing diseases like TB, Ebola, and flaviviruses, alongside initiatives to strengthen local health systems and patient support programs. This consistent high ranking underscores J&J's dedication to global health equity and its Credo values.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.947666"}], "overall_sentiment_score": 0.475586, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.491851", "ticker_sentiment_label": "Bullish"}]}, {"title": "16 surgical robotics companies you need to know", "url": "https://www.massdevice.com/16-surgical-robotics-companies-you-need-to-know/", "time_published": "20221114T171600", "authors": ["Chris Newmarker"], "summary": "This article provides an overview of 16 leading companies in the surgical robotics sector, highlighting their key products and recent developments. It details how dominant players like Intuitive Surgical are innovating while others, including Medtronic and Johnson & Johnson, are aggressively competing or advancing their own robotic systems. The piece also covers emerging technologies and strategic moves from smaller companies in this rapidly evolving medtech space.", "banner_image": null, "source": "MassDevice", "category_within_source": "General", "source_domain": "MassDevice", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "technology", "relevance_score": "0.832751"}, {"topic": "earnings", "relevance_score": "0.734507"}, {"topic": "finance", "relevance_score": "0.634473"}], "overall_sentiment_score": 0.168078, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.131061", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.829626", "ticker_sentiment_score": "0.253699", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.789636", "ticker_sentiment_score": "0.010063", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.739589", "ticker_sentiment_score": "0.235507", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZBH", "relevance_score": "0.667401", "ticker_sentiment_score": "0.208607", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson\u2019s big bet on intelligent automation", "url": "https://www.cio.com/article/411327/johnson-johnsons-big-bet-on-intelligent-automation.html", "time_published": "20221111T171640", "authors": ["Thor Olavsrud"], "summary": "Johnson & Johnson has made a significant commitment to intelligent automation (IA), aiming to achieve half a billion dollars in impact by combining robotic process automation (RPA) with machine learning and AI. Led by Ajay Anand and Stephen Sorensen, the company has successfully applied IA across its business, overcoming initial roadblocks by adopting a \"digital-first\" mindset and starting with small, impactful wins. This initiative has not only increased efficiency and effectiveness but also shifted employees to higher-value work.", "banner_image": null, "source": "CIO", "category_within_source": "General", "source_domain": "CIO", "topics": [{"topic": "life_sciences", "relevance_score": "0.903632"}, {"topic": "technology", "relevance_score": "0.811322"}, {"topic": "finance", "relevance_score": "0.645000"}, {"topic": "economy_macro", "relevance_score": "0.608153"}], "overall_sentiment_score": 0.40551, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.412125", "ticker_sentiment_label": "Bullish"}]}, {"title": "Arrowhead Gets $250M in Royalty Deal for Cardio Drug Heading to Phase 3", "url": "https://medcitynews.com/2022/11/arrowhead-gets-250m-in-royalty-deal-for-cardio-drug-heading-to-phase-3/", "time_published": "20221109T131000", "authors": ["Frank Vinluan"], "summary": "Arrowhead Pharmaceuticals sold its royalty rights for olpasiran, a promising heart drug licensed to Amgen, to Royalty Pharma for an upfront payment of $250 million, with potential for an additional $160 million. This deal follows positive Phase 2 data from Amgen for olpasiran, which is now heading into Phase 3 clinical trials. Arrowhead retains eligibility for up to $400 million in milestone payments from its original agreement with Amgen, funding further development of its TRiM platform and pipeline.", "banner_image": null, "source": "MedCity News", "category_within_source": "General", "source_domain": "MedCity News", "topics": [{"topic": "life_sciences", "relevance_score": "0.940605"}, {"topic": "financial_markets", "relevance_score": "0.609526"}], "overall_sentiment_score": 0.252089, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARWR", "relevance_score": "1.000000", "ticker_sentiment_score": "0.440181", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.832626", "ticker_sentiment_score": "0.248526", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.603757", "ticker_sentiment_score": "0.115185", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson looks inward to find new head of medtech innovation and R&D", "url": "https://www.fiercebiotech.com/medtech/johnson-johnson-looks-inward-find-new-head-medtech-innovation-and-rd", "time_published": "20221109T115400", "authors": ["Andrea Park"], "summary": "Johnson & Johnson has appointed Ahmet Tezel, Ph.D., as the new global head of medtech innovation and R&D, replacing the retiring Peter Shen, Ph.D. Tezel, who previously led R&D at Ethicon, has worked closely with Shen since joining J&J in 2020. This internal promotion highlights J&J's strategy to select a successor from within, particularly a mentee who has shadowed the outgoing leader's work.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "0.944869"}], "overall_sentiment_score": 0.257038, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.268319", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Spray Mosquito Repellent Market Share , Size - Forecast 2031", "url": "https://www.alliedmarketresearch.com/spray-mosquito-repellent-market-A16592", "time_published": "20221107T184602", "authors": ["Raju Kale", "Eswara Prasad"], "summary": "The global spray mosquito repellent market was valued at $1,374.0 million in 2021 and is projected to reach $2,581.0 million by 2031, growing at a CAGR of 6.6%. Asia-Pacific currently dominates the market, while plant-based repellents and online sales channels are expected to see the highest growth. Key drivers include rising awareness of mosquito-borne diseases, global warming, and effective marketing strategies, despite challenges like toxic chemicals and counterfeit products.", "banner_image": null, "source": "Allied Market Research", "category_within_source": "General", "source_domain": "Allied Market Research", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.816554"}, {"topic": "life_sciences", "relevance_score": "0.729595"}], "overall_sentiment_score": 0.162839, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPB", "relevance_score": "0.961910", "ticker_sentiment_score": "0.254769", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MMM", "relevance_score": "0.731713", "ticker_sentiment_score": "0.134636", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.746071", "ticker_sentiment_score": "0.131593", "ticker_sentiment_label": "Neutral"}]}, {"title": "West Pharmaceutical Services Inc. stock falls Thursday, underperforms market", "url": "https://www.marketwatch.com/story/west-pharmaceutical-services-inc-stock-falls-thursday-underperforms-market-01667511166-c973b5e82cb7?gaa_at=eafs&gaa_n=AWEtsqcWPsToBr-wkziTGhS6ow7poVerspfrWA3K4iOkIXMw4M6FZbXHVsM9&gaa_ts=6907b133&gaa_sig=YUEsv1BHoQwalmglnlT2nD4hOxJSyw4-BfERxIjuzL7llsaCZmsXY56kuv2IbvQzzFrEHC6p_IRvuOdz9X4dVg%3D%3D", "time_published": "20221103T173200", "authors": ["MarketWatch Automation"], "summary": "West Pharmaceutical Services Inc. (WST) stock fell 4.64% on Thursday, closing at $209.34, and underperformed the broader market, which also saw declines in the S&P 500 and Dow Jones Industrial Average. This marks the third consecutive day of losses for the stock, placing it $265.66 below its 52-week high. The company also underperformed against competitors like Johnson & Johnson, Medtronic PLC, and Stryker Corp., while trading volume significantly exceeded its 50-day average.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "financial_markets", "relevance_score": "0.923586"}, {"topic": "life_sciences", "relevance_score": "0.822211"}], "overall_sentiment_score": -0.201929, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "WST", "relevance_score": "0.961066", "ticker_sentiment_score": "-0.464497", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.637973", "ticker_sentiment_score": "0.233185", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.553366", "ticker_sentiment_score": "-0.254706", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Popular Dry Shampoos Found to Have Cancer-CausinTg Chemical", "url": "https://time.com/6227492/dry-shampoo-benzene-cancer/", "time_published": "20221102T110700", "authors": ["Anna Edney/Bloomberg"], "summary": "An independent study by Valisure found that 70% of 148 batches from 34 brands of spray-on dry shampoo contained high levels of benzene, a known carcinogen. Brands like Not Your Mother's, Batiste, Sun Bum, and John Paul Mitchell Systems were identified, some with significantly higher benzene levels than previously found in other personal-care products. Valisure has filed a petition with the FDA requesting a recall of these products, highlighting concerns about the complexity of the supply chain and the regulation of cosmetics.", "banner_image": null, "source": "Time Magazine", "category_within_source": "General", "source_domain": "Time Magazine", "topics": [{"topic": "life_sciences", "relevance_score": "0.925755"}, {"topic": "retail_wholesale", "relevance_score": "0.801027"}], "overall_sentiment_score": -0.088623, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CHD", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.377584", "ticker_sentiment_label": "Bearish"}, {"ticker": "PG", "relevance_score": "0.726499", "ticker_sentiment_score": "-0.246831", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UNH", "relevance_score": "0.617050", "ticker_sentiment_score": "0.100274", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.611231", "ticker_sentiment_score": "0.119956", "ticker_sentiment_label": "Neutral"}]}, {"title": "CVS, Walmart and Walgreens agree to pay $13.8bn for opioid claims \u2013 sources", "url": "https://www.theguardian.com/us-news/2022/nov/02/opioid-settlement-cvs-walmart-walgreens-138bn", "time_published": "20221102T082000", "authors": ["Reuters"], "summary": "CVS Health, Walgreens Boots Alliance, and Walmart have tentatively agreed to pay approximately $13.8 billion to settle thousands of lawsuits accusing them of mishandling opioid painkillers. This proposed nationwide settlement aims to resolve claims from US state and local governments regarding the opioid crisis. The funds will be used to combat the opioid epidemic, which has caused hundreds of thousands of overdose deaths since 1999.", "banner_image": null, "source": "The Guardian", "category_within_source": "General", "source_domain": "The Guardian", "topics": [{"topic": "life_sciences", "relevance_score": "0.928673"}, {"topic": "retail_wholesale", "relevance_score": "0.803417"}, {"topic": "finance", "relevance_score": "0.630364"}], "overall_sentiment_score": -0.345546, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.391765", "ticker_sentiment_label": "Bearish"}, {"ticker": "WBA", "relevance_score": "0.928875", "ticker_sentiment_score": "-0.336971", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WMT", "relevance_score": "0.927935", "ticker_sentiment_score": "-0.338358", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.640222", "ticker_sentiment_score": "-0.284340", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson to Buy Abiomed for $16.6B", "url": "https://www.mddionline.com/cardiovascular/johnson-johnson-to-buy-abiomed-for-16-6b", "time_published": "20221101T171642", "authors": ["Amanda Pedersen"], "summary": "Johnson & Johnson announced its plan to acquire Abiomed for approximately $16.6 billion, including a premium of 50% to Abiomed's closing stock price on Monday. The deal includes a contingent value right for Abiomed shareholders based on commercial and clinical milestones. Analysts expect Abiomed, a leader in mechanical circulatory support with its Impella heart pumps, to be a strong fit for J&J's growing medtech portfolio.", "banner_image": null, "source": "Medical Device and Diagnostic industry", "category_within_source": "General", "source_domain": "Medical Device and Diagnostic industry", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.929066"}, {"topic": "financial_markets", "relevance_score": "0.711965"}], "overall_sentiment_score": 0.48975, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.958304", "ticker_sentiment_score": "0.474268", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson to Acquire Abiomed", "url": "https://www.dicardiology.com/article/johnson-johnson-acquire-abiomed", "time_published": "20221101T171641", "authors": [], "summary": "Johnson & Johnson has announced a definitive agreement to acquire Abiomed, a leader in heart, lung, and kidney support technologies, for an upfront payment of $380.00 per share in cash, totaling approximately $16.6 billion. The acquisition aims to broaden Johnson & Johnson MedTech's cardiovascular innovation portfolio, particularly in heart failure and recovery, and includes a contingent value right for Abiomed shareholders based on commercial and clinical milestones. The transaction is expected to accelerate Johnson & Johnson's MedTech growth and enhance its position in high-growth segments.", "banner_image": null, "source": "Diagnostic and Interventional Cardiology", "category_within_source": "General", "source_domain": "Diagnostic and Interventional Cardiology", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.935448"}, {"topic": "life_sciences", "relevance_score": "0.801680"}, {"topic": "finance", "relevance_score": "0.637441"}], "overall_sentiment_score": 0.385189, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.404413", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABBV", "relevance_score": "0.630730", "ticker_sentiment_score": "0.321709", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J to buy heart device maker Abiomed for $16.6B", "url": "https://www.biopharmadive.com/news/johnson-johnson-abiomed-medtech-acquire-deal/635462/", "time_published": "20221101T171641", "authors": ["Elise Reuter"], "summary": "Johnson & Johnson announced its agreement to acquire Abiomed, a heart pump manufacturer, for $16.6 billion, marking J&J's largest deal since 2017. The acquisition includes an upfront payment of $380 per share and potential additional payments of up to $35 per share based on commercial and clinical milestones. This strategic move aims to expand J&J's cardiovascular devices business and align with the company's focus on high-growth segments within its pharmaceutical and medical device arms.", "banner_image": "https://cdn.www.biopharmadive.com/images/Mario_Tama_via_Getty_Images.width-1200.jpg", "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.926138"}, {"topic": "earnings", "relevance_score": "0.832060"}, {"topic": "finance", "relevance_score": "0.747430"}], "overall_sentiment_score": 0.128882, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.278419", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.632508", "ticker_sentiment_score": "0.001391", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson will buy medtech maker Abiomed in a $16.6 billion deal", "url": "https://www.fastcompany.com/90804526/jnj-johnson-johnson-abmd-heart-merger/", "time_published": "20221101T171641", "authors": ["Michael Grothaus"], "summary": "Johnson & Johnson announced its acquisition of Abiomed, a medical technology company specializing in cardiovascular health devices, for $16.6 billion. The deal involves J&J paying Abiomed shareholders $380 per share in cash, plus a contingent value right of $35 per share based on revenue milestones and FDA approvals. This acquisition aims to strengthen Johnson & Johnson MedTech\u2019s position as a cardiovascular innovator and is expected to close in Q1 2023.", "banner_image": null, "source": "Fast Company", "category_within_source": "General", "source_domain": "Fast Company", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.924461"}], "overall_sentiment_score": 0.28075, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.989237", "ticker_sentiment_score": "0.282473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson to acquire Abiomed in $16.6B deal", "url": "https://cardiovascularbusiness.com/topics/healthcare-management/healthcare-economics/johnson-johnson-acquire-abiomed-166b-deal", "time_published": "20221101T171641", "authors": ["Michael Walter"], "summary": "Johnson & Johnson has announced a definitive agreement to acquire Abiomed for approximately $16.6 billion. The deal involves an upfront payment of $380 per share, with additional contingent payments up to $35 per share based on specific FDA approvals and recommendation milestones for Abiomed's Impella heart pumps. This acquisition aims to enhance Johnson & Johnson's position in high-growth MedTech segments, particularly in cardiovascular disease.", "banner_image": null, "source": "Cardiovascular Business", "category_within_source": "General", "source_domain": "Cardiovascular Business", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.901267"}], "overall_sentiment_score": 0.02838, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.320006", "ticker_sentiment_score": "0.009264", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences Inc. stock outperforms competitors on strong trading day", "url": "https://www.marketwatch.com/story/gilead-sciences-inc-stock-outperforms-competitors-on-strong-trading-day-01667336168-f64eb4c492b7?gaa_at=eafs&gaa_n=AWEtsqfXR18czVNNFo1YJtbQqsHo7BwPMly0FRm36PIF8Jb5EVMvZQOuwqzi&gaa_ts=69078e4b&gaa_sig=YLbX1zQUqtEjJsKCYTRROVxl6uKJ_uRzC4mKO5M8vjwf-wujxSCZvA3OKXFPXqbhgK-F8THy_q8Nvr44oylEwg%3D%3D", "time_published": "20221101T165600", "authors": ["MarketWatch Automation"], "summary": "Gilead Sciences Inc. (GILD) saw its stock increase by 1.12% to $79.34 on a generally down day for the stock market, outperforming the S&P 500 and Dow Jones Industrial Average. The company's stock closed just shy of its 52-week high and outperformed several competitors including Johnson & Johnson and Merck & Co. Trading volume for Gilead Sciences also exceeded its 50-day average.", "banner_image": "https://images.mktw.net/im-657155?size=1.5000000000000001", "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "financial_markets", "relevance_score": "0.900596"}, {"topic": "life_sciences", "relevance_score": "0.845613"}], "overall_sentiment_score": 0.120465, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "1.000000", "ticker_sentiment_score": "0.465947", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.617585", "ticker_sentiment_score": "0.038161", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.605511", "ticker_sentiment_score": "-0.147162", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.607154", "ticker_sentiment_score": "0.013191", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences Inc. stock outperforms competitors on strong trading day", "url": "https://www.marketwatch.com/story/gilead-sciences-inc-stock-outperforms-competitors-on-strong-trading-day-01667336168-f64eb4c492b7?gaa_at=eafs&gaa_n=AWEtsqdjnG5tn2nfGPnpPmV2oghykLyzVWE0_f-l6ZYlq9V9RwqAcorFHEkr&gaa_ts=69078e48&gaa_sig=WzqLeXrqHvGaru1uYSNW65qOmH714Z1mSOf48favOcf_0Akzfg0Fx9_2O4VKXKMoQm0mC7L177dlQGs63vvkQA%3D%3D", "time_published": "20221101T165600", "authors": ["MarketWatch Automation"], "summary": "Gilead Sciences Inc. stock (GILD) rose 1.12% to $79.34 on a generally down day for the stock market, outperforming the S&P 500 and Dow Jones Industrial Average. The company's stock also outperformed some of its direct competitors like Johnson & Johnson and Merck & Co. Inc., though it closed just shy of its 52-week high. Trading volume for Gilead Sciences Inc. exceeded its 50-day average.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "financial_markets", "relevance_score": "0.908235"}, {"topic": "life_sciences", "relevance_score": "0.816974"}], "overall_sentiment_score": 0.085021, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "1.000000", "ticker_sentiment_score": "0.401483", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.629179", "ticker_sentiment_score": "-0.206946", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRK", "relevance_score": "0.643015", "ticker_sentiment_score": "-0.236360", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABBV", "relevance_score": "0.605900", "ticker_sentiment_score": "0.175504", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences Inc. stock outperforms competitors on strong trading day", "url": "https://www.marketwatch.com/story/gilead-sciences-inc-stock-outperforms-competitors-on-strong-trading-day-01667336168-f64eb4c492b7?gaa_at=eafs&gaa_n=AWEtsqe9s5xMObf-A-9G7zdqAx0rfl9uoyYxfH81h74pGsbzNeXOWyg83tIZ&gaa_ts=69078e3a&gaa_sig=HIDdyjvoklyMHd72xo9cqZCfo0xMSkFaRXFuo1ozbkwTN5VeCjTPZQAhvngjj2U-7xOSKxR52ekvKKCyvC21fA%3D%3D", "time_published": "20221101T165600", "authors": ["MarketWatch Automation"], "summary": "Gilead Sciences Inc. (GILD) stock rose 1.12% on Tuesday, closing at $79.34, despite a general downturn in the stock market. The company's stock outperformed competitors like Johnson & Johnson and Merck & Co. Inc., though it closed slightly below its 52-week high. Trading volume for Gilead Sciences Inc. also exceeded its 50-day average.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "financial_markets", "relevance_score": "0.911923"}, {"topic": "life_sciences", "relevance_score": "0.824160"}], "overall_sentiment_score": 0.066853, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "1.000000", "ticker_sentiment_score": "0.339161", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.605845", "ticker_sentiment_score": "-0.101516", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.623386", "ticker_sentiment_score": "-0.246519", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABBV", "relevance_score": "0.612582", "ticker_sentiment_score": "0.137456", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson doles out $16.6B to snatch up miniaturized heart pump maker Abiomed", "url": "https://www.fiercebiotech.com/medtech/johnson-johnson-snatches-miniaturized-heart-pump-maker-abiomed-166b", "time_published": "20221101T113300", "authors": ["By Conor Hale"], "summary": "Johnson & Johnson is acquiring Abiomed, a maker of minimally invasive heart pumps, for $16.6 billion. The deal includes an upfront cash payment of $380 per share with additional potential payments based on Abiomed's clinical and commercial milestones. This acquisition is J&J's largest M&A since 2017 and aims to integrate Abiomed into J&J MedTech as a standalone business, focusing on heart failure and recovery.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.919505"}, {"topic": "earnings", "relevance_score": "0.706524"}], "overall_sentiment_score": 0.024064, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.312953", "ticker_sentiment_score": "0.023904", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson to buy Danvers-based Abiomed for $16.6 billion", "url": "https://www.cbsnews.com/boston/news/johnson-johnson-buying-abiomed-16-6-billion-dollars-danvers-massachusetts/", "time_published": "20221101T091400", "authors": ["TOM MURPHY"], "summary": "Johnson & Johnson announced its plan to acquire Danvers-based cardiovascular technology company Abiomed for $16.6 billion, strengthening its medical device division. The deal involves J&J paying $380 per Abiomed share, with an additional $35 per share contingent on commercial and clinical milestones, and is expected to close early next year. This acquisition aligns with J&J's strategy to focus on medical devices and pharmaceuticals after spinning off its consumer health division.", "banner_image": null, "source": "CBS News", "category_within_source": "General", "source_domain": "CBS News", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.928015"}], "overall_sentiment_score": 0.283705, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.438760", "ticker_sentiment_label": "Bullish"}, {"ticker": "BSX", "relevance_score": "0.604923", "ticker_sentiment_score": "0.124889", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J to buy heart pump maker Abiomed in $16.6 billion deal", "url": "https://www.cnbc.com/2022/11/01/johnson-johnson-to-buy-abiomed-in-16point6-billion-deal.html", "time_published": "20221101T064900", "authors": [], "summary": "Johnson & Johnson announced its acquisition of heart pump maker Abiomed for $16.6 billion, marking its largest deal in nearly six years. The acquisition aims to boost J&J's medical devices unit after the planned spinoff of its consumer health business and is expected to contribute to adjusted earnings from 2024. Abiomed shareholders will receive an upfront payment of $380 per share, plus potential additional payments based on commercial and clinical milestones.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.848986"}], "overall_sentiment_score": 0.303334, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.333525", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Thermo Fisher bets big on blood cancer, immune diagnostics with $2.6B Binding Site buyout", "url": "https://medcitynews.com/2022/10/thermo-fisher-bets-big-on-blood-cancer-immune-diagnostics-with-2-6b-binding-site-buyout/", "time_published": "20221031T125900", "authors": ["Frank Vinluan"], "summary": "Thermo Fisher Scientific is set to acquire The Binding Site Group for approximately $2.6 billion, expanding its diagnostics business in blood cancers and immune disorders. This acquisition follows Thermo Fisher's 2021 buyout of PPD and will integrate The Binding Site's specialized diagnostic tests, particularly for multiple myeloma, into Thermo Fisher's Specialty Diagnostics business. The deal underscores Thermo Fisher's strategy to invest in early diagnosis and monitoring solutions, especially with the emergence of new BCMA-targeting drugs for multiple myeloma.", "banner_image": null, "source": "MedCity News", "category_within_source": "General", "source_domain": "MedCity News", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.615934"}, {"topic": "earnings", "relevance_score": "0.629869"}], "overall_sentiment_score": 0.281618, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TMO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.414953", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.700672", "ticker_sentiment_score": "0.236809", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.646213", "ticker_sentiment_score": "0.248205", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "|How Johnson & Johnson Innovation lasted 5 decades -", "url": "https://globalventuring.com/corporate/how-johnson-johnson-innovation-lasted-50-decades/", "time_published": "20221027T171640", "authors": ["|Kaloyan Andonov"], "summary": "|Johnson & Johnson Innovation (JJDC), the world's oldest CVC, attributes its five-decade longevity to unwavering management support, disciplined investment strategy, and adaptability. Debi Watson, VP of venture investments, highlights the unit's consistent vision, long-term investment horizon, and willingness to evolve business models. Despite challenges in balancing strategic focus with disruptive innovation, JJDC remains committed to its core strategy even amidst shifting economic conditions.", "banner_image": "|NULL", "source": "Global Venturing", "category_within_source": "General", "source_domain": "Global Venturing", "topics": [{"topic": "life_sciences", "relevance_score": "0.930059"}, {"topic": "finance", "relevance_score": "0.727792"}, {"topic": "economy_monetary", "relevance_score": "0.602556"}], "overall_sentiment_score": 0.205432, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.523038", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.567420", "ticker_sentiment_score": "0.147703", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.561577", "ticker_sentiment_score": "0.117231", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.593903", "ticker_sentiment_score": "0.147469", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.592369", "ticker_sentiment_score": "0.128951", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson's blood cancer therapy gets U.S. FDA approval", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/johnson-johnsons-blood-cancer-therapy-gets-us-fda-approval-2022-10-25/", "time_published": "20221025T203700", "authors": ["Khushi Mandowara"], "summary": "Johnson & Johnson has received FDA approval for its blood cancer therapy, Tecvayli, for a type of multiple myeloma. This bispecific antibody, priced at $39,500 per month, targets patients who have received multiple prior lines of therapy. While offering a new option for the incurable disease, it carries a boxed warning for cytokine release syndrome and neurologic toxicity.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.275528, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.484916", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.709886", "ticker_sentiment_score": "0.134513", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medtronic to spin off 2 businesses as part of restructuring process", "url": "https://health.economictimes.indiatimes.com/news/medical-devices/medtronic-to-spin-off-2-businesses-as-part-of-restructuring-process/95072614", "time_published": "20221025T104500", "authors": ["Reuters"], "summary": "Medtronic Plc announced its plan to spin off two smaller businesses, patient monitoring and respiratory interventions, into a new company to streamline its portfolio and accelerate revenue growth. These two businesses contributed $2.2 billion to Medtronic's revenue in the fiscal year ending April 29 and the spin-off is expected to be completed within the next 12 to 18 months, aiming to unlock value and narrow the company's focus. This move is part of Medtronic's ongoing restructuring efforts, aligning with a broader trend among U.S. companies like Johnson & Johnson and General Electric to divest non-core assets for improved performance.", "banner_image": null, "source": "ET HealthWorld", "category_within_source": "General", "source_domain": "ET HealthWorld", "topics": [{"topic": "life_sciences", "relevance_score": "0.902784"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.940196"}], "overall_sentiment_score": 0.133047, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.217872", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.702997", "ticker_sentiment_score": "0.106296", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.614591", "ticker_sentiment_score": "0.104371", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMM", "relevance_score": "0.608815", "ticker_sentiment_score": "0.132358", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Some Big Corporations Must Split Up to Survive", "url": "https://www.gsb.stanford.edu/insights/why-some-big-corporations-must-split-survive", "time_published": "20221024T165705", "authors": ["Edmund L. Andrews"], "summary": "Large corporations are increasingly splitting into smaller entities to adapt to evolving market ecosystems. This \"strategic renewal through speciation\" is necessary when different business segments diverge, making a unified strategy unsustainable. Hewlett Packard's 2015 split serves as a prime example of how this adaptation can lead to increased success for the new independent companies.", "banner_image": "NULL", "source": "Stanford Graduate School of Business", "category_within_source": "General", "source_domain": "Stanford Graduate School of Business", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.930161"}, {"topic": "technology", "relevance_score": "0.829895"}, {"topic": "life_sciences", "relevance_score": "0.601137"}], "overall_sentiment_score": 0.26789, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HPE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.438951", "ticker_sentiment_label": "Bullish"}, {"ticker": "HPQ", "relevance_score": "0.884234", "ticker_sentiment_score": "0.301177", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GE", "relevance_score": "0.725138", "ticker_sentiment_score": "0.285135", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.646970", "ticker_sentiment_score": "0.225165", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "K", "relevance_score": "0.599760", "ticker_sentiment_score": "0.157356", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AGTC yields to biotech downturn with gene therapy buyout deal", "url": "https://www.biopharmadive.com/news/agtc-syncona-gene-therapy-deal-xlrp/634763/", "time_published": "20221024T160625", "authors": ["Ben Fidler"], "summary": "Applied Genetic Technologies Corp. (AGTC) is being acquired by Syncona for $0.34 per share, or about $23.5 million, with potential additional payments up to $50 million, due to a challenging funding environment and declining stock value. The deal, which offers a significant premium over AGTC's recent stock price, aims to secure the development of its lead gene therapy program for X-linked retinitis pigmentosa, as the company faced solvency issues. This acquisition highlights a trend of genetic medicine developers selling themselves amid a biotech downturn.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.810865"}], "overall_sentiment_score": -0.202359, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AGTC", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.402251", "ticker_sentiment_label": "Bearish"}, {"ticker": "BIIB", "relevance_score": "0.716345", "ticker_sentiment_score": "-0.212967", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.644967", "ticker_sentiment_score": "0.144151", "ticker_sentiment_label": "Neutral"}]}, {"title": "Northrop Grumman Awarded Contract for E-2D Advanced Hawkeye Aircraft", "url": "https://news.clearancejobs.com/2022/10/20/northrop-grumman-awarded-contract-for-e-2d-advanced-hawkeye-aircraft/", "time_published": "20221020T175546", "authors": ["Katie Helbling"], "summary": "Northrop Grumman Systems Corp. has been awarded a $31,622,092 cost-plus-fixed-fee order for the inspection and teardown of the E-2D Advanced Hawkeye fatigue test article. This contract aims to identify fatigue critical locations and confirm the aircraft\u2019s structural service life requirement. The article also details several other defense contracts awarded to companies like Johnson & Johnson Health Care Systems, Lockheed Martin Corp., and BAE Systems Technology Solutions and Services Inc.", "banner_image": null, "source": "Security Clearance Jobs", "category_within_source": "General", "source_domain": "Security Clearance Jobs", "topics": [{"topic": "manufacturing", "relevance_score": "0.933378"}, {"topic": "economy_fiscal", "relevance_score": "0.805131"}], "overall_sentiment_score": 0.272362, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NOC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.427384", "ticker_sentiment_label": "Bullish"}, {"ticker": "LMT", "relevance_score": "0.744282", "ticker_sentiment_score": "0.301765", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.622820", "ticker_sentiment_score": "0.135732", "ticker_sentiment_label": "Neutral"}, {"ticker": "LHX", "relevance_score": "0.621956", "ticker_sentiment_score": "0.110666", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J and Corning put more than 100 New York jobs on the chopping block in latest pharma layoff round", "url": "https://www.fiercepharma.com/manufacturing/jj-and-corning-put-more-100-new-york-jobs-chopping-block-latest-pharma-layoff-round", "time_published": "20221020T105900", "authors": ["Fraiser Kansteiner"], "summary": "Johnson & Johnson is laying off 64 employees in New York due to \"economic\" reasons, coinciding with plans to \"rightsize\" its pharma infrastructure ahead of a consumer health division separation. Separately, Corning Pharmaceutical Technologies is cutting 51 New York-based positions as part of a revised business operating plan to align with supply and customer demand. In total, over 100 jobs are being eliminated across both companies in New York.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.947143"}, {"topic": "economy_macro", "relevance_score": "0.803207"}, {"topic": "manufacturing", "relevance_score": "0.721273"}], "overall_sentiment_score": -0.2318, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.261709", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GLW", "relevance_score": "0.742605", "ticker_sentiment_score": "-0.235187", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABBV", "relevance_score": "0.556812", "ticker_sentiment_score": "-0.244702", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Acute Myeloid Leukemia Market Size to Surpass US$ 4.31 Billion by 2030 - Growth Plus Reports", "url": "https://www.globenewswire.com/de/news-release/2022/10/19/2537154/0/en/Acute-Myeloid-Leukemia-Market-Size-to-Surpass-US-4-31-Billion-by-2030-Growth-Plus-Reports.html", "time_published": "20221019T061300", "authors": [], "summary": "The global acute myeloid leukemia market is projected to reach US$ 4.31 billion by 2030, growing at a CAGR of 10.2%, driven by rising incidence rates, an aging population, and advancements in drug discovery. Antineoplastics currently hold the largest market share due to their high demand as a common and effective cancer treatment. North America dominates the market, attributed to the high prevalence of AML and significant R&D investments in the region.", "banner_image": null, "source": "GlobeNewswire", "category_within_source": "General", "source_domain": "GlobeNewswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.931553"}], "overall_sentiment_score": 0.345465, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ASTX", "relevance_score": "0.904154", "ticker_sentiment_score": "0.321777", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.740283", "ticker_sentiment_score": "0.337719", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.712472", "ticker_sentiment_score": "0.301894", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.638022", "ticker_sentiment_score": "0.321126", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson beats The Street in Q3, MedTech sales rise", "url": "https://www.massdevice.com/johnson-johnson-q3-2022/", "time_published": "20221018T171642", "authors": ["Sean Whooley"], "summary": "Johnson & Johnson reported stronger-than-expected Q3 results, with sales reaching $23.8 billion and earnings per share of $2.48, beating Wall Street estimates. The company's MedTech business saw a 2.1% sales increase, driven by electrophysiology products and orthopedic therapies, though overall 2022 sales guidance was slightly lowered. Analysts noted strong MedTech volume recovery and J&J's continued interest in strategic M&A for the sector.", "banner_image": null, "source": "MassDevice", "category_within_source": "General", "source_domain": "MassDevice", "topics": [{"topic": "earnings", "relevance_score": "0.948202"}, {"topic": "life_sciences", "relevance_score": "0.837384"}, {"topic": "financial_markets", "relevance_score": "0.611131"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.644837"}], "overall_sentiment_score": 0.408132, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.428567", "ticker_sentiment_label": "Bullish"}]}, {"title": "Foldax Appoints Gregory D. Casciaro as Chief Executive Officer", "url": "https://www.dicardiology.com/content/foldax-appoints-gregory-d-casciaro-chief-executive-officer", "time_published": "20221018T164118", "authors": [], "summary": "Foldax, Inc. announced the appointment of medtech veteran Gregory D. Casciaro as its new Chief Executive Officer, effective October 17, 2022. Casciaro brings over 30 years of experience leading and growing both private and public medical technology companies, successfully guiding several through acquisitions by major industry players. He will now lead Foldax in its mission to develop and bring a \"transformational heart valve platform\" to market.", "banner_image": null, "source": "Diagnostic and Interventional Cardiology", "category_within_source": "General", "source_domain": "Diagnostic and Interventional Cardiology", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.708880"}], "overall_sentiment_score": 0.323336, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EW", "relevance_score": "0.736333", "ticker_sentiment_score": "0.319437", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAH", "relevance_score": "0.619114", "ticker_sentiment_score": "0.325850", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.600070", "ticker_sentiment_score": "0.303790", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.647388", "ticker_sentiment_score": "0.311937", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson beat on Q3 earnings despite inflationary pressures", "url": "https://finance.yahoo.com/video/johnson-johnson-beat-q3-earnings-154407154.html", "time_published": "20221018T154407", "authors": ["-0.10%"], "summary": "Johnson & Johnson exceeded Q3 earnings expectations despite ongoing inflationary pressures, with growth observed particularly in its pharmaceutical sector and medical devices. The company is actively restructuring, including potential job cuts, as it prepares to spin off its consumer products into the new Kenvue brand by late next year. The report also touched upon health officials' warnings regarding new COVID variants and the efficacy of current boosters ahead of the winter season.", "banner_image": null, "source": "Yahoo Finance", "category_within_source": "General", "source_domain": "Yahoo Finance", "topics": [{"topic": "earnings", "relevance_score": "0.939293"}, {"topic": "life_sciences", "relevance_score": "0.816049"}, {"topic": "economy_macro", "relevance_score": "0.712749"}], "overall_sentiment_score": 0.195465, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.264800", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KVUE", "relevance_score": "0.642482", "ticker_sentiment_score": "0.110790", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J sets sights on $60B in pharma sales by 2025, targets 8 brands to deliver growth", "url": "https://www.fiercepharma.com/financials/johnson-johnson-sticks-2025-projection-60-billion-pharma-sales-relying-eight-key-brands", "time_published": "20221018T114700", "authors": ["Zoey Becker"], "summary": "Johnson & Johnson aims to achieve $60 billion in pharmaceutical sales by 2025, despite the upcoming loss of exclusivity for their top drug, Stelara. This ambitious goal will be driven by eight key brands and a strong pipeline, including therapies like Darzalex, Carvykti, and upcoming treatments for thrombosis and non-small cell lung cancer. J&J also noted their readiness for strategic M&A, backed by $34 billion in cash, to further support this growth.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "earnings", "relevance_score": "0.939158"}, {"topic": "life_sciences", "relevance_score": "0.948682"}], "overall_sentiment_score": 0.346645, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.381541", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.604390", "ticker_sentiment_score": "0.292683", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J, flush with blood cancer assets, cuts one from the pipeline", "url": "https://www.fiercebiotech.com/biotech/jj-flush-blood-cancer-assets-cuts-one-pipeline", "time_published": "20221018T105000", "authors": ["Max Bayer"], "summary": "Johnson & Johnson has removed JNJ-6665, a dihydroorotate dehydrogenase inhibitor, from its pipeline, citing a strategic portfolio decision. This asset was in a phase 1 trial for acute myeloid leukemia and myelodysplastic syndrome. Despite this cut, J&J continues to expand its blood cancer pipeline with new additions like the cancer vaccine candidate VAC85135 and another phase 1 asset, JNJ-8543.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "0.908458"}], "overall_sentiment_score": 0.126289, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.108812", "ticker_sentiment_label": "Neutral"}]}, {"title": "\u2018The Magic of J&J\u2019: Announcing HRE\u2019s HR Executive of the Year", "url": "https://hrexecutive.com/the-magic-of-jj-announcing-hres-hr-executive-of-the-year/", "time_published": "20221017T171643", "authors": ["Jen Colletta"], "summary": "Peter Fasolo, Chief HR Officer at Johnson & Johnson, has been named HRE's HR Executive of the Year for his leadership, particularly during the COVID-19 pandemic. The article highlights his strategic initiatives, including prioritizing employee well-being, advancing diversity, equity, and inclusion (DEI), and guiding the HR organization through significant restructuring and the upcoming separation of the consumer health business. Fasolo emphasizes J&J's Credo and values as foundational to his leadership approach and the company's success.", "banner_image": null, "source": "HR Executive", "category_within_source": "General", "source_domain": "HR Executive", "topics": [{"topic": "life_sciences", "relevance_score": "0.936634"}], "overall_sentiment_score": 0.272675, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.492510", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.620815", "ticker_sentiment_score": "0.118092", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACN", "relevance_score": "0.589661", "ticker_sentiment_score": "0.173398", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson sells baby powder plant it never opened to Hetero", "url": "https://www.fiercepharma.com/manufacturing/johnson-johnson-sells-baby-powder-plant-it-never-opened-hetero", "time_published": "20221017T114700", "authors": ["Kevin Dunleavy"], "summary": "Johnson & Johnson has sold a manufacturing facility in India to Hetero eight years after breaking ground, a plant designed to produce cosmetic products including baby powder but never opened. Hetero plans to invest Rs 600 crore ($73 million) into restoring and upgrading the facility to become its flagship plant for biopharma products, creating 2,000 new jobs. The sale comes as J&J faces extensive litigation over its talc-based baby powder and has ceased its sales in the U.S. and Canada, with a global discontinuation planned for 2023.", "banner_image": "NULL", "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.910749"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.809988"}, {"topic": "manufacturing", "relevance_score": "0.738546"}], "overall_sentiment_score": -0.147236, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.973327", "ticker_sentiment_score": "-0.143457", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stevanato Group and IL Group Partner to Improve Safe Processing & Handling of Hazardous Injectables", "url": "https://www.contractpharma.com/breaking-news/stevanato-group-and-il-group-partner-to-improve-safe-processing-handling-of-hazardous-injectables/", "time_published": "20221014T184631", "authors": ["Charlie Sternberg"], "summary": "Stevanato Group and IL Group have partnered to develop an integrated and automated solution for the safe processing and handling of hazardous injectable drugs. This collaboration aims to enhance inspection capabilities and containment for sensitive drugs, improving safety for healthcare professionals and patients. The solution combines Stevanato Group's Vision Robot Unit (VRU) with IL Group\u2019s labeling technology and their Vial Protect Pack.", "banner_image": null, "source": "Contract Pharma", "category_within_source": "General", "source_domain": "Contract Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.934185"}, {"topic": "manufacturing", "relevance_score": "0.839882"}, {"topic": "technology", "relevance_score": "0.630884"}], "overall_sentiment_score": 0.321783, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "STVN", "relevance_score": "1.000000", "ticker_sentiment_score": "0.492101", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.558859", "ticker_sentiment_score": "0.276799", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.591446", "ticker_sentiment_score": "0.295588", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.565849", "ticker_sentiment_score": "0.288560", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.550354", "ticker_sentiment_score": "0.292901", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Viatris weighs sale of consumer health assets in Europe \u2013 Bloomberg News", "url": "https://www.pharmalive.com/viatris-weighs-sale-of-consumer-health-assets-in-europe-bloomberg-news/", "time_published": "20221011T070613", "authors": ["Reuters"], "summary": "Viatris Inc. is reportedly considering selling its European consumer health assets in a deal potentially worth over 3 billion euros ($2.9 billion). The drugmaker is working with Jefferies Financial Group Inc to find suitors, including private equity groups. This move aligns with a broader trend of drugmakers separating consumer health businesses to focus on pharmaceuticals.", "banner_image": "https://www.pharmalive.com/wp-content/uploads/2022/10/Viatrislogo_1594170421421-HR-scaled.jpg", "source": "PharmaLive", "category_within_source": "General", "source_domain": "PharmaLive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.914197"}, {"topic": "life_sciences", "relevance_score": "0.812798"}], "overall_sentiment_score": 0.103526, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VTRS", "relevance_score": "1.000000", "ticker_sentiment_score": "0.145736", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.701736", "ticker_sentiment_score": "0.120042", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.639318", "ticker_sentiment_score": "0.108363", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson 2022: Driving change, collaboration, and innovation", "url": "https://www.pharmalive.com/johnson-johnson-2022-driving-change-collaboration-and-innovation/", "time_published": "20221011T031511", "authors": ["Andrew Humphreys"], "summary": "Johnson & Johnson's 2022 overview highlights the first year under CEO Joaquin Duato and the planned separation of its consumer health business. The article details the company's financial performance, top-selling prescription products, and significant R&D investments, emphasizing its commitment to innovation. Key product approvals, pipeline updates across oncology, immunology, and HIV, and medical device advancements are also covered, alongside a renewed commitment to fighting neglected tropical diseases.", "banner_image": "https://www.pharmalive.com/wp-content/uploads/2022/10/Joaquin-Duato.jpeg", "source": "PharmaLive", "category_within_source": "General", "source_domain": "PharmaLive", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "earnings", "relevance_score": "0.925127"}], "overall_sentiment_score": 0.350041, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.403229", "ticker_sentiment_label": "Bullish"}, {"ticker": "KVUE", "relevance_score": "0.887879", "ticker_sentiment_score": "0.340887", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "HCA funds $1.5 million in scholarships at Tennessee State University", "url": "https://www.bizjournals.com/nashville/news/2022/10/10/hca-funds-scholarships-at-tennessee-state.html", "time_published": "20221010T165631", "authors": ["Joel Stinnett"], "summary": "HCA Healthcare is funding $1.5 million in scholarships at Tennessee State University. This initiative addresses long-standing racial inequities in health care that were highlighted by the Covid-19 pandemic. The scholarships will support students at the university.", "banner_image": null, "source": "The Business Journals", "category_within_source": "General", "source_domain": "The Business Journals", "topics": [{"topic": "life_sciences", "relevance_score": "0.901632"}, {"topic": "finance", "relevance_score": "0.710461"}], "overall_sentiment_score": 0.358798, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "HCA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.419228", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.734720", "ticker_sentiment_score": "0.305688", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biogen CEO search focuses on scientists, with former J&J exec as a leading candidate", "url": "https://www.statnews.com/2022/10/07/biogen-ceo-search-focuses-on-scientists-with-former-jj-exec-as-a-leading-candidate/", "time_published": "20221007T171642", "authors": ["Matthew Herper", "Adam Feuerstein", "Damian Garde"], "summary": "Biogen is reportedly considering Mathai Mammen, former head of R&D at Johnson & Johnson, as a leading candidate for its next CEO. This potential selection would mark a significant shift for Biogen, emphasizing scientific credentials to help the company recover from the troubled launch of Aduhelm. While discussions are serious, a formal offer has not yet been extended.", "banner_image": null, "source": "www.statnews.com", "category_within_source": "General", "source_domain": "www.statnews.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.920447"}, {"topic": "finance", "relevance_score": "0.607648"}], "overall_sentiment_score": 0.050631, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.922296", "ticker_sentiment_score": "-0.133111", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "1.000000", "ticker_sentiment_score": "0.201499", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "How Johnson & Johnson is supporting mental healthcare in the Hispanic and Latino communities", "url": "https://www.jnj.com/caring-and-giving/how-johnson-johnson-is-supporting-mental-healthcare-in-the-hispanic-and-latino-communities", "time_published": "20221005T171640", "authors": ["Samantha Vincenty"], "summary": "Johnson & Johnson is actively working to address the mental healthcare challenges faced by Hispanic and Latino communities, including cultural stigma, language barriers, and lack of insurance. The company supports research into healthcare gaps, helps develop Spanish-language resources like \"La Salud Mental\" with the APA, mentors medical students from these communities, and engages with local organizations through initiatives like the HOLA employee resource group. These efforts aim to improve access to culturally competent mental health support and increase diversity within the medical field.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.929627"}], "overall_sentiment_score": 0.401571, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.415052", "ticker_sentiment_label": "Bullish"}]}, {"title": "Jennifer Taubert Makes Fortune 2022 Most Powerful Women List", "url": "https://www.jnj.com/latest-news/johnson-johnson-executive-jennifer-taubert-named-to-fortunes-2022-most-powerful-women-list", "time_published": "20221004T171640", "authors": ["Johnson & Johnson"], "summary": "Jennifer Taubert, Executive Vice President and Worldwide Chairman, Pharmaceuticals at Johnson & Johnson, has been named to Fortune\u2019s 2022 Most Powerful Women list for the seventh consecutive year. The recognition highlights her leadership in guiding Janssen's global efforts to develop innovative medicines and her commitment to diversity, equity, and inclusion within Johnson & Johnson, including advocating for healthcare worker mental health. The article details her dedication to patients and the company's values, noting Janssen's significant investment in R&D under her leadership.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.941457"}, {"topic": "finance", "relevance_score": "0.706605"}], "overall_sentiment_score": 0.407835, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.440647", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson\u2019s Introduces Kenvue Portfolio of Consumer Brands and Shiseido Buys Gallin\u00e9e", "url": "https://www.happi.com/breaking-news/johnson-johnsons-introduces-kenvue-and-shiseido-buys-gallinee/", "time_published": "20221002T172647", "authors": ["TOM BRANNA"], "summary": "Johnson & Johnson's spin-off of its consumer business, now named Kenvue and including brands like Aveeno and Neutrogena, was the most-viewed news on Happi.com for the week ending October 1, 2022. This news topped the acquisition of microbiome beauty brand Gallin\u00e9e by Shiseido, highlighting significant activity in the consumer health and beauty sectors. The article lists the top 10 most-viewed news items from Happi.com for that week.", "banner_image": null, "source": "Happi | Household And Personal Products Industry", "category_within_source": "General", "source_domain": "Happi | Household And Personal Products Industry", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.901734"}, {"topic": "life_sciences", "relevance_score": "0.801027"}, {"topic": "retail_wholesale", "relevance_score": "0.723530"}], "overall_sentiment_score": 0.251871, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.303329", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.908579", "ticker_sentiment_score": "0.319751", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EL", "relevance_score": "0.700541", "ticker_sentiment_score": "0.342728", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ULTA", "relevance_score": "0.607851", "ticker_sentiment_score": "0.108512", "ticker_sentiment_label": "Neutral"}]}, {"title": "Janssen Announces Late-Breaking Data from Two Gene Therapy Programs", "url": "https://www.multivu.com/players/English/9071351-janssen-announces-late-breaking-data-from-two-gene-therapy-programs/", "time_published": "20221001T173657", "authors": [], "summary": "Janssen announced late-breaking data from two gene therapy programs at the American Academy of Ophthalmology 2022 Annual Meeting. Results from the Phase 1/2 MGT009 study of botaretigene sparoparvovec for X-linked retinitis pigmentosa demonstrated an acceptable safety profile and suggested sustained vision improvement. Additionally, Phase 1 data for JNJ-1887 in geographic atrophy met its primary safety endpoint, showing a continual decline in lesion growth over six-month increments.", "banner_image": null, "source": "MultiVu", "category_within_source": "General", "source_domain": "MultiVu", "topics": [{"topic": "life_sciences", "relevance_score": "0.946259"}], "overall_sentiment_score": 0.37755, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MGTX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.430974", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.908224", "ticker_sentiment_score": "0.327288", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson announces Kenvue as new consumer health company", "url": "https://theindustry.beauty/johnson-johnson-announces-kenvue-as-new-consumer-health-company/", "time_published": "20220930T172647", "authors": ["Tom Shearsmith"], "summary": "Johnson & Johnson has named its planned new consumer health company \"Kenvue,\" a name inspired by concepts of knowledge (\"ken\") and sight (\"vue\"). Kenvue's purpose is \"Realise the Extraordinary Power of Everyday Care,\" guiding its strategy and aiming to deliver meaningful personal health solutions. The company is expected to become a standalone global consumer health company in 2023, carrying brands like Aveeno, Listerine, Neutrogena, Johnson's, and Dr. CI:LABO.", "banner_image": null, "source": "TheIndustry.beauty", "category_within_source": "General", "source_domain": "TheIndustry.beauty", "topics": [{"topic": "life_sciences", "relevance_score": "0.918721"}, {"topic": "retail_wholesale", "relevance_score": "0.716830"}, {"topic": "ipo", "relevance_score": "0.644706"}], "overall_sentiment_score": 0.387385, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.489175", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.915022", "ticker_sentiment_score": "0.345939", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson unveils new name for planned consumer products spinoff", "url": "https://www.bizjournals.com/bizwomen/news/latest-news/2022/09/johnson-johnson-unveils-rebrand-for-planned-cons.html", "time_published": "20220930T171641", "authors": ["Anne Stych"], "summary": "Johnson & Johnson announced that its planned consumer products business spinoff will be rebranded as Kenvue. This rebranding will encompass iconic products such as Band-Aid and Tylenol. The company also mentioned its decision to stop selling talc-based baby powder.", "banner_image": null, "source": "The Business Journals", "category_within_source": "General", "source_domain": "The Business Journals", "topics": [{"topic": "life_sciences", "relevance_score": "0.931427"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.817819"}, {"topic": "retail_wholesale", "relevance_score": "0.621032"}], "overall_sentiment_score": 0.111862, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.132935", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Announce Name for New Consumer Health Company", "url": "https://supermarketnews.co.nz/news/johnson-johnson-announce-name-for-new-consumer-health-company/", "time_published": "20220929T172648", "authors": [], "summary": "Johnson & Johnson has announced Kenvue as the name for its new, independent consumer health company. The name Kenvue is inspired by \"ken\" (knowledge) and \"vue\" (sight), reflecting the company's focus on human needs and consumer insights to deliver personal health solutions. Kenvue's portfolio will include iconic brands such as Aveeno, Band-Aid, Listerine, Neutrogena, Tylenol, and Johnson's.", "banner_image": null, "source": "supermarketnews.co.nz", "category_within_source": "General", "source_domain": "supermarketnews.co.nz", "topics": [{"topic": "life_sciences", "relevance_score": "0.948036"}], "overall_sentiment_score": 0.396425, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.445087", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.812417", "ticker_sentiment_score": "0.307782", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Name change for Johnson & Johnson offshoot to Kenvue", "url": "https://pharmaphorum.com/news/name-change-for-johnson-johnson-offshoot-to-kenvue", "time_published": "20220929T171641", "authors": ["Nicole Raleigh"], "summary": "Johnson & Johnson's consumer health division is rebranding as Kenvue, an independent company set to launch in 2023. Kenvue will encompass trusted brands like Tylenol, Aveeno, and Band-Aid, focusing on everyday self-care solutions and aiming for $14.6 billion in revenue. This separation is part of J&J's strategy to reinvigorate its corporate image and focus on its pharma and medical device operations.", "banner_image": null, "source": "pharmaphorum", "category_within_source": "General", "source_domain": "pharmaphorum", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.939805"}, {"topic": "retail_wholesale", "relevance_score": "0.739993"}, {"topic": "earnings", "relevance_score": "0.620275"}], "overall_sentiment_score": 0.029139, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.308782", "ticker_sentiment_score": "0.048067", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson and Johnson names Consumer Health Business \"Kenvue\"", "url": "https://medicaldialogues.in/news/industry/pharma/johnson-and-johnson-names-consumer-health-business-kenvue-99858", "time_published": "20220929T100058", "authors": ["Ruchika Sharma"], "summary": "Johnson & Johnson has announced \"Kenvue\" as the name for its planned New Consumer Health Company, which aims to become a standalone global consumer health company in 2023. The name Kenvue is inspired by \"knowledge\" and \"sight,\" and its purpose is to \"Realize the Extraordinary Power of Everyday Care.\" The Consumer Health segment generated $14.6 billion in revenue in Full-Year 2021, and Kenvue is expected to generate sales in over 100 countries after the separation.", "banner_image": null, "source": "Medical Dialogues", "category_within_source": "General", "source_domain": "Medical Dialogues", "topics": [{"topic": "life_sciences", "relevance_score": "0.939020"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.822303"}, {"topic": "finance", "relevance_score": "0.726320"}], "overall_sentiment_score": 0.320879, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.919339", "ticker_sentiment_score": "0.305860", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.967642", "ticker_sentiment_score": "0.328547", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Band-Aids and Tylenol will have a new name on their packages", "url": "https://www.cnn.com/2022/09/29/business/johnson-and-johnson-band-aid-tylenol-kenvue", "time_published": "20220929T093100", "authors": ["Nathaniel Meyersohn"], "summary": "Johnson & Johnson (JNJ) is splitting its business into two companies, with its consumer health brands like Band-Aid and Tylenol falling under a new corporate parent named Kenvue. The new name, a combination of \"Ken\" and \"vue,\" was chosen to be distinctive, memorable, and clear of trademark issues across many languages, reflecting a strategy where the corporate identity takes a backseat to its well-known product brands. The split is expected to be completed next year.", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "life_sciences", "relevance_score": "0.933781"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.846457"}, {"topic": "retail_wholesale", "relevance_score": "0.625078"}], "overall_sentiment_score": 0.107015, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.141744", "ticker_sentiment_label": "Neutral"}, {"ticker": "KVUE", "relevance_score": "0.918130", "ticker_sentiment_score": "0.140956", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDLZ", "relevance_score": "0.626957", "ticker_sentiment_score": "0.147621", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.624268", "ticker_sentiment_score": "0.120699", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J says new Band-Aid and Tylenol company to be named Kenvue | Company Business News", "url": "https://www.livemint.com/companies/news/jj-says-new-band-aid-and-tylenol-company-to-be-named-kenvue-11664368643937.html?showGiftPopup=true", "time_published": "20220928T181500", "authors": ["KATHRYN HARDISON"], "summary": "Johnson & Johnson announced that its new consumer-health products company, which will house brands like Band-Aid and Tylenol, will be named Kenvue. This separation of the consumer unit, with $15 billion in annual revenue, from J&J's prescription-drug and medical-device business, is expected to be completed next year. Kenvue is a portmanteau of \"ken\" (knowledge) and \"vue\" (sight), signifying its focus on consumer insights and health solutions.", "banner_image": null, "source": "Mint", "category_within_source": "General", "source_domain": "Mint", "topics": [{"topic": "life_sciences", "relevance_score": "0.940466"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.813274"}, {"topic": "retail_wholesale", "relevance_score": "0.629806"}, {"topic": "finance", "relevance_score": "0.606345"}], "overall_sentiment_score": 0.220233, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.314735", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.915491", "ticker_sentiment_score": "0.339502", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.634665", "ticker_sentiment_score": "0.127977", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.614975", "ticker_sentiment_score": "0.105691", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.632710", "ticker_sentiment_score": "0.100292", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J Says New Band-Aid and Tylenol Company to Be Named Kenvue", "url": "https://www.wsj.com/articles/j-j-says-new-band-aid-and-tylenol-company-to-be-named-kenvue-11664365578?gaa_at=eafs&gaa_n=AWEtsqcGq64WlZ_EC2PvWA1RiHe9ARFsJF0u17fgCaArTNkuWFipOAibp0tO&gaa_ts=69079765&gaa_sig=0FJhYHBbVuFTzSe9emU-8jRKke7N-JsTLTQB_Tnn5KuB4CxSgOKByMeucxHv6z8zxTt6FoHvnHHkqailID43YA%3D%3D", "time_published": "20220928T172647", "authors": ["Peter Loftus and Kathryn Hardison"], "summary": "Johnson & Johnson announced that \"Kenvue\" will be the name for its new stand-alone consumer-health company, set to include brands like Band-Aid and Tylenol. This move is part of J&J's plan to separate its consumer-health business from its prescription-drug and medical-devices units in 2023. The name Kenvue signifies knowledge and sight, marking a significant step in the healthcare giant's restructuring.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.941547"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.800436"}], "overall_sentiment_score": 0.11615, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.105807", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.912709", "ticker_sentiment_score": "0.100361", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.745507", "ticker_sentiment_score": "0.121527", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J\u2019s consumer health spinout to be named Kenvue", "url": "https://www.biopharmadive.com/news/kenvue-johnson-johnson-consumer-spin-name/632871/", "time_published": "20220928T172647", "authors": ["Delilah Alvarado"], "summary": "Johnson & Johnson has announced Kenvue as the name for its consumer health spinout, which is expected to be separated next year. Kenvue will sell well-known products like Band-Aids, Tylenol, and Listerine, and the split is intended to boost the value of both the consumer health company and J&J's pharmaceutical and medical device businesses. J&J has already appointed key leadership for Kenvue, including former CVS Health CEO Larry Merlo as chair-designate.", "banner_image": "https://www.biopharmadive.com/news/kenvue-johnson-johnson-consumer-spin-name/632871/", "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.933248"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.838700"}, {"topic": "finance", "relevance_score": "0.641501"}], "overall_sentiment_score": 0.214386, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.406609", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.901281", "ticker_sentiment_score": "0.306622", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVS", "relevance_score": "0.612857", "ticker_sentiment_score": "0.135101", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.577788", "ticker_sentiment_score": "0.054955", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.568012", "ticker_sentiment_score": "0.081773", "ticker_sentiment_label": "Neutral"}]}, {"title": "Raghu Krishnan Named Johnson & Johnson\u2019s New Consumer Health Area Managing Director for Africa, Middle East, and Turkey", "url": "https://www.businesswire.com/news/home/20220927005819/en/Raghu-Krishnan-Named-Johnson-Johnsons-New-Consumer-Health-Area-Managing-Director-for-Africa-Middle-East-and-Turkey", "time_published": "20220928T171643", "authors": [], "summary": "Raghu Krishnan has been appointed as the new Area Managing Director for Africa, Middle East, and Turkey (AMET) for Johnson & Johnson Consumer Health, effective September 1, 2022. He replaces Makis Kosmatos, who will transition to Area Managing Director for Southern Europe & France after five successful years in the AMET region. Krishnan brings 25 years of international experience, having previously led Johnson & Johnson Philippines, while Kosmatos is recognized for achieving double-digit growth and transforming the AMET portfolio.", "banner_image": "https://mms.businesswire.com/media/20220927005819/en/1614214/23/J%26J_Raghu_Krishnan.jpg", "source": "Business Wire", "category_within_source": "General", "source_domain": "Business Wire", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.727667"}, {"topic": "life_sciences", "relevance_score": "0.938018"}], "overall_sentiment_score": 0.435226, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.407591", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company", "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-kenvue-as-the-name-for-planned-new-consumer-health-company", "time_published": "20220928T171640", "authors": [], "summary": "Johnson & Johnson has announced \"Kenvue\" as the name for its planned new Consumer Health Company, marking a significant step in establishing two independent, market-leading companies. Kenvue's purpose is \"Realize the Extraordinary Power of Everyday Care,\" and it will operate as a standalone global consumer health company in 2023, encompassing iconic brands like Tylenol, Neutrogena, Listerine, and Band-Aid, with full-year 2021 revenue of $14.6 billion.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.814837"}, {"topic": "retail_wholesale", "relevance_score": "0.747131"}], "overall_sentiment_score": 0.28748, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.275390", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "First Look: J&J names consumer health unit Kenvue - News", "url": "https://www.mmm-online.com/home/channel/first-look-jj-names-consumer-health-unit-kenvue/", "time_published": "20220928T134300", "authors": ["Lecia Bushak"], "summary": "Johnson & Johnson has announced that its new consumer health unit will be named Kenvue, a combination of \"ken\" (knowledge) and \"vue\" (sight). This unit, which generated $14.6 billion in revenue in 2021 and includes brands like Band-Aid and Tylenol, is set to be spun off in 2023. This move mirrors a trend in the pharma industry where large companies are separating their consumer health divisions to focus on self-care and preventive health.", "banner_image": null, "source": "Medical Marketing and Media", "category_within_source": "General", "source_domain": "Medical Marketing and Media", "topics": [{"topic": "life_sciences", "relevance_score": "0.943601"}, {"topic": "earnings", "relevance_score": "0.703299"}], "overall_sentiment_score": 0.314964, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.406219", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.915531", "ticker_sentiment_score": "0.210907", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson taps Scottish inspiration in branding its consumer spinoff", "url": "https://www.fiercepharma.com/pharma/johnson-johnson-uses-wee-bit-inspiration-branding-its-consumer-spinoff", "time_published": "20220928T103000", "authors": ["Kevin Dunleavy"], "summary": "Johnson & Johnson has named its consumer health spinoff Kenvue, drawing inspiration from Scottish etymology where \"ken\" means knowledge. This new entity, which generated $14.6 billion in revenue in 2021 from brands like Tylenol and Band-Aid, will focus on everyday care products. The move follows a trend among pharmaceutical companies to separate consumer divisions to concentrate on more profitable drug businesses.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.162104, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.114476", "ticker_sentiment_label": "Neutral"}, {"ticker": "KVUE", "relevance_score": "0.934600", "ticker_sentiment_score": "0.233581", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.642935", "ticker_sentiment_score": "0.105320", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.604982", "ticker_sentiment_score": "0.115631", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-vision-introduces-all-purpose-edof-tecnis-symfony-optiblue-iol-the-latest-pc-iol-powered-by-intelilight-technology-301634976.html", "time_published": "20220928T080000", "authors": [], "summary": "Johnson & Johnson Vision has launched the TECNIS Symfony OptiBlue IOL, an extended depth-of-focus (EDOF) intraocular lens powered by InteliLight technology, expanding presbyopia correction for cataract patients. This new lens, along with the TECNIS Synergy IOL, forms a portfolio designed to deliver superior contrast and low-light performance. The InteliLight technology incorporates a violet-light filter, echelette design, and achromatic technology to improve visual acuity and minimize disturbances.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "technology", "relevance_score": "0.747498"}], "overall_sentiment_score": 0.462014, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.492747", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson Vision Expands Access to Myopia Management for More Patients with Abiliti\u2122 Overnight Lenses", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-vision-expands-access-to-myopia-management-for-more-patients-with-abiliti-overnight-lenses-301635143.html", "time_published": "20220928T080000", "authors": [], "summary": "Johnson & Johnson Vision has received FDA approval for an expanded range of ACUVUE\u00ae Abiliti\u2122 Overnight Therapeutic Lenses for Myopia Management, now treating up to 6.00 diopters, and is increasing their nationwide availability. This expansion, coupled with the FitAbiliti\u2122 software, aims to provide more eye care professionals with options to manage the rising rates of myopia, especially in children, with a high first-fit success rate. Through the Sight For Kids\u00ae program, each annual Abiliti\u2122 product purchase will also fund a comprehensive eye health exam for a child in need.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.915410"}], "overall_sentiment_score": 0.486326, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.471336", "ticker_sentiment_label": "Bullish"}]}, {"title": "As Covid recedes, the nuclear medicine equipment market bounces back", "url": "https://medicalbuyer.co.in/as-covid-recedes-the-nuclear-medicine-equipment-market-bounces-back/", "time_published": "20220926T164641", "authors": [], "summary": "The nuclear medicine equipment market is rebounding after the COVID-19 pandemic, driven by technological advancements, increasing disease prevalence, and growing awareness of early diagnosis. While the Indian market experienced a decline in 2021, sales of PET scanners and SPECT units have significantly picked up in 2022, with PET-CT scanners dominating the segment. The global market is projected for substantial growth despite challenges like high equipment costs and reimbursement issues.", "banner_image": null, "source": "Medical Buyer", "category_within_source": "General", "source_domain": "Medical Buyer", "topics": [{"topic": "life_sciences", "relevance_score": "0.946699"}], "overall_sentiment_score": 0.3691, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GEHC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.429565", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.586715", "ticker_sentiment_score": "0.251239", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J launches Bay Area science and technology campus", "url": "https://www.drugdiscoverytrends.com/johnson-johnson-launches-bay-area-science-and-technology-campus/", "time_published": "20220920T171642", "authors": ["Brian Buntz"], "summary": "Johnson & Johnson (NYSE:JNJ) has opened a new 200,000 sq ft science and technology campus in the San Francisco Bay Area, doubling its presence in the region. The campus will unite Janssen Research and Development, Johnson & Johnson Innovation, and Johnson & Johnson Technology to foster collaboration and accelerate drug discovery and development, particularly focusing on data science, gene and RNA therapies, and emerging therapies for retinal and infectious diseases. This strategic move aims to enhance efficiency, recruit world-class data scientists, and foster in-person collaboration to expedite the development of transformative medicines.", "banner_image": null, "source": "www.drugdiscoverytrends.com", "category_within_source": "General", "source_domain": "www.drugdiscoverytrends.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.939215"}, {"topic": "technology", "relevance_score": "0.844117"}], "overall_sentiment_score": 0.498741, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.490577", "ticker_sentiment_label": "Bullish"}]}, {"title": "J&J opens new research hub near San Francisco", "url": "https://www.biopharmadive.com/news/johnson-johnson-research-facility-open-san-francisco/632237/", "time_published": "20220920T171642", "authors": ["Delilah Alvarado"], "summary": "Johnson & Johnson has opened a new 200,000-square-foot R&D facility in Brisbane, California, near San Francisco, to consolidate its presence in the Bay Area biotech hub. The site will house approximately 400 employees from Janssen R&D, J&J Technology, and J&J Innovation, focusing on gene and RNA therapies, infectious diseases, retinal diseases, digital health, and data science. This expansion aims to enhance collaboration and accelerate the development of innovative medicines.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.947109"}], "overall_sentiment_score": 0.426571, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.426260", "ticker_sentiment_label": "Bullish"}]}, {"title": "Never Mind Growth vs. Value Stocks, Look to Beta", "url": "https://www.morningstar.com/markets/never-mind-growth-vs-value-stocks-look-beta", "time_published": "20220920T165548", "authors": ["Lauren Solberg"], "summary": "This article argues that investors should focus on stock volatility, represented by beta, rather than the traditional growth vs. value distinction, especially given the current economic uncertainty. It highlights that high-beta stocks, despite their risk, are currently undervalued, particularly in cyclical sectors, presenting potential opportunities. The author also suggests that low-beta stocks can offer a haven for risk-averse investors in uncertain times.", "banner_image": null, "source": "Morningstar", "category_within_source": "General", "source_domain": "Morningstar", "topics": [{"topic": "financial_markets", "relevance_score": "0.933907"}, {"topic": "economy_monetary", "relevance_score": "0.819552"}, {"topic": "economy_macro", "relevance_score": "0.749113"}, {"topic": "finance", "relevance_score": "0.635168"}], "overall_sentiment_score": -0.068955, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOGL", "relevance_score": "0.720981", "ticker_sentiment_score": "-0.060523", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.695471", "ticker_sentiment_score": "-0.064528", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.689640", "ticker_sentiment_score": "0.075124", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.703625", "ticker_sentiment_score": "-0.053617", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson opens 400-person R&D facility to strengthen Bay Area presence", "url": "https://www.fiercebiotech.com/biotech/jjs-rd-units-move-200k-sq-ft-facility-strengthen-bay-area-presence", "time_published": "20220920T103600", "authors": ["James Waldron"], "summary": "Johnson & Johnson has opened a new 200,000-square-foot R&D facility in San Francisco's Bay Campus, more than doubling its presence in the Bay Area. The facility will house up to 400 employees focusing on Janssen\u2019s R&D priorities, including gene and RNA therapies, and utilizing AI and machine learning in drug development. This move aims to strengthen J&J's R&D capabilities, similar to the success seen with its California Innovation Center.", "banner_image": "NULL", "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "0.912628"}, {"topic": "technology", "relevance_score": "0.825824"}, {"topic": "real_estate", "relevance_score": "0.620152"}], "overall_sentiment_score": 0.42306, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.438519", "ticker_sentiment_label": "Bullish"}]}, {"title": "Theravance, flush with royalty cash, buys shares from GSK", "url": "https://www.biopharmadive.com/news/theravance-gsk-share-buyback-asthma/632146/", "time_published": "20220919T184654", "authors": ["Jonathan Gardner"], "summary": "Theravance Biopharma is buying back all 9.6 million shares owned by GSK as part of a $250 million stock repurchase plan, aiming to pivot away from legacy respiratory products developed in their long-standing collaboration. This move follows Theravance's sale of royalty rights from GSK\u2019s blockbuster asthma drug Trelegy Ellipta to Royalty Pharma for $1.1 billion upfront. The share buyback will further unwind the 2002 collaboration with GSK, which had resulted in marketed drugs like Breo, Anoro, and Trelegy.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.912106"}, {"topic": "life_sciences", "relevance_score": "0.827275"}, {"topic": "finance", "relevance_score": "0.629669"}], "overall_sentiment_score": 0.164791, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TBPH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.311532", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VTRS", "relevance_score": "0.603245", "ticker_sentiment_score": "0.127121", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.607850", "ticker_sentiment_score": "0.004868", "ticker_sentiment_label": "Neutral"}]}, {"title": "Canadian biotech venture capital firm Lumira starts hedge fund to target oversold public companies", "url": "https://www.theglobeandmail.com/business/article-canadian-biotech-venture-capital-firm-lumira-starts-hedge-fund-to/", "time_published": "20220918T161135", "authors": ["Sean Silcoff"], "summary": "Lumira Ventures, a prominent Canadian biotech venture capital firm, is launching a new hedge fund, Lumira Ventures Opportunity Fund 1, to invest in publicly traded health sciences companies it believes are oversold. This move diversifies its investment strategy beyond private startups, following a trend seen among U.S. biotech investors. The fund will primarily target established biotherapeutics and medical technology firms, seeking to capitalize on a recent deep sell-off in the biotech market, despite strong underlying industry fundamentals.", "banner_image": null, "source": "The Globe and Mail", "category_within_source": "General", "source_domain": "The Globe and Mail", "topics": [{"topic": "finance", "relevance_score": "0.804041"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.916211"}], "overall_sentiment_score": 0.26939, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AUPH", "relevance_score": "0.903209", "ticker_sentiment_score": "0.330396", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZTS", "relevance_score": "0.591691", "ticker_sentiment_score": "0.253501", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.550611", "ticker_sentiment_score": "0.250260", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.592997", "ticker_sentiment_score": "0.287799", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.555185", "ticker_sentiment_score": "0.283303", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Vision announces \u20ac100m investment in Limerick", "url": "https://www.idaireland.com/latest-news/press-release/johnson-johnson-vision-announces-100m-investment-in-limerick", "time_published": "20220916T171643", "authors": [], "summary": "Johnson & Johnson Vision Care Ireland UC announced a \u20ac100 million investment to expand its existing facility in Limerick, Ireland. This expansion aims to create 80 new jobs and increase manufacturing capacity for its ACUVUE\u00ae Astigmatism product family and future product pipeline. Production is expected to commence in 2024, reinforcing the company's commitment to the Irish MedTech sector and global eye health.", "banner_image": null, "source": "IDA Ireland", "category_within_source": "General", "source_domain": "IDA Ireland", "topics": [{"topic": "manufacturing", "relevance_score": "0.948654"}, {"topic": "life_sciences", "relevance_score": "0.886369"}, {"topic": "economy_macro", "relevance_score": "0.624022"}], "overall_sentiment_score": 0.455302, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.492087", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson and a New War on Consumer Protection", "url": "https://www.newyorker.com/magazine/2022/09/19/johnson-johnson-and-a-new-war-on-consumer-protection", "time_published": "20220912T171640", "authors": ["Casey Cep"], "summary": "This article details Johnson & Johnson's legal battles regarding allegations that its talcum powder caused cancer in consumers. It highlights the company's controversial \"Texas two-step\" bankruptcy strategy to manage tens of thousands of lawsuits and discusses the broader implications for consumer protection laws and corporate accountability.", "banner_image": null, "source": "The New Yorker", "category_within_source": "General", "source_domain": "The New Yorker", "topics": [{"topic": "life_sciences", "relevance_score": "0.920326"}, {"topic": "finance", "relevance_score": "0.740740"}], "overall_sentiment_score": -0.3476, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.720223", "ticker_sentiment_label": "Bearish"}, {"ticker": "CL", "relevance_score": "0.612460", "ticker_sentiment_score": "-0.334898", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MMM", "relevance_score": "0.638295", "ticker_sentiment_score": "-0.246180", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PG", "relevance_score": "0.587437", "ticker_sentiment_score": "-0.116178", "ticker_sentiment_label": "Neutral"}]}, {"title": "GSK Eases Cervarix Out Of India, Eyes On Trajectory Of Synflorix", "url": "https://insights.citeline.com/SC147038/GSK-Eases-Cervarix-Out-Of-India-Eyes-On-Trajectory-Of-Synflorix/", "time_published": "20220912T171552", "authors": ["Anju Ghangurde"], "summary": "GSK is withdrawing its HPV vaccine Cervarix from the Indian market, reflecting changing dynamics for HPV vaccines in the country. The company's focus will now shift to the trajectory of its pneumococcal vaccine, Synflorix. This move comes amidst increased competition and evolving market conditions for vaccines in India.", "banner_image": null, "source": "Citeline News & Insights", "category_within_source": "General", "source_domain": "Citeline News & Insights", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.172408, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IQV", "relevance_score": "0.648174", "ticker_sentiment_score": "0.021748", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.915264", "ticker_sentiment_score": "0.342247", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.894363", "ticker_sentiment_score": "0.234520", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.760582", "ticker_sentiment_score": "0.139033", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.620170", "ticker_sentiment_score": "0.148537", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J reaches $205 million settlement in Australian pelvic mesh class action", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/shine-lawyers-reach-settlement-with-jj-australian-pelvic-mesh-class-action-2022-09-12/", "time_published": "20220912T152400", "authors": ["Jaskiran Singh"], "summary": "Johnson & Johnson has agreed to a A$300 million ($204.90 million) settlement in two Australian class action lawsuits concerning defective pelvic mesh implants. This marks the largest product-liability class action settlement in Australian history, impacting over 11,000 claimants and J&J's subsidiary Ethicon. The settlement addresses claims that the company sold the implants without adequate warnings about risks and prematurely brought them to market.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.936177"}, {"topic": "finance", "relevance_score": "0.736356"}], "overall_sentiment_score": -0.429121, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.404060", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson reaches $300m settlement over pelvic mesh implants", "url": "https://www.theguardian.com/business/2022/sep/12/johnson-johnson-reaches-300m-settlement-over-pelvic-mesh-implants", "time_published": "20220911T235000", "authors": ["Melissa Davey"], "summary": "Johnson & Johnson has reached a $300m settlement in two Australian class actions concerning pelvic mesh implants, marking the largest product liability settlement in Australian history. Thousands of women reported complications such as chronic pain and incontinence from the devices, with Shine Lawyers alleging the company failed to properly test the products and downplayed risks. The settlement is subject to federal court approval and follows a landmark judgment against Johnson & Johnson in 2019.", "banner_image": null, "source": "The Guardian", "category_within_source": "General", "source_domain": "The Guardian", "topics": [{"topic": "life_sciences", "relevance_score": "0.926222"}, {"topic": "finance", "relevance_score": "0.702058"}], "overall_sentiment_score": 0.013331, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.349438", "ticker_sentiment_score": "0.009091", "ticker_sentiment_label": "Neutral"}]}, {"title": "How AI Could Speed Drug Discovery", "url": "https://www.morganstanley.com/ideas/ai-drug-discovery", "time_published": "20220909T174610", "authors": [], "summary": "Artificial intelligence and machine learning are revolutionizing drug discovery by speeding up the development process and identifying viable drug targets more efficiently. Morgan Stanley Research believes these advancements could lead to 50 additional novel therapies and a $50 billion market opportunity over the next decade. The technology offers significant cost savings and improved outcomes for patients, while analysts anticipate an inflection point for the sector as investors gain confidence in AI-enabled drug development through strong data readouts and biopharma partnerships.", "banner_image": null, "source": "Morgan Stanley", "category_within_source": "General", "source_domain": "Morgan Stanley", "topics": [{"topic": "life_sciences", "relevance_score": "0.908027"}, {"topic": "technology", "relevance_score": "0.806964"}, {"topic": "financial_markets", "relevance_score": "0.636238"}], "overall_sentiment_score": 0.263547, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MS", "relevance_score": "0.938419", "ticker_sentiment_score": "0.347994", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.732711", "ticker_sentiment_score": "0.241624", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.748285", "ticker_sentiment_score": "0.236695", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.629888", "ticker_sentiment_score": "0.204680", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.608026", "ticker_sentiment_score": "0.206060", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Animal Model Market Size, Trends, Share, Growth, Forecast 2033", "url": "https://straitsresearch.com/report/animal-model-market", "time_published": "20220909T162713", "authors": ["Debashree Bora"], "summary": "The global animal model market is projected to grow from USD 2.52 Billion in 2025 to USD 4.05 Billion by 2033, exhibiting a CAGR of 6.11%. Key drivers include the rising use of animal models in virology and infectious diseases, increased adoption of CRISPR technology, and growth opportunities in emerging markets. However, increasing regulations regarding the ethical use of animals in research pose a restraining factor.", "banner_image": null, "source": "Straits Research", "category_within_source": "General", "source_domain": "Straits Research", "topics": [{"topic": "finance", "relevance_score": "0.715108"}, {"topic": "life_sciences", "relevance_score": "0.907234"}, {"topic": "economy_macro", "relevance_score": "0.635864"}], "overall_sentiment_score": 0.234059, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CRL", "relevance_score": "0.923041", "ticker_sentiment_score": "0.301003", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LH", "relevance_score": "0.727855", "ticker_sentiment_score": "0.227945", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.645137", "ticker_sentiment_score": "0.189531", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.617025", "ticker_sentiment_score": "0.166454", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson to pay New Hampshire $40.5 million in another opioid settlement", "url": "https://www.nhbr.com/johnson-johnson-to-pay-new-hampshire-40-5-million-in-another-opioid-settlement/", "time_published": "20220901T171641", "authors": ["Jeff Feingold"], "summary": "Johnson & Johnson has agreed to pay New Hampshire $40.5 million to settle an opioid lawsuit, avoiding a trial scheduled for a week later. The settlement addresses allegations that J&J aggressively marketed opioids and misrepresented their safety and addictiveness. This payment will fund opioid abatement programs within the state.", "banner_image": null, "source": "NH Business Review", "category_within_source": "General", "source_domain": "NH Business Review", "topics": [{"topic": "life_sciences", "relevance_score": "0.941361"}, {"topic": "finance", "relevance_score": "0.731025"}], "overall_sentiment_score": 0.030066, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.302294", "ticker_sentiment_score": "0.004452", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medtronic Announces Partnership with BioIntelliSense for Exclusive U.S. Distribution of Multi-Parameter Wearable for Continuous Remote Patient Monitoring from in-Hospital to Home", "url": "https://www.dicardiology.com/content/medtronic-announces-partnership-biointellisense-exclusive-us-distribution-multi-parameter", "time_published": "20220831T173639", "authors": [], "summary": "Medtronic has partnered with BioIntelliSense for the exclusive U.S. distribution of the BioButton multi-parameter wearable, enabling continuous remote patient monitoring from in-hospital to home. This collaboration aims to provide continuous vital sign measurements, support workflow automation, and address staffing shortages for general care patients. The BioButton device offers up to 1,440 vital sign measurements daily and can help clinicians detect early signs of patient deterioration or identify stable patients for earlier discharge.", "banner_image": null, "source": "Diagnostic and Interventional Cardiology", "category_within_source": "General", "source_domain": "Diagnostic and Interventional Cardiology", "topics": [{"topic": "technology", "relevance_score": "0.806866"}, {"topic": "life_sciences", "relevance_score": "0.911698"}, {"topic": "finance", "relevance_score": "0.631294"}], "overall_sentiment_score": 0.239161, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.629022", "ticker_sentiment_label": "Bullish"}, {"ticker": "BSX", "relevance_score": "0.565853", "ticker_sentiment_score": "0.145429", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.565461", "ticker_sentiment_score": "0.115218", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.584871", "ticker_sentiment_score": "0.133714", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.574683", "ticker_sentiment_score": "0.109466", "ticker_sentiment_label": "Neutral"}]}, {"title": "Takeda ends deal with Finch as bumpy ride continues for microbiome drugs", "url": "https://www.biopharmadive.com/news/finch-takeda-end-ibd-microbiome-drug-deal/630592/", "time_published": "20220826T184649", "authors": ["Ben Fidler"], "summary": "Takeda has terminated its 2017 deal with Finch Therapeutics to develop microbiome-based medicines for inflammatory bowel disease, handing back rights to two preclinical experimental drugs. This decision marks another setback for Finch, whose share price has significantly fallen since its IPO, following other challenges in the microbiome drug development field. Despite ending this partnership, Takeda confirmed its continued interest in microbiome-targeting drugs and is advancing other programs in this area.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "ipo", "relevance_score": "0.734280"}, {"topic": "financial_markets", "relevance_score": "0.632752"}], "overall_sentiment_score": 0.022868, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TAK", "relevance_score": "0.929697", "ticker_sentiment_score": "-0.255282", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.619377", "ticker_sentiment_score": "0.139483", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.580587", "ticker_sentiment_score": "0.147998", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.578199", "ticker_sentiment_score": "0.140028", "ticker_sentiment_label": "Neutral"}]}, {"title": "Female Disruptors: Susan Nicholson of Johnson & Johnson On The Three Things You Need To Shake Up Your Industry", "url": "https://medium.com/authority-magazine/female-disruptors-yourname-and-company-on-the-three-things-you-need-to-shake-up-your-industry-880832532c", "time_published": "20220826T171641", "authors": ["Candice Georgiadis"], "summary": "This article features an interview with Dr. Susan Nicholson, Vice President of the Health of Women team at Johnson & Johnson, discussing her work in disrupting the healthcare industry to better address women's health. She highlights the importance of sex-specific data insights, addressing the Black maternal health crisis, and offers advice on persistence, leveraging strengths, and being relentless in driving change. Dr. Nicholson emphasizes the need for advocacy for women's equitable treatment in healthcare and beyond.", "banner_image": null, "source": "Medium", "category_within_source": "General", "source_domain": "Medium", "topics": [{"topic": "life_sciences", "relevance_score": "0.900668"}], "overall_sentiment_score": 0.421228, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.449593", "ticker_sentiment_label": "Bullish"}]}, {"title": "J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering", "url": "https://www.fiercepharma.com/pharma/complementing-car-t-johnson-johnson-bags-first-nod-multiple-myeloma-bispecific", "time_published": "20220825T113500", "authors": ["Angus Liu"], "summary": "Johnson & Johnson has received its first global approval in Europe for teclistamab, a BCMAxCD3 bispecific antibody for relapsed and refractory multiple myeloma, under the brand name Tecvayli. This off-the-shelf option complements their existing CAR-T therapy, Carvykti, offering a new treatment alternative for heavily pretreated patients. Teclistamab demonstrated high rates of deep and durable responses in clinical trials, positioning it as a significant development in the multiple myeloma treatment landscape and a potential challenger to existing CAR-T therapies.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.944805"}], "overall_sentiment_score": 0.166263, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.992758", "ticker_sentiment_score": "0.333361", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.740779", "ticker_sentiment_score": "0.142290", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.648813", "ticker_sentiment_score": "0.077447", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson lost to Pfizer in bidding war for Global Blood Therapeutics: Bloomberg", "url": "https://www.fiercepharma.com/pharma/johnson-johnson-lost-pfizer-global-blood-therapeutics-bidding-war-bloomberg", "time_published": "20220824T101500", "authors": ["Angus Liu"], "summary": "Johnson & Johnson was the mysterious \"company A\" that battled Pfizer for Global Blood Therapeutics (GBT), initially offering $55 per share and raising it multiple times before losing out to Pfizer's final $67.50 bid. This would have been J&J's largest acquisition in two years and the first under new CEO Joaquin Duato. For Pfizer, the acquisition brings an FDA-approved sickle cell disease drug, Oxbryta, and pipeline candidates, with SVB Securities analysts projecting GBT's SCD franchise sales to reach $2.7 billion by 2030.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.947777"}], "overall_sentiment_score": 0.050026, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.109899", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.922988", "ticker_sentiment_score": "0.129524", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.610960", "ticker_sentiment_score": "0.120734", "ticker_sentiment_label": "Neutral"}]}, {"title": "McDonald's Announces Key Changes to Board of Directors", "url": "https://www.prnewswire.com/news-releases/mcdonalds-announces-key-changes-to-board-of-directors-301609612.html", "time_published": "20220822T070000", "authors": [], "summary": "McDonald's Corporation announced changes to its Board of Directors, with Sheila A. Penrose retiring after 15 years of service. Three new members, Tony Capuano (Marriott International), Jennifer Taubert (Johnson & Johnson), and Amy Weaver (Salesforce), have been elected to the Board. These changes aim to bring diverse and experienced leadership to guide the company's continued growth, particularly in areas like sustainability, global business, and digital customer engagement.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.836931"}, {"topic": "finance", "relevance_score": "0.723353"}], "overall_sentiment_score": 0.357783, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MCD", "relevance_score": "1.000000", "ticker_sentiment_score": "0.435626", "ticker_sentiment_label": "Bullish"}, {"ticker": "MAR", "relevance_score": "0.728775", "ticker_sentiment_score": "0.317933", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.699976", "ticker_sentiment_score": "0.381820", "ticker_sentiment_label": "Bullish"}, {"ticker": "CRM", "relevance_score": "0.633474", "ticker_sentiment_score": "0.313870", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EXPE", "relevance_score": "0.595163", "ticker_sentiment_score": "0.219365", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Ends Production and Sale of Talc Baby Powder Worldwide", "url": "https://www.mesotheliomaguide.com/community/johnson-johnson-ends-talc-baby-powder-worldwide/", "time_published": "20220821T171643", "authors": ["Devin Golden"], "summary": "Johnson & Johnson has announced it will stop making and selling its talc-based baby powder worldwide by 2023, two years after discontinuing it in North America. This decision follows tens of thousands of cancer lawsuits linking the product to diseases like ovarian cancer and mesothelioma, stemming from asbestos contamination found in talc. The company plans to replace its talc baby powder with a cornstarch-based version globally.", "banner_image": null, "source": "Mesothelioma Guide", "category_within_source": "General", "source_domain": "Mesothelioma Guide", "topics": [{"topic": "life_sciences", "relevance_score": "0.901417"}, {"topic": "retail_wholesale", "relevance_score": "0.749860"}], "overall_sentiment_score": -0.135624, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.101332", "ticker_sentiment_label": "Neutral"}]}, {"title": "Asbestos Trust Created for Claims Against Owens-Illinois Inc.", "url": "https://www.mesothelioma.com/blog/asbestos-trust-created-for-owens-illinois/", "time_published": "20220816T175634", "authors": ["Tara Strand"], "summary": "An asbestos trust fund has been established to handle all claims against Owens-Illinois Inc. This follows the company's use of the \"Texas Two-Step\" strategy, splitting its assets from its asbestos liabilities into a new subsidiary, Paddock Enterprises LLC, which then declared bankruptcy. The trust, funded with $610 million, will now be the avenue for mesothelioma patients seeking compensation instead of direct lawsuits against O-I Glass Inc.", "banner_image": null, "source": "Mesothelioma.com", "category_within_source": "General", "source_domain": "Mesothelioma.com", "topics": [{"topic": "finance", "relevance_score": "0.848053"}, {"topic": "life_sciences", "relevance_score": "0.731921"}], "overall_sentiment_score": -0.248995, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "OI", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.200433", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.634091", "ticker_sentiment_score": "-0.216623", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "SELLAS Life Sciences\u2019 Announces Election of Katherine Bach Kalin to its Board of Directors", "url": "https://www.stocktitan.net/news/SLS/sellas-life-sciences-announces-election-of-katherine-bach-kalin-to-wdmcr5abbwnx.html", "time_published": "20220816T083000", "authors": [], "summary": "SELLAS Life Sciences Group has announced the election of Katherine Bach Kalin to its Board of Directors, bringing extensive experience in the life sciences and healthcare sectors. Kalin's background includes leadership roles at Celgene and Johnson & Johnson, which SELLAS expects will support the advancement of its clinical programs, galinpepimut-S (GPS) and GFH009. This strategic appointment is intended to strengthen SELLAS as it moves towards commercialization.", "banner_image": null, "source": "Stock Titan", "category_within_source": "General", "source_domain": "Stock Titan", "topics": [{"topic": "life_sciences", "relevance_score": "0.927502"}, {"topic": "finance", "relevance_score": "0.723858"}], "overall_sentiment_score": 0.414428, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SLS", "relevance_score": "1.000000", "ticker_sentiment_score": "0.374854", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.638035", "ticker_sentiment_score": "0.414345", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson Ends Worldwide Sale of Talc-Based Baby Powder", "url": "https://www.asbestos.com/news/2022/08/15/johnson-johnson-talc-worldwide-sales/", "time_published": "20220815T171641", "authors": ["Tim Povtak", "Walter Pacheco"], "summary": "Johnson & Johnson announced it would end the worldwide sale of talc-based Johnson\u2019s Baby Powder in 2023, transitioning to a cornstarch-based product. This decision comes after thousands of lawsuits claiming its talc was contaminated with asbestos, despite the company's continued insistence on the product's safety. The company is actively involved in complex litigation and bankruptcy proceedings to manage nearly 40,000 pending talc-related lawsuits.", "banner_image": null, "source": "Mesothelioma Center", "category_within_source": "General", "source_domain": "Mesothelioma Center", "topics": [{"topic": "life_sciences", "relevance_score": "0.946761"}, {"topic": "finance", "relevance_score": "0.828699"}, {"topic": "economy_macro", "relevance_score": "0.646827"}], "overall_sentiment_score": -0.382223, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.350909", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson to stop selling talc-based baby powder globally", "url": "https://www.washingtonpost.com/business/2022/08/12/johnson-and-johnson-talcum-baby-powder/", "time_published": "20220812T171642", "authors": ["Andrew Jeong"], "summary": "Johnson & Johnson announced it will cease global sales of its talc-based baby powder starting next year, citing a \"commercial decision\" for long-term growth. This follows a previous discontinuation of the product in the U.S. and Canada two years prior due to declining demand amid thousands of lawsuits alleging the powder contained carcinogens.", "banner_image": "NULL", "source": "The Washington Post", "category_within_source": "General", "source_domain": "The Washington Post", "topics": [{"topic": "life_sciences", "relevance_score": "0.949582"}, {"topic": "retail_wholesale", "relevance_score": "0.737943"}], "overall_sentiment_score": -0.228327, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.223929", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson to stop selling talc-based baby powder in 2023", "url": "https://www.aljazeera.com/news/2022/8/12/johnson-and-johnson-talc-based-baby-powder", "time_published": "20220812T171641", "authors": [], "summary": "Johnson & Johnson announced it will cease global sales of its talc-based baby powder in 2023, transitioning to an all cornstarch-based portfolio. This decision comes after the company ended sales in North America in 2020 amid numerous lawsuits alleging its talc products caused cancer due to asbestos contamination, claims J&J denies. The company faces ongoing legal challenges and previously utilized a subsidiary's bankruptcy to pause lawsuits.", "banner_image": null, "source": "Al Jazeera", "category_within_source": "General", "source_domain": "Al Jazeera", "topics": [{"topic": "life_sciences", "relevance_score": "0.908795"}, {"topic": "retail_wholesale", "relevance_score": "0.719427"}, {"topic": "finance", "relevance_score": "0.637014"}], "overall_sentiment_score": -0.330813, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.348813", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson to replace talc-based powder with cornstarch", "url": "https://www.bbc.com/news/business-62514263", "time_published": "20220812T171640", "authors": ["Peter Hoskins"], "summary": "Johnson & Johnson announced it will stop making and selling its talc-based baby powder globally from next year, transitioning to an all cornstarch-based portfolio. This decision comes over two years after sales ended in the US, amid thousands of lawsuits alleging its talcum powder caused ovarian cancer due to asbestos contamination. J&J maintains that its talc-based product is safe, does not contain asbestos, and does not cause cancer.", "banner_image": null, "source": "BBC", "category_within_source": "General", "source_domain": "BBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.906378"}], "overall_sentiment_score": -0.265805, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.269027", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson will stop selling talcum-based baby powder globally", "url": "https://www.cbsnews.com/news/johnson-johnson-baby-powder-discontinued-sale/", "time_published": "20220812T111600", "authors": ["Khristopher J. Brooks"], "summary": "Johnson & Johnson announced it will stop selling its talcum-based baby powder globally and switch to a cornstarch version due to declining demand and ongoing lawsuits claiming the product caused ovarian cancer or mesothelioma. The company maintains the product is safe but cited \"misleading talc litigation advertising\" for the change. This move follows previous legal actions, including a significant reduction in damages awarded to women in one case, and a 2020 recall after asbestos was found in a bottle of the powder.", "banner_image": null, "source": "CBS News", "category_within_source": "General", "source_domain": "CBS News", "topics": [{"topic": "life_sciences", "relevance_score": "0.933206"}, {"topic": "finance", "relevance_score": "0.734136"}], "overall_sentiment_score": -0.241147, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.214067", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "J&J to end sales of baby powder with talc globally next year", "url": "https://apnews.com/article/health-canada-lawsuits-cancer-40bbfd5bb494a3d31a1374195b287f3b", "time_published": "20220812T100828", "authors": ["Americans with Disabilities Act (ADA)"], "summary": "Johnson & Johnson announced it will stop selling its talc-based baby powder globally in 2023, transitioning to a cornstarch-based product. This decision follows thousands of lawsuits alleging that the talcum powder caused cancer, despite the company's assertion of its product's safety supported by medical research. J&J had already ceased talc-based powder sales in the U.S. and Canada in 2020 due to declining demand and \"misleading talc litigation advertising.\"", "banner_image": "https://dims.apnews.com/dims4/default/33ff89f/2147483647/strip/true/crop/3000x1997+0+231/resize/320x213!/quality/90/?url=https%3A%2F%2Fstorage.googleapis.com%2Fafs-prod%2Fmedia%2F72d57eb379e04f16a99fa70f611ba59f%2F3000.jpeg", "source": "AP News", "category_within_source": "General", "source_domain": "AP News", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.132845, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.135680", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson to end sales of baby powder with talc globally next year", "url": "https://www.nbcnews.com/news/us-news/johnson-johnson-end-sales-baby-powder-talc-globally-year-rcna42805", "time_published": "20220812T093800", "authors": ["The Associated Press"], "summary": "Johnson & Johnson announced it will stop selling baby powder containing talc globally next year, replacing it with a cornstarch-based product. This decision follows thousands of lawsuits alleging the talcum powder caused cancer, though J&J maintains the product is safe. The company had already discontinued talc-based baby powder in the U.S. and Canada.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.915914"}, {"topic": "finance", "relevance_score": "0.716360"}], "overall_sentiment_score": 0.149352, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.122789", "ticker_sentiment_label": "Neutral"}]}, {"title": "After billions in legal costs, Johnson & Johnson plans to halt talc sales worldwide", "url": "https://www.fiercepharma.com/pharma/johnson-johnson-will-halt-worldwide-sales-iconic-baby-powder-will-replace-cornstarch-based", "time_published": "20220812T090800", "authors": ["Kevin Dunleavy"], "summary": "Johnson & Johnson announced it will discontinue worldwide sales of its talc-based baby powder in 2023, replacing it with a cornstarch-based version. This decision follows years of costly litigation over its talc products, amounting to billions in legal expenses, despite the company maintaining the product's safety. J&J had previously ceased talc powder sales in the U.S. and Canada and has faced numerous lawsuits and a significant verdict related to asbestos contamination claims.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.800242"}, {"topic": "earnings", "relevance_score": "0.711366"}, {"topic": "economy_macro", "relevance_score": "0.606075"}], "overall_sentiment_score": -0.397984, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.370241", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson to stop making talc-based baby powder globally", "url": "https://www.theguardian.com/business/2022/aug/12/johnson-and-johnson-to-stop-making-talc-based-baby-powder-globally", "time_published": "20220812T053000", "authors": ["Mark Sweney"], "summary": "Johnson & Johnson announced it will stop selling and making talc-based baby powder globally in 2023, two years after ceasing sales in North America. This decision comes amidst tens of thousands of lawsuits alleging its talc products caused cancer, though the company continues to maintain the product's safety. J&J states it will transition to an all cornstarch-based baby powder portfolio, optimizing its product offerings.", "banner_image": "https://assets.guim.co.uk/img/media/b6957c86a51d4512e0e012971f113ce7bc2245b0/0_207_3126_1876/master/3126.jpg?width=1200&quality=85&auto=format&fit=max&s=2138b2926be55b6a382e20560bd708a3", "source": "The Guardian", "category_within_source": "General", "source_domain": "The Guardian", "topics": [{"topic": "life_sciences", "relevance_score": "0.917814"}, {"topic": "retail_wholesale", "relevance_score": "0.741426"}], "overall_sentiment_score": -0.22494, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.210331", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "J&J to stop selling talc-based baby powder globally in 2023", "url": "https://www.cnbc.com/2022/08/11/jj-to-stop-selling-talc-based-baby-powder-globally-in-2023.html", "time_published": "20220811T174800", "authors": [], "summary": "Johnson & Johnson announced it will stop selling its talc-based baby powder globally in 2023, two years after discontinuing sales in the U.S. and Canada. This decision comes amidst approximately 38,000 lawsuits claiming the product caused cancer due to asbestos contamination, allegations J&J denies. The company will transition its baby powder portfolio to cornstarch-based products worldwide.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.927436"}, {"topic": "retail_wholesale", "relevance_score": "0.740799"}], "overall_sentiment_score": -0.270637, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.990734", "ticker_sentiment_score": "-0.264768", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "J&J discontinues talc baby powder amid lawsuits", "url": "https://www.axios.com/2022/08/11/johnson-johnson-baby-powder-talc-lawsuits-jj", "time_published": "20220811T171642", "authors": ["Nathan Bomey"], "summary": "Johnson & Johnson announced it will discontinue its talc-based baby powder globally in 2023, transitioning to cornstarch-based products. The company maintains its talc products are safe and do not cause cancer, citing the decision as purely commercial. This move comes amid approximately 38,000 lawsuits alleging that the talc products caused cancer due to asbestos contamination.", "banner_image": null, "source": "Axios", "category_within_source": "General", "source_domain": "Axios", "topics": [{"topic": "life_sciences", "relevance_score": "0.915424"}, {"topic": "retail_wholesale", "relevance_score": "0.736646"}], "overall_sentiment_score": -0.238358, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.246259", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson Will Discontinue Talc-Based Baby Powder Globally in 2023", "url": "https://www.nytimes.com/2022/08/11/business/johnson-and-johnson-talc-corn-starch.html", "time_published": "20220811T171640", "authors": ["Tiffany Hsu", "Roni Caryn Rabin"], "summary": "Johnson & Johnson announced it will discontinue selling talc-based baby powder globally in 2023, shifting entirely to cornstarch. This decision follows thousands of lawsuits from cancer patients who claimed the talc was contaminated with asbestos; however, J&J maintains its talc products are safe and asbestos-free. The company had already stopped selling the talc version in North America in 2020.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.924102"}, {"topic": "retail_wholesale", "relevance_score": "0.712519"}], "overall_sentiment_score": -0.279753, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.267462", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "The quest to make neurodegenerative disease a thing of the past", "url": "https://www.jnj.com/innovation/the-quest-to-make-neurodegenerative-disease-a-thing-of-the-past", "time_published": "20220810T171642", "authors": ["Hallie Levine"], "summary": "Johnson & Johnson is actively researching and developing innovative solutions to prevent, slow, and potentially cure neurodegenerative diseases like Alzheimer's disease and multiple sclerosis. The company is focusing on precision medicine approaches, high-efficacy treatments for MS, and tackling rare autoantibody-driven diseases, with the ultimate goal of making these conditions a thing of the past. Researchers are also working on early detection methods and personalized treatments, including targeting specific proteins and exploring therapeutic antibodies.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.414501, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.428705", "ticker_sentiment_label": "Bullish"}]}, {"title": "HCA Healthcare announces collaboration with Johnson & Johnson to address key healthcare clinical and industry issues", "url": "https://hcahealthcaretoday.com/2022/08/09/hca-healthcare-announces-collaboration-with-johnson-johnson-to-address-key-healthcare-clinical-and-industry-issues/", "time_published": "20220809T165630", "authors": [], "summary": "HCA Healthcare and Johnson & Johnson have announced a new collaboration to tackle critical healthcare issues. The partnership will initially focus on improving health equity, specifically through early-stage lung cancer detection in the Black community, enhancing nursing support within HCA Healthcare and Galen College of Nursing, and advancing cardiovascular health initiatives. This collaboration aims to leverage the strengths of both organizations to improve patient access, outcomes, and address the nursing crisis.", "banner_image": null, "source": "HCA Healthcare Today", "category_within_source": "General", "source_domain": "HCA Healthcare Today", "topics": [{"topic": "life_sciences", "relevance_score": "0.942174"}], "overall_sentiment_score": 0.386233, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "HCA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.424887", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.907878", "ticker_sentiment_score": "0.329898", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson supports creation of the Africa Frontline First Catalytic Fund", "url": "https://www.jnj.com/global-health-equityjohnson-johnson-supports-creation-of-the-africa-frontline-first-catalytic-fund", "time_published": "20220808T171640", "authors": [], "summary": "Johnson & Johnson, through its Foundation, is committing $15 million over three years to support the Global Fund's Africa Frontline First Catalytic Fund (AFF-CF). This initiative aims to strengthen primary healthcare by professionalizing and expanding the workforce of community health workers in 10 African countries by 2030. This support aligns with the Johnson & Johnson Center for Health Worker Innovation's broader commitment to aid 1 million health workers by 2030.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.911776"}], "overall_sentiment_score": 0.03413, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.308329", "ticker_sentiment_score": "0.020584", "ticker_sentiment_label": "Neutral"}]}, {"title": "136 years of championing women\u2019s health", "url": "https://www.jnj.com/our-heritage/136-year-history-of-championing-womens-health", "time_published": "20220804T171640", "authors": ["Johnson & Johnson"], "summary": "This article chronicles Johnson & Johnson's 136-year history of advocating for women's health through various initiatives, from medical advancements to employee benefits. It highlights key milestones such as developing essential maternity products, pioneering contraception, addressing maternal mortality disparities, and supporting global public health programs for women. The company's commitment extends to supporting its female employees and innovating solutions for widespread access to healthcare, demonstrating a long-standing dedication to women's well-being.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.930037"}], "overall_sentiment_score": 0.423025, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.444059", "ticker_sentiment_label": "Bullish"}]}, {"title": "Global TNF Alpha Inhibitors Market Report 2022-2026 & 2031", "url": "https://www.globenewswire.com/news-release/2022/08/04/2492186/28124/en/Global-TNF-Alpha-Inhibitors-Market-Report-2022-2026-2031-Featuring-Major-Players-AbbVie-Amgen-J-J-UCB-Novartis-Pfizer-Merck-Co-Janssen-Biotech-Ablynx-and-Momenta-Pharmaceuticals.html", "time_published": "20220804T070400", "authors": [], "summary": "The global TNF Alpha Inhibitors market is projected to grow from $38.56 billion in 2021 to $40.73 billion in 2022, reaching $43.83 billion by 2026. This growth is primarily driven by the increasing prevalence of inflammatory diseases like inflammatory bowel disease and psoriasis. Key players in this market include AbbVie, Amgen, and Johnson & Johnson, though the market faces limitations due to the adverse side effects of TNF alpha inhibitors.", "banner_image": null, "source": "GlobeNewswire", "category_within_source": "General", "source_domain": "GlobeNewswire", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.321202, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRK", "relevance_score": "0.985301", "ticker_sentiment_score": "0.300519", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.938149", "ticker_sentiment_score": "0.339097", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.891651", "ticker_sentiment_score": "0.305626", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.800783", "ticker_sentiment_score": "0.324240", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.794203", "ticker_sentiment_score": "0.323675", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "T.J. Maxx parent company to pay $13 million for selling recalled products", "url": "https://abcnews.go.com/Business/tj-maxx-parent-company-pay-13-million-selling/story?id=87872755", "time_published": "20220803T113100", "authors": ["Max Zahn"], "summary": "TJX Companies Inc., the parent company of T.J. Maxx, Marshalls, and HomeGoods, has agreed to pay a $13 million fine for selling approximately 1,200 recalled products, including those that posed a suffocation risk to infants. The sales occurred between 2014 and 2019 at brick-and-mortar stores and online. TJX will also implement internal controls and file annual compliance reports for five years to prevent future sales of recalled items.", "banner_image": null, "source": "ABC News", "category_within_source": "General", "source_domain": "ABC News", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.825848"}, {"topic": "finance", "relevance_score": "0.741413"}, {"topic": "earnings", "relevance_score": "0.616332"}], "overall_sentiment_score": -0.172385, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "TJX", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.346966", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KHC", "relevance_score": "0.636497", "ticker_sentiment_score": "-0.116122", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.620413", "ticker_sentiment_score": "-0.128494", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.611871", "ticker_sentiment_score": "-0.131881", "ticker_sentiment_label": "Neutral"}]}, {"title": "West Virginia cities reach $400 mln opioid distributor settlement", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/west-virginia-cities-reach-400-mln-opioid-distributor-deal-2022-08-01/", "time_published": "20220801T201900", "authors": ["Dietrich Knauth"], "summary": "West Virginia cities and counties have reached a $400 million settlement with drug distributors McKesson Corp, AmerisourceBergen Corp, and Cardinal Health Inc, resolving allegations that the companies fueled the opioid crisis in the state. This settlement covers over 100 local governments and follows previous state-level agreements, though it excludes Huntington and Cabell County, which lost their federal court case. The agreement aims to provide funds to communities hard-hit by opioid abuse, which has led to nearly 500,000 overdose deaths in the U.S. over two decades.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FVF7B2U63SNJJTKSG4D6FDDOTGM.jpg?auth=9c57d7b1a208c909e1be49103e33b6329a1b5baf34a652431ff6faff58f967ad&width=960&height=540&q=80", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.947477"}, {"topic": "finance", "relevance_score": "0.749887"}], "overall_sentiment_score": 0.020553, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "0.998351", "ticker_sentiment_score": "-0.323473", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MCK", "relevance_score": "0.940527", "ticker_sentiment_score": "0.232653", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.641906", "ticker_sentiment_score": "0.146996", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Johnson & Johnson Baby Powder Safe to Use?", "url": "https://www.mesotheliomaguide.com/community/is-johnson-johnson-baby-powder-safe/", "time_published": "20220729T171642", "authors": ["Devin Golden"], "summary": "This article discusses the safety of Johnson & Johnson Baby Powder, particularly focusing on its past talc-based formulation and asbestos contamination concerns. It details the company's transition to talc-free cornstarch-based baby powders and the global discontinuation of talc products, while also providing guidance for consumers and information on related health risks and legal options.", "banner_image": null, "source": "Mesothelioma Guide", "category_within_source": "General", "source_domain": "Mesothelioma Guide", "topics": [{"topic": "life_sciences", "relevance_score": "0.921780"}, {"topic": "finance", "relevance_score": "0.705788"}], "overall_sentiment_score": -0.411886, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.420034", "ticker_sentiment_label": "Bearish"}]}, {"title": "Pharma Stocks, ETFs Can Deal With Drug Pricing Legislation", "url": "https://www.etftrends.com/tactical-allocation-content-hub/pharma-stocks-etfs-can-deal-with-drug-pricing-legislation/", "time_published": "20220727T181557", "authors": ["Tom Lydon"], "summary": "The reappearance of drug pricing legislation in a mid-term election year might seem challenging for the healthcare sector, but analysts believe blue-chip pharmaceutical companies, including those in the VanEck Vectors Pharmaceutical ETF (PPH), can manage potential lower drug prices. A proposed Senate plan would allow Medicare to negotiate reduced pharmaceutical prices, targeting 10 drugs initially and potentially more later, with discounts based on how long a drug has been on the market. Despite these developments, PPH holdings are not necessarily facing immediate downside as the proposal applies only to Medicare recipients, and companies may already be adjusting pricing in anticipation.", "banner_image": null, "source": "ETF Trends", "category_within_source": "General", "source_domain": "ETF Trends", "topics": [{"topic": "life_sciences", "relevance_score": "0.914297"}, {"topic": "financial_markets", "relevance_score": "0.826245"}, {"topic": "economy_fiscal", "relevance_score": "0.749991"}], "overall_sentiment_score": 0.146165, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PPH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.139603", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.706526", "ticker_sentiment_score": "0.125264", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.614910", "ticker_sentiment_score": "0.108125", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.605449", "ticker_sentiment_score": "0.127488", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.619995", "ticker_sentiment_score": "0.145702", "ticker_sentiment_label": "Neutral"}]}, {"title": "3M to spin off $8.6 billion health care business", "url": "https://www.startribune.com/3m-to-spin-off-8-6-billion-health-care-business-create-new-3m/600193073", "time_published": "20220726T214600", "authors": ["Brooks Johnson"], "summary": "3M announced plans to spin off its $8.6 billion health care business, a move aimed at sharpening its focus and boosting profitability. The new entity, which will be the third-largest medical technology company in Minnesota, will focus on products like bandages and medical devices, while the remaining 3M will retain its other industrial and consumer segments. This separation is expected to be complete by the end of 2023 and follows a trend among industrial conglomerates to break apart businesses.", "banner_image": null, "source": "Star Tribune", "category_within_source": "General", "source_domain": "Star Tribune", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.912230"}, {"topic": "life_sciences", "relevance_score": "0.824611"}, {"topic": "earnings", "relevance_score": "0.728638"}], "overall_sentiment_score": 0.169609, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MMM", "relevance_score": "1.000000", "ticker_sentiment_score": "0.117532", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.602452", "ticker_sentiment_score": "0.220336", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.601781", "ticker_sentiment_score": "0.238708", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GE", "relevance_score": "0.743804", "ticker_sentiment_score": "0.128486", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.603579", "ticker_sentiment_score": "0.125399", "ticker_sentiment_label": "Neutral"}]}, {"title": "Teva Reaches Tentative $4.25 Billion Settlement Over Opioids (Published 2022)", "url": "https://www.nytimes.com/2022/07/26/health/teva-opioids-settlement.html", "time_published": "20220726T185559", "authors": ["Jan Hoffman"], "summary": "Teva Pharmaceuticals has reached a tentative settlement of up to $4.25 billion with approximately 2,500 local governments, states, and tribes regarding its involvement in the opioid crisis. The agreement aims to resolve thousands of lawsuits and includes payouts over 13 years, directed toward programs designed to alleviate the opioid epidemic, including provisions for overdose reversal medications. Teva, an Israeli company, was a significant producer of generic and branded opioid painkillers during the height of the crisis, outstripping even well-known names like Johnson & Johnson and Purdue Pharma.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.828304"}], "overall_sentiment_score": -0.252698, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "TEVA", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.404256", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.640467", "ticker_sentiment_score": "-0.146960", "ticker_sentiment_label": "Neutral"}]}, {"title": "3M\u2019s Healthcare Unit to Become Separate, Public Company", "url": "https://www.mddionline.com/business/3m-s-healthcare-unit-to-become-separate-public-company", "time_published": "20220726T173714", "authors": ["Omar Ford"], "summary": "3M announced it will spin off its healthcare unit into a separate, publicly traded company by the end of 2023, creating a $9 billion diversified healthcare technology company. This spin-off is part of a trend in the medtech space, following similar moves by companies like Zimmer Biomet and BD. Additionally, 3M's Aearo Technologies subsidiary is filing for Chapter 11 due to litigation over Combat Arms Earplugs.", "banner_image": "https://www.mddionline.com/sites/mddionline.com/files/image/2022-07/GettyImages-1304561845.jpeg", "source": "Medical Device and Diagnostic industry", "category_within_source": "General", "source_domain": "Medical Device and Diagnostic industry", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.803291"}], "overall_sentiment_score": 0.122424, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MMM", "relevance_score": "1.000000", "ticker_sentiment_score": "0.130994", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.608811", "ticker_sentiment_score": "0.116392", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.709824", "ticker_sentiment_score": "0.138345", "ticker_sentiment_label": "Neutral"}]}, {"title": "3M to spin off healthcare business, earplugs unit seeks bankruptcy protection", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/3m-spin-off-healthcare-business-2022-07-26/", "time_published": "20220726T162700", "authors": ["Kannaki Deka and Abhijith Ganapavaram"], "summary": "3M Co announced plans to spin off its healthcare business into a separately listed company, while its Aearo Technologies unit, which makes earplugs for the U.S. military, filed for bankruptcy protection. The move aims to simplify 3M's business and address thousands of defective earplug claims. 3M has committed $1 billion to fund a trust to resolve these claims.", "banner_image": "https://www.reuters.com/resizer/oM1x2w_gK_oA3hE-yP3zW9I90eA=/960x0/filters:format(jpg):quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/YDUXG772YFLF5B3Z62547K6RMY.jpg", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.936557"}, {"topic": "earnings", "relevance_score": "0.833329"}, {"topic": "life_sciences", "relevance_score": "0.735196"}, {"topic": "manufacturing", "relevance_score": "0.640371"}], "overall_sentiment_score": 0.298723, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MMM", "relevance_score": "1.000000", "ticker_sentiment_score": "0.153164", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GEHC", "relevance_score": "0.657254", "ticker_sentiment_score": "0.404562", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.570684", "ticker_sentiment_score": "0.257717", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Shares of HCA Healthcare Rise on Earnings Report", "url": "https://etfdb.com/portfolio-strategies-content-hub/shares-of-hca-healthcare-rise-on-earnings-report/", "time_published": "20220725T071219", "authors": ["Elle Caruso Fitzgerald"], "summary": "HCA Healthcare Inc. reported second-quarter earnings that surpassed analyst expectations, leading to a significant rise in its stock price. Despite the quarterly earnings beat, the company's shares are down year-to-date and over the last 52 weeks. For investors seeking diversified healthcare exposure beyond market-cap weighted ETFs, the Invesco S&P 500 Equal Weight Health Care ETF (RYH) offers an alternative with equal weighting for all holdings.", "banner_image": "https://etfdb.com/media/W1siZiIsIjIwMjUvMDkvMDUvZmRmd2QwM2prX1BvcnRmb2xpb19TdHJhdGVnaWVzX21hc3RoZWFkX292ZXJsYXlfMTYwMHgxMjFfMngucGngIl1d/Portfolio_Strategies_masthead_overlay_1600x121%402x.png", "source": "ETF Database", "category_within_source": "General", "source_domain": "ETF Database", "topics": [{"topic": "earnings", "relevance_score": "0.902753"}, {"topic": "life_sciences", "relevance_score": "0.703468"}, {"topic": "financial_markets", "relevance_score": "0.643062"}], "overall_sentiment_score": 0.184995, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RSPH", "relevance_score": "0.342014", "ticker_sentiment_score": "0.038294", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.476570", "ticker_sentiment_label": "Bullish"}, {"ticker": "UNH", "relevance_score": "0.631362", "ticker_sentiment_score": "0.112689", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.611791", "ticker_sentiment_score": "0.149298", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.648805", "ticker_sentiment_score": "0.106298", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson leans on beauty trends to create Vivvi & Bloom baby care brand", "url": "https://www.glossy.co/beauty/johnson-johnson-leans-on-beauty-trends-to-create-vivvi-bloom-baby-care-brand/", "time_published": "20220721T171643", "authors": ["Emma Sandler"], "summary": "Johnson & Johnson launched a new baby care brand, Vivvi & Bloom, inspired by beauty industry trends and designed to appeal to millennial and Gen-Z parents with natural formulas and a community-led development approach. This premium brand aims to capture a larger share of the baby care market, despite a recent decline in J&J's consumer health sales attributed to supply chain constraints. Vivvi & Bloom's strategy involves co-creation with parents and a digital-first marketing approach to differentiate itself from existing J&J baby lines like Johnson's Baby and Aveeno Baby.", "banner_image": null, "source": "Glossy", "category_within_source": "General", "source_domain": "Glossy", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.805802"}, {"topic": "life_sciences", "relevance_score": "0.719671"}, {"topic": "earnings", "relevance_score": "0.625250"}], "overall_sentiment_score": 0.089736, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.270485", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMT", "relevance_score": "0.621023", "ticker_sentiment_score": "0.011939", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.630737", "ticker_sentiment_score": "0.009573", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson names successor to veteran general counsel", "url": "https://www.governance-intelligence.com/careers/johnson-johnson-names-successor-veteran-general-counsel", "time_published": "20220720T171640", "authors": ["Ben Maiden"], "summary": "Elizabeth Forminard will take over as general counsel at Johnson & Johnson in October, succeeding Michael Ullmann who is retiring after 33 years with the company. Forminard has been with Johnson & Johnson for 16 years, serving as general counsel across various divisions. Ullmann served as general counsel for 11 years and guided the company through significant changes.", "banner_image": "NULL", "source": "| Governance Intelligence", "category_within_source": "General", "source_domain": "| Governance Intelligence", "topics": [{"topic": "life_sciences", "relevance_score": "0.940134"}], "overall_sentiment_score": 0.231743, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.227403", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Georgia families accuse opioid distributors of illegal drug dealing", "url": "https://www.reuters.com/legal/government/georgia-families-accuse-opioid-distributors-illegal-drug-dealing-2022-07-19/", "time_published": "20220719T211400", "authors": ["Dietrich Knauth"], "summary": "Families of opioid addicts in Georgia are suing Cardinal Health Inc, McKesson Corp, and JM Smith Corp, accusing them of acting as illegal drug dealers and contributing to the destruction of their families. They claim the companies filled illegitimate pharmacy orders and failed to report suspicious opioid purchases. This trial is distinct from many other opioid lawsuits as it seeks civil damages for individuals under Georgia's Drug Dealer Liability Act.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FVJ6C663D7NOX3N4GSHQ4S7P2UI.jpg?auth=d99859f518e317c9197c36a4959db62f8319f39d115e45a557b4260aa7463f64&width=1200&quality=85&h=800&height=800&operation=fit", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.900861"}, {"topic": "finance", "relevance_score": "0.712546"}], "overall_sentiment_score": -0.483366, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "0.981983", "ticker_sentiment_score": "-0.610395", "ticker_sentiment_label": "Bearish"}, {"ticker": "MCK", "relevance_score": "0.877119", "ticker_sentiment_score": "-0.563492", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.640830", "ticker_sentiment_score": "-0.242457", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "JPMorgan adds former J&J chief Gorsky to board", "url": "https://www.reuters.com/business/finance/jpmorgan-adds-former-jj-chief-gorsky-board-2022-07-19/", "time_published": "20220719T204100", "authors": ["Reuters"], "summary": "JPMorgan Chase & Co has elected Alex Gorsky, the former chief executive officer of Johnson & Johnson, as a director of the bank. Gorsky, who is currently an executive chairman at J&J, previously led the development of J&J's COVID-19 vaccine and steered the company through significant crises. His appointment to JPMorgan's board is effective immediately.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FGFG2Z2J6TJL57G2P2L2N7V5KJM.jpg?auth=d8164319c5b55018619a9af5d491f0388d75eac213ee59c5d0107e3aef05efb2&width=1200&height=630&quality=85&smart=true", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "finance", "relevance_score": "0.926346"}, {"topic": "life_sciences", "relevance_score": "0.714664"}], "overall_sentiment_score": 0.222077, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JPM", "relevance_score": "1.000000", "ticker_sentiment_score": "0.302129", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.938685", "ticker_sentiment_score": "0.255592", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.638053", "ticker_sentiment_score": "0.137091", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBM", "relevance_score": "0.607607", "ticker_sentiment_score": "0.138259", "ticker_sentiment_label": "Neutral"}]}, {"title": "Unblocking the flow at J&J", "url": "https://www.scmr.com/article/unblocking_the_flow_at_jj", "time_published": "20220719T171641", "authors": ["Bob Trebilcock"], "summary": "This article discusses how Meri Stevens, Worldwide VP Consumer Health Supply Chain and Deliver at Johnson & Johnson, manages one of the most complex global supply chains. She focuses on digital transformation, reliability, resilience, and talent acquisition to overcome \"flow blockers\" and ensure product availability. The piece highlights J&J's investment in digital capabilities to sense demand, optimize logistics, and foster an inclusive workplace culture.", "banner_image": null, "source": "Supply Chain Management Review", "category_within_source": "General", "source_domain": "Supply Chain Management Review", "topics": [{"topic": "life_sciences", "relevance_score": "0.911659"}, {"topic": "manufacturing", "relevance_score": "0.835581"}, {"topic": "technology", "relevance_score": "0.746082"}, {"topic": "retail_wholesale", "relevance_score": "0.621756"}, {"topic": "economy_macro", "relevance_score": "0.625275"}], "overall_sentiment_score": 0.463, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.452155", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson Reports Q2 2022 Results", "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q2-2022-results", "time_published": "20220719T171641", "authors": [], "summary": "Johnson & Johnson reported Q2 2022 results with total sales growth of 3.0% to $24.0 billion and adjusted earnings per share increasing 4.4% to $2.59. The company maintained its 2022 full-year guidance for adjusted operational sales and earnings per share while acknowledging the impact of a strengthening U.S. dollar on reported results. Key growth drivers included pharmaceutical products like DARZALEX and STELARA, and notable regulatory announcements were made regarding CARVYKTI and talquetamab.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "earnings", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.941217"}], "overall_sentiment_score": 0.342355, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.347918", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "GE reveals brand names for 3 new companies following reorganization", "url": "https://www.upi.com/Top_News/US/2022/07/18/GE-brand-names-new-companies-reorganization/5821658166985/", "time_published": "20220718T145100", "authors": ["Don Jacobson"], "summary": "General Electric has announced the brand names for the three new companies that will result from its major reorganization. The new spinoffs will be called GE HealthCare and GE Vernova, while the remaining legacy firm will be renamed GE Aerospace. This move is part of GE's strategy to reduce debt, improve operational performance, and grow profits, with the three new companies initially valued at nearly $20 billion.", "banner_image": null, "source": "upi", "category_within_source": "General", "source_domain": "upi", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.921351"}, {"topic": "manufacturing", "relevance_score": "0.838340"}, {"topic": "life_sciences", "relevance_score": "0.729172"}, {"topic": "energy_transportation", "relevance_score": "0.700983"}], "overall_sentiment_score": 0.288053, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.315778", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GEHC", "relevance_score": "0.808848", "ticker_sentiment_score": "0.442121", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.603306", "ticker_sentiment_score": "0.147342", "ticker_sentiment_label": "Neutral"}]}, {"title": "Haleon makes market debut as GSK and Pfizer complete consumer health spin-off", "url": "https://www.proactiveinvestors.co.uk/companies/news/987650/haleon-makes-market-debut-as-gsk-and-pfizer-complete-consumer-health-spin-off-987650.html", "time_published": "20220718T074000", "authors": ["Ian Lyall"], "summary": "Haleon PLC has made its stock market debut as the largest company to list in London in over a decade, following its spin-out from GSK PLC and Pfizer. Existing GSK investors received shares in Haleon, with GSK retaining a 13.5% stake and Pfizer holding 32%. The consumer health company, known for brands like Sensodyne and Panadol, generated \u00a39.5bn in sales last year and is expected to have an enterprise valuation of \u00a340bn to \u00a345bn, placing it in the top quarter of the FTSE 100.", "banner_image": null, "source": "Proactive Investors", "category_within_source": "General", "source_domain": "Proactive Investors", "topics": [{"topic": "ipo", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.912991"}], "overall_sentiment_score": 0.244818, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HLN", "relevance_score": "1.000000", "ticker_sentiment_score": "0.325122", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.621105", "ticker_sentiment_score": "0.207951", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.564284", "ticker_sentiment_score": "0.139346", "ticker_sentiment_label": "Neutral"}]}, {"title": "Allergan, Teva to Pay $54M in San Francisco Opioid Lawsuit", "url": "https://www.nbcbayarea.com/news/local/allergan-teva-san-francisco-opioid-lawsuit/2942112/", "time_published": "20220712T115600", "authors": [], "summary": "Opioid manufacturers Allergan and Teva have agreed to a $54 million settlement with San Francisco in a federal lawsuit alleging they fueled the opioid crisis. The settlement includes $34 million in cash and $20 million worth of Narcan. This agreement comes as closing arguments against the remaining defendant, Walgreens, are set to begin.", "banner_image": null, "source": "NBC Bay Area", "category_within_source": "General", "source_domain": "NBC Bay Area", "topics": [{"topic": "life_sciences", "relevance_score": "0.918412"}, {"topic": "finance", "relevance_score": "0.749282"}], "overall_sentiment_score": -0.369978, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "TEVA", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.449682", "ticker_sentiment_label": "Bearish"}, {"ticker": "WBA", "relevance_score": "0.719864", "ticker_sentiment_score": "-0.335371", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.640542", "ticker_sentiment_score": "-0.316130", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CVS", "relevance_score": "0.648643", "ticker_sentiment_score": "-0.322995", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WMT", "relevance_score": "0.630453", "ticker_sentiment_score": "-0.333663", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-opens-first-satellite-center-for-global-health-discovery-in-asia-pacific-at-duke-nus-to-advance-dengue-research-301571141.html", "time_published": "20220620T200000", "authors": [], "summary": "Johnson & Johnson has opened its first Satellite Center for Global Health Discovery in Asia Pacific at Singapore's Duke-NUS Medical School to advance research against flaviviruses, including dengue. This initiative builds on existing collaborations and aims to develop new solutions for these diseases, which disproportionately affect the region. The center will also complement a QuickFire Challenge to crowdsource innovative ideas for treating, controlling, or preventing flavivirus infections.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.410683, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.438944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dr. Maky Zanganeh is Honored as One of the Top 10 Influential Chief Operating Officers of 2021", "url": "https://www.newswire.com/news/dr-maky-zanganeh-is-honored-as-one-of-the-top-10-influential-chief-21741580", "time_published": "20220616T183652", "authors": [], "summary": "Dr. Maky Zanganeh, the Chief Operating Officer at Summit Therapeutics, has been recognized as one of the Top 10 Influential Chief Operating Officers of 2021 by Industry Era Review Magazine. She is honored for her significant contributions and transformations in the healthcare industry, including her previous role at Pharmacyclics where she oversaw a major collaboration with Johnson & Johnson and a $21 billion sale to AbbVie Inc. Dr. Zanganeh is also a recognized speaker for the United Nations and an author.", "banner_image": null, "source": "Newswire :) Press Release Distribution", "category_within_source": "General", "source_domain": "Newswire :) Press Release Distribution", "topics": [{"topic": "life_sciences", "relevance_score": "0.948253"}], "overall_sentiment_score": 0.379436, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SMMT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.485913", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABBV", "relevance_score": "0.638103", "ticker_sentiment_score": "0.332150", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.586796", "ticker_sentiment_score": "0.281463", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Evotec enters drug discovery alliance with Janssen", "url": "https://www.drugdiscoverytrends.com/evotec-enters-drug-discovery-alliance-with-janssen/", "time_published": "20220614T163713", "authors": ["Brian Buntz"], "summary": "Evotec announced a drug discovery alliance with Janssen Pharmaceutica NV to identify drug targets and optimize chemical assets using Evotec's end-to-end drug discovery and development platform. Evotec could receive up to \u20ac210 million per project plus tiered royalties. This collaboration follows similar agreements with Bristol Myers Squibb and Almirall S.A., and the recent acquisition of Rigenerand Srl.", "banner_image": null, "source": "www.drugdiscoverytrends.com", "category_within_source": "General", "source_domain": "www.drugdiscoverytrends.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.944613"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.710000"}], "overall_sentiment_score": 0.377047, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "EVO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.407761", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.933546", "ticker_sentiment_score": "0.311549", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.626509", "ticker_sentiment_score": "0.344822", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regenxbio debuts $65M gene therapy manufacturing facility at its Maryland HQ", "url": "https://www.fiercepharma.com/manufacturing/regenxbio-debuts-65m-gene-therapy-manufacturing-facility", "time_published": "20220614T095500", "authors": ["Joseph Keenan"], "summary": "Regenxbio has launched a new $65 million gene therapy manufacturing facility in Rockville, Maryland, enhancing its capacity for adeno-associated virus vector production up to 2,000 liters. This facility is part of a larger $100 million investment to establish end-to-end gene therapy capabilities. The company also joined a U.S. initiative for rare disease gene therapies and recently received $370 million from AbbVie for its eye disease gene therapy RGX-314.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.909182"}, {"topic": "manufacturing", "relevance_score": "0.730945"}], "overall_sentiment_score": 0.379151, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "RGNX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.640172", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABBV", "relevance_score": "0.631360", "ticker_sentiment_score": "0.341449", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.643566", "ticker_sentiment_score": "0.305689", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.649897", "ticker_sentiment_score": "0.323092", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.642827", "ticker_sentiment_score": "0.341783", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Big Tobacco Is Funding Opposition to Global Covid Vaccine Access", "url": "https://inthesetimes.com/article/tobacco-industry-consumer-choice-center-wto-trips-waiver-vaccines-intellectual-property", "time_published": "20220610T161713", "authors": ["Sarah Lazare"], "summary": "Major tobacco companies, including British American Tobacco and Japan Tobacco International, are funding the Consumer Choice Center (CCC), an organization actively opposing a World Trade Organization proposal to suspend intellectual property rules for COVID-19 vaccines and treatments. Critics argue that the tobacco industry is undermining global public health efforts, driven by its reliance on intellectual property rules for profit, past use of these rules against public health measures, and even its own foray into COVID-19 vaccine development. This opposition highlights the industry's broader interest in protecting intellectual property, which it has historically used to fight regulations and secure its financial interests.", "banner_image": null, "source": "In These Times", "category_within_source": "General", "source_domain": "In These Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.931852"}, {"topic": "economy_macro", "relevance_score": "0.709996"}, {"topic": "finance", "relevance_score": "0.606720"}], "overall_sentiment_score": -0.322413, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "BTI", "relevance_score": "0.303640", "ticker_sentiment_score": "0.006501", "ticker_sentiment_label": "Neutral"}, {"ticker": "MO", "relevance_score": "0.738243", "ticker_sentiment_score": "-0.410328", "ticker_sentiment_label": "Bearish"}, {"ticker": "PM", "relevance_score": "0.700990", "ticker_sentiment_score": "-0.449312", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.615478", "ticker_sentiment_score": "-0.327622", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.606783", "ticker_sentiment_score": "-0.316224", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Dupilumab FDA Approved for AD Patients 6 months to 5 years", "url": "https://www.dermatologytimes.com/view/dupilumab-fda-approved-for-ad-patients-6-months-to-5-years", "time_published": "20220608T182549", "authors": ["Linda Stocum", "Associate Editor"], "summary": "The FDA has approved dupilumab (Dupixent) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis, marking it as the first biologic medicine for this age group. This approval is supported by data from the LIBERTY AD trial, which showed significant improvement in skin condition, itch, and quality of life for patients treated with dupilumab. The drug offers a new targeted treatment option for young children, addressing a significant unmet need.", "banner_image": null, "source": "Dermatology Times", "category_within_source": "General", "source_domain": "Dermatology Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.914173"}], "overall_sentiment_score": 0.386171, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "1.000000", "ticker_sentiment_score": "0.932196", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.644322", "ticker_sentiment_score": "0.114431", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.573183", "ticker_sentiment_score": "0.102665", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA committee OKs Novavax's late-to-the-game COVID-19 vaccine", "url": "https://www.cbsnews.com/news/covid-19-vaccine-fda-to-review-novavax-shot/", "time_published": "20220607T190400", "authors": ["Megan Cerullo"], "summary": "An independent FDA committee has voted to recommend Novavax's COVID-19 vaccine for emergency use authorization in the U.S. This vaccine, a protein-based shot, has already been approved in 41 other countries and could become the fourth FDA-approved coronavirus vaccine on the U.S. market. The decision aims to increase vaccine uptake, especially among those hesitant about mRNA technology.", "banner_image": null, "source": "CBS News", "category_within_source": "General", "source_domain": "CBS News", "topics": [{"topic": "life_sciences", "relevance_score": "0.921145"}, {"topic": "financial_markets", "relevance_score": "0.614514"}], "overall_sentiment_score": 0.139993, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.279770", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.604707", "ticker_sentiment_score": "0.143569", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.647790", "ticker_sentiment_score": "0.120045", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.551688", "ticker_sentiment_score": "0.139368", "ticker_sentiment_label": "Neutral"}]}, {"title": "What Can a Multi-Factor Screening Methodology Do for Your Core Equity Exposure?", "url": "https://www.etftrends.com/multi-asset-channel/what-can-a-multi-factor-screening-methodology-do-for-your-core-equity-exposure/", "time_published": "20220603T123622", "authors": ["Elle Caruso Fitzgerald"], "summary": "This article discusses how applying a multi-factor screening methodology can improve risk-adjusted returns for large-cap equity portfolios. It highlights factors such as value, quality, and momentum, and introduces the FlexShares US Quality Large Cap Index Fund (QLC) which integrates these factors. The fund aims to provide benefits of these factor exposures while maintaining a similar risk profile to the broader large-cap market.", "banner_image": "https://www.etftrends.com/wp-content/uploads/2023/10/multi-asset_OVERLAY_1600x121-1x.png", "source": "ETF Trends", "category_within_source": "General", "source_domain": "ETF Trends", "topics": [{"topic": "financial_markets", "relevance_score": "0.926061"}, {"topic": "finance", "relevance_score": "0.733564"}], "overall_sentiment_score": 0.325722, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QLC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.431522", "ticker_sentiment_label": "Bullish"}, {"ticker": "AAPL", "relevance_score": "0.737646", "ticker_sentiment_score": "0.345757", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.610101", "ticker_sentiment_score": "0.297577", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOGL", "relevance_score": "0.637033", "ticker_sentiment_score": "0.281668", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.587257", "ticker_sentiment_score": "0.222997", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson aims to transform the experience of clinical research with new ClinApp platform", "url": "https://diginomica.com/johnson-johnson-aims-transform-experience-clinical-research-new-clinapp-platform", "time_published": "20220602T171642", "authors": ["Derek du Preez"], "summary": "Johnson & Johnson is developing a new platform called ClinApp, built on Pega Infinity, to streamline and enhance the clinical research process. This initiative aims to address the complexity and inefficiencies associated with clinical trials, which involve managing millions of data points and numerous stakeholders. The ClinApp platform seeks to provide a unified user experience, improve operational oversight, and reduce costs throughout the clinical trial lifecycle.", "banner_image": null, "source": "Diginomica", "category_within_source": "General", "source_domain": "Diginomica", "topics": [{"topic": "life_sciences", "relevance_score": "0.929860"}, {"topic": "technology", "relevance_score": "0.832863"}], "overall_sentiment_score": 0.401903, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.962288", "ticker_sentiment_score": "0.439239", "ticker_sentiment_label": "Bullish"}]}, {"title": "Pfizer to exit GSK consumer health joint venture after spinoff", "url": "https://www.biopharmadive.com/news/pfizer-gsk-consumer-health-exit-stake/624714/", "time_published": "20220601T180645", "authors": ["Kristin Jensen"], "summary": "Pfizer plans to sell its 32% stake in the consumer health joint venture with GlaxoSmithKline after it spins off into a new standalone corporation called Haleon. GSK will contribute at least 80% of its 68% holding to Haleon, which is set to begin trading on the London Stock Exchange on July 18. Both companies aim to focus on vaccines and new medicine development, with Pfizer exiting in a \"disciplined manner\" to maximize shareholder value.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.934205"}, {"topic": "life_sciences", "relevance_score": "0.839460"}], "overall_sentiment_score": 0.144112, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.136169", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.747955", "ticker_sentiment_score": "0.133305", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.643737", "ticker_sentiment_score": "0.115235", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top 10 Players of the Internet of Medical Things (IoMT) Changing the Industry\u2019s Face", "url": "https://www.fortunebusinessinsights.com/blog/top-players-in-the-internet-of-medical-things-iomt-sector-10684", "time_published": "20220530T164640", "authors": [], "summary": "This article identifies the top 10 players in the Internet of Medical Things (IoMT) sector as of 2022, highlighting their contributions and financial performance. It discusses how the IoMT market is rapidly growing, especially accelerated by the COVID-19 pandemic, and details the strategies and key product developments of leading companies like Medtronic, Philips, and Boston Scientific.", "banner_image": null, "source": "Fortune Business Insights", "category_within_source": "General", "source_domain": "Fortune Business Insights", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "technology", "relevance_score": "0.919357"}], "overall_sentiment_score": 0.299891, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GEHC", "relevance_score": "0.943572", "ticker_sentiment_score": "0.300409", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.869331", "ticker_sentiment_score": "0.314626", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.821883", "ticker_sentiment_score": "0.302088", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.793934", "ticker_sentiment_score": "0.265207", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.731908", "ticker_sentiment_score": "0.301109", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Legg Mason Low Volatility High Dividend ETF (LVHD) Pays Off", "url": "https://www.kiplinger.com/investing/etfs/604732/legg-mason-low-volatility-high-dividend-etf-lvhd-pays-off", "time_published": "20220525T173605", "authors": ["Nellie S. Huang"], "summary": "The Legg Mason Low Volatility High Dividend ETF (LVHD) has demonstrated resilience amidst market turbulence, outperforming the S&P 500 Index with a 2.2% loss year-to-date compared to the S&P 500's 13.1% decline. The fund focuses on high-quality companies with strong dividend yields, steady profits, and low share-price volatility, favoring sectors like utilities, consumer staples, and real estate, and boasts a 3.06% dividend yield. While it lagged the S&P 500 in 2020 due to its focus on established companies over high-growth stocks, it proved 5% less volatile over a three-year period.", "banner_image": null, "source": "Kiplinger", "category_within_source": "General", "source_domain": "Kiplinger", "topics": [{"topic": "financial_markets", "relevance_score": "0.919963"}, {"topic": "economy_monetary", "relevance_score": "0.840626"}, {"topic": "real_estate", "relevance_score": "0.728086"}], "overall_sentiment_score": 0.330462, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LVHD", "relevance_score": "1.000000", "ticker_sentiment_score": "0.434067", "ticker_sentiment_label": "Bullish"}, {"ticker": "LMT", "relevance_score": "0.636458", "ticker_sentiment_score": "0.328392", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KO", "relevance_score": "0.632916", "ticker_sentiment_score": "0.334579", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.643776", "ticker_sentiment_score": "0.305158", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nigeria receives 4.4 million doses of J&J COVID vaccine from Spain", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/nigeria-receives-44-million-doses-jj-covid-vaccine-spain-2022-05-24/", "time_published": "20220525T074100", "authors": ["Reuters"], "summary": "Nigeria has received 4.4 million doses of the Johnson & Johnson COVID-19 vaccine from Spain, adding to previous donations from other EU countries. This donation will help Nigeria reach its goal of vaccinating 70% of its population, as only 15.8% are currently fully vaccinated. The country has recorded over 255,000 confirmed cases and 3,143 deaths from the virus.", "banner_image": "https://www.reuters.com/resizer/v2/4S2V2AAN4RPH3J3S7X42K2K5J4.jpg?auth=9c3a3c2c5c0c9e7e7a5e8e8e7e7e7e7e7e7e7e7e7e7e7e7e7e7e7e7e7e7e7e7e", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.941691"}, {"topic": "economy_macro", "relevance_score": "0.623750"}], "overall_sentiment_score": 0.120588, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.966874", "ticker_sentiment_score": "0.129675", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Seeking to Avoid Thousands of Lawsuits With Texas Two-Step", "url": "https://www.corporatecrimereporter.com/news/200/johnson-johnson-seeking-to-avoid-thousands-of-lawsuits-with-texas-two-step/", "time_published": "20220519T082600", "authors": ["Editor"], "summary": "Johnson & Johnson is utilizing a controversial legal strategy known as the \"Texas Two-Step\" to avoid thousands of product liability lawsuits alleging their talc products caused cancer. This strategy involves splitting a company and transferring liabilities to a new entity that then declares bankruptcy, effectively shielding the parent company's assets. Critics, including Senator Dick Durbin and legal experts, argue this tactic denies victims their right to a jury trial and fair compensation, prompting calls for legislative action to close the loophole.", "banner_image": null, "source": "Corporate Crime Reporter", "category_within_source": "General", "source_domain": "Corporate Crime Reporter", "topics": [{"topic": "life_sciences", "relevance_score": "0.928583"}, {"topic": "finance", "relevance_score": "0.736730"}], "overall_sentiment_score": -0.444038, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.403960", "ticker_sentiment_label": "Bearish"}]}, {"title": "Mondelez International strategy push hits sweet spot", "url": "https://www.just-food.com/features/mondelez-international-strategy-push-hits-sweet-spot/", "time_published": "20220518T173638", "authors": ["Dean Best"], "summary": "Mondelez International's latest strategy update, focusing on chocolate, biscuits, and baked snacks, has been well-received by investors. CEO Dirk Van De Put outlined plans for organic growth and M&A, alongside the divestment of its chewing-gum business in developed markets and the Halls cough-sweets brand. Analysts continue to view Mondelez positively, maintaining a \"buy\" rating on its shares.", "banner_image": null, "source": "Global Food Industry News", "category_within_source": "General", "source_domain": "Global Food Industry News", "topics": [{"topic": "retail_wholesale", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.905629"}, {"topic": "earnings", "relevance_score": "0.837759"}, {"topic": "economy_macro", "relevance_score": "0.720424"}], "overall_sentiment_score": 0.158284, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDLZ", "relevance_score": "0.975421", "ticker_sentiment_score": "0.449635", "ticker_sentiment_label": "Bullish"}, {"ticker": "KDP", "relevance_score": "0.641498", "ticker_sentiment_score": "0.275736", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.581134", "ticker_sentiment_score": "-0.115441", "ticker_sentiment_label": "Neutral"}, {"ticker": "GIS", "relevance_score": "0.551332", "ticker_sentiment_score": "0.063724", "ticker_sentiment_label": "Neutral"}]}, {"title": "Innovator Interview: Align Technology\u2019s Kamal Bhandal", "url": "https://brand-innovators.com/innovator-interview-align-technologys-kamal-bhandal/", "time_published": "20220512T160640", "authors": ["Dianna Dilworth"], "summary": "Kamal Bhandal, VP of Global Consumer & Brand Marketing at Align Technology, discusses the company's reliance on creator-led content and authentic storytelling, especially in reaching Gen Z. She highlights how social media and influencer marketing have been central to Align's strategy long before they became mainstream and how these approaches evolved during the pandemic. Bhandal also shares career advice for women in marketing and her predictions for 2022, emphasizing the creator economy and compassionate leadership.", "banner_image": null, "source": "Brand Innovators", "category_within_source": "General", "source_domain": "Brand Innovators", "topics": [{"topic": "life_sciences", "relevance_score": "0.806252"}, {"topic": "technology", "relevance_score": "0.703192"}], "overall_sentiment_score": 0.291052, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALGN", "relevance_score": "1.000000", "ticker_sentiment_score": "0.548050", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.643624", "ticker_sentiment_score": "0.215611", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PM", "relevance_score": "0.587427", "ticker_sentiment_score": "0.121287", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medtronic completes Intersect acquisition following FTC order", "url": "https://www.medtechdive.com/news/ftc-medtronic-divest-fiagon-intersect/623540/", "time_published": "20220511T173639", "authors": ["Nick Paul Taylor"], "summary": "Medtronic has completed its acquisition of Intersect ENT after the Federal Trade Commission (FTC) mandated the divestiture of Intersect's subsidiary, Fiagon. The $1.1 billion deal, initially announced in August, faced regulatory hurdles due to concerns about market consolidation in ear, nose, and throat navigation systems and balloon sinus dilation products. As part of the agreement, Medtronic will acquire Intersect's Propel and Sinuva sinus implant product lines, technology, intellectual property, and a California facility, with Intersect employees joining Medtronic.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.909114"}], "overall_sentiment_score": 0.177911, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.224286", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.615536", "ticker_sentiment_score": "0.128744", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.619197", "ticker_sentiment_score": "0.102600", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J appoints consumer health head Thibaut Mongon to CEO of spun-off business", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/jj-appoints-consumer-health-head-thibaut-mongon-ceo-spun-off-business-2022-05-11/", "time_published": "20220511T111600", "authors": ["Reuters"], "summary": "Johnson & Johnson has appointed Thibaut Mongon as the chief executive officer for its consumer health division, which the company plans to spin off by the end of next year. Paul Ruh was also named CFO for the upcoming entity. This move follows J&J's November announcement to spin off its consumer health segment to concentrate on pharmaceuticals and medical devices.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.903268"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.810211"}], "overall_sentiment_score": 0.41577, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.422613", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-appoints-thibaut-mongon-as-ceo-designate-of-planned-new-consumer-health-company-301544548.html", "time_published": "20220511T063000", "authors": [], "summary": "Johnson & Johnson has appointed Thibaut Mongon as CEO Designate and Paul Ruh as CFO Designate for its planned new Consumer Health Company, which is expected to separate in 2023. This move aims to create two independent global leaders, allowing for more targeted strategies and accelerated growth in both the new Johnson & Johnson and the Consumer Health Company. Mongon and Ruh bring extensive experience, with Mongon having led J&J's Consumer Health segment since 2019 and Ruh previously serving as CFO of Consumer Health at J&J and holding various roles at PepsiCo.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.935489"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.828625"}, {"topic": "finance", "relevance_score": "0.711499"}], "overall_sentiment_score": 0.444841, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.400765", "ticker_sentiment_label": "Bullish"}, {"ticker": "KVUE", "relevance_score": "0.852814", "ticker_sentiment_score": "0.409725", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson MedTech appoints new CFO", "url": "https://www.massdevice.com/johnson-johnson-medtech-appoints-new-cfo/", "time_published": "20220509T171641", "authors": ["Sean Whooley"], "summary": "Johnson & Johnson MedTech has appointed Kurt Van den Bosch as its new CFO, group finance. Van den Bosch, who previously served as area VP of mid-sized markets for J&J MedTech EMEA, will provide financial leadership to the global organization and report to Joe Wolk, EVP and CFO of Johnson & Johnson. He replaces Flavia Pease, who transitioned to Charles River Laboratories.", "banner_image": null, "source": "MassDevice", "category_within_source": "General", "source_domain": "MassDevice", "topics": [{"topic": "life_sciences", "relevance_score": "0.905492"}], "overall_sentiment_score": 0.126415, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.127254", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRL", "relevance_score": "0.629880", "ticker_sentiment_score": "0.109673", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYB", "relevance_score": "0.610997", "ticker_sentiment_score": "0.177270", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson to Continue Global Sale of Talc-Based Baby Powder", "url": "https://www.asbestos.com/news/2022/05/09/johnson-johnson-baby-powder-talc/", "time_published": "20220509T171640", "authors": ["Tim Povtak", "Walter Pacheco"], "summary": "Johnson & Johnson will continue to sell its talc-based baby powder globally after shareholders rejected a proposal to end its worldwide distribution. This decision follows J&J discontinuing sales in the U.S. and Canada in 2020 due to lawsuits alleging asbestos contamination, which led to significant legal fees and settlements. The company maintains its product is safe and has created a subsidiary, LTL Management LLC, to manage the ongoing liabilities from the estimated 40,000 talc lawsuits.", "banner_image": null, "source": "Mesothelioma Center", "category_within_source": "General", "source_domain": "Mesothelioma Center", "topics": [{"topic": "life_sciences", "relevance_score": "0.922934"}, {"topic": "finance", "relevance_score": "0.748248"}], "overall_sentiment_score": -0.404946, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.380092", "ticker_sentiment_label": "Bearish"}]}, {"title": "FDA PLACES NEW RESTRICTIONS ON JOHNSON & JOHNSON\u2019S COVID-19 VACCINE", "url": "https://www.stoptheclot.org/news/fda-places-new-restrictions-on-johnson-johnsons-covid-19-vaccine/", "time_published": "20220506T171642", "authors": [], "summary": "The FDA has placed new restrictions on Johnson & Johnson's COVID-19 vaccine, limiting its emergency use authorization to individuals 18 and older for whom other vaccines are not appropriate or accessible, or who would otherwise remain unvaccinated. This decision is due to the rare risk of thrombosis with thrombocytopenia syndrome (TTS), a dangerous clotting condition. Despite this, the FDA maintains that the vaccine's benefits still outweigh its risks for certain populations.", "banner_image": null, "source": "National Blood Clot Alliance", "category_within_source": "General", "source_domain": "National Blood Clot Alliance", "topics": [{"topic": "life_sciences", "relevance_score": "0.918723"}], "overall_sentiment_score": -0.077716, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.416807", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.622621", "ticker_sentiment_score": "0.107861", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.604369", "ticker_sentiment_score": "0.111238", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA limits J&J COVID-19 vaccine use to certain adults", "url": "https://www.aha.org/news/headline/2022-05-06-fda-limits-jj-covid-19-vaccine-use-certain-adults", "time_published": "20220506T150200", "authors": [], "summary": "The FDA has revised its emergency use authorization for the Johnson & Johnson COVID-19 vaccine, limiting its use to adults 18 and older who cannot access or are not clinically appropriate for other vaccines, or who choose it otherwise. This decision was based on an updated analysis of the risk of thrombosis with thrombocytopenia syndrome (TTS), a rare but potentially life-threatening blood clotting condition. The agency determined that this risk warrants restrictions on the vaccine's authorized use.", "banner_image": null, "source": "American Hospital Association", "category_within_source": "General", "source_domain": "American Hospital Association", "topics": [{"topic": "life_sciences", "relevance_score": "0.934886"}], "overall_sentiment_score": 0.043049, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.210082", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.732673", "ticker_sentiment_score": "0.125419", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.714926", "ticker_sentiment_score": "0.110382", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eli Lilly & Co. stock outperforms market despite losses on the day", "url": "https://www.marketwatch.com/data-news/eli-lilly-co-stock-outperforms-market-despite-losses-on-the-day-01651784670-a754361a3970?gaa_at=eafs&gaa_n=AWEtsqdQqcP33KIRgsmFEO6VwEDo8MRoYvmOilSgIhel69F8Fq9je9YgqUXv&gaa_ts=69079791&gaa_sig=qEybRxQhnDHkOzR-4weIhNDtwe75NHU542kU6uS8ZDE-W_3yhzEv8CoXPN288pHsSNjmUUuCcGo41E6fIt61pw%3D%3D", "time_published": "20220505T170400", "authors": ["MarketWatch Automation"], "summary": "Eli Lilly & Co. (LLY) stock fell 0.86% on Thursday, May 5, 2022, closing at $292.37, despite a broader market downturn where the S&P 500 and Dow Jones Industrial Average saw significant losses. The company's stock outperformed several competitors, although it closed $21.63 short of its 52-week high. Trading volume for Eli Lilly & Co. exceeded its 50-day average.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "financial_markets", "relevance_score": "0.943612"}, {"topic": "life_sciences", "relevance_score": "0.829586"}], "overall_sentiment_score": 0.128291, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.992996", "ticker_sentiment_score": "0.118750", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.666809", "ticker_sentiment_score": "0.106029", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.615172", "ticker_sentiment_score": "0.136779", "ticker_sentiment_label": "Neutral"}]}, {"title": "Opioid distributors reach $518 mln settlement with Washington state", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/opioid-distributors-reach-518-million-settlement-with-washington-state-mckesson-2022-05-03/", "time_published": "20220503T214100", "authors": ["Dietrich Knauth"], "summary": "Washington state has reached a $518 million settlement with drug distributors McKesson Corp, AmerisourceBergen Corp, and Cardinal Health Inc, concluding a trial over their role in the opioid epidemic. The state had previously opted out of a $26 billion nationwide settlement, asserting that this individual settlement provides significant additional resources for combating the opioid crisis. The settlement stipulates payments spread over 17 years and is contingent on all Washington's political subdivisions agreeing to participate by September 2022.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FDUU52B3XPNJJNB5P3BPX6G242A.JPG?auth=76b4a3c1fbbb69677271e8c4600100fe32ac64e83c07223b18590c74f5754b2d&width=960&quality=80", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.911204"}, {"topic": "finance", "relevance_score": "0.718274"}], "overall_sentiment_score": -0.290563, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.356525", "ticker_sentiment_label": "Bearish"}, {"ticker": "MCK", "relevance_score": "0.912228", "ticker_sentiment_score": "-0.395631", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.744813", "ticker_sentiment_score": "-0.381634", "ticker_sentiment_label": "Bearish"}, {"ticker": "ABBV", "relevance_score": "0.595265", "ticker_sentiment_score": "-0.147783", "ticker_sentiment_label": "Neutral"}]}, {"title": "Washington state reaches $518m settlement with opioid suppliers", "url": "https://www.aljazeera.com/economy/2022/5/3/washington-state-reaches-518m-settlement-with-opioid-suppliers", "time_published": "20220503T173633", "authors": ["Reuters"], "summary": "Washington state has reached a $518 million settlement with drug distributors McKesson Corp, AmerisourceBergen Corp, and Cardinal Health, concluding a trial over their alleged role in the opioid epidemic. This agreement is one of the largest in Washington state history and provides additional resources to combat the opioid crisis. The state had opted out of a larger $26 billion nationwide settlement to pursue its own legal action.", "banner_image": null, "source": "Al Jazeera", "category_within_source": "General", "source_domain": "Al Jazeera", "topics": [{"topic": "life_sciences", "relevance_score": "0.913409"}, {"topic": "economy_fiscal", "relevance_score": "0.711650"}], "overall_sentiment_score": -0.338072, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MCK", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.408261", "ticker_sentiment_label": "Bearish"}, {"ticker": "CAH", "relevance_score": "0.949429", "ticker_sentiment_score": "-0.437038", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.725315", "ticker_sentiment_score": "-0.303875", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WBA", "relevance_score": "0.638279", "ticker_sentiment_score": "-0.297774", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABBV", "relevance_score": "0.599428", "ticker_sentiment_score": "-0.219850", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "These innovative projects are changing the health industry", "url": "https://www.fastcompany.com/90742519/world-changing-ideas-awards-2022-health-finalists-and-honorable-mentions", "time_published": "20220503T163120", "authors": ["Fast Company Staff"], "summary": "Fast Company's 2022 World Changing Ideas Awards highlights innovative projects in the health industry, categorized into finalists and honorable mentions. These innovations are recognized for their potential to save lives, extend longevity, or increase access to care. The article lists numerous companies and their projects, spanning AI-powered modules, brain implants, genetic mapping, and various health-tech solutions.", "banner_image": null, "source": "Fast Company", "category_within_source": "General", "source_domain": "Fast Company", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "technology", "relevance_score": "0.814152"}], "overall_sentiment_score": 0.183362, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DCGO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.334359", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MMM", "relevance_score": "0.620692", "ticker_sentiment_score": "0.132467", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.628391", "ticker_sentiment_score": "0.112566", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.600142", "ticker_sentiment_score": "0.102695", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.627849", "ticker_sentiment_score": "0.141987", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J unit's challenge to Intuitive surgery robot patent revived", "url": "https://www.reuters.com/legal/litigation/jj-units-challenge-intuitive-surgery-robot-patent-revived-2022-04-29/", "time_published": "20220429T212300", "authors": ["Brendan Pierson"], "summary": "A federal appeals court revived a challenge by Johnson & Johnson unit Auris Health Inc to a patent held by rival Intuitive Surgical Operations Inc concerning a robotic tool for surgery. The court ordered the U.S. Patent and Trademark Office's patent tribunal to reconsider its decision that the patent was not obvious, citing that generic industry skepticism alone cannot prevent a finding of obviousness. The underlying patent infringement lawsuit between Auris and Intuitive over Auris' robotic bronchoscopy device is scheduled for trial in January 2023.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.945917"}, {"topic": "technology", "relevance_score": "0.806595"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.605075"}], "overall_sentiment_score": -0.216059, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.958274", "ticker_sentiment_score": "-0.247326", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.794507", "ticker_sentiment_score": "-0.208805", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pharma Expansions: Beigene, Boehringer Ingelheim to Break Ground for New Facilities", "url": "https://www.biospace.com/biopharma-makes-big-expansions-to-close-the-month", "time_published": "20220429T175643", "authors": ["Hayley Shasteen"], "summary": "Several biopharma companies are expanding their facilities, including BeiGene with a new U.S. manufacturing and R&D center in New Jersey, and Boehringer Ingelheim investing $57 million to expand its Animal Health Global Innovation Center in Georgia. Breakthrough Properties also raised $3 billion for a new life sciences real estate fund, and Catalent is expanding its manufacturing capabilities across the U.S. and Europe, while a $25 million accelerator for biotech startups is being built in Roanoke Valley.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "manufacturing", "relevance_score": "0.704254"}, {"topic": "real_estate", "relevance_score": "0.638749"}], "overall_sentiment_score": 0.146626, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ONC", "relevance_score": "0.300238", "ticker_sentiment_score": "0.034779", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.600773", "ticker_sentiment_score": "0.149820", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.619384", "ticker_sentiment_score": "0.172844", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PH", "relevance_score": "0.604371", "ticker_sentiment_score": "0.159504", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Low Volatility Stocks Usually Do Well\u2014But There Are Traps", "url": "https://www.ai-cio.com/news/low-volatility-stocks-usually-do-well-but-there-are-traps/", "time_published": "20220425T181642", "authors": ["Larry Light"], "summary": "A Northern Trust Asset Management paper warns that while low-volatility stocks generally outperform over time, they can present traps, particularly in real estate, utilities, and consumer staples sectors. Rising interest rates and economic vulnerability can negatively impact these types of low-volatility holdings. NTAM advises focusing on companies with strong cash flows, profitability, and solid balance sheets to mitigate these risks.", "banner_image": null, "source": "Chief Investment Officer", "category_within_source": "General", "source_domain": "Chief Investment Officer", "topics": [{"topic": "financial_markets", "relevance_score": "0.931180"}, {"topic": "economy_monetary", "relevance_score": "0.807966"}, {"topic": "real_estate", "relevance_score": "0.747907"}, {"topic": "finance", "relevance_score": "0.645347"}], "overall_sentiment_score": 0.195529, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QLV", "relevance_score": "1.000000", "ticker_sentiment_score": "0.122587", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.638949", "ticker_sentiment_score": "0.231040", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.620458", "ticker_sentiment_score": "0.210101", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.640138", "ticker_sentiment_score": "0.405398", "ticker_sentiment_label": "Bullish"}, {"ticker": "NTRS", "relevance_score": "0.605392", "ticker_sentiment_score": "0.024873", "ticker_sentiment_label": "Neutral"}]}, {"title": "BioXcel will use $260M finance deal to expand indications for schizophrenia drug", "url": "https://www.fiercebiotech.com/biotech/bioxcel-enters-260m-finance-deal-accelerate-growth-though-prerequisites-must-be-met-unlock", "time_published": "20220420T093000", "authors": ["Gabrielle Masson"], "summary": "BioXcel Therapeutics secured a $260 million financing agreement with Oaktree Capital Management and Qatar Investment Authority to accelerate growth and commercially launch their new schizophrenia drug, IGALMI. The funds will also support the expansion of IGALMI's clinical development, including a phase 3 program for Alzheimer's agitation, and other neuroscience and immuno-oncology programs, providing the company with a cash runway into 2025. This deal positions BioXcel to realize its vision of becoming a leading AI-enabled neuroscience company.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "0.940285"}, {"topic": "finance", "relevance_score": "0.729875"}], "overall_sentiment_score": 0.180602, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BTAI", "relevance_score": "0.950647", "ticker_sentiment_score": "0.431979", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRK", "relevance_score": "0.560561", "ticker_sentiment_score": "0.145373", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.578188", "ticker_sentiment_score": "0.112530", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.572698", "ticker_sentiment_score": "0.107616", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.576408", "ticker_sentiment_score": "0.139856", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alabama settles opioid claims with J&J, McKesson, Endo for $276 mln -attorney general", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/alabama-settles-opioid-claims-against-jj-distributors-276-mln-attorney-general-2022-04-19/", "time_published": "20220420T005100", "authors": ["Dietrich Knauth"], "summary": "Alabama has reached $276 million in settlements with Johnson & Johnson, McKesson Corp, and Endo International Plc to resolve claims related to the opioid addiction crisis. The state's attorney general stated that Alabama will receive more funds and a faster payout compared to what it would have received under a nationwide settlement. This agreement comes amidst a wave of litigation and settlements by various states addressing the U.S. opioid crisis.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.930798"}, {"topic": "finance", "relevance_score": "0.711598"}], "overall_sentiment_score": -0.13811, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MCK", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.420627", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.904000", "ticker_sentiment_score": "0.036247", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.641822", "ticker_sentiment_score": "0.015030", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tom Carey, sales leader and mentor, passes away", "url": "https://www.biocentury.com/article/643211/tom-carey-sales-leader-and-mentor-passes-away", "time_published": "20220418T115200", "authors": ["Jeff Cranmer"], "summary": "Tom Carey, a biopharma commercial veteran and sales leader, has passed away at 68. He played a key role in building BioCentury's sales team and had a distinguished career at companies like Eli Lilly, Syntex, Roche, and Johnson & Johnson. Carey was known for his leadership, mentorship, and dedication to his family.", "banner_image": "NULL", "source": "BioCentury", "category_within_source": "General", "source_domain": "BioCentury", "topics": [{"topic": "life_sciences", "relevance_score": "0.912043"}, {"topic": "finance", "relevance_score": "0.632505"}], "overall_sentiment_score": 0.120344, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PRDS", "relevance_score": "0.918438", "ticker_sentiment_score": "0.134741", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.724370", "ticker_sentiment_score": "0.135450", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.626719", "ticker_sentiment_score": "0.108932", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex CEO Kewalramani nabs more than $15M in 2021 pay, rivaling some male Big Pharma peers", "url": "https://www.fiercepharma.com/pharma/vertex-ceo-kewalramani-nabs-more-15m-2021-pay-rivaling-male-peers", "time_published": "20220408T111000", "authors": ["Fraiser Kansteiner"], "summary": "Vertex Pharmaceuticals CEO Reshma Kewalramani earned over $15 million in total compensation in 2021, a 50% increase from the previous year. This pay package positions her compensation favorably against that of several male Big Pharma CEOs. The company praised her leadership for achieving financial goals and expanding its cystic fibrosis business.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "earnings", "relevance_score": "0.921212"}, {"topic": "life_sciences", "relevance_score": "0.839212"}], "overall_sentiment_score": 0.331143, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.460797", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABBV", "relevance_score": "0.601690", "ticker_sentiment_score": "0.349654", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.554847", "ticker_sentiment_score": "0.336260", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.555830", "ticker_sentiment_score": "0.341676", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.560954", "ticker_sentiment_score": "0.346508", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J scores one-two royalty punch against Genmab in blockbuster Darzalex fight", "url": "https://www.fiercepharma.com/pharma/jj-scores-one-two-royalty-punch-against-genmab-megablockbuster-darzalex-arbitration", "time_published": "20220408T095500", "authors": ["Fraiser Kansteiner"], "summary": "An arbitration tribunal has sided with Johnson & Johnson on two key issues in its royalty dispute with Genmab over the blockbuster multiple myeloma drug Darzalex. J&J will pay royalties only through Genmab's last-held patent, not J&J's own, and can reduce royalty payments to Genmab to offset its obligations to Halozyme for drug delivery technology used in Darzalex Faspro. This decision follows J&J scaling back its payments in 2020, costing Genmab approximately $73.16 million to date.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.925138"}, {"topic": "earnings", "relevance_score": "0.717732"}], "overall_sentiment_score": 0.044032, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GMAB", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.338867", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.929218", "ticker_sentiment_score": "0.317391", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.646145", "ticker_sentiment_score": "0.113179", "ticker_sentiment_label": "Neutral"}]}, {"title": "CVS, Others To Pay Florida $860M To Settle Opioid Case", "url": "https://www.cbsnews.com/miami/news/cvs-others-to-pay-florida-860m-to-settle-opioid-case/", "time_published": "20220330T113000", "authors": [], "summary": "CVS and other pharmaceutical companies have agreed to pay Florida a combined $860 million to settle an opioid epidemic case. CVS Health Corp. and CVS Pharmacy Inc. will contribute $484 million, while Teva Pharmaceuticals Industries Ltd. will pay $195 million and provide $84 million worth of Narcan nasal spray. This settlement aims to help remediate the harm caused by the opioid crisis in Florida, with the funds allocated to state and local efforts to combat the epidemic.", "banner_image": null, "source": "CBS News", "category_within_source": "General", "source_domain": "CBS News", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "retail_wholesale", "relevance_score": "0.831658"}, {"topic": "finance", "relevance_score": "0.735821"}, {"topic": "economy_macro", "relevance_score": "0.633383"}], "overall_sentiment_score": -0.092289, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.423001", "ticker_sentiment_label": "Bearish"}, {"ticker": "CAH", "relevance_score": "0.741574", "ticker_sentiment_score": "0.102474", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.728494", "ticker_sentiment_score": "0.101119", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.728694", "ticker_sentiment_score": "0.141078", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.746839", "ticker_sentiment_score": "-0.176876", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pfizer, Moderna and J&J Face Shareholder Pressure to Broaden Covid-19 Vaccine Access", "url": "https://www.wsj.com/health/healthcare/pfizer-moderna-and-j-j-face-shareholder-pressure-to-broaden-covid-19-vaccine-access-11648373402?gaa_at=eafs&gaa_n=AWEtsqdUd-9XXW7XeGds0zFBfbJSz9pQUNV7vL4PIrPKRZ02oLncBsKVb-P-&gaa_ts=6907a0e9&gaa_sig=lOqQrfk5w02v72zLdQSsp2G8KMJgb_kjC1ZgeQZGAPVj4lsKgiiCgU0qN8fK10YLhfqji5FSV6YhOxxyy3DwIw%3D%3D", "time_published": "20220327T180645", "authors": ["Peter Loftus"], "summary": "Socially conscious investors and global health activists are pressuring Pfizer, Moderna, and Johnson & Johnson to broaden access to their Covid-19 vaccines in poorer countries. These groups have placed resolutions on annual proxy ballots, urging drugmakers to explore technology transfer to other manufacturers. This shareholder activism is the latest attempt to push vaccine makers to share technology and boost supplies in lower-income nations.", "banner_image": "NULL", "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.918158"}, {"topic": "financial_markets", "relevance_score": "0.729398"}], "overall_sentiment_score": -0.209264, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.997236", "ticker_sentiment_score": "-0.210196", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.871472", "ticker_sentiment_score": "-0.203322", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.803604", "ticker_sentiment_score": "-0.209762", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Big Pharma Pacts Benefit From Reduced HBV Biologics Competition", "url": "https://insights.citeline.com/SC146114/Big-Pharma-Pacts-Benefit-From-Reduced-HBV-Biologics-Competition/link-CPFV5OCXPRAN5OZQC3BCRF2DBU", "time_published": "20220325T160640", "authors": ["Ayisha Sharma"], "summary": "The article highlights how reduced competition in the HBV biologics market, following the discontinuation of Aligos's candidate, benefits large pharmaceutical companies. It lists various related content and companies involved in Hepatitis B research and development, underscoring ongoing efforts to find a functional cure.", "banner_image": null, "source": "insights.citeline.com", "category_within_source": "General", "source_domain": "insights.citeline.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.909634"}], "overall_sentiment_score": 0.058003, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALGS", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.628597", "ticker_sentiment_label": "Bearish"}, {"ticker": "BMY", "relevance_score": "0.710954", "ticker_sentiment_score": "0.208883", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.715031", "ticker_sentiment_score": "0.204295", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.744420", "ticker_sentiment_score": "0.241100", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.604587", "ticker_sentiment_score": "0.237605", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Academic publishers continue \u201cbusiness as usual\u201d in Russia", "url": "https://euromaidanpress.com/2022/03/24/academic-publishers-continue-business-as-usual-in-russia/", "time_published": "20220324T182552", "authors": ["George Frynas"], "summary": "Despite widespread condemnation of Russia's invasion of Ukraine, major academic publishers like John Wiley & Sons, Reed Elsevier, and Thomson Reuters continue to operate in Russia, with only Wolters Kluwer significantly reducing its business. The Ukrainian government is calling for sanctions against Russian researchers and institutions, arguing that continued access to scientific information aids Russia's war effort. The article highlights the financial interests of these publishers in Russia and urges their withdrawal.", "banner_image": null, "source": "Euromaidan Press", "category_within_source": "General", "source_domain": "Euromaidan Press", "topics": [{"topic": "finance", "relevance_score": "0.821639"}, {"topic": "economy_fiscal", "relevance_score": "0.746791"}], "overall_sentiment_score": -0.233538, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "RELX", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.244798", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.723498", "ticker_sentiment_score": "-0.223933", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "UMass Chan and Moderna to study cytomegalovirus transmission in young children", "url": "https://www.umassmed.edu/news/news-archives/2022/03/umass-chan-and-moderna-to-study-cytomegalovirus-transmission-in-young-children/", "time_published": "20220322T174607", "authors": [], "summary": "UMass Chan Medical School and Moderna, Inc. are collaborating on a comprehensive study called CMV TransmIT to investigate cytomegalovirus (CMV) transmission in young children and households. Led by Dr. Laura Gibson, the research aims to understand how CMV spreads and characterize immune responses to inform the design of prevention strategies and a potential vaccine. CMV is the most common infectious cause of birth defects, and the study will utilize public and private daycare centers in Cambridge and Worcester to identify transmission patterns.", "banner_image": null, "source": "UMass Chan Medical School", "category_within_source": "General", "source_domain": "UMass Chan Medical School", "topics": [{"topic": "life_sciences", "relevance_score": "0.912256"}], "overall_sentiment_score": 0.266711, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.957585", "ticker_sentiment_score": "0.320476", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.563513", "ticker_sentiment_score": "0.211277", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.561405", "ticker_sentiment_score": "0.215377", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here\u2019s the latest on possible 4th COVID-19 vaccine shot for Americans", "url": "https://www.oregonlive.com/business/2022/03/heres-the-latest-on-possible-4th-covid-19-vaccine-shot-for-americans.html", "time_published": "20220320T160600", "authors": ["wire reports"], "summary": "Moderna has requested FDA authorization for a fourth COVID-19 vaccine booster for all adults, while Pfizer and BioNTech sought approval for seniors aged 65 and older, citing data from Israel showing reduced infection and severe disease rates. U.S. health officials are considering additional booster doses and seeking funding to secure more vaccines, amidst ongoing studies on omicron-specific and hybrid shots. Experts like Dr. Paul Offit question the necessity of a fourth shot for most people, emphasizing that protection against severe illness should be the primary goal.", "banner_image": null, "source": "OregonLive.com", "category_within_source": "General", "source_domain": "OregonLive.com", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.084245, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.997922", "ticker_sentiment_score": "0.128559", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.887853", "ticker_sentiment_score": "0.145962", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.622181", "ticker_sentiment_score": "0.096577", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novartis, Lilly, Merck and More Halt Business Operations in Russia", "url": "https://www.biospace.com/novartis-eli-lilly-merck-and-more-join-drugmakers-in-halting-business-operations-in-russia", "time_published": "20220316T172722", "authors": ["Alex Keown"], "summary": "Following Pfizer's lead, several major pharmaceutical companies including AbbVie, Abbott, Novartis, Merck, and Eli Lilly have announced they are suspending some or all business operations in Russia in protest of the invasion of Ukraine. While halting investments and non-essential sales, many companies have committed to continuing the supply of life-saving medications. Bayer also joined the effort, stopping all non-essential business in Russia and Belarus.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "0.923145"}, {"topic": "economy_macro", "relevance_score": "0.633483"}], "overall_sentiment_score": -0.085492, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.950727", "ticker_sentiment_score": "-0.210646", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRK", "relevance_score": "0.902741", "ticker_sentiment_score": "0.106033", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.737033", "ticker_sentiment_score": "0.112734", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.826082", "ticker_sentiment_score": "-0.221687", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABT", "relevance_score": "0.725765", "ticker_sentiment_score": "-0.208150", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Renaissance Buys $174M New Jersey Community", "url": "https://www.multihousingnews.com/renaissance-buys-174m-new-jersey-community/", "time_published": "20220310T162158", "authors": ["Anda Rosu"], "summary": "Renaissance Management has acquired Plaza Square, a 415-unit Class A community in New Brunswick, N.J., for $173.5 million. CBRE represented the seller, Manulife Investment Management, who had owned the property for over a decade. The luxury property, built in 2004, last traded in 2011 for $113 million.", "banner_image": null, "source": "Multifamily Housing News", "category_within_source": "General", "source_domain": "Multifamily Housing News", "topics": [{"topic": "real_estate", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.849408"}], "overall_sentiment_score": 0.206585, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CBRE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.288576", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.628419", "ticker_sentiment_score": "0.124105", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharma major Dr. Reddy's plans 'business continuity' in Russia", "url": "https://timesofindia.indiatimes.com/business/india-business/pharma-major-dr-reddys-plans-business-continuity-in-russia/articleshow/90097892.cms", "time_published": "20220309T143500", "authors": ["Reuters"], "summary": "Pharmaceutical major Dr. Reddy's Laboratories Ltd announced its commitment to employee safety and business continuity in Russia, despite many Western companies withdrawing from the region. The company stated it has had a presence in Russia for over three decades and will continue to monitor developments closely without confirming changes to its investments. Russia accounted for over 8% of its total sales of $2.47 billion in the last fiscal year.", "banner_image": null, "source": "Times of India", "category_within_source": "General", "source_domain": "Times of India", "topics": [{"topic": "life_sciences", "relevance_score": "0.926328"}, {"topic": "financial_markets", "relevance_score": "0.605379"}], "overall_sentiment_score": -0.145587, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RDY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.143473", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.607106", "ticker_sentiment_score": "-0.108502", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.628919", "ticker_sentiment_score": "-0.101208", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.634221", "ticker_sentiment_score": "-0.143078", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.616575", "ticker_sentiment_score": "-0.528925", "ticker_sentiment_label": "Bearish"}]}, {"title": "Insurers Refuse to Pick Up Tab for Billions in Opioid Claims", "url": "https://programbusiness.com/news/insurers-refuse-pick-tab-billions-opioid-claims/", "time_published": "20220308T165645", "authors": [], "summary": "Insurers for major drug makers, distributors, and pharmacies are refusing to cover billions in opioid-related claims stemming from lawsuits, propelled by a recent Delaware Supreme Court decision. Companies like AmerisourceBergen and CVS Health are being sued by their insurers to deny coverage for public nuisance claims and defense costs, despite policyholders counter-suing. This legal battle intensifies the financial burden on companies facing over 3,000 opioid lawsuits.", "banner_image": null, "source": "Program Business", "category_within_source": "General", "source_domain": "Program Business", "topics": [{"topic": "finance", "relevance_score": "0.822261"}, {"topic": "life_sciences", "relevance_score": "0.909230"}], "overall_sentiment_score": -0.25624, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "HIG", "relevance_score": "0.977661", "ticker_sentiment_score": "-0.133546", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.899806", "ticker_sentiment_score": "-0.281847", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CAH", "relevance_score": "0.723803", "ticker_sentiment_score": "-0.313121", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.698318", "ticker_sentiment_score": "-0.325071", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MCK", "relevance_score": "0.644254", "ticker_sentiment_score": "-0.315338", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Hologic Inc. stock underperforms Thursday when compared to competitors", "url": "https://www.marketwatch.com/data-news/hologic-inc-stock-underperforms-thursday-when-compared-to-competitors-01646344685-38f28d626125?gaa_at=eafs&gaa_n=AWEtsqdM6Rq89q16p8J9IIiG5ayFMuwx698CLWSeJk-DoonwSA83ccP4aWGw&gaa_ts=69079070&gaa_sig=pf6L6ItuyVivgv9Jhr6qDI4b8B3Hhb9acICprODujiVr1J_rpf9JDnCRbRtVY5VytQoB_YTuO48KEhvJ8_3IgA%3D%3D", "time_published": "20220303T165800", "authors": ["MarketWatch Automation"], "summary": "Hologic Inc. stock (HOLX) fell 0.14% on Thursday, closing at $70.90, underperforming key market indices like the S&P 500 and Dow Jones Industrial Average. The company's stock also showed mixed results against its competitors, with Johnson & Johnson and Abbott Laboratories seeing gains, while Thermo Fisher Scientific Inc. experienced a decline. Hologic Inc.'s closing price was $10.14 short of its 52-week high, and its trading volume for the day surpassed its 50-day average.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "financial_markets", "relevance_score": "0.916274"}, {"topic": "life_sciences", "relevance_score": "0.736427"}], "overall_sentiment_score": 0.042901, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HOLX", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.238142", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.613519", "ticker_sentiment_score": "0.219015", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.642338", "ticker_sentiment_score": "0.225232", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.616051", "ticker_sentiment_score": "-0.148097", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wide Moat Stocks Can Get Their Grooves Back", "url": "https://www.etftrends.com/tactical-allocation-content-hub/wide-moat-stocks-can-get-their-grooves-back/", "time_published": "20220228T173722", "authors": ["Tom Lydon"], "summary": "The VanEck Vectors Morningstar Wide Moat ETF (MOAT) has shown durability amid market turbulence in early 2022 and is outperforming the S&P 500. Analysts believe wide moat equities have the ingredients for continued success, with the ETF's valuation methodology identifying stocks trading at attractive multiples despite their inherent quality. MOAT's sector-agnostic approach and diversified holdings, including non-tech stocks, are helping to buffer against current tech sector weaknesses.", "banner_image": null, "source": "ETF Trends", "category_within_source": "General", "source_domain": "ETF Trends", "topics": [{"topic": "financial_markets", "relevance_score": "0.935673"}], "overall_sentiment_score": 0.294854, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MOAT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.271238", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.619114", "ticker_sentiment_score": "0.337268", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.617565", "ticker_sentiment_score": "0.306431", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.594493", "ticker_sentiment_score": "0.297675", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J, Legend cell therapy approved by FDA for multiple myeloma", "url": "https://www.biopharmadive.com/news/johnson-johnson-legend-carvykti-myeloma-fda-approval/619430/", "time_published": "20220228T172703", "authors": ["Ned Pagliarulo"], "summary": "The FDA has approved Carvykti, a CAR-T cell therapy developed by Johnson & Johnson and Legend Biotech, for multiple myeloma. This treatment is the second CAR-T therapy approved for this blood cancer, following Bristol Myers Squibb and 2seventy bio\u2019s Abecma, and is priced at $465,000. J&J anticipates high annual sales and is exploring Carvykti's efficacy in earlier stages of multiple myeloma.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.935360"}], "overall_sentiment_score": 0.254888, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LEGN", "relevance_score": "1.000000", "ticker_sentiment_score": "0.403573", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.914455", "ticker_sentiment_score": "0.329701", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.726981", "ticker_sentiment_score": "0.236923", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.639521", "ticker_sentiment_score": "0.106997", "ticker_sentiment_label": "Neutral"}]}, {"title": "Surabhi Pokhriyal Named Chief Digital Growth Officer at Church & Dwight", "url": "https://consumergoods.com/surabhi-pokhriyal-named-chief-digital-growth-officer-church-dwight", "time_published": "20220228T162223", "authors": ["Lisa Johnston"], "summary": "Church & Dwight has appointed Surabhi Pokhriyal as its Chief Digital Growth Officer, where she will lead the company's digital transformation and e-commerce initiatives. Pokhriyal, previously with Colgate-Palmolive and other major consumer goods companies, is tasked with accelerating digital momentum, including e-commerce penetration and M&A integration. She is excited to leverage the company's nimble structure and focused talent to elevate its digital capabilities and expand its brand footprint.", "banner_image": null, "source": "Consumer Goods Technology", "category_within_source": "General", "source_domain": "Consumer Goods Technology", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.852444"}, {"topic": "retail_wholesale", "relevance_score": "0.815250"}, {"topic": "finance", "relevance_score": "0.720369"}, {"topic": "technology", "relevance_score": "0.632178"}], "overall_sentiment_score": 0.217629, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHD", "relevance_score": "1.000000", "ticker_sentiment_score": "0.495380", "ticker_sentiment_label": "Bullish"}, {"ticker": "CL", "relevance_score": "0.603322", "ticker_sentiment_score": "0.148479", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.568105", "ticker_sentiment_score": "0.115792", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.573812", "ticker_sentiment_score": "0.125022", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDP", "relevance_score": "0.634090", "ticker_sentiment_score": "0.162153", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Companies Finalize $26 Billion Deal With States and Cities to End Opioid Lawsuits (Published 2022)", "url": "https://www.nytimes.com/2022/02/25/health/opioids-settlement-distributors-johnson.html", "time_published": "20220225T162143", "authors": ["Jan Hoffman"], "summary": "The nation's three largest drug distributors and Johnson & Johnson have finalized a $26 billion deal to settle thousands of opioid lawsuits filed by states and local governments. This settlement, second only to the Big Tobacco agreement, will direct at least 85% of the funds towards addiction treatment and prevention, with the first checks expected in early April. The agreement resolves thousands of civil claims, but does not provide separate funds for individual victims.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.911780"}, {"topic": "finance", "relevance_score": "0.713047"}, {"topic": "economy_fiscal", "relevance_score": "0.626579"}], "overall_sentiment_score": 0.217305, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.233648", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.906299", "ticker_sentiment_score": "0.206149", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.816207", "ticker_sentiment_score": "0.240331", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COR", "relevance_score": "0.707648", "ticker_sentiment_score": "0.221998", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sanofi and GSK plan to ask regulators to authorize their COVID-19 vaccine", "url": "https://abcnews.go.com/Health/sanofi-gsk-plan-regulators-authorize-covid-19-vaccine/story?id=83061991", "time_published": "20220223T145300", "authors": ["Mary Kekatos"], "summary": "Sanofi and GlaxoSmithKline (GSK) are seeking regulatory authorization for their COVID-19 vaccine candidate, which showed 100% effectiveness against hospitalization and severe disease in trials. Their protein-based vaccine can serve as a primary vaccine or a booster shot, significantly raising antibody levels. This development offers a conventional alternative to existing mRNA and viral vector vaccines.", "banner_image": null, "source": "ABC News - Breaking News, Latest News and Videos", "category_within_source": "General", "source_domain": "ABC News - Breaking News, Latest News and Videos", "topics": [{"topic": "life_sciences", "relevance_score": "0.939762"}], "overall_sentiment_score": 0.188436, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SNY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.473973", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.626706", "ticker_sentiment_score": "0.140655", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.577549", "ticker_sentiment_score": "0.115847", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.569635", "ticker_sentiment_score": "0.117968", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mixed reality helps GE Healthcare train engineers to service complex equipment", "url": "https://www.microsoft.com/en/customers/story/1475200924660741619-ge-healthcare-health-provider-azure-iot-hololens-2", "time_published": "20220222T174617", "authors": [], "summary": "GE Healthcare, in collaboration with Microsoft MRPP partner Adjacentech Corporation, has developed a mixed-reality training system using HoloLens 2. This system aims to improve training efficiency and knowledge retention for engineers servicing complex medical equipment like CT and MRI scanners in China. By overlaying holographic 3D visualizations onto real-world objects, the solution provides accurate step-by-step guidance, reducing training time and the risk of equipment damage.", "banner_image": null, "source": "Microsoft", "category_within_source": "General", "source_domain": "Microsoft", "topics": [{"topic": "life_sciences", "relevance_score": "0.900065"}, {"topic": "technology", "relevance_score": "0.830033"}, {"topic": "manufacturing", "relevance_score": "0.747206"}], "overall_sentiment_score": 0.344728, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.939140", "ticker_sentiment_score": "0.343295", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GEHC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.445331", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.613231", "ticker_sentiment_score": "0.211649", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Money Calls the Shots", "url": "https://www.amnesty.org/en/documents/pol40/5140/2022/en/", "time_published": "20220214T184636", "authors": [], "summary": "Amnesty International published \"Money Calls the Shots\" on February 14, 2022, updating its assessment of pharmaceutical companies' restrictions on access to Covid-19 vaccines. The report evaluates five leading vaccine manufacturers (AstraZeneca plc, BioNTech SE, Johnson & Johnson, Moderna Inc., and Pfizer Inc.) and, for the first time, includes Chinese producers Sinopharm and Sinovac Biotech Ltd.", "banner_image": null, "source": "Amnesty International", "category_within_source": "General", "source_domain": "Amnesty International", "topics": [{"topic": "life_sciences", "relevance_score": "0.934354"}], "overall_sentiment_score": 0.117658, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SVA", "relevance_score": "0.908698", "ticker_sentiment_score": "0.112179", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.717573", "ticker_sentiment_score": "0.108963", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.716710", "ticker_sentiment_score": "0.126357", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.717136", "ticker_sentiment_score": "0.126610", "ticker_sentiment_label": "Neutral"}]}, {"title": "IFF Appoints Barry A. Bruno to Board of Directors", "url": "https://kommunikasjon.ntb.no/pressemelding/17926097/iff-appoints-barry-a-bruno-to-board-of-directors?publisherId=90063", "time_published": "20220209T221500", "authors": [], "summary": "IFF announced the appointment of Barry A. Bruno to its Board of Directors as an independent director, effective February 8, 2022. This appointment, which expands the board to 14 members, was made in connection with a cooperation agreement with Icahn Capital LP, which recommended Mr. Bruno. Mr. Bruno brings extensive leadership experience from Church & Dwight Co., Inc. and Johnson & Johnson, particularly in global consumer brands and international market growth.", "banner_image": null, "source": "NTB Kommunikasjon", "category_within_source": "General", "source_domain": "NTB Kommunikasjon", "topics": [{"topic": "finance", "relevance_score": "0.828123"}, {"topic": "life_sciences", "relevance_score": "0.717577"}], "overall_sentiment_score": 0.264298, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHD", "relevance_score": "0.638837", "ticker_sentiment_score": "0.266830", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IFF", "relevance_score": "1.000000", "ticker_sentiment_score": "0.420631", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.561399", "ticker_sentiment_score": "0.138792", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson\u2019s Baby Powder Is Facing More Than 30,000 Lawsuits Globally", "url": "https://www.theswaddle.com/johnson-johnsons-baby-powder-is-facing-more-than-30000-lawsuits-globally", "time_published": "20220209T171642", "authors": ["Devrupa Rakshit"], "summary": "Johnson & Johnson is currently facing over 30,000 lawsuits globally from women alleging that their baby powder caused ovarian cancer. The article details instances of J&J's talc-based products being contaminated with asbestos and formaldehyde, and outlines efforts by the company to limit financial liability through a controversial bankruptcy plan. This ongoing legal battle highlights broader issues of misleading brand marketing and lack of consumer awareness regarding product safety.", "banner_image": null, "source": "The Swaddle", "category_within_source": "General", "source_domain": "The Swaddle", "topics": [{"topic": "life_sciences", "relevance_score": "0.930822"}, {"topic": "finance", "relevance_score": "0.730568"}], "overall_sentiment_score": -0.812118, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.812414", "ticker_sentiment_label": "Bearish"}]}, {"title": "Same Drug, New Partner: Capricor in Up-to-$735M Deal for DMD Cell Therapy", "url": "https://www.genengnews.com/gen-edge/same-drug-new-partner-capricor-in-up-to-735m-deal-for-dmd-cell-therapy/", "time_published": "20220201T162146", "authors": ["Alex Philippidis"], "summary": "Capricor Therapeutics has secured a new U.S. commercialization and distribution deal with Nippon Shinyaku for its lead Duchenne muscular dystrophy (DMD) candidate, CAP-1002, worth up to $735 million. This partnership comes five years after Johnson & Johnson's Janssen subsidiary ended a previous collaboration for the cell therapy. Capricor plans to use this deal to support its pivotal Phase III HOPE-3 trial for CAP-1002 in DMD, aiming to differentiate its immune-modulating approach from other gene therapies.", "banner_image": null, "source": "Genetic Engineering and Biotechnology News", "category_within_source": "General", "source_domain": "Genetic Engineering and Biotechnology News", "topics": [{"topic": "life_sciences", "relevance_score": "0.937517"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.820304"}, {"topic": "financial_markets", "relevance_score": "0.626109"}], "overall_sentiment_score": 0.249429, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CAPR", "relevance_score": "1.000000", "ticker_sentiment_score": "0.478309", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.752883", "ticker_sentiment_score": "0.134568", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.593481", "ticker_sentiment_score": "0.148839", "ticker_sentiment_label": "Neutral"}]}, {"title": "Native American tribes reach $590 million opioid settlement with J&J, drug distributors", "url": "https://www.cbc.ca/news/health/native-american-tribes-opioid-crisis-settlement-johnson-1.6335438", "time_published": "20220201T152500", "authors": ["Thomson Reuters"], "summary": "Native American tribes have reached a $590 million opioid settlement with Johnson & Johnson and the three largest U.S. drug distributors (McKesson Corp., AmerisourceBergen Corp., and Cardinal Health Inc.). This deal aims to resolve claims that the companies fueled an opioid crisis in their communities, with the funds earmarked for addiction treatment and services. This settlement is separate from a larger $26 billion deal but allows J&J to deduct its contribution from its share of that broader agreement.", "banner_image": null, "source": "CBC", "category_within_source": "General", "source_domain": "CBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.932119"}, {"topic": "finance", "relevance_score": "0.828001"}, {"topic": "economy_fiscal", "relevance_score": "0.616470"}], "overall_sentiment_score": -0.216434, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.220814", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.922646", "ticker_sentiment_score": "-0.220107", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MCK", "relevance_score": "0.831989", "ticker_sentiment_score": "-0.240799", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COR", "relevance_score": "0.703331", "ticker_sentiment_score": "-0.224209", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/drugmaker-galapagos-names-former-jj-exec-paul-stoffels-ceo-2022-01-26/", "time_published": "20220126T230100", "authors": ["Reuters"], "summary": "Belgian drugmaker Galapagos NV has appointed Paul Stoffels, former chief scientific officer of Johnson & Johnson, as its new CEO, effective April 1. Stoffels previously spearheaded the development of J&J's single-shot COVID-19 vaccine and has a long history with Galapagos, having served on its board from 1999 to 2002. He will succeed co-founder Onno van de Stolpe, who is retiring.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FDUF4D5Q2PZP33D5R354G4H3KBM.JPG?auth=1a783776652ed9694e094191fe444005aa9c60e45d55b083c27e80d44cf67417&width=800&quality=85&smart=true", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.911915"}], "overall_sentiment_score": 0.214687, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLPG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.319066", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.863233", "ticker_sentiment_score": "0.216114", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.635444", "ticker_sentiment_score": "0.114860", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Reports Q4 and Full-Year 2021 Results", "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2021-results", "time_published": "20220125T171642", "authors": [], "summary": "Johnson & Johnson announced strong financial results for the fourth quarter and full-year 2021, showing growth across all business segments. The company reported full-year sales of $93.8 billion, a 13.6% increase, and provided 2022 guidance for adjusted operational sales growth of 7.7% and adjusted operational EPS growth of 9.2%. CEO Joaquin Duato highlighted the company's strong results, financial profile, and innovative pipeline positioning it for future success.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "earnings", "relevance_score": "0.906942"}, {"topic": "life_sciences", "relevance_score": "0.811627"}, {"topic": "finance", "relevance_score": "0.710560"}], "overall_sentiment_score": 0.417241, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.420548", "ticker_sentiment_label": "Bullish"}]}, {"title": "Gilead Withdraws Cancer Drug Amidst Uncompleted Follow-Up Trials", "url": "https://www.biospace.com/gilead-withdraws-cancer-drug-amidst-uncompleted-follow-up-trials", "time_published": "20220123T164654", "authors": ["Hayley Shasteen"], "summary": "Gilead has voluntarily withdrawn its cancer drug Zydelig (idelalisib) from the market for certain indications due to difficulties completing mandatory follow-up clinical trials to confirm efficacy and safety. The accelerated approval for relapsed follicular B-cell non-Hodgkin Lymphoma (FL) and relapsed small lymphocytic leukemia (SLL) required further studies, which were hampered by the evolving treatment landscape for these conditions. Despite the withdrawal for these specific uses, Zydelig will remain available for chronic lymphocytic leukemia (CLL) in the U.S. and for CLL, SLL, and FL in several other regions.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.720016"}], "overall_sentiment_score": -0.149877, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.413295", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.629720", "ticker_sentiment_score": "0.140915", "ticker_sentiment_label": "Neutral"}]}, {"title": "Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine ...", "url": "https://www.cdc.gov/mmwr/volumes/71/wr/mm7103a4.htm", "time_published": "20220121T171640", "authors": ["Sara E. Oliver", "MD; Megan Wallace", "DrPH; Isaac See", "MD; Sarah Mbaeyi", "MD; Monica Godfrey", "MPH; Stephen C. Hadler", "MD; Tara C. Jatlaoui", "MD; Evelyn Twentyman", "MD; Michelle M. Hughes", "PhD; Agam K. Rao", "MD; Anthony Fiore", "MD; John R. Su", "MD", "PhD; Karen R. Broder", "MD; Tom Shimabukuro", "MD; Allison Lale", "MD; David K. Shay", "MD; Lauri E. Markowitz", "MD; Melinda Wharton", "MD; Beth P. Bell", "MD; Oliver Brooks", "MD; Veronica McNally", "JD; Grace M. Lee", "MD; H. Keipp Talbot", "MD; Matthew F. Daley", "MD"], "summary": "This report from the CDC's Advisory Committee on Immunization Practices (ACIP) updates recommendations for the Janssen COVID-19 vaccine, preferentially recommending mRNA vaccines (Pfizer-BioNTech or Moderna) for all persons aged \u226518 years in the United States. The decision follows a review of updated vaccine effectiveness and safety data, including continued reports of thrombosis with thrombocytopenia syndrome (TTS) and Guillain-Barr\u00e9 syndrome (GBS) associated with the Janssen vaccine. While the benefits of the Janssen vaccine still outweigh the risks of being unvaccinated, the benefit-risk balance is more favorable for mRNA vaccines due to higher effectiveness and less severe rare adverse events.", "banner_image": null, "source": "Centers for Disease Control and Prevention | CDC (.gov)", "category_within_source": "General", "source_domain": "Centers for Disease Control and Prevention | CDC (.gov)", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.034277, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.280624", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.738318", "ticker_sentiment_score": "0.222137", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.649199", "ticker_sentiment_score": "0.130356", "ticker_sentiment_label": "Neutral"}]}, {"title": "Smith+Nephew acquires novel cementless partial knee system", "url": "https://www.prnewswire.com/news-releases/smithnephew-acquires-novel-cementless-partial-knee-system-301463369.html", "time_published": "20220119T020000", "authors": [], "summary": "Smith+Nephew announced the acquisition of Engage Surgical, a company that owns the only cementless unicompartmental (partial) knee system currently available in the US. This acquisition supports Smith+Nephew's growth strategy by enhancing its orthopedic offerings and differentiating its product portfolio. The Engage Surgical Partial Knee System is optimized for robotics and is expected to drive market expansion in the US for cementless partial knees, with an acquisition cost of up to $135 million contingent on sales performance.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.923409"}], "overall_sentiment_score": 0.186235, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SNN", "relevance_score": "1.000000", "ticker_sentiment_score": "0.476735", "ticker_sentiment_label": "Bullish"}, {"ticker": "BSX", "relevance_score": "0.591570", "ticker_sentiment_score": "0.110485", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.590158", "ticker_sentiment_score": "0.140869", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.557036", "ticker_sentiment_score": "0.108755", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.557520", "ticker_sentiment_score": "0.143341", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Alleges $250 Million of Counterfeit HIV Drugs Were Sold Over 2 Years", "url": "https://www.biospace.com/gilead-alleges-250-million-of-counterfeit-hiv-drugs-were-sold-over-2-years", "time_published": "20220118T164654", "authors": ["Mark Terry"], "summary": "Gilead Sciences reported that approximately $250 million worth of counterfeit versions of its HIV drugs, Biktarvy and Descovy, were sold to pharmacies over two years. The company filed a lawsuit against distributors, some of whom allegedly acquired the drugs from vulnerable patients and resold them with falsified documentation, sometimes containing incorrect medications like painkillers. Gilead has worked with law enforcement and conducted seizures across nine states to combat this \"complex and criminal enterprise.\"", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "0.916270"}], "overall_sentiment_score": -0.217198, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.348471", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.747480", "ticker_sentiment_score": "-0.105778", "ticker_sentiment_label": "Neutral"}]}, {"title": "GE suspends Covid vaccine and testing rules after Supreme Court blocks Biden mandate", "url": "https://www.cnbc.com/2022/01/14/ge-suspends-covid-vaccine-and-testing-rules-after-supreme-court-blocks-biden-mandate.html", "time_published": "20220114T134900", "authors": ["Spencer Kimball"], "summary": "General Electric has suspended its Covid vaccine and testing rules for employees following the Supreme Court's decision to block President Joe Biden's mandate. Despite the ruling, President Biden has urged companies to voluntarily implement such measures. Other companies like Citigroup, Nike, and Columbia Sportswear, however, have continued to enforce vaccine requirements and have begun firing unvaccinated workers.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.907641"}, {"topic": "economy_fiscal", "relevance_score": "0.802457"}, {"topic": "manufacturing", "relevance_score": "0.742993"}], "overall_sentiment_score": 0.026412, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.007297", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.643188", "ticker_sentiment_score": "0.024796", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.629480", "ticker_sentiment_score": "0.014087", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.584253", "ticker_sentiment_score": "0.000539", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.566698", "ticker_sentiment_score": "0.041045", "ticker_sentiment_label": "Neutral"}]}, {"title": "Employees say Intuitive, Boston Scientific, J&J, Medtronic are among the best places to work in 2022", "url": "https://www.medicaldesignandoutsourcing.com/employees-say-intuitive-boston-scientific-jj-medtronic-best-places-to-work-in-2022/", "time_published": "20220113T171602", "authors": ["Danielle Kirsh"], "summary": "Intuitive Surgical, Boston Scientific, Johnson & Johnson, and Medtronic have been recognized by Glassdoor as among the Best Places to Work in 2022, based on positive employee reviews. Insights from these reviews highlight work-life balance, competitive compensation, and growth opportunities within these medical device giants. The article details each company's Glassdoor ranking, star rating, employee feedback (pros and cons), and key financial and employee statistics.", "banner_image": null, "source": "Medical Design & Outsourcing", "category_within_source": "General", "source_domain": "Medical Design & Outsourcing", "topics": [{"topic": "life_sciences", "relevance_score": "0.937528"}, {"topic": "earnings", "relevance_score": "0.729803"}], "overall_sentiment_score": 0.291178, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.403138", "ticker_sentiment_label": "Bullish"}, {"ticker": "BSX", "relevance_score": "0.817253", "ticker_sentiment_score": "0.327830", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.731604", "ticker_sentiment_score": "0.287589", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.639736", "ticker_sentiment_score": "0.246039", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Medtronic to Buy Affera for Nearly $1B", "url": "https://tcbmag.com/medtronic-to-buy-affera-for-nearly-1b/", "time_published": "20220111T173639", "authors": ["Dan Niepow"], "summary": "Medtronic announced a deal to acquire Boston-based cardiac technology firm Affera Inc. for an estimated $925 million. Affera specializes in ablation technology for treating irregular heartbeats, which Medtronic says will complement its existing offerings and strengthen its presence in electrophysiology technology segments. This acquisition follows Medtronic's 2021 plan to acquire Intersect ENT for $1.1 billion.", "banner_image": null, "source": "Twin Cities Business", "category_within_source": "General", "source_domain": "Twin Cities Business", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.944740"}, {"topic": "life_sciences", "relevance_score": "0.830168"}, {"topic": "technology", "relevance_score": "0.707873"}], "overall_sentiment_score": 0.200874, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.480326", "ticker_sentiment_label": "Bullish"}, {"ticker": "BSX", "relevance_score": "0.637578", "ticker_sentiment_score": "0.123710", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.648215", "ticker_sentiment_score": "0.148017", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.619052", "ticker_sentiment_score": "0.122461", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Medical Devices Companies: Reimagining the patient journey in a digital era - Source", "url": "https://news.microsoft.com/source/features/digital-transformation/johnson-johnson-medical-devices-companies-reimagining-the-patient-journey-in-a-digital-era/", "time_published": "20220110T171640", "authors": ["Deborah Bach"], "summary": "Johnson & Johnson Medical Devices Companies (JJMDC) and Microsoft have entered a multiyear collaboration to reimagine the patient journey in a digital era. Microsoft will become JJMDC\u2019s preferred cloud provider for its digital surgery solutions, with the goal of using AI, machine learning, and data insights to improve patient outcomes, increase consistency in care, and enhance surgical performance. The partnership aims to connect medical devices, patient records, and hospital information systems through Azure to provide comprehensive patient views and predictive maintenance capabilities.", "banner_image": null, "source": "Microsoft Source", "category_within_source": "General", "source_domain": "Microsoft Source", "topics": [{"topic": "life_sciences", "relevance_score": "0.913641"}, {"topic": "technology", "relevance_score": "0.824229"}], "overall_sentiment_score": 0.351666, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.995744", "ticker_sentiment_score": "0.449150", "ticker_sentiment_label": "Bullish"}, {"ticker": "MSFT", "relevance_score": "0.902765", "ticker_sentiment_score": "0.409705", "ticker_sentiment_label": "Bullish"}, {"ticker": "HOLX", "relevance_score": "0.644255", "ticker_sentiment_score": "0.317358", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GEHC", "relevance_score": "0.558099", "ticker_sentiment_score": "0.337264", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYK", "relevance_score": "0.556629", "ticker_sentiment_score": "0.322113", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "JPM 2022: New Johnson & Johnson CEO Duato points out 5 pipeline meds that can generate $5B-plus", "url": "https://www.fiercepharma.com/pharma/johnson-johnson-ceo-duato-points-out-5-pipeline-meds-can-generate-5b", "time_published": "20220110T104500", "authors": ["Eric Sagonowsky"], "summary": "Johnson & Johnson's new CEO, Joaquin Duato, outlined the company's pharmaceutical strategy for the coming decade at the J.P. Morgan Healthcare Conference, aiming for $60 billion in pharma sales by 2025. He highlighted five pipeline drugs\u2014Carvykti, nipocalimab, Rybrevant, milvexian, and the Taris bladder cancer platform\u2014each with the potential to generate $5 billion or more in peak sales. These new therapies, alongside expanded indications for existing blockbusters, are crucial for future growth, especially as the company prepares for a consumer health spinoff and faces patent expiration for Stelara.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.927682"}], "overall_sentiment_score": 0.405547, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "LEGN", "relevance_score": "0.813032", "ticker_sentiment_score": "0.731325", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.612679", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.647647", "ticker_sentiment_score": "0.203617", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.631186", "ticker_sentiment_score": "0.133585", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Okays Phase 3 Study of Zilovertamab in R/R Mantle Cell Lymphoma", "url": "https://www.targetedonc.com/view/fda-okays-phase-3-study-of-zilovertamab-in-r-r-mantle-cell-lymphoma", "time_published": "20220106T175644", "authors": ["Nichole Tucker"], "summary": "The FDA has approved a pivotal phase 3 study for zilovertamab in combination with ibrutinib for the treatment of relapsed or refractory mantle cell lymphoma (MCL). This decision follows successful phase 2 results, which demonstrated a favorable objective response rate and progression-free survival compared to ibrutinib monotherapy, with the study expected to commence in Q2 2022. The agreement with the FDA outlines the trial design to support potential future regular or accelerated approval for zilovertamab.", "banner_image": null, "source": "Targeted Oncology", "category_within_source": "General", "source_domain": "Targeted Oncology", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.293344, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ONCT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.616441", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.629566", "ticker_sentiment_score": "0.105126", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.638087", "ticker_sentiment_score": "0.110985", "ticker_sentiment_label": "Neutral"}]}, {"title": "Teva fueled opioid addiction in New York state, jury finds", "url": "https://www.aljazeera.com/news/2021/12/30/teva-fueled-opioid-addiction-in-new-york-state-jury-finds", "time_published": "20211230T212209", "authors": ["Reuters"], "summary": "A jury in New York found Teva Pharmaceutical Industries Ltd responsible for fueling opioid addiction in the state through misleading marketing practices. This verdict is a significant setback for Teva, which faces thousands of similar lawsuits across the United States. Damages will be determined in a later proceeding, and the decision could pressure Teva to pursue a nationwide settlement.", "banner_image": null, "source": "Al Jazeera", "category_within_source": "General", "source_domain": "Al Jazeera", "topics": [{"topic": "life_sciences", "relevance_score": "0.947462"}], "overall_sentiment_score": -0.617925, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "TEVA", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.802542", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.623158", "ticker_sentiment_score": "-0.639914", "ticker_sentiment_label": "Bearish"}, {"ticker": "CAH", "relevance_score": "0.610393", "ticker_sentiment_score": "-0.507981", "ticker_sentiment_label": "Bearish"}, {"ticker": "WBA", "relevance_score": "0.612515", "ticker_sentiment_score": "-0.517787", "ticker_sentiment_label": "Bearish"}, {"ticker": "CVS", "relevance_score": "0.612108", "ticker_sentiment_score": "-0.523941", "ticker_sentiment_label": "Bearish"}]}, {"title": "Japan health panel approves Merck's oral COVID-19 treatment", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/japan-health-panel-approves-mercks-oral-covid-19-treatment-nhk-2021-12-24/", "time_published": "20211224T112100", "authors": ["Rocky Swift and Kantaro Komiya"], "summary": "A Japanese health ministry panel has recommended the approval of Merck's oral COVID-19 antiviral pill, molnupiravir, paving the way for its distribution across the country from this weekend. This move is part of Prime Minister Fumio Kishida's strategy to introduce new treatments by year-end amidst concerns about the Omicron variant. Japan has already secured substantial doses of Merck's drug and is also procuring treatments from Pfizer and developing its own with Shionogi.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.907229"}], "overall_sentiment_score": 0.18702, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.299374", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.701140", "ticker_sentiment_score": "0.228872", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.632232", "ticker_sentiment_score": "0.111618", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moody's gives Apple top 'AAA' credit rating on growth promise", "url": "https://www.reuters.com/technology/moodys-gives-apple-top-aaa-credit-rating-growth-promise-2021-12-21/", "time_published": "20211222T102800", "authors": ["Reuters"], "summary": "Ratings agency Moody's upgraded Apple Inc.'s long-term credit rating to 'AAA' with a stable outlook, citing its exceptional liquidity and robust earnings. This places Apple in an elite group of companies with the highest rating. While Apple's financial performance was strong in fiscal 2021, the company faces execution risks from short product cycles, shifting consumer preferences, and supply chain management.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "earnings", "relevance_score": "0.943254"}, {"topic": "technology", "relevance_score": "0.808787"}, {"topic": "financial_markets", "relevance_score": "0.738882"}], "overall_sentiment_score": 0.44961, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.978596", "ticker_sentiment_score": "0.701120", "ticker_sentiment_label": "Bullish"}, {"ticker": "MSFT", "relevance_score": "0.636877", "ticker_sentiment_score": "0.306036", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.567293", "ticker_sentiment_score": "0.307066", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Apple\u2019s long-term credit rating upgraded to AAA by Moody\u2019s", "url": "https://www.aljazeera.com/economy/2021/12/21/apples-long-term-credit-rating-upgraded-to-aaa-by-moodys", "time_published": "20211221T192603", "authors": ["Jack Pitcher and Mark Gurman and Bloomberg"], "summary": "Moody\u2019s Investors Service upgraded Apple Inc.\u2019s long-term credit rating to Aaa, placing it in an exclusive group with Microsoft and Johnson & Johnson as the only U.S. S&P 500 corporations with the highest possible credit score. This upgrade reflects Apple's exceptional liquidity, robust earnings, and strong business profile, as the company continues to focus on a net cash-neutral position and expand into new markets like augmented reality and cars. Despite potential chip-related supply shortages impacting revenue, investors remain optimistic about Apple's long-term prospects.", "banner_image": "NULL", "source": "Al Jazeera", "category_within_source": "General", "source_domain": "Al Jazeera", "topics": [{"topic": "earnings", "relevance_score": "0.947704"}, {"topic": "financial_markets", "relevance_score": "0.836869"}, {"topic": "economy_fiscal", "relevance_score": "0.622158"}, {"topic": "finance", "relevance_score": "0.728644"}, {"topic": "technology", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.657619, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "1.000000", "ticker_sentiment_score": "0.898111", "ticker_sentiment_label": "Bullish"}, {"ticker": "MSFT", "relevance_score": "0.614470", "ticker_sentiment_score": "0.528460", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.572593", "ticker_sentiment_score": "0.519991", "ticker_sentiment_label": "Bullish"}]}, {"title": "The Path That Brought Lara Sullivan To Biopharma", "url": "https://www.lifescienceleader.com/doc/the-path-that-brought-lara-sullivan-to-biopharma-0001", "time_published": "20211220T210610", "authors": ["Rob Wright"], "summary": "This article details the career path of Lara Sullivan, M.D., CEO of Pyxis Oncology, from her origins as the child of physicians in rural upstate New York to her current role in biopharma. It highlights her initial pivot away from medicine, her experiences on Wall Street, and her eventual return to healthcare through an M.D./MBA program at Penn and Wharton, which led her to roles at McKinsey, Pfizer, SpringWorks Therapeutics, and Pyxis Oncology. The piece emphasizes how her diverse background shaped her journey into leading biopharmaceutical companies.", "banner_image": null, "source": "Life Science Leader", "category_within_source": "General", "source_domain": "Life Science Leader", "topics": [{"topic": "life_sciences", "relevance_score": "0.931854"}], "overall_sentiment_score": 0.2037, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PYXS", "relevance_score": "0.979611", "ticker_sentiment_score": "0.338081", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.727410", "ticker_sentiment_score": "0.279473", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.633320", "ticker_sentiment_score": "0.143661", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.555296", "ticker_sentiment_score": "0.129794", "ticker_sentiment_label": "Neutral"}]}, {"title": "P&G recalls some conditioner, shampoo sprays on finding carcinogens", "url": "https://www.reuters.com/business/retail-consumer/pg-recalls-some-conditioner-shampoo-sprays-due-potential-cancer-risk-2021-12-17/", "time_published": "20211217T220800", "authors": ["Reuters"], "summary": "Procter & Gamble Co (PG.N) has voluntarily recalled some dry conditioner and shampoo sprays from several brands, including Pantene and Herbal Essences, in the United States and Canada due to the detection of a cancer-causing chemical, benzene. While the company stated that daily exposure to the detected benzene levels is not expected to cause negative health consequences, the products represented less than 1% of its overall hair care portfolio. This recall follows a similar action earlier in the year by Johnson & Johnson, which also detected benzene in some of its sunscreen products.", "banner_image": "https://www.reuters.com/resizer/v2/LDSY3H45OFI4BJG2HKC76F4L7Y.JPG?width=1200&height=628&quality=80&smart=true", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.906575"}, {"topic": "life_sciences", "relevance_score": "0.805907"}], "overall_sentiment_score": -0.376219, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "PG", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.403904", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.633200", "ticker_sentiment_score": "-0.336405", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Dyadic Announces Research, License and Collaboration", "url": "https://www.globenewswire.com/de/news-release/2021/12/17/2354376/0/en/Dyadic-Announces-Research-License-and-Collaboration-Agreement-with-Janssen-for-the-Manufacture-of-Therapeutic-Protein-Candidates-using-its-C1-Platform.html?%3Futm_source=dutchit", "time_published": "20211217T211019", "authors": [], "summary": "Dyadic International, Inc. announced a Research, License and Collaboration Agreement with Janssen Biotech, Inc., a Johnson & Johnson Pharmaceutical Company. Under the agreement, Janssen will pay Dyadic an upfront payment for non-exclusive rights to use Dyadic's C1 platform for developing therapeutic protein candidates and will provide R&D funding. The agreement also includes options for Janssen to secure exclusive licenses, milestone payments to Dyadic upon option exercise, technology transfer, and additional development, regulatory, and commercial milestones based on product development and manufacturing.", "banner_image": "https://ml.globenewswire.com/media/ZmMxMzEzZDEtOTA2Yy00NTMxLWEzZjAtYTJjYTNhODk0NzNhLTEwMzA3ODM=/tiny/Dyadic-International-Inc-.png", "source": "GlobeNewswire", "category_within_source": "General", "source_domain": "GlobeNewswire", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.401319, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DYAI", "relevance_score": "1.000000", "ticker_sentiment_score": "0.484851", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.822633", "ticker_sentiment_score": "0.312861", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The tragedy of Johnson & Johnson\u2019s Covid vaccine", "url": "https://www.statnews.com/2021/12/17/the-tragedy-of-johnson-johnsons-covid-vaccine/", "time_published": "20211217T203638", "authors": ["Matthew Herper"], "summary": "This article discusses the downfall of Johnson & Johnson's Covid-19 vaccine, once anticipated as a global solution. Despite initial hopes, its lower efficacy compared to mRNA vaccines, rare but serious blood clot side effects, and distribution issues led to a unanimous CDC advisory panel recommendation favoring Pfizer and Moderna shots. The piece reflects on the challenges J&J faced in drug development, highlighting how biology, bad luck, and strategic decisions ultimately hampered its success.", "banner_image": null, "source": "STAT", "category_within_source": "General", "source_domain": "STAT", "topics": [{"topic": "life_sciences", "relevance_score": "0.934153"}], "overall_sentiment_score": -0.150814, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.392656", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.730330", "ticker_sentiment_score": "0.282319", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.729282", "ticker_sentiment_score": "0.286558", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.561613", "ticker_sentiment_score": "-0.358180", "ticker_sentiment_label": "Bearish"}, {"ticker": "MRK", "relevance_score": "0.574803", "ticker_sentiment_score": "-0.392250", "ticker_sentiment_label": "Bearish"}]}, {"title": "CDC recommends people not get J&J vaccine if Pfizer, Moderna are available", "url": "https://www.nbcnews.com/health/health-news/cdc-panel-recommends-people-not-get-jj-vaccine-pfizer-moderna-availabl-rcna8987", "time_published": "20211216T154600", "authors": ["Berkeley Lovelace Jr.", "Sara G. Miller"], "summary": "The CDC has recommended that people prioritize Pfizer or Moderna Covid-19 vaccines over Johnson & Johnson due to the mRNA vaccines' greater protection and lower risk of rare but serious blood clots. This guidance came after the CDC's Advisory Committee on Immunization Practices unanimously voted to declare the mRNA vaccines as \"preferred\" options for adults. While not prohibiting J&J's use, the recommendation emphasizes the superior safety and efficacy profile of the Pfizer and Moderna shots when available.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.929073"}, {"topic": "finance", "relevance_score": "0.628670"}], "overall_sentiment_score": 0.100933, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.424906", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.849401", "ticker_sentiment_score": "0.300943", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.712657", "ticker_sentiment_score": "0.331298", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Chief Executive Leadership Institute Honors Dr. Albert Bourla of Pfizer and Alex Gorsky of Johnson & Johnson with Legend in Leadership Award", "url": "https://som.yale.edu/news/2021/12/chief-executive-leadership-institute-honors-dr-albert-bourla-of-pfizer-and-alex-gorsky-of-johnson-johnson-with-legend-in-leadership-award", "time_published": "20211214T210208", "authors": [], "summary": "The Yale Chief Executive Leadership Institute (CELI) awarded Dr. Albert Bourla of Pfizer and Alex Gorsky of Johnson & Johnson with the Legend in Leadership Award during its virtual CEO Summit on December 15, 2021. The award recognizes their instrumental roles in developing and distributing COVID-19 vaccines and therapeutics in record time, saving millions of lives globally. Jeffrey Sonnenfeld, senior associate dean for leadership studies at the Yale School of Management, praised their foresight in R&D investment and their leadership in navigating scientific and political challenges during the pandemic.", "banner_image": null, "source": "Yale School of Management", "category_within_source": "General", "source_domain": "Yale School of Management", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.302679, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.408460", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.956608", "ticker_sentiment_score": "0.423210", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRK", "relevance_score": "0.726409", "ticker_sentiment_score": "0.265715", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.695531", "ticker_sentiment_score": "0.237026", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IBM", "relevance_score": "0.562058", "ticker_sentiment_score": "0.180780", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nasally inhaled therapeutics and vaccination for COVID\u201019: Developments and challenges - Xi - 2021 - MedComm", "url": "https://onlinelibrary.wiley.com/doi/10.1002/mco2.101", "time_published": "20211214T193545", "authors": ["Jinxiang Xi", "Lameng Ray Lei", "William Zouzas", "Xiuhua April Si"], "summary": "This review article explores the developments and challenges of nasally inhaled therapeutics and vaccination for COVID-19. It highlights the advantages of nasal delivery, such as local immunity and ease of administration, especially for low-income countries. The authors also discuss the physiological factors affecting nasal spray efficacy and the urgent need for effective delivery systems targeting ACE2-rich regions.", "banner_image": null, "source": "Wiley Online Library", "category_within_source": "General", "source_domain": "Wiley Online Library", "topics": [{"topic": "life_sciences", "relevance_score": "0.934233"}], "overall_sentiment_score": 0.357866, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMPH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.418428", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.724254", "ticker_sentiment_score": "0.308979", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.616734", "ticker_sentiment_score": "0.309993", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.640567", "ticker_sentiment_score": "0.329869", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Using Biotechnology Stocks to Help Navigate the Ongoing COVID Crisis", "url": "https://www.etftrends.com/tactical-allocation-content-hub/using-biotechnology-stocks-to-help-navigate-the-ongoing-covid-crisis/amp/", "time_published": "20211211T194715", "authors": ["VanEck"], "summary": "This article discusses how biotechnology stocks can be a strategic investment during the ongoing COVID-19 pandemic, particularly with the emergence of new variants like Omicron. It highlights how vaccine makers like Moderna, BioNTech, and Novavax saw stock surges following Omicron news and emphasizes the potential of large-cap biotech companies and ETFs like VanEck Biotech ETF (NASDAQ: BBH) to provide diversified exposure and mitigate risks in the volatile biotech sector.", "banner_image": null, "source": "ETF Trends", "category_within_source": "General", "source_domain": "ETF Trends", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.928905"}], "overall_sentiment_score": 0.268635, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BBH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.428784", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.900913", "ticker_sentiment_score": "0.310715", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.719428", "ticker_sentiment_score": "0.216924", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.639597", "ticker_sentiment_score": "0.131305", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.585375", "ticker_sentiment_score": "0.199414", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Appoints Senior Leaders to Executive Committee", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-appoints-senior-leaders-to-executive-committee-301440952.html", "time_published": "20211209T063000", "authors": ["NULL"], "summary": "Johnson & Johnson announced several senior leadership appointments to its Executive Committee, effective January 3, 2022, reporting to incoming CEO Joaquin Duato. These appointments include new roles for Vanessa Broadhurst, Dr. Bill Hait, Dr. Mathai Mammen, and James Swanson. The company also announced the retirement of Michael Sneed, Executive Vice President, Global Corporate Affairs and Chief Communication Officer, effective April 1, 2022, and reiterated Dr. Paul Stoffels' retirement.", "banner_image": "NULL", "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.937062"}], "overall_sentiment_score": 0.427797, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.413370", "ticker_sentiment_label": "Bullish"}]}, {"title": "AbbVie settles New York opioid case for $200 mln as trial winds down", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/jury-hear-final-arguments-ny-opioid-case-against-drugmakers-2021-12-08/", "time_published": "20211208T195000", "authors": ["Brendan Pierson"], "summary": "AbbVie Inc. has agreed to pay $200 million to settle opioid addiction claims in New York related to its Allergan unit. This settlement occurred shortly before closing arguments in a five-month trial against remaining defendant Teva Pharmaceutical Industries Ltd. New York Attorney General Letitia James announced that over $150 million of the settlement would be allocated to address the harms caused by opioid addiction.", "banner_image": "https://www.reuters.com/resizer/v2/_2K7ZzT_C8TjK1t3RzL7b_R5j_I=/728x382/smart/filters:quality%2880%29/cloudfront-us-east-2.images.arcpublishing.com/reuters/V7J2GZ62IVIM5H22X377U2A2BM.jpg", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.917274"}, {"topic": "finance", "relevance_score": "0.710494"}], "overall_sentiment_score": 0.131925, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "1.000000", "ticker_sentiment_score": "0.103928", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.749880", "ticker_sentiment_score": "0.122158", "ticker_sentiment_label": "Neutral"}]}, {"title": "John Wiley & Sons (A Shares) (JW.A) Q2 2022 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2021/12/08/john-wiley-sons-a-shares-jwa-q2-2022-earnings-call/", "time_published": "20211208T040000", "authors": ["Motley Fool Transcribing"], "summary": "John Wiley & Sons (A Shares) reported strong Q2 2022 earnings, with a 9% revenue increase, 7% adjusted EBITDA growth, and 6% adjusted EPS growth. The company reaffirmed its full-year guidance, driven by growth in research, academic and professional learning, and education services, aligning with ongoing market trends in open research and career-connected education. Brian Napack highlighted the strategic focus on corporate opportunities, talent development, and digital transformation, while CFO John Kritzmacher reviewed the strong first-half performance and capital allocation strategy.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F1%2Ffeatured-transcript-logo-template.jpg&w=3840&op=resize", "source": "The Motley Fool", "category_within_source": "General", "source_domain": "The Motley Fool", "topics": [{"topic": "earnings", "relevance_score": "0.906264"}, {"topic": "finance", "relevance_score": "0.723198"}, {"topic": "economy_macro", "relevance_score": "0.619121"}], "overall_sentiment_score": 0.176492, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WLY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.322755", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.560051", "ticker_sentiment_score": "0.130538", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.521702", "ticker_sentiment_score": "0.107816", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMT", "relevance_score": "0.553982", "ticker_sentiment_score": "0.110778", "ticker_sentiment_label": "Neutral"}]}, {"title": "Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer", "url": "https://www.citybiz.co/article/183277/monte-rosa-therapeutics-appoints-jullian-g-jones-ph-d-j-d-mba-as-chief-business-officer/", "time_published": "20211202T202202", "authors": [], "summary": "Monte Rosa Therapeutics has announced the promotion of Jullian Jones, Ph.D., J.D., MBA, to Chief Business Officer. Dr. Jones brings over a decade of experience in life sciences business development, including a significant role in Monte Rosa's $255.6 million IPO and previous M&A activities at Eli Lilly and Company. Her expertise is expected to advance the company's clinical development plan and leverage its proprietary QuEEN\u2122 platform.", "banner_image": null, "source": "citybiz", "category_within_source": "General", "source_domain": "citybiz", "topics": [{"topic": "life_sciences", "relevance_score": "0.929516"}, {"topic": "ipo", "relevance_score": "0.602963"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.606337"}], "overall_sentiment_score": 0.30566, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLUE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.451706", "ticker_sentiment_label": "Bullish"}, {"ticker": "LLY", "relevance_score": "0.737085", "ticker_sentiment_score": "0.322504", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.606801", "ticker_sentiment_score": "0.228794", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.614376", "ticker_sentiment_score": "0.241403", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Target\u2019s Up & Up \u2018reef-conscious\u2019 sunscreen harms, kill reefs, class action lawsuit alleges", "url": "https://topclassactions.com/lawsuit-settlements/consumer-products/beauty-products/targets-up-up-reef-conscious-sunscreen-harm-kill-reefs-class-action-lawsuit-alleges/", "time_published": "20211201T212220", "authors": ["Jessy Edwards"], "summary": "A class action lawsuit has been filed against Target and Fruit of the Earth, alleging their Up & Up \"reef-conscious\" sunscreens falsely advertise reef-friendliness while containing chemicals harmful to reefs. Plaintiff Martin Locklin claims the companies profited from this alleged misrepresentation in the billion-dollar sunscreen market. The lawsuit seeks to represent consumers nationwide and requests an injunction, damages, and fees.", "banner_image": null, "source": "Class Action Lawsuits", "category_within_source": "General", "source_domain": "Class Action Lawsuits", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.827767"}, {"topic": "finance", "relevance_score": "0.748484"}], "overall_sentiment_score": -0.418893, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "TGT", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.430423", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.648910", "ticker_sentiment_score": "-0.443909", "ticker_sentiment_label": "Bearish"}, {"ticker": "WBA", "relevance_score": "0.608368", "ticker_sentiment_score": "-0.426914", "ticker_sentiment_label": "Bearish"}]}, {"title": "Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse", "url": "https://www.prnewswire.com/news-releases/halozyme-announces-janssen-receives-us-fda-approval-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-in-combination-with-carfilzomib-and-dexamethasone-for-patients-with-multiple-myeloma-after-first-or-subsequent-relapse-301435510.html", "time_published": "20211201T142100", "authors": [], "summary": "Halozyme announced that Janssen has received U.S. FDA approval for DARZALEX FASPRO\u00ae in combination with Kyprolis\u00ae and dexamethasone for patients with relapsed or refractory multiple myeloma. This marks the ninth indication for DARZALEX FASPRO\u00ae, which utilizes Halozyme's ENHANZE\u00ae drug delivery technology for a rapid subcutaneous administration. The approval is based on data from Janssen's PLEIADES Study, expanding treatment options for multiple myeloma patients.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.345316, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HALO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.478697", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.704116", "ticker_sentiment_score": "0.349378", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.628629", "ticker_sentiment_score": "0.262990", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.602129", "ticker_sentiment_score": "0.291492", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BD Names Dr. Joseph M. Smith as Chief Scientific Officer", "url": "https://news.bd.com/2021-11-29-BD-Names-Dr-Joseph-M-Smith-as-Chief-Scientific-Officer", "time_published": "20211129T194727", "authors": [], "summary": "BD (Becton, Dickinson and Company) announced the appointment of Dr. Joseph M. Smith as Senior Vice President and Chief Scientific Officer, effective November 29, 2021. Dr. Smith will focus on external innovation, aligning BD's technology roadmap with smart connected care, new care settings, and chronic disease management. He will also establish and co-chair the BD Scientific Advisory Board, leveraging his extensive background in digital health and medical technology.", "banner_image": null, "source": "BD Newsroom", "category_within_source": "General", "source_domain": "BD Newsroom", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "technology", "relevance_score": "0.814944"}], "overall_sentiment_score": 0.235374, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.403140", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.621059", "ticker_sentiment_score": "0.107005", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.606025", "ticker_sentiment_score": "0.104928", "ticker_sentiment_label": "Neutral"}]}, {"title": "Walmart, CVS, Walgreens helped fuel US opioid crisis, jury finds", "url": "https://www.aljazeera.com/economy/2021/11/23/walmart-cvs-walgreens-helped-fuel-us-opioid-crisis-jury-finds", "time_published": "20211123T200200", "authors": ["Jef Feeley and Bloomberg"], "summary": "A federal jury in Cleveland, Ohio, found Walmart, CVS Health Corp., and Walgreens Boots Alliance Inc. liable for contributing to the US opioid crisis by failing to monitor illegitimate prescriptions. The decision marks the first jury verdict in the four-year opioid litigation against pharmacy chains, with counties seeking billions in reimbursement for addiction and overdose costs. All three companies announced immediate plans to appeal the verdict, arguing a misapplication of public nuisance law and flawed trial proceedings.", "banner_image": null, "source": "Al Jazeera", "category_within_source": "General", "source_domain": "Al Jazeera", "topics": [{"topic": "life_sciences", "relevance_score": "0.914555"}, {"topic": "retail_wholesale", "relevance_score": "0.837437"}, {"topic": "finance", "relevance_score": "0.612741"}], "overall_sentiment_score": -0.335345, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.388365", "ticker_sentiment_label": "Bearish"}, {"ticker": "WMT", "relevance_score": "0.926351", "ticker_sentiment_score": "-0.387937", "ticker_sentiment_label": "Bearish"}, {"ticker": "WBA", "relevance_score": "0.929867", "ticker_sentiment_score": "-0.353011", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.613260", "ticker_sentiment_score": "-0.138562", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson is proud to lead efforts to outpace antimicrobial resistance", "url": "https://www.jnj.com/our-company/johnson-johnson-is-proud-to-lead-efforts-to-outpace-antimicrobial-resistance", "time_published": "20211118T203638", "authors": [], "summary": "Johnson & Johnson has been recognized as a top company in addressing antimicrobial resistance (AMR) for the third consecutive year, according to the AMR Benchmark. The company is actively involved in R&D, stewardship, and access initiatives, particularly focusing on drug-resistant tuberculosis and contributing to broader efforts like the AMR Action Fund. These efforts aim to safeguard existing treatments and accelerate the development of new ones to combat the growing global threat of AMR.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.910950"}], "overall_sentiment_score": 0.468992, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.463257", "ticker_sentiment_label": "Bullish"}]}, {"title": "Banks that helped GE, others bulk up now profit from break-ups", "url": "https://www.reuters.com/business/finance/banks-profit-building-up-breaking-up-companies-2021-11-16/", "time_published": "20211116T210400", "authors": ["Anirban Sen and David French"], "summary": "A Reuters analysis reveals that some Wall Street banks, including Goldman Sachs, JPMorgan, and UBS, are now profiting from the break-ups of conglomerates like GE, Toshiba, and Johnson & Johnson, after previously advising them on acquisitions. Banks have earned over $1 billion from global spin-offs this year, nearly doubling last year's figures. The article highlights how these banks are paid to undo deals they once helped create, prompting questions about independent advice and the incentives within the banking industry.", "banner_image": "https://www.reuters.com/resizer/v2/L4LIX7W7D5L3RMNV2FDRD55XYA.JPG?auth=1af64b82522736b04337a6a43b2f2d95b5463f01901ddde5a448a31e8093d939&width=1200&height=628&quality=80&smart=true", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.912366"}, {"topic": "finance", "relevance_score": "0.848006"}], "overall_sentiment_score": 0.126595, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.146029", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.885727", "ticker_sentiment_score": "0.128115", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.830956", "ticker_sentiment_score": "0.108527", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.768694", "ticker_sentiment_score": "0.096059", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.688837", "ticker_sentiment_score": "0.087626", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer to allow generic versions of its COVID pill in 95 countries", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-allow-generic-versions-its-covid-19-pill-95-countries-2021-11-16/", "time_published": "20211116T154600", "authors": ["Michael Erman", "Emma Farge"], "summary": "Pfizer announced a licensing agreement with the Medicines Patent Pool (MPP) to allow generic manufacturers to supply its experimental antiviral COVID-19 pill to 95 low- and middle-income countries. This deal, similar to one by rival Merck & Co, aims to make the life-saving drug accessible at lower costs, although Medecins Sans Frontieres expressed disappointment that certain countries with generic drug production capacity were excluded. Pfizer expects to produce 180,000 treatment courses by the end of next month and at least 50 million by the end of 2022, with a tiered pricing approach based on country income level.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.935057"}, {"topic": "economy_macro", "relevance_score": "0.604016"}], "overall_sentiment_score": 0.148277, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.985422", "ticker_sentiment_score": "0.299419", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.712202", "ticker_sentiment_score": "0.188852", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.594538", "ticker_sentiment_score": "-0.100702", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharmacy chains defend actions as landmark U.S. opioid trial nears its end", "url": "https://www.reuters.com/world/us/cvs-walgreens-walmart-set-closing-arguments-ohio-opioid-trial-2021-11-15/", "time_published": "20211116T101400", "authors": ["Grant Segall"], "summary": "Pharmacy chains CVS, Walgreens, and Walmart are defending themselves in a landmark U.S. opioid trial in Ohio, arguing they are not to blame for the epidemic. Lawyers for Lake and Trumbull counties assert that the pharmacies created a public nuisance by failing to prevent excessive amounts of addictive pain pills, with potential costs of $1 billion for each county. The trial is the first of thousands of lawsuits facing pharmacy chains and its outcome could have significant national ramifications.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FLLUWHWOP5FN33DBIEKCP3K43Y4.JPG?auth=5e6833c873322d71b3127814c330f65345710609384501a1d60b54e7d4dcf2d9&width=960&quality=80", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "retail_wholesale", "relevance_score": "0.839906"}, {"topic": "finance", "relevance_score": "0.726731"}], "overall_sentiment_score": -0.04512, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "1.000000", "ticker_sentiment_score": "0.033185", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.923481", "ticker_sentiment_score": "0.034070", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.734565", "ticker_sentiment_score": "0.042199", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.649697", "ticker_sentiment_score": "-0.134785", "ticker_sentiment_label": "Neutral"}]}, {"title": "Emerging technologies in POCT", "url": "https://healthcare-in-europe.com/en/news/emerging-technologies-in-poct.html", "time_published": "20211115T212644", "authors": ["Bernard Banga", "MD"], "summary": "Point-of-care testing (POCT) is rapidly advancing with innovations in lab-on-a-chip, smartphone-based technology, and wearable devices, further enhanced by cloud-based deep learning. These developments are expanding POCT applications beyond traditional uses like glucose monitoring to include tumor markers and advanced infectious disease detection, and were critical during the COVID-19 pandemic. The global POCT market is projected for significant growth, driven by key players and diverse applications.", "banner_image": null, "source": "healthcare-in-europe.com", "category_within_source": "General", "source_domain": "healthcare-in-europe.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.901157"}, {"topic": "technology", "relevance_score": "0.803339"}], "overall_sentiment_score": 0.285711, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TRIB", "relevance_score": "0.911938", "ticker_sentiment_score": "0.324962", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.802198", "ticker_sentiment_score": "0.316628", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DHR", "relevance_score": "0.707613", "ticker_sentiment_score": "0.330213", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDX", "relevance_score": "0.618429", "ticker_sentiment_score": "0.285517", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.558442", "ticker_sentiment_score": "0.299453", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$95B Opioid Trial Begins Against Drug Distributors, Watch On-Demand via CVN", "url": "https://blog.cvn.com/95b-opioid-trial-begins-against-drug-distributors-watch-gavel-to-gavel-via-cvn", "time_published": "20211115T133950", "authors": ["David Siegel"], "summary": "A $95 billion opioid trial has begun in Washington State, with Attorney General Bob Ferguson suing major drug distributors McKesson Corp., Cardinal Health Inc., and AmerisourceBergen Corp. The lawsuit accuses the companies of creating a \"public nuisance\" by contributing to the opioid epidemic, seeking $38.2 billion in damages after Ferguson rejected a $26 billion nationwide settlement. The trial, being webcast live by Courtroom View Network, will test the \"public nuisance\" theory's effectiveness in holding drug companies liable for opioid-related claims.", "banner_image": null, "source": "CVN News", "category_within_source": "General", "source_domain": "CVN News", "topics": [{"topic": "life_sciences", "relevance_score": "0.945344"}, {"topic": "finance", "relevance_score": "0.707128"}], "overall_sentiment_score": -0.576253, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "0.963411", "ticker_sentiment_score": "-0.602034", "ticker_sentiment_label": "Bearish"}, {"ticker": "MCK", "relevance_score": "0.937671", "ticker_sentiment_score": "-0.636620", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.709889", "ticker_sentiment_score": "-0.444553", "ticker_sentiment_label": "Bearish"}]}, {"title": "Energy-Based Aesthetic Devices Market 2021 by Product and Geography \u2013 Forecast and Analysis", "url": "https://www.openpr.com/news/2461480/energy-based-aesthetic-devices-market-2021-by-product", "time_published": "20211115T074200", "authors": [], "summary": "The Global Energy-Based Aesthetic Devices Market is projected for rapid growth from 2021 to 2028, driven by new product approvals and launches, as well as R&D in novel materials and non-invasive platforms. Key players like Alma, Hologic\u2019s Cynosure division, and Lumenis are actively expanding their product portfolios, contributing to market expansion, particularly in regions like Asia Pacific. The report offers a comprehensive analysis of market segments, competitive landscapes, and future growth opportunities within the industry.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.917953"}, {"topic": "finance", "relevance_score": "0.729191"}], "overall_sentiment_score": 0.209662, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IRIX", "relevance_score": "0.342328", "ticker_sentiment_score": "0.014738", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.612470", "ticker_sentiment_score": "0.294747", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOLX", "relevance_score": "0.648937", "ticker_sentiment_score": "0.279544", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.593783", "ticker_sentiment_score": "0.221949", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson stock rises on split news: Here's why and when the company is separating", "url": "https://www.fastcompany.com/90696510/johnson-johnson-jnj-stock-price-split-explained/", "time_published": "20211112T203640", "authors": ["Christopher Zara"], "summary": "Johnson & Johnson announced plans to split into two separate publicly traded companies: one focused on consumer health products and the other on pharmaceuticals and medical devices. The pharmaceutical division, set to retain the Johnson & Johnson name, is projected to generate $77 billion in 2021, significantly more than the consumer health unit's estimated $15 billion. The separation is expected to be completed within 18 months to two years, following legal requirements.", "banner_image": null, "source": "Fast Company", "category_within_source": "General", "source_domain": "Fast Company", "topics": [{"topic": "earnings", "relevance_score": "0.814328"}, {"topic": "life_sciences", "relevance_score": "0.908140"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.812893"}, {"topic": "financial_markets", "relevance_score": "0.612733"}], "overall_sentiment_score": 0.508695, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.531070", "ticker_sentiment_label": "Bullish"}]}, {"title": "Some of the world\u2019s biggest companies are breaking apart. Here\u2019s why.", "url": "https://www.washingtonpost.com/business/2021/11/12/johnson-johnson-split/", "time_published": "20211112T203640", "authors": ["Aaron Gregg"], "summary": "Johnson & Johnson announced plans to split into two publicly traded companies, a move that parallels similar decisions by GE and Toshiba. The pharmaceutical and medical devices divisions will separate from the consumer products business. This decision led to an increase in Johnson & Johnson's share price.", "banner_image": null, "source": "The Washington Post", "category_within_source": "General", "source_domain": "The Washington Post", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.939860"}, {"topic": "life_sciences", "relevance_score": "0.801408"}, {"topic": "finance", "relevance_score": "0.603113"}], "overall_sentiment_score": 0.413036, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.425117", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson, Iconic Company Under Pressure, Plans to Split in Two (Published 2021)", "url": "https://www.nytimes.com/2021/11/12/business/johnson-johnson-split.html", "time_published": "20211112T203637", "authors": ["Rebecca Robbins and Michael J. de la Merced"], "summary": "Johnson & Johnson announced plans to spin off its consumer-products division, which includes brands like Tylenol and Band-Aid, into a separate company. The 135-year-old company will retain its more profitable pharmaceutical and medical devices businesses. This breakup follows years of legal challenges and a trend of other conglomerates splitting to focus on higher-margin sectors.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.910365"}], "overall_sentiment_score": 0.136432, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.149748", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.615984", "ticker_sentiment_score": "0.126032", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.638498", "ticker_sentiment_score": "0.119084", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.625511", "ticker_sentiment_score": "0.105856", "ticker_sentiment_label": "Neutral"}]}, {"title": "Encompass Health looking to expand Northern Virginia rehab hospital", "url": "https://www.bizjournals.com/washington/news/2021/11/12/encompass-health-rehab-hospital-expansion-proposal.html", "time_published": "20211112T200726", "authors": ["Sara Gilgore"], "summary": "Encompass Health is planning to expand its Rehabilitation Hospital of Northern Virginia. This expansion proposal comes as the health system is also working on a new inpatient rehab hospital in Bowie. The existing facility is located in Aldie.", "banner_image": null, "source": "The Business Journals", "category_within_source": "General", "source_domain": "The Business Journals", "topics": [{"topic": "life_sciences", "relevance_score": "0.942584"}], "overall_sentiment_score": 0.19325, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EHC", "relevance_score": "0.348844", "ticker_sentiment_score": "0.041110", "ticker_sentiment_label": "Neutral"}, {"ticker": "UHS", "relevance_score": "0.741385", "ticker_sentiment_score": "0.297490", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCA", "relevance_score": "0.628525", "ticker_sentiment_score": "0.203664", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.597440", "ticker_sentiment_score": "0.213953", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J to spin off consumer products and focus on pharmaceuticals", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/johnson-johnson-plans-split-into-two-companies-wsj-2021-11-12/", "time_published": "20211112T182200", "authors": ["Michael Erman and Manas Mishra"], "summary": "Johnson & Johnson announced plans to spin off its consumer health division to focus on pharmaceuticals and medical devices, marking the biggest shake-up in the company's 135-year history. This strategic move aims to simplify the company's structure and increase focus, following a trend seen among other large conglomerates and healthcare rivals. The separation is expected to take 18 to 24 months and cost between $500 million to $1 billion.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.922390"}, {"topic": "life_sciences", "relevance_score": "0.817827"}, {"topic": "financial_markets", "relevance_score": "0.637841"}, {"topic": "finance", "relevance_score": "0.611791"}], "overall_sentiment_score": 0.229332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.307098", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.648958", "ticker_sentiment_score": "0.117506", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson to split into 2 public companies", "url": "https://www.npr.org/2021/11/12/1055346617/johnson-split-public-health-care-company", "time_published": "20211112T163100", "authors": ["The Associated Press"], "summary": "Johnson & Johnson announced its plan to split into two public companies, separating its consumer health business from its pharmaceutical and medical device segments. This move is intended to make each business more agile and better adapted to its respective market, with the consumer health division potentially mitigating future litigation risks. The split is expected to be completed within two years and follows similar moves by other large pharmaceutical companies.", "banner_image": "https://media.npr.org/assets/img/2021/11/12/ap21316527568160-b6f72de515d18e95089201f1ae6a80df30b42f63.jpg?s=6", "source": "NPR", "category_within_source": "General", "source_domain": "NPR", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.915009"}, {"topic": "life_sciences", "relevance_score": "0.817633"}, {"topic": "financial_markets", "relevance_score": "0.627987"}, {"topic": "earnings", "relevance_score": "0.626424"}], "overall_sentiment_score": 0.116053, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.145234", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson to spin off consumer arm to focus on medical division", "url": "https://www.theguardian.com/business/2021/nov/12/johnson-johnson-to-spin-off-consumer-arm-to-focus-on-medical-division", "time_published": "20211112T124300", "authors": ["Julia Kollewe"], "summary": "Johnson & Johnson announced it will spin off its consumer health division to focus on its pharmaceutical and medical devices businesses. This strategic move, the largest in the company's 135-year history, is expected to create more value for shareholders by separating the lower-growth consumer unit from the high-margin medical divisions. The consumer arm, known for brands like Band-Aid and Listerine, will become a new publicly traded company within 18 to 24 months.", "banner_image": null, "source": "The Guardian", "category_within_source": "General", "source_domain": "The Guardian", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.008195, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.333048", "ticker_sentiment_score": "0.024029", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson is breaking up Band-Aids and pharmaceuticals", "url": "https://www.cnn.com/2021/11/12/investing/johnson-johnson-split", "time_published": "20211112T094200", "authors": ["Jordan Valinsky"], "summary": "Johnson & Johnson announced it will split into two publicly traded companies: one focused on consumer health products and the other on prescription drugs and medical devices. This separation aims to create two global leaders better positioned for innovation and improved health outcomes. The move follows similar announcements from companies like Toshiba and General Electric, focusing on more profitable business units.", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.935821"}, {"topic": "life_sciences", "relevance_score": "0.928760"}], "overall_sentiment_score": 0.446582, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.408258", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson to spin out consumer health business in new publicly traded company", "url": "https://www.fiercepharma.com/pharma/johnson-johnson-to-separate-its-consumer-health-business-create-new-publicly-traded-company", "time_published": "20211112T083500", "authors": ["Kevin Dunleavy"], "summary": "Johnson & Johnson announced it will spin off its consumer health business into a new publicly traded company within 18 to 24 months, a move mirroring similar initiatives by other large pharmaceutical firms. This separation will allow J&J to focus on its highly profitable pharmaceutical and medical device units, while the new consumer health company will retain iconic brands like Neutrogena and Tylenol. The decision was driven by the increasing complexity of global healthcare and consumer environments, demanding more focused innovation and agility from both entities.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.934358"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.822670"}, {"topic": "ipo", "relevance_score": "0.615861"}], "overall_sentiment_score": 0.290874, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.419815", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRK", "relevance_score": "0.613634", "ticker_sentiment_score": "0.229148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.645261", "ticker_sentiment_score": "0.245484", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson to split into two companies", "url": "https://www.cbsnews.com/news/johnson-johnson-split-two-companies/", "time_published": "20211112T081300", "authors": ["CBS/AP"], "summary": "Johnson & Johnson announced its plan to split into two separate companies. One entity will retain the Johnson & Johnson name and focus on prescription drugs and medical devices, while the other new consumer health company will manage brands like Neutrogena, Tylenol, and Band-Aid. The split is anticipated to be finalized by the fall of 2023.", "banner_image": null, "source": "CBS News", "category_within_source": "General", "source_domain": "CBS News", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.944431"}, {"topic": "life_sciences", "relevance_score": "0.812940"}, {"topic": "earnings", "relevance_score": "0.731129"}], "overall_sentiment_score": 0.392153, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.409268", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson to split into two companies, separating consumer health business", "url": "https://www.nbcnews.com/business/business-news/johnson-johnson-split-two-companies-separating-consumer-health-busines-rcna5394", "time_published": "20211112T065800", "authors": ["Jesse Pound", "CNBC"], "summary": "Johnson & Johnson announced it will split into two publicly traded companies: one focused on consumer products and another on prescription drugs and medical devices. Shares of J&J rose 4 percent in premarket trading following the news. This move follows General Electric's plan earlier in the week to divide into three separate units.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.938084"}, {"topic": "life_sciences", "relevance_score": "0.804220"}, {"topic": "financial_markets", "relevance_score": "0.730973"}], "overall_sentiment_score": 0.423326, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.423225", "ticker_sentiment_label": "Bullish"}]}, {"title": "GE Was Once a Model for Siemens but Now Follows Its Rival\u2019s Path", "url": "https://www.wsj.com/business/ge-was-once-a-model-for-siemens-but-now-follows-its-rivals-path-11636656545?gaa_at=eafs&gaa_n=AWEtsqeU-76Sct5tj_BTB-FwIkl-A1fJSTbKgY6Bl1IyCczyXU7TK_pFAmDg&gaa_ts=6907c086&gaa_sig=OJkpVN7phyv7OkhLkPFtv1sZu1lGhGJN5_ZcIrz6HqZIivDfNO91av4WxwdRy5svpdFi149PTmzPGS23fBEp3Q%3D%3D", "time_published": "20211111T202137", "authors": ["Georgi Kantchev"], "summary": "General Electric, once a benchmark for Siemens, is now adopting a similar strategy to its German competitor. This shift comes as both GE and Johnson & Johnson recently announced plans to split, reflecting a broader trend of conglomerate breakups. The article suggests this realignment could narrow the gap that has formed between GE and Siemens over the years.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.830249"}, {"topic": "manufacturing", "relevance_score": "0.710378"}], "overall_sentiment_score": 0.033342, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.000721", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.601013", "ticker_sentiment_score": "0.049613", "ticker_sentiment_label": "Neutral"}]}, {"title": "News | Foulkes Refuses to Respond to Questions About CVS and Her Role in Opioid Crisis - Lawsuits Pile Up", "url": "https://www.golocalprov.com/news/foulkes-refuses-to-respond-to-questions-about-cvs-and-her-role-in-opioid-cr", "time_published": "20211108T200200", "authors": ["GoLocalProv News Team"], "summary": "Helena Foulkes, former President of CVS and now a Rhode Island gubernatorial candidate, is facing scrutiny for her role at CVS during the opioid crisis. Multiple lawsuits, including one from the Attorney General of Kentucky, accuse CVS of profiting from the epidemic and failing to prevent the diversion of opioids. Foulkes has refused to directly answer questions regarding CVS's culpability and her oversight of the pharmacy function, with her campaign issuing a statement highlighting her efforts to combat opioid over-prescribing.", "banner_image": null, "source": "GoLocalProv", "category_within_source": "General", "source_domain": "GoLocalProv", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.924809"}, {"topic": "life_sciences", "relevance_score": "0.818687"}, {"topic": "finance", "relevance_score": "0.639074"}, {"topic": "economy_macro", "relevance_score": "0.619941"}], "overall_sentiment_score": -0.371527, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.437294", "ticker_sentiment_label": "Bearish"}, {"ticker": "WMT", "relevance_score": "0.601982", "ticker_sentiment_score": "-0.316694", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WBA", "relevance_score": "0.645182", "ticker_sentiment_score": "-0.335535", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.649763", "ticker_sentiment_score": "-0.338348", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "\u2018Layer Upon Layer of Regulation\u2019: Breaking Down the CMS Vaccination Mandate", "url": "https://homehealthcarenews.com/2021/11/layer-upon-layer-of-regulation-breaking-down-the-cms-vaccination-mandate/", "time_published": "20211108T192637", "authors": ["Andrew Donlan"], "summary": "This article breaks down the Centers for Medicare & Medicaid Services (CMS) vaccination mandate, clarifying which health care providers are included, exemption possibilities, and enforcement methods. It highlights the exclusion of home- and community-based services (HCBS) providers and discusses the complexities facing providers due to overlapping regulations. The piece also delves into the implications of the mandate, particularly regarding opt-out options, religious exemptions, and the requirements for compliance.", "banner_image": null, "source": "Home Health Care News", "category_within_source": "General", "source_domain": "Home Health Care News", "topics": [{"topic": "life_sciences", "relevance_score": "0.919649"}], "overall_sentiment_score": 0.068565, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ADUS", "relevance_score": "0.932822", "ticker_sentiment_score": "0.203307", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.643723", "ticker_sentiment_score": "-0.124011", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson advances global health and avoids supply chain disruptions - Source", "url": "https://news.microsoft.com/source/features/digital-transformation/johnson-johnson-advances-global-health-and-avoids-supply-chain-disruptions/", "time_published": "20211102T203638", "authors": ["Kevin Noschese"], "summary": "Johnson & Johnson leverages its collaboration with Microsoft to implement digital manufacturing transformation, including Azure, AI, and IoT, to enhance its global supply chain efficiency and resilience. By shifting to a pull supply chain and using smart manufacturing, J&J can ensure products are delivered precisely when needed, reduce errors, and mitigate disruptions. The company has seen improved quality output, a reduction in \"field actions,\" and moved from 28th to 3rd globally in Gartner's Magic Quadrant for Supply Chain Leaders, driven by its technological advancements.", "banner_image": null, "source": "Microsoft Source", "category_within_source": "General", "source_domain": "Microsoft Source", "topics": [{"topic": "life_sciences", "relevance_score": "0.902006"}, {"topic": "manufacturing", "relevance_score": "0.915460"}, {"topic": "technology", "relevance_score": "0.806893"}], "overall_sentiment_score": 0.380661, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.455603", "ticker_sentiment_label": "Bullish"}, {"ticker": "MSFT", "relevance_score": "0.879831", "ticker_sentiment_score": "0.318385", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pfizer expects 2021, 2022 COVID-19 vaccine sales to total at least $65 bln", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-raises-covid-19-vaccine-sales-forecast-36-billion-2021-11-02/", "time_published": "20211102T060400", "authors": ["Michael Erman and Manas Mishra"], "summary": "Pfizer announced expected COVID-19 vaccine sales of $36 billion for 2021 and an additional $29 billion for 2022, surpassing analyst estimates. The company plans to sign more vaccine deals, potentially driving sales even higher, and is urging low- and middle-income countries to place orders early. Pfizer also anticipates a durable market for COVID-19 vaccines beyond 2022, with plans for private markets to emerge.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "earnings", "relevance_score": "0.913381"}, {"topic": "life_sciences", "relevance_score": "0.844940"}, {"topic": "economy_macro", "relevance_score": "0.615055"}], "overall_sentiment_score": 0.203274, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.400302", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.608469", "ticker_sentiment_score": "0.146012", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.551063", "ticker_sentiment_score": "0.104605", "ticker_sentiment_label": "Neutral"}]}, {"title": "At the F.D.A.\u2019s urging, Pfizer-BioNTech and Moderna are expanding their trials for children 5 to 11. (Published 2021)", "url": "https://www.nytimes.com/2021/07/26/us/politics/fda-covid-vaccine-trials-children.html", "time_published": "20211101T204728", "authors": ["Sheryl Gay Stolberg", "Sharon LaFraniere", "Noah Weiland"], "summary": "Pfizer-BioNTech and Moderna are expanding their clinical trials for children ages 5 to 11 at the urging of the F.D.A. This expansion is a precautionary measure to detect rare side effects like heart inflammation that were observed in younger vaccinated individuals. It is unclear how this will impact the timeline for emergency authorization of pediatric vaccines.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.933701"}], "overall_sentiment_score": 0.079825, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.120579", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.933298", "ticker_sentiment_score": "0.129814", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.585990", "ticker_sentiment_score": "-0.121342", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J, Costco settle lawsuits over recalled sunscreen", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/jj-costco-settle-lawsuits-over-recalled-sunscreen-2021-11-01/", "time_published": "20211101T162100", "authors": ["Brendan Pierson"], "summary": "Johnson & Johnson (JNJ.N) and Costco Wholesale Corp (COST.O) have reached a tentative agreement to settle lawsuits concerning a cancer-causing substance found in several recalled J&J sunscreen products. The settlement, which is subject to court approval by November 19, aims to resolve all claims from lawsuits consolidated in a Florida federal court. J&J maintains it marketed its products appropriately and responsibly, despite voluntarily recalling the items after finding small amounts of benzene.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FJ24L5ZJ67JL4PDT2AYVBYL3M3I.jpg?auth=19c43d2fc590059f81a1795ca248386377e8a939f40c74be59c6368d71220a8d&width=960&quality=80", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "retail_wholesale", "relevance_score": "0.902882"}, {"topic": "finance", "relevance_score": "0.720557"}], "overall_sentiment_score": -0.05428, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COST", "relevance_score": "0.967141", "ticker_sentiment_score": "0.033544", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.996621", "ticker_sentiment_score": "-0.126488", "ticker_sentiment_label": "Neutral"}]}, {"title": "What We Know About the Breast Cancer Vaccine", "url": "https://www.snopes.com/fact-check/breast-cancer-vaccine/", "time_published": "20211029T193555", "authors": ["Madison Dapcevich"], "summary": "The Cleveland Clinic has launched a Phase I human clinical trial for a vaccine designed to prevent triple-negative breast cancer, the most aggressive form of the disease. This vaccine targets a lactation protein, \u03b1-lactalbumin, to activate the immune system against potential emerging tumors. The study follows two decades of research and successful animal trials, with the long-term goal of a preventive vaccine for healthy women at high risk.", "banner_image": "https://www.snopes.com/uploads/2021/10/GettyImages-1229712604-scaled.jpg?resize=800,450", "source": "Snopes.com", "category_within_source": "General", "source_domain": "Snopes.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.932668"}], "overall_sentiment_score": 0.607778, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ANIX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.809702", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRK", "relevance_score": "0.634551", "ticker_sentiment_score": "0.505833", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.621797", "ticker_sentiment_score": "0.536644", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.634675", "ticker_sentiment_score": "0.513529", "ticker_sentiment_label": "Bullish"}]}, {"title": "How Moderna nearly lost the race to develop a Covid-19 vaccine", "url": "https://www.statnews.com/2021/10/26/how-moderna-nearly-lost-the-race-to-develop-a-covid-19-vaccine/", "time_published": "20211026T204729", "authors": ["Gregory Zuckerman"], "summary": "This article details how Moderna, despite its eventual success in developing a Covid-19 vaccine, came perilously close to failure. The company faced severe financial pressures in early 2020, struggling to secure funding for manufacturing capacity, despite having a promising vaccine candidate. It was only through a combination of a private stock sale to Morgan Stanley and a timely positive Phase 1 trial result that Moderna secured the necessary funds to scale production and compete in the vaccine race.", "banner_image": null, "source": "STAT", "category_within_source": "General", "source_domain": "STAT", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.847741"}], "overall_sentiment_score": 0.217337, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.413791", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.605056", "ticker_sentiment_score": "0.137260", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.613758", "ticker_sentiment_score": "0.119920", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kraft Heinz CEO: Miguel Patricio Biography", "url": "https://brooksysociety.com/kraft-heinz-ceo-miguel-patricio-biography/", "time_published": "20211026T192610", "authors": ["Nick Dunehew"], "summary": "This article provides a biography of Miguel Patricio, the CEO of Kraft Heinz, detailing his career progression from various global CPG companies, through his significant tenure at AB InBev where he focused on marketing and growing the Asia Pacific region, to his current role leading Kraft Heinz's transformation. It highlights his strategies for premiumization, marketing innovation, and fostering creativity to drive growth, along with recent financial performance and strategic asset divestitures under his leadership.", "banner_image": null, "source": "Brooksy Society", "category_within_source": "General", "source_domain": "Brooksy Society", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "earnings", "relevance_score": "0.928961"}, {"topic": "retail_wholesale", "relevance_score": "0.744679"}], "overall_sentiment_score": 0.02528, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABEV", "relevance_score": "0.327994", "ticker_sentiment_score": "0.034652", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.418012", "ticker_sentiment_label": "Bullish"}, {"ticker": "PM", "relevance_score": "0.614583", "ticker_sentiment_score": "-0.103639", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.602726", "ticker_sentiment_score": "-0.101281", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.633599", "ticker_sentiment_score": "-0.129524", "ticker_sentiment_label": "Neutral"}]}, {"title": "Diaper, Tissue, Toilet Paper Prices Likely to Rise, Kimberly-Clark Warns", "url": "https://www.nbcdfw.com/news/business/diaper-tissue-and-toilet-paper-prices-likely-to-rise-as-kimberly-clark-warns-of-inflation-pressures/2786756/", "time_published": "20211026T183400", "authors": ["Paul O'Donnell"], "summary": "Kimberly-Clark, the maker of Huggies and Kleenex, has warned that prices for diapers, tissues, and toilet paper are likely to increase due to inflation and persistent supply chain issues. The Irving-based company also revised its annual earnings forecast downwards for the third consecutive quarter, citing a \"volatile and difficult macro environment.\" This signals potential higher costs for everyday household products for consumers.", "banner_image": null, "source": "NBC 5 Dallas-Fort Worth", "category_within_source": "General", "source_domain": "NBC 5 Dallas-Fort Worth", "topics": [{"topic": "earnings", "relevance_score": "0.938069"}, {"topic": "economy_monetary", "relevance_score": "0.822435"}, {"topic": "economy_macro", "relevance_score": "0.737242"}, {"topic": "retail_wholesale", "relevance_score": "0.848328"}, {"topic": "manufacturing", "relevance_score": "0.616162"}], "overall_sentiment_score": -0.245173, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "KMB", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.398809", "ticker_sentiment_label": "Bearish"}, {"ticker": "PG", "relevance_score": "0.664305", "ticker_sentiment_score": "-0.237463", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CLX", "relevance_score": "0.620065", "ticker_sentiment_score": "-0.233691", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.569229", "ticker_sentiment_score": "-0.100028", "ticker_sentiment_label": "Neutral"}]}, {"title": "Texas reaches $290 million settlement with Johnson & Johnson in nationwide opioid case", "url": "https://www.texastribune.org/2021/10/26/paxton-texas-opioid-settlement-johnson/", "time_published": "20211026T124100", "authors": ["James Pollard"], "summary": "Texas Attorney General Ken Paxton announced a $290 million settlement with Johnson & Johnson over deceptive marketing tactics contributing to the opioid crisis. This settlement is part of a larger $1.5 billion expected for Texas from multiple pharmaceutical companies, intended to fund opioid abatement efforts. Overdose deaths related to opioids have seen a significant increase nationally, and Texas counties like Harris and Dallas are set to receive funds to combat the crisis.", "banner_image": null, "source": "The Texas Tribune", "category_within_source": "General", "source_domain": "The Texas Tribune", "topics": [{"topic": "life_sciences", "relevance_score": "0.948022"}], "overall_sentiment_score": -0.249539, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.403751", "ticker_sentiment_label": "Bearish"}, {"ticker": "MCK", "relevance_score": "0.614378", "ticker_sentiment_score": "-0.228279", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CAH", "relevance_score": "0.614198", "ticker_sentiment_score": "-0.190451", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COR", "relevance_score": "0.606295", "ticker_sentiment_score": "-0.202149", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Moderna and J&J COVID-19 vaccine boosters: What doctors must know", "url": "https://www.ama-assn.org/public-health/infectious-diseases/moderna-and-jj-covid-19-vaccine-boosters-what-doctors-must-know", "time_published": "20211022T203639", "authors": ["Sara Berg", "MS"], "summary": "The FDA has authorized and the CDC has recommended booster doses for Moderna and Johnson & Johnson COVID-19 vaccines, allowing for \"mixing and matching\" with other authorized boosters. Doctors must consider clinical considerations, including rare adverse events like myocarditis or blood clots, and perform individual benefit-risk assessments for patients. The goal is to provide continued protection against COVID-19, especially given the decline in vaccine effectiveness against the Delta variant, and to increase immune response.", "banner_image": null, "source": "American Medical Association", "category_within_source": "General", "source_domain": "American Medical Association", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.134596, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.119391", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.918228", "ticker_sentiment_score": "0.118583", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.747228", "ticker_sentiment_score": "0.110656", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intuitive says delta variant slows Q3 da Vinci procedure growth", "url": "https://www.medtechdive.com/news/intuitive-delta-variant-robotics-q3-da-vinci-procedures/608555/", "time_published": "20211020T203214", "authors": ["Susan Kelly"], "summary": "Intuitive Surgical reported that the resurgent COVID-19 delta variant impacted da Vinci procedure growth in the third quarter, leading to a trimmed full-year forecast. Despite a 20% increase year-over-year, procedures were down 3% from Q2, and the company is bracing for potential supply chain and cost challenges. Intuitive beat revenue expectations due to strong system placements but faces increasing competition.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.915540"}, {"topic": "earnings", "relevance_score": "0.911152"}], "overall_sentiment_score": 0.031548, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.979563", "ticker_sentiment_score": "-0.131737", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.704070", "ticker_sentiment_score": "0.136712", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.604135", "ticker_sentiment_score": "0.080649", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson looking to bankruptcy to resolve 40,000 baby powder cancer suits", "url": "https://abcnews.go.com/Business/johnson-johnson-bankruptcy-resolve-40000-baby-powder-cancer/story?id=80680409", "time_published": "20211020T094600", "authors": ["Aaron Katersky"], "summary": "Johnson & Johnson is attempting to use bankruptcy proceedings to resolve approximately 40,000 lawsuits alleging its baby powder products caused cancer. The company denies the allegations, calling them an \u201cunrelenting assault\u201d by trial lawyers, and has already spent nearly $1 billion on defense. Critics however, are condemning the move as an \"unconscionable abuse of the legal system.\"", "banner_image": null, "source": "ABC News", "category_within_source": "General", "source_domain": "ABC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.911729"}, {"topic": "finance", "relevance_score": "0.707413"}], "overall_sentiment_score": -0.711391, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.738280", "ticker_sentiment_label": "Bearish"}]}, {"title": "J&J foresees end to not-for-profit sales of coronavirus vaccine", "url": "https://www.biopharmadive.com/news/johnson-johnson-vaccine-not-for-profit-price/608477/", "time_published": "20211019T203639", "authors": ["Ned Pagliarulo"], "summary": "Johnson & Johnson announced its intention to transition away from not-for-profit sales of its coronavirus vaccine by late 2022 or early 2023, moving towards a commercial market model. This shift comes as the company anticipates a focus on booster doses and seeks full regulatory approvals, despite lower sales compared to competitors and previous manufacturing setbacks. J&J previously committed to not-for-profit pricing through the pandemic but did not specify an end date for this commitment.", "banner_image": "Jon Cherry via Getty Images", "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.917339"}, {"topic": "earnings", "relevance_score": "0.826265"}, {"topic": "finance", "relevance_score": "0.628355"}], "overall_sentiment_score": 0.162779, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.290860", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.699589", "ticker_sentiment_score": "0.140357", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.659228", "ticker_sentiment_score": "0.144392", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Reports Q3 2021 Results", "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q3-2021-results", "time_published": "20211019T203638", "authors": [], "summary": "Johnson & Johnson announced strong third-quarter 2021 results, with total sales growing 10.7% to $23.3 billion, driven by robust performance in Pharmaceuticals, recovery in Medical Devices, and growth in Consumer Health. The company reported an 18.2% increase in adjusted earnings per share and raised its full-year 2021 guidance. CEO Alex Gorsky highlighted solid performance across all segments and the company's commitment to innovation and addressing global healthcare challenges as he prepares to transition his role.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "earnings", "relevance_score": "0.947165"}, {"topic": "life_sciences", "relevance_score": "0.828020"}], "overall_sentiment_score": 0.411858, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.403000", "ticker_sentiment_label": "Bullish"}]}, {"title": "Intuitive Surgical names new C-suite leaders, reports Street-beating Q3", "url": "https://www.medicaldesignandoutsourcing.com/intuitive-surgical-strategy-growh-global-business-services-q3-2021-financial-results/", "time_published": "20211019T203214", "authors": ["Jim Hammerand Jamie Samath"], "summary": "Intuitive Surgical announced new C-suite leaders and organizational changes, including the creation of Strategy and Growth and Global Business Services divisions. The company reported strong Q3 2021 financial results, exceeding analyst expectations for revenue and EPS, driven by a 20% increase in robotic surgery procedures using its da Vinci system. This positive performance and leadership restructuring occurred as a competitor, Johnson & Johnson, announced a delay in its surgical robot development.", "banner_image": null, "source": "Medical Design & Outsourcing", "category_within_source": "General", "source_domain": "Medical Design & Outsourcing", "topics": [{"topic": "earnings", "relevance_score": "0.901352"}, {"topic": "life_sciences", "relevance_score": "0.815593"}, {"topic": "technology", "relevance_score": "0.702125"}], "overall_sentiment_score": 0.332775, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.407994", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.641482", "ticker_sentiment_score": "0.215584", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Merck, Pfizer COVID-19 Antivirals Different From Ivermectin", "url": "https://www.factcheck.org/2021/10/scicheck-merck-pfizer-covid-19-antivirals-different-from-ivermectin/", "time_published": "20211015T204726", "authors": ["Jessica McDonald"], "summary": "Merck and Pfizer are developing oral antiviral drugs for COVID-19 that are distinct from ivermectin, contrary to online claims of similarities or repackaging for profit. The article details how these new antivirals like Paxlovid and molnupiravir work by different mechanisms, such as protease inhibition and lethal mutagenesis, respectively, and highlights that their chemical structures bear no resemblance to ivermectin. It also explains why ivermectin, despite its in vitro antiviral effects, is unlikely to be effective against COVID-19 at human-achievable concentrations and warns against using it for this purpose.", "banner_image": null, "source": "FactCheck.org", "category_within_source": "General", "source_domain": "FactCheck.org", "topics": [{"topic": "life_sciences", "relevance_score": "0.926670"}], "overall_sentiment_score": 0.317868, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.410157", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.983556", "ticker_sentiment_score": "0.422742", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.579834", "ticker_sentiment_score": "0.106272", "ticker_sentiment_label": "Neutral"}]}, {"title": "An extra J. & J. shot substantially boosts protection against Covid, the company reports. (Published 2021)", "url": "https://www.nytimes.com/2021/09/21/health/johnson-and-johnson-shot.html", "time_published": "20211015T203639", "authors": ["Carl Zimmer"], "summary": "Johnson & Johnson announced that a second dose of its Covid-19 vaccine substantially increased protection, showing 94 percent efficacy against mild to severe Covid-19 in the U.S. This booster shot also significantly raised antibody levels, particularly when administered several months after the initial dose. The data has been submitted to the FDA for review.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.900806"}], "overall_sentiment_score": 0.028551, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.339502", "ticker_sentiment_score": "0.036677", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson earns a spot on Fortune's 2021 Change the World list.", "url": "https://www.jnj.com/latest-news/johnson-johnson-earns-spot-on-2021-change-the-world-list", "time_published": "20211015T203637", "authors": ["Johnson & Johnson"], "summary": "Johnson & Johnson has been recognized on Fortune's 2021 Change the World list for its significant role in battling the COVID-19 pandemic through its Janssen vaccine. The company's commitment to social responsibility, innovation, and global partnerships, guided by \"Our Credo,\" allowed it to respond urgently to the global health crisis. This recognition adds to other recent accolades from Fortune, including Jennifer Taubert's inclusion in the Most Powerful Women in Business list and the company's ranking among the World's Most Admired Companies.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.916801"}], "overall_sentiment_score": 0.450466, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.474917", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson talc powder spinoff files for bankruptcy", "url": "https://www.cbsnews.com/news/johnson-johnson-talc-powder-cancer-lawsuits-bankruptcy-ltl-management/", "time_published": "20211015T122100", "authors": ["Khristopher J. Brooks"], "summary": "Johnson & Johnson has created a new subsidiary, LTL Management, transferring $2 billion in talc powder lawsuit settlement money to it before filing LTL for bankruptcy. This move could stall settlements for thousands of families suing the company over claims that its talcum powder caused ovarian cancer. J&J maintains the bankruptcy filing is not a concession of liability but a strategy to resolve the lawsuits efficiently.", "banner_image": null, "source": "CBS News", "category_within_source": "General", "source_domain": "CBS News", "topics": [{"topic": "finance", "relevance_score": "0.818838"}, {"topic": "life_sciences", "relevance_score": "0.910058"}], "overall_sentiment_score": -0.405769, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.419939", "ticker_sentiment_label": "Bearish"}]}, {"title": "U.S. donates 3.6 million doses of Pfizer COVID-19 vaccines to Nigeria", "url": "https://www.reuters.com/world/africa/us-donates-36-million-doses-pfizer-covid-19-vaccines-nigeria-state-tv-2021-10-14/", "time_published": "20211015T072400", "authors": ["Reuters"], "summary": "The United States has donated 3.6 million doses of Pfizer Inc/BioNTech COVID-19 vaccines to Nigeria, two months after previously sending Moderna Inc vaccines. The shipment arrived in Abuja, bringing the total number of Pfizer doses committed to Nigeria to 3.57 million. Nigeria aims to inoculate at least 70% of its population against COVID-19.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.930265"}, {"topic": "economy_macro", "relevance_score": "0.647315"}], "overall_sentiment_score": 0.196267, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.273136", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.605656", "ticker_sentiment_score": "0.124012", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.576456", "ticker_sentiment_score": "0.141385", "ticker_sentiment_label": "Neutral"}]}, {"title": "F.D.A. Panel Unanimously Recommends Johnson & Johnson Booster Shots (Published 2021)", "url": "https://www.nytimes.com/2021/10/15/health/johnson-johnson-vaccine-booster.html", "time_published": "20211015T000000", "authors": ["Sharon LaFraniere", "Noah Weiland", "Carl Zimmer"], "summary": "A key federal advisory committee unanimously recommended Johnson & Johnson booster shots, likely paving the way for all 15 million initial recipients to receive a second dose. The panel also suggested J&J recipients might benefit from the option of an mRNA booster (Pfizer-BioNTech or Moderna), a possibility the FDA is considering. This recommendation comes despite some scientific skepticism about the necessity of boosters and a call to focus on vaccinating the unvaccinated globally.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.942962"}], "overall_sentiment_score": 0.277058, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.288778", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Boosters for Moderna and Johnson & Johnson vaccine recipients weren\u2019t up for debate during a C.D.C. panel.", "url": "https://www.nytimes.com/2021/09/23/science/moderna-johnson-covid-boosters.html", "time_published": "20211014T204730", "authors": ["Apoorva Mandavilli and Benjamin Mueller"], "summary": "A CDC advisory committee recommended Pfizer-BioNTech booster shots for older Americans and those with certain medical conditions, but it did not address boosters for Moderna and Johnson & Johnson vaccine recipients. This decision left some experts concerned about public health policy and equity as data for other vaccine boosters are still under review. The FDA is reviewing Moderna booster data, and Johnson & Johnson has not yet applied for booster authorization.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.943491"}], "overall_sentiment_score": 0.004517, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.027244", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.919926", "ticker_sentiment_score": "0.026222", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.827674", "ticker_sentiment_score": "0.040010", "ticker_sentiment_label": "Neutral"}]}, {"title": "What the ketamine boom could mean for pharma", "url": "https://www.drugdiscoverytrends.com/what-the-ketamine-boom-could-mean-for-pharma/", "time_published": "20211014T203731", "authors": ["Brian Buntz"], "summary": "The article discusses the surging demand for ketamine, particularly its off-label use for depression, anxiety, and PTSD, and its implications for the pharmaceutical industry. It highlights the distinction between ketamine-assisted psychotherapy (KAP) and FDA-approved esketamine (Spravato), as well as future opportunities in psychedelic medicine. While ketamine offers significant potential, the article notes the current lack of rigorous evidence for KAP compared to IV ketamine or Spravato.", "banner_image": null, "source": "www.drugdiscoverytrends.com", "category_within_source": "General", "source_domain": "www.drugdiscoverytrends.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.902118"}], "overall_sentiment_score": 0.18296, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KTTA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.317369", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.731519", "ticker_sentiment_score": "0.149925", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.624397", "ticker_sentiment_score": "0.114070", "ticker_sentiment_label": "Neutral"}]}, {"title": "WATCH: FDA advisory committee debates Johnson & Johnson COVID-19 booster shots", "url": "https://www.pbs.org/newshour/health/watch-live-fda-advisory-committee-debates-johnson-johnson-covid-19-booster-shots", "time_published": "20211014T192200", "authors": ["Matthew Perrone", "Lauran Neergaard"], "summary": "U.S. health advisers have endorsed a booster shot for Johnson & Johnson's COVID-19 vaccine, citing concerns about its lower effectiveness compared to two-dose brands. The FDA's advisory panel unanimously recommended offering the booster at least two months after the initial immunization, and also discussed the potential benefits of \"mix-and-match\" boosting with Moderna or Pfizer vaccines for J&J recipients. The decision aims to bolster protection for those who received the single-dose J&J vaccine, especially given the prevalence of the delta variant.", "banner_image": null, "source": "PBS", "category_within_source": "General", "source_domain": "PBS", "topics": [{"topic": "life_sciences", "relevance_score": "0.932995"}], "overall_sentiment_score": 0.182872, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.245097", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.710998", "ticker_sentiment_score": "0.307203", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.605695", "ticker_sentiment_score": "0.328259", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/mixing-covid-19-booster-shots-safe-says-nih-study-2021-10-13/", "time_published": "20211014T043900", "authors": ["Carl O'donnell"], "summary": "A National Institutes of Health (NIH) study found that people who initially received Johnson & Johnson's COVID-19 vaccine had a stronger immune response when boosted with shots from Moderna or Pfizer. The preliminary study also indicated that \"mixing and matching\" booster shots of different types is safe and can produce comparable or higher antibody responses. This research comes as the U.S. Food and Drug Administration prepares to discuss booster shots for Moderna and J&J vaccines.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.906798"}], "overall_sentiment_score": 0.2726, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.975592", "ticker_sentiment_score": "0.270325", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.935740", "ticker_sentiment_score": "0.208447", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.850431", "ticker_sentiment_score": "0.259072", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "How your own DNA could someday save your vision", "url": "https://www.jnj.com/innovation/about-gene-therapy-for-retinitis-pigmentosa-and-eye-conditions", "time_published": "20211011T203637", "authors": ["Hallie Levine"], "summary": "Johnson & Johnson is developing investigational gene therapies to treat genetic eye diseases like Retinitis Pigmentosa (RP), an X-linked disorder that causes blindness, and achromatopsia. The company's collaboration with MeiraGTx focuses on gene replacement therapy, injecting a healthy gene to restore function, with clinical trials underway for XLRP and promising results leading to Fast Track and Orphan designations from the FDA. This research aims to preserve and improve vision for patients with limited treatment options.", "banner_image": "NULL", "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.926099"}], "overall_sentiment_score": 0.545952, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.502718", "ticker_sentiment_label": "Bullish"}]}, {"title": "Gossamer unveils new pipeline plans a year after lead program fizzled out in phase 2", "url": "https://www.fiercebiotech.com/biotech/gossamer-unveils-2-new-pipeline-candidates-a-year-after-lead-program-fizzled-out-phase-2", "time_published": "20211011T185500", "authors": ["Annalee Armstrong"], "summary": "Gossamer Bio, a year after its lead program failed in phase 2, is introducing two new preclinical assets, GB5121 and GB7208, both central nervous system-penetrant Bruton\u2019s tyrosine kinase (BTK) inhibitors. These therapies are designed to address CNS indications like lymphoma and multiple sclerosis, differentiating them from existing BTK inhibitors. The company plans to advance these candidates into human testing soon, hoping to turn things around after previous setbacks and an executive reshuffle.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "0.912787"}, {"topic": "earnings", "relevance_score": "0.610244"}], "overall_sentiment_score": 0.107749, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOSS", "relevance_score": "1.000000", "ticker_sentiment_score": "0.106324", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.608837", "ticker_sentiment_score": "0.139272", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.581851", "ticker_sentiment_score": "0.141345", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.591665", "ticker_sentiment_score": "0.134266", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top 50 Pharma Companies 2021: Notes & Methodology", "url": "https://www.pharmalive.com/top-50-pharma-companies-2021-notes-methodology/", "time_published": "20211011T004808", "authors": ["Andrew Humphreys"], "summary": "This article outlines the notes and methodology used by Med Ad News editors for their 35th annual Top 50 Pharma Companies report in 2021. It details the criteria for company inclusion, financial data definitions like revenue, earnings, R&D, and assets, and explains the exchange rate conversions for non-U.S. companies. The report also includes the selection criteria for the \"Company of the Year\" and a list of past recipients.", "banner_image": "https://www.pharmalive.com/wp-content/uploads/2021/10/MAN1021_Front-Cover.jpg", "source": "PharmaLive", "category_within_source": "General", "source_domain": "PharmaLive", "topics": [{"topic": "earnings", "relevance_score": "0.928636"}, {"topic": "life_sciences", "relevance_score": "0.924954"}, {"topic": "finance", "relevance_score": "0.748795"}], "overall_sentiment_score": 0.148637, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INCY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.122743", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.705952", "ticker_sentiment_score": "0.147745", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.635193", "ticker_sentiment_score": "0.146415", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.618895", "ticker_sentiment_score": "0.138618", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.614183", "ticker_sentiment_score": "0.142228", "ticker_sentiment_label": "Neutral"}]}, {"title": "Relay\u2019s targeted cancer drug could be safer than its competitors. Is it more effective?", "url": "https://www.biopharmadive.com/news/relay-therapeutics-fgfr-cancer-study-results/607885/", "time_published": "20211008T210652", "authors": ["Ned Pagliarulo"], "summary": "Relay Therapeutics has released initial Phase 1 clinical trial results for its cancer drug, RLY-4008, which aims to be a safer FGFR2 inhibitor. The drug demonstrated lower rates of common side effects like hyperphosphatemia and diarrhea compared to competitors, supporting Relay's protein motion technology. While effectiveness data is still preliminary and limited by small sample sizes, the company is preparing for Phase 2 testing and believes RLY-4008 could be broadly applicable to FGFR2-altered tumors.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.943906"}, {"topic": "financial_markets", "relevance_score": "0.619193"}], "overall_sentiment_score": 0.139952, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RLAY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.124711", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.744283", "ticker_sentiment_score": "0.102087", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.615923", "ticker_sentiment_score": "0.140215", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.630583", "ticker_sentiment_score": "0.147351", "ticker_sentiment_label": "Neutral"}]}, {"title": "Extra Shots from J. & J. and Pfizer Give Immune Boost, Companies Report (Published 2021)", "url": "https://www.nytimes.com/2021/08/25/health/johnson-johnson-vaccine-booster-shot.html", "time_published": "20211004T203638", "authors": ["Carl Zimmer and Sharon LaFraniere"], "summary": "New studies from Johnson & Johnson and Pfizer-BioNTech demonstrate that booster shots can significantly increase antibodies against the coronavirus. Both companies are submitting this new data to the FDA for evaluation, with Pfizer formally requesting authorization for a booster shot. The data supports the Biden administration's push for a booster shot strategy, which initially excluded the Johnson & Johnson vaccine but now includes new data from the company.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.905595"}], "overall_sentiment_score": 0.290445, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.966811", "ticker_sentiment_score": "0.345195", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.807755", "ticker_sentiment_score": "0.250630", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Jabil expects to hit over $8B in net revenue in Q1 of 2022", "url": "https://stpetecatalyst.com/jabil-expects-to-hit-over-8b-in-net-revenue-in-q1-of-2022/", "time_published": "20210929T203627", "authors": ["Veronica Brezina"], "summary": "Jabil Inc. (NYSE: JBL) reported strong financial results for the fourth quarter and fiscal year, with net revenue of $7.4 billion and $29.3 billion respectively, despite supply chain challenges. Looking ahead to Q1 2022, the company projects net revenue between $8 billion and $8.6 billion, driven by its diversified business model and opportunities in vehicle electrification, connected healthcare, and infrastructure development. Jabil continues to work with major clients such as Amazon, Tesla, Apple, and Johnson & Johnson.", "banner_image": null, "source": "St Pete Catalyst", "category_within_source": "General", "source_domain": "St Pete Catalyst", "topics": [{"topic": "earnings", "relevance_score": "0.903106"}, {"topic": "manufacturing", "relevance_score": "0.826903"}, {"topic": "technology", "relevance_score": "0.703636"}, {"topic": "life_sciences", "relevance_score": "0.635920"}, {"topic": "energy_transportation", "relevance_score": "0.600317"}], "overall_sentiment_score": 0.284426, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JBL", "relevance_score": "1.000000", "ticker_sentiment_score": "0.426641", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMZN", "relevance_score": "0.623470", "ticker_sentiment_score": "0.240631", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.610905", "ticker_sentiment_score": "0.238580", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.604289", "ticker_sentiment_score": "0.236337", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.600901", "ticker_sentiment_score": "0.205390", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Activists Shame Johnson & Johnson over Pharma Greed", "url": "https://www.aidshealth.org/2021/09/activists-shame-johnson-johnson-over-pharma-greed/", "time_published": "20210927T203637", "authors": ["Julie"], "summary": "Activists protested at Johnson & Johnson's New Jersey headquarters, demanding the pharmaceutical giant cease \"pandemic profiteering\" and share its vaccine technology. The protest highlighted J&J's decision to shift its one-shot COVID-19 vaccine production from South Africa to Europe while less than 4% of Africans are fully vaccinated. Concerns were also raised about J&J's plan to end nonprofit pricing for its vaccine by the end of 2021.", "banner_image": null, "source": "AIDS Healthcare Foundation", "category_within_source": "General", "source_domain": "AIDS Healthcare Foundation", "topics": [{"topic": "life_sciences", "relevance_score": "0.947434"}, {"topic": "economy_macro", "relevance_score": "0.628710"}], "overall_sentiment_score": -0.406398, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.623049", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.647575", "ticker_sentiment_score": "-0.305229", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.622439", "ticker_sentiment_score": "-0.340126", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "New Johnson & Johnson data shows second shot boosts antibodies and protection against COVID-19 \u2013 but one dose is still strong against delta variant", "url": "https://theconversation.com/new-johnson-and-johnson-data-shows-second-shot-boosts-antibodies-and-protection-against-covid-19-but-one-dose-is-still-strong-against-delta-variant-168463", "time_published": "20210925T091200", "authors": ["Maureen Ferran"], "summary": "Johnson & Johnson released new data on its COVID-19 vaccine, confirming that a single dose provides strong protection against the delta variant, with 79% efficacy against infection and 81% against hospitalization based on a real-world study. The data also showed that a booster shot significantly increases antibody levels and protection against moderate to severe disease, raising efficacy to 94% when given two months after the initial dose. While a single dose offers durable protection, boosters are suggested to further enhance the vaccine's effectiveness.", "banner_image": null, "source": "The Conversation", "category_within_source": "General", "source_domain": "The Conversation", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.028358, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.308273", "ticker_sentiment_score": "0.041881", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson says additional dose boosts Covid vaccine efficacy", "url": "https://www.statnews.com/2021/09/21/johnson-johnson-says-additional-dose-boosts-covid-vaccine-efficacy/", "time_published": "20210921T203639", "authors": ["Matthew Herper"], "summary": "Johnson & Johnson announced that a global study revealed its Covid-19 vaccine is more effective as a two-dose regimen, showing 75% efficacy against moderate to severe cases globally and 94% in the U.S., with 100% effectiveness against severe disease. The company also stated that the efficacy of its single-shot vaccine does not wane and that a booster dose further enhances protection, submitting this data to the FDA and other regulators. These findings could support broader booster availability and increase the vaccine's usage.", "banner_image": null, "source": "STAT", "category_within_source": "General", "source_domain": "STAT", "topics": [{"topic": "life_sciences", "relevance_score": "0.915012"}, {"topic": "financial_markets", "relevance_score": "0.646747"}], "overall_sentiment_score": 0.293406, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.535050", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.728887", "ticker_sentiment_score": "0.317186", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.742140", "ticker_sentiment_score": "0.338861", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.573963", "ticker_sentiment_score": "0.105412", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.579358", "ticker_sentiment_score": "0.137688", "ticker_sentiment_label": "Neutral"}]}, {"title": "Seagen, Genmab win speedy FDA approval for cervical cancer drug", "url": "https://www.biopharmadive.com/news/seagen-genmab-fda-approval-cervical-cancer-tivdak/606926/", "time_published": "20210921T202208", "authors": ["Jonathan Gardner"], "summary": "The FDA has granted accelerated approval to Seagen and Genmab's drug Tivdak for cervical cancer patients whose tumors have relapsed or spread after chemotherapy. Tivdak targets a protein frequently expressed on cancerous cells and is the fourth approval for both companies. The drug's list price is set at approximately $34,000 per month, and further trials are underway to confirm its long-term benefits and effectiveness in combination therapies.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.933200"}], "overall_sentiment_score": 0.210514, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GMAB", "relevance_score": "1.000000", "ticker_sentiment_score": "0.401262", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.720828", "ticker_sentiment_score": "0.117594", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.615048", "ticker_sentiment_score": "0.137043", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.609947", "ticker_sentiment_score": "0.126312", "ticker_sentiment_label": "Neutral"}]}, {"title": "Two dose version of Johnson & Johnson shot 94% effective against Covid-19, study finds", "url": "https://www.cnn.com/2021/09/21/health/johnson-vaccine-two-doses-booster", "time_published": "20210921T064000", "authors": ["Maggie Fox"], "summary": "Johnson & Johnson announced that a two-dose regimen of its coronavirus vaccine provides 94% protection against symptomatic infection, comparable to Moderna's and Pfizer's two-dose vaccines. The company also stated that a booster dose significantly increases immunity. These findings were based on three studies examining various aspects of the Janssen vaccine's efficacy and longevity.", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "life_sciences", "relevance_score": "0.902224"}], "overall_sentiment_score": 0.396443, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.934818", "ticker_sentiment_score": "0.510027", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.600366", "ticker_sentiment_score": "0.327956", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.628451", "ticker_sentiment_score": "0.346011", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Says Its Booster Shot Provides Increased Protection From COVID-19", "url": "https://www.npr.org/2021/09/21/1039168781/johnson-johnson-booster-shot-provides-increased-protection-from-covid", "time_published": "20210921T063000", "authors": ["Jaclyn Diaz"], "summary": "Johnson & Johnson announced data from its Phase 3 trial indicating their COVID-19 booster shot offers increased protection. A booster administered six months after the initial single dose resulted in a 12-fold increase in antibodies. The company shared that a booster two months after the initial dose increased protection against COVID-19 to 94%, with overall efficacy against severe or critical infections at 75% across all age groups.", "banner_image": null, "source": "NPR", "category_within_source": "General", "source_domain": "NPR", "topics": [{"topic": "life_sciences", "relevance_score": "0.924907"}], "overall_sentiment_score": 0.429514, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.442778", "ticker_sentiment_label": "Bullish"}]}, {"title": "Vicarious Surgical Starts Trading As It Prepares To Launch Its Surgical Robots \u2014 And Take On Intuitive", "url": "https://www.forbes.com/sites/aayushipratap/2021/09/20/vicarious-surgical-starts-trading-as-it-prepares-to-launch-its-surgical-robots---and-take-on-intuitive/", "time_published": "20210920T092300", "authors": ["Aayushi Pratap"], "summary": "Vicarious Surgical has gone public via SPAC, trading under the ticker RBOT, with the goal of revolutionizing abdominal surgery with its miniature robotic system. Co-founder and CEO Adam Sachs aims to challenge Intuitive Surgical's dominance in the market. The company plans to use its recent $220 million funding from the SPAC merger for product development, FDA clearance, and projects $1 billion in annual revenue by 2027.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6148a04b1e5aae91cc2f623e/Vicarious-Surgical-Co-Founder-And-CEO-Adam-Sachs-/0x0.jpg?cropX1=0&cropX2=1740&cropY1=67&cropY2=1043", "source": "Forbes", "category_within_source": "General", "source_domain": "Forbes", "topics": [{"topic": "ipo", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.915350"}, {"topic": "technology", "relevance_score": "0.824738"}, {"topic": "financial_markets", "relevance_score": "0.739169"}], "overall_sentiment_score": 0.149333, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.901568", "ticker_sentiment_score": "0.142987", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.633237", "ticker_sentiment_score": "0.148799", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.613285", "ticker_sentiment_score": "0.121262", "ticker_sentiment_label": "Neutral"}]}, {"title": "What Investors Should Know About the $26 Billion Opioid Settlement", "url": "https://www.morningstar.com/sustainable-investing/what-investors-should-know-about-26-billion-opioid-settlement", "time_published": "20210913T195220", "authors": ["Karen Wallace"], "summary": "This article examines the potential impact of the $26 billion opioid settlement on the valuations of four major companies: Johnson & Johnson, Cardinal Health, McKesson, and AmerisourceBergen. It reviews how Morningstar and Sustainalytics assess the ongoing opioid-related risks for these companies, considering potential financial impacts and mitigation steps. The analysis concludes that while significant, the litigation costs are generally manageable relative to the companies' total profits, though specific outlooks vary.", "banner_image": null, "source": "Morningstar", "category_within_source": "General", "source_domain": "Morningstar", "topics": [{"topic": "life_sciences", "relevance_score": "0.918043"}, {"topic": "finance", "relevance_score": "0.706922"}], "overall_sentiment_score": -0.179561, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.283145", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MCK", "relevance_score": "0.984968", "ticker_sentiment_score": "-0.269182", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.940335", "ticker_sentiment_score": "0.244356", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COR", "relevance_score": "0.889503", "ticker_sentiment_score": "-0.294712", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "NEXGEL Appoints Miranda Toledano to Board of Directors", "url": "https://www.citybiz.co/article/138228/nexgel-appoints-miranda-toledano-to-board-of-directors/", "time_published": "20210909T195735", "authors": [], "summary": "NEXGEL, Inc. announced the appointment of Miranda Toledano to its Board of Directors, bringing over 20 years of biotech, principal investment, and capital markets experience. Ms. Toledano previously served as COO, CFO, and Board member at TRIGR Therapeutics and held executive roles at Sorrento Therapeutics and MLV & Co. Her expertise is expected to be invaluable as NEXGEL continues to develop its hydrogel technology for healthcare and consumer markets.", "banner_image": null, "source": "citybiz", "category_within_source": "General", "source_domain": "citybiz", "topics": [{"topic": "life_sciences", "relevance_score": "0.922451"}, {"topic": "finance", "relevance_score": "0.708802"}], "overall_sentiment_score": 0.196747, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMPX", "relevance_score": "0.809588", "ticker_sentiment_score": "0.322292", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.631669", "ticker_sentiment_score": "0.146622", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.635597", "ticker_sentiment_score": "0.137337", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.601853", "ticker_sentiment_score": "0.101110", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bill Gates-backed Vicarious Surgical targets Intuitive, J&J, Medtronic in abdominal robotic surgery", "url": "https://www.medtechdive.com/news/bill-gates-backed-vicarious-surgical-targets-intuitive-jj-medtronic/606122/", "time_published": "20210907T203214", "authors": ["Greg Slabodkin"], "summary": "Vicarious Surgical, backed by Bill Gates and BD, aims to disrupt the abdominal robotic surgery market by offering a cost-effective and efficient alternative to current systems from giants like Intuitive Surgical, Johnson & Johnson, and Medtronic. The company plans a 510(k) submission in 2023 with a goal of $1 billion in sales by 2027, leveraging its breakthrough-designated robotic device that offers enhanced maneuverability through a single 1.5 cm incision. CEO Adam Sachs emphasizes the new technology's ability to overcome the limitations and high costs associated with existing surgical robots.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.910089"}, {"topic": "technology", "relevance_score": "0.801876"}], "overall_sentiment_score": -0.07994, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.940375", "ticker_sentiment_score": "0.009009", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.728926", "ticker_sentiment_score": "-0.138214", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.702816", "ticker_sentiment_score": "-0.125678", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna stock extends rally after price target gets a 77% boost at Morgan Stanley", "url": "https://www.marketwatch.com/story/moderna-stock-extends-rally-after-price-target-gets-a-77-boost-at-morgan-stanley-11631043323?gaa_at=eafs&gaa_n=AWEtsqdgKr1Xf-DEAUechJI8TK0yCqGtppr78Ou6X1-NNFvS_rMg5RMdyCrZ&gaa_ts=6907c67e&gaa_sig=8Grj3-6Xb8UoWYqiGivmgTkfza9vAml-l5dUHfELew0uH_TANmZz1lmonDaIgMgxUGkbDK2xVUc6DMdcb-O9OA%3D%3D", "time_published": "20210907T153500", "authors": ["Tomi Kilgore"], "summary": "Moderna stock extended its rally after Morgan Stanley analyst Matthew Harrison significantly increased his price target by nearly $150, driven by an improved outlook for the company's COVID-19 vaccine sales. Despite the price target boost, Harrison maintained a neutral stance on Moderna. He also downgraded several other biopharma stocks, including Johnson & Johnson, Merck, and Amgen, citing valuation concerns and a lack of potential upside catalysts.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "financial_markets", "relevance_score": "0.935549"}, {"topic": "life_sciences", "relevance_score": "0.906547"}, {"topic": "earnings", "relevance_score": "0.821727"}], "overall_sentiment_score": -0.03495, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.450356", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.719409", "ticker_sentiment_score": "0.325410", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.615692", "ticker_sentiment_score": "-0.273867", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRK", "relevance_score": "0.619606", "ticker_sentiment_score": "-0.334917", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.618609", "ticker_sentiment_score": "-0.288654", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Moderna stock extends rally after price target gets a 77% boost at Morgan Stanley", "url": "https://www.marketwatch.com/story/moderna-stock-extends-rally-after-price-target-gets-a-77-boost-at-morgan-stanley-11631043323?gaa_at=eafs&gaa_n=AWEtsqc2875Dj5ZFzo5qHA3ggcFfsOphZQNyZtYpfP2RZ8pB_LmbR6HlNDYz&gaa_ts=6907c67d&gaa_sig=q3lHfqhr1sw7kt5OhJZk1GPPnKIa1Hz1o1DPZTJl_90Hsg08RXrRmTxTFhq1cI5uSnpc_XThrFZ1u_AkCp-XTw%3D%3D", "time_published": "20210907T153500", "authors": ["Tomi Kilgore"], "summary": "Moderna's stock extended its rally after Morgan Stanley analyst Matthew Harrison significantly increased his price target on the company, citing an improved outlook for its COVID-19 vaccine sales. Despite the boost to Moderna, Harrison downgraded several other biopharma stocks including Johnson & Johnson, Merck, and Amgen, based on valuation concerns and lack of potential upside catalysts. All three of the downgraded stocks are components of the Dow Jones Industrial Average.", "banner_image": "AFP via Getty Images", "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "financial_markets", "relevance_score": "0.913291"}, {"topic": "life_sciences", "relevance_score": "0.801145"}], "overall_sentiment_score": -0.167799, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.504177", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.727657", "ticker_sentiment_score": "-0.443675", "ticker_sentiment_label": "Bearish"}, {"ticker": "MRK", "relevance_score": "0.618640", "ticker_sentiment_score": "-0.302466", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.626773", "ticker_sentiment_score": "-0.348858", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "US drug companies say $26bn opioid settlement will proceed", "url": "https://www.aljazeera.com/news/2021/9/4/us-drug-companies-say-26bn-opioid-settlement-will-proceed", "time_published": "20210904T204621", "authors": ["Reuters"], "summary": "Three major US drug distributors and Johnson & Johnson have announced that a proposed $26bn settlement resolving claims they fueled the opioid epidemic will proceed after enough states joined the agreement. The settlement aims to provide funds for opioid treatment and other services, with the first annual payment expected by September 30. While a complex formula envisioned 44 states, the companies ultimately decided that a \"critical mass\" had joined to finalize the deal.", "banner_image": null, "source": "Al Jazeera", "category_within_source": "General", "source_domain": "Al Jazeera", "topics": [{"topic": "life_sciences", "relevance_score": "0.931953"}, {"topic": "finance", "relevance_score": "0.708834"}], "overall_sentiment_score": 0.213209, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MCK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.202453", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAH", "relevance_score": "0.834908", "ticker_sentiment_score": "0.203813", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.831120", "ticker_sentiment_score": "0.204933", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COR", "relevance_score": "0.739427", "ticker_sentiment_score": "0.209268", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson\u2019s HIV vaccine fails first efficacy trial", "url": "https://www.statnews.com/2021/08/31/first-efficacy-trial-of-johnson-johnsons-hiv-vaccine-fails/", "time_published": "20210831T203639", "authors": ["Matthew Herper"], "summary": "Johnson & Johnson's HIV vaccine, which uses the same technology as its Covid-19 shot, failed to prevent infection in its first efficacy trial, Imbokodo, conducted in southern Africa. While the actual efficacy was 25.2%, this result was not statistically significant, indicating it could be due to chance. A second study, Mosaico, testing a different vaccine regimen, will continue, as researchers emphasize the persistent challenge of developing an effective HIV vaccine.", "banner_image": null, "source": "www.statnews.com", "category_within_source": "General", "source_domain": "www.statnews.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.932549"}], "overall_sentiment_score": 0.036192, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.348394", "ticker_sentiment_score": "0.022949", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna\u2019s path to vaccine innovation: A talk with CEO St\u00e9phane Bancel", "url": "https://www.mckinsey.com/industries/life-sciences/our-insights/modernas-path-to-vaccine-innovation-a-talk-with-ceo-stephane-bancel", "time_published": "20210827T204728", "authors": ["St\u00e9phane Bancel", "Olivier Leclerc", "Jennifer Heller", "Adam Sabow", "Jeff Smith", "Ramesh Srinivasan", "Astrid Sandoval"], "summary": "This interview with Moderna CEO St\u00e9phane Bancel discusses the company's rapid development of a COVID-19 vaccine, highlighting the role of mRNA technology, collaboration with the US government, and the challenges of clinical trial diversity. Bancel also elaborates on the future potential of mRNA as a platform for new medicines and Moderna's commitment to digitalization and leadership strategies for long-term impact.", "banner_image": null, "source": "McKinsey & Company", "category_within_source": "General", "source_domain": "McKinsey & Company", "topics": [{"topic": "life_sciences", "relevance_score": "0.917724"}], "overall_sentiment_score": 0.591922, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.737887", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.619858", "ticker_sentiment_score": "0.546455", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.594252", "ticker_sentiment_score": "0.506839", "ticker_sentiment_label": "Bullish"}]}, {"title": "F.D.A. Attaches Warning of Rare Nerve Syndrome to Johnson & Johnson Vaccine (Published 2021)", "url": "https://www.nytimes.com/2021/07/12/us/politics/fda-warning-johnson-johnson-vaccine-nerve-syndrome.html", "time_published": "20210825T203639", "authors": ["Sharon LaFraniere and Noah Weiland"], "summary": "The FDA issued a warning that Johnson & Johnson's COVID-19 vaccine may lead to an increased risk of Guillain-Barr\u00e9 syndrome, a rare neurological condition. While the risk is considered low and the benefits of the vaccine still outweigh the risks, 100 suspected cases of the syndrome have been identified among vaccine recipients, with 95% requiring hospitalization. This serves as another setback for the Johnson & Johnson vaccine, which has been less widely used in the U.S. compared to Pfizer's and Moderna's vaccines.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.905593"}], "overall_sentiment_score": -0.302742, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.322230", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "J&J Says A Booster Shot For Its Vaccine May Have Big Benefits", "url": "https://www.npr.org/sections/coronavirus-live-updates/2021/08/25/1030909283/johnson-and-johnson-covid-vaccine-booster-six-months", "time_published": "20210825T083700", "authors": ["Joe Hernandez", "Joe Neel", "Rob Stein"], "summary": "Johnson & Johnson announced that a booster shot of its COVID-19 vaccine, administered six months after the first dose, significantly increased antibody levels. The company plans to submit this data to the FDA to support authorization for a booster. This comes as the Biden administration prepares to roll out boosters for Pfizer and Moderna vaccine recipients, and as health officials express concerns about waning immunity and the Delta variant.", "banner_image": "https://media.npr.org/assets/img/2021/08/25/gettyimages-1234857434_wide-be1a53ae60d80e722514107144e057fd9341459a.jpg", "source": "NPR", "category_within_source": "General", "source_domain": "NPR", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.301935, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.471478", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.718410", "ticker_sentiment_score": "0.249418", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.719517", "ticker_sentiment_score": "0.225235", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pfizer-BioNTech COVID-19 vaccine gains full U.S. regulatory approval", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-grants-full-approval-pfizer-biontech-covid-19-vaccine-2021-08-23/", "time_published": "20210823T212800", "authors": ["Carl O'donnell and Manas Mishra"], "summary": "The U.S. drug regulator has granted full approval to the Pfizer Inc (PFE.N)/BioNTech SE COVID-19 vaccine for individuals aged 16 and older, making it the first COVID-19 vaccine to secure such Food and Drug Administration validation. This decision has prompted President Joe Biden to encourage unvaccinated Americans to get the shot and is expected to lead to more vaccine mandates from governments and private employers. The approval also confirmed an increased risk of heart inflammation, particularly among young men, and allows for easier off-label prescription of a third dose for those who may benefit from additional protection.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.949354"}], "overall_sentiment_score": 0.172767, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BNTX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.481128", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.948612", "ticker_sentiment_score": "0.345286", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.641193", "ticker_sentiment_score": "-0.117708", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.561504", "ticker_sentiment_score": "-0.128551", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna applies for full F.D.A. approval for its Covid vaccine. (Published 2021)", "url": "https://www.nytimes.com/2021/06/01/science/moderna-vaccine-fda-approval.html", "time_published": "20210823T204728", "authors": ["Daniel E. Slotnik"], "summary": "Moderna has applied for full FDA approval for its Covid-19 vaccine for individuals 18 and older, following a similar move by Pfizer and BioNTech. Full approval would enable direct marketing to consumers, potentially boosting public confidence and facilitating vaccination mandates by various institutions. The application comes as over 50% of the U.S. population has received at least one vaccine dose, though the vaccination rate has slowed since mid-April.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.941743"}], "overall_sentiment_score": 0.265633, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.459228", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.723473", "ticker_sentiment_score": "0.281288", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.596308", "ticker_sentiment_score": "0.100142", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.561415", "ticker_sentiment_score": "0.108535", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson names Joaquin Duato as its next CEO", "url": "https://www.cnn.com/2021/08/19/business/johnson--johnson-joaquin-duato-ceo", "time_published": "20210819T191200", "authors": ["Rob McLean"], "summary": "Johnson & Johnson announced that Joaquin Duato will take over as CEO on January 3, replacing Alex Gorsky who will become executive chairman. Duato has been with the company for over 30 years and currently serves as vice chairman of the executive committee. Gorsky, who led the company since 2012, oversaw the development of J&J's one-dose Covid-19 vaccine and faced lawsuits regarding its talcum powder.", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "life_sciences", "relevance_score": "0.923835"}, {"topic": "finance", "relevance_score": "0.733472"}], "overall_sentiment_score": 0.149672, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.143791", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alex Gorsky to Serve as Executive Chairman and Transition Role of Chief Executive Officer of Johnson & Johnson to Joaquin Duato, Effective January 3, 2022", "url": "https://www.prnewswire.com/news-releases/alex-gorsky-to-serve-as-executive-chairman-and-transition-role-of-chief-executive-officer-of-johnson--johnson-to-joaquin-duato-effective-january-3-2022-301359453.html", "time_published": "20210819T171800", "authors": [], "summary": "Johnson & Johnson (NYSE: JNJ) announced that Alex Gorsky will transition from Chairman and CEO to Executive Chairman, with Joaquin Duato taking over as Chief Executive Officer, effective January 3, 2022. Gorsky's decision to step down is due to family health reasons after leading the company for nearly a decade, during which R&D investments increased significantly and market capitalization grew from nearly $180 billion to over $470 billion. Duato, currently Vice Chairman of the Executive Committee, will also join the Board of Directors.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "earnings", "relevance_score": "0.836576"}], "overall_sentiment_score": 0.434432, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.423363", "ticker_sentiment_label": "Bullish"}]}, {"title": "Pharma Market Update: H1 2021 in Review", "url": "https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/pharma-market-update/", "time_published": "20210818T131500", "authors": ["Bryan Mc Govern"], "summary": "The pharmaceutical industry experienced both challenges and opportunities in the first half of 2021, largely driven by the COVID-19 pandemic. While vaccine development proved victorious, discussions around patent removal impacted investor sentiment, and financial institutions reported mixed fund performances for pharma ETFs. Despite some setbacks, analysts believe in the sector's long-term recovery and potential for attractive stock valuations.", "banner_image": null, "source": "Investing News Network", "category_within_source": "General", "source_domain": "Investing News Network", "topics": [{"topic": "life_sciences", "relevance_score": "0.923623"}, {"topic": "earnings", "relevance_score": "0.825570"}, {"topic": "financial_markets", "relevance_score": "0.704284"}, {"topic": "economy_macro", "relevance_score": "0.616479"}], "overall_sentiment_score": 0.342296, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IHE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.257962", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.964831", "ticker_sentiment_score": "0.424972", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.925040", "ticker_sentiment_score": "0.399852", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.850067", "ticker_sentiment_score": "0.339420", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "China's Sinovac to invest $60 mln in vaccine facility in Chile", "url": "https://www.marcachile.cl/en/chinas-sinovac-to-invest-60-mln-in-vaccine-facility-in-chile/", "time_published": "20210813T212136", "authors": [], "summary": "Chinese pharmaceutical company Sinovac Biotech Ltd announced an investment of $60 million to build a fill-and-finish vaccine plant in Chile. This move aims to solidify Sinovac's presence in Latin America, particularly in Chile, which has extensively utilized its COVID-19 vaccine, CoronaVac. Chile has achieved one of the world's fastest vaccination campaigns, with over 60% of its population fully vaccinated using substantial doses from Sinovac.", "banner_image": null, "source": "Marca Chile", "category_within_source": "General", "source_domain": "Marca Chile", "topics": [{"topic": "life_sciences", "relevance_score": "0.949639"}, {"topic": "manufacturing", "relevance_score": "0.727977"}], "overall_sentiment_score": 0.219008, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SVA", "relevance_score": "0.300565", "ticker_sentiment_score": "0.032919", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.780652", "ticker_sentiment_score": "0.254718", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.825837", "ticker_sentiment_score": "0.298040", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.808555", "ticker_sentiment_score": "0.296693", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.820733", "ticker_sentiment_score": "0.267641", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DexCom Inc. stock rises Thursday, outperforms market", "url": "https://www.marketwatch.com/story/dexcom-inc-stock-rises-thursday-outperforms-market-01628801423-5aa1d1c471ec?gaa_at=eafs&gaa_n=AWEtsqcVUKSHfdPJ99MN_P9HRCAN244uqP9j6MnFht-DXlfOY9-zvTvW-BWv&gaa_ts=6907bd01&gaa_sig=AbsZa5kYC7Ntn7DPOp9fTiJCf6PddBEK2xzJQzI1ow4PsXmek0NHfE-JAF1Zpta5fJNCZTw6yH1VmgtXR0C2ug%3D%3D", "time_published": "20210812T165000", "authors": ["MarketWatch Automation"], "summary": "DexCom Inc. (DXCM) stock saw a modest increase of 0.53% on Thursday, closing at $492.85, outperforming the broader market despite a two-day losing streak. The company's stock, however, underperformed compared to some competitors like Johnson & Johnson, Abbott Laboratories, and Medtronic PLC on the specified day. Trading volume for DexCom Inc. was also below its 50-day average.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "financial_markets", "relevance_score": "0.917797"}, {"topic": "life_sciences", "relevance_score": "0.732831"}], "overall_sentiment_score": 0.301276, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "1.000000", "ticker_sentiment_score": "0.302291", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.615130", "ticker_sentiment_score": "0.315648", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.612640", "ticker_sentiment_score": "0.301374", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.631791", "ticker_sentiment_score": "0.320553", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nanox Enters into Acquisition via Merger Agreement with Zebra Medical Vision Ltd. and Announces Entry into Binding Letter of Intent with USARAD Holdings Inc.", "url": "https://www.businesswire.com/news/home/20210810005555/en/Nanox-Enters-into-Acquisition-via-Merger-Agreement-with-Zebra-Medical-Vision-Ltd.-and-Announces-Entry-into-Binding-Letter-of-Intent-with-USARAD-Holdings-Inc.", "time_published": "20210810T205149", "authors": ["NULL"], "summary": "Nanox (Nasdaq: NNOX) has announced two strategic acquisitions aimed at creating an integrated, end-to-end radiology solution. The company plans to acquire medical AI developer Zebra Medical Vision for up to $200 million in Nanox shares and has entered a binding letter of intent to acquire teleradiology company USARAD Holdings Inc. for $30 million in cash and shares. These acquisitions are designed to address global shortages in medical imaging devices and radiologists, while leveraging AI for preventive health.", "banner_image": "NULL", "source": "Business Wire", "category_within_source": "General", "source_domain": "Business Wire", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.917744"}, {"topic": "technology", "relevance_score": "0.828364"}], "overall_sentiment_score": 0.39956, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "NNOX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.452175", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.629185", "ticker_sentiment_score": "0.334267", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Global Opioid Settlement", "url": "https://www.texasattorneygeneral.gov/globalopioidsettlement", "time_published": "20210806T193546", "authors": [], "summary": "Texas has reached final agreements with numerous companies, including Purdue Pharma, Johnson & Johnson, CVS, Walmart, and distributors, to resolve legal claims related to the opioid crisis. The settlements, totaling almost $60 billion nationally, include significant financial terms for Texas, bringing its combined share to $3.347 billion, which must be used for opioid crisis strategies. These agreements also incorporate industry-changing injunctive terms to increase oversight and accountability for opioid manufacturers, distributors, and pharmacies.", "banner_image": null, "source": "Office of the Attorney General (.gov)", "category_within_source": "General", "source_domain": "Office of the Attorney General (.gov)", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.846263"}, {"topic": "economy_fiscal", "relevance_score": "0.640945"}], "overall_sentiment_score": -0.167961, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AMRX", "relevance_score": "0.349207", "ticker_sentiment_score": "0.001190", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.837892", "ticker_sentiment_score": "-0.200935", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CVS", "relevance_score": "0.827923", "ticker_sentiment_score": "-0.234346", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.805193", "ticker_sentiment_score": "-0.180387", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KR", "relevance_score": "0.838029", "ticker_sentiment_score": "-0.233884", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Moderna's Covid vaccine 93 percent effective six months after second dose, company says", "url": "https://www.nbcnews.com/news/us-news/moderna-s-covid-vaccine-93-percent-effective-six-months-after-n1276020", "time_published": "20210805T073300", "authors": ["Reuters"], "summary": "Moderna announced its Covid-19 vaccine maintained 93% effectiveness six months after the second dose, comparable to its initial clinical trial results. However, the company stated that a booster shot would likely be necessary before winter due to waning antibody levels, especially in light of the Delta variant. Moderna also confirmed robust antibody responses from its booster candidates against several variants and detailed significant vaccine contract sales for 2021 and 2022.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.928768"}, {"topic": "earnings", "relevance_score": "0.814020"}], "overall_sentiment_score": 0.196594, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.472105", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.745077", "ticker_sentiment_score": "0.261601", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.576217", "ticker_sentiment_score": "-0.127838", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.568519", "ticker_sentiment_score": "0.144796", "ticker_sentiment_label": "Neutral"}]}, {"title": "A breakdown of US value ETFs", "url": "https://www.etfstream.com/articles/a-breakdown-of-us-value-etfs", "time_published": "20210802T200703", "authors": ["Jamie Gordon"], "summary": "This article analyzes five US value ETFs, highlighting that only three of them outperformed Vanguard's S&P 500 ETF despite 2021 being anticipated as a strong year for value factor resurgence. It details the methodologies, holdings, and performance of each ETF (iShares Edge MSCI USA Value Factor UCITS ETF, Ossiam Shiller Barclays Cape US Sector Value UCITS ETF, UBS ETF Factor MSCI USA Value UCITS ETF, UBS ETF Factor MSCI USA Prime Value UCITS ETF, and SPDR MSCI USA Value Weighted UCITS ETF) and discusses the importance of index design and Total Expense Ratios (TERs) in their relative performance.", "banner_image": null, "source": "ETF Stream", "category_within_source": "General", "source_domain": "ETF Stream", "topics": [{"topic": "financial_markets", "relevance_score": "0.913722"}, {"topic": "finance", "relevance_score": "0.712303"}, {"topic": "economy_macro", "relevance_score": "0.641725"}], "overall_sentiment_score": 0.09977, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DYNF", "relevance_score": "0.344896", "ticker_sentiment_score": "0.026296", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.618008", "ticker_sentiment_score": "0.121242", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.605693", "ticker_sentiment_score": "0.144354", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.616910", "ticker_sentiment_score": "0.124391", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.634290", "ticker_sentiment_score": "0.132925", "ticker_sentiment_label": "Neutral"}]}, {"title": "Extra Bullish on Healthcare? Consider Leverage, the CURE ETF", "url": "https://www.etftrends.com/leveraged-inverse-content-hub/extra-bullish-on-healthcare-consider-leverage-cure/", "time_published": "20210802T200154", "authors": ["Ben Hernandez"], "summary": "This article suggests considering the Direxion Daily Healthcare Bull 3X ETF (CURE) for investors who are extra bullish on the healthcare sector due to ongoing dynamic trading opportunities despite market volatility. CURE seeks 300% daily performance of the Health Care Select Sector Index and has shown a 56% gain in 2021, driven in part by strong Q2 earnings from holdings like United Health. The article emphasizes that CURE is intended for seasoned investors due to the inherent risks of leveraged ETFs.", "banner_image": null, "source": "ETF Trends", "category_within_source": "General", "source_domain": "ETF Trends", "topics": [{"topic": "life_sciences", "relevance_score": "0.915901"}, {"topic": "financial_markets", "relevance_score": "0.837791"}, {"topic": "earnings", "relevance_score": "0.749425"}], "overall_sentiment_score": 0.200974, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CURE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.502039", "ticker_sentiment_label": "Bullish"}, {"ticker": "UNH", "relevance_score": "0.718053", "ticker_sentiment_score": "0.320843", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.610683", "ticker_sentiment_score": "0.141044", "ticker_sentiment_label": "Neutral"}, {"ticker": "UHS", "relevance_score": "0.611753", "ticker_sentiment_score": "-0.143976", "ticker_sentiment_label": "Neutral"}]}, {"title": "US authorities probing Emergent BioSolutions over COVID-19 vaccine issues - filing", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-authorities-probing-emergent-biosolutions-over-covid-19-vaccine-issues-filing-2021-07-30/", "time_published": "20210730T160300", "authors": ["Reuters"], "summary": "Emergent BioSolutions Inc is facing probes from multiple U.S. authorities, including the Department of Justice and SEC, concerning its COVID-19 bulk drug substance manufacturing capabilities. This scrutiny follows an error at its Baltimore facility that led to millions of Johnson & Johnson vaccine doses being ruined due to contamination from AstraZeneca vaccine ingredients. Emergent has resumed production at the Baltimore plant after remedial actions.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FV7W7K374RZO3XN755VFX36BHTQ.jpg?auth=6bdc76a5b6f3654519961a681c5d0124ccb5ae5cc9f0298a002636f32e29307d&width=960&height=540&quality=80&smart=true", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.944497"}, {"topic": "manufacturing", "relevance_score": "0.805220"}], "overall_sentiment_score": -0.521898, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "EBS", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.601139", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.734169", "ticker_sentiment_score": "-0.423432", "ticker_sentiment_label": "Bearish"}]}, {"title": "Emergent to resume J&J COVID-19 vaccine production at Baltimore plant", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/jj-contractor-plans-resume-covid-19-vaccine-production-baltimore-plant-wsj-2021-07-29/", "time_published": "20210729T223000", "authors": ["By Reuters"], "summary": "Emergent BioSolutions is set to resume production of Johnson & Johnson's COVID-19 vaccine at its Baltimore facility, which had been halted since April due to contamination issues. This decision follows additional reviews and collaboration with the FDA and manufacturing partners. The facility could produce up to 120 million doses monthly once fully operational, though finished doses may not be available until the fall.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2F2E4GR3446ZPPJGN6Q4H5Z57XSM.JPG?auth=5bc7bc476e33fdc81525afc2c1c3fcd06ee6073111f1857945d812d1b0d23805&width=1200&height=628&smart=true", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.903077"}, {"topic": "manufacturing", "relevance_score": "0.711389"}, {"topic": "earnings", "relevance_score": "0.609085"}], "overall_sentiment_score": 0.251671, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.295974", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Targeted Black Women With Products Linked To Cancer, Lawsuit Says", "url": "https://www.npr.org/2021/07/29/1022355144/johnson-johnson-targeted-black-women-powder-products-cancer-lawsuit", "time_published": "20210729T152800", "authors": ["Joe Hernandez"], "summary": "A new lawsuit alleges that Johnson & Johnson deliberately marketed its talcum-based powder products to Black women despite evidence of cancer links. The National Council of Negro Women states that the company made Black women a \"central part\" of its business strategy while failing to warn them of potential dangers. Johnson & Johnson denies these allegations, maintaining its products are safe and its marketing campaigns are inclusive.", "banner_image": "https://media.npr.org/assets/img/2021/07/29/gettyimages-1232876646-e578c7c98616a2ef7402dc45fe9895c1c8f18de0.jpg?s=1600", "source": "NPR", "category_within_source": "General", "source_domain": "NPR", "topics": [{"topic": "life_sciences", "relevance_score": "0.935227"}, {"topic": "retail_wholesale", "relevance_score": "0.700020"}], "overall_sentiment_score": -0.643637, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.614972", "ticker_sentiment_label": "Bearish"}]}, {"title": "Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists", "url": "https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-amendment-of-agreement-with-janssen-biotech-for-the-continued-development-and-commercialization-of-il-23-antagonists-301343621.html", "time_published": "20210728T160500", "authors": [], "summary": "Protagonist Therapeutics announced an amended collaboration agreement with Janssen Biotech for the continued development and commercialization of multiple oral IL-23 receptor antagonist drug candidates. Under the revised terms, Janssen will lead worldwide development and commercialization, taking sole financial responsibility for future studies beyond those currently ongoing. Protagonist remains eligible for approximately $900 million in future milestone payments, in addition to $80 million already received.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.905502"}, {"topic": "finance", "relevance_score": "0.714139"}], "overall_sentiment_score": 0.328398, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PTGX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.453257", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.726808", "ticker_sentiment_score": "0.328923", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.575295", "ticker_sentiment_score": "0.126816", "ticker_sentiment_label": "Neutral"}]}, {"title": "Boston Scientific tops expectations with 53% sales growth over 2020", "url": "https://www.fiercebiotech.com/medtech/boston-scientific-tops-expectations-53-sales-growth-over-2020", "time_published": "20210727T115100", "authors": ["Conor Hale"], "summary": "Boston Scientific exceeded its own expectations by posting net sales of $3.08 billion in the second quarter of 2021, representing a 53.6% gain over the previous year amidst COVID-19 recovery. The company saw strong growth across all major business segments and key markets, outperforming its own sales increase forecasts and adjusted earnings-per-share projections. This strong performance follows several strategic acquisitions earlier in the year to bolster its cardiovascular and surgical laser businesses.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "0.935575"}, {"topic": "earnings", "relevance_score": "0.940759"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.810817"}], "overall_sentiment_score": 0.480705, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.843368", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.612062", "ticker_sentiment_score": "0.313103", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.649432", "ticker_sentiment_score": "0.229251", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Posts Higher Profit as Healthcare Demand Returns - WSJ", "url": "https://www.wsj.com/health/healthcare/johnson-johnson-posts-higher-quarterly-profit-as-healthcare-demand-returns-11626867300?gaa_at=eafs&gaa_n=AWEtsqd3EiRgDOiHxLuNtjUcMuvOe37xoOP3TtwNf209oH7hJSBdTTakn7Lo&gaa_ts=6907c409&gaa_sig=3kKU030-LWC3cdouBrqx9KJAc8NQuU8aM05dfT1yRbHZEkJ0wASCnqU3TTo7Bam288yFnh2oFoHZO6yP09LqCQ%3D%3D", "time_published": "20210721T203637", "authors": ["Laura Cooper", "Matt Grossman"], "summary": "Johnson & Johnson reported higher profits and sales in its latest quarter, driven by increased demand for medical devices, drugs, and consumer-health products as healthcare services deferred during the pandemic resumed. The company's sales rose by 27% year-over-year to $23.31 billion, surpassing analyst expectations, and adjusted earnings per share reached $2.48. J&J also raised its guidance for the rest of the year, anticipating a pickup in sales of its Covid-19 vaccine.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "earnings", "relevance_score": "0.924488"}, {"topic": "life_sciences", "relevance_score": "0.825364"}, {"topic": "economy_macro", "relevance_score": "0.638863"}], "overall_sentiment_score": 0.409768, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.409345", "ticker_sentiment_label": "Bullish"}]}, {"title": "Drug Distributors and J.&J. Reach $26 Billion Deal to End Opioid Lawsuits (Published 2021)", "url": "https://www.nytimes.com/2021/07/21/health/opioids-distributors-settlement.html", "time_published": "20210721T195220", "authors": ["Jan Hoffman"], "summary": "Three major drug distributors and Johnson & Johnson have reached a $26 billion deal with states to settle opioid lawsuits, releasing them from civil liability in the public health crisis. The agreement will allow funds to flow to communities for addiction treatment, prevention, and other related services. This settlement is a significant step in the national litigation against companies involved in the opioid epidemic, which has claimed hundreds of thousands of lives.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.745284"}], "overall_sentiment_score": -0.085345, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.219631", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.960090", "ticker_sentiment_score": "-0.274948", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MCK", "relevance_score": "0.903425", "ticker_sentiment_score": "0.119850", "ticker_sentiment_label": "Neutral"}, {"ticker": "COR", "relevance_score": "0.861669", "ticker_sentiment_score": "0.105554", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson to pay $5bn in landmark $26bn US opioid settlement", "url": "https://www.theguardian.com/us-news/2021/jul/21/us-opioid-settlement-state-attorneys-general-johnson-and-johnson", "time_published": "20210721T184500", "authors": ["Guardian staff and agencies"], "summary": "A landmark $26bn settlement has been unveiled with major drug companies, including Johnson & Johnson, McKesson Corp, Cardinal Health Inc, and AmerisourceBergen Corp, to address the US opioid epidemic. Johnson & Johnson will pay $5bn, while the three distributors will pay a combined $21bn over several years. The funds are earmarked for addiction treatment, family support, and educational programs, though some states, like Washington, have expressed dissatisfaction with the agreement.", "banner_image": null, "source": "The Guardian", "category_within_source": "General", "source_domain": "The Guardian", "topics": [{"topic": "life_sciences", "relevance_score": "0.945579"}, {"topic": "economy_fiscal", "relevance_score": "0.729344"}, {"topic": "finance", "relevance_score": "0.625661"}], "overall_sentiment_score": 0.049926, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.337679", "ticker_sentiment_score": "0.029114", "ticker_sentiment_label": "Neutral"}]}, {"title": "Drugmakers, pharmacies next targets for U.S. opioid settlements", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-pharmacies-next-targets-us-opioid-settlements-2021-07-21/", "time_published": "20210721T134300", "authors": ["Brendan Pierson"], "summary": "Following an anticipated $26 billion opioid settlement with major drug distributors and Johnson & Johnson, U.S. state attorneys general are now setting their sights on pharmacies and other drugmakers. These companies, including Walgreens, Walmart, Rite Aid, CVS, AbbVie, Teva, and Endo, are accused of contributing to the opioid crisis by ignoring red flags or deceptively marketing drugs, and are expected to face significant legal pressure. The move marks a new phase in the widespread litigation over the opioid epidemic that has claimed nearly 500,000 lives from 1999 to 2019.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FG7FX6J6FGFJ4RFF7D66ABYDB6Y.jpg?auth=d8164ba7f8b9e6f3d1796c8c4a4a8368ed152504b8823b2046467389a9f237bf&width=960&height=540&quality=80&smart=true", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.912303"}, {"topic": "finance", "relevance_score": "0.744478"}], "overall_sentiment_score": -0.430341, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.468199", "ticker_sentiment_label": "Bearish"}, {"ticker": "MCK", "relevance_score": "0.992509", "ticker_sentiment_score": "-0.468870", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.930690", "ticker_sentiment_score": "-0.401247", "ticker_sentiment_label": "Bearish"}, {"ticker": "WBA", "relevance_score": "0.740324", "ticker_sentiment_score": "-0.411144", "ticker_sentiment_label": "Bearish"}]}, {"title": "Opioid maker J&J, distributors near $26B deal with US states", "url": "https://www.aljazeera.com/economy/2021/7/20/opioid-maker-jj-distributors-near-26bn-deal-with-us-states", "time_published": "20210720T195220", "authors": ["Jef Feeley and Bloomberg"], "summary": "Johnson & Johnson and three major drug distributors are finalizing a $26 billion settlement to resolve thousands of opioid-related lawsuits across the US. The deal involves McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp paying $21 billion and J&J contributing $5 billion. States have the option to accept the full settlement or parts of it, with bonuses for broader local government participation.", "banner_image": null, "source": "Al Jazeera", "category_within_source": "General", "source_domain": "Al Jazeera", "topics": [{"topic": "life_sciences", "relevance_score": "0.913108"}, {"topic": "finance", "relevance_score": "0.705946"}], "overall_sentiment_score": 0.146918, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.353568", "ticker_sentiment_label": "Bearish"}, {"ticker": "MCK", "relevance_score": "0.904498", "ticker_sentiment_score": "0.342869", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.914994", "ticker_sentiment_score": "0.319370", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.600875", "ticker_sentiment_score": "0.315051", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson takes to Twitter to expand its network of storytelling patients", "url": "https://www.fiercepharma.com/marketing/j-j-s-invites-people-to-tell-their-janssen-stories-creating-200-plus-strong-patient", "time_published": "20210720T112900", "authors": ["Natalie Missakian"], "summary": "Johnson & Johnson is expanding its SHARE Network, a program encouraging patients to share positive experiences with Janssen drugs, onto Twitter. This initiative aims to recruit more volunteers to the network, which currently numbers around 200 patients and caregivers, to inspire others and combat stigma. The company utilizes these patient stories for various campaigns and platforms to highlight the impact of their innovations.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.906469"}], "overall_sentiment_score": 0.295265, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.261522", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "U.S. states to unveil $26 billion opioid settlement with drug distributors, J&J - sources", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/drug-distributors-jj-announce-26-bln-opioid-settlement-this-week-source-2021-07-19/", "time_published": "20210720T100000", "authors": ["Nate Raymond"], "summary": "U.S. state attorneys general are expected to announce a $26 billion settlement with three major drug distributors and Johnson & Johnson to resolve claims they fueled the opioid epidemic. The settlement involves McKesson Corp, Cardinal Health Inc, and AmerisourceBergen Corp paying a combined $21 billion, and Johnson & Johnson paying $5 billion. The funds are intended to remediate the opioid crisis, which has caused nearly 500,000 overdose deaths in the U.S. between 1999 and 2019.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FVJCYL4PBYZPFDBB6X5M2C5GZ7A.jpg?auth=9ce29cb9ddb174776b22ae392d4f585a088907865239a068019a2e6f981dd4fc&width=1200&height=628&smart=true", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.929709"}, {"topic": "finance", "relevance_score": "0.705551"}], "overall_sentiment_score": 0.233823, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.242813", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.938339", "ticker_sentiment_score": "0.237614", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.903934", "ticker_sentiment_score": "0.242952", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gelesis, a Consumer-Focused Biotherapeutics Company and the Maker of Plenity\u00ae, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.", "url": "https://www.businesswire.com/news/home/20210719005350/en/Gelesis-a-Consumer-Focused-Biotherapeutics-Company-and-the-Maker-of-Plenity-to-Become-a-Publicly-Traded-Company-via-Merger-with-Capstar-Special-Purpose-Acquisition-Corp.", "time_published": "20210719T000000", "authors": [], "summary": "Gelesis, a biotherapeutics company known for its weight management product Plenity\u00ae, announced its merger with Capstar Special Purpose Acquisition Corp. The transaction values the combined company at an implied market value of approximately $1.3 billion and an enterprise value of $1.0 billion, aiming to fund the full commercial launch of Plenity and expand manufacturing. The combined company's securities are expected to trade on the NYSE under the symbol \"GLS.\"", "banner_image": null, "source": "Business Wire", "category_within_source": "General", "source_domain": "Business Wire", "topics": [{"topic": "ipo", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.914829"}, {"topic": "finance", "relevance_score": "0.738107"}], "overall_sentiment_score": 0.212106, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CPSR", "relevance_score": "1.000000", "ticker_sentiment_score": "0.644987", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.619294", "ticker_sentiment_score": "0.123369", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.642850", "ticker_sentiment_score": "0.113727", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMS", "relevance_score": "0.637366", "ticker_sentiment_score": "0.109020", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.601273", "ticker_sentiment_score": "0.110764", "ticker_sentiment_label": "Neutral"}]}, {"title": "HeartFlow Is Going Public via a SPAC Merger, Key Details Revealed", "url": "https://marketrealist.com/p/heartflow-spac-ipo-date/", "time_published": "20210716T094600", "authors": ["Kathryn Underwood"], "summary": "HeartFlow, a company specializing in a non-invasive cardiac test, is set to go public through a SPAC merger with Longview Acquisition Corp. II. The merger is expected to value HeartFlow at $2.4 billion and will result in the company trading on the NYSE under the symbol \"HFLO\" during the fourth quarter of 2021. This move aims to fund growth and allow existing shareholders to repurchase equity.", "banner_image": null, "source": "Market Realist", "category_within_source": "General", "source_domain": "Market Realist", "topics": [{"topic": "ipo", "relevance_score": "0.910015"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.814664"}, {"topic": "life_sciences", "relevance_score": "0.714828"}], "overall_sentiment_score": 0.082454, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HTFL", "relevance_score": "0.324114", "ticker_sentiment_score": "0.011494", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.624776", "ticker_sentiment_score": "0.100540", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.575532", "ticker_sentiment_score": "0.110824", "ticker_sentiment_label": "Neutral"}]}, {"title": "CVS Pulls Two Sun-Care Products After Neutrogena Sunscreen Recall", "url": "https://www.wsj.com/health/healthcare/cvs-pulls-two-sun-care-products-after-neutrogena-sunscreen-recall-11626380245?gaa_at=eafs&gaa_n=AWEtsqfU-WIOr8CM8mFG_1KIZIyngmG1w34nF07rP3fkzo-c1C7aLVqrbo43&gaa_ts=6907bbea&gaa_sig=mTEAd-7YdotcIQzPIBL_gGAHUAPaw0xp6DJSgg83qbggV8pwecmlIfF0YS1VZDJfrSjz6ylxQP79Vbts3utHPg%3D%3D", "time_published": "20210715T200159", "authors": ["Sharon Terlep"], "summary": "CVS Health Corp. has halted sales of two of its own brand sun-care products as a precautionary measure. This action follows Johnson & Johnson's recall of Neutrogena and Aveeno spray sunscreens due to the detection of a potentially cancer-causing chemical, benzene. The recall was prompted by an online pharmacy, Valisure LLC, which found high levels of benzene in several sunscreens.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.923449"}, {"topic": "retail_wholesale", "relevance_score": "0.844540"}], "overall_sentiment_score": -0.113146, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "1.000000", "ticker_sentiment_score": "0.134624", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.887423", "ticker_sentiment_score": "-0.313562", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA\u00ae and AVEENO\u00ae Aerosol Sunscreen Products Due to the Presence of Benzene", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-consumer-inc-issues-voluntary-recall-of-specific-neutrogena-and-aveeno-aerosol-sunscreen-products-due-to-the-presence-of-benzene-301334144.html", "time_published": "20210714T170000", "authors": [], "summary": "Johnson & Johnson Consumer Inc. (JJCI) is voluntarily recalling all lots of five NEUTROGENA\u00ae and AVEENO\u00ae aerosol sunscreen product lines due to the detection of low levels of benzene. While benzene is not an ingredient, it was found in some samples, prompting the recall out of an abundance of caution, despite exposure modeling suggesting no adverse health consequences at the detected levels. Consumers are advised to stop using and discard the affected products and contact JJCI for refunds, while continuing to use alternative sun protection measures.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.939949"}, {"topic": "retail_wholesale", "relevance_score": "0.712321"}, {"topic": "finance", "relevance_score": "0.610352"}], "overall_sentiment_score": -0.258298, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.285560", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Hospitals are taking on a surgical robot \"monopoly\"", "url": "https://www.axios.com/2021/07/13/hospitals-are-taking-on-a-surgical-robot-monopoly", "time_published": "20210713T203214", "authors": ["Bob Herman"], "summary": "Several hospitals have filed class-action lawsuits against Intuitive Surgical, the maker of the da Vinci surgical robot, alleging antitrust violations. They claim the company abuses its monopoly to force hospitals into expensive maintenance contracts and to buy overpriced replacement parts, even resorting to remotely shutting down a robot during a procedure when a hospital considered a third-party service. Hospitals also allege that Intuitive Surgical forces them to buy new, costly instruments after only 10 uses and threatens to disable machines if hospitals use outside vendors.", "banner_image": "https://assets.axios.com/image/upload/f_auto,q_auto,w_1080/v1626105315/2021/07/12/1626105310619.jpg", "source": "Axios", "category_within_source": "General", "source_domain": "Axios", "topics": [{"topic": "life_sciences", "relevance_score": "0.943917"}, {"topic": "technology", "relevance_score": "0.814846"}], "overall_sentiment_score": -0.059111, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.515649", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.613163", "ticker_sentiment_score": "0.133672", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.627676", "ticker_sentiment_score": "0.143372", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMT", "relevance_score": "0.619478", "ticker_sentiment_score": "0.115012", "ticker_sentiment_label": "Neutral"}]}, {"title": "Experts differ on need for Johnson & Johnson COVID-19 booster shot", "url": "https://abcnews.go.com/Health/experts-differ-johnson-johnson-covid-19-booster-shot/story?id=78632475", "time_published": "20210709T050000", "authors": ["Dr. Stephanie Widmer"], "summary": "Medical experts are divided on the necessity of a Johnson & Johnson COVID-19 booster shot, despite promising new data suggesting the single-dose vaccine holds up against the delta variant. While some experts advocate for a booster to ensure uniform protection levels across all vaccinated individuals, others, including the FDA and CDC, currently advise against it, citing a lack of formal studies and recommendations. The debate highlights the ongoing scientific deliberation regarding booster shots, especially for immunocompromised individuals.", "banner_image": null, "source": "ABC News", "category_within_source": "General", "source_domain": "ABC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.925962"}], "overall_sentiment_score": 0.141547, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.123707", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.741915", "ticker_sentiment_score": "0.111312", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.643413", "ticker_sentiment_score": "0.107429", "ticker_sentiment_label": "Neutral"}]}, {"title": "Innovations Meet Growing Demand for Prefilled Syringes", "url": "https://www.pharmtech.com/view/innovations-meet-growing-demand-for-prefilled-syringes", "time_published": "20210702T213303", "authors": ["Hallie Forcinio"], "summary": "The prefilled syringe market is experiencing significant growth, driven by vaccine production and the adoption of self-administered biologics for chronic conditions. Innovations are focusing on enhancing user-friendliness, increasing automation in fill/finish lines, and addressing product safety concerns like needlestick injuries and silicone sensitivity. Suppliers are also working on larger volume syringes, finer needles for patient comfort, and systems for efficient low-temperature storage.", "banner_image": null, "source": "PharmTech", "category_within_source": "General", "source_domain": "PharmTech", "topics": [{"topic": "life_sciences", "relevance_score": "0.906189"}, {"topic": "manufacturing", "relevance_score": "0.742677"}], "overall_sentiment_score": 0.206735, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WST", "relevance_score": "0.980910", "ticker_sentiment_score": "0.312288", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAX", "relevance_score": "0.841502", "ticker_sentiment_score": "0.268607", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MMM", "relevance_score": "0.612341", "ticker_sentiment_score": "0.114279", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.587693", "ticker_sentiment_score": "0.183494", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson vaccine seems to stand up against delta variant, preliminary research suggests", "url": "https://abcnews.go.com/Health/jj-vaccine-stand-delta-variant-preliminary-research-suggests/story?id=78612193", "time_published": "20210701T204000", "authors": ["Sony Salzman"], "summary": "New preliminary research suggests that the single-shot Johnson & Johnson COVID-19 vaccine offers good protection against the delta variant, a highly transmissible strain predicted to become dominant in the U.S. A laboratory experiment showed the vaccine generated neutralizing antibodies and other immune responses against the delta variant. The study also highlighted the surprising durability of the immune response, lasting up to eight months.", "banner_image": null, "source": "ABC News - Breaking News, Latest News and Videos", "category_within_source": "General", "source_domain": "ABC News - Breaking News, Latest News and Videos", "topics": [{"topic": "life_sciences", "relevance_score": "0.914679"}], "overall_sentiment_score": 0.410921, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.407174", "ticker_sentiment_label": "Bullish"}]}, {"title": "3 cutting-edge eye lenses designed to help improve how you see", "url": "https://www.jnj.com/innovation/latest-eye-innovations-iol-contact-lens-technology", "time_published": "20210630T203638", "authors": ["Jennifer Rainey Marquez"], "summary": "Johnson & Johnson Vision is revolutionizing eye care with three cutting-edge lens innovations. These include implantable intraocular lenses (IOLs) that adapt to digital demands after cataract surgery, highly personalized multifocal contact lenses optimized for individual pupil sizes, and drug-releasing contact lenses that provide vision correction and allergy relief. These advancements aim to improve sight and well-being for millions worldwide.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.949530"}, {"topic": "technology", "relevance_score": "0.708313"}], "overall_sentiment_score": 0.472251, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.474967", "ticker_sentiment_label": "Bullish"}]}, {"title": "FDA Grants Fast Track Designation to SNDX-5613 for R/R MLLr and NMP1-Mutant Acute Leukemias", "url": "https://www.targetedonc.com/view/fda-grants-fast-track-designation-to-sndx-5613-for-r-r-mllr-and-nmp1-mutant-acute-leukemias", "time_published": "20210628T211650", "authors": ["Nichole Tucker"], "summary": "The FDA has granted fast track designation to SNDX-5613 for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias who harbor a mixed lineage leukemia rearranged or nucleophosmin mutation. SNDX-5613, an oral menin inhibitor developed by Syndax Pharmaceuticals, Inc., is currently being investigated in the phase 1/2 AUGEMENT clinical trial, which has shown robust clinical responses in the dose-escalation portion. This designation underscores the drug's potential to significantly improve outcomes for patients with these genetically-defined acute leukemias, an underserved area with poor prognosis.", "banner_image": null, "source": "Targeted Oncology", "category_within_source": "General", "source_domain": "Targeted Oncology", "topics": [{"topic": "life_sciences", "relevance_score": "0.938816"}], "overall_sentiment_score": 0.269201, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SNDX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.849226", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.739201", "ticker_sentiment_score": "0.130959", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.723988", "ticker_sentiment_score": "0.119097", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.738305", "ticker_sentiment_score": "0.149249", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.700528", "ticker_sentiment_score": "0.122811", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson to pay $230m to settle opioid claim", "url": "https://www.bbc.com/news/business-57628322", "time_published": "20210627T203637", "authors": [], "summary": "Johnson & Johnson has agreed to pay $230 million to settle claims that it fueled an opioid addiction crisis in New York State, without admitting liability. The settlement allows J&J to avoid an upcoming trial and requires the company to stop selling painkillers nationwide. This payment is consistent with a prior agreement for J&J to pay $5 billion to settle US opioid claims.", "banner_image": null, "source": "BBC", "category_within_source": "General", "source_domain": "BBC", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.036418, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.294895", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CAH", "relevance_score": "0.717998", "ticker_sentiment_score": "0.146829", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.749250", "ticker_sentiment_score": "0.103031", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.648979", "ticker_sentiment_score": "0.135059", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.641882", "ticker_sentiment_score": "0.115551", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson to Pay New York $230 Million to Settle Opioid Case (Published 2021)", "url": "https://www.nytimes.com/2021/06/26/nyregion/johnson-johnson-opioid-lawsuit-new-york.html", "time_published": "20210626T203640", "authors": ["Sarah Maslin Nir"], "summary": "Johnson & Johnson has agreed to pay New York State over $230 million in a settlement that also requires the company to exit the opioid business permanently in the United States. This settlement occurred just days before a major trial against several defendants, including J&J, was set to begin in New York, addressing the opioid epidemic's impact. The company stated the settlement is not an admission of liability or wrongdoing, maintaining its actions regarding prescription pain medications were appropriate.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.717288"}], "overall_sentiment_score": -0.424333, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.407847", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson to end sale of opioids, settles New York case for $230 million", "url": "https://abcnews.go.com/Health/johnson-johnson-end-sale-opioids-settles-york-case/story?id=78508483", "time_published": "20210626T144500", "authors": ["Aaron Katersky and Marlene Lenthang"], "summary": "Johnson & Johnson has agreed to pay $230 million to settle an opioid lawsuit with New York Attorney General Letitia James and will cease the sale of all opioid products nationwide. This settlement was reached days before the company was scheduled to go to trial, though the trial will proceed against other pharmaceutical companies. The funds will be allocated over nine years to address the opioid crisis in New York communities.", "banner_image": null, "source": "ABC News", "category_within_source": "General", "source_domain": "ABC News", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.701788"}], "overall_sentiment_score": 0.007141, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.344630", "ticker_sentiment_score": "0.027864", "ticker_sentiment_label": "Neutral"}]}, {"title": "Arrowhead Pharma hands Horizon rights to gene-silencing gout drug for $40M", "url": "https://medcitynews.com/2021/06/arrowhead-pharma-hands-horizon-rights-to-gene-silencing-gout-drug-for-40m/", "time_published": "20210621T115200", "authors": ["Frank Vinluan"], "summary": "Horizon Therapeutics has acquired global rights to Arrowhead Pharmaceuticals' preclinical gene-silencing drug, ARO-XDH, for gout, in a deal worth $40 million upfront. Arrowhead could receive up to $660 million in additional milestone payments and royalties. This agreement marks the latest in a series of RNA interference drug licensing deals for Arrowhead.", "banner_image": null, "source": "MedCity News", "category_within_source": "General", "source_domain": "MedCity News", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.940951"}], "overall_sentiment_score": 0.442424, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ARWR", "relevance_score": "1.000000", "ticker_sentiment_score": "0.836878", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.600905", "ticker_sentiment_score": "0.214280", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.644721", "ticker_sentiment_score": "0.245401", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Will Intuitive Surgical Be a Trillion-Dollar Stock by 2031?", "url": "https://www.fool.com/investing/2021/06/21/will-intuitive-surgical-be-worth-1-trillion/", "time_published": "20210621T060000", "authors": ["Adria Cimino"], "summary": "This article analyzes whether Intuitive Surgical (ISRG) can achieve a trillion-dollar market capitalization by 2031. It compares Intuitive's current market cap and growth trajectory to trillion-dollar tech companies, noting its dominance in robotic surgery market but also potential challenges from rivals and revenue growth limitations. Although reaching $1 trillion is deemed unlikely, the author remains optimistic about Intuitive Surgical as a strong long-term investment for healthcare portfolios.", "banner_image": null, "source": "The Motley Fool", "category_within_source": "General", "source_domain": "The Motley Fool", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.930716"}, {"topic": "technology", "relevance_score": "0.817497"}], "overall_sentiment_score": 0.28833, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.223327", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.717297", "ticker_sentiment_score": "0.346669", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.649527", "ticker_sentiment_score": "0.314561", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.567697", "ticker_sentiment_score": "0.204973", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.580854", "ticker_sentiment_score": "0.247604", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "How fund managers are bracing for inflation", "url": "https://www.morningstar.com.au/funds/how-fund-managers-are-bracing-for-inflation", "time_published": "20210618T200710", "authors": ["Sunniva Kolostyak"], "summary": "This article explores how fund managers are adjusting their portfolios in response to rising inflation, which has surpassed central bank targets in both the UK and US. Fund managers are implementing strategies such as diversification, investing in cyclical stocks and commodities, seeking companies with strong pricing power, and utilizing real assets to protect investments against inflationary pressures. While some managers are making significant changes, others are maintaining their low-risk equity positions, acknowledging inflation as a risk but not necessarily requiring drastic portfolio overhauls.", "banner_image": null, "source": "Morningstar", "category_within_source": "General", "source_domain": "Morningstar", "topics": [{"topic": "economy_monetary", "relevance_score": "0.902234"}, {"topic": "financial_markets", "relevance_score": "0.810940"}, {"topic": "economy_macro", "relevance_score": "0.747666"}], "overall_sentiment_score": 0.019124, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EBAY", "relevance_score": "0.718168", "ticker_sentiment_score": "0.031284", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOGL", "relevance_score": "0.635012", "ticker_sentiment_score": "0.043146", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.623076", "ticker_sentiment_score": "0.007576", "ticker_sentiment_label": "Neutral"}]}, {"title": "Driving change to defeat diabetes and other serious chronic diseases", "url": "https://www.nature.com/articles/d42473-021-00267-4", "time_published": "20210617T205621", "authors": ["Bernt Johan von Scholten", "Frederik Flindt Kreiner", "Stephen Charles Langford Gough", "Peter Kurtzhals"], "summary": "Novo Nordisk, a leading healthcare company, is dedicated to addressing unmet medical needs in diabetes, obesity, and other serious chronic diseases, building on its rich history since the discovery of insulin. The article highlights Novo Nordisk's advancements in insulin therapies, GLP-1 analogues for diabetes and obesity, and treatments for rare disorders like haemophilia and growth hormone deficiency. The company emphasizes its commitment to sustainable business practices, global partnerships, and continued innovation in prevention and regenerative interventions.", "banner_image": null, "source": "Nature", "category_within_source": "General", "source_domain": "Nature", "topics": [{"topic": "life_sciences", "relevance_score": "0.920999"}], "overall_sentiment_score": 0.445922, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.851314", "ticker_sentiment_label": "Bullish"}, {"ticker": "LLY", "relevance_score": "0.717938", "ticker_sentiment_score": "0.405934", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.619553", "ticker_sentiment_score": "0.342610", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.621111", "ticker_sentiment_score": "0.309520", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.647662", "ticker_sentiment_score": "0.317506", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "First patient receives controversial Biogen Alzheimer\u2019s drug", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/first-patient-set-receive-controversial-biogen-alzheimers-drug-2021-06-16/", "time_published": "20210617T163400", "authors": ["Deena Beasley"], "summary": "The first patient outside of clinical trials received Biogen's controversial Alzheimer's drug, Aduhelm, in the U.S. The drug, approved despite expert panel objections, is expensive at $56,000 a year, raising concerns about insurance coverage and patient access, especially since its efficacy beyond reducing brain plaques is still debated.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.936550"}, {"topic": "finance", "relevance_score": "0.739373"}, {"topic": "economy_fiscal", "relevance_score": "0.639281"}], "overall_sentiment_score": 0.046168, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.225284", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CI", "relevance_score": "0.713691", "ticker_sentiment_score": "0.129021", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.607792", "ticker_sentiment_score": "0.122823", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.605227", "ticker_sentiment_score": "0.145626", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.628004", "ticker_sentiment_score": "0.148765", "ticker_sentiment_label": "Neutral"}]}, {"title": "CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/curevacs-covid-19-vaccine-misses-efficacy-goal-mass-trial-2021-06-16/", "time_published": "20210617T120500", "authors": ["Ludwig Burger"], "summary": "CureVac's COVID-19 vaccine achieved only 47% efficacy in a late-stage trial, missing its main goal and casting doubt on its agreements to supply hundreds of millions of doses to the European Union and Germany. The disappointing results, influenced by a broad diversity of virus variants, caused CureVac's U.S. traded shares to fall 50.6%. The company hopes for a better outcome with further analysis and plans a second-generation vaccine for late 2022.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.936179"}, {"topic": "earnings", "relevance_score": "0.635849"}], "overall_sentiment_score": -0.096391, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVAC", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.745151", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.636494", "ticker_sentiment_score": "-0.332880", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.707156", "ticker_sentiment_score": "0.426120", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.711418", "ticker_sentiment_score": "0.445924", "ticker_sentiment_label": "Bullish"}]}, {"title": "LENZ Therapeutics gets fresh set of eyes with $47M funding to bring eyedrop to market", "url": "https://www.fiercebiotech.com/biotech/lenz-therapeutics-gets-fresh-set-eyes-47m-series-a-to-bring-nda-into-view", "time_published": "20210617T103400", "authors": ["Kyle LaHucik"], "summary": "LENZ Therapeutics, formerly Presbyopia Therapies, has secured $47 million in funding to advance its aceclidine eyedrop for improving near vision towards FDA submission. The company also announced a new CEO, Eef Schimmelpennink, and gained investments from Versant Ventures and RA Capital Management. This financing aims to bring their late-stage candidate to market for presbyopia, a condition affecting nearly 2 billion people worldwide.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "0.933741"}, {"topic": "finance", "relevance_score": "0.715531"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.635753"}], "overall_sentiment_score": 0.282664, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LENZ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.400387", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.739433", "ticker_sentiment_score": "0.122143", "ticker_sentiment_label": "Neutral"}]}, {"title": "U.S. authorizes another 14 mln doses of Johnson & Johnson's COVID-19 vaccine -sources", "url": "https://www.reuters.com/world/us/us-authorizes-additional-batch-johnson-johnsons-covid-19-vaccine-2021-06-15/", "time_published": "20210616T001000", "authors": ["Michael Erman"], "summary": "The U.S. FDA authorized approximately 14 million more doses of Johnson & Johnson's COVID-19 vaccine produced at a troubled Baltimore factory. These doses are expected to be exported, as U.S. authorities had previously halted production due to contamination issues and poor manufacturing practices at the Emergent BioSolutions plant. The FDA has not yet authorized the plant to resume making new J&J vaccines, and millions of other previously manufactured doses have been discarded.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.910692"}], "overall_sentiment_score": -0.090116, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.079902", "ticker_sentiment_label": "Neutral"}]}, {"title": "Troubled J&J vaccine manufacturer Emergent promises to fix plant", "url": "https://www.aljazeera.com/economy/2021/6/14/troubled-jj-vaccine-manufacturer-emergent-promises-to-fix-plant", "time_published": "20210614T140000", "authors": ["Riley Griffin and Anna Edney and Bloomberg"], "summary": "Emergent BioSolutions Inc. has promised the FDA a series of fixes after an inspection led to a production halt at its facility manufacturing Johnson & Johnson's COVID-19 vaccine. The contract manufacturer detailed steps to address issues like biowaste handling, gowning protocols, and training, following citations for problems that included accidental cross-contamination with the AstraZeneca vaccine. These efforts aim to overcome manufacturing issues that have significantly curtailed the availability of J&J vaccine doses in the US.", "banner_image": null, "source": "Al Jazeera", "category_within_source": "General", "source_domain": "Al Jazeera", "topics": [{"topic": "life_sciences", "relevance_score": "0.942404"}, {"topic": "manufacturing", "relevance_score": "0.813337"}, {"topic": "finance", "relevance_score": "0.600452"}], "overall_sentiment_score": -0.143238, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EBS", "relevance_score": "0.314813", "ticker_sentiment_score": "0.004615", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.886481", "ticker_sentiment_score": "-0.246617", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Drug distributor McKesson docked CEO\u2019s pay over the opioid crisis. He still made $15 million.", "url": "https://www.washingtonpost.com/business/2021/06/11/mckesson-opioid-ceo-pay/", "time_published": "20210611T204620", "authors": ["Douglas MacMillan", "Kevin Schaul"], "summary": "McKesson's board reduced CEO Brian Tyler's pay by $2.9 million due to a tentative $8.1 billion opioid settlement, although he still received nearly $15 million in total compensation. This decision, a rare move among drug giants, came after activist investors demanded accountability for legal settlements related to the opioid crisis. Other companies like Cardinal Health, AmerisourceBergen, and Johnson & Johnson excluded settlement costs from their CEO compensation calculations, leading to shareholder backlash.", "banner_image": null, "source": "The Washington Post", "category_within_source": "General", "source_domain": "The Washington Post", "topics": [{"topic": "earnings", "relevance_score": "0.827902"}, {"topic": "finance", "relevance_score": "0.731039"}, {"topic": "life_sciences", "relevance_score": "0.944680"}, {"topic": "economy_macro", "relevance_score": "0.607871"}], "overall_sentiment_score": -0.238056, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MCK", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.269678", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CAH", "relevance_score": "0.815612", "ticker_sentiment_score": "-0.204389", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.703946", "ticker_sentiment_score": "-0.200441", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COR", "relevance_score": "0.734685", "ticker_sentiment_score": "-0.218944", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "FDA tells Johnson & Johnson to toss 60 million Covid vaccine doses", "url": "https://www.nbcnews.com/health/health-news/fda-tells-johnson-johnson-toss-60-million-covid-vaccine-doses-n1270521", "time_published": "20210611T143600", "authors": ["Laura Strickler", "Heidi Przybyla"], "summary": "The FDA has instructed Johnson & Johnson to discard approximately 60 million doses of its Covid-19 vaccine produced at a problematic Baltimore plant, deeming them \"not suitable for use\" due to contamination issues. However, the agency will allow the distribution of 10 million doses from the same facility, some of which may be exported to other countries. This decision follows an extensive review of the plant's production history and a recent extension of the vaccine's shelf life.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.910277"}, {"topic": "manufacturing", "relevance_score": "0.703691"}], "overall_sentiment_score": -0.430771, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.446807", "ticker_sentiment_label": "Bearish"}]}, {"title": "The F.D.A. tells Johnson & Johnson that about 60 million doses made at a troubled plant cannot be used.", "url": "https://www.nytimes.com/2021/06/11/us/politics/johnson-covid-vaccine-emergent.html", "time_published": "20210611T000000", "authors": ["Sharon LaFraniere", "Noah Weiland", "Sheryl Gay Stolberg"], "summary": "The FDA has told Johnson & Johnson that approximately 60 million doses of its coronavirus vaccine, produced at a troubled Baltimore factory operated by Emergent BioSolutions, cannot be used due to potential contamination. This decision follows a major production mishap where Johnson & Johnson's vaccine was contaminated with AstraZeneca's ingredients. While 10 million doses may still be distributed with a warning about manufacturing practices, the recall impacts the Biden administration's plan to donate vaccines internationally, though Pfizer-BioNTech has now agreed to supply 500 million doses for global donation.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.942906"}, {"topic": "manufacturing", "relevance_score": "0.730447"}], "overall_sentiment_score": -0.300691, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.329375", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "FDA extends shelf life of Johnson & Johnson COVID-19 vaccine", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/fda-extends-shelf-life-johnson-johnson-covid-19-vaccine-2021-06-10/", "time_published": "20210610T153800", "authors": ["Reuters"], "summary": "The U.S. FDA has extended the shelf life of Johnson & Johnson's single-shot COVID-19 vaccine from three months to four-and-a-half months due to millions of unused doses nearing expiration and safety concerns impacting demand. This decision was based on data showing the vaccine's stability at refrigerated temperatures for the extended period. A White House official urged state governors to work with the FDA on this extension amidst uncertainty over existing dose expiration.", "banner_image": "https://www.reuters.com/resizer/v2/T3B46T7FDBPNZATX7R45KNY2KM.JPG?auth=d2de1c89f58352613ed8da388de9453982f143715c0e15919010ab285090fbe2&width=1200&height=628&q=80&unsharp=1.5,0.75,2,0&crop=0,0,3500,1839&quality=80", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.930963"}, {"topic": "finance", "relevance_score": "0.621212"}], "overall_sentiment_score": 0.288359, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.958774", "ticker_sentiment_score": "0.292791", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Usual three Jacksonville firms in Fortune 500", "url": "https://www.jaxdailyrecord.com/news/2021/jun/10/usual-three-jacksonville-firms-in-fortune-500/", "time_published": "20210610T051000", "authors": ["Mark Basch"], "summary": "The 2021 Fortune 500 list includes three Jacksonville-based companies: CSX Corp., Fidelity National Financial Inc., and FIS. Two other large Jacksonville companies, Southeastern Grocers Inc. and GuideWell Mutual Holding Corp., did not qualify for the list because they are not public, despite having revenues that would place them within the Fortune 500. The article also discusses other Jacksonville businesses, including Landstar System Inc. moving up in the Fortune 1000 and local acquisitions.", "banner_image": null, "source": "Jacksonville Daily Record", "category_within_source": "General", "source_domain": "Jacksonville Daily Record", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.944201"}, {"topic": "earnings", "relevance_score": "0.814754"}, {"topic": "ipo", "relevance_score": "0.716761"}, {"topic": "finance", "relevance_score": "0.619764"}], "overall_sentiment_score": 0.215484, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FIS", "relevance_score": "1.000000", "ticker_sentiment_score": "0.439124", "ticker_sentiment_label": "Bullish"}, {"ticker": "CSX", "relevance_score": "0.841143", "ticker_sentiment_score": "-0.220575", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.609055", "ticker_sentiment_score": "0.369259", "ticker_sentiment_label": "Bullish"}, {"ticker": "PNC", "relevance_score": "0.631746", "ticker_sentiment_score": "0.293644", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Releases 2020 Health for Humanity Report Highlighting Performance and Progress on Environmental, Social and Governance Priorities", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-releases-2020-health-for-humanity-report-highlighting-performance-and-progress-on-environmental-social-and-governance-priorities-301308995.html", "time_published": "20210609T083000", "authors": ["NULL"], "summary": "Johnson & Johnson (NYSE: JNJ) has released its 2020 Health for Humanity Report, detailing its performance and progress on environmental, social, and governance (ESG) priorities. The report highlights COVID-19 response efforts, initiatives for better health access, and responsible business practices, including new Health for Humanity 2025 Goals. The company also announced an upcoming ESG Investor Update Webcast on June 23, 2021.", "banner_image": "NULL", "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.900857"}, {"topic": "earnings", "relevance_score": "0.836027"}, {"topic": "economy_macro", "relevance_score": "0.618703"}], "overall_sentiment_score": 0.442865, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.430297", "ticker_sentiment_label": "Bullish"}]}, {"title": "With new CEO, Veracyte outlines \u20ac260M deal for French test maker HalioDx and global cancer testing expansion", "url": "https://www.fiercebiotech.com/medtech/new-ceo-veracyte-outlines-eu260m-deal-for-french-test-maker-haliodx-and-global-cancer", "time_published": "20210602T095500", "authors": ["Conor Hale"], "summary": "Veracyte announced a \u20ac260 million deal to acquire French test maker HalioDx, aiming to expand its global footprint in cancer diagnostics and enter immuno-oncology testing and in vitro diagnostic kit manufacturing. This acquisition, Veracyte's second this year, also broadens its testing menu to include HalioDx's colon cancer immune response test and Immunoscore platform. The deal coincides with the first day of Veracyte's new CEO, Marc Stapley, and follows its $600 million acquisition of Decipher Biosciences for urological cancers.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.907132"}, {"topic": "finance", "relevance_score": "0.734284"}], "overall_sentiment_score": 0.197021, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VCYT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.408768", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.635065", "ticker_sentiment_score": "0.125532", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.612545", "ticker_sentiment_score": "0.139163", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.607580", "ticker_sentiment_score": "0.138263", "ticker_sentiment_label": "Neutral"}]}, {"title": "U.S. Supreme Court rebuffs J&J appeal over $2 billion baby powder judgment", "url": "https://www.reuters.com/legal/government/us-supreme-court-declines-hear-jj-appeal-over-2-billion-baby-powder-judgment-2021-06-01/", "time_published": "20210601T221700", "authors": ["Lawrence Hurley"], "summary": "The U.S. Supreme Court declined to hear Johnson & Johnson's appeal to overturn a $2.12 billion damages award to women who claimed their ovarian cancer was caused by asbestos in the company's baby powder. This decision upholds a Missouri state court ruling, which had reduced the initial jury award. J&J maintains its product is safe and non-carcinogenic and plans to continue litigating the outstanding legal issues.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.939686"}, {"topic": "finance", "relevance_score": "0.736532"}], "overall_sentiment_score": -0.438148, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.425627", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson asks Supreme Court to void $2B talc verdict", "url": "https://www.nbcnews.com/politics/supreme-court/johnson-johnson-asks-supreme-court-void-2b-talc-verdict-n1269144", "time_published": "20210531T095200", "authors": ["The Associated Press"], "summary": "Johnson & Johnson is seeking a Supreme Court review to overturn a $2 billion verdict in favor of women who claim their ovarian cancer was caused by the company's talc products. The company argues it did not receive a fair trial and disputes the link between its talc and cancer, while plaintiffs and lower courts found evidence of reprehensible conduct. The Supreme Court could decide as early as Tuesday whether to take up the case.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.946628"}, {"topic": "finance", "relevance_score": "0.741941"}], "overall_sentiment_score": -0.340322, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.347807", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "US DOJ probes Eli Lilly\u2019s Branchburg manufacturing site", "url": "https://www.pharmaceutical-technology.com/news/us-lilly-branchburg-site/", "time_published": "20210528T204157", "authors": [], "summary": "The US Department of Justice (DOJ) has launched a criminal investigation into Eli Lilly's manufacturing facility in Branchburg, New Jersey, following a subpoena seeking documents related to alleged manufacturing and records violations. Eli Lilly is cooperating with the probe and had previously initiated an independent inquiry into allegations concerning the plant, which produces Covid-19 antibody drugs, among others. The company has been under scrutiny from the US Food and Drug Administration (FDA) for alleged issues at the site for nearly a year.", "banner_image": null, "source": "Pharmaceutical Technology", "category_within_source": "General", "source_domain": "Pharmaceutical Technology", "topics": [{"topic": "life_sciences", "relevance_score": "0.947226"}, {"topic": "manufacturing", "relevance_score": "0.843894"}], "overall_sentiment_score": -0.30758, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.440261", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.708329", "ticker_sentiment_score": "-0.230034", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "The Future of Virtual Healthcare", "url": "https://newsroom.cardinalhealth.com/2021-05-27-The-Future-of-Virtual-Healthcare", "time_published": "20210527T195220", "authors": ["Suzanne Foster"], "summary": "The article discusses the accelerated shift to virtual healthcare, particularly since the COVID-19 pandemic, highlighting how it has overcome previous limitations in hospital push-out, reimbursement, and acceptance. It details how virtual care can address health disparities and provide hospital-level care at home through technological advancements and strategic partnerships, such as Cardinal Health's collaboration with Medically Home. The author argues that virtual healthcare is here to stay and will become an integral part of good healthcare.", "banner_image": null, "source": "Cardinal Health", "category_within_source": "General", "source_domain": "Cardinal Health", "topics": [{"topic": "life_sciences", "relevance_score": "0.913807"}, {"topic": "technology", "relevance_score": "0.748922"}], "overall_sentiment_score": 0.348732, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.480200", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.699530", "ticker_sentiment_score": "0.311916", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.635402", "ticker_sentiment_score": "0.258808", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clayton-based managed health care provider Centene hires former J&J exec as new chief marketing officer", "url": "https://www.bizjournals.com/stlouis/news/2021/05/26/centene-hires-new-chief-marketing-officer.html", "time_published": "20210527T140300", "authors": ["Diana Barr"], "summary": "Centene, a Clayton-based managed health care provider, has hired Suzy DePrizio, a former Johnson & Johnson executive, as its new chief marketing officer. DePrizio will be responsible for leading the company's marketing strategy, brand position, and advertising efforts. This appointment comes amidst other recent C-suite changes and ongoing developments for the company.", "banner_image": null, "source": "The Business Journals", "category_within_source": "General", "source_domain": "The Business Journals", "topics": [{"topic": "life_sciences", "relevance_score": "0.936331"}], "overall_sentiment_score": 0.150862, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CNC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.242438", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.608822", "ticker_sentiment_score": "0.107847", "ticker_sentiment_label": "Neutral"}]}, {"title": "Inovio\u2019s Electrical Device Zaps a COVID-19 Vaccine Into the Body", "url": "https://spectrum.ieee.org/inovios-electrical-device-zaps-a-covid19-vaccine-into-the-body", "time_published": "20210526T203150", "authors": ["Emily Waltz"], "summary": "Inovio Pharmaceuticals is developing a DNA-based COVID-19 vaccine delivered using an electrical electroporation device, which may overcome the cold-chain storage and significant side effect issues of current mRNA vaccines. Although the device adds logistical complexity and has drawn skepticism, its ability to deliver a stable, room-temperature vaccine without strong side effects holds significant promise for global distribution, especially in remote regions or for military applications. The company is currently completing Phase 2 trials and addressing FDA questions regarding its Cellectra 3PSP device.", "banner_image": null, "source": "IEEE Spectrum", "category_within_source": "General", "source_domain": "IEEE Spectrum", "topics": [{"topic": "life_sciences", "relevance_score": "0.928636"}, {"topic": "technology", "relevance_score": "0.842502"}], "overall_sentiment_score": 0.091688, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.002694", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.705021", "ticker_sentiment_score": "0.101768", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.629438", "ticker_sentiment_score": "0.146296", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.565396", "ticker_sentiment_score": "0.059394", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rybrevant approved for some non-small cell lung cancer patients", "url": "https://medicalxpress.com/news/2021-05-rybrevant-non-small-cell-lung-cancer.html", "time_published": "20210526T202146", "authors": [], "summary": "The U.S. Food and Drug Administration has approved Rybrevant (amivantamab-vmjw) for adults with non-small cell lung cancer featuring epidermal growth factor receptor (EGFR) exon 20 insertion mutations. This approval, based on efficacy data from the Phase 1 CHRYSALIS study, also includes the Guardant360 CDx liquid biopsy test as a companion diagnostic. Patients in the study showed a 40 percent response rate, with common side effects including rash and infusion-related reactions.", "banner_image": null, "source": "Medical Xpress", "category_within_source": "General", "source_domain": "Medical Xpress", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.595369, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.627725", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.817273", "ticker_sentiment_score": "0.518579", "ticker_sentiment_label": "Bullish"}]}, {"title": "Moderna Vaccine Highly Effective in Adolescents, Company Says (Published 2021)", "url": "https://www.nytimes.com/2021/05/25/health/coronavirus-moderna-vaccine-adolescents.html", "time_published": "20210525T204728", "authors": ["Emily Anthes"], "summary": "Moderna announced that its coronavirus vaccine is highly effective in 12- to 17-year-olds, with no symptomatic Covid-19 cases among fully vaccinated teens in a clinical trial. The company plans to seek FDA authorization in June, potentially making it the second vaccine available for U.S. adolescents. This development adds to evidence of vaccine safety and effectiveness in younger populations, potentially aiding societal reopening.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.938551"}], "overall_sentiment_score": 0.331224, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.481815", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.739340", "ticker_sentiment_score": "0.340652", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.582706", "ticker_sentiment_score": "0.106316", "ticker_sentiment_label": "Neutral"}]}, {"title": "JNJ's Stelara Fails to Beat AbbVie's Humira In Crohn's Disease Patients", "url": "https://finance.yahoo.com/news/jnjs-stelara-fails-beat-abbvies-121603134.html", "time_published": "20210524T121603", "authors": ["Vandana Singh"], "summary": "A head-to-head study (SEAVUE) revealed that Johnson & Johnson's Stelara did not achieve statistical superiority over AbbVie's Humira in treating Crohn's disease patients. While Stelara showed numerically higher rates in several efficacy measures, the differences were not statistically significant at the 52-week mark. Stelara did demonstrate a better safety profile, with fewer patients discontinuing treatment due to side effects compared to Humira.", "banner_image": null, "source": "Yahoo Finance", "category_within_source": "General", "source_domain": "Yahoo Finance", "topics": [{"topic": "life_sciences", "relevance_score": "0.936064"}], "overall_sentiment_score": 0.078213, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "1.000000", "ticker_sentiment_score": "0.416668", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.335298", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "May 24 Quick Takes: Neurology play Eliem raises $60M series B; plus Xeris-Strongbridge, CARsgen, Janssen, Abivax and Takeda", "url": "https://www.biocentury.com/article/636640/may-24-quick-takes-neurology-play-eliem-raises-60m-series-b-plus-xeris-strongbridge-carsgen-janssen-abivax-and-takeda", "time_published": "20210524T113200", "authors": ["BioCentury Staff"], "summary": "Eliem Therapeutics Inc. closed a $60 million Series B round to advance its pipeline in neurological disorders, aiming for clinical data on ETX-810 and ETX-155. Strongbridge Biopharma plc was acquired by Xeris Pharmaceuticals Inc. for approximately $267 million in stock and contingent value rights, focusing on endocrinology and rare diseases. Other companies, including CARsgen, Janssen, Abivax, and Takeda, are also noted in these quick takes on recent financial and corporate developments in the biotech sector.", "banner_image": "NULL", "source": "BioCentury", "category_within_source": "General", "source_domain": "BioCentury", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.912843"}, {"topic": "finance", "relevance_score": "0.813211"}], "overall_sentiment_score": 0.023132, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CLYM", "relevance_score": "0.322251", "ticker_sentiment_score": "0.017766", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.647513", "ticker_sentiment_score": "0.030264", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gavi signs agreement with Johnson & Johnson for supply of its COVID-19 vaccine to COVAX", "url": "https://www.gavi.org/news/media-room/gavi-signs-agreement-johnson-johnson-supply-its-covid-19-vaccine-covax", "time_published": "20210521T203638", "authors": [], "summary": "Gavi, the Vaccine Alliance, announced an agreement with Johnson & Johnson for the supply of 200 million doses of its single-dose COVID-19 vaccine to the COVAX Facility in 2021. This supply is intended for both self-financing and Gavi COVAX AMC-eligible participants, with potential for an additional 300 million doses in 2022. The Johnson & Johnson vaccine is highlighted for its single-dose nature, making it particularly suitable for regions with challenging infrastructure.", "banner_image": null, "source": "Gavi, the Vaccine Alliance", "category_within_source": "General", "source_domain": "Gavi, the Vaccine Alliance", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.727341"}], "overall_sentiment_score": 0.475946, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.473479", "ticker_sentiment_label": "Bullish"}]}, {"title": "Judge won't enjoin Alcon product sales in J&J code theft case", "url": "https://www.reuters.com/legal/government/judge-wont-enjoin-alcon-product-sales-jj-code-theft-case-2021-05-27/", "time_published": "20210517T224100", "authors": ["Brendan Pierson"], "summary": "A federal judge denied Johnson & Johnson subsidiary AMO Development LLC's request to block Alcon from selling cataract surgery products, despite J&J's claims of copyright infringement involving stolen computer code. The judge ruled that any harm could be remedied by money damages, allowing Alcon to continue selling its LenSx Laser Systems. J&J alleges that Alcon copied over 26,000 lines of its computer code for use in its LenSx system, calling it \"theft and deception on a grand and shocking scale.\"", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FLLU4P5Z4CVPBBAE4O2CSTK43LI.JPG?auth=d784a96b4ef84c3ea8909ea39151525a743c33d7b420f188354c01ca756999a0&width=800&quality=85&smart=true", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.939442"}, {"topic": "technology", "relevance_score": "0.845186"}], "overall_sentiment_score": -0.048928, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.304997", "ticker_sentiment_score": "0.012173", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.205703", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ALGN", "relevance_score": "0.647286", "ticker_sentiment_score": "0.146152", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson vaccine linked to 28 cases of blood clots, CDC reports", "url": "https://www.nbcnews.com/health/health-news/johnson-johnson-vaccine-linked-28-cases-blood-clots-cdc-reports-n1267128", "time_published": "20210512T170500", "authors": ["Sara G. Miller and Reuters"], "summary": "The CDC reported 28 cases of blood clots linked to the Johnson & Johnson Covid-19 vaccine among over 8.7 million people vaccinated. Most cases were thrombosis with thrombocytopenia syndrome (TTS) and occurred in women aged 18 to 49, with three fatalities. The CDC and FDA previously paused and then lifted the vaccine's use, advising against heparin for TTS treatment.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.922945"}], "overall_sentiment_score": 0.015853, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.605466", "ticker_sentiment_label": "Bearish"}, {"ticker": "MRNA", "relevance_score": "0.640187", "ticker_sentiment_score": "0.307495", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.643793", "ticker_sentiment_score": "0.336772", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Questions about the Johnson & Johnson COVID-19 vaccines? UF Health experts have answers", "url": "https://ufhealth.org/news/2021/questions-about-johnson-johnson-covid-19-vaccines-uf-health-experts-have-answers", "time_published": "20210511T203638", "authors": ["Doug Bennett"], "summary": "UF Health experts, including critical care chief epidemiology officer Dr. Nicole M. Iovine and hematology and oncology professor Dr. Marc S. Zumberg, answer common questions regarding the Johnson & Johnson COVID-19 vaccine, particularly concerning rare blood clot issues. They discuss the context of side effects, symptoms requiring medical attention, the nature of the blood clots, and hypotheses about their cause. Emphasizing that the benefits of vaccination outweigh the risks, especially for those not in the high-risk group for clots, they advise vigilance for specific symptoms post-vaccination.", "banner_image": null, "source": "UF Health - University of Florida Health", "category_within_source": "General", "source_domain": "UF Health - University of Florida Health", "topics": [{"topic": "life_sciences", "relevance_score": "0.941511"}], "overall_sentiment_score": -0.101056, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.118379", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cardinal Health Invests In An Advanced Visibility Solution", "url": "https://www.forbes.com/sites/stevebanker/2021/05/07/cardinal-health-invests-in-an-advanced-visibility-solution/", "time_published": "20210507T140200", "authors": ["Steve Banker"], "summary": "Cardinal Health invested in FourKites' advanced visibility solution to enhance tracking of PPE shipments during the Covid-19 pandemic and build a next-generation control tower. This initiative aims to improve real-time visibility across all transportation modes for its pharmaceutical and medical segments, leading to greater supply chain efficiency, better customer service, and more predictable deliveries. The company is leveraging this data for predictive analytics and is working towards a \"cognitive self-healing network.\"", "banner_image": null, "source": "Forbes", "category_within_source": "General", "source_domain": "Forbes", "topics": [{"topic": "life_sciences", "relevance_score": "0.902809"}, {"topic": "retail_wholesale", "relevance_score": "0.815854"}, {"topic": "technology", "relevance_score": "0.704141"}, {"topic": "manufacturing", "relevance_score": "0.603782"}, {"topic": "energy_transportation", "relevance_score": "0.619693"}], "overall_sentiment_score": 0.228208, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.440028", "ticker_sentiment_label": "Bullish"}, {"ticker": "CVS", "relevance_score": "0.605269", "ticker_sentiment_score": "0.203609", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.622188", "ticker_sentiment_score": "0.148473", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.591037", "ticker_sentiment_score": "0.147435", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna Dominates COVID-19 Vaccine Manufacturers, at Least for Now", "url": "https://www.morningstar.com/stocks/moderna-dominates-covid-19-vaccine-manufacturers-least-now", "time_published": "20210505T204729", "authors": ["Karen Andersen", "CFA"], "summary": "The COVID-19 vaccine market is dominated by mRNA firms like Moderna and BioNTech in the short term, despite emerging competitors and uncertainties about long-term dominance. The article explores the market's future, considering factors like vaccine efficacy duration, variant evolution, pricing, and the potential for annual vaccinations, especially for high-risk groups. It also touches upon Moderna's strong intellectual property and its future in the non-COVID-19 vaccine market.", "banner_image": null, "source": "Morningstar", "category_within_source": "General", "source_domain": "Morningstar", "topics": [{"topic": "life_sciences", "relevance_score": "0.934542"}], "overall_sentiment_score": 0.153525, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.348410", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.738192", "ticker_sentiment_score": "0.273607", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.638303", "ticker_sentiment_score": "-0.243895", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRK", "relevance_score": "0.555748", "ticker_sentiment_score": "0.148811", "ticker_sentiment_label": "Neutral"}]}, {"title": "Next Generation of Covid-19 Vaccines Could Be Pill or Spray - WSJ", "url": "https://www.wsj.com/health/healthcare/next-generation-of-covid-19-vaccines-could-be-pill-or-spray-11620034381?gaa_at=eafs&gaa_n=AWEtsqcGopIIhCxmq7R9ZpHyhK4C27Y_0aP3co10Bj2wajpS4CYJeeOy7mAT&gaa_ts=6907b5cc&gaa_sig=qWVdvafBhRR9TwxrcATN2IA06DEQZLDAe2JrsEQLrjoc-W_5F2_eU_Cc1LIEjVkGkrFT8PK-8XdqV2em04yhDg%3D%3D", "time_published": "20210503T193533", "authors": ["Peter Loftus and Gregory Zuckerman"], "summary": "The next generation of Covid-19 vaccines is being developed in forms such as pills or nasal sprays, aiming for easier storage and transport compared to current injectable vaccines. These new vaccines, developed by government labs and companies like Sanofi SA, Altimmune Inc., and Gritstone Oncology Inc., also seek to provide longer-lasting immunity and better protection against new viral variants, potentially preventing future pandemics. The article mentions that as more adults receive current vaccines, a variety of side effects are emerging.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.918686"}], "overall_sentiment_score": 0.161217, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.341197", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.616546", "ticker_sentiment_score": "0.117013", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.634261", "ticker_sentiment_score": "0.135372", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.622734", "ticker_sentiment_score": "0.125091", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.609286", "ticker_sentiment_score": "0.118469", "ticker_sentiment_label": "Neutral"}]}, {"title": "BioNTech Hits Record as Vaccine Success Spurs on Biotechs", "url": "https://www.bloomberg.com/news/articles/2021-05-03/biontech-soars-to-record-as-vaccine-success-spurs-on-biotechs", "time_published": "20210503T151800", "authors": ["Cristin Flanagan"], "summary": "BioNTech (BNTX) stock surged 10% to over $200 a share, setting a new record and continuing its rally from the previous week. This rise reflects renewed optimism in the biotech sector as economies reopen and vaccine efforts, including those from Pfizer and BioNTech, successfully administer millions of doses in the U.S.", "banner_image": null, "source": "Bloomberg.com", "category_within_source": "General", "source_domain": "Bloomberg.com", "topics": [{"topic": "earnings", "relevance_score": "0.937217"}, {"topic": "financial_markets", "relevance_score": "0.949763"}, {"topic": "economy_macro", "relevance_score": "0.638946"}, {"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.143215, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IBB", "relevance_score": "0.321175", "ticker_sentiment_score": "0.043466", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.817354", "ticker_sentiment_score": "0.434659", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.703278", "ticker_sentiment_score": "-0.241590", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.730735", "ticker_sentiment_score": "0.329639", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pfizer begins to export US-made COVID shots: Report", "url": "https://www.aljazeera.com/economy/2021/4/30/pfizer-begins-to-export-us-made-covid-shots-report", "time_published": "20210430T210208", "authors": ["Reuters"], "summary": "Pfizer has begun exporting US-made COVID-19 vaccine doses, with the first shipment sent to Mexico. This marks the first time the drugmaker has delivered abroad from US facilities since a Trump-era restriction on dose exports expired in March. The move comes as the US faces growing pressure to share surplus vaccines with other countries in need, using extra capacity in its US facilities while fulfilling its domestic commitment.", "banner_image": null, "source": "Al Jazeera", "category_within_source": "General", "source_domain": "Al Jazeera", "topics": [{"topic": "life_sciences", "relevance_score": "0.944690"}], "overall_sentiment_score": 0.173032, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.321912", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.601415", "ticker_sentiment_score": "0.274761", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.589397", "ticker_sentiment_score": "-0.108333", "ticker_sentiment_label": "Neutral"}]}, {"title": "Antibody cocktail shown to neutralise SARS-CoV-2 variants of concern", "url": "https://www.drugtargetreview.com/news/90144/antibody-cocktail-shown-to-neutralise-sars-cov-2-variants-of-concern/", "time_published": "20210428T203143", "authors": ["Victoria Rees (Drug Target Review)"], "summary": "A new antibody cocktail called IMM-BCP-01, developed by Immunome, Inc., has demonstrated the ability to neutralise several SARS-CoV-2 variants, including those from the UK, Brazil, South Africa, and California, in pre-clinical studies. This cocktail contains three monoclonal antibodies that bind to non-overlapping regions of the SARS-CoV-2 Spike protein with high affinity and exhibit combinatorial effects against multiple variants. The company plans to advance IMM-BCP-01 towards an Investigational New Drug (IND) filing, emphasizing the importance of antibodies targeting conserved epitopes to address mutational drift.", "banner_image": null, "source": "Drug Target Review", "category_within_source": "General", "source_domain": "Drug Target Review", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.254717, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IMNM", "relevance_score": "1.000000", "ticker_sentiment_score": "0.406671", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.592586", "ticker_sentiment_score": "0.215482", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.561756", "ticker_sentiment_score": "0.231866", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.589330", "ticker_sentiment_score": "0.207412", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.596184", "ticker_sentiment_score": "0.226396", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Capture Cloud Computing\u2019s Sunny Future with \u2018WCLD\u2019", "url": "https://www.etftrends.com/model-portfolio-channel/capture-cloud-computings-sunny-future-with-wcld/", "time_published": "20210427T213235", "authors": ["Evan Harp"], "summary": "The COVID-19 pandemic significantly boosted cloud computing, turning it into an essential technology, and the WisdomTree Cloud Computing Fund (WCLD) saw an 89% increase over the past 12 months. Despite a recent 3.2% drop year-to-date and questions about its performance post-pandemic, analysts remain optimistic about cloud computing's long-term growth due to its integration into workflow and future potential, with estimates suggesting a doubling of workloads on the cloud by 2023.", "banner_image": null, "source": "ETF Trends", "category_within_source": "General", "source_domain": "ETF Trends", "topics": [{"topic": "financial_markets", "relevance_score": "0.805397"}, {"topic": "technology", "relevance_score": "1.000000"}, {"topic": "economy_macro", "relevance_score": "0.617148"}, {"topic": "finance", "relevance_score": "0.706742"}], "overall_sentiment_score": 0.061702, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WCLD", "relevance_score": "1.000000", "ticker_sentiment_score": "0.250748", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.640159", "ticker_sentiment_score": "-0.201775", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Moderna expanding near Norwood manufacturing campus", "url": "https://www.bizjournals.com/boston/news/2021/04/27/moderna-expanding-near-norwood-manufacturing-campu.html", "time_published": "20210427T193611", "authors": ["Catherine Carlock"], "summary": "Moderna Inc. is expanding its manufacturing operations in Norwood, Massachusetts, by leasing a 236,566-square-foot office space that Alexandria Real Estate Equities acquired for $105 million. This expansion is part of Moderna's strategy to rapidly scale up production of its COVID-19 vaccine, with the new facility located near its existing manufacturing campus.", "banner_image": null, "source": "The Business Journals", "category_within_source": "General", "source_domain": "The Business Journals", "topics": [{"topic": "life_sciences", "relevance_score": "0.913278"}, {"topic": "real_estate", "relevance_score": "0.815203"}, {"topic": "manufacturing", "relevance_score": "0.749466"}], "overall_sentiment_score": 0.34792, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.319039", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.969269", "ticker_sentiment_score": "0.314895", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.618390", "ticker_sentiment_score": "0.348017", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.639269", "ticker_sentiment_score": "0.334508", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.641486", "ticker_sentiment_score": "0.341249", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What women should know about the Johnson & Johnson coronavirus vaccine", "url": "https://www.cnn.com/2021/04/27/health/women-johnson-johnson-vaccine-wellness", "time_published": "20210427T053200", "authors": ["Katia Hetter"], "summary": "The CDC and FDA lifted the pause on the Johnson & Johnson Covid-19 vaccine after a review of rare blood clotting cases, primarily affecting women younger than 50. Dr. Leana Wen discusses the specific risks of TTS (thrombosis with thrombocytopenia syndrome) associated with the J&J vaccine, differentiating it from common blood clots, and advises women under 50 to consider mRNA vaccines (Pfizer-BioNTech and Moderna) as first-line alternatives due to their lack of this rare risk. The article emphasizes informed decision-making based on individual circumstances, benefits, risks, and available alternatives.", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "life_sciences", "relevance_score": "0.924826"}], "overall_sentiment_score": -0.062139, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.298994", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.732564", "ticker_sentiment_score": "0.117362", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.747111", "ticker_sentiment_score": "0.148806", "ticker_sentiment_label": "Neutral"}]}, {"title": "Accelmed posts 5-fold return in NeuroPace IPO", "url": "https://www.globes.co.il/news/article.aspx?did=1001368776", "time_published": "20210426T122100", "authors": ["Gali Weinreb"], "summary": "Accelmed Partners, led by Dr. Uri Geiger, achieved a fivefold return on its $15 million investment in US epilepsy treatment company NeuroPace following its Nasdaq IPO. NeuroPace, valued at $500 million post-IPO, develops an electrical stimulation system for drug-resistant epilepsy, with Accelmed's investment representing a minority stake in a company poised for significant growth. The IPO raised $100 million, and Accelmed further capitalized by exercising an option for an additional $10 million investment at a lower price.", "banner_image": null, "source": "\u05d2\u05dc\u05d5\u05d1\u05e1", "category_within_source": "General", "source_domain": "\u05d2\u05dc\u05d5\u05d1\u05e1", "topics": [{"topic": "ipo", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.922371"}, {"topic": "finance", "relevance_score": "0.847360"}, {"topic": "financial_markets", "relevance_score": "0.725386"}, {"topic": "technology", "relevance_score": "0.634853"}], "overall_sentiment_score": 0.324252, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NPCE", "relevance_score": "0.953955", "ticker_sentiment_score": "0.603689", "ticker_sentiment_label": "Bullish"}, {"ticker": "JPM", "relevance_score": "0.644995", "ticker_sentiment_score": "0.215871", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.553849", "ticker_sentiment_score": "0.102972", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Lessons of the Johnson & Johnson Vaccine Saga", "url": "https://www.newyorker.com/news/daily-comment/the-lessons-of-the-johnson-and-johnson-vaccine-saga", "time_published": "20210425T203638", "authors": ["Amy Davidson Sorkin"], "summary": "The article discusses the FDA and CDC's decision to lift the pause on the Johnson & Johnson COVID-19 vaccine, emphasizing the importance of transparency in public health communication. It highlights the rare blood clot risk, particularly for women under fifty, and stresses the need to provide clear information while reaffirming the vaccine's overall benefits. The author argues that acknowledging and addressing such risks, rather than ignoring them, builds public trust in vaccines.", "banner_image": null, "source": "The New Yorker", "category_within_source": "General", "source_domain": "The New Yorker", "topics": [{"topic": "life_sciences", "relevance_score": "0.909883"}], "overall_sentiment_score": 0.161188, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.257852", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.618799", "ticker_sentiment_score": "0.123320", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.647406", "ticker_sentiment_score": "0.119781", "ticker_sentiment_label": "Neutral"}]}, {"title": "Blood Clots and the Johnson & Johnson Vaccine: What We Know So Far", "url": "https://www.scientificamerican.com/article/blood-clots-and-the-johnson-johnson-vaccine-what-we-know-so-far/", "time_published": "20210423T203639", "authors": ["Jim Daley"], "summary": "This article discusses the rare blood clot cases linked to the Johnson & Johnson COVID-19 vaccine, detailing the FDA and CDC's pause and eventual recommendation for resuming its use with a warning. Infectious disease expert Wilbur Chen explains the unique nature of these clots, their symptoms, potential causes, and the importance of transparency in public health communication.", "banner_image": null, "source": "Scientific American", "category_within_source": "General", "source_domain": "Scientific American", "topics": [{"topic": "life_sciences", "relevance_score": "0.936837"}], "overall_sentiment_score": -0.130038, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.119864", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Approves Loncastuximab Tesirine for Relapsed/Refractory Large B-Cell Lymphoma", "url": "https://www.onclive.com/view/fda-approves-loncastuximab-tesirine-for-relapsed-refractory-large-b-cell-lymphoma", "time_published": "20210423T192629", "authors": ["Gina Mauro"], "summary": "The FDA has granted accelerated approval to loncastuximab tesirine (Zynlonta) for adults with relapsed/refractory large B-cell lymphoma after two or more lines of systemic therapy. This approval is based on the LOTIS-2 study, where the drug achieved a 48.3% objective response rate, including a 24.1% complete response rate, demonstrating significant clinical outcomes across various disease subtypes. Loncastuximab tesirine is also being investigated in combination with other treatments for similar lymphoma types.", "banner_image": null, "source": "OncLive", "category_within_source": "General", "source_domain": "OncLive", "topics": [{"topic": "life_sciences", "relevance_score": "0.946114"}], "overall_sentiment_score": 0.309143, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ADCT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.869929", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.717335", "ticker_sentiment_score": "0.111758", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.608267", "ticker_sentiment_score": "0.103771", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.627405", "ticker_sentiment_score": "0.116679", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson vaccine pause may have had important benefit", "url": "https://abcnews.go.com/Health/johnson-johnson-vaccine-pause-important-benefit/story?id=77274891", "time_published": "20210423T191700", "authors": ["Dr. Karine Tawagi"], "summary": "A nearly two-week pause on the Johnson & Johnson vaccine has ended, with an added warning about an extremely rare blood clot condition called thrombosis with thrombocytopenia syndrome (TTS). This pause allowed doctors to become aware of this complication and learn how to treat it properly, including avoiding heparin as a treatment. The added warning aims to empower both patients and healthcare workers, emphasizing that the risks of COVID-19 infection far outweigh the vaccine's rare risks.", "banner_image": null, "source": "ABC News", "category_within_source": "General", "source_domain": "ABC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.933913"}], "overall_sentiment_score": 0.104677, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.144288", "ticker_sentiment_label": "Neutral"}]}, {"title": "WATCH: U.S. health panel urges restart of vaccinations with Johnson & Johnson shot", "url": "https://www.pbs.org/newshour/health/watch-live-cdc-advisory-committee-to-vote-on-pause-for-johnson-johnson-vaccine", "time_published": "20210423T104000", "authors": ["Lauran Neergaard", "Mike Stobbe"], "summary": "A U.S. health panel has recommended restarting vaccinations with Johnson & Johnson's single-dose COVID-19 shot, concluding its benefits outweigh the rare risk of blood clots. The recommendation comes after 15 cases of unusual blood clots, resulting in three deaths, were identified among nearly 8 million recipients, primarily women under 50. The panel stressed the importance of informing younger women about the risk to allow them to choose an alternative vaccine.", "banner_image": null, "source": "PBS", "category_within_source": "General", "source_domain": "PBS", "topics": [{"topic": "life_sciences", "relevance_score": "0.901575"}, {"topic": "finance", "relevance_score": "0.627860"}], "overall_sentiment_score": 0.009651, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.347866", "ticker_sentiment_score": "0.022221", "ticker_sentiment_label": "Neutral"}]}, {"title": "WHO sets dates for reviews of Sinopharm and Sinovac COVID-19 vaccines", "url": "https://www.reuters.com/world/china/who-sets-dates-reviews-sinopharm-sinovac-covid-19-vaccines-2021-04-22/", "time_published": "20210422T113500", "authors": ["Reuters"], "summary": "The World Health Organization (WHO) has scheduled reviews for COVID-19 vaccines from Chinese manufacturers Sinopharm and Sinovac for potential emergency use listing. Sinopharm's vaccine will be reviewed on April 26, followed by Sinovac's on May 3, with decisions expected a few days after each review. This move could endorse the vaccines' safety and efficacy, guiding regulatory agencies in various countries.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2FDUGVW5YPFNLCXPFD3C4S3X7S5Q.jpg?auth=d25fb26fb77950244db8f59fbf6ae0e78c187be005b5f54316d3f3f095bd4122&width=1200&height=628&quality=85&smart=true", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.918326"}], "overall_sentiment_score": 0.19719, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SVA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.340359", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.646790", "ticker_sentiment_score": "0.112322", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.626654", "ticker_sentiment_score": "0.149253", "ticker_sentiment_label": "Neutral"}]}, {"title": "These 3 dividend ETFs are a retiree's best friend", "url": "https://www.foxbusiness.com/personal-finance/these-3-dividend-etfs-are-a-retirees-best-friend", "time_published": "20210421T055700", "authors": ["Robin Hartill"], "summary": "This article recommends three dividend ETFs \u2014 SPDR S&P Dividend ETF, Vanguard High Dividend Yield ETF, and Schwab U.S. Dividend Equity ETF \u2014 as excellent options for retirees seeking a steady stream of passive income. It highlights the importance of diversification in retirement investing and details the characteristics, holdings, and expense ratios of each ETF, emphasizing their potential to provide income that keeps pace with inflation while managing risk. The author advises investors to look beyond just the yield and focus on the sustainability of dividends.", "banner_image": null, "source": "Fox Business", "category_within_source": "General", "source_domain": "Fox Business", "topics": [{"topic": "financial_markets", "relevance_score": "0.947102"}, {"topic": "finance", "relevance_score": "0.719889"}], "overall_sentiment_score": 0.344683, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SCHD", "relevance_score": "1.000000", "ticker_sentiment_score": "0.500240", "ticker_sentiment_label": "Bullish"}, {"ticker": "T", "relevance_score": "0.700545", "ticker_sentiment_score": "0.346656", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.735873", "ticker_sentiment_score": "0.326892", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HD", "relevance_score": "0.604515", "ticker_sentiment_score": "0.348697", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TXN", "relevance_score": "0.619076", "ticker_sentiment_score": "0.329645", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Investigation Launched Into Whether Johnson & Johnson Vaccine Maker Used Tie With Trump Official To Profit From Federal Contracts", "url": "https://www.cbsnews.com/baltimore/news/house-oversight-committee-investigation-emergent-biosolutions-johnson-and-johnson-covid-vaccine-trump-official/", "time_published": "20210420T153000", "authors": [], "summary": "The House Committee on Oversight and Reform has launched an investigation into Emergent BioSolutions, the manufacturer of Johnson & Johnson's COVID-19 vaccine, over concerns it leveraged ties with a Trump official to secure federal contracts. The investigation will examine claims that Emergent received multi-million-dollar contracts despite a history of quality control issues and inadequately trained staff, potentially impeding the nation's coronavirus response. The company's CEO and Executive Chairman have been called to testify before the Select Subcommittee.", "banner_image": null, "source": "CBS News", "category_within_source": "General", "source_domain": "CBS News", "topics": [{"topic": "life_sciences", "relevance_score": "0.915484"}, {"topic": "economy_fiscal", "relevance_score": "0.810652"}, {"topic": "manufacturing", "relevance_score": "0.727559"}], "overall_sentiment_score": -0.154913, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "EBS", "relevance_score": "0.345343", "ticker_sentiment_score": "0.043824", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.716197", "ticker_sentiment_score": "-0.266123", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Emergent BioSolutions halts operations at its Baltimore plant, where J.&J. doses were ruined, at the F.D.A.\u2019s request.", "url": "https://www.nytimes.com/2021/04/19/us/emergent-johnson-covid-vaccine.html", "time_published": "20210419T200711", "authors": ["Sheryl Gay Stolberg"], "summary": "Emergent BioSolutions announced it has temporarily halted operations at its Baltimore manufacturing facility at the request of the F.D.A., after the plant ruined up to 15 million doses of the Johnson & Johnson coronavirus vaccine. The company acknowledged the need for improvements to restore confidence in its quality systems and manufacturing processes. This setback further delays the release of Johnson & Johnson vaccine doses.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.943443"}, {"topic": "manufacturing", "relevance_score": "0.738783"}], "overall_sentiment_score": -0.157224, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "EBS", "relevance_score": "0.334975", "ticker_sentiment_score": "0.015477", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.848575", "ticker_sentiment_score": "-0.342808", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Map: How Countries\u2019 Stock Markets Stack Up on ESG Practices and Carbon Risk", "url": "https://www.morningstar.com/sustainable-investing/map-how-countries-stock-markets-stack-up-esg-practices-carbon-risk", "time_published": "20210416T212817", "authors": ["Valerio Baselli"], "summary": "This article examines global stock markets' performance on ESG practices and carbon risk, based on the Morningstar Sustainability Atlas. It highlights that European countries, especially the Netherlands, lead in sustainability scores, while emerging markets generally lag. The report also identifies countries with the lowest carbon risk, such as Switzerland and the U.S., contrasting them with high-risk nations like Russia due to their energy sector exposure.", "banner_image": null, "source": "Morningstar", "category_within_source": "General", "source_domain": "Morningstar", "topics": [{"topic": "financial_markets", "relevance_score": "0.915289"}, {"topic": "economy_macro", "relevance_score": "0.842061"}, {"topic": "finance", "relevance_score": "0.734353"}], "overall_sentiment_score": 0.020396, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "V", "relevance_score": "0.878835", "ticker_sentiment_score": "0.192782", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.830836", "ticker_sentiment_score": "0.209010", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.624003", "ticker_sentiment_score": "-0.195123", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMZN", "relevance_score": "0.601040", "ticker_sentiment_score": "-0.215565", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Robotic system introduced to help fight cancer at Cape Town hospital", "url": "https://metalworkingnews.info/robotic-system-introduced-to-help-fight-cancer-at-cape-town-hospital/", "time_published": "20210413T203215", "authors": [], "summary": "Life Kingsbury Hospital in Cape Town has introduced the da Vinci X robotic surgical system, the first of its kind in Africa, to enhance cancer treatment, particularly for prostate cancer. This minimally invasive technology offers patients benefits like shorter hospital stays, reduced pain, and quicker recovery. Intuitive Surgical, Inc., the system's developer, works with global suppliers to manufacture these advanced robotic-assisted platforms.", "banner_image": null, "source": "Metalworking News", "category_within_source": "General", "source_domain": "Metalworking News", "topics": [{"topic": "life_sciences", "relevance_score": "0.933621"}, {"topic": "technology", "relevance_score": "0.829591"}, {"topic": "manufacturing", "relevance_score": "0.602247"}], "overall_sentiment_score": 0.268736, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.403323", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.643250", "ticker_sentiment_score": "0.104905", "ticker_sentiment_label": "Neutral"}]}, {"title": "CAR-T provides superior efficacy for multiple myeloma at higher cost, report states", "url": "https://www.healio.com/news/hematology-oncology/20210412/cart-provides-superior-efficacy-for-multiple-myeloma-at-higher-cost-report-states", "time_published": "20210412T204145", "authors": [], "summary": "A report by the Institute for Clinical and Economic Review found that CAR T-cell therapies offer superior clinical effectiveness for heavily pretreated multiple myeloma patients compared to standard care. However, these therapies are significantly more expensive and would require steep discounts from their current list prices to meet recommended health-benefit price benchmarks. The report highlighted concerns about potential disparities in access due to the high cost and complex nature of CAR T-cell treatments.", "banner_image": null, "source": "Healio", "category_within_source": "General", "source_domain": "Healio", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.12427, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LEGN", "relevance_score": "1.000000", "ticker_sentiment_score": "0.145715", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.923701", "ticker_sentiment_score": "0.106851", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.837014", "ticker_sentiment_score": "0.094166", "ticker_sentiment_label": "Neutral"}]}, {"title": "How the Johnson & Johnson COVID-19 vaccine works", "url": "https://www.nebraskamed.com/COVID/how-the-johnson-johnson-covid-19-vaccine-works", "time_published": "20210412T203638", "authors": ["James Lawler", "MD", "MPH; David Brett-Major", "MD", "MPH"], "summary": "The Johnson & Johnson (Janssen) COVID-19 vaccine utilizes an adenovirus, a viral vector, to deliver the virus' DNA to cells, prompting the immune system to produce antibodies against the spike protein. This approach differs from mRNA vaccines like Pfizer and Moderna, but both ultimately equip the body to recognize and fight the coronavirus. Researchers have been working with adenovirus technology since the 1970s, with similar platforms used for Ebola and HIV vaccines, contributing to the quick approval processes due to existing safety data.", "banner_image": null, "source": "Nebraska Medicine", "category_within_source": "General", "source_domain": "Nebraska Medicine", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.169756, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.307853", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.606493", "ticker_sentiment_score": "0.127422", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.624692", "ticker_sentiment_score": "0.147041", "ticker_sentiment_label": "Neutral"}]}, {"title": "Golf cart-maker Club Car sold to investment firm run by Detroit Pistons owner", "url": "https://golfweek.usatoday.com/story/sports/golf/2021/04/12/golf-carts-club-car-sold-detroit-pistons-owner-tom-gores/76516114007/", "time_published": "20210412T203208", "authors": ["Jason Lusk"], "summary": "Ingersoll Rand Inc. has sold its golf car-making subsidiary, Club Car, to Platinum Equity, an investment firm owned by Detroit Pistons owner Tom Gores, for $1.7 billion. This acquisition is part of Platinum Equity's strategy to expand its portfolio in the growing electric vehicle market, while Ingersoll Rand uses the sale to reduce debt. Club Car's management will remain in place as it operates as a standalone company.", "banner_image": null, "source": "Golfweek", "category_within_source": "General", "source_domain": "Golfweek", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "manufacturing", "relevance_score": "0.831362"}, {"topic": "finance", "relevance_score": "0.748739"}, {"topic": "economy_macro", "relevance_score": "0.625067"}], "overall_sentiment_score": 0.0817, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IR", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.114658", "ticker_sentiment_label": "Neutral"}, {"ticker": "EMR", "relevance_score": "0.636590", "ticker_sentiment_score": "0.135748", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.638659", "ticker_sentiment_score": "0.138604", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMM", "relevance_score": "0.606759", "ticker_sentiment_score": "0.149159", "ticker_sentiment_label": "Neutral"}]}, {"title": "Platinum Equity To Acquire Club Car From Ingersoll Rand For $1.7 Billion", "url": "https://www.prnewswire.com/news-releases/platinum-equity-to-acquire-club-car-from-ingersoll-rand-for-1-7-billion-301266633.html", "time_published": "20210412T073800", "authors": [], "summary": "Platinum Equity announced its definitive agreement to acquire Club Car from Ingersoll Rand for approximately $1.7 billion. Club Car, a global leader in golf, consumer, and utility vehicles, is expected to benefit from Platinum Equity's operational expertise and carve-out experience to support its continued growth and expansion. The acquisition is subject to standard closing conditions and is anticipated to be completed by the third quarter of 2021.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "manufacturing", "relevance_score": "0.841087"}], "overall_sentiment_score": 0.185416, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IR", "relevance_score": "1.000000", "ticker_sentiment_score": "0.425762", "ticker_sentiment_label": "Bullish"}, {"ticker": "EMR", "relevance_score": "0.635709", "ticker_sentiment_score": "0.110887", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.619055", "ticker_sentiment_score": "0.120850", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBM", "relevance_score": "0.616675", "ticker_sentiment_score": "0.117714", "ticker_sentiment_label": "Neutral"}, {"ticker": "BALL", "relevance_score": "0.647857", "ticker_sentiment_score": "0.133537", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex CEO Kewalramani collects $9.1M in 2020 pay, less than her biopharma peers", "url": "https://www.fiercepharma.com/pharma/vertex-s-new-ceo-kewalramani-collects-9-11m-pay-package-2020-less-than-most-if-not-all-her", "time_published": "20210409T110600", "authors": ["Eric Sagonowsky"], "summary": "Vertex CEO Reshma Kewalramani received a 2020 pay package of $9.11 million, which is significantly less than her predecessor, Jeffrey Leiden, and most Big Biotech and Big Pharma peers. While her compensation did not cover a full year as CEO, it highlights a disparity compared to other industry leaders, including the only other female CEO in the group, Emma Walmsley of GlaxoSmithKline. Despite this, Vertex demonstrated strong performance in 2020, with significant growth in cystic fibrosis product revenues and pipeline expansion.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "earnings", "relevance_score": "0.901547"}, {"topic": "life_sciences", "relevance_score": "0.834107"}, {"topic": "finance", "relevance_score": "0.604168"}], "overall_sentiment_score": 0.063965, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.231473", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.625076", "ticker_sentiment_score": "0.019318", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.636535", "ticker_sentiment_score": "0.019081", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.637647", "ticker_sentiment_score": "0.012004", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.611610", "ticker_sentiment_score": "0.006224", "ticker_sentiment_label": "Neutral"}]}, {"title": "Chad Richison\u2019s wife Charis\u2019s donation provided for Oklahoma City students in pandemic: Here\u2019s all about her", "url": "https://meaww.com/who-is-paycom-boss-chad-richison-wife-charis-1-m-donation-oklahoma-city-public-schools-philantrophy", "time_published": "20210407T205717", "authors": ["PATHIKRIT SANYAL"], "summary": "The article highlights Charis Richison, wife of Paycom CEO Chad Richison, and her $1 million donation to The Foundation for Oklahoma City Public Schools for coronavirus relief efforts. It details her background, involvement in school activities, and Chad Richison's significant compensation in 2020. Charis's philanthropic efforts and personal history, including her education and previous marriages, are also discussed.", "banner_image": null, "source": "MEAWW", "category_within_source": "General", "source_domain": "MEAWW", "topics": [{"topic": "life_sciences", "relevance_score": "0.638518"}, {"topic": "finance", "relevance_score": "0.614507"}], "overall_sentiment_score": 0.176859, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PAYC", "relevance_score": "0.992876", "ticker_sentiment_score": "0.295814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADP", "relevance_score": "0.632673", "ticker_sentiment_score": "0.127356", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.744766", "ticker_sentiment_score": "0.120193", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer Expanding Operations in Fast-Growing Tampa and Restarting Manufacturing in Michigan", "url": "https://www.biospace.com/pfizer-expanding-operations-in-florida-and-michigan", "time_published": "20210402T210209", "authors": ["Mark Terry"], "summary": "Pfizer announced plans to create a professional services office in Tampa, Florida, consolidating finance, HR, digital services, and sourcing into a central hub, generating hundreds of new jobs. Concurrently, Pfizer is restarting a major construction project in Portage, Michigan, near Kalamazoo, originally approved in 2018, which is expected to create 450 new jobs and involves an $800 million investment for a new modular aseptic processing facility. These expansions highlight Pfizer's growth and investment in key operational and manufacturing capabilities.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "0.921171"}, {"topic": "real_estate", "relevance_score": "0.704348"}, {"topic": "manufacturing", "relevance_score": "0.610633"}, {"topic": "economy_macro", "relevance_score": "0.610686"}], "overall_sentiment_score": 0.287089, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.439112", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.601554", "ticker_sentiment_score": "0.242121", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.644142", "ticker_sentiment_score": "0.234966", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.606239", "ticker_sentiment_score": "0.224757", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson vaccine: Quality issue at Baltimore plant delays some of the J&J supply", "url": "https://www.cnn.com/2021/03/31/health/johnson--johnson-vaccine-manufacturing-problem", "time_published": "20210331T221900", "authors": ["Jen Christensen"], "summary": "Johnson & Johnson announced a quality issue at its Baltimore contract manufacturing plant, Emergent BioSolutions, where ingredients for its single-dose coronavirus vaccine were accidentally mixed, potentially spoiling 15 million doses. This incident has delayed FDA authorization for the plant and led J&J to assign additional experts to supervise manufacturing there. Despite the setback, the company maintains it is on track to deliver 20 million vaccine doses in March from its Netherlands plant and 24 million additional doses through April, according to White House officials.", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "life_sciences", "relevance_score": "0.915032"}, {"topic": "manufacturing", "relevance_score": "0.814492"}, {"topic": "economy_macro", "relevance_score": "0.610360"}], "overall_sentiment_score": -0.062425, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.231518", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRK", "relevance_score": "0.614981", "ticker_sentiment_score": "0.123955", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson COVID- 19 Vaccine Manufacturing Error Affects 15 Million Doses", "url": "https://time.com/5951709/johnson-johnson-covid-19-vaccine-error/", "time_published": "20210331T185400", "authors": ["Josh Wingrove", "Riley Griffin and Emma Court / Bloomberg"], "summary": "A manufacturing error at a Baltimore facility affected 15 million doses worth of an ingredient for Johnson & Johnson\u2019s COVID-19 vaccine. Johnson & Johnson stated that the affected batch did not meet quality standards and was not advanced to later manufacturing stages, and confirmed it still met its March delivery targets and expects to meet future commitments. The company is now expanding its oversight at the Emergent BioSolutions facility to ensure quality control.", "banner_image": "NULL", "source": "Time Magazine", "category_within_source": "General", "source_domain": "Time Magazine", "topics": [{"topic": "life_sciences", "relevance_score": "0.916511"}, {"topic": "manufacturing", "relevance_score": "0.848809"}], "overall_sentiment_score": -0.122254, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EBS", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.387008", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.993103", "ticker_sentiment_score": "-0.263205", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.605858", "ticker_sentiment_score": "0.106275", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.646145", "ticker_sentiment_score": "0.122131", "ticker_sentiment_label": "Neutral"}]}, {"title": "Boston Scientific to Pay $189 Million in Vaginal Mesh Lawsuit", "url": "https://www.biospace.com/boston-scientific-settles-multistate-vaginal-mesh-lawsuit-for-189-million", "time_published": "20210324T195157", "authors": ["Alex Keown"], "summary": "Boston Scientific is set to pay $189 million to settle a multi-state lawsuit regarding the marketing of its surgical mesh devices, though the company did not admit misconduct. The settlement, which will be distributed among 47 states and Washington, D.C., also requires clearer communication of product risks to consumers. This action follows previous settlements by other companies and a 2019 FDA order halting the sale of transvaginal surgical mesh products from Boston Scientific and Coloplast A/S due to safety concerns.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.718554"}, {"topic": "earnings", "relevance_score": "0.632297"}], "overall_sentiment_score": -0.3332, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.428389", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.646425", "ticker_sentiment_score": "-0.268598", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BDX", "relevance_score": "0.560135", "ticker_sentiment_score": "-0.267178", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Investing in Psychedelics with MindMed Stock", "url": "https://www.nanalyze.com/2021/03/mindmed-stock-investing-psychedelics/", "time_published": "20210323T204708", "authors": [], "summary": "This article discusses investing in psychedelic companies, focusing on MindMed stock. It details MindMed's pipeline, including LSD therapeutics and psychedelic-inspired medicines, and addresses the risks and potential of this emerging pharmaceutical sector. The piece also mentions the first psychedelic ETF and key players in the industry.", "banner_image": null, "source": "Nanalyze", "category_within_source": "General", "source_domain": "Nanalyze", "topics": [{"topic": "life_sciences", "relevance_score": "0.925177"}, {"topic": "finance", "relevance_score": "0.743422"}], "overall_sentiment_score": 0.15558, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MNMD", "relevance_score": "0.341514", "ticker_sentiment_score": "0.010069", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.603124", "ticker_sentiment_score": "0.200776", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.555715", "ticker_sentiment_score": "0.236382", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stick to the Fundamentals with the Value-Focused 'VTV'", "url": "https://www.etftrends.com/smart-beta-channel/stick-to-fundamentals-with-value-focused-vtv/", "time_published": "20210316T213225", "authors": ["Ben Hernandez"], "summary": "The article highlights the Vanguard Value ETF (VTV) as a promising investment option for those looking to capitalize on the ongoing value stock comeback. VTV focuses on large-cap value stocks, offering stability during downturns and capturing upside potential in a recovering economic climate. The fund, which tracks the CRSP U.S. Large Cap Value Index, is up significantly in the past year and provides a convenient way to invest in large value stocks with stable revenues and dividend potential.", "banner_image": null, "source": "ETF Trends", "category_within_source": "General", "source_domain": "ETF Trends", "topics": [{"topic": "financial_markets", "relevance_score": "0.924929"}, {"topic": "finance", "relevance_score": "0.746625"}], "overall_sentiment_score": 0.287983, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VTV", "relevance_score": "1.000000", "ticker_sentiment_score": "0.500281", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.604009", "ticker_sentiment_score": "0.241187", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.604046", "ticker_sentiment_score": "0.234717", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.605731", "ticker_sentiment_score": "0.238701", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Chemomab Completes Merger with Anchiano Therapeutics", "url": "https://www.prnewswire.com/news-releases/chemomab-completes-merger-with-anchiano-therapeutics-301248816.html", "time_published": "20210316T210859", "authors": ["NULL"], "summary": "Chemomab Therapeutics has completed its merger with Anchiano Therapeutics Ltd. and will trade on the Nasdaq Capital Market under the symbol \"CMMB\" beginning March 17, 2021. The combined company secured $45.5 million in a PIPE financing led by prominent healthcare investors, which will be used to advance three Phase 2 clinical trials for its lead product, CM-101, targeting rare fibrotic conditions like Primary Sclerosing Cholangitis and Systemic Sclerosis. This merger positions Chemomab for accelerated clinical development and further pipeline expansion with sufficient funding through the second half of 2023.", "banner_image": "NULL", "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.837891"}], "overall_sentiment_score": 0.408211, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CMMB", "relevance_score": "1.000000", "ticker_sentiment_score": "0.857220", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.571712", "ticker_sentiment_score": "0.182949", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.588549", "ticker_sentiment_score": "0.181039", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna begins testing its COVID-19 vaccine in children as young as 6 months", "url": "https://www.latimes.com/science/story/2021-03-16/moderna-begins-testing-covid-19-vaccine-young-children", "time_published": "20210316T130600", "authors": ["Karen Kaplan"], "summary": "Moderna has initiated a clinical trial for its COVID-19 vaccine in children as young as 6 months old, aiming to determine its safety and efficacy in young populations. The trial will enroll approximately 6,750 volunteers in the U.S. and Canada, testing various doses and comparing the vaccine to a placebo. This study is crucial as COVID-19 cases are less frequent in children, potentially affecting the statistical significance of efficacy calculations based solely on infection rates, thus immune response will also be a key metric.", "banner_image": "https://ca-times.brightspotcdn.com/dims4/default/0753066/2147483647/strip/true/crop/3000x2000+0+0/resize/1200x800!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F09%2F22%2F62ef76f849b29311e4000b957682%2Fla-sci-covid-moderna-testing-vaccine-in-children.jpg", "source": "Los Angeles Times", "category_within_source": "General", "source_domain": "Los Angeles Times", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.330927, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.423856", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.626468", "ticker_sentiment_score": "0.326940", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.581386", "ticker_sentiment_score": "0.290570", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ocugen Needs Pieces To Fall Into Place Before It\u2019s a Solid Vaccine Play", "url": "https://investorplace.com/2021/03/ocgn-stock-is-purely-a-speculative-covid-19-vaccine-play/", "time_published": "20210315T061600", "authors": ["Muslim Farooque"], "summary": "Ocugen (OCGN) stock, despite a significant rally, remains a speculative investment in the Covid-19 vaccine space. While its partner Bharat Biotech reported 81% efficacy for Covaxin in interim trials, the vaccine faces high hurdles for U.S. approval, including potential FDA requirements for U.S.-based studies and intense competition from established players like Moderna, Pfizer, Johnson & Johnson, and Novavax. The company's valuation of over $1.5 billion is considered largely unjustified given these challenges.", "banner_image": "NULL", "source": "InvestorPlace", "category_within_source": "General", "source_domain": "InvestorPlace", "topics": [{"topic": "life_sciences", "relevance_score": "0.939186"}, {"topic": "financial_markets", "relevance_score": "0.848296"}], "overall_sentiment_score": 0.114875, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OCGN", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.276434", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.636763", "ticker_sentiment_score": "0.203534", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.645092", "ticker_sentiment_score": "0.234360", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.565257", "ticker_sentiment_score": "0.218381", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BioNTech Recruits Rivals to Boost Covid-19 Vaccine Production - WSJ", "url": "https://www.wsj.com/health/pharma/biontech-recruits-rivals-to-boost-covid-19-vaccine-production-11615640401?gaa_at=eafs&gaa_n=AWEtsqdZ-kzjCgQLau7w1eTtFDGjN9bHhVs8XwP38P_dSCT2JIebS56QGCYc&gaa_ts=6907b966&gaa_sig=rlnmCwqInn68NVEVr8W7_q74tU5_fib0Yja-SGpV50KLeqX0TjsxWhyM2bKDuXfUApi2x99jJY2mHOv3QIosOg%3D%3D", "time_published": "20210313T195140", "authors": ["Bojan Pancevski"], "summary": "BioNTech is forming a new manufacturing alliance with 13 companies, including Novartis AG, Merck KGaA, and Sanofi SA, to boost Covid-19 vaccine production. This initiative aims to address a global shortage of vaccine doses and counter a rebound in infections. Their ambitious goal is to produce two billion doses this year.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.915076"}, {"topic": "manufacturing", "relevance_score": "0.723347"}], "overall_sentiment_score": 0.233405, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BNTX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.408881", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.947825", "ticker_sentiment_score": "0.296872", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.647755", "ticker_sentiment_score": "0.152899", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.562038", "ticker_sentiment_score": "0.147165", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cardinal Health sells troubled Cordis unit to private equity firm for $1B", "url": "https://www.medtechdive.com/news/cardinal-health-sells-troubled-cordis-unit-to-private-equity-firm-for-1b/596629/", "time_published": "20210312T195220", "authors": ["Greg Slabodkin"], "summary": "Cardinal Health has agreed to sell its Cordis medical device unit to private equity firm Hellman & Friedman for approximately $1 billion. Cardinal had acquired Cordis in 2015 for $1.9 billion but faced integration issues and product liability lawsuits. The divestiture is expected to reduce Cardinal's medical segment profit by $60 million to $70 million annually, and the company will retain liability for certain lawsuits related to inferior vena cava filters.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.946960"}, {"topic": "life_sciences", "relevance_score": "0.928128"}, {"topic": "earnings", "relevance_score": "0.744122"}], "overall_sentiment_score": 0.084486, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.269566", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.661532", "ticker_sentiment_score": "-0.136407", "ticker_sentiment_label": "Neutral"}, {"ticker": "KKR", "relevance_score": "0.618252", "ticker_sentiment_score": "0.228278", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.523151", "ticker_sentiment_score": "-0.083727", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.533405", "ticker_sentiment_score": "0.054702", "ticker_sentiment_label": "Neutral"}]}, {"title": "Indiana Attorney General Continues Business Advisory Roles", "url": "https://www.wfyi.org/news/articles/indiana-attorney-general-continues-business-advisory-roles", "time_published": "20210311T205149", "authors": ["Associated Press"], "summary": "Indiana Attorney General Todd Rokita has disclosed ongoing advisory roles with several private businesses, including a $25,000 annual payment from a pharmaceutical company and $15,000 in stock. These roles continued into his term as Attorney General, raising concerns from the state Democratic Party about potential conflicts of interest. Rokita's office states he is in compliance with legal and ethics guidelines.", "banner_image": null, "source": "WFYI", "category_within_source": "General", "source_domain": "WFYI", "topics": [{"topic": "life_sciences", "relevance_score": "0.945207"}, {"topic": "economy_fiscal", "relevance_score": "0.834910"}, {"topic": "finance", "relevance_score": "0.741137"}], "overall_sentiment_score": 0.11206, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NNVC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.121381", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.615006", "ticker_sentiment_score": "0.124981", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.617952", "ticker_sentiment_score": "0.133148", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.602154", "ticker_sentiment_score": "0.112998", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.620558", "ticker_sentiment_score": "0.128102", "ticker_sentiment_label": "Neutral"}]}, {"title": "Brain Implants Market Size, Share & Growth Report [2032]", "url": "https://www.fortunebusinessinsights.com/brain-implants-market-105021", "time_published": "20210308T205155", "authors": [], "summary": "The global brain implants market is projected to grow from USD 2.36 billion in 2025 to USD 4.93 billion by 2032, exhibiting a CAGR of 11.1%. This growth is driven by the increasing prevalence of neurological disorders, ongoing research and development into new probe technologies, and rising investments in innovative products. North America currently dominates the market, with deep brain stimulation being the leading product segment due to multiple FDA approvals and expanding clinical applications.", "banner_image": null, "source": "Fortune Business Insights", "category_within_source": "General", "source_domain": "Fortune Business Insights", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.297581, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NPCE", "relevance_score": "0.923196", "ticker_sentiment_score": "0.337378", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.846430", "ticker_sentiment_score": "0.319578", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.748408", "ticker_sentiment_score": "0.309908", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.635987", "ticker_sentiment_score": "0.293813", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.566311", "ticker_sentiment_score": "0.278386", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna taps Baxter to support fill and finish of 60-90 mln COVID-19 vaccine", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-taps-baxter-support-fill-finish-60-90-mln-covid-19-vaccine-2021-03-08/", "time_published": "20210308T150300", "authors": ["Reuters"], "summary": "Moderna has partnered with Baxter International Inc. to fill and finish 60-90 million doses of its COVID-19 vaccine in 2021. This agreement aims to support the final stages of vaccine production after Moderna experienced short-term delays with a previous contractor, Catalent Inc. The fill and finish process, involving putting the vaccine into vials, sealing, and packaging, will occur at Baxter's facilities in Bloomington, Indiana.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "manufacturing", "relevance_score": "0.807044"}], "overall_sentiment_score": 0.297628, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.434426", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.924779", "ticker_sentiment_score": "0.334487", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.617712", "ticker_sentiment_score": "0.233285", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.616583", "ticker_sentiment_score": "0.215581", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Inspira Technologies Appoints Benad Goldwasser as Chairman of the Board", "url": "https://www.prnewswire.com/news-releases/inspira-technologies-appoints-benad-goldwasser-as-chairman-of-the-board-301233962.html", "time_published": "20210224T020000", "authors": [], "summary": "Inspira Technologies announced the appointment of Professor Benad Goldwasser as Chairman of its Board of Directors. Prof. Goldwasser brings decades of experience in founding and developing medical device companies, including Vidamed Inc. and Medinol Ltd., and will leverage his expertise to guide Inspira Technologies' growth and the development of its Augmented Respiration Technology.", "banner_image": "https://mma.prnewswire.com/media/1443253/Inspira_Technologies_Benad_Goldwasser_Chairman.jpg", "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.916201"}, {"topic": "finance", "relevance_score": "0.700866"}], "overall_sentiment_score": 0.306051, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IINN", "relevance_score": "1.000000", "ticker_sentiment_score": "0.451958", "ticker_sentiment_label": "Bullish"}, {"ticker": "BSX", "relevance_score": "0.592060", "ticker_sentiment_score": "0.276073", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.566391", "ticker_sentiment_score": "0.250443", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.589004", "ticker_sentiment_score": "0.260078", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Genmab creates new CMO, head of experimental medicines role for Ahmadi", "url": "https://www.fiercebiotech.com/biotech/genmab-creates-new-cmo-head-experimental-medicines-role-for-tahamtan-ahmadi", "time_published": "20210222T093500", "authors": ["Ben Adams"], "summary": "Genmab has promoted Tahamtan Ahmadi, M.D., Ph.D., to a newly created role as executive vice president, chief medical officer, and head of experimental medicines. In this position, Ahmadi will lead research, discovery, regulatory, and medical activities, leveraging his prior experience at Janssen on Darzalex. He will oversee Genmab's pipeline, which includes numerous partnered deals across various cancer targets and earlier research in other diseases.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "0.943698"}], "overall_sentiment_score": 0.252099, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GMAB", "relevance_score": "0.344929", "ticker_sentiment_score": "0.015178", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.635297", "ticker_sentiment_score": "0.323426", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.700514", "ticker_sentiment_score": "0.322265", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.602776", "ticker_sentiment_score": "0.344808", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AbbVie, Eli Lilly lead Big Pharma's 2020 market cap growth as Merck, Gilead lag", "url": "https://www.fiercepharma.com/pharma/abbvie-lilly-lead-pharma-s-2020-market-cap-growth-as-merck-gilead-lag", "time_published": "20210219T120700", "authors": ["Angus Liu"], "summary": "AbbVie and Eli Lilly led market cap growth among top biopharma companies in 2020, even as some COVID-19 product makers like Pfizer and AstraZeneca saw declines. AbbVie's growth was fueled by its Allergan acquisition and strong performance of new immunology drugs Skyrizi and Rinvoq, while Lilly benefited from its COVID-19 antibody and diabetes drug Trulicity. In contrast, Merck and Gilead experienced market cap drops, with Gilead's COVID antiviral Veklury not sustaining long-term stock growth.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.913425"}, {"topic": "earnings", "relevance_score": "0.826607"}], "overall_sentiment_score": 0.103361, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.981853", "ticker_sentiment_score": "0.333415", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.905576", "ticker_sentiment_score": "0.391752", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.834701", "ticker_sentiment_score": "-0.281691", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.736562", "ticker_sentiment_score": "0.178042", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.611073", "ticker_sentiment_score": "-0.209017", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "AAFP Publishes Opioid Use Disorder Treatment Manual", "url": "https://www.aafp.org/news/health-of-the-public/20210209oudmanual.html", "time_published": "20210209T081000", "authors": ["Michael Devitt"], "summary": "The AAFP has published a new guide, \"Treating Opioid Use Disorder as a Chronic Condition: A Practice Manual for Family Physicians,\" funded by an unrestricted grant from Indivior PLC. This manual aims to provide family physicians with the resources and information needed to care for patients with opioid use disorder (OUD), especially given the increase in opioid-related drug overdose deaths during the COVID-19 pandemic. It covers screening, diagnosis, treatment options, practice preparation, and payment/coding, and emphasizes OUD as a treatable medical disease.", "banner_image": "NULL", "source": "American Academy of Family Physicians | AAFP", "category_within_source": "General", "source_domain": "American Academy of Family Physicians | AAFP", "topics": [{"topic": "life_sciences", "relevance_score": "0.944740"}], "overall_sentiment_score": 0.247656, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "INDV", "relevance_score": "0.912397", "ticker_sentiment_score": "0.318599", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.613656", "ticker_sentiment_score": "0.214673", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAH", "relevance_score": "0.605295", "ticker_sentiment_score": "0.248443", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.563631", "ticker_sentiment_score": "0.200165", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.555646", "ticker_sentiment_score": "0.240731", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Understanding the pharmaceutical lifecycle and the benefits of a menu-driven approach", "url": "https://www.fiercebiotech.com/sponsored/understanding-pharmaceutical-lifecycle-and-benefits-a-menu-driven-approach", "time_published": "20210208T080000", "authors": ["Avid Bioservices"], "summary": "This article discusses the evolution of the biopharmaceutical industry towards full-service contract development and manufacturing organizations (CDMOs) and highlights Avid Bioservices' menu-driven approach. Avid Bioservices, a clinical and commercial CDMO, offers flexible services that support projects of various sizes and stages, helping clients avoid the pitfalls of all-or-nothing contracts. The company emphasizes its extensive regulatory compliance, manufacturing capabilities, and analytical services designed to meet diverse client needs throughout the pharmaceutical lifecycle.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "manufacturing", "relevance_score": "0.843168"}], "overall_sentiment_score": 0.17138, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CDMO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.437812", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.649992", "ticker_sentiment_score": "0.144902", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.606735", "ticker_sentiment_score": "0.114857", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.624742", "ticker_sentiment_score": "0.114142", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.617222", "ticker_sentiment_score": "0.106528", "ticker_sentiment_label": "Neutral"}]}, {"title": "Malin-backed Immunocore files for $258m Nasdaq IPO", "url": "https://www.irishtimes.com/business/health-pharma/malin-backed-immunocore-files-for-258m-nasdaq-ipo-1.4476944", "time_published": "20210205T172300", "authors": ["Colin Gleeson"], "summary": "Immunocore, a UK biotech company partially owned by Dublin-listed Malin, has filed for a $258 million IPO on the Nasdaq. The company plans to use the proceeds to advance its lead product, an eye cancer therapy, through its phase-three clinical trial and prepare for its commercial launch, as well as fund other product candidates. Malin retains a 6 percent stake in Immunocore, valued at approximately \u20ac51 million, and will not participate in the IPO.", "banner_image": null, "source": "The Irish Times", "category_within_source": "General", "source_domain": "The Irish Times", "topics": [{"topic": "ipo", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.921092"}, {"topic": "financial_markets", "relevance_score": "0.636766"}, {"topic": "finance", "relevance_score": "0.621746"}], "overall_sentiment_score": 0.241727, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IMCR", "relevance_score": "1.000000", "ticker_sentiment_score": "0.435687", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.618594", "ticker_sentiment_score": "0.108132", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.609857", "ticker_sentiment_score": "0.116953", "ticker_sentiment_label": "Neutral"}]}, {"title": "Restless Legs Syndrome Market is Booming with Market Strategies", "url": "https://www.openpr.com/news/2251079/restless-legs-syndrome-market-is-booming-with-market-strategies", "time_published": "20210203T195900", "authors": [], "summary": "This report provides an in-depth study of the global Restless Legs Syndrome (RLS) market, utilizing SWOT analysis and surveying key market players. The market is expected to grow significantly due to the development of new, more efficient drugs with fewer side effects, with North America projected to exhibit the highest CAGR. The report also highlights a collaboration between Boehringer Ingelheim and CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy, showcasing ongoing innovation in related medical fields.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.908625"}], "overall_sentiment_score": 0.314087, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OMER", "relevance_score": "0.941226", "ticker_sentiment_score": "0.340990", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.735019", "ticker_sentiment_score": "0.321779", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.714194", "ticker_sentiment_score": "0.321309", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson", "url": "https://www.statnews.com/2021/02/02/comparing-the-covid-19-vaccines-developed-by-pfizer-moderna-and-johnson-johnson/", "time_published": "20210202T204728", "authors": ["Helen Branswell"], "summary": "This article provides a detailed comparison of the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson, covering their types, target populations, efficacy, number of doses, durability of protection, booster status, mix-and-match booster options, vaccine uptake, side-effect profiles, safety during pregnancy, and storage requirements. It highlights the differences in mRNA and viral vector technology, varying efficacy rates, and the evolving challenges each vaccine has faced since its introduction. The article was last updated on January 31, 2022, reflecting ongoing developments in vaccine science and policy.", "banner_image": null, "source": "STAT", "category_within_source": "General", "source_domain": "STAT", "topics": [{"topic": "life_sciences", "relevance_score": "0.938236"}], "overall_sentiment_score": 0.163669, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.234112", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.958103", "ticker_sentiment_score": "0.189041", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.915704", "ticker_sentiment_score": "0.073911", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.620362", "ticker_sentiment_score": "0.129834", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.583183", "ticker_sentiment_score": "0.121935", "ticker_sentiment_label": "Neutral"}]}, {"title": "With latest deal, Merck wades into cell therapy for cancer", "url": "https://www.biopharmadive.com/news/merck-cell-therapy-deal-artiva-car-nk/594148/", "time_published": "20210128T193618", "authors": ["Kristin Jensen"], "summary": "Merck & Co. has partnered with Artiva Biotherapeutics to develop CAR-NK cell therapies for cancer, a move that diversifies Merck's oncology pipeline beyond Keytruda. Artiva's \"off-the-shelf\" allogeneic cell manufacturing platform for solid tumors could offer advantages over existing CAR-T therapies. The deal includes $30 million upfront, potential milestone payments up to $612 million, and research funding from Merck.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.916775"}, {"topic": "life_sciences", "relevance_score": "0.938604"}], "overall_sentiment_score": 0.194562, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARTV", "relevance_score": "0.318571", "ticker_sentiment_score": "0.034708", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.426043", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.608071", "ticker_sentiment_score": "0.137406", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.642989", "ticker_sentiment_score": "0.123371", "ticker_sentiment_label": "Neutral"}]}, {"title": "Jim Cramer: Industrial ETFs 'Miraculous', 'Incredible'", "url": "https://www.etftrends.com/cramer-industrial-etfs-miraculous-incredible/", "time_published": "20210127T053144", "authors": ["Ian Young"], "summary": "Jim Cramer highlighted the \"miraculous\" performance of industrial companies like General Electric and Raytheon, pushing back against skepticism about the stock market's rally. Despite the pandemic's impact, these companies are posting strong earnings and free cash flow, leading Cramer to suggest the market's gains are justified. He points to industrial ETFs such as FIDU, XLI, VIS, and ITA as potential investment opportunities.", "banner_image": null, "source": "ETF Trends", "category_within_source": "General", "source_domain": "ETF Trends", "topics": [{"topic": "earnings", "relevance_score": "0.918200"}, {"topic": "financial_markets", "relevance_score": "0.849076"}, {"topic": "economy_macro", "relevance_score": "0.727334"}, {"topic": "manufacturing", "relevance_score": "0.932420"}, {"topic": "life_sciences", "relevance_score": "0.613550"}], "overall_sentiment_score": 0.308112, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FIDU", "relevance_score": "1.000000", "ticker_sentiment_score": "0.202289", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GE", "relevance_score": "0.916940", "ticker_sentiment_score": "0.430176", "ticker_sentiment_label": "Bullish"}, {"ticker": "RTX", "relevance_score": "0.846325", "ticker_sentiment_score": "0.319164", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.623613", "ticker_sentiment_score": "0.328304", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Merck Shuts Down Covid Vaccine Program After Lackluster Data", "url": "https://www.bloomberg.com/news/articles/2021-01-25/merck-shuts-down-covid-vaccine-program-after-lackluster-data", "time_published": "20210125T114500", "authors": ["Riley Griffin"], "summary": "Merck & Co. is discontinuing the development of its two experimental Covid-19 vaccines after early trial data showed they failed to generate immune responses comparable to natural infection or existing vaccines. The company, which historically has had success with vaccines, will re-purpose its resources to focus on Covid-19 therapies instead. This decision follows a different strategy taken by Merck compared to rivals Pfizer Inc., Moderna Inc., and Johnson & Johnson, as Merck opted for a more traditional approach using weakened viruses.", "banner_image": null, "source": "Bloomberg.com", "category_within_source": "General", "source_domain": "Bloomberg.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.928915"}], "overall_sentiment_score": -0.206337, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MRK", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.352792", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.632812", "ticker_sentiment_score": "-0.189237", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.613872", "ticker_sentiment_score": "-0.196559", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.633522", "ticker_sentiment_score": "-0.184700", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Sound Income ETFs Bring Active Approach to Creating Retirement Income", "url": "https://www.etftrends.com/active-etf-content-hub/new-sound-income-etfs-bring-active-approach-to-generating-retirement-income/", "time_published": "20210106T201720", "authors": ["Tom Lydon"], "summary": "Sound Income Strategies launched two actively managed income-based ETFs, SDEI and SDEF, designed to make income-generating strategies more accessible, especially for retirees. The Sound Equity Income ETF (SDEI) focuses on current income and long-term capital appreciation from dividend-paying companies, targeting a dividend yield double that of the S&P 500. The Sound Enhanced Fixed Income ETF (SDEF) seeks current income and capital appreciation from a mix of investment-grade and high-yield fixed income securities.", "banner_image": null, "source": "ETF Trends", "category_within_source": "General", "source_domain": "ETF Trends", "topics": [{"topic": "financial_markets", "relevance_score": "0.907496"}, {"topic": "finance", "relevance_score": "0.808130"}, {"topic": "life_sciences", "relevance_score": "0.635555"}], "overall_sentiment_score": 0.16647, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FXED", "relevance_score": "0.305965", "ticker_sentiment_score": "0.006927", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.625918", "ticker_sentiment_score": "0.231139", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "T", "relevance_score": "0.617109", "ticker_sentiment_score": "0.213083", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.620425", "ticker_sentiment_score": "0.200734", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Arcturus\u2014a clinical-stage mRNA therapeutics and vaccines company", "url": "https://www.nature.com/articles/d43747-021-00073-3", "time_published": "20210101T000000", "authors": ["Arcturus Therapeutics Holdings"], "summary": "Arcturus Therapeutics, a clinical-stage mRNA company, is developing infectious disease vaccines and treatments for rare liver and respiratory diseases using its proprietary LUNAR lipid-mediated delivery and STARR technology. Their lead candidates include a self-amplifying mRNA COVID-19 vaccine (ARCT-021), which is lyophilized and requires a smaller dose and no ultra-cold supply chain, and an mRNA replacement therapy (ARCT-810) for OTC deficiency. The company's platform allows for versatile application across various nucleic acid medicines and has a diverse pipeline in clinical and preclinical stages.", "banner_image": null, "source": "Nature", "category_within_source": "General", "source_domain": "Nature", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.415701, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.878366", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.616379", "ticker_sentiment_score": "0.302244", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.629192", "ticker_sentiment_score": "0.298987", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.595224", "ticker_sentiment_score": "0.229909", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Novavax begins U.S. phase 3 trial of coronavirus vaccine", "url": "https://www.seattletimes.com/seattle-news/health/novavax-begins-final-stage-trial-of-its-coronavirus-vaccine-in-u-s-mexico/", "time_published": "20201228T114600", "authors": ["Linus Chua", "John Tozzi"], "summary": "Novavax Inc. has initiated a final-stage Phase 3 trial for its coronavirus vaccine, NVX-CoV2373, in the U.S. and Mexico, enrolling 30,000 participants. This trial, supported by Operation Warp Speed, aims to evaluate the vaccine's efficacy and broaden the available vaccine options alongside those from Pfizer and Moderna. Initial results from a separate U.K. trial are expected early next year, as the company ramps up global manufacturing capacity.", "banner_image": null, "source": "The Seattle Times", "category_within_source": "General", "source_domain": "The Seattle Times", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.173045, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVAX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.267163", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.669727", "ticker_sentiment_score": "0.119659", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.615985", "ticker_sentiment_score": "0.116674", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.553946", "ticker_sentiment_score": "0.073004", "ticker_sentiment_label": "Neutral"}]}, {"title": "US FDA approves Moderna vaccine on emergency basis: Report", "url": "https://www.aljazeera.com/news/2020/12/18/us-panel-recommends-moderna-vaccine-paving-way-for-authorisation", "time_published": "20201218T225212", "authors": ["News Agencies"], "summary": "The US FDA has decided to approve Moderna Inc's coronavirus vaccine on an emergency basis after a panel of doctors overwhelmingly recommended it. This approval provides a second COVID-19 vaccine for the US, following Pfizer-BioNTech's, offering hope despite the rapidly spreading pandemic. Moderna's vaccine has a logistical advantage as it does not require specialised ultra-cold refrigeration, unlike the Pfizer-BioNTech vaccine.", "banner_image": null, "source": "Al Jazeera", "category_within_source": "General", "source_domain": "Al Jazeera", "topics": [{"topic": "life_sciences", "relevance_score": "0.921320"}, {"topic": "economy_macro", "relevance_score": "0.625526"}], "overall_sentiment_score": 0.20615, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.400518", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.716820", "ticker_sentiment_score": "0.170959", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.560106", "ticker_sentiment_score": "0.024781", "ticker_sentiment_label": "Neutral"}]}, {"title": "CDK Global taps Eric Guerin of Corning Incorporated as executive VP", "url": "https://canadianautodealer.ca/2020/12/cdk-global-taps-eric-guerin-of-corning-incorporated-as-executive-vp/", "time_published": "20201217T222626", "authors": ["Todd Phillips"], "summary": "CDK Global has appointed Eric Guerin as its new Executive Vice President and Chief Financial Officer, effective January 18, 2021. Guerin, previously with Corning Incorporated, will be responsible for CDK Global's financial strategy and growth. This move will also allow current EVP and CFO Joe Tautges to transition to Chief Operating Officer.", "banner_image": null, "source": "Canadian Auto Dealer", "category_within_source": "General", "source_domain": "Canadian Auto Dealer", "topics": [{"topic": "finance", "relevance_score": "0.945959"}, {"topic": "retail_wholesale", "relevance_score": "0.628587"}], "overall_sentiment_score": 0.146369, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GLW", "relevance_score": "0.749923", "ticker_sentiment_score": "0.141939", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.609324", "ticker_sentiment_score": "0.120369", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kroger To Provide COVID-19 Vaccines At Smith\u2019s Stores", "url": "https://ksltv.com/local-news/kroger-will-eventually-provide-covid-19-vaccine-at-smiths-stores/451160/", "time_published": "20201215T151300", "authors": ["CARY J. SCHWANITZ"], "summary": "Kroger, parent company of Smith's Food & Drug, announced plans to offer COVID-19 vaccines nationwide through its stores. Vaccinations will be deployed in collaboration with state health departments and the federal government, following CDC rollout plans. Smith's has previously been involved in COVID-19 response efforts, including offering free drive-through testing and rapid antibody tests.", "banner_image": null, "source": "KSL TV 5", "category_within_source": "General", "source_domain": "KSL TV 5", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.811860"}, {"topic": "life_sciences", "relevance_score": "0.723208"}], "overall_sentiment_score": 0.333177, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KR", "relevance_score": "1.000000", "ticker_sentiment_score": "0.449900", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.639429", "ticker_sentiment_score": "0.344218", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.632412", "ticker_sentiment_score": "0.319829", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.605598", "ticker_sentiment_score": "0.339407", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVS", "relevance_score": "0.643427", "ticker_sentiment_score": "0.330663", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Relay Therapeutics, fresh off IPO, partners with Roche in cancer drug deal", "url": "https://www.biopharmadive.com/news/relay-roche-kras-shp2-cancer-drug-deal/592126/", "time_published": "20201214T231125", "authors": ["Ned Pagliarulo"], "summary": "Relay Therapeutics has announced a licensing deal with Roche for its targeted cancer drug RLY-1971, which targets the SHP2 protein. The deal includes an upfront payment of $75 million, $25 million in near-term cash, and potential milestone payments ranging from $410 million to $695 million. This partnership marks Relay's first significant alliance since its IPO and focuses on combination studies, particularly with Roche's experimental KRAS-blocking drug.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "ipo", "relevance_score": "0.903498"}], "overall_sentiment_score": 0.199032, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RLAY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.442729", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.648452", "ticker_sentiment_score": "0.116165", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.635710", "ticker_sentiment_score": "0.104977", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.646740", "ticker_sentiment_score": "0.119468", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.618733", "ticker_sentiment_score": "0.210415", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 ways Johnson & Johnson is innovating to help fight tuberculosis", "url": "https://www.jnj.com/innovation/innovating-global-tuberculosis-medication-treatment", "time_published": "20201210T223708", "authors": ["Amanda Kelly"], "summary": "Johnson & Johnson is actively innovating to combat tuberculosis (TB), which remains one of the world's deadliest infectious diseases. The company is focusing on improving disease detection, broadening access to its novel medicine for multidrug-resistant TB (MDR-TB), and accelerating research for new treatments, especially in light of challenges posed by the COVID-19 pandemic. Their efforts include initiatives like the DR-TB Lifeline QuickFire Challenge and a historic 10-year commitment to address the global TB crisis.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.901544"}], "overall_sentiment_score": 0.480691, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.469474", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson cuts size of Covid-19 vaccine study due to prevalence of disease in U.S.", "url": "https://www.statnews.com/2020/12/09/johnson-johnson-cuts-size-of-covid-19-vaccine-study-due-to-prevalence-of-disease-in-u-s/", "time_published": "20201209T223708", "authors": ["Matthew Herper"], "summary": "Johnson & Johnson is reducing the size of its pivotal U.S. Covid-19 vaccine trial from 60,000 to 40,000 volunteers due to the widespread prevalence of the disease, which allows researchers to reach conclusions with fewer participants. This change does not affect the timeline for results, with interim data still expected by the end of January and a potential emergency use authorization application in February. The J&J study remains comparable in size to other leading vaccine trials that have already shown positive results.", "banner_image": null, "source": "www.statnews.com", "category_within_source": "General", "source_domain": "www.statnews.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.926799"}], "overall_sentiment_score": 0.134036, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.133034", "ticker_sentiment_label": "Neutral"}]}, {"title": "BioCryst Announces FDA Approval of ORLADEYO\u2122", "url": "https://www.globenewswire.com/news-release/2020/12/04/2139588/0/en/BioCryst-Announces-FDA-Approval-of-ORLADEYO-berotralstat-First-Oral-Once-daily-Therapy-to-Prevent-Attacks-in-Hereditary-Angioedema-Patients.html", "time_published": "20201203T204500", "authors": [], "summary": "BioCryst Pharmaceuticals announced FDA approval for ORLADEYO\u2122 (berotralstat), the first oral, once-daily therapy to prevent hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years and older. Clinical trials demonstrated a significant and sustained reduction in HAE attacks, improving quality of life for patients. BioCryst is launching a patient support program, EMPOWER Patient Services, to help ensure access to the new medication.", "banner_image": "https://www.globenewswire.com/NewsRoom/AttachmentNg/bf57a925-5da4-4c72-8a93-02e9c4308123", "source": "GlobeNewswire", "category_within_source": "General", "source_domain": "GlobeNewswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.921094"}], "overall_sentiment_score": 0.244224, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCRX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.890863", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.593373", "ticker_sentiment_score": "-0.102848", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.567304", "ticker_sentiment_score": "-0.101709", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson\u2019s new robotic surgical system to rival Intuitive Surgical\u2019s da Vinci", "url": "https://www.medicaldevice-network.com/features/ottava-robotic-johnson/", "time_published": "20201201T223637", "authors": [], "summary": "Johnson & Johnson has announced its new robotic surgical system, Ottava, which aims to compete with Intuitive Surgical\u2019s da Vinci robot, a long-time market leader. The robotic surgical systems market is expanding, with procedures expected to increase by 6.5\u201312% from 2020 to 2030, attracting major medical device manufacturers like J&J. With acquisitions and the inclusion of Intuitive Surgical co-founder Dr. Frederic Moll on its team, Johnson & Johnson is positioning itself as a key player in this growing and innovative sector.", "banner_image": null, "source": "Medical Device Network", "category_within_source": "General", "source_domain": "Medical Device Network", "topics": [{"topic": "life_sciences", "relevance_score": "0.905490"}, {"topic": "technology", "relevance_score": "0.822083"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.745261"}, {"topic": "finance", "relevance_score": "0.616297"}], "overall_sentiment_score": 0.057391, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.968598", "ticker_sentiment_score": "-0.273701", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.931760", "ticker_sentiment_score": "0.281986", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYK", "relevance_score": "0.643597", "ticker_sentiment_score": "0.145342", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.575607", "ticker_sentiment_score": "0.056705", "ticker_sentiment_label": "Neutral"}]}, {"title": "Osteoarthritis Therapeutics Market 2020-2024- Featuring Abbott Laboratories, Bayer AG, Among Others to Contribute to the Market Growth | Industry Analysis, Market Trends, Opportunities, and Forecast 2024", "url": "https://www.businesswire.com/news/home/20201130005551/en/Osteoarthritis-Therapeutics-Market-2020-2024--Featuring-Abbott-Laboratories-Bayer-AG-Among-Others-to-Contribute-to-the-Market-Growth-Industry-Analysis-Market-Trends-Opportunities-and-Forecast-2024", "time_published": "20201130T213729", "authors": [], "summary": "The osteoarthritis therapeutics market is projected to grow by USD 2.99 billion between 2020 and 2024, with a CAGR of almost 9%, driven by the increasing incidence of osteoarthritis. Technavio's latest report provides a detailed analysis of market size, trends, drivers, challenges, and vendor landscape, including key players like Abbott Laboratories and Bayer AG. The report also addresses the impact of COVID-19 on the market.", "banner_image": null, "source": "Business Wire", "category_within_source": "General", "source_domain": "Business Wire", "topics": [{"topic": "life_sciences", "relevance_score": "0.946824"}, {"topic": "financial_markets", "relevance_score": "0.747404"}], "overall_sentiment_score": 0.361399, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.928117", "ticker_sentiment_score": "0.403289", "ticker_sentiment_label": "Bullish"}, {"ticker": "ZBH", "relevance_score": "0.830123", "ticker_sentiment_score": "0.434150", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.737179", "ticker_sentiment_score": "0.356900", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.703234", "ticker_sentiment_score": "0.378501", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.641211", "ticker_sentiment_score": "0.317723", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson assures docs and patients its Janssen pharma unit 'Never Stops'", "url": "https://www.fiercepharma.com/marketing/j-j-s-janssen-debuts-pandemic-related-campaign-to-assure-people-pharma-unit-never-stops", "time_published": "20201125T094400", "authors": ["Beth Snyder Bulik"], "summary": "Johnson & Johnson's Janssen pharmaceutical unit has launched a \"Janssen Never Stops\" digital and social campaign to assure patients and doctors that it continues to develop and produce medicines despite the pandemic. The campaign highlights Janssen's connection to Johnson & Johnson to emphasize the broader organizational effort against the pandemic and ensures access to critical resources. It aims to reinforce trust and reliability in Janssen's operations across its six therapeutic areas.", "banner_image": "NULL", "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "retail_wholesale", "relevance_score": "0.724901"}, {"topic": "technology", "relevance_score": "0.642250"}], "overall_sentiment_score": 0.441562, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.430996", "ticker_sentiment_label": "Bullish"}]}, {"title": "Chinese Government Arrests GenScript and Legend Biotech Founder for Smuggling", "url": "https://www.biospace.com/genscript-and-legend-biotech-founder-frank-zhang-arrested-by-chinese-government", "time_published": "20201124T224214", "authors": ["Alex Keown"], "summary": "Fangliang \u201cFrank\u201d Zhang, founder of Legend Biotech and co-founder of GenScript, has been arrested by the Chinese government for allegedly smuggling genetic resources. Following his arrest, Zhang resigned from Legend Biotech's board to avoid company distraction, and two other GenScript employees were also arrested in connection with the investigation. The arrests are related to China's strict regulations on human genetic resources, which prohibit their collection or distribution abroad by foreign entities.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "0.902968"}], "overall_sentiment_score": -0.125905, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LEGN", "relevance_score": "0.951244", "ticker_sentiment_score": "-0.328711", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.600475", "ticker_sentiment_score": "0.116736", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Unveils Details On Ottava Soft-Tissue Robot, Chasing Intuitive, Medtronic", "url": "https://insights.citeline.com/MT143115/Johnson--Johnson-Unveils-Details-On-Ottava-SoftTissue-Robot-Chasing-Intuitive-Medtronic/", "time_published": "20201120T223638", "authors": ["Marion Webb"], "summary": "Johnson & Johnson has unveiled details about its Ottava soft-tissue robot, positioning itself to compete with industry leaders Intuitive Surgical and Medtronic. This move indicates J&J's aggressive entry into the robotic surgery market. The announcement follows previous developments, including J&J taking full ownership of Verb Surgical and Medtronic introducing its Hugo system.", "banner_image": null, "source": "Citeline News & Insights", "category_within_source": "General", "source_domain": "Citeline News & Insights", "topics": [{"topic": "life_sciences", "relevance_score": "0.930256"}, {"topic": "technology", "relevance_score": "0.843023"}], "overall_sentiment_score": 0.109473, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.128668", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.934404", "ticker_sentiment_score": "0.140809", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.845206", "ticker_sentiment_score": "0.142224", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.611876", "ticker_sentiment_score": "0.121408", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson ordered to pay $120 mln damages in New York baby powder case", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/johnson-johnson-ordered-pay-120-mln-damages-new-york-baby-powder-case-2020-11-20/", "time_published": "20201120T164200", "authors": ["Jonathan Stempel"], "summary": "A New York state judge has ordered Johnson & Johnson to pay $120 million in damages to a woman and her husband who blamed her cancer on asbestos exposure from the company's baby powder. The payout was reduced from an initial $325 million awarded by a jury, and Johnson & Johnson plans to appeal the verdict, maintaining its talc products are safe and asbestos-free. The company continues to face lawsuits and appeals regarding its talc products.", "banner_image": "https://www.reuters.com/resizer/v2/W3K2Y24J2FIULI4M72K44W4T2I.jpg?random=1700684277864", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.901847"}, {"topic": "finance", "relevance_score": "0.735086"}], "overall_sentiment_score": -0.303181, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.300014", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Gilead Sciences\u2019 Product Line Extension", "url": "https://marketrealist.com/2015/08/gilead-sciences-product-line-extension/", "time_published": "20201120T160400", "authors": ["Margaret Patrick"], "summary": "Gilead Sciences (GILD) is expanding its product line beyond HIV and HCV into new therapeutic areas such as oncology, pulmonology, and cardiology. The company launched Zydelig for chronic lymphocytic leukemia (CLL) and has other promising drugs in various clinical trial phases for cancers, respiratory diseases, and cardiovascular conditions. Investors can gain exposure to Gilead's diversified pipeline through the iShares NASDAQ Biotechnology ETF (IBB).", "banner_image": null, "source": "Market Realist", "category_within_source": "General", "source_domain": "Market Realist", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.22104, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "1.000000", "ticker_sentiment_score": "0.414912", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABBV", "relevance_score": "0.641510", "ticker_sentiment_score": "0.100805", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.646628", "ticker_sentiment_score": "0.149975", "ticker_sentiment_label": "Neutral"}]}, {"title": "Understanding Johnson & Johnson\u2019s Ownership Structure", "url": "https://marketrealist.com/2015/03/understanding-johnson-johnsons-ownership-structure/", "time_published": "20201120T104800", "authors": ["Mike Benson"], "summary": "As of January 2015, Johnson & Johnson's ownership structure is predominantly characterized by passive investments, accounting for over 80% of the total, with key holders including BlackRock, Vanguard, and State Street. Active investors, such as hedge funds and individuals, hold a smaller share, around 2.5%, while institutional investors collectively own 2.1 billion shares. Johnson & Johnson is also a significant component of the Health Care Select Sector SPDR ETF (XLV).", "banner_image": null, "source": "Market Realist", "category_within_source": "General", "source_domain": "Market Realist", "topics": [{"topic": "finance", "relevance_score": "0.820165"}, {"topic": "financial_markets", "relevance_score": "0.722019"}, {"topic": "life_sciences", "relevance_score": "0.600643"}], "overall_sentiment_score": 0.010371, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.317363", "ticker_sentiment_score": "0.038737", "ticker_sentiment_label": "Neutral"}]}, {"title": "BREAKING: Johnson & Johnson finally unveils its new robot-assisted surgery system", "url": "https://www.massdevice.com/breaking-johnson-johnson-finally-unveils-its-new-robot-assisted-surgery-system/", "time_published": "20201119T223710", "authors": ["Sean Whooley"], "summary": "Johnson & Johnson has unveiled Ottava, its new robot-assisted surgery system designed for unrivaled flexibility and control with six arms integrated into the operating table. The company plans to begin verification and validation processes in 2021, followed by clinical trials in 2022, and aims to combine it with the FDA-cleared Monarch platform for minimally invasive procedures and targeted drug delivery. J&J remains optimistic about the medtech market's recovery post-pandemic, expecting double-digit operational sales growth in 2021.", "banner_image": null, "source": "MassDevice", "category_within_source": "General", "source_domain": "MassDevice", "topics": [{"topic": "life_sciences", "relevance_score": "0.944126"}, {"topic": "technology", "relevance_score": "0.822071"}], "overall_sentiment_score": 0.215019, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.309640", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.823118", "ticker_sentiment_score": "0.232839", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOGL", "relevance_score": "0.646315", "ticker_sentiment_score": "0.146404", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Celularity is Leading the Next Evolution in Cellular Medicine", "url": "https://bioinformant.com/celularity-robert-hariri/", "time_published": "20201118T034341", "authors": ["Cade Hildreth"], "summary": "Celularity is a clinical-stage cell therapeutics company focusing on allogeneic cellular therapies derived from the postpartum human placenta. Founded by Robert Hariri, MD, PhD, the company is developing innovative and scalable off-the-shelf treatments for cancer, inflammatory, and age-related diseases. The article details Celularity's progress, including its lead products like CYNK-001 (a placental-derived NK cell therapy), its IMPACT\u2122 platform for manufacturing, and its strategic relocation to a new headquarters to support late-stage clinical trials and commercialization.", "banner_image": "NULL", "source": "BioInformant", "category_within_source": "General", "source_domain": "BioInformant", "topics": [{"topic": "life_sciences", "relevance_score": "0.902873"}, {"topic": "finance", "relevance_score": "0.720246"}], "overall_sentiment_score": 0.476399, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CELU", "relevance_score": "1.000000", "ticker_sentiment_score": "0.842215", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.709555", "ticker_sentiment_score": "0.317358", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.645118", "ticker_sentiment_score": "0.338415", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vaccine tested at Emory highly effective in preventing COVID-19, study says | Emory University | Atlanta GA", "url": "https://news.emory.edu/stories/2020/11/coronavirus_moderna_vaccine_highly_effective/index.html", "time_published": "20201117T225214", "authors": [], "summary": "An investigational COVID-19 vaccine, mRNA-1273, co-developed by NIAID and Moderna, Inc., has shown to be 94.5 percent effective based on early results from a large-scale clinical trial. Emory University played a significant role in this Phase 3 trial, known as the COVE study, enrolling approximately 700 participants and previously contributing to the Phase 1 study. The vaccine was well-tolerated and stimulated a robust immune response, with all severe COVID-19 cases in the trial occurring in the placebo group.", "banner_image": null, "source": "Emory University", "category_within_source": "General", "source_domain": "Emory University", "topics": [{"topic": "life_sciences", "relevance_score": "0.911903"}, {"topic": "finance", "relevance_score": "0.602023"}], "overall_sentiment_score": 0.277708, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.461842", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.620862", "ticker_sentiment_score": "0.135982", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J commits $100M over next 5 years to promote health equity solutions for people of color", "url": "https://www.roi-nj.com/2020/11/17/healthcare/jj-commits-100m-over-next-5-years-to-promote-health-equity-solutions-for-people-of-color/", "time_published": "20201117T223710", "authors": ["ROI-NJ Staff"], "summary": "Johnson & Johnson has pledged $100 million over the next five years to advance health equity solutions for people of color in the United States. This commitment addresses systemic racism, the COVID-19 pandemic, and economic decline, focusing on healthier communities, enduring alliances, and a diverse corporate culture. The initiative aims to improve access to care, support diverse representation in health professions, and increase clinical trial participation among diverse populations.", "banner_image": null, "source": "ROI-NJ", "category_within_source": "General", "source_domain": "ROI-NJ", "topics": [{"topic": "life_sciences", "relevance_score": "0.917919"}], "overall_sentiment_score": 0.416467, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.410385", "ticker_sentiment_label": "Bullish"}]}, {"title": "Rutgers Recruiting Participants for Johnson & Johnson Phase 3 COVID-19 Vaccine Clinical Trial", "url": "https://www.rutgers.edu/news/rutgers-recruiting-participants-johnson-johnson-phase-3-covid-19-vaccine-clinical-trial", "time_published": "20201117T223708", "authors": ["Patti Verbanas"], "summary": "Rutgers University is participating as a clinical trial site for Johnson & Johnson's Phase 3 COVID-19 vaccine candidate study, aiming to enroll up to 2,000 participants from its community and across New Jersey. Researchers will evaluate the vaccine's safety and efficacy, particularly focusing on diverse representation in the participant pool. This marks Rutgers' second Phase 3 vaccine trial, highlighting its commitment to combating the pandemic.", "banner_image": null, "source": "Rutgers University", "category_within_source": "General", "source_domain": "Rutgers University", "topics": [{"topic": "life_sciences", "relevance_score": "0.933493"}], "overall_sentiment_score": 0.437544, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.426015", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson to Address Racial and Social Injustice Through Platform that Aims to Eliminate Health Inequities for People of Color", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-to-address-racial-and-social-injustice-through-platform-that-aims-to-eliminate-health-inequities-for-people-of-color-301174429.html", "time_published": "20201117T080000", "authors": [], "summary": "Johnson & Johnson announced a $100 million commitment over five years to address racial and social injustice by eliminating health inequities for Black people and other communities of color in the United States. The initiative focuses on three key areas: healthier communities, enduring alliances, and a diverse and inclusive corporate culture. This commitment responds to the impact of systemic racism, the COVID-19 pandemic, and economic decline on healthcare inequities.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.923046"}], "overall_sentiment_score": 0.413556, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.442575", "ticker_sentiment_label": "Bullish"}]}, {"title": "|Tesla to Join S&P 500 Next Month as Largest-Ever New Member", "url": "https://www.bloomberg.com/news/articles/2020-11-16/tesla-will-join-s-p-500-in-december-as-largest-ever-new-member", "time_published": "20201116T222800", "authors": ["|Esha Dey and Dana Hull"], "summary": "|Tesla Inc. (TSLA) is set to join the S&P 500 index on December 21, becoming the largest company ever added to the gauge. This announcement follows months of speculation and a significant rally in the stock this year, elevating the electric vehicle pioneer's market value to nearly $390 billion. Tesla's inclusion is expected to greatly broaden its investor base and make it one of the index's most influential constituents.", "banner_image": "|NULL", "source": "Bloomberg.com", "category_within_source": "General", "source_domain": "Bloomberg.com", "topics": [{"topic": "financial_markets", "relevance_score": "0.910080"}, {"topic": "technology", "relevance_score": "0.847656"}, {"topic": "energy_transportation", "relevance_score": "0.719394"}], "overall_sentiment_score": 0.335742, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TSLA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.469023", "ticker_sentiment_label": "Bullish"}, {"ticker": "SPGI", "relevance_score": "0.739183", "ticker_sentiment_score": "0.325989", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.630857", "ticker_sentiment_score": "0.248183", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.622076", "ticker_sentiment_score": "0.204373", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Wayfair Names Michael E. Sneed to its Board of Directors", "url": "https://investor.wayfair.com/news/news-details/2020/Wayfair-Names-Michael-E.-Sneed-to-its-Board-of-Directors/default.aspx", "time_published": "20201113T233619", "authors": [], "summary": "Wayfair Inc. announced the appointment of Michael E. Sneed, Executive Vice President of Global Corporate Affairs and Chief Communication Officer for Johnson & Johnson, to its board of directors. Sneed brings extensive experience in corporate affairs, communications, and operations to Wayfair, having driven international growth and held various senior leadership positions at Johnson & Johnson. His addition is expected to provide valuable insights as Wayfair continues its growth and aims to solidify its position as a leader in online home retail.", "banner_image": null, "source": "Wayfair Investor Relations", "category_within_source": "General", "source_domain": "Wayfair Investor Relations", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.807397"}, {"topic": "finance", "relevance_score": "0.725221"}], "overall_sentiment_score": 0.382136, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "W", "relevance_score": "1.000000", "ticker_sentiment_score": "0.434325", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.742271", "ticker_sentiment_score": "0.306488", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Medical Devices Market In Japan- Baxter International Inc., Becton, Dickinson and Co., Among Others to Contribute to the Market Growth | Industry Analysis, Trends, Opportunities and Forecast 2020-2024", "url": "https://www.businesswire.com/news/home/20201113005398/en/The-Medical-Devices-Market-In-Japan--Baxter-International-Inc.-Becton-Dickinson-and-Co.-Among-Others-to-Contribute-to-the-Market-Growth-Industry-Analysis-Trends-Opportunities-and-Forecast-2020-2024", "time_published": "20201113T214721", "authors": ["NULL"], "summary": "The medical devices market in Japan is projected to grow by USD 6.65 billion between 2020 and 2024, at a CAGR of almost 4%. This growth is driven by sophisticated healthcare infrastructure and the advent of DevOps. Key companies contributing to this market include Baxter International Inc., Becton, Dickinson and Co., and others.", "banner_image": "https://www.businesswire.com/news/home/20201113005398/en/The-Medical-Devices-Market-In-Japan--Baxter-International-Inc.-Becton-Dickinson-and-Co.-Among-Others-to-Contribute-to-the-Market-Growth-Industry-Analysis-Trends-Opportunities-and-Forecast-2020-2024", "source": "Business Wire", "category_within_source": "General", "source_domain": "Business Wire", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.46267, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "BAX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.464694", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDX", "relevance_score": "0.877410", "ticker_sentiment_score": "0.482354", "ticker_sentiment_label": "Bullish"}, {"ticker": "GEHC", "relevance_score": "0.749022", "ticker_sentiment_score": "0.473083", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.609280", "ticker_sentiment_score": "0.497082", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.849208", "ticker_sentiment_score": "0.485598", "ticker_sentiment_label": "Bullish"}]}, {"title": "Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund", "url": "https://www.businesswire.com/news/home/20201112005085/en/Metagenomi-closes-USD-65-million-Series-A-financing-led-by-Leaps-by-Bayer-and-Humboldt-Fund", "time_published": "20201112T224712", "authors": [], "summary": "Metagenomi, a genomic medicines company, successfully closed a USD 65 million Series A financing round led by Leaps by Bayer and Humboldt Fund. The company, which specializes in precision gene editing systems, emerged from stealth mode and plans to use the capital to expand its gene editing systems for therapeutic use and advance its own pipeline. Metagenomi aims to improve patient access to gene editing technologies by developing safe and accurate modalities for therapeutic development.", "banner_image": null, "source": "Business Wire", "category_within_source": "General", "source_domain": "Business Wire", "topics": [{"topic": "life_sciences", "relevance_score": "0.938470"}, {"topic": "finance", "relevance_score": "0.709255"}], "overall_sentiment_score": 0.477079, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MGX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.810237", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.645734", "ticker_sentiment_score": "0.309944", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.645016", "ticker_sentiment_score": "0.344957", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson confident in 1B dose goal for COVID-19 vaccine next year, looking ahead to 2022", "url": "https://www.fiercepharma.com/manufacturing/j-j-touts-covid-vaccine-supply-chain-stability-eyes-plans-for-2022", "time_published": "20201112T060900", "authors": ["Fraiser Kansteiner"], "summary": "Johnson & Johnson is confident in its ability to produce 1 billion doses of its COVID-19 vaccine in 2021, with plans extending into 2022. The company has established a global network of manufacturers and packagers and secured key partnerships and contracts to meet its supply goals. J&J's vaccine also offers a logistical advantage due to its less stringent cold-chain storage requirements compared to other candidates.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "manufacturing", "relevance_score": "0.941900"}], "overall_sentiment_score": 0.480797, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.493260", "ticker_sentiment_label": "Bullish"}]}, {"title": "Gold slides amid Pfizer\u2019s hopeful COVID-19 vaccine news", "url": "https://www.aljazeera.com/economy/2020/11/9/gold-slides-most-since-august-amid-hopeful-covid-19-vaccine-news", "time_published": "20201109T230212", "authors": ["Yvonne Yue Li and Bloomberg"], "summary": "Gold prices plummeted below $1,900 an ounce following the announcement of Pfizer's COVID-19 vaccine showing over 90% effectiveness, sparking hopes for economic recovery and dimming prospects for further stimulus. This led to gold's biggest slide since August, as investors reacted to reduced needs for economic stimulus and a potential reopening of economies. Industrial metals, equities, and oil prices concurrently saw jumps, indicating a shift in investor sentiment.", "banner_image": null, "source": "Al Jazeera", "category_within_source": "General", "source_domain": "Al Jazeera", "topics": [{"topic": "financial_markets", "relevance_score": "0.926025"}, {"topic": "life_sciences", "relevance_score": "0.716857"}, {"topic": "economy_macro", "relevance_score": "0.648675"}], "overall_sentiment_score": 0.339539, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.436186", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.643522", "ticker_sentiment_score": "0.327580", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.619115", "ticker_sentiment_score": "0.339606", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.613876", "ticker_sentiment_score": "0.323524", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "'Great day for humanity': Pfizer says COVID-19 vaccine over 90% effective", "url": "https://www.weforum.org/stories/2020/11/pfizer-pharmaceutical-covid19-vaccine-health/", "time_published": "20201109T230211", "authors": ["Michael Erman", "Julie Steenhuysen"], "summary": "Pfizer announced that its experimental COVID-19 vaccine, developed with BioNTech, is over 90% effective, marking a significant milestone in the fight against the pandemic. This news caused world markets to surge, with particular gains for Pfizer and BioNTech stocks, and raised optimism for a return to normalcy, though questions remain about duration of protection and distribution. The companies plan to seek U.S. emergency authorization and project producing 1.3 billion doses in 2021.", "banner_image": null, "source": "The World Economic Forum", "category_within_source": "General", "source_domain": "The World Economic Forum", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "economy_macro", "relevance_score": "0.921408"}, {"topic": "financial_markets", "relevance_score": "0.809368"}], "overall_sentiment_score": 0.509554, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.865775", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.712028", "ticker_sentiment_score": "0.319404", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.638178", "ticker_sentiment_score": "0.310325", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pfizer vaccine news 'as good as you could hope for'", "url": "https://abcnews.go.com/Health/pfizer-vaccine-news-good-hope/story?id=74114151", "time_published": "20201109T165600", "authors": ["Sony Salzman"], "summary": "Pfizer announced that its COVID-19 vaccine appears to be at least 90% effective in an early analysis, a result widely celebrated by doctors and scientists as \"extraordinary.\" While this early data is promising, experts caution that more safety data is needed, and the efficacy rate could change as the trial continues. The article also highlights Pfizer's independence from Operation Warp Speed funding for its research, which CEO Albert Bourla believes allowed the company to remain agile.", "banner_image": null, "source": "ABC News", "category_within_source": "General", "source_domain": "ABC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.936258"}], "overall_sentiment_score": 0.334014, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.502849", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.718979", "ticker_sentiment_score": "0.332795", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.607171", "ticker_sentiment_score": "0.145851", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer says COVID-19 vaccine is looking 90 percent effective", "url": "https://www.pbs.org/newshour/health/pfizer-says-covid-19-vaccine-is-looking-90-percent-effective", "time_published": "20201109T113100", "authors": ["Associated Press"], "summary": "Pfizer announced that an early analysis of its COVID-19 vaccine data suggests it is 90% effective, putting the company on track for emergency-use approval from the FDA. This news was met with significant optimism in markets and by health experts like Dr. Anthony Fauci, though officials noted that further data is needed and initial supplies will be limited. The company funded its own testing and manufacturing, distinguishing it from other vaccine developers involved in Operation Warp Speed.", "banner_image": null, "source": "PBS", "category_within_source": "General", "source_domain": "PBS", "topics": [{"topic": "life_sciences", "relevance_score": "0.916408"}], "overall_sentiment_score": 0.483394, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.808035", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.726896", "ticker_sentiment_score": "0.317672", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.643041", "ticker_sentiment_score": "0.305843", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "McKesson says states seek $21 billion from drug distributors in opioid settlement", "url": "https://www.fijitimes.com.fj/mckesson-says-states-seek-21-billion-from-drug-distributors-in-opioid-settlement/", "time_published": "20201105T215629", "authors": ["Reuters"], "summary": "McKesson Corp announced that it, along with AmerisourceBergen Corp and Cardinal Health Inc, could face a $21 billion settlement to resolve thousands of lawsuits related to their alleged role in the U.S. opioid crisis. This new proposal, which is subject to further negotiations, is an increase from a previous $18 billion offer by the distributors and complements a $5 billion contribution from Johnson & Johnson. The lawsuits accuse drugmakers of deceptive marketing and distributors of ignoring red flags concerning prescription painkiller diversion, seeking to hold them responsible for the epidemic.", "banner_image": null, "source": "The Fiji Times", "category_within_source": "General", "source_domain": "The Fiji Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.942905"}, {"topic": "finance", "relevance_score": "0.715280"}, {"topic": "earnings", "relevance_score": "0.617801"}], "overall_sentiment_score": -0.033464, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "0.927107", "ticker_sentiment_score": "0.021513", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.815812", "ticker_sentiment_score": "0.031053", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.620774", "ticker_sentiment_score": "-0.125424", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stryker closes Wright Medical acquisition after year-long wait", "url": "https://www.medtechdive.com/news/stryker-says-wright-deal-closing-imminent-after-key-antitrust-green-lights/588353/", "time_published": "20201104T232159", "authors": ["Maria Rachal"], "summary": "Stryker has completed its acquisition of Wright Medical after a year-long wait, following approvals from U.S. and U.K. antitrust authorities. The deal, valued at $4 billion, strengthens Stryker's position in the trauma and extremities markets, after addressing concerns with divestitures of certain ankle replacement and finger joint implant products to Colfax subsidiary DJO Global. Wright Medical saw a sharp rebound in sales in Q3, suggesting a recovery in the medical device market demand.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.900818"}, {"topic": "earnings", "relevance_score": "0.704797"}], "overall_sentiment_score": 0.283445, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SYK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.487151", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.649155", "ticker_sentiment_score": "0.088538", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Virtual Reality Impacts Healthcare: Johnson & Johnson Case Study", "url": "https://www.xrtoday.com/virtual-reality/how-virtual-reality-impacts-healthcare-johnson-johnson-case-study/", "time_published": "20201104T223710", "authors": ["Rebekah Carter"], "summary": "This article examines how virtual reality (VR) is transforming the healthcare industry, with a particular focus on a case study involving Johnson & Johnson, Oculus for Business, and Osso VR. It highlights VR's role in improving surgical training opportunities, enabling remote collaboration, and ensuring continuity of education for medical professionals, especially during events like the Covid-19 pandemic. The case study demonstrates significant improvements in skill proficiency for VR-trained students compared to those using passive learning methods.", "banner_image": null, "source": "XR Today", "category_within_source": "General", "source_domain": "XR Today", "topics": [{"topic": "life_sciences", "relevance_score": "0.941875"}, {"topic": "technology", "relevance_score": "0.826793"}], "overall_sentiment_score": 0.410643, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.448777", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson fails to overturn $2.12 bln baby powder verdict, plans Supreme Court appeal", "url": "https://www.reuters.com/world/asia-pacific/johnson-johnson-fails-overturn-212-bln-baby-powder-verdict-plans-supreme-court-2020-11-03/", "time_published": "20201104T080600", "authors": ["Jonathan Stempel"], "summary": "Missouri's highest court refused to overturn a $2.12 billion damages award against Johnson & Johnson in a baby powder lawsuit, prompting the company to announce an appeal to the U.S. Supreme Court. J&J maintains its product is safe and asbestos-free, despite facing over 21,800 lawsuits and court findings of \"significant reprehensibility\" in its conduct regarding asbestos contamination. The company will set aside a $2.1 billion reserve for the verdict and its shares closed down nearly 20 cents.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "finance", "relevance_score": "0.815482"}, {"topic": "life_sciences", "relevance_score": "0.911741"}, {"topic": "earnings", "relevance_score": "0.721278"}], "overall_sentiment_score": -0.609251, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.615978", "ticker_sentiment_label": "Bearish"}]}, {"title": "Eliquis partners BMS and Pfizer join the pharma crowd urging doctor visits during COVID-19", "url": "https://www.fiercepharma.com/marketing/bms-and-pfizer-join-pharma-crowd-encouraging-well-visits-during-covid-19", "time_published": "20201102T082100", "authors": ["Beth Snyder Bulik"], "summary": "Bristol Myers Squibb and Pfizer have launched a new campaign called \"No Time to Wait\" to encourage people to seek prompt medical attention for conditions like atrial fibrillation, deep vein thrombosis, and pulmonary embolism during the COVID-19 pandemic. The campaign, which includes TV ads featuring real doctors, aims to raise awareness of symptoms and address the significant drop in primary care visits observed during the pandemic. This initiative promotes their co-marketed anticoagulant, Eliquis, which saw sales of $4.8 billion in the first half of 2020.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.921705"}], "overall_sentiment_score": 0.27793, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.384163", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.900190", "ticker_sentiment_score": "0.379807", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.604551", "ticker_sentiment_score": "0.117949", "ticker_sentiment_label": "Neutral"}]}, {"title": "Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen", "url": "https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-advancement-of-oral-il-23-receptor-antagonists-program-in-collaboration-with-janssen-301163376.html", "time_published": "20201029T163000", "authors": [], "summary": "Protagonist Therapeutics announced the advancement of two additional oral peptide IL-23 receptor antagonist candidates, PN-235 and PN-232, into clinical development in collaboration with Janssen Biotech. This expands their portfolio of oral IL-23 receptor antagonists, building on the ongoing Phase 2 study of PTG-200 for Crohn's disease. The company expects to initiate a Phase 1 study for PN-235 in Q4 2020, highlighting the success of their peptide engineering platform and commitment to the IL-23 pathway.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.380412, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PTGX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.484996", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.606923", "ticker_sentiment_score": "0.309779", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Mary J. Blige and other women touched by breast cancer talk importance of screening", "url": "https://abcnews.go.com/GMA/Culture/mary-blige-women-touched-breast-cancer-talk-importance/story?id=73819658", "time_published": "20201028T040000", "authors": ["Hayley FitzPatrick", "Nidhi Singh"], "summary": "Mary J. Blige and other women affected by breast cancer are advocating for the importance of breast cancer screening in the \"P.O.W.E.R. of Sure\" campaign. The initiative addresses the racial disparity in breast cancer death rates, which are 40% higher for Black women, and encourages early detection and self-advocacy. Survivors and those currently battling the disease share their experiences to highlight the critical role of mammograms and overcoming fear.", "banner_image": null, "source": "ABC News", "category_within_source": "General", "source_domain": "ABC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.918712"}], "overall_sentiment_score": 0.25123, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HOLX", "relevance_score": "0.925731", "ticker_sentiment_score": "0.320542", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.630175", "ticker_sentiment_score": "0.210924", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Apple shrinks, Amazon grows among Jabil\u2019s largest customers", "url": "https://stpetecatalyst.com/apple-shrinks-amazon-grows-among-jabils-largest-customers/", "time_published": "20201027T223657", "authors": ["Margie Manning"], "summary": "Jabil's annual report shows a shift in its largest customer base, with Apple's share of revenue decreasing while Amazon's grows significantly. This diversification strategy aims to reduce Jabil's reliance on a single customer, a concern previously highlighted by analysts. The company also reported an increase in employees and manufacturing space, along with COVID-19 related costs.", "banner_image": null, "source": "St Pete Catalyst", "category_within_source": "General", "source_domain": "St Pete Catalyst", "topics": [{"topic": "earnings", "relevance_score": "0.935265"}, {"topic": "technology", "relevance_score": "0.840259"}, {"topic": "manufacturing", "relevance_score": "0.728162"}], "overall_sentiment_score": 0.126389, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JBL", "relevance_score": "1.000000", "ticker_sentiment_score": "0.106626", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.932256", "ticker_sentiment_score": "-0.233835", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMZN", "relevance_score": "0.740851", "ticker_sentiment_score": "0.305543", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CSCO", "relevance_score": "0.620269", "ticker_sentiment_score": "0.127866", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.635378", "ticker_sentiment_score": "0.124507", "ticker_sentiment_label": "Neutral"}]}, {"title": "Postpartum Hemorrhage (PPH) Devices Market Top-Companies, Future-Growth, Regional Analysis, Business-Opportunities 2027", "url": "https://www.openpr.com/news/2171980/postpartum-hemorrhage-pph-devices-market-top-companies", "time_published": "20201026T161900", "authors": ["Allied Market Research"], "summary": "The Postpartum Hemorrhage (PPH) Devices Market was valued at $637 million in 2015 and is projected to reach $906 million by 2022, growing at a CAGR of 5.2%. Key drivers include increasing pregnancy complications and technological advancements, though lack of trained professionals in developing countries may hinder growth. The report also addresses the impact of COVID-19 on the market and provides segmentation by product and region.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.918151"}, {"topic": "finance", "relevance_score": "0.705154"}], "overall_sentiment_score": 0.277073, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UTMD", "relevance_score": "0.948258", "ticker_sentiment_score": "0.381493", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDX", "relevance_score": "0.737772", "ticker_sentiment_score": "0.255623", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.641338", "ticker_sentiment_score": "0.243934", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.575679", "ticker_sentiment_score": "0.228504", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Young Leaders Stepping Up in Tough Times!", "url": "https://www.jnj.com/our-company/young-leaders-stepping-up-in-tough-times", "time_published": "20201023T223711", "authors": ["Annet Eijkelkamp"], "summary": "This article highlights how young leaders within Johnson & Johnson's One Young World (OYW) program are stepping up to address global challenges, particularly during the COVID-19 pandemic. It showcases several J&J OYW Ambassadors making a significant impact in their communities, from digital storytelling to sanitation training, and emphasizes the program's role in building socially conscious and motivated change-makers. The article also touches on the resilience required to adapt and grow in the face of adversity, a theme that has become increasingly relevant.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.916306"}], "overall_sentiment_score": 0.407927, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.404972", "ticker_sentiment_label": "Bullish"}]}, {"title": "WSJ News Exclusive | Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&J Resuming", "url": "https://www.wsj.com/health/healthcare/covid-19-vaccine-trial-from-astrazeneca-oxford-can-resume-in-u-s-11603476923?gaa_at=eafs&gaa_n=AWEtsqdw2TMfq_1LbM-KzXm3k_j2qmnQWQz8qvlBIWygme6yfDkAAVldTd1i&gaa_ts=6907d479&gaa_sig=GnEtSH7pgk1CEWcBgoxHR0EDcVUzYY-5wVZc3BScRbSqpx20yRC3YBSHDmAFQBWCrXhhuxE8URvY1h3r5CZFoA%3D%3D", "time_published": "20201023T214708", "authors": ["Thomas M. Burton and Peter Loftus"], "summary": "Pivotal studies for Covid-19 vaccines from AstraZeneca and Johnson & Johnson are resuming after temporary pauses. The companies announced on Friday that testing for their advanced vaccine candidates can restart, as investigators found no link between previously observed medical events and the vaccine shots. This restart is crucial for regulatory evaluation of the vaccines' safety and efficacy.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.943388"}], "overall_sentiment_score": 0.358978, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "1.000000", "ticker_sentiment_score": "0.425911", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.936458", "ticker_sentiment_score": "0.341919", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Trump Sets Up Pharma Billionaires for Coronavirus Payday", "url": "https://theintercept.com/2020/10/23/trump-covid-19-pharma-regeneron-coronavirus-treatment/", "time_published": "20201023T122600", "authors": ["Sharon Lerner"], "summary": "The article details how the Trump administration's funding for Regeneron's Covid-19 antibody treatment, used by Donald Trump, lacked affordability guarantees, potentially leading to high costs and limited access for most patients. It highlights that Regeneron received hundreds of millions in public funds, and executives profited from stock sales following positive news about the treatment, while concerns about transparency and public access remain. Critics argue that the government's contracting methods may have been designed to avoid oversight and public interest safeguards.", "banner_image": null, "source": "The Intercept", "category_within_source": "General", "source_domain": "The Intercept", "topics": [{"topic": "life_sciences", "relevance_score": "0.917889"}, {"topic": "economy_fiscal", "relevance_score": "0.743954"}, {"topic": "finance", "relevance_score": "0.602557"}], "overall_sentiment_score": -0.150968, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.313510", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.626213", "ticker_sentiment_score": "-0.117467", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.618015", "ticker_sentiment_score": "-0.117098", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.647348", "ticker_sentiment_score": "-0.147343", "ticker_sentiment_label": "Neutral"}]}, {"title": "European sales of Samsung Bioepis' 3 biosimilars up 13% in Q3", "url": "https://www.koreaherald.com/article/2459506", "time_published": "20201022T093409", "authors": [], "summary": "South Korean drugmaker Samsung Bioepis Co. reported a 13 percent year-on-year increase in European sales for its three biosimilar products during the third quarter of this year, reaching $279 million. This growth was driven by strong performances from Benepali, Flixabi, and Imraldi, which treat various autoimmune diseases. The company also sells the breast cancer biosimilar Ontruzant in Europe.", "banner_image": null, "source": "The Korea Herald", "category_within_source": "General", "source_domain": "The Korea Herald", "topics": [{"topic": "earnings", "relevance_score": "0.906993"}, {"topic": "life_sciences", "relevance_score": "0.812518"}], "overall_sentiment_score": 0.202394, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.841788", "ticker_sentiment_score": "-0.130353", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.722754", "ticker_sentiment_score": "0.311921", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.708804", "ticker_sentiment_score": "0.320958", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.604793", "ticker_sentiment_score": "0.318410", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson leader Jennifer Taubert named to Fortune's 2020 Most Powerful Women in Business list", "url": "https://www.jnj.com/latest-news/johnson-johnson-leader-makes-2020-fortune-most-powerful-women-list", "time_published": "20201021T223708", "authors": ["Johnson & Johnson"], "summary": "Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals at Johnson & Johnson, has been named to Fortune's 2020 Most Powerful Women in Business list for the fifth consecutive year. The recognition highlights her leadership in guiding the Janssen Pharmaceutical Companies during the COVID-19 pandemic, overseeing crucial pharmaceutical developments, and championing patient access and affordability. Fortune's criteria for the list include business scale, health of the business, career arc, social influence, and how executives wield their power for positive impact.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.802478"}, {"topic": "finance", "relevance_score": "0.601013"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.648500"}], "overall_sentiment_score": 0.429839, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.430324", "ticker_sentiment_label": "Bullish"}]}, {"title": "Moderna Nears Finish Line For Enrollment In Phase 3 Coronavirus Vaccine Study", "url": "https://finance.yahoo.com/news/moderna-nears-finish-line-enrollment-181754492.html", "time_published": "20201019T225214", "authors": ["Shanthi Rexaline"], "summary": "Moderna is close to completing enrollment for its Phase 3 COVE study for a coronavirus vaccine, with 98.4% of the targeted 30,000 participants already enrolled. The company has seen an uptick in enrollment pace and expects the first interim analysis results to be available in November. Moderna is also pursuing regulatory submissions in the EU and Canada, with further updates expected during its Q3 earnings call on October 29.", "banner_image": null, "source": "Yahoo Finance", "category_within_source": "General", "source_domain": "Yahoo Finance", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.829881"}, {"topic": "earnings", "relevance_score": "0.724571"}], "overall_sentiment_score": 0.105471, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.412774", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.644224", "ticker_sentiment_score": "0.003074", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.637133", "ticker_sentiment_score": "0.038604", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.574250", "ticker_sentiment_score": "0.024864", "ticker_sentiment_label": "Neutral"}]}, {"title": "Southwest Airlines Expands during COVID-19, Other Airlines Try to Survive", "url": "https://www.newsweek.com/southwest-airlines-expands-despite-covid-19-while-other-airlines-try-survive-1539883", "time_published": "20201016T151400", "authors": ["Scott Reeves"], "summary": "During the COVID-19 pandemic, while many airlines struggled and cut services, Southwest Airlines strategically expanded its operations into major airports in Chicago and Houston. Industry experts view this as a bold move, betting on a long-term rebound in corporate travel. Other airlines like Delta and United reported significant losses, and the industry as a whole faced unprecedented challenges, with air travel demand plummeting and manufacturers like Boeing and Airbus suffering order cancellations.", "banner_image": null, "source": "Newsweek", "category_within_source": "General", "source_domain": "Newsweek", "topics": [{"topic": "earnings", "relevance_score": "0.924444"}, {"topic": "economy_macro", "relevance_score": "0.807184"}, {"topic": "energy_transportation", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.722239"}], "overall_sentiment_score": -0.199456, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "LUV", "relevance_score": "1.000000", "ticker_sentiment_score": "0.204173", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UAL", "relevance_score": "0.888072", "ticker_sentiment_score": "-0.336720", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DAL", "relevance_score": "0.880516", "ticker_sentiment_score": "-0.333512", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BA", "relevance_score": "0.714938", "ticker_sentiment_score": "-0.416499", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.577788", "ticker_sentiment_score": "-0.103490", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 ways Johnson & Johnson is cultivating outside-the-box innovations for COVID-19", "url": "https://www.jnj.com/innovation/ways-johnson-johnson-is-cultivating-health-innovations-for-covid-19", "time_published": "20201015T223708", "authors": ["Jennifer Rainey Marquez"], "summary": "Johnson & Johnson is proactively addressing the COVID-19 pandemic and future health threats by fostering external innovation and supporting scientists and entrepreneurs globally. This includes investing in rapid diagnostic tests, collaborating on programs like BLUE KNIGHT\u2122 for emerging infectious diseases, and sponsoring initiatives like the Healthy Longevity Global Competition to tackle chronic conditions. The company is embracing new healthcare models such as telemedicine through programs like the QuickFire Challenge and investments in digital healthcare startups.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.937527"}], "overall_sentiment_score": 0.413485, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.406184", "ticker_sentiment_label": "Bullish"}]}, {"title": "J&J executives shed light on their family culture, breakthroughs, innovations, and worldwide opportunities", "url": "https://blogs.chapman.edu/career/2020/10/15/thriving-at-johnson-johnson/", "time_published": "20201015T223708", "authors": ["Tryphena Yeboah"], "summary": "This article highlights Johnson & Johnson's culture, innovations, and opportunities, drawing from an event where J&J leaders shared insights. It emphasizes the company's Credo-driven approach, commitment to diversity, and extensive employee benefits. The company actively seeks new talent, particularly from Chapman University, for various roles and leadership development programs.", "banner_image": null, "source": "Chapman Blogs", "category_within_source": "General", "source_domain": "Chapman Blogs", "topics": [{"topic": "life_sciences", "relevance_score": "0.912177"}, {"topic": "finance", "relevance_score": "0.725518"}], "overall_sentiment_score": 0.725902, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.743574", "ticker_sentiment_label": "Bullish"}]}, {"title": "Datavant dials corporates for $40m series B -", "url": "https://globalventuring.com/blog/2020/10/14/datavant-dials-corporates-for-40m-series-b/", "time_published": "20201014T231131", "authors": ["Callum Cyrus"], "summary": "Datavant, a US-based medical data exchange technology developer, has secured $40 million in Series B funding, bringing its total funding to $83 million. The round was led by Transformation Capital and included corporate investors such as Roivant Sciences, Johnson & Johnson, and Cigna. Datavant specializes in connecting health data to improve patient outcomes while maintaining privacy, and the new funding will be used to expand its data exchange service.", "banner_image": null, "source": "Global Corporate Venturing", "category_within_source": "General", "source_domain": "Global Corporate Venturing", "topics": [{"topic": "life_sciences", "relevance_score": "0.925122"}, {"topic": "finance", "relevance_score": "0.826045"}, {"topic": "technology", "relevance_score": "0.711131"}], "overall_sentiment_score": 0.447013, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ROIV", "relevance_score": "1.000000", "ticker_sentiment_score": "0.479983", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.862476", "ticker_sentiment_score": "0.427838", "ticker_sentiment_label": "Bullish"}, {"ticker": "CI", "relevance_score": "0.754452", "ticker_sentiment_score": "0.421354", "ticker_sentiment_label": "Bullish"}]}, {"title": "With rivals delayed, Intuitive Surgical extends use of robotic instruments", "url": "https://www.medtechdive.com/news/intuitive-surgical-rivals-daVinci-extends-use-of-robotic-instruments/586969/", "time_published": "20201014T223637", "authors": ["Susan Kelly"], "summary": "Intuitive Surgical has launched an Extended Use Program for its da Vinci robotic surgery systems, lengthening the lifespan of certain instruments and reducing per-procedure costs. The move aims to boost customer loyalty and market penetration while competitors Medtronic and Johnson & Johnson face delays in bringing their own robotic systems to market. This strategy is expected to expand da Vinci's use in high-volume procedures like hernia repair and gallbladder removal, offering cost savings to hospitals facing revenue strains during the pandemic.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.928598"}], "overall_sentiment_score": 0.316443, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.449742", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.841340", "ticker_sentiment_score": "0.235129", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.730871", "ticker_sentiment_score": "0.233812", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson\u2019s $100 Million Baby Powder Lawsuit Settlement Is Overdue For Black & Hispanic Women", "url": "https://www.forbes.com/sites/korihale/2020/10/14/johnson--johnsons-100-million-baby-powder-lawsuit-settlement-is-overdue-for-black--hispanic-women/", "time_published": "20201014T075700", "authors": ["Kori Hale"], "summary": "Johnson & Johnson has agreed to a $100 million settlement for approximately 1,000 lawsuits from women who claim its talcum powder caused cancer. The article highlights that J&J aggressively marketed its baby powder, despite potential carcinogenic concerns, particularly to Black and Hispanic women in underserved communities. Despite the settlement, J&J maintains that its talc is safe and does not cause cancer, while critics argue the company continues to deny liability.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/5f86b72d245999814429e74d/0x0.jpg?format=jpg&crop=2667,1501,x0,y162,safe&guid=c099303d-8625-450f-a496-ec6196232596&interpolation=lanczos-none", "source": "Forbes", "category_within_source": "General", "source_domain": "Forbes", "topics": [{"topic": "life_sciences", "relevance_score": "0.925138"}, {"topic": "finance", "relevance_score": "0.740096"}], "overall_sentiment_score": -0.454024, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.496310", "ticker_sentiment_label": "Bearish"}]}, {"title": "Eli Lilly\u2019s Antibody Trial Is Paused Over Potential Safety Concern (Published 2020)", "url": "https://www.nytimes.com/2020/10/13/health/eli-lilly-antibody.html", "time_published": "20201013T224226", "authors": ["Katherine J. Wu and Katie Thomas"], "summary": "A government-sponsored clinical trial for an antibody treatment for Covid-19 developed by Eli Lilly has been paused due to a \"potential safety concern.\" This news follows similar pauses in trials for coronavirus vaccines from Johnson & Johnson and AstraZeneca. The experimental drug is similar to the one President Trump received and was being tested on hundreds of hospitalized Covid-19 patients.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.904543"}], "overall_sentiment_score": -0.169247, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.385028", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.621224", "ticker_sentiment_score": "-0.178310", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.642729", "ticker_sentiment_score": "0.109807", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Reports 2020 Third-Quarter Results", "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-2020-third-quarter-results", "time_published": "20201013T223708", "authors": [], "summary": "Johnson & Johnson announced strong third-quarter 2020 results, with sales of $21.1 billion and adjusted EPS of $2.20, driven by better-than-expected recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals. The company is increasing its full-year guidance for reported sales and adjusted EPS, reflecting robust business fundamentals and ongoing recovery despite the COVID-19 pandemic. CEO Alex Gorsky highlighted the company's efforts in fighting the pandemic, including advancing its COVID-19 vaccine trials.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "earnings", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.921921"}], "overall_sentiment_score": 0.407787, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.412913", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson beats third-quarter earnings expectations, raises guidance", "url": "https://www.cnbc.com/2020/10/13/johnson-johnson-jnj-earnings-q3-2020.html", "time_published": "20201013T064400", "authors": ["Berkeley Lovelace Jr."], "summary": "Johnson & Johnson reported stronger-than-expected third-quarter earnings and revenue, driven by its medical-device unit and increased demand for some drugs, leading the company to raise its full-year guidance. This financial success occurred despite the temporary pause of its late-stage Covid-19 vaccine trial due to an \"adverse event\" in a participant. Shares of J&J fell following the news of the paused vaccine trial, but the company emphasized its commitment to transparency and safety.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "earnings", "relevance_score": "0.938906"}, {"topic": "life_sciences", "relevance_score": "0.846836"}], "overall_sentiment_score": 0.011732, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.303757", "ticker_sentiment_score": "0.044171", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson pauses Covid vaccine trial over participant's 'unexplained illness'", "url": "https://www.theguardian.com/world/2020/oct/12/johnson-johnson-pauses-covid-vaccine-trial-over-participants-unexplained-illness", "time_published": "20201012T222000", "authors": ["Maanvi Singh"], "summary": "Johnson & Johnson has temporarily paused its Covid-19 vaccine trial due to an unexplained illness in a participant. The company, which is conducting a 60,000-patient study, has not revealed if the patient received the vaccine or a placebo, citing privacy. This pause is being closely watched, especially after a similar, temporary halt in AstraZeneca's vaccine trial.", "banner_image": null, "source": "The Guardian", "category_within_source": "General", "source_domain": "The Guardian", "topics": [{"topic": "life_sciences", "relevance_score": "0.941233"}, {"topic": "financial_markets", "relevance_score": "0.614514"}], "overall_sentiment_score": -0.261634, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.250931", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Trump\u2019s endorsement sends Regeneron and Eli Lilly stocks rising", "url": "https://www.cnn.com/2020/10/08/investing/regeneron-eli-lilly-trump-covid", "time_published": "20201008T102100", "authors": ["Paul R. La Monica"], "summary": "Shares of Regeneron and Eli Lilly rose after President Trump publicly praised their experimental antibody treatments for COVID-19 and expressed a desire for their emergency approval and free distribution. Trump attributed his rapid recovery from coronavirus to Regeneron's drug, though his claims about it being a \"cure\" were misleading as it is a therapeutic, not a cure, and is still experimental. Both companies are seeking emergency authorization for their treatments, and Eli Lilly is also collaborating with the Bill & Melinda Gates Foundation to make its treatments accessible globally.", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "life_sciences", "relevance_score": "0.910760"}, {"topic": "financial_markets", "relevance_score": "0.831311"}], "overall_sentiment_score": 0.186476, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.300673", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "1.000000", "ticker_sentiment_score": "0.316497", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.618744", "ticker_sentiment_score": "0.111966", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.633659", "ticker_sentiment_score": "0.113762", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.602482", "ticker_sentiment_score": "0.144250", "ticker_sentiment_label": "Neutral"}]}, {"title": "Accenture Launches Vaccine Management Solution to Support COVID-19 Immunization Programs", "url": "https://newsroom.accenture.com/news/2020/accenture-launches-vaccine-management-solution-to-support-covid-19-immunization-programs", "time_published": "20201007T220217", "authors": ["NULL"], "summary": "Accenture has launched a comprehensive vaccine management solution to help governments and healthcare organizations rapidly plan and execute COVID-19 vaccination programs. The solution expands on Accenture\u2019s contact tracing capabilities and includes modular components for vaccine management and tracking, supply management, community education, contact management, analytics, and organizational support. Built in part on the Salesforce platform, this initiative aims to address the varied needs for developing and running mass immunization efforts worldwide.", "banner_image": "NULL", "source": "Accenture", "category_within_source": "General", "source_domain": "Accenture", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "technology", "relevance_score": "0.849475"}], "overall_sentiment_score": 0.363996, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CRM", "relevance_score": "1.000000", "ticker_sentiment_score": "0.450899", "ticker_sentiment_label": "Bullish"}, {"ticker": "ACN", "relevance_score": "0.938187", "ticker_sentiment_score": "0.434308", "ticker_sentiment_label": "Bullish"}, {"ticker": "UNH", "relevance_score": "0.618194", "ticker_sentiment_score": "0.314502", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.590960", "ticker_sentiment_score": "0.349247", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Baby Powder Lawsuit: J&J to Pay $100M", "url": "https://www.asbestos.com/news/2020/10/06/johnson-johnson-settles-asbestos-lawsuits/", "time_published": "20201006T223709", "authors": ["Tim Povtak", "Walter Pacheco"], "summary": "Johnson & Johnson has agreed to pay over $100 million to settle more than a thousand lawsuits claiming its talc-based baby powder caused cancer, marking the first time the company has settled such lawsuits in bulk. Despite the settlement, J&J maintains its products' safety and continues to face an estimated 20,000 talc-related lawsuits. The litigation highlights concerns about asbestos contamination in talc and its link to cancers like ovarian cancer and mesothelioma.", "banner_image": null, "source": "Mesothelioma Center", "category_within_source": "General", "source_domain": "Mesothelioma Center", "topics": [{"topic": "life_sciences", "relevance_score": "0.901888"}, {"topic": "finance", "relevance_score": "0.726765"}], "overall_sentiment_score": -0.316883, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.304538", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pfizer preps Kalamazoo plant for COVID-19 vaccine approval", "url": "https://www.detroitnews.com/story/news/local/michigan/2020/10/05/kalamazoo-takes-spotlight-pfizer-plan-covid-19-vaccine/3572655001/", "time_published": "20201005T225215", "authors": ["Karen Bouffard"], "summary": "Pfizer is preparing its Kalamazoo manufacturing facility for potential federal approval of its COVID-19 vaccine, with clinical trial data expected by late October. The company has invested $87 million to reconfigure the plant for vaccine production and anticipates making millions of doses by year-end if approved. The article also discusses the mRNA technology used by Pfizer and Moderna, and challenges including potential virus mutations and the scientific community's call for more extensive safety monitoring.", "banner_image": null, "source": "The Detroit News", "category_within_source": "General", "source_domain": "The Detroit News", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "manufacturing", "relevance_score": "0.800193"}], "overall_sentiment_score": 0.264753, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.994959", "ticker_sentiment_score": "0.281542", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.998158", "ticker_sentiment_score": "0.334219", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.636763", "ticker_sentiment_score": "0.122367", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson completes $6.5B takeover of Momenta", "url": "https://www.foxbusiness.com/markets/johnson-and-johnson-momenta", "time_published": "20201002T105700", "authors": ["Daniella Genovese"], "summary": "Johnson & Johnson has finalized its $6.5 billion cash acquisition of Momenta Pharmaceuticals, allowing the pharmaceutical giant to expand its portfolio in drugs used to treat autoimmune diseases. Momenta's expertise in developing therapies for rare diseases will be integrated into Johnson & Johnson's research and development efforts. Autoimmune diseases affect approximately 195 million people worldwide and are often attributed to autoantibodies attacking the body's own resources.", "banner_image": null, "source": "Fox Business", "category_within_source": "General", "source_domain": "Fox Business", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.926303"}, {"topic": "life_sciences", "relevance_score": "0.825454"}], "overall_sentiment_score": 0.327418, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.915783", "ticker_sentiment_score": "0.301690", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc.", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-completes-acquisition-of-momenta-pharmaceuticals-inc-301143938.html", "time_published": "20201001T084000", "authors": [], "summary": "Johnson & Johnson has successfully completed its acquisition of Momenta Pharmaceuticals, Inc. for approximately $6.5 billion in an all-cash transaction. This acquisition broadens Janssen's leadership in autoimmune diseases and is expected to drive sustained growth and advance patient care in autoantibody-driven conditions. Momenta will now operate as a wholly-owned subsidiary of Johnson & Johnson, with its common stock delisted from NASDAQ.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.901014"}], "overall_sentiment_score": 0.483492, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.490457", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson signs on Michigan's Grand River to help with COVID-19 vaccine finishing work", "url": "https://www.fiercepharma.com/manufacturing/johnson-johnson-signs-michigan-s-grand-river-to-help-covid-19-vaccine-finishing-work", "time_published": "20200929T074000", "authors": ["Kyle Blankenship"], "summary": "Johnson & Johnson has partnered with Michigan's Grand River Aseptic Manufacturing (GRAM) to handle fill-finish duties for its recombinant COVID-19 vaccine. GRAM will produce up to 100 million doses for the U.S. strategic reserve, leveraging a recent $60 million expansion. This collaboration is part of J&J's broader strategy to secure manufacturing partners for global vaccine demand, including existing deals with Emergent BioSolutions and Catalent.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.902710"}, {"topic": "manufacturing", "relevance_score": "0.810674"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.602677"}], "overall_sentiment_score": 0.349226, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.428748", "ticker_sentiment_label": "Bullish"}, {"ticker": "CDNS", "relevance_score": "0.604178", "ticker_sentiment_score": "0.309882", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRL", "relevance_score": "0.643295", "ticker_sentiment_score": "0.304600", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "As Johnson & Johnson kick-starts phase 3 COVID-19 test, early data show up its promise", "url": "https://www.fiercebiotech.com/biotech/as-johnson-johnson-kickstarts-phase-3-covid-test-early-data-shows-up-its-promise", "time_published": "20200928T073200", "authors": ["Ben Adams"], "summary": "Johnson & Johnson has revealed promising phase 1/2 trial data for its COVID-19 vaccine candidate, Ad26.COV2.S, which has now entered late-stage testing. The data suggest a single dose can elicit strong immune responses and neutralizing antibodies. This early success supports J&J's strategy for a single-shot vaccine, potentially simplifying logistics and accelerating global vaccination efforts against the pandemic.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "0.934752"}], "overall_sentiment_score": 0.201489, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.954083", "ticker_sentiment_score": "0.333454", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.606079", "ticker_sentiment_score": "0.146825", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.625696", "ticker_sentiment_score": "0.109224", "ticker_sentiment_label": "Neutral"}]}, {"title": "Early Trial Results Show Promise For Johnson & Johnson And Beth Israel Vaccine", "url": "https://www.wbur.org/news/2020/09/26/phase-three-trial-beth-israel-vaccine", "time_published": "20200926T223710", "authors": ["Angus Chen"], "summary": "Early clinical trial results for a potential coronavirus vaccine developed by Beth Israel Deaconess Medical Center and Johnson & Johnson show promise, indicating it is safe and may provide protection against COVID-19. The vaccine, which is now moving into a large-scale phase three clinical trial, has the advantage of being a single-shot vaccine that does not require freezing for distribution. This could significantly simplify mass vaccination campaigns compared to other leading vaccine candidates.", "banner_image": null, "source": "WBUR", "category_within_source": "General", "source_domain": "WBUR", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.459641, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.450584", "ticker_sentiment_label": "Bullish"}]}, {"title": "Company to pay $60 million for deceptive marketing with pelvic mesh", "url": "https://www.cbsnews.com/news/pelvic-mesh-settlement-cr-bard-60-million/", "time_published": "20200925T180600", "authors": ["CBS/AP"], "summary": "C.R. Bard Inc. and its parent company Becton, Dickinson and Company will pay $60 million in a settlement with 48 states and the District of Columbia for deceptive marketing practices related to pelvic mesh devices. The settlement addresses allegations that C.R. Bard failed to adequately inform women of dangerous side effects, despite evidence that the company was aware of potential serious medical complications. This follows a 2019 FDA ban on pelvic mesh products for organ prolapse repair and similar settlements involving other manufacturers like Johnson & Johnson.", "banner_image": null, "source": "CBS News", "category_within_source": "General", "source_domain": "CBS News", "topics": [{"topic": "life_sciences", "relevance_score": "0.912344"}, {"topic": "finance", "relevance_score": "0.741984"}], "overall_sentiment_score": -0.315297, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "BDX", "relevance_score": "0.927163", "ticker_sentiment_score": "-0.382766", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.732529", "ticker_sentiment_score": "-0.283382", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "3 quick reasons I like the IOO ETF", "url": "https://www.bestetfs.com.au/2020/09/25/3-quick-reasons-i-like-the-ioo-etf/", "time_published": "20200925T040246", "authors": ["Jaz Harrison"], "summary": "The iShares Global 100 ETF (ASX: IOO) is recommended for its three key features: diversification from the Australian market, exposure to global developed and emerging markets, and investment in strong, growing businesses with entrenched economic moats. The article highlights its holdings in major global companies like Apple and Microsoft, and its 10-year average annual return of 13.1%. The author suggests it's a good option for investors seeking to diversify beyond ASX shares.", "banner_image": "https://www.bestetfs.com.au/wp-content/uploads/2020/09/IOO-share-price-1024x392.png", "source": "bestetfs.com.au", "category_within_source": "General", "source_domain": "bestetfs.com.au", "topics": [{"topic": "financial_markets", "relevance_score": "0.938451"}, {"topic": "finance", "relevance_score": "0.806741"}], "overall_sentiment_score": 0.340116, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IOO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.418664", "ticker_sentiment_label": "Bullish"}, {"ticker": "AAPL", "relevance_score": "0.722144", "ticker_sentiment_score": "0.323349", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.647695", "ticker_sentiment_score": "0.336672", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.613842", "ticker_sentiment_score": "0.307005", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.604592", "ticker_sentiment_score": "0.321340", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J's next-gen Darzalex sparks drug delivery royalties battle", "url": "https://www.fiercepharma.com/pharma/genmab-takes-j-j-to-arbitration-court-over-subq-darzalex-royalties", "time_published": "20200924T115800", "authors": ["Fraiser Kansteiner"], "summary": "Janssen, a unit of Johnson & Johnson, has scaled back royalty payments to Genmab for Darzalex, arguing Genmab owes a portion of those royalties to Halozyme for its subcutaneous drug delivery technology used in Darzalex Faspro. Genmab disputes this claim and is taking J&J to arbitration to resolve the royalty dispute. The arbitration will also address whether royalties will continue after Genmab's Darzalex patents expire.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.949750"}, {"topic": "earnings", "relevance_score": "0.744242"}], "overall_sentiment_score": 0.030685, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GMAB", "relevance_score": "0.323292", "ticker_sentiment_score": "0.043752", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.962757", "ticker_sentiment_score": "-0.143403", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.602082", "ticker_sentiment_score": "0.102061", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZO", "relevance_score": "0.602109", "ticker_sentiment_score": "0.116640", "ticker_sentiment_label": "Neutral"}]}, {"title": "Genmab and Janssen Head to Arbitration Table Over Darzalex Royalties", "url": "https://www.biospace.com/genmab-and-janssen-head-to-arbitration-table-over-darzalex-royalties", "time_published": "20200923T222630", "authors": ["Alex Keown"], "summary": "Genmab has initiated binding arbitration with Janssen Biotech over two matters concerning their Darzalex license agreement. The dispute involves royalty payments from Genmab to Halozyme Therapeutics for a subcutaneous formulation and the duration of Janssen's royalty payments to Genmab, with Genmab's shares falling significantly after the announcement. Despite the legal battle, both companies will continue their collaboration on a successor to Darzalex.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "0.934392"}, {"topic": "finance", "relevance_score": "0.733752"}], "overall_sentiment_score": -0.105595, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GMAB", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.265427", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.861077", "ticker_sentiment_score": "-0.111938", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.615223", "ticker_sentiment_score": "0.106233", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is the VGS ETF the best for passive investing?", "url": "https://www.bestetfs.com.au/2020/09/23/is-the-vgs-etf-the-best-for-passive-investing/", "time_published": "20200923T221614", "authors": ["Jaz Harrison"], "summary": "This article examines the Vanguard MSCI Index International Shares ETF (ASX: VGS) as a strong option for passive investing due to its broad diversification across over 1,500 businesses in major developed countries. It highlights VGS's sector allocation, top holdings including tech giants, and its average annual return of 9.65% over the past five years. The piece concludes that while VGS offers good diversification, investors should consider its management fee compared to other ETFs and explore various options for growth and dividends.", "banner_image": null, "source": "Best ETFs", "category_within_source": "General", "source_domain": "Best ETFs", "topics": [{"topic": "financial_markets", "relevance_score": "0.935196"}, {"topic": "finance", "relevance_score": "0.804079"}], "overall_sentiment_score": 0.252597, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EXI", "relevance_score": "0.322340", "ticker_sentiment_score": "0.018273", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.707888", "ticker_sentiment_score": "0.315103", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.707726", "ticker_sentiment_score": "0.345581", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.736839", "ticker_sentiment_score": "0.339714", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.729793", "ticker_sentiment_score": "0.330315", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Genmab shares drop on legal battle with J&J over cancer drug", "url": "https://www.reuters.com/world/americas/genmab-shares-drop-legal-battle-with-jj-over-cancer-drug-2020-09-23/", "time_published": "20200923T190800", "authors": ["Reuters"], "summary": "Shares in Danish biotech firm Genmab fell by as much as 14% after the company announced it is engaged in a legal dispute with its partner Johnson & Johnson regarding royalty payments for the cancer drug Darzalex. The arbitration court will decide on Genmab's entitlement to a portion of Janssen's royalty payments to Halozyme and the duration of Genmab's royalty payments for Darzalex, which could significantly impact Genmab's market value. This legal battle introduces considerable uncertainty and an \"overhang\" for Genmab's stock.", "banner_image": "https://www.reuters.com/resizer/v2/L77YPFK6QFLXDK4DGDV3OIEZFM.JPG?auth=cad2b842323a6c117d983416ac344933a39e80b27accdcc56176395b0586e927&quality=80&smart=true", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "financial_markets", "relevance_score": "0.911977"}, {"topic": "life_sciences", "relevance_score": "0.944207"}], "overall_sentiment_score": -0.342338, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "GMAB", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.469718", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.866448", "ticker_sentiment_score": "-0.247324", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate-301136522.html", "time_published": "20200923T064500", "authors": [], "summary": "Johnson & Johnson has launched its pivotal global Phase 3 clinical trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, developed by Janssen Pharmaceutical Companies. The trial will evaluate the safety and efficacy of a single vaccine dose versus placebo in up to 60,000 volunteers across multiple countries. The company aims to make the vaccine available for emergency use authorization in early 2021, if proven safe and effective, and is committed to providing it on a not-for-profit basis for pandemic emergency use.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.816786, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.805540", "ticker_sentiment_label": "Bullish"}]}, {"title": "From bailout debacle to global dominance: Inside the turnaround at UBS", "url": "https://fortune.com/2020/09/21/ubs-turnaround-scandal-to-banking-superpower-sergio-ermotti/", "time_published": "20200921T233129", "authors": ["Bernhard Warner"], "summary": "This article details the remarkable turnaround of UBS under former CEO Sergio Ermotti, transforming it from a scandal-ridden bank on the brink of collapse to a global wealth management powerhouse. Ermotti's strategy involved slashing the investment banking division, focusing on wealth management, and rebuilding trust with ultra-wealthy clients, leading to significant capital growth and profitable years. The bank's resilient business model, particularly its strong wealth management focus and healthy loan book, has positioned it well even amidst economic challenges like the COVID-19 pandemic.", "banner_image": null, "source": "Fortune", "category_within_source": "General", "source_domain": "Fortune", "topics": [{"topic": "finance", "relevance_score": "0.930197"}, {"topic": "economy_macro", "relevance_score": "0.847893"}, {"topic": "earnings", "relevance_score": "0.723123"}], "overall_sentiment_score": -0.083167, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "UBS", "relevance_score": "1.000000", "ticker_sentiment_score": "0.383337", "ticker_sentiment_label": "Bullish"}, {"ticker": "JPM", "relevance_score": "0.634285", "ticker_sentiment_score": "-0.210051", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WFC", "relevance_score": "0.619745", "ticker_sentiment_score": "-0.204331", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "C", "relevance_score": "0.604459", "ticker_sentiment_score": "-0.243577", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.584704", "ticker_sentiment_score": "0.068938", "ticker_sentiment_label": "Neutral"}]}, {"title": "R&D Council of NJ Announces 2020 Thomas Edison Patent Award Winners", "url": "https://njbmagazine.com/njb-news-now/rd-council-of-nj-announces-2020-thomas-edison-patent-award-winners/", "time_published": "20200921T225211", "authors": [], "summary": "The Research & Development Council of New Jersey announced the 2020 Thomas Edison Patent Award winners and special individual honorees. Awards will be presented on November 12, 2020, to 14 companies and institutions, recognizing innovations from biomaterials to water-efficient toilets. Special awards will be given to Dr. Roger Perlmutter of Merck for the Chairman's Award, Dr. Joachim Messing (posthumously) for the Science and Technology Medal, and Dr. Dawood Farahi for the Educator of the Year Award.", "banner_image": null, "source": "New Jersey Business Magazine", "category_within_source": "General", "source_domain": "New Jersey Business Magazine", "topics": [{"topic": "life_sciences", "relevance_score": "0.830544"}, {"topic": "technology", "relevance_score": "0.706193"}], "overall_sentiment_score": 0.323987, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.438167", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.745204", "ticker_sentiment_score": "0.303306", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CL", "relevance_score": "0.609515", "ticker_sentiment_score": "0.315381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.610814", "ticker_sentiment_score": "0.348030", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVGO", "relevance_score": "0.569211", "ticker_sentiment_score": "0.327913", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "-Johnson & Johnson charged by New York with civil insurance fraud over opioid claims", "url": "https://www.reuters.com/business/johnson-johnson-charged-by-new-york-with-civil-insurance-fraud-over-opioid-2020-09-17/", "time_published": "20200917T183500", "authors": ["Jonathan Stempel"], "summary": "New York state has filed civil charges against Johnson & Johnson, accusing the company of insurance fraud for downplaying the risks of opioid painkillers, including to doctors and elderly patients. J&J is accused of targeting elderly patients for opioid treatment despite side effect risks and using marketing to dismiss opioid addiction as a myth. This is the fourth such charge in New York's opioid industry probe, and J&J has proposed a $4 billion settlement for opioid claims across the U.S.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fcloudfront-us-east-2.images.arcpublishing.com%2Freuters%2F2E4GR4MTSBO6BJ5M2S5P5M7EFE.jpg?auth=d946892694ce2624a0d8a436ae184081c7429671f64483b8a1c93a0780410ff7&width=800&quality=80&ampformat=webp", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.938011"}, {"topic": "finance", "relevance_score": "0.738238"}], "overall_sentiment_score": -0.62105, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.623212", "ticker_sentiment_label": "Bearish"}]}, {"title": "Cancer-detection company Grail, which counts Jeff Bezos among its investors, files to go public", "url": "https://www.cnbc.com/2020/09/09/-grail-which-counts-jeff-bezos-among-investors-files-for-ipo.html", "time_published": "20200909T171800", "authors": ["Christina Farr", "Jordan Novet"], "summary": "Grail, a biotechnology company focused on developing a blood test for early-stage cancer detection, has filed for an initial public offering (IPO). The company, which counts Jeff Bezos and Illumina among its investors, currently has no product or revenue and reported a significant loss in the first half of 2020. Grail aims to use the IPO funds to finance extensive clinical trials and prove the safety and efficacy of its \"Galleri\" test.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "ipo", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.945087"}, {"topic": "technology", "relevance_score": "0.713610"}, {"topic": "finance", "relevance_score": "0.637219"}], "overall_sentiment_score": 0.07673, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GRAL", "relevance_score": "0.349472", "ticker_sentiment_score": "0.016073", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.618387", "ticker_sentiment_score": "0.144543", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.579597", "ticker_sentiment_score": "0.060040", "ticker_sentiment_label": "Neutral"}]}, {"title": "Covid-19 Vaccine Race Turns Deep Freezers Into a Hot Commodity", "url": "https://www.wsj.com/health/healthcare/covid-19-vaccine-race-turns-deep-freezers-into-a-hot-commodity-11599217201?gaa_at=eafs&gaa_n=AWEtsqfPVdc6KujLGr1Ccf57bc0T6dSA9YKK1XaM-7O4KV66L87cuQWjpJi3&gaa_ts=6907d905&gaa_sig=hazYwn0n9EmwQvjr5gzkbZJUSPvirPjDuyqm3QA7pvRg71XTkANQ7ygwELa4za3TclY3_cQ1MwEdtPtSw_vmSw%3D%3D", "time_published": "20200904T220634", "authors": ["Jared S. Hopkins"], "summary": "The distribution of Covid-19 vaccines depends heavily on the availability of specialized deep freezers capable of maintaining extremely low temperatures, as some experimental vaccines require storage at minus 80 degrees Celsius. This need is creating a supply chain challenge for drug, logistics, and public-health officials.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.906474"}, {"topic": "manufacturing", "relevance_score": "0.722551"}], "overall_sentiment_score": 0.248603, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CYRX", "relevance_score": "0.333842", "ticker_sentiment_score": "0.031918", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.733041", "ticker_sentiment_score": "0.306512", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.677169", "ticker_sentiment_score": "0.290884", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.640987", "ticker_sentiment_score": "0.344801", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.583356", "ticker_sentiment_score": "0.247907", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dr Reddys unveils Methylphenidate Hydrochloride ER Tablets in US", "url": "https://medicaldialogues.in/news/industry/pharma/dr-reddys-unveils-methylphenidate-hydrochloride-er-tablets-in-us-69234", "time_published": "20200904T060944", "authors": ["Ruchika Sharma"], "summary": "Dr. Reddy's Laboratories Ltd. has launched Methylphenidate Hydrochloride Extended-Release Tablets USP, a generic version of Concerta, in the U.S. market. The U.S. Food and Drug Administration (USFDA) approved the drug, which is indicated for the treatment of attention deficit hyperactivity disorder (ADHD). The market for Concerta and its generics had U.S. sales of approximately USD 1.159 billion in the twelve months ending June 2020.", "banner_image": null, "source": "Medical Dialogues", "category_within_source": "General", "source_domain": "Medical Dialogues", "topics": [{"topic": "life_sciences", "relevance_score": "0.902625"}], "overall_sentiment_score": 0.330504, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RDY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.430402", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.730228", "ticker_sentiment_score": "0.342255", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.611252", "ticker_sentiment_score": "0.252841", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.596402", "ticker_sentiment_score": "0.227838", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "CDC tells states: Be ready to distribute vaccines on Nov. 1", "url": "https://kfoxtv.com/news/local/gallery/cdc-tells-states-be-ready-to-distribute-vaccines-on-nov-1?photo=0", "time_published": "20200902T162800", "authors": ["By MICHELLE R. SMITH"], "summary": "The CDC has instructed states to prepare for coronavirus vaccine distribution by November 1st, raising concerns among public health experts about potential political influence on vaccine approval before the presidential election. McKesson Corp. is contracted to distribute vaccines, and states are asked to expedite facility applications and consider waiving requirements to meet the aggressive timeline. Many experts doubt adequate safety and efficacy data will be available by then, highlighting a \"credibility gap\" despite the urgent need for a safe and effective vaccine.", "banner_image": "https://kfoxtv.com/news/local/gallery/cdc-tells-states-be-ready-to-distribute-vaccines-on-nov-1?photo=0", "source": "KFOX", "category_within_source": "General", "source_domain": "KFOX", "topics": [{"topic": "life_sciences", "relevance_score": "0.946961"}, {"topic": "economy_fiscal", "relevance_score": "0.643435"}], "overall_sentiment_score": 0.092885, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MCK", "relevance_score": "0.956919", "ticker_sentiment_score": "0.147579", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.571042", "ticker_sentiment_score": "0.052816", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.583959", "ticker_sentiment_score": "0.097729", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.568418", "ticker_sentiment_score": "0.077519", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.583829", "ticker_sentiment_score": "0.071042", "ticker_sentiment_label": "Neutral"}]}, {"title": "China approves Sinovac's COVID-19 vaccine candidate for emergency use | Daily Sabah", "url": "https://www.dailysabah.com/world/asia-pacific/china-approves-sinovacs-covid-19-vaccine-candidate-for-emergency-use", "time_published": "20200828T115400", "authors": ["REUTERS"], "summary": "China has approved Sinovac Biotech Ltd.'s coronavirus vaccine candidate, CoronaVac, for emergency use as part of a program to vaccinate high-risk groups. Another state-owned pharmaceutical giant, China National Biotec Group (CNBG), also secured emergency use approval for one of its vaccine candidates. These approvals are part of China's strategy to prevent possible outbreaks during autumn and winter, although specifics on deployment remain scarce.", "banner_image": null, "source": "Daily Sabah", "category_within_source": "General", "source_domain": "Daily Sabah", "topics": [{"topic": "life_sciences", "relevance_score": "0.929296"}], "overall_sentiment_score": 0.168536, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SVA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.322568", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.639347", "ticker_sentiment_score": "0.104239", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.640161", "ticker_sentiment_score": "0.123254", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.623850", "ticker_sentiment_score": "0.143642", "ticker_sentiment_label": "Neutral"}]}, {"title": "How employee feedback drove Johnson & Johnson\u2019s response to uncertainty", "url": "https://www.hrdive.com/news/how-employee-feedback-drove-johnson-johnsons-response-to-uncertainty/584273/", "time_published": "20200827T223709", "authors": ["Aman Kidwai"], "summary": "Johnson & Johnson leveraged employee feedback and pre-existing emergency plans to rapidly respond to the COVID-19 pandemic, quickly shifting a majority of its workforce to remote operations while continuing essential medical supply production. The company also addressed racial inequality through a $10 million pledge and internal diversity initiatives, guided by CEO Alex Gorsky's call for white men to listen more and Chief Diversity & Inclusion Officer Wanda Bryant Hope's leadership. J&J expanded employee benefits, mental health support, and workplace safety measures, using weekly employee sentiment surveys to adapt policies and enhance support during these concurrent crises.", "banner_image": null, "source": "HR Dive", "category_within_source": "General", "source_domain": "HR Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.940562"}, {"topic": "manufacturing", "relevance_score": "0.708875"}, {"topic": "economy_macro", "relevance_score": "0.649086"}], "overall_sentiment_score": 0.439265, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.421383", "ticker_sentiment_label": "Bullish"}]}, {"title": "Teva Pharmaceutical\u2019s U.S. Unit Indicted on Price-Fixing Charges - WSJ", "url": "https://www.wsj.com/health/pharma/teva-pharmaceuticals-u-s-unit-indicted-on-price-fixing-charges-11598392891?gaa_at=eafs&gaa_n=AWEtsqd-vBXtFYzbqmd-3YCtnDx5ukEbFVBAtheDk0gZtcy3ARUw8UejcH29&gaa_ts=6907ebc8&gaa_sig=QM-eEKYh_lsTA6aQFHcvYkJdY3c1CBlhM0tM4YLVnstK2nMPg-KCGcoj2PFgq_5WS7tQcykL5hvK8eeoB0dSQw%3D%3D", "time_published": "20200825T232614", "authors": ["Brent Kendall", "Jared S. Hopkins"], "summary": "Teva Pharmaceutical Industries Ltd.'s U.S. unit has been indicted on price-fixing charges by the Justice Department. The generic drugmaker is accused of participating in three different conspiracies, leading to at least $350 million in overcharges for consumers on cholesterol medication and other drugs. This indictment marks the highest-profile action in an ongoing investigation into the generic-drug industry.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.948522"}, {"topic": "finance", "relevance_score": "0.705828"}], "overall_sentiment_score": -0.263602, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "TEVA", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.731950", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.638117", "ticker_sentiment_score": "-0.106817", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.637219", "ticker_sentiment_score": "-0.141465", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.564387", "ticker_sentiment_score": "-0.140674", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.599746", "ticker_sentiment_score": "-0.123761", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Borrows $7.5B to Fund Its Purchase Of Momenta", "url": "https://www.cfo.com/news/johnson-johnson-borrows-75b-to-fund-its-purchase-of-momenta/656298/", "time_published": "20200821T231135", "authors": ["Vincent Ryan"], "summary": "Johnson & Johnson has borrowed $7.5 billion through a bond issuance to finance its acquisition of Momenta Pharmaceuticals, a deal valued at $6.5 billion. This marks their first debt market capital raise in three years, despite a pristine AAA credit rating, and comes amid record-low yields. The increased leverage is expected to impact J&J's ability to cover liabilities from ongoing talc and opioid litigation.", "banner_image": null, "source": "CFO.com", "category_within_source": "General", "source_domain": "CFO.com", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.946300"}, {"topic": "financial_markets", "relevance_score": "0.808459"}, {"topic": "finance", "relevance_score": "0.712654"}], "overall_sentiment_score": 0.071891, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ROP", "relevance_score": "0.328556", "ticker_sentiment_score": "0.011595", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.946870", "ticker_sentiment_score": "0.111245", "ticker_sentiment_label": "Neutral"}]}, {"title": "Teva neck-deep in legal trouble with no end in sight", "url": "https://www.calcalistech.com/ctech/articles/0,7340,L-3845899,00.html", "time_published": "20200820T223600", "authors": ["Sophie Shulman"], "summary": "Teva Pharmaceutical Industries Ltd. is facing a growing number of legal challenges stemming from past conduct, including bribery allegations and involvement in the opioid crisis. These legal episodes, which began around 2007, are overshadowing the company's performance and present significant financial risks, with potential fines reaching billions of dollars. The relentless legal battles are diverting management's focus from business operations and are exacerbated by the company's precarious financial position due to prior failed acquisitions.", "banner_image": null, "source": "CTech", "category_within_source": "General", "source_domain": "CTech", "topics": [{"topic": "life_sciences", "relevance_score": "0.910729"}, {"topic": "finance", "relevance_score": "0.700486"}], "overall_sentiment_score": -0.780223, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "TEVA", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.807772", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.609361", "ticker_sentiment_score": "-0.725623", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson to Buy Momenta Pharmaceuticals for $6.5 Billion - WSJ", "url": "https://www.wsj.com/health/pharma/johnson-johnson-to-buy-momenta-pharmaceuticals-for-6-5-billion-11597835648?gaa_at=eafs&gaa_n=AWEtsqc4hUtzVYZXQDdl5d25VLlBUuuG3J8Eobv9H_lP9GVC8QCM5LN_12gk&gaa_ts=6907e04b&gaa_sig=KAdk0LWLXAaMdjEDWg9SxcZNxxHCrJXUKqeh6QRgBKQCwPhyCvnvw1xCU-AT6P-R9gh8Abb9LW7lJbrLjCB1HQ%3D%3D", "time_published": "20200819T223710", "authors": ["Peter Loftus and Colin Kellaher"], "summary": "Johnson & Johnson announced its agreement to acquire Momenta Pharmaceuticals Inc. for approximately $6.5 billion. This acquisition provides J&J with access to a promising new class of drugs for treating autoimmune diseases, representing a roughly 70% premium over Momenta's closing share price.", "banner_image": "NULL", "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.948299"}], "overall_sentiment_score": 0.438087, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.445760", "ticker_sentiment_label": "Bullish"}]}, {"title": "J&J strikes $6.5 billion deal for autoimmune disease specialist Momenta", "url": "https://www.cnbc.com/2020/08/19/johnson-johnson-to-buy-momenta-for-about-6point5-billion.html", "time_published": "20200819T064500", "authors": [], "summary": "Johnson & Johnson is set to acquire Momenta Pharmaceuticals for approximately $6.5 billion in cash to strengthen its autoimmune disease treatment portfolio. This deal grants J&J's Janssen unit access to nipocalimab, an experimental therapy for myasthenia gravis and other autoantibody-driven diseases, which J&J anticipates will generate blockbuster sales. The acquisition comes as J&J expands its pharmaceuticals unit and follows similar moves in the biotech sector.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.932735"}, {"topic": "life_sciences", "relevance_score": "0.841514"}], "overall_sentiment_score": 0.443353, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.444924", "ticker_sentiment_label": "Bullish"}]}, {"title": "Momenta Enters Definitive Agreement with Johnson & Johnson", "url": "https://www.globenewswire.com/news-release/2020/08/19/2080519/0/en/Momenta-Enters-Definitive-Agreement-with-Johnson-Johnson.html", "time_published": "20200819T063400", "authors": [], "summary": "Johnson & Johnson has entered into a definitive agreement to acquire Momenta Pharmaceuticals for $52.50 per share in cash, totaling an equity value of $6.5 billion. This transaction represents a 70% premium to Momenta\u2019s closing price on August 18, 2020, and is expected to close in the second half of 2020. The acquisition highlights the potential of Momenta's FcRn inhibitor, nipocalimab, for treating autoantibody-driven autoimmune diseases.", "banner_image": null, "source": "GlobeNewswire", "category_within_source": "General", "source_domain": "GlobeNewswire", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.943677"}], "overall_sentiment_score": 0.346765, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.959254", "ticker_sentiment_score": "0.332948", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-to-acquire-momenta-pharmaceuticals-inc-expanding-janssens-leadership-in-novel-treatments-for-autoimmune-diseases-301114715.html", "time_published": "20200819T063000", "authors": [], "summary": "Johnson & Johnson announced its acquisition of Momenta Pharmaceuticals for approximately $6.5 billion in an all-cash transaction. This acquisition aims to expand Janssen's leadership in immune-mediated diseases, particularly through Momenta's lead asset, nipocalimab, which targets autoantibody-driven autoimmune diseases. The deal is expected to provide Janssen with significant growth opportunities and a pipeline of clinical and pre-clinical assets, along with Momenta's scientific capabilities and a presence in Cambridge, Massachusetts.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.946980"}], "overall_sentiment_score": 0.0461, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.317240", "ticker_sentiment_score": "0.015459", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Johnson & Johnson is investing in this niche telehealth startup", "url": "https://www.fiercehealthcare.com/tech/why-johnson-johnson-investing-a-telehealth-startup", "time_published": "20200817T155000", "authors": ["Heather Landi"], "summary": "Johnson & Johnson, through its innovation arm, has invested in direct-to-consumer telehealth company Thirty Madison, which specializes in chronic conditions like hair loss, migraines, and acid reflux. This Series B funding round, led by Polaris Partners, underscores J&J's strategy to back new healthcare models outside of traditional doctor's offices and tap into the growing virtual care market. Thirty Madison, which has seen rapid growth during the COVID-19 pandemic, plans to use the investment to further innovate and launch new brands.", "banner_image": null, "source": "Fierce Healthcare", "category_within_source": "General", "source_domain": "Fierce Healthcare", "topics": [{"topic": "life_sciences", "relevance_score": "0.923503"}, {"topic": "technology", "relevance_score": "0.840313"}, {"topic": "finance", "relevance_score": "0.715146"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.623219"}], "overall_sentiment_score": 0.403719, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.439264", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson invests in Thirty Madison, signaling the resilience of pharma\u2019s interest in health tech", "url": "https://www.statnews.com/2020/08/14/johnson-johnson-invests-in-thirty-madison-signaling-the-resilience-of-pharmas-interest-in-health-tech/", "time_published": "20200814T223711", "authors": ["Rebecca Robbins"], "summary": "Johnson & Johnson's innovation arm has invested in health tech startup Thirty Madison, signaling continued interest from big pharma in companies that rethink medication delivery despite previous partnership failures. Thirty Madison offers telemedicine and online prescriptions for common ailments, operating on an out-of-pocket payment model rather than through insurance. This investment highlights the growing influence of startups enabling online prescriptions for generic medications.", "banner_image": null, "source": "STAT", "category_within_source": "General", "source_domain": "STAT", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.827714"}, {"topic": "life_sciences", "relevance_score": "0.939045"}, {"topic": "technology", "relevance_score": "0.729858"}], "overall_sentiment_score": 0.310558, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.338017", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "On heels of U.S. pact, Johnson & Johnson advances COVID-19 vaccine talks with Europe", "url": "https://www.fiercepharma.com/pharma/heels-u-s-deal-johnson-johnson-strikes-covid-vaccine-supply-pact-europe", "time_published": "20200813T132500", "authors": ["Eric Sagonowsky"], "summary": "Johnson & Johnson is in advanced talks with the European Union to supply 200 million doses of its COVID-19 vaccine candidate, with an option for an additional 200 million doses. This follows a $1 billion deal with the U.S. for 100 million doses. J&J's vaccine candidate recently entered human testing, with initial results expected next month and potential phase 3 efficacy testing in September.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "manufacturing", "relevance_score": "0.746946"}], "overall_sentiment_score": 0.403504, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.414471", "ticker_sentiment_label": "Bullish"}]}, {"title": "4 innovative ways Johnson & Johnson has helped protect the public's health during outbreaks since the late 1800s", "url": "https://www.jnj.com/our-heritage/how-johnson-johnson-has-helped-improve-public-health-during-outbreaks", "time_published": "20200812T223707", "authors": ["Tamekia Reece"], "summary": "Johnson & Johnson has a long history of contributing to public health during outbreaks, dating back to the late 1800s. The company's efforts include educating the public about hygiene, being one of the first to vaccinate employees during a smallpox outbreak, mass-producing epidemic masks during the Spanish flu, and actively working on treatments and vaccines for current global health threats like COVID-19, tuberculosis, and Ebola. These initiatives demonstrate Johnson & Johnson's sustained commitment to safeguarding global public health.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.916794"}], "overall_sentiment_score": 0.277563, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.465165", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.617006", "ticker_sentiment_score": "0.279518", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.612694", "ticker_sentiment_score": "0.297204", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.559702", "ticker_sentiment_score": "0.211748", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAX", "relevance_score": "0.578736", "ticker_sentiment_score": "0.244353", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Five Top Drugmakers Reveal List vs. Net Price Gaps (Plus: The Trouble With Insulin Prices)", "url": "https://www.drugchannels.net/2020/08/five-top-drugmakers-reveal-list-vs-net.html", "time_published": "20200811T225210", "authors": ["Adam J. Fein", "Ph.D."], "summary": "This article examines the growing disparity between list and net prices for drugs from five major pharmaceutical manufacturers in 2019: Eli Lilly, Janssen, Merck, Novartis, and Sanofi. It highlights how rebates and discounts significantly reduce actual selling prices, leading to a \"gross-to-net bubble,\" especially problematic for insulin where patients' out-of-pocket costs are based on inflated list prices. The author argues for legislative changes to protect patients and increase transparency in drug pricing.", "banner_image": null, "source": "Drug Channels", "category_within_source": "General", "source_domain": "Drug Channels", "topics": [{"topic": "life_sciences", "relevance_score": "0.944547"}, {"topic": "economy_fiscal", "relevance_score": "0.710233"}, {"topic": "finance", "relevance_score": "0.623338"}], "overall_sentiment_score": 0.004668, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRK", "relevance_score": "0.916477", "ticker_sentiment_score": "0.041171", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.902858", "ticker_sentiment_score": "0.033211", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.642315", "ticker_sentiment_score": "0.026134", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ligand Buys Pfenex in $516 Million Deal to Access Protein Production Platform", "url": "https://www.biospace.com/ligand-buys-pfenex-for-516-million", "time_published": "20200811T224218", "authors": ["Mark Terry"], "summary": "Ligand Pharmaceuticals is acquiring Pfenex for a total deal transaction of up to $516 million, gaining access to Pfenex's proprietary protein production platform. The deal, expected to close in the fourth quarter, includes $438 million in equity value and a potential $78 million as a Contingent Value Right. This acquisition will expand Ligand's licensing and royalty revenue streams and enhance its position in developing therapeutics.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.903664"}, {"topic": "earnings", "relevance_score": "0.809062"}], "overall_sentiment_score": 0.223681, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "1.000000", "ticker_sentiment_score": "0.433872", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRK", "relevance_score": "0.649111", "ticker_sentiment_score": "0.105182", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.617090", "ticker_sentiment_score": "0.129208", "ticker_sentiment_label": "Neutral"}]}, {"title": "US government strikes $1.525 billion deal with Moderna for 100 million doses of its Covid-19 vaccine", "url": "https://www.cnn.com/2020/08/11/health/moderna-vaccine-government-deal", "time_published": "20200811T191200", "authors": ["Jen Christensen"], "summary": "The US government has finalized a $1.525 billion deal with Moderna Inc. to secure 100 million doses of its Covid-19 vaccine, mRNA-1273, once approved. The contract allows for an additional 400 million doses and aims to provide vaccines to Americans at no cost as part of Operation Warp Speed. This agreement follows similar deals with Pfizer and Janssen, emphasizing the Trump administration's efforts to create a diverse vaccine portfolio.", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "life_sciences", "relevance_score": "0.909519"}, {"topic": "economy_fiscal", "relevance_score": "0.720962"}], "overall_sentiment_score": 0.293747, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.996358", "ticker_sentiment_score": "0.404587", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.609311", "ticker_sentiment_score": "0.229917", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.575428", "ticker_sentiment_score": "0.210343", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bausch + Lomb to be spun off. Rochester impact out of focus for now", "url": "https://www.democratandchronicle.com/story/news/2020/08/06/bausch-lomb-eye-care-business-spun-off-rochester-impact-unclear/3309021001/", "time_published": "20200806T215115", "authors": ["Mary Chao"], "summary": "Bausch Health announced plans to spin off its Bausch + Lomb eye care division into a separate publicly traded entity. The immediate impact on Rochester, where Bausch + Lomb has over 1,100 employees and manufactures key eye products, is currently unclear though the Rochester facility is expected to be part of the new eye care business. This move follows Valeant's acquisition of Bausch + Lomb in 2013 and recent expansions at the Rochester site for contact lens production.", "banner_image": null, "source": "Democrat and Chronicle", "category_within_source": "General", "source_domain": "Democrat and Chronicle", "topics": [{"topic": "life_sciences", "relevance_score": "0.922750"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.806775"}, {"topic": "manufacturing", "relevance_score": "0.700769"}], "overall_sentiment_score": 0.155521, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BHC", "relevance_score": "0.963912", "ticker_sentiment_score": "0.241674", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.631835", "ticker_sentiment_score": "0.111919", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.554127", "ticker_sentiment_score": "0.094175", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson pledges 100M coronavirus vaccine doses to U.S. for $10 each", "url": "https://www.fiercepharma.com/pharma/j-j-scores-1b-contract-from-u-s-to-deliver-100-million-coronavirus-vaccine-doses", "time_published": "20200805T110500", "authors": ["Eric Sagonowsky"], "summary": "Johnson & Johnson has secured a deal with the U.S. government to supply 100 million doses of its COVID-19 vaccine candidate, Ad26.COV2.S, for just over $1 billion, pricing each dose at approximately $10. This agreement, which includes manufacturing in the U.S., allows for an additional purchase of 200 million doses. While still in early human trials, J&J anticipates initial results in September and could begin phase 3 efficacy testing next month.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.915676"}, {"topic": "economy_fiscal", "relevance_score": "0.707002"}], "overall_sentiment_score": 0.268973, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.423198", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.707120", "ticker_sentiment_score": "0.227579", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.607123", "ticker_sentiment_score": "0.129594", "ticker_sentiment_label": "Neutral"}]}, {"title": "Starkman: Beaumont Executive Paid $932,000 by Hospital Vendor Whose Implants Were Pushed on Surgeons", "url": "https://www.deadlinedetroit.com/articles/25892/starkman_beaumont_executive_paid_932_000_by_hospital_vendor_whose_implants_were_pushed_on_surgeons", "time_published": "20200802T211400", "authors": ["Eric Starkman"], "summary": "Dr. Jeffrey Fischgrund, a chief at Beaumont Health, received nearly $1 million in consulting fees from Stryker Corp. and Relievant Medsystems since 2013. This comes as Beaumont signed a contract committing to use Stryker implants for 75% of orthopedic trauma procedures, a move that is controversial among Beaumont surgeons who prefer rival products. The article also highlights a significant exodus of top surgeons from Beaumont and widespread dissatisfaction with CEO John Fox and COO Carolyn Wilson, particularly regarding a proposed merger with Advocate Aurora.", "banner_image": null, "source": "Deadline Detroit", "category_within_source": "General", "source_domain": "Deadline Detroit", "topics": [{"topic": "life_sciences", "relevance_score": "0.903335"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.838925"}, {"topic": "finance", "relevance_score": "0.625616"}], "overall_sentiment_score": -0.207586, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "SYK", "relevance_score": "0.949146", "ticker_sentiment_score": "-0.324250", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.740385", "ticker_sentiment_score": "-0.236430", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MDT", "relevance_score": "0.605224", "ticker_sentiment_score": "-0.119789", "ticker_sentiment_label": "Neutral"}]}, {"title": "Patient Champions", "url": "https://www.pharmavoice.com/news/2020-07-pharmavoice100-patient-champions/615823/", "time_published": "20200801T230646", "authors": ["PharmaVoice Team"], "summary": "This article highlights several \"Patient Champions\" who are leaders in the pharmaceutical and healthcare industries, dedicated to re-imagining patient engagement and improving the lives of patients, particularly those with rare diseases. The profiles showcase their innovative approaches, leadership styles, and commitment to advocating for better access, understanding, and care within the healthcare system. Each individual's unique contributions, ranging from building patient advocacy programs to leading clinical trials and influencing policy, are detailed, demonstrating their significant impact on patients and the industry.", "banner_image": null, "source": "PharmaVoice", "category_within_source": "General", "source_domain": "PharmaVoice", "topics": [{"topic": "life_sciences", "relevance_score": "0.933385"}], "overall_sentiment_score": 0.350965, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PTCT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.402927", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.861420", "ticker_sentiment_score": "0.320613", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.747848", "ticker_sentiment_score": "0.332125", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.681651", "ticker_sentiment_score": "0.336426", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.614060", "ticker_sentiment_score": "0.314031", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "U.S. Reaches $2.1 Billion Deal With Sanofi, GlaxoSmithKline For COVID-19 Vaccine Push", "url": "https://www.npr.org/sections/coronavirus-live-updates/2020/07/31/897701128/u-s-reaches-2-1-billion-deal-with-sanofi-and-glaxosmithkline-for-coronavirus-vac", "time_published": "20200731T120200", "authors": ["Sydney Lupkin"], "summary": "The U.S. government announced a $2.1 billion deal with Sanofi and GlaxoSmithKline for COVID-19 vaccine development, including the purchase of 100 million doses. This agreement is part of Operation Warp Speed and marks the sixth vaccine candidate to join the portfolio and the largest vaccine deal to date. The companies have committed to making the vaccine affordable and accessible, with 100 million doses to be available to Americans at no cost if approved.", "banner_image": null, "source": "NPR", "category_within_source": "General", "source_domain": "NPR", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "economy_fiscal", "relevance_score": "0.814560"}], "overall_sentiment_score": 0.364474, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SNY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.426947", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.627795", "ticker_sentiment_score": "0.316709", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.633988", "ticker_sentiment_score": "0.335279", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.607015", "ticker_sentiment_score": "0.301519", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sonoco ThermoSafe Creating Industrywide PharmaPortal\u2122", "url": "https://www.globenewswire.com/news-release/2020/07/30/2070160/26553/en/Sonoco-ThermoSafe-Creating-Industrywide-PharmaPortal-Platform-Using-IBM-Blockchain-Technology-To-Help-Deliver-Improved-Transparency-and-Traceability-Across-the-Temperature-Controll.html", "time_published": "20200730T064500", "authors": [], "summary": "Sonoco ThermoSafe is developing PharmaPortal\u2122, a vendor-neutral blockchain platform built on IBM Blockchain Transparent Supply, to enhance transparency and traceability in the temperature-controlled pharmaceutical supply chain. This initiative aims to address inefficiencies contributing to an estimated $35 billion in losses within the $230 billion cold chain pharmaceutical distribution market. The platform will initially focus on traceability of temperature-controlled drugs like vaccines, ensuring an audit trail of environmental conditions, and will invite industry leaders to collaborate on its development.", "banner_image": null, "source": "GlobeNewswire", "category_within_source": "General", "source_domain": "GlobeNewswire", "topics": [{"topic": "blockchain", "relevance_score": "0.938700"}, {"topic": "life_sciences", "relevance_score": "0.940748"}, {"topic": "technology", "relevance_score": "0.838281"}, {"topic": "manufacturing", "relevance_score": "0.716442"}], "overall_sentiment_score": 0.290343, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SON", "relevance_score": "1.000000", "ticker_sentiment_score": "0.463428", "ticker_sentiment_label": "Bullish"}, {"ticker": "IBM", "relevance_score": "0.825273", "ticker_sentiment_score": "0.342575", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.616094", "ticker_sentiment_score": "0.219796", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.643341", "ticker_sentiment_score": "0.242277", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.646030", "ticker_sentiment_score": "0.207623", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Trump Administration Selects Five Coronavirus Vaccine Candidates as Finalists (Published 2020)", "url": "https://www.nytimes.com/2020/06/03/us/politics/coronavirus-vaccine-trump-moderna.html", "time_published": "20200727T225214", "authors": ["Noah Weiland and David E. Sanger"], "summary": "The Trump administration has selected five companies as finalists to develop a coronavirus vaccine, aiming for widespread inoculation by the end of the year. The chosen companies are Moderna, Oxford University/AstraZeneca, Johnson & Johnson, Merck, and Pfizer. While seen by the White House as a critical step in progress, many scientists view the goal of early availability as optimistic due to the complex nature of vaccine development.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.911837"}, {"topic": "economy_fiscal", "relevance_score": "0.732760"}], "overall_sentiment_score": 0.285357, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.982210", "ticker_sentiment_score": "0.347185", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.831322", "ticker_sentiment_score": "0.292689", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.792193", "ticker_sentiment_score": "0.265589", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.738126", "ticker_sentiment_score": "0.232499", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna Gets OK to Start Larger Trial for a Coronavirus Vaccine (Published 2020)", "url": "https://www.nytimes.com/2020/05/07/health/coronavirus-vaccine-moderna.html", "time_published": "20200727T225213", "authors": ["Knvul Sheikh"], "summary": "Moderna has received approval from the FDA to proceed with a larger Phase 2 clinical trial for its experimental coronavirus vaccine, involving approximately 600 people. This trial aims to assess the vaccine's safety and replicate positive results from its initial phase. This move marks a significant step forward in the global race to develop a vaccine against the highly infectious coronavirus.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.906512"}], "overall_sentiment_score": 0.216209, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.423782", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.601012", "ticker_sentiment_score": "0.121723", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.610278", "ticker_sentiment_score": "0.133725", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna and Pfizer Begin Late-Stage Vaccine Trials (Published 2020)", "url": "https://www.nytimes.com/2020/07/27/health/moderna-vaccine-covid.html", "time_published": "20200727T225213", "authors": ["Denise Grady"], "summary": "Moderna and Pfizer have both initiated late-stage clinical trials for their respective coronavirus vaccines, each aiming to enroll 30,000 participants to assess safety and effectiveness. Moderna's trial began with volunteers receiving shots, while Pfizer, in partnership with BioNTech, also started its study after securing a $1.95 billion deal with the U.S. government for vaccine doses. Both studies will monitor for side effects and evaluate the vaccines' ability to prevent Covid-19 infection and severe illness.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.928466"}], "overall_sentiment_score": 0.328676, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.429588", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.902965", "ticker_sentiment_score": "0.347477", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.647510", "ticker_sentiment_score": "0.212867", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Robust Growth Visible for Inhalation Anesthesia Market", "url": "https://www.openpr.com/news/2097540/robust-growth-visible-for-inhalation-anesthesia-market", "time_published": "20200727T220600", "authors": [], "summary": "The Global Inhalation Anesthesia Market is projected to experience robust growth between 2020 and 2025, driven by an increase in emergency cases, accidents, and the aging population suffering from various diseases. Key players in this market include Baxter, AbbVie, Piramal Enterprises, Halocarbon Products, Hikma Pharmaceuticals, Lunan Pharmaceutical Group, Jiangsu Hengrui Medicine, and Fresenius Kabi. The market is segmented by type (Sevoflurane, Desflurane, Isoflurane), application (Induction, Maintenance), and region, with North America expected to show the highest CAGR.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.937231"}, {"topic": "financial_markets", "relevance_score": "0.632549"}], "overall_sentiment_score": 0.179402, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAX", "relevance_score": "0.945527", "ticker_sentiment_score": "0.333900", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.741096", "ticker_sentiment_score": "0.204937", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.627721", "ticker_sentiment_score": "0.128017", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.609883", "ticker_sentiment_score": "0.120975", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.645925", "ticker_sentiment_score": "0.149454", "ticker_sentiment_label": "Neutral"}]}, {"title": "Final test of Moderna\u2019s COVID-19 vaccine trial begins", "url": "https://nypost.com/2020/07/27/final-test-of-modernas-coronavirus-vaccine-trial-begins/", "time_published": "20200727T133200", "authors": ["Amanda Woods"], "summary": "The final stage of Moderna's COVID-19 vaccine study has commenced, with 30,000 US participants testing the experimental immunization. This trial, co-developed by the National Institutes of Health and Moderna, Inc., is the first of several large-scale studies planned for leading vaccine candidates through the fall. Researchers will monitor participants for infections to assess the vaccine's efficacy and safety.", "banner_image": null, "source": "New York Post", "category_within_source": "General", "source_domain": "New York Post", "topics": [{"topic": "life_sciences", "relevance_score": "0.925860"}], "overall_sentiment_score": 0.283663, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.410074", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.734110", "ticker_sentiment_score": "0.258801", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.637497", "ticker_sentiment_score": "0.232712", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.594445", "ticker_sentiment_score": "0.212647", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "An Easier Way to Understand the Pharma Industry", "url": "https://marketrealist.com/2019/12/easier-way-understand-pharma-industry/", "time_published": "20200726T130300", "authors": ["Sybil Prowse"], "summary": "This article provides an overview of the global pharmaceutical industry, detailing its subfields, regulatory bodies, and growth drivers. It covers publicly traded stocks and ETFs, the industry's supply chain, and critical regulations, highlighting why the pharma sector is unique due to its high regulation and capital intensity. The piece also explores factors contributing to the industry's growth, such as an aging population, changing lifestyles, increased income, chronic diseases, and globalization.", "banner_image": null, "source": "Market Realist", "category_within_source": "General", "source_domain": "Market Realist", "topics": [{"topic": "life_sciences", "relevance_score": "0.946220"}, {"topic": "financial_markets", "relevance_score": "0.637181"}], "overall_sentiment_score": 0.337524, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IHE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.422912", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.906110", "ticker_sentiment_score": "0.321777", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.871464", "ticker_sentiment_score": "0.314781", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.825297", "ticker_sentiment_score": "0.342147", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Getting to know the iShares Global Healthcare ETF (ASX:IXJ)", "url": "https://www.raskmedia.com.au/2020/07/23/getting-to-know-the-ishares-global-healthcare-etf-asxixj/", "time_published": "20200723T130700", "authors": ["Max Wagner"], "summary": "This article introduces the iShares Global Healthcare ETF (ASX:IXJ) as a way to gain exposure to the healthcare sector. It details the ETF's holdings, geographic allocation, performance, fees, and risks, highlighting the sector's tailwinds from an aging population and technological advancements. The article also provides a comparison of IXJ's valuation metrics against the iShares S&P 500 ETF (ASX:IVV).", "banner_image": null, "source": "Rask Media", "category_within_source": "General", "source_domain": "Rask Media", "topics": [{"topic": "financial_markets", "relevance_score": "0.914684"}, {"topic": "life_sciences", "relevance_score": "0.910687"}, {"topic": "finance", "relevance_score": "0.722011"}], "overall_sentiment_score": 0.300987, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IXJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.309836", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.639817", "ticker_sentiment_score": "0.310094", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Investing in Robotics Companies and Stocks", "url": "https://www.nanalyze.com/investing-robotics-companies-stocks/", "time_published": "20200721T215150", "authors": [], "summary": "This article provides an in-depth guide to investing in robotics companies and stocks, categorizing the industry into drones, autonomous vehicles, industrial robotics, robots in healthcare, and consumer robots. It discusses the importance of robotics due to competitive advantages for companies, current technological advancements, and specific investment opportunities and risks within each sector, including various publicly traded companies, ETFs, and industry trends like machine vision and warehouse automation. The article also touches on ethical concerns and the challenges of finding pure-play robotics investments.", "banner_image": null, "source": "Nanalyze", "category_within_source": "General", "source_domain": "Nanalyze", "topics": [{"topic": "technology", "relevance_score": "0.927972"}, {"topic": "manufacturing", "relevance_score": "0.716536"}, {"topic": "life_sciences", "relevance_score": "0.637810"}, {"topic": "retail_wholesale", "relevance_score": "0.649008"}], "overall_sentiment_score": 0.16061, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BOTT", "relevance_score": "0.330139", "ticker_sentiment_score": "0.001853", "ticker_sentiment_label": "Neutral"}, {"ticker": "TER", "relevance_score": "0.621109", "ticker_sentiment_score": "0.144786", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.648408", "ticker_sentiment_score": "0.313570", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.615322", "ticker_sentiment_score": "0.307386", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.631240", "ticker_sentiment_score": "0.136335", "ticker_sentiment_label": "Neutral"}]}, {"title": "6 Robotic Surgery Stocks for Retail Investors", "url": "https://www.nanalyze.com/2020/07/robotic-surgery-stocks/", "time_published": "20200720T223637", "authors": [], "summary": "This article examines the surgical robotics market and identifies six robotic surgery stocks for retail investors. It discusses major healthcare companies entering the market and highlights Intuitive Surgical as the dominant pure-play option. The article also covers smaller, struggling companies and specialized robotic surgery firms, concluding that only Intuitive Surgical offers robust exposure for retail investors.", "banner_image": null, "source": "Nanalyze", "category_within_source": "General", "source_domain": "Nanalyze", "topics": [{"topic": "life_sciences", "relevance_score": "0.907748"}, {"topic": "technology", "relevance_score": "0.823080"}, {"topic": "financial_markets", "relevance_score": "0.724575"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.619731"}], "overall_sentiment_score": 0.132815, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.947836", "ticker_sentiment_score": "0.334530", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.720341", "ticker_sentiment_score": "0.136756", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.698769", "ticker_sentiment_score": "0.122522", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.585433", "ticker_sentiment_score": "0.006276", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.630127", "ticker_sentiment_score": "0.123059", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vor Biopharma Raises $110M to Develop Engineered Hematopoietic Stem Cells", "url": "https://bioinformant.com/vor-biopharma/", "time_published": "20200716T233226", "authors": ["Cade Hildreth"], "summary": "Vor Biopharma announced it has raised $110 million in Series B financing, led by RA Capital Management. The funding will advance their lead candidate VOR33 into clinical trials for acute myeloid leukemia and expand their portfolio of engineered hematopoietic stem cells (eHSCs). Vor's technology aims to make transplanted stem cells \"invisible\" to targeted therapies while leaving diseased cells vulnerable, potentially revolutionizing cancer treatment.", "banner_image": null, "source": "BioInformant", "category_within_source": "General", "source_domain": "BioInformant", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.840835"}], "overall_sentiment_score": 0.438777, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VOR", "relevance_score": "1.000000", "ticker_sentiment_score": "0.626198", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.604006", "ticker_sentiment_score": "0.203443", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Readies to Start Covid-19 Vaccine Studies", "url": "https://www.wsj.com/articles/johnson-johnson-raises-2020-earnings-guidance-11594897686?gaa_at=eafs&gaa_n=AWEtsqc4plQZdK3XpyJswd8WB6TJODPnUYaQeVNU1WsDkiY6ic6jnSa-cDUx&gaa_ts=6907e045&gaa_sig=BAk1TUGLw9d_wYcf0PHwcHRv2cvlpjmJMCSUWLrHJhQFVz-mTpZdJnMZsyzPMauesXWS0a-_kAs0RGR83cJ1kA%3D%3D", "time_published": "20200716T223709", "authors": ["Peter Loftus", "Matt Grossman"], "summary": "Johnson & Johnson announced plans to begin human trials for its experimental Covid-19 vaccine next week, aiming to make it available by early next year. The initial study will enroll over 1,000 healthy adults in Belgium and the U.S. to assess safety and immune response. This development comes as the company also raised its financial guidance for the remainder of the year.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "earnings", "relevance_score": "0.838911"}, {"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.447476, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.428716", "ticker_sentiment_label": "Bullish"}]}, {"title": "Investing in Life Sciences Stocks and Companies", "url": "https://www.nanalyze.com/investing-life-sciences-stocks-companies/", "time_published": "20200716T221131", "authors": [], "summary": "This extensive article explores investment opportunities in life sciences, a broad field encompassing numerous specialized areas. It highlights key themes such as genomics, proteomics, human longevity, medical devices, telehealth, big data in healthcare, brain-computer interfaces, drug discovery, and medical testing, offering insights into relevant public and private companies. The article also provides cautionary advice on avoiding penny stocks and underscores the complexity and potential for innovation within the life sciences sector.", "banner_image": null, "source": "Nanalyze", "category_within_source": "General", "source_domain": "Nanalyze", "topics": [{"topic": "life_sciences", "relevance_score": "0.924621"}, {"topic": "technology", "relevance_score": "0.713044"}, {"topic": "finance", "relevance_score": "0.620386"}], "overall_sentiment_score": 0.189773, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EKG", "relevance_score": "0.607925", "ticker_sentiment_score": "0.113536", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.711089", "ticker_sentiment_score": "0.119135", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.804795", "ticker_sentiment_score": "0.217868", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.648070", "ticker_sentiment_score": "0.334926", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.611101", "ticker_sentiment_score": "0.221548", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Statement attributed to Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson on the occasion of the launch of the AMR Action Fund", "url": "https://www.jnj.com/our-company/statement-attributed-to-paul-stoffels-m-d-vice-chairman-of-the-executive-committee-and-chief-scientific-officer-johnson-johnson-on-the-occasion-of-the-launch-of-the-amr-action-fund", "time_published": "20200709T223710", "authors": [], "summary": "Johnson & Johnson, along with over 20 pharmaceutical companies, has collectively invested nearly $1 billion through the AMR Action Fund to combat antimicrobial resistance (AMR). Paul Stoffels of Johnson & Johnson announced the company's $100 million commitment to the fund, aiming to bring 2-4 new antibiotics to patients by the end of the next decade. This initiative addresses the critical public health threat of AMR, which has the potential to make currently treatable diseases incurable and is a greater global health challenge than even COVID-19.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.900350"}], "overall_sentiment_score": 0.455976, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.451271", "ticker_sentiment_label": "Bullish"}]}, {"title": "Shares of obscure biotech firm Novavax soar 32% on coronavirus vaccine funding", "url": "https://fortune.com/2020/07/07/novavax-stock-nvax-shares-covid-vaccine-coronavirus-funding/", "time_published": "20200707T050914", "authors": ["Jeff John Roberts"], "summary": "Novavax, a lesser-known Maryland biotech firm, saw its shares jump 32% after receiving a $1.6 billion U.S. government contract to produce 100 million doses of a COVID vaccine. This funding, part of Operation Warp Speed, is notable because Novavax has never brought a drug to market, unlike other larger pharmaceutical companies participating in the program. The company plans to use the funds for Stage 3 clinical trials and to ramp up manufacturing with the goal of delivering vaccines as early as this year.", "banner_image": "NULL", "source": "Fortune", "category_within_source": "General", "source_domain": "Fortune", "topics": [{"topic": "financial_markets", "relevance_score": "0.949521"}, {"topic": "life_sciences", "relevance_score": "0.825374"}, {"topic": "finance", "relevance_score": "0.709754"}, {"topic": "economy_fiscal", "relevance_score": "0.620045"}], "overall_sentiment_score": 0.18128, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GERM", "relevance_score": "0.720235", "ticker_sentiment_score": "0.418490", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.615097", "ticker_sentiment_score": "0.142583", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.589209", "ticker_sentiment_score": "0.087209", "ticker_sentiment_label": "Neutral"}]}, {"title": "MSF welcomes Johnson & Johnson price cut on lifesaving TB drug as an important step forward", "url": "https://www.doctorswithoutborders.org/latest/msf-welcomes-johnson-johnson-price-cut-lifesaving-tb-drug-important-step-forward", "time_published": "20200706T223709", "authors": [], "summary": "Doctors Without Borders (MSF) applauds Johnson & Johnson's decision to reduce the price of its tuberculosis (TB) drug bedaquiline to $1.50 per day, urging governments to incorporate it into drug-resistant TB (DR-TB) regimens. While this is a positive development, MSF stresses the need for wider availability of the reduced price to all high-burden countries and for J&J to cease blocking generic production of the drug. MSF highlights that bedaquiline was developed with significant public funding and calls for J&J to not enforce its patents, allowing more affordable generic versions to enter the market.", "banner_image": null, "source": "Doctors Without Borders", "category_within_source": "General", "source_domain": "Doctors Without Borders", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": -0.131272, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.981355", "ticker_sentiment_score": "-0.104289", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J sews up 5 years of coronavirus vaccine supply in $480M-plus deal with Emergent", "url": "https://www.fiercepharma.com/manufacturing/johnson-johnson-emergent-ink-480m-work-order-for-covid-19-vaccine-hopeful", "time_published": "20200706T105800", "authors": ["Kyle Blankenship"], "summary": "Johnson & Johnson (J&J) has secured a five-year deal worth at least $480 million with CDMO Emergent BioSolutions for the large-scale manufacturing of its COVID-19 vaccine candidate. This agreement, which begins in 2021, follows earlier pacts and is part of J&J's efforts to rapidly scale production for an anticipated commercial rollout, pending approval. Emergent BioSolutions continues to expand its role in the COVID-19 vaccine race, having also previously signed deals with AstraZeneca and BARDA for vaccine production.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "manufacturing", "relevance_score": "0.926378"}], "overall_sentiment_score": 0.236458, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.309739", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVS", "relevance_score": "0.706022", "ticker_sentiment_score": "0.243193", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AFL", "relevance_score": "0.606390", "ticker_sentiment_score": "0.100399", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Announces European Commission Approval for Janssen\u2019s Preventive Ebola Vaccine", "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-european-commission-approval-for-janssens-preventive-ebola-vaccine", "time_published": "20200701T223708", "authors": [], "summary": "Johnson & Johnson announced that the European Commission has granted Marketing Authorisation for Janssen\u2019s Ebola vaccine regimen, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo), for individuals aged one year and above. This approval marks a significant step in the global fight against Ebola, enabling Janssen to collaborate with the WHO for broader access, especially in African countries. The same AdVac\u00ae technology used in the Ebola vaccine is also being utilized for vaccine candidates to prevent COVID-19, Zika, RSV, and HIV.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.902246"}], "overall_sentiment_score": 0.64556, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.633049", "ticker_sentiment_label": "Bullish"}]}, {"title": "Envoy Medical Receives FDA Breakthrough Device Designation for its Fully Implanted Acclaim\u00ae Cochlear Implant", "url": "https://www.businesswire.com/news/home/20200629005146/en/Envoy-Medical-Receives-FDA-Breakthrough-Device-Designation-for-its-Fully-Implanted-Acclaim-Cochlear-Implant", "time_published": "20200629T220144", "authors": [], "summary": "Envoy Medical Corporation announced that its fully implanted Acclaim\u00ae cochlear implant has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This device aims to be the first fully implanted cochlear implant without external components, offering significant benefits to users. The company also celebrated the 10-year anniversary of its fully implanted Esteem\u00ae osseointegrated active middle ear implant.", "banner_image": null, "source": "Business Wire", "category_within_source": "General", "source_domain": "Business Wire", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.34212, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COCH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.896585", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.604460", "ticker_sentiment_score": "0.207265", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.585916", "ticker_sentiment_score": "0.166879", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.564455", "ticker_sentiment_score": "0.103948", "ticker_sentiment_label": "Neutral"}]}, {"title": "Halozyme Announces Roche Receives FDA Approval For Phesgo\u2122 (Fixed-Dose Combination Of Perjeta\u00ae And Herceptin\u00ae For Subcutaneous Injection) Utilizing Halozyme's ENHANZE\u00ae Technology For The Treatment Of Patients With HER2-Positive Breast C", "url": "https://www.prnewswire.com/news-releases/halozyme-announces-roche-receives-fda-approval-for-phesgo-fixed-dose-combination-of-perjeta-and-herceptin-for-subcutaneous-injection-utilizing-halozymes-enhanze-technology-for-the-treatment-of-patients-with-her2-positive-br-301085169.html", "time_published": "20200629T125400", "authors": [], "summary": "Halozyme announced that the FDA has approved Roche's Phesgo\u2122, a fixed-dose combination of Perjeta and Herceptin utilizing Halozyme's ENHANZE technology, for subcutaneous injection in patients with HER2-positive breast cancer. This approval marks the first time a product combining two monoclonal antibodies for single subcutaneous injection using ENHANZE technology has been approved, significantly reducing administration time from hours to minutes. Clinical data showed high patient preference for Phesgo\u2122 due to less clinic time and more comfortable treatment, with a safety profile comparable to existing IV administrations.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.940010"}], "overall_sentiment_score": 0.60959, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "HALO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.837808", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.614514", "ticker_sentiment_score": "0.530111", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.639087", "ticker_sentiment_score": "0.538766", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.619941", "ticker_sentiment_score": "0.517504", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABBV", "relevance_score": "0.624480", "ticker_sentiment_score": "0.521625", "ticker_sentiment_label": "Bullish"}]}, {"title": "Jane Hertzmark Hudis Promoted to Executive Group President at The Est\u00e9e Lauder Companies", "url": "https://www.thebeautyinfluencers.com/2020/06/26/jane-hertzmark-hudis-promoted-to-executive-group-president-at-the-estee-lauder-companies/", "time_published": "20200626T221131", "authors": ["Christine Schott Ledes"], "summary": "Jane Hertzmark Hudis has been promoted to Executive Group President at The Est\u00e9e Lauder Companies, effective July 1, 2020, overseeing major brands like Est\u00e9e Lauder and La Mer. Her promotion recognizes her leadership in driving growth, particularly in skin care and the APAC region. Additionally, St\u00e9phane de La Faverie was promoted to Group President, managing a new cluster of artisanal and luxury fragrance brands while continuing his role as Global Brand President for Est\u00e9e Lauder and AERIN.", "banner_image": null, "source": "The Beauty Influencers", "category_within_source": "General", "source_domain": "The Beauty Influencers", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.834422"}, {"topic": "finance", "relevance_score": "0.740624"}], "overall_sentiment_score": 0.316465, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EL", "relevance_score": "1.000000", "ticker_sentiment_score": "0.469897", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.617771", "ticker_sentiment_score": "0.121635", "ticker_sentiment_label": "Neutral"}]}, {"title": "Unilever, Johnson & Johnson will pull or rebrand skin-lightening creams in India", "url": "https://www.cnn.com/2020/06/25/business/hindustan-unilever-fair-and-lovely-intl-hnk", "time_published": "20200626T112500", "authors": ["Michelle Toh"], "summary": "Unilever, Johnson & Johnson, and L'Oreal are rebranding or discontinuing some of their skin-lightening products in India and Asia following growing controversy and global protests against racial discrimination. Hindustan Unilever will remove the word \"Fair\" from its \"Fair & Lovely\" brand, while Johnson & Johnson has already pulled products with \"Fairness\" labels. L'Oreal is also removing terms like \"white,\" \"fair,\" and \"light\" from similar products, aiming for a more inclusive vision of beauty.", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.819435"}], "overall_sentiment_score": 0.060208, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.960793", "ticker_sentiment_score": "0.031797", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.632464", "ticker_sentiment_score": "0.097003", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson drops skin-whitening creams", "url": "https://www.reuters.com/article/lifestyle/johnson-johnson-drops-skin-whitening-creams-idUSKBN23Q2BY/", "time_published": "20200619T152200", "authors": ["Martinne Geller"], "summary": "Johnson & Johnson announced it would stop selling skin-whitening creams in Asia and the Middle East, citing renewed social pressure amidst global discussions on racial inequality. The company stated that product names suggesting \"fair\" or \"white\" as better contradict their view that \"healthy skin is beautiful skin.\" This decision affects product lines like Clean & Clear Fairness and Neutrogena Fine Fairness, though existing stock may still be available on shelves.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fselectra.info%2Fs%2Fv%2Fwww.newyorkfed.org%2Fmedialibrary%2Fmedia%2Faboutthefed%2Fhistory%2Ffrbny%2FJohnson%26Johnson%202.jpg%3Fh%3D338%26w%3D600%26hash%3D66B40BA67709590DF0A101569A5AD67C", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.943968"}, {"topic": "retail_wholesale", "relevance_score": "0.706818"}], "overall_sentiment_score": 0.100164, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.149025", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.741253", "ticker_sentiment_score": "0.112243", "ticker_sentiment_label": "Neutral"}]}, {"title": "This NAACP-backed ETF will help you invest in companies that care about equality", "url": "https://fortune.com/2020/06/19/naacp-etf-racial-equality-antiracist-investing/", "time_published": "20200619T072726", "authors": ["Rey Mashayekhi"], "summary": "The Impact Shares NAACP Minority Empowerment ETF (NACP) allows investors to support companies committed to diversity and racial equality. Developed in partnership with the NAACP and Impact Shares, the ETF screens companies based on their practices in hiring, pay, promotion, and supply chains, with net proceeds going to the NAACP for social advocacy. With over $4 million in net assets and holdings in major companies like Amazon and Microsoft, the fund aims to achieve \"social alpha\" by investing in corporate leaders in social justice.", "banner_image": "https://fortune.com/img-assets/wp-content/uploads/2018/12/Mashayekhi_bio.jpg?format=webp&w=1440&q=100", "source": "Fortune", "category_within_source": "General", "source_domain": "Fortune", "topics": [{"topic": "finance", "relevance_score": "0.918805"}, {"topic": "financial_markets", "relevance_score": "0.713834"}, {"topic": "economy_macro", "relevance_score": "0.627692"}], "overall_sentiment_score": 0.320946, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NACP", "relevance_score": "1.000000", "ticker_sentiment_score": "0.480196", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMZN", "relevance_score": "0.620598", "ticker_sentiment_score": "0.340985", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.621298", "ticker_sentiment_score": "0.335450", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.620538", "ticker_sentiment_score": "0.306353", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.576279", "ticker_sentiment_score": "0.275280", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "STAAR Surgical Adds Renowned Eye Care Executives To Board Of Directors", "url": "https://thehealthcaretechnologyreport.com/staar-surgical-adds-renowned-eye-care-executives-to-board-of-directors/", "time_published": "20200610T232140", "authors": [], "summary": "STAAR Surgical, a leading developer of implantable lenses, has announced the addition of Dr. Gilbert H. Kliman and Thomas G. Frinzi to its Board of Directors. Both individuals bring extensive experience in the eye care and medical device industries, enhancing STAAR's leadership. The company also plans to nominate its current directors for re-election at the 2020 Annual Meeting of Shareholders.", "banner_image": null, "source": "The Healthcare Technology Report.", "category_within_source": "General", "source_domain": "The Healthcare Technology Report.", "topics": [{"topic": "life_sciences", "relevance_score": "0.926342"}, {"topic": "finance", "relevance_score": "0.749057"}], "overall_sentiment_score": 0.134778, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "STAA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.490211", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.608942", "ticker_sentiment_score": "0.147386", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.610575", "ticker_sentiment_score": "0.120154", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLW", "relevance_score": "0.586497", "ticker_sentiment_score": "-0.075791", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.570918", "ticker_sentiment_score": "-0.085945", "ticker_sentiment_label": "Neutral"}]}, {"title": "Legend Biotech Closes Initial Public Offering Raising Big Money", "url": "https://www.geneonline.com/legend-biotech-closes-initial-public-offering-raising-big-money/", "time_published": "20200610T224214", "authors": ["Ruchi Jhonsa"], "summary": "Legend Biotech, a clinical-stage CAR-T immune-oncology biotech, successfully closed its initial public offering on Nasdaq, raising approximately $487.3 million. The company's shares soared following the announcement, reflecting strong investor interest, particularly after promising data from its Phase 1 CARTITUDE-1 study for its lead compound, JNJ-4528. This IPO marks a significant financial boost for Legend, which plans to allocate the capital towards clinical development, manufacturing facilities, and commercial launch of its multiple myeloma drug.", "banner_image": null, "source": "www.geneonline.com", "category_within_source": "General", "source_domain": "www.geneonline.com", "topics": [{"topic": "ipo", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.927330"}], "overall_sentiment_score": 0.403703, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "LEGN", "relevance_score": "1.000000", "ticker_sentiment_score": "0.522817", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.611090", "ticker_sentiment_score": "0.309063", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson to begin human trials for coronavirus vaccine in late July, earlier than expected", "url": "https://www.cnbc.com/2020/06/10/johnson-johnson-to-begin-human-trials-for-coronavirus-vaccine-in-late-july-earlier-than-expected.html", "time_published": "20200610T102400", "authors": ["Berkeley Lovelace Jr."], "summary": "Johnson & Johnson announced that its early-stage human trial for a potential coronavirus vaccine will begin in late July, moving up its initial September forecast. The company is developing the vaccine using technology from its Ebola vaccine and aims to produce over 1 billion doses globally by 2021 if proven safe and effective. The trial will involve 1,045 healthy adults in the United States and Belgium across two age groups.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.912300"}], "overall_sentiment_score": 0.401408, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.464824", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.583091", "ticker_sentiment_score": "0.323615", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Are You Ready FDA's Transition From Computer System Validation To Computer Software Assurance", "url": "https://www.pharmaceuticalonline.com/doc/are-you-ready-fda-s-transition-from-computer-system-validation-to-computer-software-assurance-0001", "time_published": "20200603T231100", "authors": ["Kathleen Warner", "Ph.D."], "summary": "The FDA is preparing to release new guidance for Computer Software Assurance (CSA), moving away from the more documentation-heavy Computer System Validation (CSV). This shift, initially for the medical device industry but applicable broadly, emphasizes critical thinking, risk management, patient safety, data integrity, and quality assurance. Life sciences companies must proactively develop a strategy to transition their current CSV methodologies to CSA to align with these new guidelines.", "banner_image": null, "source": "Pharmaceutical Online", "category_within_source": "General", "source_domain": "Pharmaceutical Online", "topics": [{"topic": "life_sciences", "relevance_score": "0.911076"}, {"topic": "technology", "relevance_score": "0.847667"}, {"topic": "manufacturing", "relevance_score": "0.616487"}], "overall_sentiment_score": 0.169455, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RCMT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.282125", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.629761", "ticker_sentiment_score": "0.141676", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.601178", "ticker_sentiment_score": "0.102281", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.616046", "ticker_sentiment_score": "0.145193", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.613714", "ticker_sentiment_score": "0.125927", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson CEO on George Floyd protests: White men need to 'do more listening'", "url": "https://www.cnbc.com/2020/06/03/george-floyd-protests-johnson-johnson-ceo-says-white-men-need-to-listen-more.html", "time_published": "20200603T090400", "authors": ["Berkeley Lovelace Jr."], "summary": "Johnson & Johnson CEO Alex Gorsky stated that white men need to \"do more listening\" following George Floyd's death. J&J is committing $10 million over three years to fight racism and injustice in America and is investigating why Covid-19 disproportionately affects black communities. Gorsky emphasized the importance of empathy and understanding the experiences of the black community.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.946053"}, {"topic": "economy_macro", "relevance_score": "0.642115"}], "overall_sentiment_score": 0.253263, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.289720", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Merck to buy Austrian vaccine maker as it jumps into COVID-19 race", "url": "https://www.theglobeandmail.com/business/international-business/article-merck-jumps-into-the-race-for-covid-19-treatments-and-vaccines/", "time_published": "20200526T225211", "authors": ["Julie Steenhuysen and Michael Erman"], "summary": "Merck & Co Inc. announced its entry into the COVID-19 treatment race by acquiring Austrian vaccine maker Themis Bioscience and partnering with IAVI to develop two separate vaccines. The company also collaborated with Ridgeback Biotherapeutics for an experimental oral antiviral drug. Merck aims to use proven technologies for its vaccine candidates and is committed to global accessibility.", "banner_image": "https://www.theglobeandmail.com/resizer/v2/PZJ46V3DDRGPXP3G66SWMK2WBM.JPG?auth=6fa628c68eb87ce27bf482c3c978b27cf1f94d930f65bdc95503d650085ec351&quality=80&width=332&height=221", "source": "The Globe and Mail", "category_within_source": "General", "source_domain": "The Globe and Mail", "topics": [{"topic": "life_sciences", "relevance_score": "0.901895"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.832590"}, {"topic": "financial_markets", "relevance_score": "0.636357"}], "overall_sentiment_score": 0.21453, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.434397", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.630347", "ticker_sentiment_score": "0.131494", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.615828", "ticker_sentiment_score": "0.103781", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson CIO: Transformational leadership needed now more than ever", "url": "https://enterprisersproject.com/article/2020/5/why-transformational-leadership-needed-now", "time_published": "20200521T223710", "authors": ["James Swanson"], "summary": "Johnson & Johnson CIO Jim Swanson discusses how COVID-19 accelerated IT transformation efforts within the company, highlighting the critical role of technology in crisis management and business transformation. He outlines a three-pronged approach focusing on business outcomes, talent, and ways of working to align IT's mission with the company's broader goals and drive positive change. The article emphasizes the importance of transformational leadership in navigating unforeseen challenges and preparing for a more digital future.", "banner_image": null, "source": "The Enterprisers Project", "category_within_source": "General", "source_domain": "The Enterprisers Project", "topics": [{"topic": "life_sciences", "relevance_score": "0.913339"}, {"topic": "technology", "relevance_score": "0.839036"}], "overall_sentiment_score": 0.441597, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.404278", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson will stop selling talc-based baby powder", "url": "https://www.cnn.com/2020/05/20/health/johnson-and-johnson-stops-selling-talc-based-baby-powder-trnd", "time_published": "20200520T220300", "authors": ["Jen Christensen"], "summary": "Johnson & Johnson announced it will stop selling talc-based baby powder in the US and Canada, discontinuing about 100 products. The decision follows a decline in product demand and tens of thousands of lawsuits linking talcum powder to ovarian cancer, despite the company's continued confidence in its safety", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "life_sciences", "relevance_score": "0.936841"}, {"topic": "retail_wholesale", "relevance_score": "0.703000"}, {"topic": "finance", "relevance_score": "0.602677"}], "overall_sentiment_score": -0.642549, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.647740", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson to stop selling talc baby powder in U.S. and Canada", "url": "https://www.reuters.com/article/world/johnson-johnson-to-stop-selling-talc-baby-powder-in-us-and-canada-idUSKBN22W09C/", "time_published": "20200520T141900", "authors": ["Carl O'Donnell and Lisa Girion"], "summary": "Johnson & Johnson announced it will discontinue sales of its talc-based Baby Powder in the U.S. and Canada, citing declining demand due to \"misinformation\" and numerous legal challenges. The company faces over 19,000 lawsuits alleging its talc products caused cancer due to asbestos contamination, despite J&J maintaining the product's safety. This decision is seen as a victory for public health advocates but legal battles are expected to continue.", "banner_image": "https://www.reuters.com/resizer/v2/L42B2L6XCNI3FOW2N45IFQO3QE.JPG?width=1200&height=628", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.941047"}, {"topic": "finance", "relevance_score": "0.734061"}, {"topic": "retail_wholesale", "relevance_score": "0.649837"}], "overall_sentiment_score": -0.23592, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.200658", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson Discontinues Talcum Baby Powder in U.S. and Canada", "url": "https://time.com/5839391/johnson-johnson-ends-talcum-baby-powder/", "time_published": "20200520T103600", "authors": ["Riley Griffin and Jef Feeley / Bloomberg"], "summary": "Johnson & Johnson has decided to discontinue its talc-based baby powder in the U.S. and Canada after experiencing a decline in sales due to thousands of lawsuits alleging asbestos contamination. The company will continue to sell existing inventory until supplies run out and will still offer its cornstarch-based baby powder in these markets, while the talc-based product will continue to be sold internationally. J&J maintains its confidence in the safety of its talc-based product despite the litigation.", "banner_image": null, "source": "Time Magazine", "category_within_source": "General", "source_domain": "Time Magazine", "topics": [{"topic": "life_sciences", "relevance_score": "0.903633"}, {"topic": "retail_wholesale", "relevance_score": "0.739495"}], "overall_sentiment_score": -0.283276, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.380632", "ticker_sentiment_label": "Bearish"}, {"ticker": "BAX", "relevance_score": "0.612516", "ticker_sentiment_score": "-0.122266", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson to discontinue sales of talc-based baby powder in U.S., Canada", "url": "https://www.cbsnews.com/news/johnson-johnson-talc-baby-powder-discontinued-us-canada-asbestos-claims-denied/", "time_published": "20200520T061800", "authors": ["Victoria Albert"], "summary": "Johnson & Johnson announced it will discontinue sales of its talc-based baby powder in the U.S. and Canada, citing declining demand and \"misinformation\" amid thousands of lawsuits. The company denies claims that the product contains asbestos and maintains its safety, while an Illinois Representative celebrated the decision as a victory for public health. J&J's cornstarch-based baby powder will remain on the market.", "banner_image": null, "source": "CBS News", "category_within_source": "General", "source_domain": "CBS News", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "retail_wholesale", "relevance_score": "0.749713"}], "overall_sentiment_score": -0.117313, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.290731", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KMB", "relevance_score": "0.612997", "ticker_sentiment_score": "0.139588", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson to End Talc-Based Baby Powder Sales in North America (Published 2020)", "url": "https://www.nytimes.com/2020/05/19/business/johnson-baby-powder-sales-stopped.html", "time_published": "20200519T223708", "authors": ["Tiffany Hsu and Roni Caryn Rabin"], "summary": "Johnson & Johnson announced it is discontinuing sales of its talc-based baby powder in North America due to declining demand and thousands of lawsuits claiming the product caused cancer. The company maintains the product's safety and will continue to defend against lawsuits while still selling cornstarch-based baby powder and talc-based baby powder in other regions. This decision marks a significant concession for a product once central to the company's image.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.945945"}, {"topic": "retail_wholesale", "relevance_score": "0.716892"}], "overall_sentiment_score": -0.608227, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.609996", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson Stops Selling Talc-Based Baby Powder In U.S. And Canada", "url": "https://www.npr.org/2020/05/19/859182015/johnson-johnson-stops-selling-talc-based-baby-powder-in-u-s-and-canada", "time_published": "20200519T212900", "authors": ["Vanessa Romo"], "summary": "Johnson & Johnson announced it will stop selling talc-based baby powder in the U.S. and Canada due to declining demand and ongoing litigation alleging the product causes cancer. The company denies the allegations, citing decades of scientific studies supporting the product's safety, and is appealing several multi-million dollar verdicts against it. Despite discontinuation in North America, cornstarch-based baby powder will still be available, and both types will continue to be sold internationally.", "banner_image": "https://media.npr.org/assets/img/2020/05/19/ap_20140689255866-2_wide-0f2c4179379853a016f4618da4d1d9600b3e7aa1-s1400-c100.jpg", "source": "NPR", "category_within_source": "General", "source_domain": "NPR", "topics": [{"topic": "life_sciences", "relevance_score": "0.910299"}, {"topic": "retail_wholesale", "relevance_score": "0.743161"}], "overall_sentiment_score": 0.025099, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.343043", "ticker_sentiment_score": "0.022987", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Discontinues Talc Baby Powder in U.S., Canada", "url": "https://www.bloomberg.com/news/articles/2020-05-19/johnson-johnson-discontinues-talc-baby-powder-in-u-s-canada", "time_published": "20200519T203000", "authors": ["Riley Griffin and Jef Feeley"], "summary": "Johnson & Johnson has decided to discontinue its talc-based baby powder products in the U.S. and Canada, labeling it a \"commercial decision\" due to declining sales. This move follows thousands of lawsuits alleging asbestos contamination and hiddden cancer risks associated with the product, which have resulted in billions of dollars in damages against the company. Existing inventory will continue to be sold until supplies run out in these markets.", "banner_image": null, "source": "Bloomberg.com", "category_within_source": "General", "source_domain": "Bloomberg.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.908062"}, {"topic": "retail_wholesale", "relevance_score": "0.704676"}], "overall_sentiment_score": -0.41901, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.447233", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson to stop selling baby powder in US and Canada", "url": "https://www.theguardian.com/business/2020/may/19/johnson-johnson-baby-powder-us-canada", "time_published": "20200519T182100", "authors": ["Guardian staff and agencies"], "summary": "Johnson & Johnson announced it will stop selling its talcum-based baby powder in the US and Canada, attributing the decision to declining demand and a broad reassessment of its consumer product portfolio. This move comes amid tens of thousands of lawsuits alleging the product caused cancer, although J&J continues to defend its safety, planning to sell talc-based powder in other global markets and cornstarch-based powder in North America. The company also faced a product recall in October for asbestos contamination, a claim it denies.", "banner_image": "https://i.guim.co.uk/img/media/e1cf4e3341b53c714d23fffc8e1c6cd14301d0a5/0_146_3226_1936/master/3226.jpg?width=1200&height=630&quality=85&auto=format&fit=crop&overlay-align=bottom%2Cleft&overlay-width=100p&overlay-content=%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20https%3A%2F%2Fuploads.guim.co.uk%2F2020%2F05%2F19%2FReuters.png&s=4ff1f38e6587002492f254e427d142b6", "source": "The Guardian", "category_within_source": "General", "source_domain": "The Guardian", "topics": [{"topic": "life_sciences", "relevance_score": "0.920560"}, {"topic": "retail_wholesale", "relevance_score": "0.739796"}], "overall_sentiment_score": -0.278728, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.268230", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson to Stop Selling Talc-Based Baby Powder in North America", "url": "https://www.usnews.com/news/national-news/articles/2020-05-19/johnson-johnson-to-stop-selling-talc-based-baby-powder-in-north-america", "time_published": "20200519T181400", "authors": ["Claire Hansen"], "summary": "Johnson & Johnson has announced it will discontinue sales of its talc-based baby powder in North America citing declining demand and litigation publicity. The company faces nearly 20,000 lawsuits alleging safety concerns, though it maintains the product's safety. J&J will continue to sell a cornstarch-based version and the talc-based product in other parts of the world.", "banner_image": null, "source": "U.S. News & World Report", "category_within_source": "General", "source_domain": "U.S. News & World Report", "topics": [{"topic": "life_sciences", "relevance_score": "0.946877"}, {"topic": "retail_wholesale", "relevance_score": "0.739795"}], "overall_sentiment_score": -0.397846, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.421944", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson discontinues talc-based baby powder in U.S., Canada amid lawsuits", "url": "https://www.nbcnews.com/news/us-news/johnson-johnson-discontinues-talc-based-baby-powder-u-s-canada-n1210751", "time_published": "20200519T174400", "authors": ["Doha Madani"], "summary": "Johnson & Johnson has announced it will discontinue talc-based baby powder in the U.S. and Canada, citing declining sales due to \"misinformation\" and litigation. The company maintains the safety of the product despite numerous lawsuits alleging a link to cancer. Johnson & Johnson plans to continue selling the talc-based powder in other global markets where demand remains high.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.930524"}, {"topic": "retail_wholesale", "relevance_score": "0.731626"}], "overall_sentiment_score": -0.22662, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.236421", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson to discontinue talc-based baby powder", "url": "https://www.foxbusiness.com/markets/johnson-johnson-to-discontinue-talc-based-baby-powder", "time_published": "20200519T173800", "authors": ["James Leggate"], "summary": "Johnson & Johnson announced it will discontinue its talc-based baby powder in North America due to declining demand, influenced by changing consumer habits and ongoing litigation. The decision is also framed as a reprioritization of its portfolio in light of the coronavirus pandemic, despite the company maintaining confidence in the product's safety. J&J faces thousands of lawsuits alleging cancer causation from asbestos contamination in its talc products.", "banner_image": null, "source": "Fox Business", "category_within_source": "General", "source_domain": "Fox Business", "topics": [{"topic": "life_sciences", "relevance_score": "0.922400"}, {"topic": "finance", "relevance_score": "0.741914"}, {"topic": "retail_wholesale", "relevance_score": "0.614915"}], "overall_sentiment_score": -0.226279, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.234099", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Beta-alanine and the importance of quality", "url": "https://www.newfoodmagazine.com/article/110309/beta-alanine-and-the-importance-of-quality/", "time_published": "20200515T225244", "authors": ["Mark LeDoux"], "summary": "This article discusses the growing market for beta-alanine supplements and the critical importance of using high-quality, scientifically tested ingredients. It highlights issues with generic beta-alanine, such as potential FDA violations, risks to consumer health, and damage to brand reputation due to lacking consistent quality, potency, and purity. The author emphasizes that while beta-alanine is effective for athletic performance, its benefits are only realized when manufacturers use properly tested and regulated forms.", "banner_image": null, "source": "New Food magazine", "category_within_source": "General", "source_domain": "New Food magazine", "topics": [{"topic": "life_sciences", "relevance_score": "0.939046"}, {"topic": "retail_wholesale", "relevance_score": "0.705031"}], "overall_sentiment_score": 0.258015, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NAII", "relevance_score": "0.926435", "ticker_sentiment_score": "0.435998", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.600276", "ticker_sentiment_score": "0.100850", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cancer biotech stocks shift on glimpse of ASCO data", "url": "https://www.biopharmadive.com/news/asco-abstract-cancer-biotech-allogene/577961/", "time_published": "20200514T214156", "authors": ["Ned Pagliarulo"], "summary": "The stocks of several cancer drug developers saw significant shifts in value following the early release of clinical trial data abstracts for the American Society of Clinical Oncology's (ASCO) annual meeting. Allogene Therapeutics saw a nearly 30% rise in shares due to promising data for its \"off-the-shelf\" cancer cell therapy, while other companies like Arcus Biosciences, Arvinas, and Macrogenics experienced stock declines after their abstract releases. These early glimpses from ASCO abstracts, even with limited information, can trigger substantial market reactions in the biotech sector.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.946675"}, {"topic": "financial_markets", "relevance_score": "0.847072"}], "overall_sentiment_score": 0.203223, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALLO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.423560", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.719442", "ticker_sentiment_score": "0.100618", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.605468", "ticker_sentiment_score": "0.137701", "ticker_sentiment_label": "Neutral"}]}, {"title": "Flex Kallang helps customers deliver critical tools in the fight against COVID-19", "url": "https://flex.com/resources/flex-kallang-helps-customers-deliver-critical-medical-tools", "time_published": "20200512T221702", "authors": [], "summary": "Flex Kallang in Singapore has been instrumental in assisting customers to deliver critical medical equipment during the COVID-19 pandemic. They rapidly increased production of hand-held blood analyzers for diagnostics in China, supported the delivery of nebulizer systems for patient treatment, and helped produce immunoassay analyzers for virus research and vaccine development. These efforts have provided essential tools for diagnostics, treatment, and research globally to combat the pandemic.", "banner_image": null, "source": "Flextronics", "category_within_source": "General", "source_domain": "Flextronics", "topics": [{"topic": "life_sciences", "relevance_score": "0.918000"}, {"topic": "manufacturing", "relevance_score": "0.816357"}], "overall_sentiment_score": 0.307516, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FLEX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.429512", "ticker_sentiment_label": "Bullish"}, {"ticker": "BAX", "relevance_score": "0.668297", "ticker_sentiment_score": "0.322006", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.615069", "ticker_sentiment_score": "0.297031", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.602691", "ticker_sentiment_score": "0.286701", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STE", "relevance_score": "0.569564", "ticker_sentiment_score": "0.256078", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Kevin O'Leary: If you're worried about dividend cuts, it's 'time to use actively managed ETFs'", "url": "https://www.cnbc.com/2020/05/12/shark-tanks-kevin-oleary-makes-the-case-for-actively-managed-etfs.html", "time_published": "20200512T101300", "authors": ["Lizzy Gurdus"], "summary": "Kevin O'Leary suggests that actively managed ETFs are a valuable tool for investors concerned about dividend cuts and market volatility, particularly in an uncertain market environment. He highlights O'Shares FTSE U.S. Quality Dividend ETF (OUSA) as an example of an actively managed fund that focuses on companies with high-quality balance sheets and lower likelihood of cutting dividends. O'Leary emphasizes that in these times, quality really matters and active management can help cherry-pick sound investments.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "financial_markets", "relevance_score": "0.930164"}], "overall_sentiment_score": 0.335122, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OUSA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.442914", "ticker_sentiment_label": "Bullish"}, {"ticker": "AAPL", "relevance_score": "0.740287", "ticker_sentiment_score": "0.344986", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.620235", "ticker_sentiment_score": "0.331487", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.624690", "ticker_sentiment_score": "0.330389", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.621968", "ticker_sentiment_score": "0.318085", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The New York Times: NYU Langone Among First Centers to Dose Patients in Pfizer-Led U.S. COVID-19 Vaccine Trials", "url": "https://nyulangone.org/news/new-york-times-nyu-langone-among-first-centers-dose-patients-pfizer-led-us-covid-19-vaccine-trials", "time_published": "20200505T230211", "authors": [], "summary": "NYU Langone, specifically NYU Grossman School of Medicine, is among the first centers in the U.S. to begin dosing patients in the Pfizer-led COVID-19 vaccine trials. The vaccine uses an RNA-based technique to instruct cells to produce viral proteins, aiming to train the immune system to fight the virus without causing illness. Infectious diseases expert Dr. Mark J. Mulligan emphasizes the critical need for vaccines to be very safe as they are administered to healthy individuals.", "banner_image": null, "source": "NYU Langone Health", "category_within_source": "General", "source_domain": "NYU Langone Health", "topics": [{"topic": "life_sciences", "relevance_score": "0.935458"}], "overall_sentiment_score": 0.281274, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.427652", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.649971", "ticker_sentiment_score": "0.268296", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.640340", "ticker_sentiment_score": "0.257097", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.590436", "ticker_sentiment_score": "0.214755", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.566498", "ticker_sentiment_score": "0.235768", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine", "url": "https://www.globenewswire.com/news-release/2020/05/04/2026754/0/en/Arcturus-Therapeutics-and-Catalent-Announce-Partnership-to-Manufacture-mRNA-Based-COVID-19-Vaccine.html", "time_published": "20200504T083900", "authors": ["NULL"], "summary": "Arcturus Therapeutics and Catalent, Inc. announced a partnership to manufacture Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19). The collaboration aims to support human clinical studies and potential commercialization, leveraging Arcturus' STARR\u2122 technology and Catalent's scalable cGMP manufacturing capabilities to produce millions of doses in 2020. Preparations are already underway, with technology transfer and initial GMP batches expected to be completed in May and June 2020, respectively.", "banner_image": "NULL", "source": "GlobeNewswire", "category_within_source": "General", "source_domain": "GlobeNewswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.930100"}, {"topic": "manufacturing", "relevance_score": "0.723408"}], "overall_sentiment_score": 0.348934, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.493441", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.586264", "ticker_sentiment_score": "0.218420", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Oklahoma AG Mike Hunter refiles lawsuits against 3 opioid distribution companies", "url": "https://www.oklahoman.com/story/news/columns/2020/05/02/oklahoma-ag-mike-hunter-files-lawsuits-against-3-opioid-distribution-companies/60402656007/", "time_published": "20200502T215629", "authors": ["Randy Ellis"], "summary": "Oklahoma Attorney General Mike Hunter refiled state lawsuits against McKesson Corporation, Cardinal Health Inc., and AmerisourceBergen Corp., accusing them of significantly contributing to the opioid crisis by oversupplying highly addictive painkillers to the state. The lawsuits, filed in Bryan County District Court, allege negligence and public nuisance, seeking unspecified damages and the return of unjust profits. Hunter previously won a $465 million verdict against Johnson & Johnson and has reached settlements with other opioid manufacturers.", "banner_image": null, "source": "The Oklahoman", "category_within_source": "General", "source_domain": "The Oklahoman", "topics": [{"topic": "life_sciences", "relevance_score": "0.942990"}], "overall_sentiment_score": -0.611777, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.626045", "ticker_sentiment_label": "Bearish"}, {"ticker": "MCK", "relevance_score": "0.915625", "ticker_sentiment_score": "-0.607787", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.626398", "ticker_sentiment_score": "-0.501582", "ticker_sentiment_label": "Bearish"}]}, {"title": "Vertex, even amid pandemic, raises sales projections thanks to gangbusters start for Trikafta", "url": "https://www.fiercepharma.com/pharma/even-amid-a-pandemic-vertex-raises-guidance-thanks-to-gangbusters-start-for-trikafta", "time_published": "20200430T094100", "authors": ["Eric Sagonowsky"], "summary": "Vertex Pharmaceuticals raised its 2020 sales projections after its new cystic fibrosis drug, Trikafta, achieved an $895 million launch in its first full quarter, despite the COVID-19 pandemic. The company's overall revenues grew 77% from the previous year, leading to an increased revenue guidance to between $5.3 billion and $5.6 billion. Vertex acknowledged potential future uncertainties due to the pandemic, such as shifts in payer mix and impact on new patient initiations, but plans to maintain a strong negotiation stance for Trikafta's pricing internationally.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "earnings", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.004247, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.980618", "ticker_sentiment_score": "0.435623", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.637643", "ticker_sentiment_score": "-0.348091", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRK", "relevance_score": "0.604560", "ticker_sentiment_score": "-0.342608", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.569778", "ticker_sentiment_score": "0.102395", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.561944", "ticker_sentiment_score": "0.125264", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cleaning Brands Urge Consumers Not to Inject Their Products", "url": "https://www.adweek.com/brand-marketing/cleaning-brands-urge-against-injecting-disinfectants-following-president-trumps-comments/", "time_published": "20200424T220120", "authors": ["Kathryn Lundstrom"], "summary": "Following President Donald Trump's suggestion of injecting disinfectants as a potential COVID-19 treatment, cleaning product manufacturers Reckitt Benckiser and Clorox issued statements advising against such actions. Medical experts quickly refuted Trump's claims, emphasizing the fatal risks and lack of benefit. The article highlights the dangerous nature of the President's comments and the swift response from brands and health professionals.", "banner_image": null, "source": "ADWEEK", "category_within_source": "General", "source_domain": "ADWEEK", "topics": [{"topic": "life_sciences", "relevance_score": "0.702619"}, {"topic": "retail_wholesale", "relevance_score": "0.634007"}], "overall_sentiment_score": -0.071203, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CLX", "relevance_score": "0.962305", "ticker_sentiment_score": "0.107482", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMM", "relevance_score": "0.647095", "ticker_sentiment_score": "-0.188387", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.551834", "ticker_sentiment_score": "-0.128714", "ticker_sentiment_label": "Neutral"}]}, {"title": "$350,000 on Hand Sanitizer: How Werner is Responding to the COVID-19 Pandemic", "url": "https://www.truckinginfo.com/356592/350-000-on-hand-sanitizer-how-werner-is-responding-to-the-covid-19-pandemic", "time_published": "20200422T233630", "authors": ["Deborah Lockridge"], "summary": "Werner Enterprises has spent over $350,000 on hand sanitizer and implemented comprehensive measures to protect its drivers and employees during the COVID-19 pandemic. CEO Derek Leathers emphasizes compassion and data-driven decisions, drawing on the company's existing pandemic plan and emergency response experience. Werner has adapted to significant disruptions in supply chains, with executives taking salary reductions while supporting drivers with pay if impacted by the virus.", "banner_image": null, "source": "Heavy Duty Trucking", "category_within_source": "General", "source_domain": "Heavy Duty Trucking", "topics": [{"topic": "economy_macro", "relevance_score": "0.947389"}, {"topic": "energy_transportation", "relevance_score": "0.944893"}, {"topic": "life_sciences", "relevance_score": "0.720109"}, {"topic": "finance", "relevance_score": "0.606556"}], "overall_sentiment_score": 0.151902, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WERN", "relevance_score": "0.978895", "ticker_sentiment_score": "0.290420", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.645475", "ticker_sentiment_score": "0.127545", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.643991", "ticker_sentiment_score": "0.106247", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.562547", "ticker_sentiment_score": "0.114842", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Johnson & Johnson IT is managing a global crisis", "url": "https://www.cio.com/article/193297/how-johnson-johnson-it-is-managing-a-global-crisis.html", "time_published": "20200422T223710", "authors": ["Martha Heller"], "summary": "J&J CIO Jim Swanson describes how his IT team managed operations during the COVID-19 pandemic, impacting its $82 billion healthcare giant and 132,000 employees globally. The article covers their crisis management strategy, leveraging existing capabilities, lessons learned, and the unexpected boost in digital acumen across the company. Swanson emphasizes the criticality of IT and collaboration in navigating global crises and preparing for future healthcare technology advancements.", "banner_image": null, "source": "www.cio.com", "category_within_source": "General", "source_domain": "www.cio.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.946354"}, {"topic": "technology", "relevance_score": "0.819719"}], "overall_sentiment_score": 0.475903, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.498943", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson execs offer upbeat view of second-half recovery from COVID-19 pandemic", "url": "https://www.marketwatch.com/story/johnson-johnson-execs-offer-upbeat-view-of-second-half-recovery-from-covid-19-pandemic-2020-04-15?gaa_at=eafs&gaa_n=AWEtsqfDFXAuZ1amlE_hpbIXtyfJBOQL6HFr58wGab_5kYvjPq5nee1ivrk2&gaa_ts=6907e045&gaa_sig=q3Nd_bnDsKQjhaN8yURtRlNzAqrvjwUGWUkT0nr0_zHGn7YG_cxmfqIPeSbWvRmlMewBkVVmEhazByr4StxxCA%3D%3D", "time_published": "20200417T062200", "authors": [], "summary": "Johnson & Johnson executives expressed an optimistic outlook for an economic recovery in the second half of the year, despite the significant impact of the COVID-19 pandemic on its medical-device business in Q1 2020. The company projects a phased impact from the pandemic: initial in Q1, significant in Q2, stabilization in Q3, and recovery in Q4. CFO John Wolk anticipates a much better-prepared world if the virus returns, with an improving global economy and better healthcare capacity post-Q2.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "earnings", "relevance_score": "0.947596"}, {"topic": "life_sciences", "relevance_score": "0.807692"}, {"topic": "economy_macro", "relevance_score": "0.723514"}], "overall_sentiment_score": 0.409451, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.427809", "ticker_sentiment_label": "Bullish"}]}, {"title": "Continuous Pharmaceutical Manufacturing", "url": "https://chemanager-online.com/en/topics/continuous-pharmaceutical-manufacturing", "time_published": "20200415T233607", "authors": [], "summary": "The pharmaceutical industry is increasingly adopting continuous manufacturing (CM) due to its undeniable advantages over batch manufacturing, including reduced CAPEX, automation, improved quality control, and shorter lead times. Despite these benefits, challenges like existing infrastructure and regulatory uncertainties have led to slow adoption. However, continuous manufacturing offers a robust solution for fragile pharmaceutical supply chains, especially relevant during global health crises.", "banner_image": null, "source": "CHEManager", "category_within_source": "General", "source_domain": "CHEManager", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "manufacturing", "relevance_score": "0.920826"}], "overall_sentiment_score": 0.276552, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.923887", "ticker_sentiment_score": "0.325454", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.711444", "ticker_sentiment_score": "0.251099", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.681737", "ticker_sentiment_score": "0.214612", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.633598", "ticker_sentiment_score": "0.244718", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Lowers Revenue Forecast on Coronavirus Impact", "url": "https://www.wsj.com/articles/johnson-johnsons-profit-rises-on-higher-consumer-products-sales-11586862436?gaa_at=eafs&gaa_n=AWEtsqfNVFZLhwt0cuCvn9YVSFOd1JaOcSQVqr9hx3zpsquFVACfugX2D3jX&gaa_ts=6907e04a&gaa_sig=HBv1TGowC_HSlEn8wUpA8IMUluzEplUDDcyz8Qj2HMaOwLEvcZQAAuapUi9zg7tdgHO34OXWbzfrOyrhDT7TMQ%3D%3D", "time_published": "20200414T223710", "authors": ["Peter Loftus and Dave Sebastian"], "summary": "Johnson & Johnson (J&J) has lowered its 2020 revenue forecast due to the impact of Covid-19, despite rising first-quarter profit driven by increased demand for over-the-counter medicines. The company, considered a bellwether for health-care stocks, experienced a slowdown in sales of medical devices because of a decrease in elective-health procedures. J&J, however, remains optimistic about a recovery later in the year.", "banner_image": "https://www.wsj.com/articles/johnson-johnsons-profit-rises-on-higher-consumer-products-sales-11586862436", "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "earnings", "relevance_score": "0.946065"}, {"topic": "life_sciences", "relevance_score": "0.949072"}, {"topic": "economy_macro", "relevance_score": "0.609368"}], "overall_sentiment_score": -0.425559, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.425974", "ticker_sentiment_label": "Bearish"}]}, {"title": "Blackstone backs Alnylam with up to $2B investment", "url": "https://www.biopharmadive.com/news/blackstone-alnylam-investment-inclisiran-heart-drug/575917/", "time_published": "20200413T214158", "authors": ["Jacob Bell"], "summary": "Private equity firm Blackstone has committed up to $2 billion in investment to genetic medicines maker Alnylam Pharmaceuticals, marking one of the largest private financings for a biotech company. The deal includes $1 billion for a share of royalties and milestones from an experimental heart drug, $100 million in stock purchases, up to $150 million for drug development, and a $750 million loan. This investment aims to provide Alnylam with a self-sustainable financial profile and highlights Blackstone's growing presence in the pharmaceutical and biotech sectors.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.901365"}, {"topic": "life_sciences", "relevance_score": "0.935874"}, {"topic": "finance", "relevance_score": "0.825381"}], "overall_sentiment_score": 0.286527, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.503225", "ticker_sentiment_label": "Bullish"}, {"ticker": "BX", "relevance_score": "0.906802", "ticker_sentiment_score": "0.413398", "ticker_sentiment_label": "Bullish"}, {"ticker": "REGN", "relevance_score": "0.640142", "ticker_sentiment_score": "0.121760", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.601693", "ticker_sentiment_score": "0.116214", "ticker_sentiment_label": "Neutral"}]}, {"title": "Disposable Medical Supplies Market Set to Witness Huge Growth", "url": "https://www.openpr.com/news/2008163/disposable-medical-supplies-market-set-to-witness-huge-growth", "time_published": "20200413T131000", "authors": ["A2Z Market Research"], "summary": "The Disposable Medical Supplies Market is projected for significant growth by 2026, driven by factors like the necessity for infection-free medical processes. The report highlights key players such as Johnson & Johnson and Medtronic, delves into market dynamics including drivers, restraints, and competitive landscape, and answers essential questions about future market size and growth.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "manufacturing", "relevance_score": "0.712444"}], "overall_sentiment_score": 0.427434, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "BAX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.491072", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.884553", "ticker_sentiment_score": "0.407266", "ticker_sentiment_label": "Bullish"}, {"ticker": "BSX", "relevance_score": "0.836277", "ticker_sentiment_score": "0.442520", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.794604", "ticker_sentiment_score": "0.392836", "ticker_sentiment_label": "Bullish"}, {"ticker": "MMM", "relevance_score": "0.709224", "ticker_sentiment_score": "0.373991", "ticker_sentiment_label": "Bullish"}]}, {"title": "Prisma Health Collaborates with Ethicon Inc., part of the Johnson & Johnson Medical Devices Companies, to Manufacture and Distribute the VESper\u2122 Ventilator Expansion Splitter Device that is Authorized for Emergency Use Only During the COVID-19 Pand", "url": "https://www.prnewswire.com/news-releases/prisma-health-collaborates-with-ethicon-inc-part-of-the-johnson--johnson-medical-devices-companies-to-manufacture-and-distribute-the-vesper-ventilator-expansion-splitter-device-that-is-authorized-for-emergency-use-only-during-301035945.html", "time_published": "20200406T112100", "authors": [], "summary": "Prisma Health has partnered with Ethicon Inc., a Johnson & Johnson Medical Devices Company, to manufacture and distribute the VESper\u2122 Ventilator Expansion Splitter. This device, authorized for emergency use during the COVID-19 pandemic, allows a single ventilator to support two patients. Ethicon will provide the splitters at no cost to healthcare providers in the United States, utilizing 3D printing technology to address the predicted ventilator shortage.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.938594"}, {"topic": "manufacturing", "relevance_score": "0.728572"}], "overall_sentiment_score": 0.379994, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.460811", "ticker_sentiment_label": "Bullish"}, {"ticker": "CRM", "relevance_score": "0.604018", "ticker_sentiment_score": "0.327772", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HPQ", "relevance_score": "0.647249", "ticker_sentiment_score": "0.334643", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Fate Therapeutics Strikes Multi-Billion Dollar Cell Therapy Deal with Janssen", "url": "https://www.biospace.com/fate-therapeutics-strikes-multi-billion-cell-therapy-deal-with-janssen", "time_published": "20200403T221627", "authors": ["Alex Keown"], "summary": "Fate Therapeutics has entered into a multi-billion dollar deal with Janssen Biotech to develop cell therapies for cancer, causing Fate Therapeutics' shares to rise over 21% in premarket trading. The collaboration will leverage Fate's iPSC product platform and Janssen's tumor-targeting technology to create novel CAR NK and CAR T-Cell candidates for hematologic malignancies and solid tumors, with potential payments to Fate of up to $3 billion in milestones and double-digit royalties.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "0.947172"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.803200"}, {"topic": "finance", "relevance_score": "0.736833"}], "overall_sentiment_score": 0.47561, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "FATE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.882267", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.724202", "ticker_sentiment_score": "0.443519", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRK", "relevance_score": "0.572658", "ticker_sentiment_score": "0.148037", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fate inks $100M J&J pact for \u2018off-the-shelf\u2019 cancer cell therapies", "url": "https://www.biopharmadive.com/news/fate-johnson-johnson-cancer-cell-therapy/575439/", "time_published": "20200403T221627", "authors": ["Ben Fidler"], "summary": "Johnson & Johnson and Fate Therapeutics have announced a $100 million deal to co-develop allogeneic, or \"off-the-shelf,\" cancer cell therapies. J&J will also purchase $50 million in Fate shares at a premium. This partnership aims to advance therapies for blood cancers and solid tumors, which could be more accessible and cost-effective than current autologous CAR-T treatments, despite the early stage of allogeneic research and potential COVID-19 related delays.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.921839"}, {"topic": "life_sciences", "relevance_score": "0.842249"}], "overall_sentiment_score": 0.285271, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FATE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.417582", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.921272", "ticker_sentiment_score": "0.333670", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.614876", "ticker_sentiment_score": "0.107186", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J inks Fate deal to move into allogeneic CAR therapies", "url": "https://www.fiercebiotech.com/biotech/j-j-inks-fate-deal-to-move-into-allogeneic-car-therapies", "time_published": "20200403T084000", "authors": ["Nick Paul Taylor"], "summary": "Johnson & Johnson is partnering with Fate Therapeutics in a deal worth up to $3 billion in milestones, with a $50 million upfront payment, to develop allogeneic CAR NK and CAR-T cell therapies. Fate will use its induced pluripotent stem cell (iPSC) platform for up to four targets chosen by J&J, which will fund the development and hold exclusive rights for commercialization. This collaboration expands J&J's cell therapy portfolio and provides Fate with significant funding and the option to co-commercialize in the U.S.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "0.927259"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.845931"}], "overall_sentiment_score": 0.357677, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "FATE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.431622", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.934539", "ticker_sentiment_score": "0.334835", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Robotic surgery: a race to the top", "url": "https://www.medicaldevice-network.com/features/da-vinci-surgical-robot-competitors/", "time_published": "20200331T223637", "authors": ["Chloe Kent"], "summary": "The article discusses the expiring patents of Intuitive Surgical's da Vinci system, which has long dominated the robotic surgery market. This opens opportunities for new competitors like CMR Surgical, Medtronic, Auris Health, and Zimmer Biomet, who are introducing innovative robotic systems for various surgical applications. The market for surgical robots is projected to significantly grow, with new entrants focusing on modular designs, competitive pricing, and specialized procedures.", "banner_image": null, "source": "Medical Device Network", "category_within_source": "General", "source_domain": "Medical Device Network", "topics": [{"topic": "life_sciences", "relevance_score": "0.903981"}, {"topic": "technology", "relevance_score": "0.832911"}], "overall_sentiment_score": 0.081669, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.131611", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.830700", "ticker_sentiment_score": "0.240318", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.741835", "ticker_sentiment_score": "0.113781", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.711158", "ticker_sentiment_score": "0.148757", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Is the Pharmaceutical Industry Responding to COVID-19?", "url": "https://insights.som.yale.edu/insights/how-is-the-pharmaceutical-industry-responding-to-covid-19", "time_published": "20200331T223205", "authors": ["Greg Licholai"], "summary": "Dr. Greg Licholai discusses the pharmaceutical industry's rapid response to COVID-19, highlighting the numerous clinical trials underway for vaccines and treatments. He details the accelerated regulatory processes and the industry's adoption of digital tools like remote monitoring to continue research and patient care amidst the pandemic's challenges. The article emphasizes the speedy development of diagnostics and potential treatments, while also acknowledging the long timelines for widespread vaccine availability.", "banner_image": null, "source": "Yale Insights", "category_within_source": "General", "source_domain": "Yale Insights", "topics": [{"topic": "life_sciences", "relevance_score": "0.919435"}, {"topic": "technology", "relevance_score": "0.645951"}, {"topic": "finance", "relevance_score": "0.615170"}], "overall_sentiment_score": 0.237554, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ICLR", "relevance_score": "0.822568", "ticker_sentiment_score": "0.307030", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.701398", "ticker_sentiment_score": "0.416199", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.621471", "ticker_sentiment_score": "0.230885", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.643561", "ticker_sentiment_score": "0.339278", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.572366", "ticker_sentiment_score": "-0.114084", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson coronavirus vaccine could scale up to a billion doses by end of 2021: CEO", "url": "https://www.foxbusiness.com/markets/coronavirus-johnson-and-johnson-vaccine-alex-gorsky-covid", "time_published": "20200331T083200", "authors": ["Evie Fordham"], "summary": "Johnson & Johnson CEO Alex Gorsky announced plans to scale up production of its coronavirus vaccine candidate to nearly one billion doses by the end of 2021 if proven effective and safe. The company expects to move to human clinical studies by September and aims for emergency use authorization by early 2021, a process that usually takes five years. Johnson & Johnson is investing over $1 billion with the U.S. Biomedical Advanced Research and Development Authority to combat the coronavirus.", "banner_image": null, "source": "Fox Business", "category_within_source": "General", "source_domain": "Fox Business", "topics": [{"topic": "life_sciences", "relevance_score": "0.900137"}, {"topic": "earnings", "relevance_score": "0.649628"}], "overall_sentiment_score": 0.4346, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.407692", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson CEO on how close company is to coronavirus vaccine", "url": "https://www.cnbc.com/video/2020/03/30/johnson-johnson-ceo-on-how-close-company-is-to-coronavirus-vaccine.html", "time_published": "20200330T095300", "authors": [], "summary": "Johnson & Johnson announced a lead COVID-19 vaccine candidate and expects to begin phase one human clinical trials by September at the latest. CEO Alex Gorsky discusses the company's progress on the coronavirus vaccine. The announcement highlights significant steps towards developing a vaccine.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.940068"}], "overall_sentiment_score": 0.322832, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.348377", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-us-department-of-health--human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use-301031582.html", "time_published": "20200330T072200", "authors": [], "summary": "Johnson & Johnson announced a lead vaccine candidate for COVID-19 and a landmark partnership with the U.S. Department of Health & Human Services. The company committed to supplying one billion vaccines worldwide for emergency pandemic use, with human clinical studies expected by September 2020 and potential emergency use in early 2021. This initiative involves a more than $1 billion co-investment in vaccine research, development, and clinical testing.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.026041, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.317862", "ticker_sentiment_score": "0.027648", "ticker_sentiment_label": "Neutral"}]}, {"title": "Altria CEO Howard Willard contracts coronavirus, takes temporary leave", "url": "https://www.foxbusiness.com/business-leaders/altria-ceo-howard-willard-coronavirus-temporary-leave", "time_published": "20200320T074300", "authors": ["Reuters"], "summary": "Altria Group Inc. CEO Howard Willard has contracted coronavirus and is taking a temporary medical leave. Chief Financial Officer William Gifford Jr. will serve as interim CEO. The company also temporarily suspended operations at a manufacturing facility after a second employee tested positive for the virus.", "banner_image": null, "source": "Fox Business", "category_within_source": "General", "source_domain": "Fox Business", "topics": [{"topic": "financial_markets", "relevance_score": "0.806821"}, {"topic": "life_sciences", "relevance_score": "0.714454"}], "overall_sentiment_score": -0.069502, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MO", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.172726", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PM", "relevance_score": "0.639347", "ticker_sentiment_score": "0.006225", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.588568", "ticker_sentiment_score": "0.038242", "ticker_sentiment_label": "Neutral"}]}, {"title": "Opioid Settlement Offer Provokes Clash Between States and Cities (Published 2020)", "url": "https://www.nytimes.com/2020/03/13/health/opioids-settlement.html", "time_published": "20200313T215629", "authors": ["Jan Hoffman"], "summary": "A proposed $19.2 billion opioid settlement between three major drug distributors and states is facing strong objections from cities and counties. While 31 states have tentatively agreed, municipalities argue the deal blindsides them, giving states control over the funds and potentially forcing their compliance. This dispute highlights concerns over the division of money and the 18-year payment timeline, with cities and counties advocating for a larger, quicker payout.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.940225"}, {"topic": "finance", "relevance_score": "0.717835"}, {"topic": "economy_fiscal", "relevance_score": "0.613835"}], "overall_sentiment_score": -0.30507, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "0.983124", "ticker_sentiment_score": "-0.300646", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MCK", "relevance_score": "0.968611", "ticker_sentiment_score": "-0.317066", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COR", "relevance_score": "0.922635", "ticker_sentiment_score": "-0.327263", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.683605", "ticker_sentiment_score": "-0.204234", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Thermo Fisher, J&J partner on next-generation sequencing diagnostic for cancer clinical trials", "url": "https://medcitynews.com/2020/03/thermo-fisher-jj-partner-on-next-generation-sequencing-diagnostic-for-cancer-clinical-trials/", "time_published": "20200312T110500", "authors": ["Alaric DeArment"], "summary": "Thermo Fisher Scientific has partnered with Johnson & Johnson's Janssen Research & Development to develop a companion diagnostic for cancer clinical trials, focusing particularly on non-small cell lung cancer. This diagnostic will utilize Thermo Fisher\u2019s Oncomine Dx Target Test, an NGS-based system, to validate multiple biomarkers and support patient stratification for targeted therapies. This collaboration follows a similar agreement Thermo Fisher made with Eli Lilly in September 2019 for a companion diagnostic.", "banner_image": null, "source": "MedCity News", "category_within_source": "General", "source_domain": "MedCity News", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.273518, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TMO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.403885", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.939279", "ticker_sentiment_score": "0.335307", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.702874", "ticker_sentiment_score": "0.275095", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GEHC", "relevance_score": "0.624459", "ticker_sentiment_score": "0.128031", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.557757", "ticker_sentiment_score": "0.124060", "ticker_sentiment_label": "Neutral"}]}, {"title": "Opinion: As Bernie Sanders is essentially finished, health-care stocks are screaming buys", "url": "https://www.marketwatch.com/story/bernie-sanders-is-finished-and-health-care-stocks-are-screaming-buys-2020-03-11?gaa_at=eafs&gaa_n=AWEtsqcrXFBGSVRWttvsLfNpjNFzFkoMlu_kOvRiNl5PY7fOB-90EMdEcn2P&gaa_ts=6907e85f&gaa_sig=sdiyMdy5mTDgUi27oBDtG0IR2j2pT9_wL9dUJUIBGHqOx85qHwaiovpVSMnKVL-Q158EeMdjJ9Lo0HojVVTpdg%3D%3D", "time_published": "20200311T170100", "authors": ["Howard Gold"], "summary": "This opinion piece argues that healthcare stocks have become \"screaming buys\" due to Bernie Sanders's diminishing chances of winning the presidency, which removes the threat of \"Medicare for All.\" Despite concerns about the U.S. healthcare system's preparedness for COVID-19 and a recent drop in healthcare stock prices, investors are advised to consider these stocks given the changed political landscape. The article suggests that Joe Biden's looming victory eliminates a major political risk for the sector.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "financial_markets", "relevance_score": "0.927943"}, {"topic": "life_sciences", "relevance_score": "0.821620"}], "overall_sentiment_score": 0.341669, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RSPH", "relevance_score": "0.917829", "ticker_sentiment_score": "0.437243", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.715952", "ticker_sentiment_score": "0.315098", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.741594", "ticker_sentiment_score": "0.310375", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.749977", "ticker_sentiment_score": "0.306124", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.702046", "ticker_sentiment_score": "0.346643", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J partner Legend plans IPO to fund CAR-T pipeline", "url": "https://www.fiercebiotech.com/biotech/j-j-partner-legend-plans-ipo-to-fund-car-t-pipeline", "time_published": "20200310T124800", "authors": ["Nick Paul Taylor"], "summary": "Legend Biotech, a Chinese CAR-T player and partner of Johnson & Johnson, has filed for an IPO in the U.S. to fund its pipeline, which includes the advanced JNJ-4528. This move comes as its parent company, Genscript Biotech, is experiencing increased R&D expenses due to Legend's clinical trials and planned investment in a CAR-T plant. The IPO aims to secure funding for JNJ-4528, which is nearing an approval filing, and other CAR-T programs, amidst a turbulent financial market.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "ipo", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.704435"}], "overall_sentiment_score": 0.192715, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LEGN", "relevance_score": "0.956564", "ticker_sentiment_score": "0.330060", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.826242", "ticker_sentiment_score": "0.267240", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.553595", "ticker_sentiment_score": "-0.107437", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fibrin Glue Market Size, Share and Forecast Report by 2023 - Top", "url": "https://www.openpr.com/news/1997986/fibrin-glue-market-size-share-and-forecast-report-by-2023-top", "time_published": "20200304T093700", "authors": [], "summary": "The global fibrin glue market is projected to grow at a 10.9% CAGR between 2017 and 2023, driven by increasing healthcare expenditure, chronic diseases, and surgical procedures. Cardiac surgery dominated the market during the historical period and is expected to continue its dominance, while cosmetic surgeries are identified as a key trend boosting market growth. Key players in this market include Johnson & Johnson, Baxter International Inc., and CSL Behring.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.931604"}], "overall_sentiment_score": 0.28465, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAX", "relevance_score": "0.917879", "ticker_sentiment_score": "0.319911", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.701876", "ticker_sentiment_score": "0.298950", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dividend Growth Investing Made Easy with ETFs", "url": "https://www.myownadvisor.ca/dividend-growth-investing-made-easy-with-etfs/", "time_published": "20200303T215118", "authors": ["Mark", "Tom"], "summary": "This article, a guest post by Tom of Dividends Diversify, explains how dividend growth investing can be made easy through the use of Exchange Traded Funds (ETFs). It highlights the benefits of diversification offered by ETFs and discusses several popular dividend ETFs such as VYM, VIG, VYMI, and NOBL, outlining their characteristics and investment strategies. The article also touches on considerations for Canadian investors regarding withholding taxes and briefly mentions individual stock holdings.", "banner_image": null, "source": "My Own Advisor", "category_within_source": "General", "source_domain": "My Own Advisor", "topics": [{"topic": "financial_markets", "relevance_score": "0.922063"}, {"topic": "economy_macro", "relevance_score": "0.605157"}], "overall_sentiment_score": 0.247375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIDD", "relevance_score": "0.349907", "ticker_sentiment_score": "0.031322", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.637672", "ticker_sentiment_score": "0.335745", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.602048", "ticker_sentiment_score": "0.336143", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.632560", "ticker_sentiment_score": "0.314960", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.624622", "ticker_sentiment_score": "0.314149", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing", "url": "https://www.businesswire.com/news/home/20200302005061/en/Akrevia-Therapeutics-Rebrands-as-Xilio-Therapeutics-and-Announces-%24100.5-Million-Series-B-Financing", "time_published": "20200302T233716", "authors": [], "summary": "Akrevia Therapeutics has rebranded as Xilio Therapeutics and successfully closed a $100.5 million Series B financing round. The proceeds will fund the advancement of XTX201 and XTX101 into clinical trials and expand their tumor-selective cytokine pipeline. This financing, led by Takeda Ventures, marks a pivotal moment for the company as it moves from research to development-stage, focusing on potent, tumor-selective immuno-oncology therapies.", "banner_image": null, "source": "Business Wire", "category_within_source": "General", "source_domain": "Business Wire", "topics": [{"topic": "life_sciences", "relevance_score": "0.913145"}, {"topic": "finance", "relevance_score": "0.724086"}], "overall_sentiment_score": 0.593695, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "XLO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.898292", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRK", "relevance_score": "0.619799", "ticker_sentiment_score": "0.538732", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.717122", "ticker_sentiment_score": "0.533852", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.608815", "ticker_sentiment_score": "0.532930", "ticker_sentiment_label": "Bullish"}]}, {"title": "Kevin Lobo\u2019s 8+ years as Stryker CEO: Leading 20+ acquisitions, boosting robotics & more", "url": "https://www.beckersspine.com/spinal-tech/kevin-lobo-s-8-years-as-stryker-ceo-leading-20-acquisitions-boosting-robotics-more/", "time_published": "20200302T232200", "authors": ["Alan Condon"], "summary": "This article highlights Kevin Lobo's significant tenure as Stryker's CEO, detailing his leadership in over 20 acquisitions, including key robotics companies like Mako Surgical. It outlines his background, financial standing, and strategic focus on advancing Stryker's spine program and robotics.", "banner_image": null, "source": "Becker's Spine Review", "category_within_source": "General", "source_domain": "Becker's Spine Review", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.941806"}, {"topic": "technology", "relevance_score": "0.806918"}, {"topic": "finance", "relevance_score": "0.744153"}, {"topic": "earnings", "relevance_score": "0.639184"}], "overall_sentiment_score": 0.284604, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SYK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.490450", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.627771", "ticker_sentiment_score": "0.107274", "ticker_sentiment_label": "Neutral"}]}, {"title": "Avoiding Pool Construction Lawsuits", "url": "https://www.poolmagazine.com/contractors-and-builders/avoiding-pool-construction-lawsuits/", "time_published": "20200301T230623", "authors": ["Pool News"], "summary": "This article discusses strategies for pool contractors to avoid lawsuits and navigate legal disputes in the construction industry. It emphasizes the importance of good communication, clear written contracts, and considering alternative dispute resolution methods like mediation and arbitration. Experts Scott Cohen and Matt Reynolds share insights on preventing legal action through diligence and precise work.", "banner_image": null, "source": "Pool Magazine", "category_within_source": "General", "source_domain": "Pool Magazine", "topics": [{"topic": "real_estate", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.20044, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "POOL", "relevance_score": "0.911909", "ticker_sentiment_score": "0.300503", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.625800", "ticker_sentiment_score": "0.121966", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Johnson & Johnson fills its procurement talent pipeline", "url": "https://www.supplychaindive.com/news/johnson-johnson-procurement-talent/573138/", "time_published": "20200227T223709", "authors": ["Jen A. Miller"], "summary": "Johnson & Johnson addresses the procurement talent crunch through its Procurement Leadership Development Program (PLDP), an in-house initiative launched in 2008. This two-year program trains recent MBA graduates to become business leaders with procurement expertise, focusing on developing essential skills and adapting to the evolving demands of the procurement field. The PLDP has successfully trained 119 employees, creating a vital pipeline for J&J's global procurement needs amidst increasing competition for top talent and a shift towards strategic procurement functions.", "banner_image": null, "source": "Supply Chain Dive", "category_within_source": "General", "source_domain": "Supply Chain Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.803378"}, {"topic": "finance", "relevance_score": "0.703797"}], "overall_sentiment_score": 0.300291, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.300882", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech company Moderna says its coronavirus vaccine is ready for first tests", "url": "https://www.cnn.com/2020/02/25/business/moderna-coronavirus-vaccine", "time_published": "20200226T054300", "authors": ["Hanna Ziady"], "summary": "Moderna, a US biotech firm, has shipped an experimental coronavirus vaccine to US government researchers just six weeks after beginning development. Initial trials for the vaccine, mRNA-1273, are expected to begin in April, with full testing and approval likely taking at least a year. The rapid development highlights a breakthrough in vaccine creation using mRNA technology, as other pharmaceutical companies also race to find treatments for the virus.", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "life_sciences", "relevance_score": "0.909270"}], "overall_sentiment_score": 0.432949, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.982922", "ticker_sentiment_score": "0.614212", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.633463", "ticker_sentiment_score": "0.295077", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.667547", "ticker_sentiment_score": "0.346116", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Apple and Johnson & Johnson's new heart study is a big deal for digital health", "url": "https://www.cnbc.com/2020/02/25/apple-johnson-johnson-heart-study-is-a-big-deal-for-digital-health.html", "time_published": "20200225T153200", "authors": ["Christina Farr"], "summary": "Apple and Johnson & Johnson are partnering on a large-scale study to determine if the Apple Watch can detect atrial fibrillation in seniors, making it one of the largest randomized digital health trials ever. The study involves a unique collaboration between a tech company, a pharma giant, and a retailer (Best Buy), aiming to provide subsidized Apple Watches to 150,000 participants and address cardiologists' concerns about broad-based screening by focusing on a high-risk demographic. If successful, the initiative could lead to private Medicare plans covering Apple Watches and advance the concept of \"aging in place\" through digital health solutions.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.913121"}, {"topic": "technology", "relevance_score": "0.833610"}, {"topic": "retail_wholesale", "relevance_score": "0.620509"}], "overall_sentiment_score": 0.423992, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.455342", "ticker_sentiment_label": "Bullish"}, {"ticker": "AAPL", "relevance_score": "1.000000", "ticker_sentiment_score": "0.417982", "ticker_sentiment_label": "Bullish"}, {"ticker": "BBY", "relevance_score": "0.640155", "ticker_sentiment_score": "0.321434", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.638042", "ticker_sentiment_score": "0.390201", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson Launches Heartline\u2122, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-launches-heartline-the-first-of-its-kind-virtual-study-designed-to-explore-if-a-new-iphone-app-and-apple-watch-can-help-reduce-the-risk-of-stroke-301010792.html", "time_published": "20200225T082500", "authors": [], "summary": "Johnson & Johnson, in collaboration with Apple, has launched the Heartline Study, a virtual clinical study designed to investigate if a new iPhone app and Apple Watch features can help reduce the risk of stroke by earlier detection of atrial fibrillation (AFib). The study targets U.S. adults aged 65 and older with Original Medicare and an iPhone 6s or later. Participants will receive heart health education and utilize the Heartline Study app, with one arm of the study also using the Apple Watch's ECG app and irregular rhythm notification feature.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.932966"}, {"topic": "technology", "relevance_score": "0.843166"}], "overall_sentiment_score": 0.031994, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.349362", "ticker_sentiment_score": "0.005161", "ticker_sentiment_label": "Neutral"}]}, {"title": "Battle of the \u2019bots: 4 robotic surgery rivalries to watch in the year ahead", "url": "https://www.medtechdive.com/news/battle-of-the-bots-4-robotic-surgery-rivalries-to-watch-in-the-year-ahead/572519/", "time_published": "20200224T223637", "authors": ["Susan Kelly"], "summary": "The article discusses the intensifying competition in the robotic-assisted surgery market, highlighting four key rivalries across different surgical specialties. It details how new players like Medtronic and Johnson & Johnson are challenging the long-standing dominance of Intuitive Surgical, while other companies like Stryker and Zimmer Biomet are competing in orthopedics and spine surgery. The piece emphasizes the growing investment in the sector, leading to increased awareness and potentially lower costs for robotic surgery.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "technology", "relevance_score": "0.913096"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.803324"}], "overall_sentiment_score": 0.284946, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.129331", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.904621", "ticker_sentiment_score": "0.332539", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.826639", "ticker_sentiment_score": "0.246378", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYK", "relevance_score": "0.736530", "ticker_sentiment_score": "0.423820", "ticker_sentiment_label": "Bullish"}, {"ticker": "ZBH", "relevance_score": "0.623859", "ticker_sentiment_score": "0.226437", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J\u2019s Ethicon mostly fends off Intuitive Surgical\u2019s robotic surgery patent challenge", "url": "https://www.massdevice.com/jjs-ethicon-mostly-fends-off-intuitive-surgicals-robotic-surgery-patent-challenge/", "time_published": "20200221T223637", "authors": ["Chris Newmarker"], "summary": "Johnson & Johnson's Ethicon subsidiary successfully defended most of its robotic surgery tool patent against a challenge from Intuitive Surgical. The Patent Trial and Appeal Board found that Intuitive failed to prove the patent was obvious, upholding 25 of 28 claims. This decision highlights the ongoing intellectual property disputes in the competitive robotic surgery market, where J&J and others are challenging Intuitive Surgical's dominance.", "banner_image": null, "source": "MassDevice", "category_within_source": "General", "source_domain": "MassDevice", "topics": [{"topic": "life_sciences", "relevance_score": "0.913447"}, {"topic": "technology", "relevance_score": "0.819528"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.707517"}], "overall_sentiment_score": 0.229004, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.165434", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.927077", "ticker_sentiment_score": "0.300328", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOGL", "relevance_score": "0.645664", "ticker_sentiment_score": "0.136962", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ethicon subsidiary of J&J holds onto most of robotic surgery patent in Intuitive Surgical challenge", "url": "https://www.therobotreport.com/ethicon-holds-robotic-surgery-patent-intuitive-surgical-challenge/", "time_published": "20200221T223637", "authors": ["Chris Newmarker"], "summary": "Ethicon, a subsidiary of Johnson & Johnson, has largely retained a key patent for a robot-assisted surgical tool following a challenge by rival Intuitive Surgical. The Patent Trial and Appeal Board upheld most of Ethicon's patent claims, finding Intuitive Surgical failed to prove obviousness based on prior art. This ruling is significant in the competitive and rapidly growing field of robot-assisted surgery, where Johnson & Johnson is striving to challenge Intuitive Surgical's market leadership.", "banner_image": null, "source": "The Robot Report", "category_within_source": "General", "source_domain": "The Robot Report", "topics": [{"topic": "life_sciences", "relevance_score": "0.914825"}, {"topic": "technology", "relevance_score": "0.838771"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.710784"}], "overall_sentiment_score": 0.158065, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.946940", "ticker_sentiment_score": "0.028517", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.822542", "ticker_sentiment_score": "0.304758", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sanofi Announces It Will Work with HHS to Develop Coronavirus Vaccine", "url": "https://www.scientificamerican.com/article/sanofi-announces-it-will-work-with-hhs-to-develop-coronavirus-vaccine/", "time_published": "20200218T232109", "authors": ["Helen Branswell & STAT"], "summary": "Sanofi Pasteur announced its partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a vaccine against the new coronavirus using its recombinant DNA platform. The company anticipates having a vaccine candidate for in vitro testing within six months and potentially ready for human trials within a year to 18 months, leveraging its prior SARS vaccine work and established manufacturing capacity. Johnson & Johnson's Janssen division has also announced efforts to create a vaccine.", "banner_image": null, "source": "Scientific American", "category_within_source": "General", "source_domain": "Scientific American", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.310797, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SNY", "relevance_score": "0.987379", "ticker_sentiment_score": "0.317782", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.678453", "ticker_sentiment_score": "0.277144", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sanofi announces it will work with HHS to develop coronavirus vaccine", "url": "https://www.statnews.com/2020/02/18/sanofi-announces-it-will-work-with-hhs-to-develop-coronavirus-vaccine/", "time_published": "20200218T232108", "authors": ["Helen Branswell"], "summary": "Sanofi Pasteur announced it will partner with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a vaccine for the new coronavirus. While Sanofi hopes to leverage its SARS vaccine development experience and recombinant DNA platform, a licensed vaccine is still estimated to be three to four years away, even with emergency approval. The company will initially develop vaccine candidates and produce pilot lots, with BARDA financing the initial stages of this collaborative effort.", "banner_image": null, "source": "www.statnews.com", "category_within_source": "General", "source_domain": "www.statnews.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.918929"}], "overall_sentiment_score": 0.326471, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SNY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.480133", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.638250", "ticker_sentiment_score": "0.281116", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.591288", "ticker_sentiment_score": "0.237472", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson to Expand Partnership with U.S. Department of Health & Human Services to Accelerate the Discovery of Potential COVID-19 Treatments", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-to-expand-partnership-with-us-department-of-health--human-services-to-accelerate-the-discovery-of-potential-covid-19-treatments-301006642.html", "time_published": "20200218T093000", "authors": [], "summary": "Johnson & Johnson announced an expanded partnership with the Biomedical Advanced Research and Development Authority (BARDA) to find treatment solutions for COVID-19. This collaboration will involve screening existing antiviral molecules to identify potential treatments for the novel coronavirus, SARS-CoV-2. The effort builds on Johnson & Johnson's broader response to the outbreak, including vaccine development.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.908273"}], "overall_sentiment_score": 0.483595, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.495901", "ticker_sentiment_label": "Bullish"}]}, {"title": "The Global Surgical Robotics Market to Reach $13 Billion by 2026", "url": "https://emag.medicalexpo.com/the-surgical-robotics-global-market-to-reach-13-billion-by-2026/", "time_published": "20200215T223637", "authors": ["Guest"], "summary": "The global surgical robotics market is projected to reach $13.36 billion by 2026, growing at a CAGR of 15.4% from 2019. This growth is driven by increasing demand for minimally invasive surgery, higher precision compared to conventional methods, an aging population, and technological innovations. Key players like Intuitive Surgical and Zimmer Biomet are advancing robotic systems like the da Vinci and ROSA for various procedures including gynecology, urology, and orthopedics.", "banner_image": null, "source": "MedicalExpo e-Magazine", "category_within_source": "General", "source_domain": "MedicalExpo e-Magazine", "topics": [{"topic": "life_sciences", "relevance_score": "0.930492"}, {"topic": "technology", "relevance_score": "0.815072"}], "overall_sentiment_score": 0.328268, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.450203", "ticker_sentiment_label": "Bullish"}, {"ticker": "ZBH", "relevance_score": "0.852567", "ticker_sentiment_score": "0.330703", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.818655", "ticker_sentiment_score": "0.281726", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYK", "relevance_score": "0.747198", "ticker_sentiment_score": "0.265080", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.614546", "ticker_sentiment_score": "0.206718", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Medtronic buys British surgical AI company, adding to Hugo robot effort", "url": "https://www.medtechdive.com/news/medtronic-buy-digital-surgery-ai-hugo-robot/572259/", "time_published": "20200213T223637", "authors": ["Maria Rachal"], "summary": "Medtronic announced its acquisition of Digital Surgery, a British company specializing in digital surgical tools, to bolster its Minimally Invasive Therapies Group's surgical robotics business. This acquisition supports Medtronic's development of the Hugo soft tissue robot, intended to compete with Intuitive Surgical's da Vinci robot. Digital Surgery's simulation platform is expected to contribute to clinical decision support and cost reduction in surgical procedures.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "technology", "relevance_score": "0.825083"}], "overall_sentiment_score": 0.181037, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.912067", "ticker_sentiment_score": "0.130318", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.420632", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.648457", "ticker_sentiment_score": "0.107911", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.613276", "ticker_sentiment_score": "0.141268", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.618561", "ticker_sentiment_score": "0.100780", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA approves first peanut allergy drug", "url": "https://www.nature.com/articles/d41573-020-00025-z", "time_published": "20200211T220648", "authors": ["Asher Mullard"], "summary": "The FDA has approved Aimmune Therapeutics\u2019 peanut-flour product, palforzia, marking the first drug approval for peanut allergy. This approval establishes a regulatory pathway for future food allergy treatments.", "banner_image": null, "source": "Nature", "category_within_source": "General", "source_domain": "Nature", "topics": [{"topic": "life_sciences", "relevance_score": "0.912134"}], "overall_sentiment_score": 0.428443, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DBVT", "relevance_score": "0.927103", "ticker_sentiment_score": "0.748321", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.635927", "ticker_sentiment_score": "0.329109", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.581775", "ticker_sentiment_score": "0.273160", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Global Medical Devices Market 2020-2024 | Evolving Opportunities with Becton, Dickinson and Co. and F. Hoffmann-La Roche Ltd. | Technavio", "url": "https://www.businesswire.com/news/home/20200211005728/en/Global-Medical-Devices-Market-2020-2024-Evolving-Opportunities-with-Becton-Dickinson-and-Co.-and-F.-Hoffmann-La-Roche-Ltd.-Technavio", "time_published": "20200211T215102", "authors": [], "summary": "The global medical devices market is projected to grow by USD 134.2 billion from 2020 to 2024, at a CAGR of over 5%. This growth is primarily driven by the increasing penetration of medical devices in emerging economies, fueled by lower manufacturing costs, increasing geriatric populations, and a rise in chronic diseases. Key players contributing to this market include Becton, Dickinson and Co., F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA, General Electric Co., and Johnson and Johnson Services Inc.", "banner_image": null, "source": "Business Wire", "category_within_source": "General", "source_domain": "Business Wire", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.803834"}, {"topic": "economy_macro", "relevance_score": "0.709790"}], "overall_sentiment_score": 0.253821, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.255536", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.606455", "ticker_sentiment_score": "0.200636", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GEHC", "relevance_score": "0.632166", "ticker_sentiment_score": "0.216212", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.561994", "ticker_sentiment_score": "0.228563", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.581036", "ticker_sentiment_score": "0.207394", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Growth Spurt at OSI Systems", "url": "https://labusinessjournal.com/manufacturing/growth-spurt-osi-systems/", "time_published": "20200207T070000", "authors": ["Mediha DiMartino"], "summary": "OSI Systems Inc., a manufacturer of security scanning equipment, medical monitoring devices, and optoelectronic components, reported strong financial results with $1.18 billion in revenue for its 2019 fiscal year and continued growth in the first half of fiscal 2020. CEO Deepak Chopra attributes this growth, particularly in the security division, to increased global demand for border security. The company has a history of strategic acquisitions and evolution, adapting to significant global events like the Pan Am Flight 103 downing to expand its security offerings.", "banner_image": null, "source": "Los Angeles Business Journal", "category_within_source": "General", "source_domain": "Los Angeles Business Journal", "topics": [{"topic": "earnings", "relevance_score": "0.939319"}, {"topic": "manufacturing", "relevance_score": "0.810361"}, {"topic": "technology", "relevance_score": "0.718351"}, {"topic": "life_sciences", "relevance_score": "0.642330"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.608773"}], "overall_sentiment_score": 0.228086, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OSIS", "relevance_score": "1.000000", "ticker_sentiment_score": "0.494266", "ticker_sentiment_label": "Bullish"}, {"ticker": "GE", "relevance_score": "0.730745", "ticker_sentiment_score": "0.147196", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMT", "relevance_score": "0.648481", "ticker_sentiment_score": "0.127909", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.602869", "ticker_sentiment_score": "0.138782", "ticker_sentiment_label": "Neutral"}]}, {"title": "Subcutaneous Drug Delivery Market 2020 - 2027 | Industry Experts", "url": "https://www.openpr.com/news/1996515/subcutaneous-drug-delivery-market-2020-2027-industry-experts", "time_published": "20200204T120400", "authors": [], "summary": "This article provides an in-depth analysis of the Subcutaneous Drug Delivery Market from 2020 to 2027, highlighting considerable growth during this forecast period. It details key market players, emerging trends, drivers, challenges, and opportunities, alongside segmentation by usability, disease indication, and geographic regions. The report is designed to assist organizations in developing effective strategies and making informed business decisions within this sector.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.944451"}, {"topic": "finance", "relevance_score": "0.718911"}], "overall_sentiment_score": 0.129136, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.923353", "ticker_sentiment_score": "0.107762", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.862065", "ticker_sentiment_score": "0.113449", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.821553", "ticker_sentiment_score": "0.146902", "ticker_sentiment_label": "Neutral"}]}, {"title": "The World Congress 8th Annual Patient Congress", "url": "https://www.drugchannels.net/2020/02/the-world-congress-8th-annual-patient.html", "time_published": "20200203T221620", "authors": ["Adam J. Fein", "Ph.D."], "summary": "The 8th Annual World Congress Patient Congress, scheduled for April 6-7, 2020, in Philadelphia, focuses on improving patient access and health outcomes. The event features multiple tracks, including Patient Adherence and Engagement, Patient Advocacy, and a Copay Summit, with speakers from prominent healthcare organizations. Drug Channels readers can receive a discount by registering with a special promo code by March 31, 2020.", "banner_image": null, "source": "Drug Channels", "category_within_source": "General", "source_domain": "Drug Channels", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.15935, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EYPT", "relevance_score": "0.848620", "ticker_sentiment_score": "0.233565", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.734009", "ticker_sentiment_score": "0.228701", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.619367", "ticker_sentiment_score": "0.121524", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.619656", "ticker_sentiment_score": "0.134041", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.644388", "ticker_sentiment_score": "0.129688", "ticker_sentiment_label": "Neutral"}]}, {"title": "Oral Care Products & Other Dental Consumables Market 2020", "url": "https://www.openpr.com/news/1915197/oral-care-products-other-dental-consumables-market-2020", "time_published": "20200131T092700", "authors": [], "summary": "The global oral care products & other dental consumables market is projected to reach $70.46 billion by 2026, growing at a CAGR of 6.1% from 2019-2026, driven by an increase in dental diseases and demand for cosmetic dentistry. Key players like Straumann AG, Danaher, Dentsply Sirona, and 3M Company are employing various strategies including new product launches and acquisitions to expand their market footprint. The market report segments the industry by product type, distribution channel, and geography, highlighting market drivers such as rising dental disease incidence and restraints like high costs.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.930014"}, {"topic": "finance", "relevance_score": "0.701954"}], "overall_sentiment_score": 0.170615, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHD", "relevance_score": "0.911577", "ticker_sentiment_score": "0.245345", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MMM", "relevance_score": "0.643105", "ticker_sentiment_score": "0.142139", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSIC", "relevance_score": "0.604975", "ticker_sentiment_score": "0.231929", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.635594", "ticker_sentiment_score": "0.122279", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.623744", "ticker_sentiment_score": "0.111251", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Is Told to Pay $344 Million in Pelvic Mesh Suit (Published 2020)", "url": "https://www.nytimes.com/2020/01/30/business/transvaginal-mesh-johnson-and-johnson.html", "time_published": "20200130T223710", "authors": ["Matthew Goldstein"], "summary": "A judge has ordered Johnson & Johnson to pay $344 million in damages for deceptively marketing transvaginal pelvic mesh implants in California. This ruling is part of years of personal injury litigation related to these devices, which have resulted in billions of dollars in payouts from various manufacturers. Johnson & Johnson plans to appeal the decision.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.935787"}, {"topic": "finance", "relevance_score": "0.737813"}], "overall_sentiment_score": -0.408297, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.402142", "ticker_sentiment_label": "Bearish"}]}, {"title": "Bristol-Myers Squibb: Strong Quality And Attractive Valuation", "url": "https://newyork.citybuzz.co/article/593632/bristol-myers-squibb-strong-quality-and-attractive-valuation", "time_published": "20200128T215143", "authors": ["Andr\u00e9s Cardenal"], "summary": "Bristol-Myers Squibb is presented as a high-quality pharmaceutical company with a strong track record of growth and profitability. The recent acquisition of Celgene is viewed as a financially and strategically sound move that is expected to be accretive to earnings. The stock is considered reasonably valued, offering an attractive risk-reward trade-off for investors.", "banner_image": "NULL", "source": "citybuzz -", "category_within_source": "General", "source_domain": "citybuzz -", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.943065"}, {"topic": "financial_markets", "relevance_score": "0.748119"}, {"topic": "earnings", "relevance_score": "0.604334"}], "overall_sentiment_score": 0.225144, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.457920", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.609305", "ticker_sentiment_score": "0.147831", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.632216", "ticker_sentiment_score": "0.137140", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.636074", "ticker_sentiment_score": "0.146299", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson CEO to testify at trial for first time on Baby Powder risks", "url": "https://www.foxbusiness.com/money/johnson-johnson-alex-gorsky-trial", "time_published": "20200127T092400", "authors": [], "summary": "Johnson & Johnson CEO Alex Gorsky was subpoenaed to testify for the first time in a jury trial concerning allegations that the company's Baby Powder causes cancer. The trial in New Brunswick, New Jersey, is for four plaintiffs with mesothelioma who claim asbestos in the product caused their illness, and the jury is now considering punitive damages after finding J&J liable. J&J faces over 16,000 such lawsuits and has been under federal investigation regarding its product safety claims.", "banner_image": null, "source": "Fox Business", "category_within_source": "General", "source_domain": "Fox Business", "topics": [{"topic": "life_sciences", "relevance_score": "0.945252"}, {"topic": "earnings", "relevance_score": "0.745624"}], "overall_sentiment_score": -0.423133, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.434355", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson to disclose robot-assisted surgery plans in May", "url": "https://www.therobotreport.com/johnson-johnson-disclose-robot-assisted-surgery-plans-may/", "time_published": "20200123T223637", "authors": ["Chris Newmarker"], "summary": "Johnson & Johnson announced it will preview its robotic and digital surgery plans at a Medical Device Business Review Day on May 13 in New York. This comes after recent acquisitions of Auris Health and the remaining stake in Verb Surgical, positioning J&J to compete with market leader Intuitive Surgical in the rapidly growing robot-assisted surgery space. CEO Alex Gorsky emphasized that the event will provide clear, tangible evidence of their machines and digital platform.", "banner_image": null, "source": "The Robot Report", "category_within_source": "General", "source_domain": "The Robot Report", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.937244"}, {"topic": "life_sciences", "relevance_score": "0.834466"}, {"topic": "technology", "relevance_score": "0.736688"}, {"topic": "earnings", "relevance_score": "0.621715"}], "overall_sentiment_score": 0.103714, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.959381", "ticker_sentiment_score": "-0.146979", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.904196", "ticker_sentiment_score": "0.243140", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.735302", "ticker_sentiment_score": "0.050333", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOGL", "relevance_score": "0.621648", "ticker_sentiment_score": "0.125157", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson\u2019s Profit, Sales Rise", "url": "https://www.wsj.com/articles/johnson-johnsons-profit-sales-rise-11579694356?gaa_at=eafs&gaa_n=AWEtsqfdE9CWW1M6dLAc_tehpr_5aIcc6ZdlLaAby7KS590Ch2iN-Kd0E4bD&gaa_ts=6907e03e&gaa_sig=8EthDQmqCb7QSFxCEZ6AlhhBE63oqUqUpTrd315zY5j94iuMDStpW_EqLH8IZrGRtypYL9Fzz3pWt3GJgyf9YQ%3D%3D", "time_published": "20200122T223708", "authors": ["Dave Sebastian and Peter Loftus"], "summary": "Johnson & Johnson reported a rise in fourth-quarter profit and sales, driven by increased pharmaceutical and consumer-product sales. While adjusted earnings surpassed Wall Street estimates, overall sales fell slightly short of expectations. The company's shares experienced a decline in morning trading following the announcement.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "earnings", "relevance_score": "0.937288"}, {"topic": "life_sciences", "relevance_score": "0.816675"}], "overall_sentiment_score": 0.136523, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.126313", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Is Regaining Its Health", "url": "https://www.wsj.com/articles/johnson-johnson-is-regaining-its-health-11579711771?gaa_at=eafs&gaa_n=AWEtsqcICAVshDLbgZkEnxVwwcOxsHcqlUJR33TiNDb3Y4BrCCY4WoxNIGTX&gaa_ts=6907e043&gaa_sig=RdK5E8HddqeNdr451ZNsgLctUzs1YzP-bNQIGaloAj97FjpKkh2ENqTx61BB2-GEhuPbMR3yr8yh7yDOulsBrQ%3D%3D", "time_published": "20200122T223708", "authors": ["Charley Grant"], "summary": "Johnson & Johnson (JNJ) appears to be stabilizing after a challenging year, with its fourth-quarter results showing solid, though not spectacular, performance. Despite slightly missing analyst expectations on sales with $20.7 billion, the pharmaceutical giant exceeded earnings estimates at $1.88 per share. This indicates a potential recovery, suggesting that a recent brief selloff in shares might reverse.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "earnings", "relevance_score": "0.940454"}, {"topic": "life_sciences", "relevance_score": "0.935042"}], "overall_sentiment_score": 0.473901, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.475932", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson planning a robotic surgery reveal in May", "url": "https://www.massdevice.com/johnson-johnson-planning-a-robotic-surgery-reveal-in-may/", "time_published": "20200122T223638", "authors": ["Chris Newmarker"], "summary": "Johnson & Johnson is set to provide a preview of its robotic and digital surgery plans at a Medical Device Business Review Day on May 13 in New York City. CEO Alex Gorsky emphasized the event will offer clear evidence of their machines and digital platform. This move positions J&J to compete in the growing robotic-assisted surgery market, challenging dominant player Intuitive Surgical with recent acquisitions like Verb Surgical and Auris Health.", "banner_image": null, "source": "MassDevice", "category_within_source": "General", "source_domain": "MassDevice", "topics": [{"topic": "life_sciences", "relevance_score": "0.936257"}, {"topic": "technology", "relevance_score": "0.805130"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.717172"}, {"topic": "earnings", "relevance_score": "0.614900"}], "overall_sentiment_score": 0.346367, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.901638", "ticker_sentiment_score": "0.389720", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.964215", "ticker_sentiment_score": "0.431178", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.734938", "ticker_sentiment_score": "0.259186", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOGL", "relevance_score": "0.680732", "ticker_sentiment_score": "0.230336", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYK", "relevance_score": "0.617638", "ticker_sentiment_score": "0.294015", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson beats Wall Street expectations on profit, misses on revenue", "url": "https://www.cnbc.com/2020/01/22/johnson-johnson-jnj-earnings-q4-2019.html", "time_published": "20200122T064800", "authors": ["Berkeley Lovelace Jr."], "summary": "Johnson & Johnson (JNJ) reported fourth-quarter profit that exceeded Wall Street's expectations but missed slightly on revenue. The company's stock fell about 1.6% pre-market, despite strong underlying sales and earnings growth driven by its pharmaceutical and medical devices businesses. Litigation expenses dramatically decreased to $264 million in the quarter, down from $1.29 billion a year earlier.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "earnings", "relevance_score": "0.919502"}, {"topic": "life_sciences", "relevance_score": "0.748788"}], "overall_sentiment_score": 0.11662, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.977510", "ticker_sentiment_score": "0.135755", "ticker_sentiment_label": "Neutral"}]}, {"title": "Photo Gallery of New Imaging Technologies at RSNA 2019", "url": "https://www.itnonline.com/article/photo-gallery-new-imaging-technologies-rsna-2019", "time_published": "20200120T222218", "authors": ["Dave Fornell"], "summary": "This article provides a photo gallery showcasing new medical imaging technologies displayed at the Radiological Society of North America (RSNA) 2019 meeting. It covers advancements in AI for image analysis, robotic systems, 3D printing in medicine, and various new imaging hardware across modalities like CT, MRI, DR, and ultrasound. The featured innovations aim to improve diagnostic accuracy, workflow efficiency, and patient experience.", "banner_image": null, "source": "Imaging Technology News", "category_within_source": "General", "source_domain": "Imaging Technology News", "topics": [{"topic": "life_sciences", "relevance_score": "0.919739"}, {"topic": "technology", "relevance_score": "0.822075"}], "overall_sentiment_score": 0.310386, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GEHC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.436571", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.602475", "ticker_sentiment_score": "0.241956", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Judge slashes $8 billion Risperdal award against Johnson & Johnson to $6.8 million", "url": "https://www.reuters.com/article/business/healthcare-pharmaceuticals/judge-slashes-8-billion-risperdal-award-against-johnson-johnson-to-68-milli-idUSKBN1ZG292/", "time_published": "20200117T224900", "authors": ["Jonathan Stempel"], "summary": "A Pennsylvania judge reduced a punitive damages award against Johnson & Johnson from $8 billion to $6.8 million in a Risperdal lawsuit. The lawsuit involved claims that Johnson & Johnson failed to warn users about the potential for boys using the antipsychotic drug to develop breasts. Both the plaintiff and Johnson & Johnson plan to appeal the decision.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fview.reuters.com%2F%3Furi%3Dhttps%253A%2F%2Fresources.reuters.com%252Fimages%252F2019%252F09%252F17%252F2019-09-17T150937Z_1_LYNXNPEF8G15N_RTROPTP_3_USA-TRUMP-JOHNSON-JOHNSON-idUSKBN1W32C5%253Fw%253D800%2526resize%253Dtrue and https://www.reuters.com/resizer/v2/https%3A%2F%2Fwww.reuters.com%2Fpf%2Fresources%2Fimages%2Flogo%2Freuters-default.png%3F1693895963?w=800&quality=80", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.946464"}, {"topic": "financial_markets", "relevance_score": "0.620428"}], "overall_sentiment_score": 0.339268, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.347054", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "We Did It! Pharma Giant Bristol-Myers Squibb Bans Forced Swim Test", "url": "https://www.peta.org.uk/blog/bristol-myers-squibb-bans-forced-swim-test/", "time_published": "20200116T215143", "authors": ["Priya S"], "summary": "Bristol-Myers Squibb has banned the cruel forced swim test after more than a year of campaigning by PETA and its international affiliates. This decision makes Bristol-Myers Squibb one of several major pharmaceutical companies to stop using the test, which involves forcing small animals to swim to avoid drowning and is considered by PETA to be both cruel and scientifically unsound. PETA is now urging Eli Lilly to follow suit and end its use of the forced swim test.", "banner_image": null, "source": "PETA UK", "category_within_source": "General", "source_domain": "PETA UK", "topics": [{"topic": "life_sciences", "relevance_score": "0.917715"}], "overall_sentiment_score": 0.153427, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.211612", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.744302", "ticker_sentiment_score": "0.213941", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.704007", "ticker_sentiment_score": "0.234364", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.715397", "ticker_sentiment_score": "0.205421", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.707584", "ticker_sentiment_score": "-0.232233", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "\u2018Blood on their hands\u2019: Oklahoma sues opioid distributors", "url": "https://nondoc.com/2020/01/13/oklahoma-sues-opioid-distributors/", "time_published": "20200113T224650", "authors": ["Tres Savage"], "summary": "Oklahoma Attorney General Mike Hunter has sued three major opioid distributors: McKesson Corporation, Cardinal Health, and AmerisourceBergen, alleging they ignored red flags and contributed to the opioid crisis in the state. Hunter seeks damages for negligence and misconduct, separate from previous \"public nuisance\" claims against manufacturers. This lawsuit follows other settlements Oklahoma has reached with opioid manufacturers like Purdue Pharma, Teva Pharmaceuticals, and Endo Pharmaceuticals.", "banner_image": null, "source": "NonDoc", "category_within_source": "General", "source_domain": "NonDoc", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.722506"}, {"topic": "economy_macro", "relevance_score": "0.643524"}], "overall_sentiment_score": -0.543662, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "MCK", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.627245", "ticker_sentiment_label": "Bearish"}, {"ticker": "CAH", "relevance_score": "0.997807", "ticker_sentiment_score": "-0.607766", "ticker_sentiment_label": "Bearish"}, {"ticker": "COR", "relevance_score": "0.960657", "ticker_sentiment_score": "-0.628023", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.888068", "ticker_sentiment_score": "-0.530796", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.627682", "ticker_sentiment_score": "-0.335473", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "RNA: Philly drug developer Aro to get $1.4 billion if it meets Ionis\u2019 targets", "url": "https://www.inquirer.com/news/aro-biopharmaceuticals-ionis-dillon-rna-20200110.html", "time_published": "20200110T050000", "authors": ["Joseph N. DiStefano"], "summary": "Philadelphia-based Aro Biotherapeutics has signed a pact with Ionis Pharmaceuticals Inc. that could generate up to $1.4 billion in payments if Aro meets specific research, development, and market targets. The partnership will focus on developing RNA drugs using Aro's Centyrin technology to deliver treatments more efficiently to hard-to-reach areas of the body, expanding Ionis's existing pipeline. This investment highlights the growing vitality and talent within Philadelphia's biotech community.", "banner_image": null, "source": "Inquirer.com", "category_within_source": "General", "source_domain": "Inquirer.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.901053"}, {"topic": "earnings", "relevance_score": "0.745459"}], "overall_sentiment_score": 0.115233, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IONS", "relevance_score": "0.321585", "ticker_sentiment_score": "0.048273", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.721231", "ticker_sentiment_score": "0.259114", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.611655", "ticker_sentiment_score": "0.144135", "ticker_sentiment_label": "Neutral"}]}, {"title": "Merck adds to lung cancer wall with Otsuka deal", "url": "https://www.biopharmadive.com/news/merck-adds-to-lung-cancer-wall-with-otsuka-deal/569843/", "time_published": "20200106T214644", "authors": ["Jonathan Gardner"], "summary": "Merck & Co. has paid $50 million to Otsuka subsidiaries Astex Pharmaceuticals and Taiho Pharmaceutical to collaborate on targeted cancer drugs, including KRAS inhibitors. This deal positions Merck in a competitive race against other major pharmaceutical companies to develop agents for KRAS-mutated tumors. The collaboration, though smaller than previous acquisitions, signifies Merck's continued interest in diversifying its oncology portfolio beyond Keytruda, especially given potential future competition in the lung cancer market.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.926812"}, {"topic": "life_sciences", "relevance_score": "0.849663"}], "overall_sentiment_score": 0.161082, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ASTX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.268314", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.967350", "ticker_sentiment_score": "0.242565", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.715796", "ticker_sentiment_score": "0.146307", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.678845", "ticker_sentiment_score": "0.106765", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.612633", "ticker_sentiment_score": "0.085537", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kisses for breakfast? General Mills partners with Hershey on new cereals", "url": "https://www.fooddive.com/news/kisses-for-breakfast-general-mills-partners-with-hershey-on-new-cereals/569730/", "time_published": "20200103T222228", "authors": ["Jessi Devenyns"], "summary": "General Mills is launching five new cereals in 2020, including three in collaboration with Hershey: Hershey's Kisses, Jolly Rancher, and Reese's Puffs Big Puffs. These indulgent new options are part of a broader strategy by cereal manufacturers to boost declining sales by targeting millennials and children with sweet, nostalgic flavors. General Mills is also releasing a new Nature Valley granola flavor, indicating a multi-pronged approach to cater to both indulgence and health-conscious consumers.", "banner_image": null, "source": "Food Dive", "category_within_source": "General", "source_domain": "Food Dive", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.825323"}], "overall_sentiment_score": 0.118382, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GIS", "relevance_score": "0.981688", "ticker_sentiment_score": "0.122176", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSY", "relevance_score": "0.863433", "ticker_sentiment_score": "0.229143", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.630301", "ticker_sentiment_score": "0.071493", "ticker_sentiment_label": "Neutral"}]}, {"title": "AG Ferguson sues opioid manufacturer Johnson & Johnson over state\u2019s opioid epidemic", "url": "https://www.atg.wa.gov/news/news-releases/ag-ferguson-sues-opioid-manufacturer-johnson-johnson-over-state-s-opioid-epidemic", "time_published": "20200102T223708", "authors": [], "summary": "Washington State Attorney General Bob Ferguson has filed a lawsuit against Johnson & Johnson, accusing the company of fueling the opioid epidemic through deceptive marketing and its role as a major supplier of raw opioid materials. The lawsuit seeks civil penalties and damages, estimating millions for Washington state, and follows previous actions against other opioid manufacturers and distributors. Ferguson highlights the devastating impact of the opioid crisis on Washington families and its healthcare system.", "banner_image": null, "source": "Washington State | Office of the Attorney General (.gov)", "category_within_source": "General", "source_domain": "Washington State | Office of the Attorney General (.gov)", "topics": [{"topic": "life_sciences", "relevance_score": "0.942616"}, {"topic": "finance", "relevance_score": "0.702514"}], "overall_sentiment_score": 0.011808, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.332244", "ticker_sentiment_score": "0.029294", "ticker_sentiment_label": "Neutral"}]}, {"title": "China Approves New Varicella Vaccine For Children", "url": "https://www.vax-before-travel.com/sinovac-biotech-varicella-vaccine-showed-about-87-percent-protection-rate", "time_published": "20191227T012623", "authors": ["Robert Carlson", "MD"], "summary": "China's National Medical Products Administration (NMPA) has approved Sinovac Biotech's varicella vaccine for children aged 1 to 12, with a protection rate of 87.1 percent. This marks the first vaccine approved by the Chinese government under the new Vaccine Management Law. Sinovac plans to explore international markets for its new product given the global inclusion of varicella vaccines in national immunization programs.", "banner_image": null, "source": "Vax-Before-Travel", "category_within_source": "General", "source_domain": "Vax-Before-Travel", "topics": [{"topic": "life_sciences", "relevance_score": "0.907880"}], "overall_sentiment_score": 0.435105, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SVA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.866621", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRK", "relevance_score": "0.625543", "ticker_sentiment_score": "0.341222", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.625720", "ticker_sentiment_score": "0.307886", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.575203", "ticker_sentiment_score": "0.286077", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "First generics to Bristol-Myers and Pfizer's Eliquis are here. But can they launch before 2026?", "url": "https://www.fiercepharma.com/pharma/first-generics-to-bristol-myers-and-pfizer-s-eliquis-are-here-but-might-not-launch-until", "time_published": "20191226T104000", "authors": ["Angus Liu"], "summary": "The FDA has approved the first two generic versions of Bristol-Myers Squibb and Pfizer's blockbuster blood thinner Eliquis, made by Mylan and Micro Labs. Despite these approvals, the generics are unlikely to launch before 2026 due to ongoing patent disputes and settlements, as Bristol-Myers Squibb and Pfizer are strenuously defending the drug which generates billions in revenue. Eliquis remains a significant growth driver for both companies, outperforming competitors like Johnson & Johnson's Xarelto in the novel oral anticoagulants market.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "earnings", "relevance_score": "0.919069"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.809043"}], "overall_sentiment_score": -0.067148, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.244923", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.878451", "ticker_sentiment_score": "-0.114407", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.718407", "ticker_sentiment_score": "0.038436", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.640343", "ticker_sentiment_score": "0.022020", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.580708", "ticker_sentiment_score": "0.000506", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intra-Cellular approval keeps focus on FDA\u2019s neuroscience review process", "url": "https://www.biopharmadive.com/news/intracellular-lumateperone-approval-Caplyta-neuroscience-fda/569607/", "time_published": "20191223T234134", "authors": ["Jacob Bell"], "summary": "The FDA's approval of Intra-Cellular's lumateperone (Caplyta) for schizophrenia, despite mixed clinical data, indicates a more flexible approach to evaluating neuroscience drugs. This decision could have positive implications for other neuroscience drug developers facing similar situations. While the FDA shows increased flexibility, the article also notes there are limits, as evidenced by previous rejections for drugs with shaky evidence.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.928038"}, {"topic": "finance", "relevance_score": "0.628924"}], "overall_sentiment_score": 0.121118, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACAD", "relevance_score": "0.939276", "ticker_sentiment_score": "0.275604", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.733644", "ticker_sentiment_score": "0.117858", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.615171", "ticker_sentiment_score": "-0.104538", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson to take over Verb Surgical, its robotics venture with Verily", "url": "https://www.fiercebiotech.com/medtech/j-j-to-take-over-verb-surgical-its-robotics-venture-verily", "time_published": "20191220T083700", "authors": ["Conor Hale"], "summary": "Johnson & Johnson is acquiring the remaining stake in Verb Surgical, its four-year-old robotic surgery joint venture with Verily, aiming to complete the deal in the first half of 2020. This move will integrate Verb's \"Surgery 4.0\" initiative into J&J's growing digital surgery ecosystem, leveraging expertise from recent acquisitions like Auris Health. The acquisition is intended to advance J&J's vision for improving patient outcomes through differentiated digital surgery.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.919474"}, {"topic": "life_sciences", "relevance_score": "0.838322"}, {"topic": "technology", "relevance_score": "0.738532"}], "overall_sentiment_score": 0.406436, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.401936", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson Announces Agreement to Acquire Remaining Stake in Verb Surgical Inc.", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-announces-agreement-to-acquire-remaining-stake-in-verb-surgical-inc-300978167.html", "time_published": "20191220T064500", "authors": [], "summary": "Johnson & Johnson announced an agreement to acquire the remaining stake in Verb Surgical Inc., augmenting its digital surgery portfolio. This acquisition, following a successful collaboration with Verily, aims to make medical interventions smarter, less invasive, and more personalized by combining robotics, data science, and advanced instrumentation. The transaction is expected to close in the first half of 2020, enhancing J&J's leadership in the medical devices sector.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.925693"}, {"topic": "technology", "relevance_score": "0.845012"}], "overall_sentiment_score": 0.353733, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.456894", "ticker_sentiment_label": "Bullish"}, {"ticker": "GOOGL", "relevance_score": "0.632980", "ticker_sentiment_score": "0.323243", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.608654", "ticker_sentiment_score": "0.334262", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3M to sell drug-delivery biz to Altaris Capital Partners for $650m", "url": "https://www.massdevice.com/3m-to-sell-drug-delivery-biz-to-altaris-capital-partners-for-650m/", "time_published": "20191212T005213", "authors": ["Sean Whooley"], "summary": "3M announced it will sell most of its drug-delivery business to an affiliate of Altaris Capital Partners for approximately $650 million. The divestiture, which generated $380 million in annual global sales, is expected to close in the first half of 2020 and will result in 900 employees joining the new company. 3M anticipates a gain of 45\u00a2 to 50\u00a2 per share from the transaction, allowing it to focus on its core healthcare business.", "banner_image": null, "source": "MassDevice", "category_within_source": "General", "source_domain": "MassDevice", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.926019"}, {"topic": "earnings", "relevance_score": "0.827938"}, {"topic": "financial_markets", "relevance_score": "0.609147"}], "overall_sentiment_score": 0.189937, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MMM", "relevance_score": "1.000000", "ticker_sentiment_score": "0.298215", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.624766", "ticker_sentiment_score": "0.109928", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.576831", "ticker_sentiment_score": "0.133076", "ticker_sentiment_label": "Neutral"}]}, {"title": "Employees say Intuitive Surgical, J&J, Stryker best places to work in 2020", "url": "https://www.massdevice.com/employees-say-intuitive-surgical-jj-stryker-best-places-to-work-in-2020/", "time_published": "20191211T003700", "authors": ["Danielle Kirsh"], "summary": "Intuitive Surgical, Johnson & Johnson, and Stryker were recognized by Glassdoor as top employers in 2020, based on employee feedback. Intuitive Surgical ranked seventh, J&J 71st, and Stryker 87th, all receiving high ratings for work-life balance and company mission, despite some challenges noted by employees regarding demanding environments or resource limitations. The article highlights employee perspectives on these medical device giants, including their financial performance and headcount from 2018.", "banner_image": null, "source": "MassDevice", "category_within_source": "General", "source_domain": "MassDevice", "topics": [{"topic": "life_sciences", "relevance_score": "0.919055"}], "overall_sentiment_score": 0.502931, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.519920", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.949129", "ticker_sentiment_score": "0.469836", "ticker_sentiment_label": "Bullish"}, {"ticker": "SYK", "relevance_score": "0.924104", "ticker_sentiment_score": "0.485788", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson CEO refuses to attend US hearing on carcinogens", "url": "https://www.aljazeera.com/economy/2019/12/10/johnson-johnson-ceo-refuses-to-attend-us-hearing-on-carcinogens", "time_published": "20191210T004127", "authors": ["Reuters"], "summary": "Johnson & Johnson CEO Alex Gorsky declined to appear before a US congressional hearing concerning cancer-causing asbestos in the company's talc products, citing that he is not an expert on the subject. The House subcommittee expressed disappointment, while J&J stated they offered other executives or experts but were rejected, suggesting the hearing's composition was biased. Gorsky has previously defended the safety of J&J's talc products amidst numerous lawsuits and a recall following FDA findings of asbestos.", "banner_image": null, "source": "Al Jazeera", "category_within_source": "General", "source_domain": "Al Jazeera", "topics": [{"topic": "life_sciences", "relevance_score": "0.902163"}], "overall_sentiment_score": -0.732629, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.711225", "ticker_sentiment_label": "Bearish"}]}, {"title": "Market Intel: After A Year Of Partnerships, Insulin Pump Manufacturers Will Face Fierce Competition In 2020", "url": "https://insights.citeline.com/MT125985/Market-Intel-After-A-Year-Of-Partnerships-Insulin-Pump-Manufacturers-Will-Face-Fierce-Competition-In-2020/", "time_published": "20191209T010701", "authors": ["Marion Webb"], "summary": "The insulin pump market, after a year of significant partnerships, is expected to face intense competition in 2020. Key players like Medtronic, Insulet, and Tandem Diabetes Care, along with new entrants, are vying for market share. The landscape is also influenced by advancements in continuous glucose monitoring and digital health solutions.", "banner_image": null, "source": "Citeline News & Insights", "category_within_source": "General", "source_domain": "Citeline News & Insights", "topics": [{"topic": "life_sciences", "relevance_score": "0.916945"}], "overall_sentiment_score": 0.075631, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.966342", "ticker_sentiment_score": "0.118961", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.817852", "ticker_sentiment_score": "0.082750", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.605587", "ticker_sentiment_score": "0.134809", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.584796", "ticker_sentiment_score": "-0.097879", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Weekly | Johnson & Johnson Lawsuits Raise Fears Over Baby Powder (Published 2019)", "url": "https://www.nytimes.com/2019/10/04/the-weekly/johnson-johnson-baby-powder-cancer-lawsuits.html", "time_published": "20191208T004126", "authors": ["Roni Caryn Rabin", "Tiffany Hsu"], "summary": "Thousands of people are suing Johnson & Johnson, alleging their baby powder caused cancer due to asbestos contamination. The article investigates these lawsuits, the scientific and legal battles, and the company's long-standing knowledge and denial of potential asbestos presence in its talc products. It also highlights the lack of government oversight in regulating cosmetic products for safety.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.941039"}, {"topic": "finance", "relevance_score": "0.740010"}], "overall_sentiment_score": -0.611416, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.834280", "ticker_sentiment_label": "Bearish"}, {"ticker": "CL", "relevance_score": "0.644828", "ticker_sentiment_score": "-0.419825", "ticker_sentiment_label": "Bearish"}]}, {"title": "Janssen to Acquire Investigational Bermekimab from XBiotech", "url": "https://www.prnewswire.com/news-releases/janssen-to-acquire-investigational-bermekimab-from-xbiotech-300970952.html", "time_published": "20191207T024000", "authors": [], "summary": "Janssen Biotech, Inc., a Johnson & Johnson company, announced an agreement to acquire all rights to the investigational compound bermekimab from XBiotech Inc. for $750 million. Bermekimab is an anti-IL-1alpha monoclonal antibody in Phase 2 development for atopic dermatitis and hidradenitis suppurativa, and Janssen will take over the clinical program. The acquisition aims to expand Janssen's expertise in immuno-dermatology and address unmet needs in these immune-mediated diseases.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.648103"}], "overall_sentiment_score": 0.517311, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "XBIT", "relevance_score": "0.961089", "ticker_sentiment_score": "0.735370", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.913365", "ticker_sentiment_score": "0.344502", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version", "url": "https://www.statnews.com/2019/12/07/johnson-johnson-car-t-myeloma-data-efficacy/", "time_published": "20191207T004128", "authors": ["Adam Feuerstein"], "summary": "New clinical data for Johnson & Johnson's CAR-T therapy (JNJ-4528) for multiple myeloma confirmed strong efficacy, easing skepticism previously aimed at similar data presented by a Chinese scientist a year prior. The initial Chinese data, which showed high patient responses, were met with doubt, but the new U.S.-developed data validate the earlier findings. This confirmation was presented at the American Society of Hematology (ASH) annual meeting.", "banner_image": null, "source": "www.statnews.com", "category_within_source": "General", "source_domain": "www.statnews.com", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.425994, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.435134", "ticker_sentiment_label": "Bullish"}]}, {"title": "Sharon Schulzki: New COO of CARLSMED", "url": "https://ryortho.com/2019/12/sharon-schulzki-new-coo-of-carlsmed/", "time_published": "20191205T235735", "authors": ["Elizabeth Hofheinz", "M.P.H.", "M.Ed."], "summary": "Sharon Schulzki, known for her experience in building venture-backed MedTech startups and leading successful exits, has been appointed as the new Chief Operating Officer of CARLSMED, Inc. Her role will focus on collaborating with spine surgeons to implement CARLSMED's personalized medical device platform for complex spine surgery. CEO Mike Cordonnier highlighted Schulzki's proven track record of creating value through executing evidence development plans and engaging key surgeons.", "banner_image": null, "source": "Orthopedics This Week", "category_within_source": "General", "source_domain": "Orthopedics This Week", "topics": [{"topic": "life_sciences", "relevance_score": "0.906044"}, {"topic": "finance", "relevance_score": "0.746896"}, {"topic": "technology", "relevance_score": "0.609839"}], "overall_sentiment_score": 0.196475, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CARL", "relevance_score": "0.346097", "ticker_sentiment_score": "0.034727", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.742376", "ticker_sentiment_score": "0.332315", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.640643", "ticker_sentiment_score": "0.202078", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYK", "relevance_score": "0.609976", "ticker_sentiment_score": "0.228940", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vicarious Surgical wins FDA breakthrough designation for surgical robot", "url": "https://www.massdevice.com/vicarious-surgical-wins-fda-breakthrough-designation-for-surgical-robot/", "time_published": "20191205T011129", "authors": ["Sean Whooley"], "summary": "Vicarious Surgical announced it received FDA breakthrough device designation for its virtual reality-based robot-assisted surgical device. The company claims its technology allows surgeons to perform minimally invasive procedures through a single micro-incision, effectively \"shrinking the surgeon and putting them inside the patient.\" This designation validates the platform and its clinical value, supporting its path toward commercialization.", "banner_image": null, "source": "MassDevice", "category_within_source": "General", "source_domain": "MassDevice", "topics": [{"topic": "life_sciences", "relevance_score": "0.924013"}, {"topic": "technology", "relevance_score": "0.805907"}], "overall_sentiment_score": 0.335939, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RBOT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.612725", "ticker_sentiment_label": "Bullish"}, {"ticker": "GOOG", "relevance_score": "0.605524", "ticker_sentiment_score": "0.213052", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.619513", "ticker_sentiment_score": "0.204575", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson confirms no asbestos in Johnson's Baby Powder", "url": "https://www.cnbc.com/2019/12/03/johnson-johnson-confirms-no-asbestos-in-johnsons-baby-powder.html", "time_published": "20191203T191800", "authors": [], "summary": "Johnson & Johnson announced that new tests confirmed its Baby Powder is free of asbestos, following an FDA investigation that previously found trace amounts. The company suggested the FDA's earlier findings might have resulted from test sample contamination or analyst error. This latest effort aims to reassure consumers about the safety of its product amidst ongoing lawsuits.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.107128, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.148390", "ticker_sentiment_label": "Neutral"}]}, {"title": "7 Biopharma Manufacturing Execs Detail What To Expect in 2020 -- And Beyond", "url": "https://www.lifescienceleader.com/doc/biopharma-manufacturing-execs-detail-what-to-expect-in-and-beyond-0001", "time_published": "20191202T003132", "authors": ["Rob Wright"], "summary": "Seven biopharmaceutical manufacturing executives share their perspectives on key trends, innovations, and challenges facing the industry in 2020 and beyond. Topics covered include the impact of cell and gene therapies, emerging innovations, disruptive technologies, and strategies for improving product quality, compliance, and supply chain resilience. The executives also discuss their vision for global biopharma manufacturing in 2030 and exciting current trends.", "banner_image": null, "source": "Life Science Leader", "category_within_source": "General", "source_domain": "Life Science Leader", "topics": [{"topic": "life_sciences", "relevance_score": "0.946160"}, {"topic": "manufacturing", "relevance_score": "0.817330"}], "overall_sentiment_score": 0.216264, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HALO", "relevance_score": "0.923844", "ticker_sentiment_score": "0.320093", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.835058", "ticker_sentiment_score": "0.219308", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.831619", "ticker_sentiment_score": "0.226698", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.817001", "ticker_sentiment_score": "0.103031", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.724127", "ticker_sentiment_score": "0.240345", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Jon Serbousek New President, CEO of Orthofix Medical", "url": "https://ryortho.com/2019/11/jon-serbousek-new-president-ceo-of-orthofix-medical/", "time_published": "20191129T010142", "authors": ["Elizabeth Hofheinz", "M.P.H.", "M.Ed."], "summary": "Jon Serbousek, a veteran of the medical device and biotech industries, has been appointed as the new President and CEO of Orthofix Medical Inc., and will also join its Board of Directors. He succeeds Brad Mason, who is retiring but will continue as a consultant for 12 months for a smooth transition. Serbousek's immediate focus will be on strengthening the spine business leadership and strategy, and assessing the needs of the Extremities business for growth.", "banner_image": null, "source": "Orthopedics This Week", "category_within_source": "General", "source_domain": "Orthopedics This Week", "topics": [{"topic": "life_sciences", "relevance_score": "0.909526"}, {"topic": "finance", "relevance_score": "0.711657"}], "overall_sentiment_score": 0.214895, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OFIX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.411194", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.715042", "ticker_sentiment_score": "0.202230", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZBH", "relevance_score": "0.601691", "ticker_sentiment_score": "0.114384", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.630346", "ticker_sentiment_score": "0.136244", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fight is not over, says winner of vaginal mesh implant court victory", "url": "https://www.cnn.com/2019/11/22/health/johnson-and-johnson-pelvic-mesh-case-intl-hnk", "time_published": "20191122T051400", "authors": ["Helen Regan"], "summary": "Following a landmark legal victory in Australia against Johnson & Johnson over defective vaginal mesh implants, lead claimant Julie Davis stated that while the battle was won, the \"war will still go on.\" The Australian federal court ruled that Johnson & Johnson and its affiliated companies misled patients and doctors about the safety of the implants and were negligent. This decision marks a significant step towards justice for thousands of women worldwide who suffered severe complications from these devices, prompting calls for international regulation and compensation.", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "life_sciences", "relevance_score": "0.923206"}], "overall_sentiment_score": -0.409145, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.404642", "ticker_sentiment_label": "Bearish"}]}, {"title": "How Johnson & Johnson Shares Can Get Well", "url": "https://www.wsj.com/articles/how-johnson-johnson-shares-can-get-well-11574180520?gaa_at=eafs&gaa_n=AWEtsqflNWmdJYn7CsqH6a7vN3Ua3VFyDCbT73swz99akdGEc4Hh57VKhk4h&gaa_ts=6907fd7d&gaa_sig=xbXptuzKmisp05Rw5i-kCQV1DyAIPrsZZa1ZajxhXbMc8sAcnkfo90rwyXF3Cog--85gRY8qatUOtSXEHxlYHQ%3D%3D", "time_published": "20191119T004127", "authors": ["Charley Grant"], "summary": "Johnson & Johnson shares have been negatively impacted by legal challenges, particularly those concerning the company's baby powder. Despite the broader market reaching record highs, J&J's stock remains nearly 10% below its previous year's high. The article suggests that better news might be on the horizon for the company's shareholders.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.910694"}, {"topic": "financial_markets", "relevance_score": "0.819282"}], "overall_sentiment_score": 0.252477, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.294347", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson rushed baby powder tests after FDA warning: report", "url": "https://www.foxbusiness.com/money/johnson-johnson-baby-powder-tests-report", "time_published": "20191117T162700", "authors": ["Matthew McNulty"], "summary": "Johnson & Johnson reportedly rushed independent tests on its baby powder after the FDA warned of asbestos contamination, according to the Wall Street Journal. While J&J announced that follow-up tests showed no asbestos, the initial lab findings were complicated by a contaminated testing room and the company used preliminary negative results from a second lab. J&J explained they expedited testing due to the serious nature of the FDA's findings, as the company continues to face numerous lawsuits related to its baby powder products.", "banner_image": null, "source": "Fox Business", "category_within_source": "General", "source_domain": "Fox Business", "topics": [{"topic": "life_sciences", "relevance_score": "0.908351"}, {"topic": "retail_wholesale", "relevance_score": "0.740698"}, {"topic": "finance", "relevance_score": "0.609245"}], "overall_sentiment_score": -0.392872, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.365340", "ticker_sentiment_label": "Bearish"}]}, {"title": "Longtime Abbott chief Miles White, designer of AbbVie spinoff, bows out of CEO job", "url": "https://www.fiercepharma.com/pharma/longtime-abbott-chief-miles-white-designer-abbvie-spinoff-to-step-down-as-ceo", "time_published": "20191113T120200", "authors": ["Angus Liu"], "summary": "Miles White, the longtime CEO of Abbott Laboratories, will step down from his role on March 31, 2020, after a 21-year tenure marked by significant transformations, including the spinoff of AbbVie and several major acquisitions and divestitures. Robert Ford, currently Abbott's president and COO, will succeed White as CEO, while White will remain executive chairman. Ford has been instrumental in the success of Abbott's medical devices division, particularly the Freestyle Libre glucose monitor and the acquisitions of St. Jude Medical and Alere.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.933342"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.816274"}], "overall_sentiment_score": 0.08578, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.287845", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.747708", "ticker_sentiment_score": "0.112581", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.555217", "ticker_sentiment_score": "-0.168652", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.553248", "ticker_sentiment_score": "0.071087", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZTS", "relevance_score": "0.582320", "ticker_sentiment_score": "0.059029", "ticker_sentiment_label": "Neutral"}]}, {"title": "Under the Hood of QRAFT AI Enhanced U.S. Large Cap ETF (QRFT)", "url": "https://www.etftrends.com/innovative-etfs-channel/qraft-ai-enhanced-us-large-cap-etf-qrft/", "time_published": "20191112T192819", "authors": ["Ian Young"], "summary": "The QRAFT AI Enhanced U.S. Large Cap ETF (QRFT) is an actively managed ETF that uses a proprietary artificial intelligence system to select large-capitalization U.S. stocks. The fund aims for long-term capital appreciation by focusing on factors like quality, size, valuation, momentum, and low risk, with AI continuously learning optimal factor weights based on macroeconomic and valuation conditions. QRFT may serve as a large-cap equity allocation, offer factor exposure, or act as an alternative investment due to its cutting-edge technology.", "banner_image": "https://www.etftrends.com/wp-content/uploads/2025/10/Innovative_ETFs_Invesco_masthead_overlay_1600x121@2x-1.png", "source": "ETF Trends", "category_within_source": "General", "source_domain": "ETF Trends", "topics": [{"topic": "financial_markets", "relevance_score": "0.940175"}, {"topic": "technology", "relevance_score": "0.819909"}], "overall_sentiment_score": 0.166023, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QRFT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.445048", "ticker_sentiment_label": "Bullish"}, {"ticker": "MSFT", "relevance_score": "0.609112", "ticker_sentiment_score": "0.105943", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.646918", "ticker_sentiment_score": "0.107956", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOGL", "relevance_score": "0.636676", "ticker_sentiment_score": "0.112770", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.635956", "ticker_sentiment_score": "0.104155", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bausch Yanked Talc From Its Body Powder Months Before J&J Recall", "url": "https://www.claimsjournal.com/news/national/2019/11/06/293978.htm", "time_published": "20191106T235220", "authors": ["Jef Feeley"], "summary": "Bausch Health Cos. Inc., maker of Shower to Shower powder, reformulated its product last year to replace talc with corn starch, months before Johnson & Johnson's talc-based baby powder recall due to asbestos contamination. Bausch stated the change was for market trends and customer preferences, not safety concerns, though it faces lawsuits alleging hidden asbestos in its talc products. This move by Bausch is seen by legal experts as an effort to limit its liability in talc-related lawsuits, especially given an indemnity agreement with J&J.", "banner_image": null, "source": "Claims Journal", "category_within_source": "General", "source_domain": "Claims Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.911671"}, {"topic": "retail_wholesale", "relevance_score": "0.748286"}], "overall_sentiment_score": 0.026886, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BHC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.283451", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.901671", "ticker_sentiment_score": "0.043757", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.746989", "ticker_sentiment_score": "-0.119415", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.637767", "ticker_sentiment_score": "-0.122683", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.568642", "ticker_sentiment_score": "0.037592", "ticker_sentiment_label": "Neutral"}]}, {"title": "Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease", "url": "https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-first-patient-dosed-in-a-phase-2-study-of-oral-il-23-receptor-antagonist-ptg-200-jnj-67864238-in-the-treatment-of-crohns-disease-300953227.html", "time_published": "20191106T160100", "authors": [], "summary": "Protagonist Therapeutics announced the dosing of the first patient in a Phase 2 study for its oral IL-23 receptor antagonist, PTG-200 (JNJ-67864238), for moderate to severe Crohn's disease. This drug, co-developed with Janssen, aims to offer an oral alternative to injectable treatments, with clinical efficacy results anticipated in 2021. Protagonist is eligible for over $1 billion in milestone payments and has an option to co-detail the drug in the U.S.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.925177"}], "overall_sentiment_score": 0.271364, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PTGX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.314854", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.745959", "ticker_sentiment_score": "0.234369", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Throw Out All Your Baby Powder and Talc Products?", "url": "https://www.self.com/story/johnson-and-johnson-baby-powder-recall-asbestos", "time_published": "20191106T004128", "authors": ["Carolyn L. Todd"], "summary": "Johnson & Johnson voluntarily recalled a lot of its talc-based baby powder after the FDA found asbestos in a sample, reigniting concerns about the product's safety. The company disputes the FDA's findings, suggesting potential lab contamination, while both entities stand by their testing results. Consumers with the recalled lot number (#22318RB) are advised to stop use, and alternatives like cornstarch-based powders are suggested for those with concerns about talc products.", "banner_image": "https://www.self.com/story/johnson-and-johnson-baby-powder-recall-asbestos", "source": "SELF Magazine", "category_within_source": "General", "source_domain": "SELF Magazine", "topics": [{"topic": "life_sciences", "relevance_score": "0.907816"}, {"topic": "retail_wholesale", "relevance_score": "0.721001"}, {"topic": "finance", "relevance_score": "0.623084"}], "overall_sentiment_score": -0.389943, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.411862", "ticker_sentiment_label": "Bearish"}]}, {"title": "Theramex Buys Janssen\u2019s Evorel Amid Ongoing HRT Shortages", "url": "https://insights.citeline.com/SC126141/Theramex-Buys-Janssens-Evorel-Amid-Ongoing-HRT-Shortages/", "time_published": "20191105T013638", "authors": ["Eleanor Malone"], "summary": "Theramex has acquired Janssen's Evorel, a move occurring amidst persistent shortages of Hormone Replacement Therapy (HRT) products. This acquisition is significant as both Evorel and Theramex's own HRT patches were experiencing stockouts at the time, highlighting the ongoing supply challenges in the HRT market. The article suggests that these HRT shortages were expected to continue beyond 2019.", "banner_image": null, "source": "Citeline News & Insights", "category_within_source": "General", "source_domain": "Citeline News & Insights", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.920656"}, {"topic": "life_sciences", "relevance_score": "0.846095"}, {"topic": "manufacturing", "relevance_score": "0.735535"}], "overall_sentiment_score": 0.126701, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VTRS", "relevance_score": "0.925216", "ticker_sentiment_score": "0.127702", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.744099", "ticker_sentiment_score": "0.148622", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Announces Donation of up to 500,000 Regimens of Janssen's Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC)", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-announces-donation-of-up-to-500-000-regimens-of-janssens-investigational-ebola-vaccine-to-support-outbreak-response-in-democratic-republic-of-the-congo-drc-300948746.html", "time_published": "20191031T071000", "authors": [], "summary": "Johnson & Johnson (NYSE: JNJ) has announced a donation of up to 500,000 regimens of Janssen's investigational Ebola vaccine to support the outbreak response in the Democratic Republic of the Congo (DRC). This decision follows the DRC government's support for using the vaccine regimen as part of an expanded public health initiative to contain the country's second-worst Ebola outbreak on record. The initiative aligns with recent WHO recommendations and aims to prevent further geographic spread of the virus.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.910672"}, {"topic": "finance", "relevance_score": "0.602565"}], "overall_sentiment_score": 0.006568, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.321601", "ticker_sentiment_score": "0.047706", "ticker_sentiment_label": "Neutral"}]}, {"title": "Where Is The Headquarters Of Johnson & Johnson?", "url": "https://www.worldatlas.com/articles/where-is-the-headquarters-of-johnson-and-johnson.html", "time_published": "20191030T004127", "authors": ["Benjamin Elisha Sawe"], "summary": "This article details the headquarters, business divisions, revenues, and founding history of Johnson & Johnson. It highlights the company's global presence and its three main business areas: consumer products, medical devices, and pharmaceutical products, along with their respective revenue contributions. The company's origin in 1886, driven by an interest in antiseptic surgical dressings, is also discussed.", "banner_image": null, "source": "WorldAtlas", "category_within_source": "General", "source_domain": "WorldAtlas", "topics": [{"topic": "life_sciences", "relevance_score": "0.945771"}, {"topic": "earnings", "relevance_score": "0.749221"}, {"topic": "finance", "relevance_score": "0.621954"}], "overall_sentiment_score": 0.046, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.322099", "ticker_sentiment_score": "0.018661", "ticker_sentiment_label": "Neutral"}]}, {"title": "Walmart, CVS Pulling J&J Baby Powder Off Shelves Amid Recall", "url": "https://www.bloomberg.com/news/articles/2019-10-24/cvs-pulling-all-22-oz-j-j-baby-powder-from-shelves-amid-recall", "time_published": "20191024T190300", "authors": ["Jef Feeley"], "summary": "Walmart Stores Inc. and CVS Health Corp. are removing certain bottles of Johnson & Johnson's Baby Powder from their shelves after government regulators found trace amounts of asbestos in one product lot. CVS, the largest U.S. pharmacy chain, announced it is pulling all 22-ounce bottles of the product, following J&J's limited recall last week. This action comes amidst ongoing concerns and lawsuits alleging that asbestos-laced talc caused cancer in some users.", "banner_image": null, "source": "Bloomberg.com", "category_within_source": "General", "source_domain": "Bloomberg.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.915720"}, {"topic": "retail_wholesale", "relevance_score": "0.817497"}], "overall_sentiment_score": -0.417597, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.427420", "ticker_sentiment_label": "Bearish"}, {"ticker": "WMT", "relevance_score": "0.907374", "ticker_sentiment_score": "-0.401136", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.890127", "ticker_sentiment_score": "-0.460871", "ticker_sentiment_label": "Bearish"}]}, {"title": "Ameris Bank moves headquarters, top executives to Atlanta", "url": "https://www.jaxdailyrecord.com/news/2019/oct/24/ameris-bank-moves-headquarters-top-executives-to-atlanta/", "time_published": "20191024T052000", "authors": ["Mark Basch"], "summary": "Ameris Bank has moved its corporate headquarters and top executives to Atlanta, following the acquisition of Fidelity Southern Corp. and the unexpected resignation of its CEO. While the headquarters is now in Atlanta, Ameris Bank will maintain a significant presence in Jacksonville at the Riverplace Tower, including new signage on the building. The bank reported strong third-quarter earnings and successful integration of Fidelity Southern's operations, despite closing several branches.", "banner_image": null, "source": "Jacksonville Daily Record", "category_within_source": "General", "source_domain": "Jacksonville Daily Record", "topics": [{"topic": "earnings", "relevance_score": "0.904445"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.822547"}, {"topic": "finance", "relevance_score": "0.822994"}, {"topic": "retail_wholesale", "relevance_score": "0.638896"}, {"topic": "life_sciences", "relevance_score": "0.645562"}], "overall_sentiment_score": -0.045928, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABCB", "relevance_score": "1.000000", "ticker_sentiment_score": "0.295276", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.646261", "ticker_sentiment_score": "0.262844", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CSX", "relevance_score": "0.846734", "ticker_sentiment_score": "-0.232505", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TPR", "relevance_score": "0.730035", "ticker_sentiment_score": "-0.400734", "ticker_sentiment_label": "Bearish"}]}, {"title": "$50 Billion and 100,000 Plaintiffs: Johnson & Johnson\u2019s Painful Reputational Risk Lesson", "url": "https://riskandinsurance.com/johnson-johnson-lawsuits-reputation/", "time_published": "20191024T004128", "authors": ["Autumn Demberger"], "summary": "Johnson & Johnson is facing a multitude of class-action lawsuits, ranging from opioid litigation to asbestos allegations, with analysts predicting potential costs between $20 billion and $50 billion. This legal onslaught has significantly impacted J&J's corporate reputation, although the company maintains its reputation for quality products remains strong among consumers. The situation serves as a stark lesson for other companies on the critical value of corporate reputation in the face of widespread legal challenges.", "banner_image": null, "source": "Risk & Insurance", "category_within_source": "General", "source_domain": "Risk & Insurance", "topics": [{"topic": "life_sciences", "relevance_score": "0.937810"}, {"topic": "finance", "relevance_score": "0.723323"}, {"topic": "earnings", "relevance_score": "0.604378"}], "overall_sentiment_score": -0.364241, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.632097", "ticker_sentiment_label": "Bearish"}, {"ticker": "MRK", "relevance_score": "0.607703", "ticker_sentiment_score": "-0.101426", "ticker_sentiment_label": "Neutral"}]}, {"title": "Jabil details costs of its deal with Johnson & Johnson", "url": "https://stpetecatalyst.com/jabil-details-costs-of-its-deal-with-johnson-johnson/", "time_published": "20191023T004117", "authors": ["Margie Manning"], "summary": "Jabil Inc. has detailed the costs associated with its \"transformational\" deal to acquire Johnson & Johnson Medical Devices assets, spending $270.3 million in cash and an additional $52.7 million for onboarding and integration since February. The acquisition is part of Jabil's diversification strategy, aiming to reduce its reliance on Apple Inc. while expanding its medical device manufacturing footprint. The company reported a significant increase in revenue and net income for FY 2019, reflecting the initial impact of the Johnson & Johnson operations.", "banner_image": null, "source": "St Pete Catalyst", "category_within_source": "General", "source_domain": "St Pete Catalyst", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.945878"}, {"topic": "earnings", "relevance_score": "0.831526"}, {"topic": "manufacturing", "relevance_score": "0.744738"}, {"topic": "life_sciences", "relevance_score": "0.606371"}, {"topic": "technology", "relevance_score": "0.635850"}], "overall_sentiment_score": 0.257424, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JBL", "relevance_score": "1.000000", "ticker_sentiment_score": "0.314732", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.821565", "ticker_sentiment_score": "0.278203", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.721545", "ticker_sentiment_score": "0.146572", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson CEO testified Baby Powder was safe days before FDA bombshell", "url": "https://www.foxbusiness.com/healthcare/johnson-johnson-ceo-testified-baby-powder-was-safe-days-before-fda-bombshell", "time_published": "20191022T202700", "authors": ["Reuters"], "summary": "Johnson & Johnson CEO Alex Gorsky testified on October 3rd that the company's Baby Powder was safe and didn't contain asbestos, just 13 days before the FDA announced it had found asbestos in a bottle of the product. This FDA finding led to J&J\u2019s first-ever Baby Powder recall for asbestos contamination and complicates the company's defense against thousands of lawsuits claiming its talc powders caused cancer, despite Gorsky's prior insistence that he \"believed\" the products were clean. The recall prompted a renewed stock sell-off and could lead to Gorsky being deposed again.", "banner_image": null, "source": "Fox Business", "category_within_source": "General", "source_domain": "Fox Business", "topics": [{"topic": "life_sciences", "relevance_score": "0.915297"}, {"topic": "finance", "relevance_score": "0.709112"}], "overall_sentiment_score": -0.615865, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.605074", "ticker_sentiment_label": "Bearish"}]}, {"title": "Lung Cancer: Nasal Swab Test Allows Early Detection, Diagnosis", "url": "https://respiratory-therapy.com/disorders-diseases/cardiopulmonary-thoracic/lung-cancer/lung-cancer-nasal-swab-test-allows-early-detection-diagnosis/", "time_published": "20191022T013609", "authors": [], "summary": "Veracyte Inc. has developed the first noninvasive nasal swab test for lung cancer, enabling early detection and diagnosis based on preliminary clinical data presented at Chest 2019. The genomic test accurately classifies lung cancer risk in patients with lung nodules, directing those at high risk to invasive procedures and those at low risk to noninvasive monitoring. This innovation aims to improve patient outcomes by facilitating timely treatment and reducing unnecessary invasive procedures.", "banner_image": null, "source": "respiratory-therapy.com", "category_within_source": "General", "source_domain": "respiratory-therapy.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.914554"}, {"topic": "technology", "relevance_score": "0.635164"}], "overall_sentiment_score": 0.566257, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VCYT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.817844", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.739780", "ticker_sentiment_score": "0.301267", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Drugs firms reach $260m US opioid settlement", "url": "https://www.bbc.co.uk/news/business-50121708", "time_published": "20191021T235732", "authors": [], "summary": "Four pharmaceutical companies have agreed to a $260 million settlement with two Ohio counties over their alleged role in fueling the US opioid crisis, averting a major trial. The agreement includes payments and treatment medication contributions from McKesson Corp, Cardinal Health, AmerisourceBergen Corp, and Teva. Teva also announced an \"agreement in principle\" for a broader global settlement worth an estimated $23 billion in medication over 10 years.", "banner_image": null, "source": "BBC", "category_within_source": "General", "source_domain": "BBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.934486"}, {"topic": "finance", "relevance_score": "0.827418"}, {"topic": "economy_macro", "relevance_score": "0.639995"}], "overall_sentiment_score": -0.1762, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.294288", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MCK", "relevance_score": "0.921584", "ticker_sentiment_score": "-0.285926", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WBA", "relevance_score": "0.727594", "ticker_sentiment_score": "-0.142836", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.639683", "ticker_sentiment_score": "-0.119029", "ticker_sentiment_label": "Neutral"}]}, {"title": "Drug distributors, opioid maker reach deal with Ohio counties in historic lawsuit", "url": "https://www.usatoday.com/story/news/nation/2019/10/21/opioid-trial-settlement-report/4051076002/", "time_published": "20191021T235731", "authors": ["John Bacon", "Jorge L. Ortiz"], "summary": "A landmark settlement was reached between a key drugmaker and multiple distributors and two Ohio counties, just hours before opening statements were set in a historic opioid lawsuit. The deal, totaling $215 million, is seen as a benchmark for local government settlements nationwide, though lawyers stressed it is not a \"global resolution.\" This settlement allows resources to combat opioid addiction to be deployed much sooner than a lengthy trial process.", "banner_image": null, "source": "USA Today", "category_within_source": "General", "source_domain": "USA Today", "topics": [{"topic": "life_sciences", "relevance_score": "0.919362"}, {"topic": "finance", "relevance_score": "0.707750"}], "overall_sentiment_score": 0.115736, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.113950", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.938298", "ticker_sentiment_score": "0.119023", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSIC", "relevance_score": "0.808047", "ticker_sentiment_score": "0.113903", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.724313", "ticker_sentiment_score": "0.148181", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.631339", "ticker_sentiment_score": "0.149637", "ticker_sentiment_label": "Neutral"}]}, {"title": "Major drug companies reach $260 million settlement in federal opioid trial", "url": "https://www.axios.com/2019/10/21/drug-companies-opioid-settlement", "time_published": "20191021T235730", "authors": ["Jacob Knutson"], "summary": "Major drug distributors McKesson Corp., Cardinal Health Inc., AmerisourceBergen Corp., and Teva Pharmaceutical Industries reached a $260 million settlement to avoid the first federal opioid trial. The settlement addresses cases brought by Ohio's Cuyahoga and Summit counties, with McKesson, Cardinal Health, and AmerisourceBergen contributing $215 million, and Teva paying $20 million plus $25 million in addiction-treatment drugs. This agreement precedes potential broader settlements involving thousands of opioid lawsuits across the U.S.", "banner_image": null, "source": "Axios", "category_within_source": "General", "source_domain": "Axios", "topics": [{"topic": "life_sciences", "relevance_score": "0.936996"}, {"topic": "finance", "relevance_score": "0.730486"}], "overall_sentiment_score": -0.415197, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.448453", "ticker_sentiment_label": "Bearish"}, {"ticker": "MCK", "relevance_score": "0.922299", "ticker_sentiment_score": "-0.428838", "ticker_sentiment_label": "Bearish"}, {"ticker": "WBA", "relevance_score": "0.825741", "ticker_sentiment_score": "-0.428589", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.627035", "ticker_sentiment_score": "-0.448797", "ticker_sentiment_label": "Bearish"}]}, {"title": "Prosecutors probe German dialysis firm", "url": "https://www.dw.com/en/german-prosecutors-probe-dialysis-firm-fresenius/a-50922473", "time_published": "20191021T002148", "authors": ["Ian P. Johnson"], "summary": "Frankfurt prosecutors are investigating employees of Fresenius Medical Care (FMC) for alleged bribery in 17 countries between 2007 and 2016. This probe stems from a US out-of-court settlement where FMC paid $231.7 million to the US Department of Justice and the SEC. The bribes were reportedly paid to doctors and state employees to establish dialysis wards and purchase FMC products.", "banner_image": "https://p.dw.com/p/3RfGD", "source": "DW", "category_within_source": "General", "source_domain": "DW", "topics": [{"topic": "life_sciences", "relevance_score": "0.923277"}, {"topic": "finance", "relevance_score": "0.710292"}], "overall_sentiment_score": -0.239682, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "FMS", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.445925", "ticker_sentiment_label": "Bearish"}, {"ticker": "BAX", "relevance_score": "0.625554", "ticker_sentiment_score": "-0.332201", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.648676", "ticker_sentiment_score": "-0.137440", "ticker_sentiment_label": "Neutral"}, {"ticker": "GEHC", "relevance_score": "0.638193", "ticker_sentiment_score": "-0.116005", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson recalls baby powder due to asbestos concerns", "url": "https://www.cnn.com/2019/10/18/health/johnson-and-johnson-baby-powder-recall-bn-trnd", "time_published": "20191018T215100", "authors": ["Jacqueline Howard"], "summary": "Johnson & Johnson announced a voluntary recall in the United States of one lot of its Johnson\u2019s Baby Powder due to low levels of asbestos contamination found in an FDA test. The recall involves 33,000 bottles from lot #22318RB, and consumers are advised to stop using the product and contact the company for a refund. The company is investigating the findings, while the FDA stands by its testing accuracy and is conducting a broader survey of cosmetic products for asbestos.", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "life_sciences", "relevance_score": "0.922749"}, {"topic": "retail_wholesale", "relevance_score": "0.702937"}], "overall_sentiment_score": -0.535486, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.704018", "ticker_sentiment_label": "Bearish"}, {"ticker": "KVUE", "relevance_score": "0.636972", "ticker_sentiment_score": "-0.312864", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson to recall baby powder after asbestos found", "url": "https://www.nbcnews.com/health/health-news/johnson-johnson-recall-baby-powder-after-asbestos-found-n1068686", "time_published": "20191018T113300", "authors": ["Reuters"], "summary": "Johnson & Johnson announced a voluntary recall of approximately 33,000 bottles of baby powder in the U.S. after the FDA found trace amounts of asbestos in a sample. The company is investigating the integrity of the tested sample and has reiterated that its talc products are safe and asbestos-free based on thousands of prior tests. This recall affects a specific lot produced and shipped in 2018.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.910048"}, {"topic": "retail_wholesale", "relevance_score": "0.717210"}], "overall_sentiment_score": -0.600285, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.635556", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson recalls lot of baby powder", "url": "https://www.foxbusiness.com/markets/johnson-johnson-recalls-lot-of-johnsons-baby-powder", "time_published": "20191018T091800", "authors": ["Daniella Genovese"], "summary": "Johnson & Johnson is voluntarily recalling a single lot of its baby powder in the U.S. after the FDA found sub-trace levels of chrysotile asbestos. The company is investigating the integrity of the tested sample and the validity of the results, noting possibilities of cross-contamination or a counterfeit product.", "banner_image": null, "source": "Fox Business", "category_within_source": "General", "source_domain": "Fox Business", "topics": [{"topic": "life_sciences", "relevance_score": "0.907861"}, {"topic": "retail_wholesale", "relevance_score": "0.730675"}], "overall_sentiment_score": -0.627664, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.636332", "ticker_sentiment_label": "Bearish"}]}, {"title": "Lawsuits, payouts, opioids crisis: what happened to Johnson & Johnson?", "url": "https://www.theguardian.com/business/2019/oct/18/johnson-and-johnson-opioids-lawsuits-product-recalls", "time_published": "20191018T020000", "authors": ["Edward Helmore"], "summary": "Johnson & Johnson, historically a trusted household name with a 75-year-old \"credo\" of corporate social responsibility, has seen its reputation plummet due to numerous lawsuits and massive payouts. The company is facing an existential crisis from claims related to its anti-psychotic drug Risperdal, blood thinner Xarelto, talc-based baby powder, pelvic mesh products, and a significant role in the US opioid crisis, with potential liabilities reaching billions of dollars alongside a substantial public relations challenge.", "banner_image": null, "source": "The Guardian", "category_within_source": "General", "source_domain": "The Guardian", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.846745"}, {"topic": "economy_macro", "relevance_score": "0.605760"}], "overall_sentiment_score": -0.614196, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.606538", "ticker_sentiment_label": "Bearish"}]}, {"title": "Asbestos discovery triggers Johnson & Johnson baby powder recall in US", "url": "https://www.bbc.com/news/business-50101758", "time_published": "20191018T004128", "authors": [], "summary": "Johnson & Johnson has recalled 33,000 bottles of baby powder in the US after health regulators found trace amounts of asbestos. The company initiated a voluntary recall of one lot produced in 2018, stating it was out of \"an abundance of caution\" and that prior tests found no asbestos. This recall is part of ongoing legal challenges the company faces over claims its talc products caused cancer, with its shares falling over 3% following the news.", "banner_image": null, "source": "BBC", "category_within_source": "General", "source_domain": "BBC", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.714718"}, {"topic": "life_sciences", "relevance_score": "0.908864"}], "overall_sentiment_score": -0.645038, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.623648", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson Recalls Baby Powder Over Asbestos Worry (Published 2019)", "url": "https://www.nytimes.com/2019/10/18/business/johnson-johnson-baby-powder-recall.html", "time_published": "20191018T004126", "authors": ["Tiffany Hsu and Roni Caryn Rabin"], "summary": "Johnson & Johnson announced a recall of 33,000 bottles of its baby powder in the U.S. after the FDA found asbestos in one product sample. This marks the first time the company has recalled baby powder due to asbestos concerns, potentially undermining its defense against thousands of lawsuits alleging its talc-based products cause cancer. The recall could have significant repercussions for the company's consumer trust and ability to market other products.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.930131"}, {"topic": "finance", "relevance_score": "0.711079"}, {"topic": "retail_wholesale", "relevance_score": "0.620737"}], "overall_sentiment_score": 0.038648, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.313686", "ticker_sentiment_score": "0.030597", "ticker_sentiment_label": "Neutral"}]}, {"title": "\u2018We\u2019re Not As Healthy As We Should Be.\u2019 Fitbit CEO James Park Discusses New AFib Detection Partnership With Bristol-Myers Squibb-Pfizer", "url": "https://time.com/5702746/fitbit-james-park-afib-time-100-summit/", "time_published": "20191017T173800", "authors": ["Patrick Lucas Austin"], "summary": "Fitbit CEO James Park announced a new partnership with Bristol-Myers Squibb-Pfizer Alliance to detect symptoms of atrial fibrillation (AFib) at the TIME 100 Health Summit. Park emphasized Fitbit's transformation into a \"behavior-change company\" to address serious health conditions and rising healthcare costs, contrasting their approach with competitors by focusing on education instead of just alerts. Fitbit is also in talks with the FDA for approval of its AFib detection software and highlights the profound impact of data from wearables on public health and cost savings.", "banner_image": null, "source": "Time Magazine", "category_within_source": "General", "source_domain": "Time Magazine", "topics": [{"topic": "life_sciences", "relevance_score": "0.930281"}, {"topic": "technology", "relevance_score": "0.804664"}], "overall_sentiment_score": 0.235455, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "1.000000", "ticker_sentiment_score": "0.301038", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.813038", "ticker_sentiment_score": "0.340788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.621275", "ticker_sentiment_score": "0.131037", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.560671", "ticker_sentiment_score": "0.124002", "ticker_sentiment_label": "Neutral"}]}, {"title": "DNA Tests For Psychiatric Drugs Are Controversial But Some Insurers Are Covering Them", "url": "https://www.npr.org/sections/health-shots/2019/10/17/766473930/dna-tests-for-psychiatric-drugs-are-controversial-but-some-insurers-are-covering", "time_published": "20191017T162500", "authors": ["Graison Dangor"], "summary": "Genetic tests aiming to match patients with psychiatric medications are gaining insurance coverage despite controversy over their efficacy. UnitedHealthcare began covering these tests, and other insurers are expected to follow, fueling a market where companies like Myriad Genetics are seeing significant sales. While some advocate for their use as an additional tool, many researchers and even the FDA express skepticism due to weak evidence and the potential for inappropriate treatment decisions.", "banner_image": null, "source": "NPR", "category_within_source": "General", "source_domain": "NPR", "topics": [{"topic": "life_sciences", "relevance_score": "0.947311"}, {"topic": "finance", "relevance_score": "0.729702"}], "overall_sentiment_score": 0.125951, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MYGN", "relevance_score": "0.957631", "ticker_sentiment_score": "0.240853", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.811159", "ticker_sentiment_score": "0.280444", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KR", "relevance_score": "0.607567", "ticker_sentiment_score": "0.102067", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.595508", "ticker_sentiment_score": "-0.095713", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson pays $117M to settle surgical mesh device lawsuit", "url": "https://www.foxbusiness.com/money/johnson-johnson-surgical-mesh-device-lawsuit-settlement", "time_published": "20191017T155500", "authors": ["Kristian Dyer"], "summary": "Johnson & Johnson has agreed to pay $117 million to settle a lawsuit brought by 41 state attorney generals concerning its transvaginal surgical mesh devices. The lawsuit alleged the company misrepresented risks and failed to include serious risks in marketing materials. This settlement follows a previous $9.9 million payment to settle a similar lawsuit in Washington state, though Johnson & Johnson admits no culpability in the current settlement.", "banner_image": null, "source": "Fox Business", "category_within_source": "General", "source_domain": "Fox Business", "topics": [{"topic": "life_sciences", "relevance_score": "0.911007"}, {"topic": "finance", "relevance_score": "0.718459"}], "overall_sentiment_score": -0.287, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.253604", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Drug Giants Close In on a $50 Billion Settlement of Opioid Cases (Published 2019)", "url": "https://www.nytimes.com/2019/10/16/health/opioids-settlement-distributors.html", "time_published": "20191016T235731", "authors": ["Jan Hoffman"], "summary": "The nation\u2019s three largest drug distributors and two manufacturers are close to a $50 billion settlement to resolve thousands of opioid cases. While states have largely agreed to the framework, cities and counties are seeking more details regarding the distribution of funds. All parties are under pressure to reach a deal before a federal trial in Cleveland begins, which is poised to determine responsibility for the opioid epidemic.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.913586"}, {"topic": "finance", "relevance_score": "0.705221"}], "overall_sentiment_score": -0.301254, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.306208", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MCK", "relevance_score": "0.983374", "ticker_sentiment_score": "-0.317174", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.805670", "ticker_sentiment_score": "-0.224937", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "What you need to know about Johnson & Johnson's 2019 third-quarter earnings", "url": "https://www.jnj.com/latest-news/johnson-johnsons-2019-third-quarter-earnings-report-what-you-need-to-know", "time_published": "20191015T004126", "authors": ["Johnson & Johnson"], "summary": "Johnson & Johnson shared its strong third-quarter 2019 performance, reporting significant revenue and earnings growth across its consumer, pharmaceutical, and medical devices businesses. Executive Vice President and CFO Joe Wolk highlighted strategic investments and the commitment of employees in driving robust results. The article provides an infographic with key stats and insights from Chairman and CEO Alex Gorsky.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "earnings", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.809553"}], "overall_sentiment_score": 0.409894, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.414803", "ticker_sentiment_label": "Bullish"}]}, {"title": "U.S. Stock ETFs Jump on Promising Start to Earnings Season", "url": "https://www.etftrends.com/innovative-etfs-content-hub/us-stock-etfs-jump-on-promising-start-to-earnings-season/", "time_published": "20191015T001154", "authors": ["Max Chen"], "summary": "U.S. stock ETFs surged due to a strong start to the third-quarter earnings season, driven by upbeat results from companies like UnitedHealth Group, Johnson & Johnson, and JPMorgan Chase. Despite this optimism, Wall Street analysts maintain a pessimistic outlook for overall S&P 500 earnings, forecasting a significant drop. Meanwhile, global markets remain cautious due to ongoing U.S.-China trade tensions.", "banner_image": null, "source": "ETF Trends", "category_within_source": "General", "source_domain": "ETF Trends", "topics": [{"topic": "earnings", "relevance_score": "0.924839"}, {"topic": "financial_markets", "relevance_score": "0.818945"}, {"topic": "economy_macro", "relevance_score": "0.720554"}, {"topic": "economy_monetary", "relevance_score": "0.621422"}, {"topic": "finance", "relevance_score": "0.607224"}], "overall_sentiment_score": 0.407762, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DIA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.386413", "ticker_sentiment_label": "Bullish"}, {"ticker": "UNH", "relevance_score": "0.649132", "ticker_sentiment_score": "0.432957", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.637642", "ticker_sentiment_score": "0.408350", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson under pressure as FDA approves new use for Xarelto", "url": "https://www.foxbusiness.com/markets/johnson-johnson-xarelto-fda-approval-lawsuits", "time_published": "20191014T213500", "authors": ["Thomas Barrabi"], "summary": "The FDA has approved a new use for Johnson & Johnson's prescription blood thinner Xarelto, allowing it to prevent blood clots in acutely ill patients during and after hospitalization. Despite this positive development for the drug, J&J's stock remained flat due to ongoing legal challenges, including a recent $8 billion punitive damages verdict related to its antipsychotic drug Risperdal and lawsuits concerning its role in the opioid crisis and talc-based powders. This approval comes as Xarelto's U.S. sales had previously declined, highlighting the company's struggle to balance new drug approvals with its significant legal liabilities.", "banner_image": null, "source": "Fox Business", "category_within_source": "General", "source_domain": "Fox Business", "topics": [{"topic": "life_sciences", "relevance_score": "0.921538"}, {"topic": "earnings", "relevance_score": "0.824676"}], "overall_sentiment_score": 0.012556, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.307742", "ticker_sentiment_score": "0.020584", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson\u2019s Legal Challenges Mount", "url": "https://www.wsj.com/articles/johnson-johnsons-legal-challenges-mount-11571055242?gaa_at=eafs&gaa_n=AWEtsqc5i3UM0gucaupr_cSpsV45y0LWScU_AM_LjQsp-0Z0moljpB0DFWfP&gaa_ts=6907fd74&gaa_sig=5HH880MpqVelM6C8gUyhmF_LZG5JzVyGsj_4EuwyUkLjjgHS-6rhCGvFHcaXBeI_owhii1S34FpYywsJ2ALVjg%3D%3D", "time_published": "20191014T004126", "authors": ["Peter Loftus"], "summary": "Johnson & Johnson is currently facing over 100,000 lawsuits concerning its product safety and marketing tactics. The health-care company has adopted an aggressive strategy of battling many of these cases in court, a strategy that has frequently resulted in losses for the company.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.928771"}, {"topic": "finance", "relevance_score": "0.715613"}], "overall_sentiment_score": -0.427948, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.418866", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson CEO silent on legal troubles at speech in Philly, days after $8 billion verdict", "url": "https://www.inquirer.com/business/johnson-and-johnson-philadelphia-verdict-chamber-breakfast-20191011.html", "time_published": "20191011T124600", "authors": ["Christian Hetrick"], "summary": "Johnson & Johnson CEO Alex Gorsky spoke at a Chamber of Commerce event in Philadelphia without addressing the company's recent legal setbacks, including an $8 billion verdict against it days prior. Gorsky focused on the future of healthcare and J&J's role in the Business Roundtable's shift from exclusive shareholder prioritization. The company faces numerous lawsuits and large verdicts related to its products and marketing practices.", "banner_image": null, "source": "Inquirer.com", "category_within_source": "General", "source_domain": "Inquirer.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.811999"}, {"topic": "finance", "relevance_score": "0.648967"}], "overall_sentiment_score": 0.003009, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.347149", "ticker_sentiment_score": "0.002623", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J comes out on top: California jury rules against claim woman developed cancer from baby powder", "url": "https://www.foxbusiness.com/markets/johnson-johnson-talc-powder-cancer-verdict", "time_published": "20191011T120800", "authors": ["Stephanie Pagones"], "summary": "A California jury ruled in favor of Johnson & Johnson, rejecting a woman's claim that the company's talc products caused her cancer. The jury found by a 10-2 vote that Johnson & Johnson did not withhold information about asbestos in its talc products, a key element of Carolyn Weirick's lawsuit. This legal victory marks the seventh jury ruling in favor of Johnson & Johnson in similar cases, with the company asserting that the woman's terminal cancer spontaneously occurred rather than being linked to talc powder.", "banner_image": null, "source": "Fox Business", "category_within_source": "General", "source_domain": "Fox Business", "topics": [{"topic": "life_sciences", "relevance_score": "0.923055"}, {"topic": "finance", "relevance_score": "0.704763"}], "overall_sentiment_score": 0.426171, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.421020", "ticker_sentiment_label": "Bullish"}]}, {"title": "J&J, besieged by lawsuits, could be a steal for investors: analyst", "url": "https://www.fiercepharma.com/pharma/johnson-johnson-s-shares-historically-cheap-possible-talc-opioid-deals-give-analysts-hopes", "time_published": "20191011T103800", "authors": ["By Kyle Blankenship"], "summary": "A Bernstein analyst suggests Johnson & Johnson's stock is \"historically cheap\" due to looming settlements for opioid and talcum powder lawsuits, and an $8 billion Risperdal verdict. The analyst believes J&J could resolve these cases for $10 billion to $12 billion, significantly below the \"worst-case scenario\" of $50 billion, making the company a potential \"steal\" for investors with a projected peak share price of $155. J&J scored a win in a retried California talcum powder suit, and is working towards settlements in its many other lawsuits.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.940093"}, {"topic": "financial_markets", "relevance_score": "0.716342"}], "overall_sentiment_score": 0.308296, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.347757", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Interventional Neurology Market: New Business Opportunities", "url": "https://www.openpr.com/news/1846397/interventional-neurology-market-new-business-opportunities", "time_published": "20191010T165900", "authors": [], "summary": "Coherent Market Insights has released a new market study on the 2018-2026 Interventional Neurology Market, detailing current trends, growth factors, and forecasts. The report highlights factors such as increasing prevalence of brain aneurysms and stroke, government programs, and technological advancements driving market demand, despite challenges like high costs. Key players identified include Medtronic, Penumbra, Stryker Corporation, Johnson & Johnson, and Terumo Corporation.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.315618, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PEN", "relevance_score": "0.830817", "ticker_sentiment_score": "0.316537", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.749700", "ticker_sentiment_score": "0.338461", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYK", "relevance_score": "0.646123", "ticker_sentiment_score": "0.319632", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.627531", "ticker_sentiment_score": "0.316170", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson has to pay $8 billion after male breast growth linked to antipsychotic drug, jury says", "url": "https://www.cnn.com/2019/10/09/uk/johnson-and-johnson-male-breast-growth-damages", "time_published": "20191009T175900", "authors": ["Rob Frehse"], "summary": "A jury ruled that Johnson & Johnson must pay $8 billion in punitive damages because the company did not adequately warn young men about the risk of breast growth associated with its antipsychotic drug, Risperdal. The plaintiff, Nicholas Murray, had previously won $680,000 and his lawyers characterized J&J's actions as \"deliberate and malicious.\" Johnson & Johnson plans to appeal the decision, calling the award \"grossly disproportionate.\"", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "life_sciences", "relevance_score": "0.929262"}, {"topic": "finance", "relevance_score": "0.722250"}], "overall_sentiment_score": -0.834342, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.836163", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson ordered to pay man $8bn over breast growth", "url": "https://www.bbc.com/news/business-49982237", "time_published": "20191009T004127", "authors": [], "summary": "A Philadelphia jury has ordered Johnson & Johnson to pay $8 billion in punitive damages to Nicholas Murray, who claimed he was not warned that the anti-psychotic drug Risperdal could lead to breast growth. The company plans to appeal the ruling, calling it \"grossly disproportionate.\" This case is one of many Johnson & Johnson faces regarding Risperdal's side effects, as well as other legal challenges concerning vaginal mesh implants, baby powder, and its role in the opioid crisis.", "banner_image": null, "source": "BBC", "category_within_source": "General", "source_domain": "BBC", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.724316"}], "overall_sentiment_score": -0.607171, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.957854", "ticker_sentiment_score": "-0.648385", "ticker_sentiment_label": "Bearish"}]}, {"title": "Jury says Johnson & Johnson must pay $8 billion over antipsychotic drug", "url": "https://www.marketwatch.com/story/jury-says-johnson-johnson-must-pay-8-billion-over-antipsychotic-drug-2019-10-08?gaa_at=eafs&gaa_n=AWEtsqeo2-VzeOmZUpqT01QUzgCehip8OwfzVnZL0USymVW0jldlWiXFhIXk&gaa_ts=6907fd8d&gaa_sig=fRucDwvtCctEK50SwhPPZSf3sH9ACkXQkVaquyWzytvg0h91tBVL3cg4ByljgIpV4WSudUSdPTjbmXO0sli7NA%3D%3D", "time_published": "20191008T195200", "authors": [], "summary": "A Philadelphia jury ordered Johnson & Johnson to pay $8 billion in damages to a Maryland man who claimed that using Risperdal as a child caused enlarged breasts and that the company failed to warn of this risk. This award is the largest to date among over 13,000 similar lawsuits against J&J concerning Risperdal. Plaintiffs generally allege that J&J was aware of the risk of gynecomastia but downplayed it to healthcare providers.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "life_sciences", "relevance_score": "0.923470"}, {"topic": "financial_markets", "relevance_score": "0.646554"}], "overall_sentiment_score": -0.706572, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.708832", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson Releases Inaugural You Belong: Diversity & Inclusion Impact Review", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-releases-inaugural-you-belong-diversity--inclusion-impact-review-300932796.html", "time_published": "20191007T080000", "authors": [], "summary": "Johnson & Johnson has released its inaugural \"You Belong: Diversity & Inclusion Impact Review,\" highlighting how its strategic D&I philosophy has driven innovation and business outcomes for over 130 years. The review showcases key initiatives such as diversifying clinical trials, supporting minority-owned businesses, cultivating inclusive communities through ERGs, and addressing unconscious bias. The company also launched a Diversity in Innovation QuickFire Challenge to support multicultural innovators in life science research.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.901841"}, {"topic": "finance", "relevance_score": "0.731179"}], "overall_sentiment_score": 0.406795, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.412385", "ticker_sentiment_label": "Bullish"}]}, {"title": "Walgreens, CVS suspend sales of heartburn drug due to cancer-linked contaminant", "url": "https://www.nbcnews.com/health/health-news/cvs-suspends-sales-zantac-brand-due-contaminant-fears-n1060256", "time_published": "20190930T100500", "authors": ["Sara G. Miller"], "summary": "Walgreens and CVS have suspended sales of the popular heartburn medicine Zantac and its generic versions due to contaminant fears after the FDA found traces of a known carcinogen, N-nitrosodimethylamine (NDMA), in some products. This move is a precaution while the FDA continues its review, as low levels of NDMA have been linked to an increased risk of certain cancers, though the FDA notes the levels found barely exceed amounts in common foods. Other companies like Novartis AG's Sandoz unit and Apotex Corp have also taken steps to halt distribution or recall ranitidine products.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.944105"}, {"topic": "retail_wholesale", "relevance_score": "0.737394"}], "overall_sentiment_score": -0.226777, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.324007", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WBA", "relevance_score": "0.938202", "ticker_sentiment_score": "-0.309348", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WMT", "relevance_score": "0.635032", "ticker_sentiment_score": "-0.104215", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.602448", "ticker_sentiment_score": "-0.209890", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Jabil Inc. (JBL) Q4 2019 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2019/09/24/jabil-inc-jbl-q4-2019-earnings-call-transcript.aspx", "time_published": "20190924T132300", "authors": ["Motley Fool Transcribers"], "summary": "Jabil Inc. reported strong Q4 and fiscal year 2019 earnings, with net revenue increasing 14% year-over-year. The company outlined its strategy for fiscal years 2020 and 2021, focusing on margin expansion, cash flow generation, and footprint optimization, while also providing guidance for future EPS and free cash flow. Executives discussed segment performance, capital allocation, and market trends impacting their DMS and EMS businesses.", "banner_image": "https://g.foolcdn.com/editorial/images/539129/jbl-1-getty-e1442436737380.jpg", "source": "The Motley Fool", "category_within_source": "General", "source_domain": "The Motley Fool", "topics": [{"topic": "earnings", "relevance_score": "0.916378"}, {"topic": "manufacturing", "relevance_score": "0.733280"}, {"topic": "technology", "relevance_score": "0.624472"}], "overall_sentiment_score": 0.475706, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JBL", "relevance_score": "1.000000", "ticker_sentiment_score": "0.569817", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.623103", "ticker_sentiment_score": "0.311779", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "GSK's over-the-counter nicotine oral spray gets FDA panel backing", "url": "https://www.reuters.com/article/business/gsks-over-the-counter-nicotine-oral-spray-gets-fda-panel-backing-idUSKBN1W32XP/", "time_published": "20190918T213700", "authors": ["Saumya Joseph and Manas Mishra"], "summary": "An independent expert panel to the U.S. Food and Drug Administration (FDA) has recommended approval for GlaxoSmithKline Plc's over-the-counter nicotine oral spray, designed to help smokers quit. The panel voted 9-6 in favor, despite concerns raised by FDA staffers and some panel members about potential misuse by non-smokers and teenagers, similar to issues seen with e-cigarettes. The spray, which delivers 1mg of nicotine per dose and aims for gradual reduction over 12 weeks, is already sold by development partner Johnson & Johnson in 45 other countries.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.921625"}], "overall_sentiment_score": 0.106518, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GSK", "relevance_score": "0.312315", "ticker_sentiment_score": "0.022845", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.848477", "ticker_sentiment_score": "0.239126", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WBA", "relevance_score": "0.728718", "ticker_sentiment_score": "0.133714", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.609689", "ticker_sentiment_score": "0.104732", "ticker_sentiment_label": "Neutral"}]}, {"title": "Prozac maker paid millions to secure favorable verdict in mass shooting lawsuit, victims say", "url": "https://www.usatoday.com/story/news/nation/2019/09/12/prozac-makers-secret-payment-mass-shooting-lawsuit-revealed/2302888001/", "time_published": "20190912T004633", "authors": ["Andrew Wolfson"], "summary": "Eli Lilly, the maker of Prozac, secretly paid $20 million to the victims of a 1989 mass shooting to ensure a favorable verdict in a lawsuit that blamed the antidepressant for inciting the rampage. The payment, kept secret for over two decades, influenced the jury's decision to absolve Lilly of liability for the shooting by Joseph Wesbecker, who had been taking Prozac. A Louisville judge fought for years to expose the deal, which also involved plaintiffs agreeing to withhold damaging evidence about another Lilly drug, Oraflex.", "banner_image": null, "source": "USA Today", "category_within_source": "General", "source_domain": "USA Today", "topics": [{"topic": "life_sciences", "relevance_score": "0.937783"}, {"topic": "finance", "relevance_score": "0.704709"}], "overall_sentiment_score": -0.248603, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.619894", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.611422", "ticker_sentiment_score": "-0.141827", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.615109", "ticker_sentiment_score": "0.117919", "ticker_sentiment_label": "Neutral"}]}, {"title": "Purdue Pharma agrees to pay billions of dollars for the opioid epidemic\u2014and it\u2019s not done yet", "url": "https://www.popsci.com/johnson-johnson-opioid-lawsuit-purdue-pharma/", "time_published": "20190911T210000", "authors": ["Nicole Wetsman"], "summary": "Purdue Pharma has reached a tentative settlement of up to $12 billion with thousands of state, tribal, and local governments regarding its role in the opioid epidemic. This agreement, which will likely lead to the company's bankruptcy and resurrection, follows a recent $572 million judgment against Johnson & Johnson in Oklahoma for similar deceptive marketing practices. While Purdue Pharma aims to settle, some state attorneys plan to pursue further legal action against the Sackler family, the company's owners.", "banner_image": null, "source": "Popular Science", "category_within_source": "General", "source_domain": "Popular Science", "topics": [{"topic": "life_sciences", "relevance_score": "0.911237"}, {"topic": "finance", "relevance_score": "0.736444"}, {"topic": "economy_fiscal", "relevance_score": "0.610880"}], "overall_sentiment_score": -0.340538, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.967438", "ticker_sentiment_score": "-0.331958", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Two Children\u2019s National spin-outs join Johnson & Johnson\u2013JLABS", "url": "https://innovationdistrict.childrensnational.org/two-childrens-national-spin-outs-join-johnson-and-johnson-jlabs/", "time_published": "20190911T105128", "authors": [], "summary": "Two Children's National Health System spin-out companies, AlgometRx and Adipomics, have been selected to join Johnson & Johnson Innovation \u2013 JLABS. AlgometRx focuses on objective pain measurement to address the opioid epidemic, while Adipomics aims to detect obesity-related disease risk non-invasively. This announcement also highlights a broader collaboration between Children's National and JLABS to establish JLABS @ Washington, DC, a new research facility.", "banner_image": "https://innovationdistrict.childrensnational.org/wp-content/uploads/2019/09/Julia-Finkel.png", "source": "Children's National Hospital", "category_within_source": "General", "source_domain": "Children's National Hospital", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "technology", "relevance_score": "0.845015"}], "overall_sentiment_score": 0.48489, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.495333", "ticker_sentiment_label": "Bullish"}]}, {"title": "Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor", "url": "https://www.prnewswire.com/news-releases/thermo-fisher-scientific-signs-agreement-with-lilly-oncology-for-companion-diagnostic-to-be-used-with-ret-inhibitor-300913716.html", "time_published": "20190909T030000", "authors": [], "summary": "Thermo Fisher Scientific announced an agreement with Eli Lilly and Company to develop a companion diagnostic using the Oncomine Dx Target Test. This test will identify non-small cell lung cancer and thyroid cancer patients with RET alterations who may benefit from Lilly's investigational therapy, LOXO-292. Thermo Fisher will retain commercialization rights globally and will submit a supplemental premarket approval application to the FDA to broaden the test's clinical claims.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.904057"}], "overall_sentiment_score": 0.294957, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TMO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.404436", "ticker_sentiment_label": "Bullish"}, {"ticker": "LLY", "relevance_score": "0.937167", "ticker_sentiment_score": "0.341632", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.624993", "ticker_sentiment_score": "0.253777", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.585282", "ticker_sentiment_score": "0.208960", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stryker acquires Mobius Imaging, Cardan Robotics for $500M", "url": "https://www.therobotreport.com/stryker-mobius-imaging-cardan-robotics-500m/", "time_published": "20190906T012631", "authors": ["Steve Crowe"], "summary": "Stryker, a leading medical technology company, has acquired Mobius Imaging and its subsidiary Cardan Robotics for $500 million. This acquisition aims to enhance Stryker's offerings in advanced imaging and robotics, particularly for spine surgeries, and includes development and commercialization milestone payments. Mobius Imaging develops point-of-care imaging technology, while Cardan Robotics focuses on robotics and navigation for surgical procedures.", "banner_image": null, "source": "The Robot Report", "category_within_source": "General", "source_domain": "The Robot Report", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.905417"}, {"topic": "technology", "relevance_score": "0.845751"}], "overall_sentiment_score": 0.356741, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SYK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.415037", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.632242", "ticker_sentiment_score": "0.347167", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J-Jabil Deal Truly Is Transformative for the Medtech Supply Chain", "url": "https://www.mpo-mag.com/jj-jabil-deal-truly-is-transformative-for-the-medtech-supply-chain/", "time_published": "20190906T004117", "authors": ["Tony Freeman"], "summary": "Johnson & Johnson's decision to transfer a large portion of its medical device manufacturing to Jabil Inc. marks a significant shift in the medtech supply chain, moving manufacturing capabilities from an OEM to a global contract manufacturer rooted in electronics. This deal, involving 14 J&J plants and 6,000 employees, is set to save J&J hundreds of millions annually and allows them to focus on core strengths like design and marketing, while simultaneously providing Jabil with higher profitability margins compared to its previous electronics focus. The transaction suggests a broader trend where large-scale, diversified contract manufacturers may increasingly dominate the medical device supply chain, challenging traditional specialized suppliers.", "banner_image": null, "source": "Medical Product Outsourcing", "category_within_source": "General", "source_domain": "Medical Product Outsourcing", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.937089"}, {"topic": "life_sciences", "relevance_score": "0.833367"}, {"topic": "manufacturing", "relevance_score": "0.731364"}], "overall_sentiment_score": 0.291545, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JBL", "relevance_score": "1.000000", "ticker_sentiment_score": "0.346849", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.903963", "ticker_sentiment_score": "0.286594", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stryker spends up to $500M to boost spine unit with imaging, robotics tech", "url": "https://www.medtechdive.com/news/stryker-to-spend-up-to-500m-to-boost-spine-division-with-imaging-robotics/562201/", "time_published": "20190904T012630", "authors": ["Maria Rachal"], "summary": "Stryker is acquiring Mobius Imaging and Cardan Robotics for an upfront cash payment of $370 million, with an additional $130 million possible based on performance. This acquisition will bring Mobius' Airo CT scanner and Cardan Robotics' surgical robotics and navigation systems to Stryker, significantly expanding its spine division and intra-operative imaging capabilities. The move follows a trend of medical technology companies deepening their robotic surgery capabilities through strategic acquisitions.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.932242"}, {"topic": "technology", "relevance_score": "0.827608"}, {"topic": "earnings", "relevance_score": "0.722435"}], "overall_sentiment_score": 0.104917, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SYK", "relevance_score": "0.988704", "ticker_sentiment_score": "0.333978", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.645000", "ticker_sentiment_score": "0.120393", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.620113", "ticker_sentiment_score": "0.139111", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.637971", "ticker_sentiment_score": "-0.117436", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.634915", "ticker_sentiment_score": "-0.100158", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pat Miles Beats NuVasive Lawsuit", "url": "https://ryortho.com/2019/09/pat-miles-beats-nuvasive-lawsuit/", "time_published": "20190903T234723", "authors": ["Walter Eisner"], "summary": "A Delaware judge ruled in favor of Patrick Miles, Chairman and CEO of Alphatec Holdings, stating he did not violate his non-compete agreement with his former company, NuVasive, Inc. The judge found that California law, which has a strong public policy against non-competes, applied to Miles' contract despite NuVasive's allegations of Miles stealing employees and business strategies. This ruling validates Miles' stance when he left NuVasive and clears Alphatec of the lawsuit filed against it.", "banner_image": null, "source": "Orthopedics This Week", "category_within_source": "General", "source_domain": "Orthopedics This Week", "topics": [{"topic": "life_sciences", "relevance_score": "0.948740"}, {"topic": "finance", "relevance_score": "0.720596"}], "overall_sentiment_score": 0.279103, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ATEC", "relevance_score": "0.958117", "ticker_sentiment_score": "0.709106", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.611263", "ticker_sentiment_score": "0.109372", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.597417", "ticker_sentiment_score": "0.124463", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.582421", "ticker_sentiment_score": "0.146767", "ticker_sentiment_label": "Neutral"}]}, {"title": "Oral Care: Comparative Market Share Analysis, Know Who\u2019s", "url": "https://www.openpr.com/news/1827444/oral-care-comparative-market-share-analysis-know-who-s", "time_published": "20190828T230000", "authors": ["HTF Market Intelligence Consulting Pvt. Ltd."], "summary": "This press release announces a new research study by HTF MI providing a comprehensive analysis of the Global and China Oral Care Market. The study covers historical progress, ongoing market scenarios, future prospects, and detailed data on leading companies, products, strategies, and market shares. It also examines market dynamics, key growth drivers, challenges, and regional segmentation with a forecast up to 2025.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.921823"}, {"topic": "financial_markets", "relevance_score": "0.837837"}], "overall_sentiment_score": 0.261915, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHD", "relevance_score": "0.912874", "ticker_sentiment_score": "0.268821", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.743225", "ticker_sentiment_score": "0.282552", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CL", "relevance_score": "0.732255", "ticker_sentiment_score": "0.287544", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.701041", "ticker_sentiment_score": "0.275135", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GM", "relevance_score": "0.626424", "ticker_sentiment_score": "0.131609", "ticker_sentiment_label": "Neutral"}]}, {"title": "Analysts view Johnson & Johnson\u2019s $572 million fine as a win", "url": "https://www.marketwatch.com/story/analysts-view-johnson-johnsons-572-million-fine-as-a-win-2019-08-27?gaa_at=eafs&gaa_n=AWEtsqeLnZu6HHy1il4In2YtjNJs6owW9XTc1g73cqcezpmw5jPeJqafOz_F&gaa_ts=6907fd79&gaa_sig=WpaYSPuAJA5-pJ2pjj3shpoICteeKrpmJC2BxRbH8zDNs9ol9zYq_Xtlc9xkvy6c5mbYXB_lURkbh8l-FzRvZw%3D%3D", "time_published": "20190828T092600", "authors": [], "summary": "Johnson & Johnson was ordered to pay $572 million for its role in the Oklahoma opioid crisis, a figure that Wall Street analysts and investors view positively. This is because the fine was significantly lower than the anticipated range of $500 million to $5 billion, and far less than the state's proposed abatement plan of up to $17.5 billion. As a result, J&J's shares rose by 3% following the announcement.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "financial_markets", "relevance_score": "0.907000"}, {"topic": "life_sciences", "relevance_score": "0.846161"}, {"topic": "earnings", "relevance_score": "0.739233"}], "overall_sentiment_score": 0.374053, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.364041", "ticker_sentiment_label": "Bullish"}]}, {"title": "S.C. Johnson, Maker of Windex, Wants You to Know It\u2019s Not in Opioid Business", "url": "https://nymag.com/intelligencer/2019/08/s-c-johnson-wants-you-to-know-its-not-johnson-and-johnson.html", "time_published": "20190828T004127", "authors": ["Josh Barro"], "summary": "S.C. Johnson is actively trying to distance itself from Johnson & Johnson, particularly after Johnson & Johnson was ordered to pay a $572 million judgment for its role in the opioid crisis. S.C. Johnson's CEO even sent a letter threatening legal action against Oklahoma's attorney general for mistakenly associating their \"A Family Company\" tagline with Johnson & Johnson, despite legal experts questioning the viability of such a lawsuit. The campaign aims to clarify that S.C. Johnson, a household products manufacturer, is not involved in pharmaceuticals or the opioid business.", "banner_image": null, "source": "New York Magazine", "category_within_source": "General", "source_domain": "New York Magazine", "topics": [{"topic": "life_sciences", "relevance_score": "0.934659"}, {"topic": "finance", "relevance_score": "0.720372"}, {"topic": "manufacturing", "relevance_score": "0.619862"}], "overall_sentiment_score": -0.390311, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.403929", "ticker_sentiment_label": "Bearish"}]}, {"title": "Opinion | Purdue and Johnson & Johnson cases expose Big Pharma's addiction lies", "url": "https://www.nbcnews.com/think/opinion/purdue-pharma-johnson-johnson-opioid-cases-expose-big-pharma-s-ncna1046906", "time_published": "20190827T160700", "authors": ["Beth Macy"], "summary": "This opinion piece discusses the recent legal rulings against Johnson & Johnson and Purdue Pharma, highlighting how these cases expose the pharmaceutical industry's deceptive practices regarding the addictive nature of opioids. The author emphasizes the significant financial penalties imposed and how they are intended to fund addiction treatment, while also addressing the pervasive stigma associated with opioid use disorder and the need for education and empathy. The article argues that profit-seeking companies deliberately fueled the opioid crisis, necessitating a shift from ignorance to evidence-based solutions.", "banner_image": "NULL", "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.927500"}, {"topic": "economy_fiscal", "relevance_score": "0.713580"}], "overall_sentiment_score": 0.004566, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.307993", "ticker_sentiment_score": "0.012203", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J liable for $572 million in Oklahoma opioid epidemic trial; shares rise", "url": "https://www.reuters.com/article/business/jj-liable-for-572-million-in-oklahoma-opioid-epidemic-trial-shares-rise-idUSKCN1VG0V2/", "time_published": "20190827T093100", "authors": ["Heide Brandes and Nate Raymond"], "summary": "An Oklahoma judge ordered Johnson & Johnson to pay $572.1 million for its role in fueling the opioid epidemic through deceptive marketing, a sum significantly lower than anticipated by investors, causing J&J's shares to rise. The company plans to appeal the decision, while other pharmaceutical companies involved in similar lawsuits also saw their stock increase. The ruling is a bellwether for thousands of other opioid-related lawsuits nationwide, with the award covering only one year of abatement efforts.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fbinary.reuters.com%2F__initial_collection__%2F53%2F22%2F5322bd58-29cb-4a6c-b72e-c762512f451f.jpg?auth=818d05e2d6349547d21b14ec0a996f8a44b8ee3468593a595304af79e2a6d705&width=960&quality=80", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.916123"}, {"topic": "earnings", "relevance_score": "0.734773"}], "overall_sentiment_score": 0.272136, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.294639", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson opioid ruling explained \u2013 the key points", "url": "https://www.theguardian.com/us-news/ng-interactive/2019/aug/26/johnson-johnson-opioid-ruling-explained-the-key-points", "time_published": "20190827T020800", "authors": ["Chris McGreal"], "summary": "An Oklahoma judge has ordered Johnson & Johnson to pay $572m for its role in creating the state's opioid epidemic through \"false and dangerous\" sales campaigns. The ruling highlights J&J's marketing strategy that promoted opioids as safe and effective while downplaying addiction risks, and their influence on medical practices. This landmark decision is expected to have significant consequences for other opioid manufacturers and distributors facing similar lawsuits across the country.", "banner_image": null, "source": "The Guardian", "category_within_source": "General", "source_domain": "The Guardian", "topics": [{"topic": "life_sciences", "relevance_score": "0.927458"}], "overall_sentiment_score": -0.614329, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.608768", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson hit with $572 million opioid ruling \u2014 what happens now?", "url": "https://www.marketplace.org/story/2019/08/27/the-ripple-effects-of-johnson-johnson-being-ordered-to-pay-572-million", "time_published": "20190827T004128", "authors": ["David Brancaccio and Redmond Carolipio"], "summary": "Johnson & Johnson has been ordered to pay $572 million in connection with the opioid crisis in Oklahoma, a ruling the company plans to appeal. This verdict is seen as the first of many potential legal battles, as other states may pursue similar public nuisance lawsuits against pharmaceutical companies. The case highlights that FDA approval does not protect against claims of misleading marketing, suggesting pharmaceutical companies will need to be more careful with their advertising practices.", "banner_image": null, "source": "www.marketplace.org", "category_within_source": "General", "source_domain": "www.marketplace.org", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": -0.239841, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.245798", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Opioid crisis: Johnson & Johnson hit by landmark ruling", "url": "https://www.bbc.com/news/business-49452373", "time_published": "20190827T004127", "authors": ["Russell Hotten"], "summary": "Johnson & Johnson has been ordered to pay $572 million for its role in fueling Oklahoma's opioid crisis, a landmark ruling that the company plans to appeal. This case is the first of thousands of lawsuits against opioid makers to go to trial, with the state arguing J&J's marketing campaign minimized risks and promoted addictive painkillers, contributing to a \"public nuisance.\" Despite the large sum, the company's share price rose as investors had anticipated a much higher fine.", "banner_image": null, "source": "BBC", "category_within_source": "General", "source_domain": "BBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.943976"}, {"topic": "finance", "relevance_score": "0.744077"}, {"topic": "economy_macro", "relevance_score": "0.634976"}], "overall_sentiment_score": -0.416697, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.395105", "ticker_sentiment_label": "Bearish"}]}, {"title": "Oklahoma judge orders Johnson & Johnson to pay $572M in opioid suit", "url": "https://abcnews.go.com/US/oklahoma-judge-set-reach-decision-latest-major-opioid/story?id=65193231", "time_published": "20190826T172100", "authors": ["Meghan Keneally"], "summary": "An Oklahoma judge ordered Johnson & Johnson to pay $572 million for its role in the state's opioid crisis, a landmark decision that the company plans to appeal. The judgment is significantly less than the $17 billion initially sought by the state, but attorneys for Oklahoma expressed pride in the outcome. This follows a previous $270 million settlement from Purdue Pharma related to the opioid crisis.", "banner_image": null, "source": "ABC News - Breaking News, Latest News and Videos", "category_within_source": "General", "source_domain": "ABC News - Breaking News, Latest News and Videos", "topics": [{"topic": "life_sciences", "relevance_score": "0.906204"}, {"topic": "finance", "relevance_score": "0.701313"}], "overall_sentiment_score": -0.401164, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.405700", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson Ordered To Pay Oklahoma $572 Million In Opioid Trial", "url": "https://www.npr.org/sections/health-shots/2019/08/26/754481268/judge-in-opioid-trial-rules-johnson-johnson-must-pay-oklahoma-572-million", "time_published": "20190826T161900", "authors": ["Jackie Forti\u00e9r", "Brian Mann"], "summary": "An Oklahoma judge has ruled that Johnson & Johnson must pay $572 million to the state for its role in fueling the opioid crisis through deceptive marketing. While this amount is significantly less than the $17.5 billion the state sought, it marks the first time a pharmaceutical company has been held responsible in this manner. Johnson & Johnson plans to appeal the decision, arguing it is a misapplication of public nuisance law.", "banner_image": null, "source": "NPR", "category_within_source": "General", "source_domain": "NPR", "topics": [{"topic": "finance", "relevance_score": "0.721851"}, {"topic": "life_sciences", "relevance_score": "0.945833"}], "overall_sentiment_score": -0.740556, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.748897", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson must pay over $572 million for its role in Oklahoma opioid crisis, judge rules", "url": "https://www.nbcnews.com/news/us-news/johnson-johnson-must-pay-over-572-million-its-role-oklahoma-n1046476", "time_published": "20190826T160800", "authors": ["Doha Madani"], "summary": "An Oklahoma judge ordered Johnson & Johnson to pay over $572 million for its role in fueling the state's opioid crisis through deceptive marketing. The judge found that J&J's marketing of opioids created a public nuisance, leading to thousands of deaths. Johnson & Johnson plans to appeal the decision, arguing it is a misapplication of public nuisance law.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.922875"}, {"topic": "finance", "relevance_score": "0.734970"}, {"topic": "economy_fiscal", "relevance_score": "0.636601"}], "overall_sentiment_score": -0.409215, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.420689", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson ordered to pay $572 million for its role in Oklahoma\u2019s opioid crisis", "url": "https://www.washingtonpost.com/health/johnson-and-johnson-is-responsible-for-fueling-oklahomas-opioid-crisis-judge-rules-in-landmark-case/2019/08/26/ed7bc6dc-c7fe-11e9-a4f3-c081a126de70_story.html", "time_published": "20190826T004128", "authors": ["Lenny Bernstein"], "summary": "An Oklahoma judge has ordered Johnson & Johnson to pay $572 million to address the state's opioid crisis. The judge found the company liable for deceptively marketing painkillers, contributing to the devastation caused by the epidemic. The funds are intended to remedy the crisis and support treatment programs in Oklahoma.", "banner_image": null, "source": "The Washington Post", "category_within_source": "General", "source_domain": "The Washington Post", "topics": [{"topic": "life_sciences", "relevance_score": "0.920215"}, {"topic": "finance", "relevance_score": "0.729972"}], "overall_sentiment_score": -0.603112, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.625715", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson Ordered to Pay $572 Million in Landmark Opioid Trial", "url": "https://www.nytimes.com/2019/08/26/health/oklahoma-opioids-johnson-and-johnson.html", "time_published": "20190826T004125", "authors": ["Jan Hoffman"], "summary": "A judge in Oklahoma ordered Johnson & Johnson to pay $572 million for its role in the opioid crisis, ruling that the company intentionally downplayed risks and oversold benefits of its opioid products. This landmark decision marks the first trial against a drug manufacturer for the opioid epidemic and sets a precedent for over 2,000 similar lawsuits across the country, though the amount awarded was significantly less than sought by the state. The ruling found Johnson & Johnson breached Oklahoma's \"public nuisance\" law through \"false, misleading, and dangerous marketing campaigns.\"", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.905566"}, {"topic": "finance", "relevance_score": "0.743424"}], "overall_sentiment_score": -0.419601, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.416217", "ticker_sentiment_label": "Bearish"}]}, {"title": "Intuitive Surgical wins two gold International Design Excellence Awards", "url": "https://www.therobotreport.com/intuitive-surgical-wins-two-gold-international-design-excellence-awards/", "time_published": "20190825T003659", "authors": ["Chris Newmarker"], "summary": "Intuitive Surgical Inc. won two gold International Design Excellence Awards (IDEA) for its da Vinci SP surgical robotics system and Ion endoluminal system. This recognition highlights the growing importance and innovation within the robot-assisted surgery market, with Intuitive Surgical maintaining its dominance amidst increasing competition. The article also mentions the FDA approvals for both systems and other related news in the medical robotics field.", "banner_image": null, "source": "The Robot Report", "category_within_source": "General", "source_domain": "The Robot Report", "topics": [{"topic": "life_sciences", "relevance_score": "0.922763"}, {"topic": "manufacturing", "relevance_score": "0.643837"}, {"topic": "technology", "relevance_score": "0.814833"}], "overall_sentiment_score": 0.3216, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.857478", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.638875", "ticker_sentiment_score": "0.106449", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.584142", "ticker_sentiment_score": "0.138259", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.585888", "ticker_sentiment_score": "0.130030", "ticker_sentiment_label": "Neutral"}]}, {"title": "Boston Scientific completes $4.2bn acquisition of BTG", "url": "https://www.medicaldevice-network.com/features/boston-scientific-btg-acqusition/", "time_published": "20190820T235700", "authors": [], "summary": "Boston Scientific has completed its $4.2 billion acquisition of British minimally invasive device manufacturer BTG, marking its second-largest acquisition to date. This strategic move aims to expand Boston Scientific's portfolio in minimally invasive surgical devices and interventional oncology therapeutics, despite regulatory scrutiny that led to the divestiture of its global embolic microspheres line-up. The acquisition is expected to add to Boston Scientific's adjusted earnings per share in 2020 and reinforces its leadership in advanced medical technologies.", "banner_image": null, "source": "Medical Device Network", "category_within_source": "General", "source_domain": "Medical Device Network", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.928334"}, {"topic": "earnings", "relevance_score": "0.744416"}, {"topic": "finance", "relevance_score": "0.624833"}], "overall_sentiment_score": 0.29065, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.432331", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.737915", "ticker_sentiment_score": "0.143742", "ticker_sentiment_label": "Neutral"}]}, {"title": "Boston Scientific closes acquisition of BTG", "url": "https://www.medtechdive.com/news/boston-scientific-closes-acquisition-of-btg/561173/", "time_published": "20190819T235659", "authors": ["Maria Rachal"], "summary": "Boston Scientific has completed its $4.2 billion acquisition of U.K. interventional medicine company BTG, aiming to become a leader in interventional oncology tools. The deal necessitates Boston Scientific selling its drug-loadable microsphere and bland embolic bead products to Varian Medical Systems to address antitrust concerns and divesting BTG's Zytiga royalty stream. This acquisition is expected to be immaterial to adjusted earnings per share in 2019 but four to five cents accretive on an adjusted basis in 2020.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.914027"}, {"topic": "earnings", "relevance_score": "0.807227"}], "overall_sentiment_score": 0.287394, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.409558", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.632647", "ticker_sentiment_score": "0.127000", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market cap of Israel-founded Novocure exceeds $9b", "url": "https://en.globes.co.il/en/article-market-cap-of-israel-founded-novocure-exceeds-9b-1001297630", "time_published": "20190818T173900", "authors": ["Gali Weinreb"], "summary": "Novocure's market cap surpassed $9 billion after its share price rose significantly, driven by strong financial results and promising trials for its electrical stimulation cancer treatment. The company, founded in Israel, has seen its technology extend the lives of cancer patients and is expanding its product applications and global reach. Novocure's success is a testament to the long-term vision of its inventor and the early investors.", "banner_image": null, "source": "Globes - Israel Business News", "category_within_source": "General", "source_domain": "Globes - Israel Business News", "topics": [{"topic": "earnings", "relevance_score": "0.922593"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.845429"}, {"topic": "ipo", "relevance_score": "0.715165"}], "overall_sentiment_score": 0.401137, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "NVCR", "relevance_score": "1.000000", "ticker_sentiment_score": "0.880250", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.573638", "ticker_sentiment_score": "0.267135", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.560709", "ticker_sentiment_score": "0.271928", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.558436", "ticker_sentiment_score": "0.284968", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDX", "relevance_score": "0.567403", "ticker_sentiment_score": "0.270784", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Busy Bee Forms Joint Venture With Real Estate Development Company", "url": "https://csnews.com/busy-bee-forms-joint-venture-real-estate-development-company", "time_published": "20190814T004129", "authors": [], "summary": "Busy Bee and The St. Joe Co. have formed a joint venture to build, own, and manage a new Busy Bee branded convenience store and gas station in Panama City Beach, Fla. This 15,500-square-foot store, expected to open in early 2020, will be the largest c-store in the region and the first of several planned for northwest Florida by the joint venture. The partnership aims to combine Busy Bee's operational success and brand loyalty with St. Joe's strategy for diversifying recurring operating income.", "banner_image": null, "source": "Convenience Store News", "category_within_source": "General", "source_domain": "Convenience Store News", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.837728"}, {"topic": "real_estate", "relevance_score": "0.743445"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.612918"}], "overall_sentiment_score": -0.122642, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JOE", "relevance_score": "0.314511", "ticker_sentiment_score": "0.018888", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.739532", "ticker_sentiment_score": "-0.201327", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "SurveyMonkey to Acquire Customer Experience Management Company GetFeedback", "url": "https://www.globenewswire.com/news-release/2019/08/05/1897184/0/en/SurveyMonkey-to-Acquire-Customer-Experience-Management-Company-GetFeedback.html", "time_published": "20190805T172600", "authors": [], "summary": "SurveyMonkey announced its agreement to acquire GetFeedback, a customer experience management company and a top-rated feedback solution for Salesforce, for approximately $68 million in cash and equity. This acquisition aims to enhance SurveyMonkey's enterprise offerings and integrations with customer systems of record, accelerating businesses' ability to act on customer insights. The transaction, expected to close in Q3 2019, is anticipated to be accretive to SurveyMonkey's revenue growth for the full year 2019.", "banner_image": null, "source": "GlobeNewswire", "category_within_source": "General", "source_domain": "GlobeNewswire", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.921319"}, {"topic": "technology", "relevance_score": "0.829868"}], "overall_sentiment_score": 0.26456, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CRM", "relevance_score": "0.927852", "ticker_sentiment_score": "0.330916", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CSCO", "relevance_score": "0.616130", "ticker_sentiment_score": "0.226507", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MMM", "relevance_score": "0.604965", "ticker_sentiment_score": "0.246816", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.644663", "ticker_sentiment_score": "0.217000", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WBA", "relevance_score": "0.618610", "ticker_sentiment_score": "0.232749", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson scores latest talc trial win as case count reaches 15,500", "url": "https://www.fiercepharma.com/pharma/johnson-johnson-scores-latest-talc-win-as-case-count-reaches-15-500", "time_published": "20190805T105600", "authors": ["Eric Sagonowsky"], "summary": "Johnson & Johnson recently secured another talc trial win in Kentucky, marking its sixth victory in recent months, with previous losses overturned on appeal. Despite these wins, J&J faces approximately 15,500 talc-related cases and has suffered significant financial losses in other judgments, which it plans to appeal. The company is actively trying to dismiss thousands of remaining cases based on a Daubert hearing challenging the admissibility of plaintiffs' expert evidence.", "banner_image": "NULL", "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.903855"}], "overall_sentiment_score": 0.116346, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.128336", "ticker_sentiment_label": "Neutral"}, {"ticker": "CL", "relevance_score": "0.628988", "ticker_sentiment_score": "0.122013", "ticker_sentiment_label": "Neutral"}]}, {"title": "GSK completes transaction with Pfizer to form new world-leading Consumer Healthcare Joint Venture", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-completes-transaction-with-pfizer-to-form-new-world-leading-consumer-healthcare-joint-venture/", "time_published": "20190801T003121", "authors": [], "summary": "GSK announced the completion of its transaction with Pfizer to combine their consumer healthcare businesses into a world-leading Joint Venture. This new entity will integrate two highly complementary portfolios of consumer health brands and aims for \u00a30.5bn in annual cost savings by 2022. GSK intends to demerge and list the Consumer Healthcare business on the UK equity market within three years, marking a significant step in GSK's transformation.", "banner_image": null, "source": "GSK", "category_within_source": "General", "source_domain": "GSK", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.905568"}], "overall_sentiment_score": 0.296775, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GSK", "relevance_score": "0.314729", "ticker_sentiment_score": "0.001582", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.965389", "ticker_sentiment_score": "0.615158", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.557761", "ticker_sentiment_score": "0.223057", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex joins the new-CEO brigade with Leiden jumping to exec chairman, CMO stepping up", "url": "https://www.fiercepharma.com/pharma/vertex-cmo-kewalramani-set-to-become-next-ceo-april-2020-leiden-moving-up-to-executive", "time_published": "20190725T083900", "authors": ["Eric Sagonowsky"], "summary": "Vertex Pharmaceuticals CEO Jeffrey Leiden is transitioning to executive chairman, with Chief Medical Officer Reshma Kewalramani set to become the new CEO. This move makes Kewalramani one of the few female CEOs in biopharma, bringing her R&D background to lead Vertex. Her appointment comes as Vertex anticipates FDA review for its triple-combo cystic fibrosis therapy and looks to diversify its pipeline, with Leiden noting the company's strong growth under his leadership.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.948760"}, {"topic": "finance", "relevance_score": "0.721295"}], "overall_sentiment_score": 0.131177, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.993968", "ticker_sentiment_score": "0.286700", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.626634", "ticker_sentiment_score": "0.077510", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.560257", "ticker_sentiment_score": "-0.093545", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Cuts Plans in Rhode Island, Wexford Opens With Only 12 New Jobs", "url": "https://www.golocalprov.com/business/johnson-johnson-cuts-plans-in-rhode-island-wexford-opens-with-only-12-new-j", "time_published": "20190724T004128", "authors": ["GoLocalProv Business Team"], "summary": "Johnson & Johnson, which received over $6.1 million in incentives for 75 high-tech healthcare jobs in Rhode Island, has significantly scaled back its presence by occupying only 40% of its planned space and missing its job creation target by 25%. The Wexford Innovation Center, built with significant taxpayer subsidies, has only generated 12 new permanent jobs through the Cambridge Innovation Center, despite initial projections of much larger economic impact and job creation from J&J and Brown University's involvement.", "banner_image": null, "source": "GoLocalProv", "category_within_source": "General", "source_domain": "GoLocalProv", "topics": [{"topic": "economy_fiscal", "relevance_score": "0.911123"}, {"topic": "real_estate", "relevance_score": "0.845973"}, {"topic": "life_sciences", "relevance_score": "0.745800"}, {"topic": "economy_macro", "relevance_score": "0.620647"}], "overall_sentiment_score": -0.410041, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.907539", "ticker_sentiment_score": "-0.397189", "ticker_sentiment_label": "Bearish"}]}, {"title": "These San Diego Biotechs Fell Hard, But Managed to Bounce Back", "url": "https://www.sdbj.com/special-report/biotechs-recover-momentum/", "time_published": "20190718T005620", "authors": ["staff-author"], "summary": "This article highlights the comebacks of several San Diego life sciences companies, including Neurocrine Biosciences, Arena Pharmaceuticals, and Tandem Diabetes Care, after facing significant setbacks like clinical trial failures or market challenges. It delves into the strategies they employed, such as switching focus, maintaining strong leadership, and diversifying their drug pipelines, to regain investor trust and achieve market success. The article also emphasizes the rarity of such successful turnarounds in the biotech industry.", "banner_image": null, "source": "San Diego Business Journal", "category_within_source": "General", "source_domain": "San Diego Business Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.905426"}, {"topic": "financial_markets", "relevance_score": "0.727054"}], "overall_sentiment_score": 0.301524, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NBIX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.637308", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABBV", "relevance_score": "0.718051", "ticker_sentiment_score": "0.237091", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.629879", "ticker_sentiment_score": "0.141878", "ticker_sentiment_label": "Neutral"}]}, {"title": "Genmab Raises $506 Million in IPO", "url": "https://www.biospace.com/genmab-raises-506-million-in-ipo", "time_published": "20190718T002721", "authors": ["Mark Terry"], "summary": "Genmab A/S, a Danish biotech company, successfully raised $506 million through its initial public offering on the Nasdaq, trading under the ticker symbol GMAB. The company, known for its partnered oncology drugs Darzalex and Arzerra, aims to launch its own proprietary product by 2025 and is advancing a pipeline of antibody candidates. Despite a drop in Q1 2019 revenues and net profit, Genmab saw significant revenue growth in 2018, largely driven by Darzalex.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "ipo", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.911501"}], "overall_sentiment_score": 0.263031, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GMAB", "relevance_score": "1.000000", "ticker_sentiment_score": "0.402509", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.721492", "ticker_sentiment_score": "0.321776", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.649061", "ticker_sentiment_score": "0.142779", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.618376", "ticker_sentiment_score": "0.136260", "ticker_sentiment_label": "Neutral"}]}, {"title": "BiomX to raise $70m in NYSE reverse merger with Chardan", "url": "https://en.globes.co.il/en/article-biomx-to-raise-70m-in-nyse-reverse-merger-with-chardan-1001293917", "time_published": "20190717T153600", "authors": ["Jonathan Solomon", "Gali Weinreb"], "summary": "Israeli microbiome and phage therapy company BiomX announced a reverse merger with blank check company Chardan Healthcare Acquisition Corp. (CHAC) to list on the NYSE. The merged entity, valued at $250 million, will raise $70 million, with BiomX shareholders owning 73% of the new company. This funding will support clinical trials for treatments targeting acne, Crohn's Disease, colitis, and primary sclerosing cholangitis.", "banner_image": null, "source": "Globes - Israel Business News", "category_within_source": "General", "source_domain": "Globes - Israel Business News", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.932769"}, {"topic": "ipo", "relevance_score": "0.827473"}], "overall_sentiment_score": 0.425722, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PHGE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.522930", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.733191", "ticker_sentiment_score": "0.348703", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Special Edition: Surgical Robots ExcelsiusGPS\u00ae (Mid-Course Notes From Users)", "url": "https://ryortho.com/2019/07/special-edition-surgical-robots-excelsiusgps-mid-course-notes-from-users/", "time_published": "20190717T002721", "authors": ["Robin Young"], "summary": "This article provides an in-depth look at Globus Medical\u2019s ExcelsiusGPS\u00ae surgical robotic system, gathering mid-course notes from orthopedic and neurosurgical users. It compares ExcelsiusGPS with Medtronic\u2019s Mazor X, discussing market penetration and user experiences regarding precision, accuracy, and reduced radiation exposure. The piece features insights from Jeffrey Goldstein, M.D., Andrew Manista, M.D., and Scott Kutz, M.D., highlighting the benefits of combined navigation and robotics.", "banner_image": null, "source": "Orthopedics This Week", "category_within_source": "General", "source_domain": "Orthopedics This Week", "topics": [{"topic": "life_sciences", "relevance_score": "0.925044"}, {"topic": "technology", "relevance_score": "0.814273"}], "overall_sentiment_score": 0.207403, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GMED", "relevance_score": "1.000000", "ticker_sentiment_score": "0.448615", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.856992", "ticker_sentiment_score": "0.213997", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZBH", "relevance_score": "0.706157", "ticker_sentiment_score": "0.122038", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.612320", "ticker_sentiment_score": "0.143222", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.613734", "ticker_sentiment_score": "0.148339", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Growth Led By Biosense Webster And Cerenovus", "url": "https://insights.citeline.com/MT125378/Johnson--Johnson-Growth-Led-By-Biosense-Webster-And-Cerenovus/", "time_published": "20190716T002212", "authors": ["Reed Miller"], "summary": "This article discusses Johnson & Johnson's growth being driven by its Biosense Webster and Cerenovus divisions. It highlights various related content concerning market intelligence, robotic systems, acquisitions, and J&J's medical device developments. The content provides a snapshot of J&J's strategic movements and product successes in the medical technology sector.", "banner_image": null, "source": "Citeline News & Insights", "category_within_source": "General", "source_domain": "Citeline News & Insights", "topics": [{"topic": "life_sciences", "relevance_score": "0.919265"}, {"topic": "earnings", "relevance_score": "0.835596"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.626572"}], "overall_sentiment_score": 0.105099, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FTV", "relevance_score": "0.628036", "ticker_sentiment_score": "0.018222", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.430733", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDX", "relevance_score": "0.630084", "ticker_sentiment_score": "0.039071", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.609216", "ticker_sentiment_score": "0.031022", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.627219", "ticker_sentiment_score": "0.039783", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J Faces Criminal Probe over Asbestos in Baby Powder", "url": "https://www.asbestos.com/news/2019/07/15/jj-faces-criminal-probe-over-asbestos-in-baby-powder/", "time_published": "20190715T004126", "authors": ["Tim Povtak", "Walter Pacheco"], "summary": "Johnson & Johnson is currently facing a criminal investigation by the U.S. Justice Department concerning whether the company misled the public about asbestos in its talcum powder and its associated cancer risks. This probe coincides with an ongoing regulatory investigation and thousands of lawsuits, prompting a federal grand jury to examine the company's knowledge and denials regarding trace amounts of asbestos in its products. J&J maintains its talc is safe, citing decades of medical studies, despite other studies and court findings indicating asbestos presence and linking its products to cancers like mesothelioma and ovarian cancer.", "banner_image": null, "source": "Mesothelioma Center", "category_within_source": "General", "source_domain": "Mesothelioma Center", "topics": [{"topic": "life_sciences", "relevance_score": "0.939489"}, {"topic": "finance", "relevance_score": "0.743462"}], "overall_sentiment_score": -0.418932, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.449709", "ticker_sentiment_label": "Bearish"}]}, {"title": "Genmab Partners on Cancer Antibodies with BliNK Biomedical, Launches $503M U.S. IPO", "url": "https://www.genengnews.com/news/genmab-partners-on-cancer-antibodies-with-blink-biomedical-launches-503m-u-s-ipo/", "time_published": "20190715T002721", "authors": [], "summary": "Genmab has entered into a partnership with BliNK Biomedical for cancer antibodies, paying $2.25 million upfront and up to $200 million per product in milestones. Concurrently, Genmab successfully launched a U.S. initial public offering (IPO), raising $503 million, which will be used to advance its pipeline of proprietary product candidates and build commercial capabilities. The collaboration focuses on combining Genmab\u2019s DuoBody\u00ae Platform with BliNK Biomedical\u2019s CD47-targeting antibodies to develop new bispecific antibodies for cancer treatment.", "banner_image": null, "source": "Genetic Engineering and Biotechnology News", "category_within_source": "General", "source_domain": "Genetic Engineering and Biotechnology News", "topics": [{"topic": "ipo", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "finance", "relevance_score": "0.831351"}], "overall_sentiment_score": 0.321085, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GMAB", "relevance_score": "1.000000", "ticker_sentiment_score": "0.474113", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.644633", "ticker_sentiment_score": "0.310965", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.550021", "ticker_sentiment_score": "0.137543", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson to test HIV vaccine in US and Europe", "url": "https://www.cnbc.com/2019/07/12/johnson-johnson-to-test-hiv-vaccine-in-us-and-europe.html", "time_published": "20190712T103400", "authors": ["Berkeley Lovelace Jr.", "Ashley Turner"], "summary": "Johnson & Johnson plans to test an experimental HIV vaccine in the U.S. and Europe this year, while a separate phase 2 clinical trial is already underway in Africa with results expected by 2021. This initiative aligns with President Trump's goal to end the HIV epidemic by 2030, and the company is also developing a once-a-month injectable HIV treatment. The experimental vaccine is a mosaic-based preventative immunization targeting various strains of the virus.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.020005, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.303592", "ticker_sentiment_score": "0.049323", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Much Can Intuitive Surgical's System Revenue Grow Over The Next Three Years?", "url": "https://www.forbes.com/sites/greatspeculations/2019/07/09/how-much-can-intuitive-surgicals-system-revenue-grow-over-the-next-three-years/", "time_published": "20190709T155200", "authors": ["Trefis Team"], "summary": "This article analyzes the potential growth of Intuitive Surgical's da Vinci surgical system revenue over the next three years, projecting an increase from $1.13 billion in 2018 to $1.50 billion in 2021. This growth is expected due to an expansion of procedures and an increasing installed base of da Vinci systems, which also supports the company's other revenue segments like instruments, accessories, and services. The company currently faces limited direct competition in the robotic surgery market.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/5d23e59334a5c400084c7ef3/A-da-Vinci-surgical-robot-operates-on-the-Intuitive-Surgical-Inc--exhibition-stand-at/0x0.jpg?cropX1=0&cropX2=5472&cropY1=427&cropY2=3401", "source": "Forbes", "category_within_source": "General", "source_domain": "Forbes", "topics": [{"topic": "earnings", "relevance_score": "0.921636"}, {"topic": "life_sciences", "relevance_score": "0.933717"}, {"topic": "technology", "relevance_score": "0.700651"}], "overall_sentiment_score": 0.168609, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.490840", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.603441", "ticker_sentiment_score": "0.013775", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.585230", "ticker_sentiment_score": "0.026037", "ticker_sentiment_label": "Neutral"}]}, {"title": "U.S. judge strikes down Trump administration rule requiring drug prices in TV ads", "url": "https://www.reuters.com/article/business/healthcare-pharmaceuticals/us-judge-strikes-down-trump-administration-rule-requiring-drug-prices-in-tv-ad-idUSKCN1U32L1/", "time_published": "20190709T150400", "authors": ["Tina Bellon and Nate Raymond"], "summary": "A federal judge has struck down a Trump administration rule that would have mandated pharmaceutical companies include wholesale drug prices in television advertisements. U.S. District Judge Amit Mehta sided with drugmakers Merck & Co Inc, Eli Lilly and Co, and Amgen Inc, stating that the Department of Health and Human Services (HHS) lacked the authority from Congress to enforce such a disclosure. The White House and HHS expressed disappointment with the ruling, reaffirming their commitment to lowering drug prices through increased transparency, while drugmakers argued the rule would confuse consumers and that list prices do not reflect actual out-of-pocket costs.", "banner_image": "https://www.reuters.com/resizer/vPZ5j-x57yC8_b3k0T_61k_1y0Y=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/YQ4JLYN3PZPIBHP34C73C65GCE.jpg", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "economy_fiscal", "relevance_score": "0.838527"}], "overall_sentiment_score": 0.087982, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.126491", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.916227", "ticker_sentiment_score": "0.124914", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.916922", "ticker_sentiment_score": "0.126312", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.577993", "ticker_sentiment_score": "0.085596", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.589771", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dermatitis Drugs Market to Reach US$ 13,630.8 Mn by 2026, Increasing Approval of Novel Therapies Will Favor Growth, says Fortune Business Insights", "url": "https://www.globenewswire.com/news-release/2019/07/08/1879267/0/en/Dermatitis-Drugs-Market-to-Reach-US-13-630-8-Mn-by-2026-Increasing-Approval-of-Novel-Therapies-Will-Favor-Growth-says-Fortune-Business-Insights.html", "time_published": "20190708T041500", "authors": [], "summary": "The global dermatitis drugs market is projected to reach US$ 13,630.8 Mn by 2026, growing at a CAGR of 10.2% from its 2018 valuation of US$ 6,097.4 Mn, driven by advancements in drug classes and increasing usage approvals. The market growth is also significantly influenced by strategic mergers and acquisitions within the industry, such as Pfizer's acquisition of Anacor Pharmaceuticals. Key developments include FDA approval for new topical treatments like 'Eucrisa' for atopic dermatitis, which has positively impacted market expansion.", "banner_image": null, "source": "GlobeNewswire", "category_within_source": "General", "source_domain": "GlobeNewswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.941613"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.749737"}], "overall_sentiment_score": 0.28398, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.802373", "ticker_sentiment_score": "0.320165", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.748588", "ticker_sentiment_score": "0.310406", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.716788", "ticker_sentiment_score": "0.349320", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.642478", "ticker_sentiment_score": "0.315633", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.620792", "ticker_sentiment_score": "0.242248", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What's the Latest Trends of Hip Replacement Market? Get Full Information By Stryker, Smith & Nephew, Exactech, Zimmer Biomet, DePuy Synthes Companies", "url": "https://www.openpr.com/news/1790548/what-s-the-latest-trends-of-hip-replacement-market-get-full-information-by-stryker-smith-nephew-exactech-zimmer-biomet-depuy-synthes-companies.html", "time_published": "20190627T160200", "authors": [], "summary": "The hip replacement market is driven by an aging population, obesity, arthritis, advancements in minimally invasive surgeries, and 3D printing technologies, with emerging economies being key growth areas. Despite high costs and stringent regulations, the market is competitive, featuring major players like Zimmer Biomet Holdings Inc., Smith & Nephew, and Stryker Corporation. The market is projected to reach US$9,128.5 million by 2024, growing at a CAGR of 4.2% from 2017.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.942037"}, {"topic": "economy_macro", "relevance_score": "0.625219"}, {"topic": "finance", "relevance_score": "0.616731"}], "overall_sentiment_score": 0.210921, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ZBH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.265377", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYK", "relevance_score": "0.841649", "ticker_sentiment_score": "0.235605", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.747874", "ticker_sentiment_score": "0.226856", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.646596", "ticker_sentiment_score": "0.186011", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.575445", "ticker_sentiment_score": "0.180264", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "5 reasons AbbVie bought Allergan, and why they may not be enough", "url": "https://www.biopharmadive.com/news/5-reasons-abbvie-bought-allergan-and-why-they-may-not-be-enough/557611/", "time_published": "20190626T234127", "authors": ["Andrew Dunn"], "summary": "AbbVie's $63 billion acquisition of Allergan aimed to diversify revenue away from Humira, acquire a seemingly cheap target, leverage strong cash generation, secure durable sales from Botox, and present low deal risk. However, the market reacted negatively, with AbbVie's stock dropping over 15%, and analysts questioning the synergy, integration challenges, and the potential for increased reliance on Humira's cash flows amidst debt repayment plans. Concerns about Botox competition and FTC scrutiny also suggest the deal's benefits may not be as clear-cut as AbbVie anticipates.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.910478"}, {"topic": "finance", "relevance_score": "0.602687"}], "overall_sentiment_score": -0.080265, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.345621", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.588307", "ticker_sentiment_score": "0.015943", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.572355", "ticker_sentiment_score": "0.118483", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie buying Allergan in $63B deal for its post-Humira future", "url": "https://www.biopharmadive.com/news/abbvie-buy-allergan-deal-63-billion/557554/", "time_published": "20190625T234127", "authors": ["Ned Pagliarulo", "Andrew Dunn"], "summary": "AbbVie announced it will acquire Allergan in a $63 billion deal, aiming to reduce its reliance on Humira ahead of biosimilar competition. The acquisition addresses shareholder concerns about AbbVie's future revenue streams and provides Allergan an exit strategy after clinical setbacks and M&A missteps. The combined company expects Humira sales to represent less than 40% of its total revenues, with Allergan's medical aesthetics and neuroscience assets contributing significantly to future growth.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.935101"}], "overall_sentiment_score": 0.123665, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "1.000000", "ticker_sentiment_score": "0.294702", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.708296", "ticker_sentiment_score": "0.079120", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.604994", "ticker_sentiment_score": "0.095407", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.576771", "ticker_sentiment_score": "0.056467", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson scraps global CMO role as part of \u2018streamlined\u2019 business model", "url": "http://www.thedrum.com/news/johnson-johnson-scraps-global-cmo-role-part-streamlined-business-model", "time_published": "20190620T004128", "authors": ["Katie Deighton"], "summary": "Johnson & Johnson has eliminated its global chief marketing officer role as part of a new streamlined business model, leading to the departure of Alison Lewis. Her responsibilities will be distributed among other leaders within the organization. This move follows a trend among other major brands like Lyft and Uber in restructuring their marketing leadership.", "banner_image": null, "source": "The Drum", "category_within_source": "General", "source_domain": "The Drum", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.718028"}, {"topic": "life_sciences", "relevance_score": "0.609023"}], "overall_sentiment_score": 0.110597, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.117405", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J\u2019s Ethicon wins clearance for devices to deliver Grifols surgical sealant", "url": "https://www.medicaldesignandoutsourcing.com/jjs-ethicon-wins-clearance-for-devices-to-deliver-grifols-surgical-sealant/", "time_published": "20190619T002736", "authors": ["Chris Newmarker"], "summary": "Johnson & Johnson's Ethicon has received FDA clearance for airless spray devices designed to deliver Grifols' fibrin sealant, Vistaseal, to control surgical bleeding. This clearance marks the introduction of the first product under a global partnership between Grifols (NSDQ:GRFS) and Johnson & Johnson (NYSE:JNJ), specifically with its Ethicon division. The Vistaseal fibrin sealant will be used to help stop bleeding during surgical procedures.", "banner_image": null, "source": "Medical Design & Outsourcing", "category_within_source": "General", "source_domain": "Medical Design & Outsourcing", "topics": [{"topic": "life_sciences", "relevance_score": "0.925380"}], "overall_sentiment_score": 0.692476, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GRFS", "relevance_score": "0.961706", "ticker_sentiment_score": "0.726661", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.889097", "ticker_sentiment_score": "0.629249", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stryker allots share of $225.8M to develop 3D printing R&D in Ireland", "url": "https://3dprintingindustry.com/news/stryker-allots-share-of-225-8m-to-develop-3d-printing-rd-in-ireland-156966/", "time_published": "20190613T115100", "authors": ["Beau Jackson"], "summary": "Global medical technology firm Stryker is investing \u20ac200 million (approximately $225.8 million) to expand its R&D facilities in Cork, Ireland, focusing on 3D printing for medical implants. This investment will benefit Stryker's neurovascular business, Instruments Innovation Centre, and the AMagine Institute, which develops 3D printed products for spine, head, and joints. Ireland is emerging as a MedTech hub, supported by IDA Ireland, with other major healthcare companies also investing in the region.", "banner_image": null, "source": "3D Printing Industry", "category_within_source": "General", "source_domain": "3D Printing Industry", "topics": [{"topic": "life_sciences", "relevance_score": "0.919133"}, {"topic": "manufacturing", "relevance_score": "0.836230"}, {"topic": "technology", "relevance_score": "0.714982"}], "overall_sentiment_score": 0.27259, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SYK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.493795", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.626590", "ticker_sentiment_score": "0.285739", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.585884", "ticker_sentiment_score": "0.136915", "ticker_sentiment_label": "Neutral"}]}, {"title": "Asia Deal Watch: Everest Licenses Asia Rights To Calliditas\u2019 IgA Nephropathy Candidate", "url": "https://insights.citeline.com/SC125377/Asia-Deal-Watch-Everest-Licenses-Asia-Rights-To-Calliditas-IgA-Nephropathy-Candidate/", "time_published": "20190612T234722", "authors": ["Ian Haydock", "Jung Won Shin", "Brian Yang", "and Joseph Haas"], "summary": "Everest Medicines Limited has licensed the Asia rights to Calliditas Therapeutics AB's IgA nephropathy candidate. This deal highlights the significant prevalence of IgA nephropathy in China compared to Western countries, indicating a strategic focus on the Asian market. The article discusses a key partnership in the pharmaceutical sector for a specific kidney disease treatment.", "banner_image": null, "source": "Citeline News & Insights", "category_within_source": "General", "source_domain": "Citeline News & Insights", "topics": [{"topic": "life_sciences", "relevance_score": "0.928744"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.831234"}], "overall_sentiment_score": 0.085593, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ASTX", "relevance_score": "0.347654", "ticker_sentiment_score": "0.044717", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.603649", "ticker_sentiment_score": "0.146304", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.586367", "ticker_sentiment_score": "0.055225", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.599190", "ticker_sentiment_score": "0.085858", "ticker_sentiment_label": "Neutral"}]}, {"title": "Judge orders Johnson & Johnson, Colgate to pay $10M in cancer case", "url": "https://www.upi.com/Top_News/US/2019/06/12/Judge-orders-Johnson-Johnson-Colgate-to-pay-10M-in-cancer-case/1561560382423/", "time_published": "20190612T204000", "authors": ["Daniel Uria"], "summary": "A California jury ordered Johnson & Johnson and Colgate-Palmolive Co. to pay nearly $10 million in damages to a woman who developed mesothelioma, attributed to her use of their talc-based products. Both companies have denied their products cause cancer and plan to appeal the ruling, citing procedural and evidentiary errors. Johnson & Johnson is currently facing over 14,000 lawsuits related to its talc powders.", "banner_image": null, "source": "upi", "category_within_source": "General", "source_domain": "upi", "topics": [{"topic": "life_sciences", "relevance_score": "0.943791"}, {"topic": "finance", "relevance_score": "0.722464"}], "overall_sentiment_score": -0.406536, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "CL", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.420976", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.959285", "ticker_sentiment_score": "-0.443182", "ticker_sentiment_label": "Bearish"}]}, {"title": "Expert witness: Johnson & Johnson\u2019s role in opioid crisis may be \u2018worse\u2019 than Purdue\u2019s", "url": "https://www.cnn.com/2019/06/11/health/oklahoma-opioid-trial-day-11", "time_published": "20190611T165800", "authors": ["Wayne Drash", "CNN"], "summary": "An expert witness testified that Johnson & Johnson's role in the opioid crisis might be \"worse\" than Purdue Pharma's, a company widely associated with the epidemic. Dr. Andrew Kolodny, co-director of the Opioid Policy Research Collaborative at Brandeis University, made these comments during a historic trial in Oklahoma aimed at holding Johnson & Johnson accountable. The trial highlights the pharmaceutical industry's alleged role in fueling the opioid crisis and seeks to expose deceptive practices.", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "life_sciences", "relevance_score": "0.930445"}], "overall_sentiment_score": -0.647813, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.624354", "ticker_sentiment_label": "Bearish"}]}, {"title": "J&J bags $150M option on Genmab's Darzalex successor", "url": "https://www.fiercebiotech.com/biotech/j-j-bags-150m-option-genmab-s-darzalex-successor", "time_published": "20190611T081300", "authors": ["Nick Paul Taylor"], "summary": "Johnson & Johnson has secured an option to license a successor to its blockbuster multiple myeloma drug Darzalex from Genmab for $150 million, plus milestones and royalties, after clinical proof of concept. The new asset, HexaBody-CD38, utilizes Genmab's HexaBody technology to potentially enhance cancer-killing power, building on the success of Darzalex which generated $2 billion in sales last year. This deal allows J&J to evaluate the preclinical data across multiple myeloma, lymphoma, and leukemia models and compare it to competing drugs before committing further investment.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.943524"}, {"topic": "ipo", "relevance_score": "0.601570"}], "overall_sentiment_score": 0.29713, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GMAB", "relevance_score": "1.000000", "ticker_sentiment_score": "0.316682", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.935797", "ticker_sentiment_score": "0.279068", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "New court documents allege that Johnson and Johnson quietly played a key role in the opioid crisis.", "url": "https://www.motherjones.com/politics/2019/06/johnson-and-johnson-opioid-poppies-tasmania-oklahoma-lawsuit/", "time_published": "20190611T004127", "authors": ["Julia Lurie"], "summary": "New court documents allege that Johnson & Johnson quietly dominated the opioid market, producing rare poppies to supply the raw materials for painkillers to companies like Purdue Pharma. The article details Johnson & Johnson's dual role as a supplier of opioid ingredients and a pharmaceutical company that allegedly oversold its own opioid products, Nucynta and Duragesic, while also exploring high-risk patient targeting. These allegations emerged during an ongoing trial in Oklahoma, which is part of a larger legal battle against opioid manufacturers.", "banner_image": null, "source": "Mother Jones", "category_within_source": "General", "source_domain": "Mother Jones", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": -0.514934, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.515485", "ticker_sentiment_label": "Bearish"}]}, {"title": "Building a Simple, Low Cost Indexed ETF Portfolio in USD", "url": "https://milliondollarjourney.com/building-a-simple-low-cost-indexed-etf-portfolio-in-usd.htm", "time_published": "20190610T004105", "authors": ["FT"], "summary": "This article discusses the advantages of building a low-cost, indexed ETF portfolio using USD-denominated ETFs, primarily to reduce withholding taxes in registered accounts like RRSPs. It explains the concept of withholding taxes on ETFs, strategies to efficiently convert CAD to USD using Norbert's Gambit, and outlines several USD ETF portfolio options with significantly lower total MERs compared to their CAD counterparts. The author emphasizes the potential savings, especially for larger portfolios, despite the initial effort involved in currency conversion and managing US-listed ETFs.", "banner_image": null, "source": "Million Dollar Journey", "category_within_source": "General", "source_domain": "Million Dollar Journey", "topics": [{"topic": "financial_markets", "relevance_score": "0.941676"}, {"topic": "economy_fiscal", "relevance_score": "0.838292"}, {"topic": "finance", "relevance_score": "0.735494"}], "overall_sentiment_score": 0.092697, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IUSB", "relevance_score": "0.335962", "ticker_sentiment_score": "0.026738", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.622907", "ticker_sentiment_score": "0.135405", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.637941", "ticker_sentiment_score": "0.124352", "ticker_sentiment_label": "Neutral"}, {"ticker": "DIS", "relevance_score": "0.614621", "ticker_sentiment_score": "0.106141", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson: How opioid claims may tarnish the company's family-friendly image", "url": "https://www.cbsnews.com/news/johnson-johnson-opioid-claims-tarnishing-johnson-johnsons-family-friendly-image/", "time_published": "20190604T174900", "authors": ["Kate Gibson"], "summary": "Johnson & Johnson is facing significant legal challenges over its alleged role in the opioid crisis and claims linking its talc-based products to cancer, threatening its long-cultivated family-friendly image. While the company disputes the opioid claims and plans to appeal a recent talc-related jury award, brand experts suggest the lawsuits could cause substantial reputational damage and stock volatility despite J&J's strong financial position. The company is opting to fight opioid claims in court rather than settle, unlike other drugmakers.", "banner_image": null, "source": "CBS News", "category_within_source": "General", "source_domain": "CBS News", "topics": [{"topic": "life_sciences", "relevance_score": "0.923303"}, {"topic": "finance", "relevance_score": "0.721384"}, {"topic": "earnings", "relevance_score": "0.627729"}], "overall_sentiment_score": -0.195258, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.983202", "ticker_sentiment_score": "-0.694593", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.633482", "ticker_sentiment_score": "0.112220", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.595359", "ticker_sentiment_score": "0.144893", "ticker_sentiment_label": "Neutral"}]}, {"title": "7 companies transforming orthopedics with robot-assisted surgery", "url": "https://www.designworldonline.com/7-companies-transforming-orthopedics-with-robot-assisted-surgery/", "time_published": "20190604T012631", "authors": ["Design World Staff"], "summary": "This article highlights seven companies that are revolutionizing orthopedic surgery through the integration of robot-assisted surgical platforms. Key players like Stryker with Mako, Medtronic with Mazor X Stealth, and Zimmer Biomet with Rosa are rapidly advancing the field, driven by significant investments and strategic acquisitions. The adoption of robotics is seen as a crucial strategic move for orthopedic device companies, even as the ultimate medical superiority of these systems is still being evaluated.", "banner_image": null, "source": "Design World", "category_within_source": "General", "source_domain": "Design World", "topics": [{"topic": "life_sciences", "relevance_score": "0.909058"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.831458"}, {"topic": "technology", "relevance_score": "0.801299"}], "overall_sentiment_score": 0.318298, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SYK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.408455", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.828994", "ticker_sentiment_score": "0.341067", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.700326", "ticker_sentiment_score": "0.252109", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZBH", "relevance_score": "0.701597", "ticker_sentiment_score": "0.255892", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Hit with $325M Verdict in Talc-Mesothelioma Case", "url": "https://www.asbestos.com/news/2019/06/03/johnson-johnson-asbestos-talc-verdict/", "time_published": "20190603T004127", "authors": ["Tim Povtak", "Walter Pacheco"], "summary": "A New York jury ordered Johnson & Johnson to pay Donna Olson and her husband $300 million in punitive damages and $25 million in compensatory damages, totaling $325 million, in a talc-mesothelioma case. This verdict is among the highest in nearly three years of litigation alleging asbestos in J&J's talc products caused cancer. Johnson & Johnson plans to appeal, reiterating its stance that its products do not contain asbestos or cause cancer, despite facing approximately 14,200 talc-related claims.", "banner_image": null, "source": "Mesothelioma Center", "category_within_source": "General", "source_domain": "Mesothelioma Center", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": -0.449799, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.443940", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson Hit With $300 Million in Punitive Damages in Talc Case", "url": "https://www.wsj.com/articles/johnson-johnson-hit-with-300-million-in-punitive-damages-in-talc-case-11559339141?gaa_at=eafs&gaa_n=AWEtsqd5dwcrno6XYZMECaQ5jhrXrygjDKKh3q4GYvCvF0yy-IfJ3XvblbLP&gaa_ts=6907fd84&gaa_sig=9BmzaF3-7tDECi7eGXe9sWBXB8ZgAUkJihttuhSXceHrg4P3Ta4UMqKgLZA5tuY0WYJSxdUjdc_HYv6bXidyag%3D%3D", "time_published": "20190531T004127", "authors": ["Peter Loftus"], "summary": "A New York state court jury ordered Johnson & Johnson to pay $300 million in punitive damages to a woman who claimed her use of the company\u2019s talc powder caused asbestos-linked cancer. This award is among the largest in cases alleging cancer risks from J&J's talc products. The total damages in the case, including previous awards for pain and suffering to the woman and her husband, now stand at $325 million.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.940796"}, {"topic": "finance", "relevance_score": "0.604336"}], "overall_sentiment_score": -0.403494, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.401300", "ticker_sentiment_label": "Bearish"}]}, {"title": "FTI Consulting assisting pharma giant Pfizer with drug pricing", "url": "https://www.consulting.us/news/2308/fti-consulting-assisting-pharma-giant-pfizer-with-drug-pricing", "time_published": "20190531T001711", "authors": [], "summary": "FTI Consulting is currently assisting Pfizer with drug pricing matters, an engagement that comes amid a federal lawsuit accusing Pfizer and 19 other pharmaceutical companies of conspiring to inflate generic drug prices. Charlene MacDonald, a managing director at FTI, is working directly with Pfizer, though FTI denies its work is connected to the pending litigation. The lawsuit, brought by 44 states, alleges a \"multibillion dollar fraud\" impacting healthcare costs for various drugs.", "banner_image": null, "source": "Consulting.us", "category_within_source": "General", "source_domain": "Consulting.us", "topics": [{"topic": "life_sciences", "relevance_score": "0.937940"}, {"topic": "finance", "relevance_score": "0.748594"}], "overall_sentiment_score": -0.133861, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FCN", "relevance_score": "0.346851", "ticker_sentiment_score": "0.013516", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.246228", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BMY", "relevance_score": "0.615017", "ticker_sentiment_score": "-0.107612", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.601266", "ticker_sentiment_score": "-0.118815", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.639204", "ticker_sentiment_score": "-0.101147", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aphakia Market by Top Key Players: The Cooper Companies Inc.,", "url": "https://www.openpr.com/news/1758377/aphakia-market-by-top-key-players-the-cooper-companies-inc-menicon-co-ltd-labtician-ophthalmics-inc-artificial-eye-co-contact-fill-allergan-mjs-lens-technology-ltd-alsanza-medizintechnik-und-pharma-gmbh-aetna-inc.html", "time_published": "20190529T214800", "authors": [], "summary": "The Global Aphakia Market is projected to grow at a CAGR of 9.4% from 2018 to 2024, driven by increasing ophthalmic disease treatment demand and an aging population. Key players include Johnson & Johnson Services, Inc., Novartis, and The Cooper Companies Inc. The market is segmented by types, causes, treatments, and end-users, with North America expected to dominate the market.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.927000"}, {"topic": "finance", "relevance_score": "0.711154"}], "overall_sentiment_score": 0.259217, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.253622", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.720923", "ticker_sentiment_score": "0.287345", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.709201", "ticker_sentiment_score": "0.264230", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "A", "relevance_score": "0.550508", "ticker_sentiment_score": "0.250821", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "J&J Slide Deepens as Legal Woes Weigh on Shares Again", "url": "https://www.bloomberg.com/news/articles/2019-05-29/johnson-johnson-slide-deepens-as-legal-woes-weigh-on-shares", "time_published": "20190529T154000", "authors": ["Cristin Flanagan and Tatiana Darie"], "summary": "Johnson & Johnson (JNJ) shares experienced their largest drop in five months, falling as much as 6.2%, due to ongoing legal proceedings related to the opioid crisis in Oklahoma. While competitors Teva Pharmaceutical Industries and Purdue Pharma LP have settled, Johnson & Johnson has opted to continue fighting the case in court. This decision has caused investor concern and negatively impacted the company's stock performance.", "banner_image": null, "source": "Bloomberg.com", "category_within_source": "General", "source_domain": "Bloomberg.com", "topics": [{"topic": "financial_markets", "relevance_score": "0.939152"}, {"topic": "life_sciences", "relevance_score": "0.842329"}], "overall_sentiment_score": -0.400465, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.402556", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson opioids helped create 'worst man-made public health crisis in history,' Oklahoma says in court", "url": "https://www.nbcnews.com/news/us-news/johnson-johnson-opioids-helped-create-worst-man-made-public-health-n1011161", "time_published": "20190528T214800", "authors": ["Xuan Thai"], "summary": "The first trial against a pharmaceutical opioid manufacturer began in Oklahoma, with the state accusing Johnson & Johnson of prioritizing profits over public health and contributing to the \"worst man-made public health crisis in history.\" Oklahoma lawyers argued that J&J misled doctors about the addictive nature of opioids and pushed sales of their drugs, while J&J's defense stated its products were clearly labeled and its market share in Oklahoma was too small to be responsible for the crisis. This case is seen as a potential precedent for hundreds of other claims nationwide.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": -0.808057, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.801745", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson faces trial over opioid crisis in Oklahoma", "url": "https://www.bbc.com/news/world-us-canada-48437082", "time_published": "20190528T004127", "authors": [], "summary": "Johnson & Johnson is on trial in Oklahoma facing accusations of deceptively marketing painkillers and downplaying addiction risks, contributing to the opioid crisis. Prosecutors claim the company created a public nuisance costing billions, while Johnson & Johnson denies wrongdoing, stating its marketing was responsible and aligned with FDA guidance. This trial is the first of thousands filed against pharmaceutical firms by state, local, and tribal governments in the US.", "banner_image": null, "source": "BBC", "category_within_source": "General", "source_domain": "BBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.923931"}, {"topic": "finance", "relevance_score": "0.730353"}], "overall_sentiment_score": -0.444591, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.419019", "ticker_sentiment_label": "Bearish"}]}, {"title": "Opioid Maker Agrees to Pay Oklahoma $85 Million Over Claims Company Helped Create Addiction Crisis", "url": "https://time.com/5596265/teva-pharmaceuticals-oklahoma-settlement/", "time_published": "20190526T131000", "authors": ["Jef Feeley and Anders Melin"], "summary": "Teva Pharmaceutical Industries Ltd. has agreed to pay an $85 million settlement to Oklahoma to resolve a lawsuit claiming the company illegally marketed its opioid painkillers, contributing to the state's addiction crisis. The settlement comes just before the case was set to go to trial, leaving Johnson & Johnson as the sole remaining defendant. The money from the settlement will be used to abate the opioid crisis in Oklahoma, which had sought at least $10 billion in damages.", "banner_image": null, "source": "Time Magazine", "category_within_source": "General", "source_domain": "Time Magazine", "topics": [{"topic": "life_sciences", "relevance_score": "0.928948"}, {"topic": "finance", "relevance_score": "0.730605"}], "overall_sentiment_score": -0.337252, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "TEVA", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.421462", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.731946", "ticker_sentiment_score": "-0.268340", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "First Opioid Trial Takes Aim at Johnson & Johnson (Published 2019)", "url": "https://www.nytimes.com/2019/05/26/health/opioid-trial-oklahoma-johnsonandjohnson.html", "time_published": "20190526T004126", "authors": ["Jan Hoffman"], "summary": "Oklahoma is bringing the first civil trial against prescription opioid manufacturers, distributors, and sellers, targeting Johnson & Johnson. This trial follows settlements with Purdue Pharma and Teva Pharmaceuticals Ltd., and a key aspect will be the public's first glimpse into the evidence and legal strategies concerning the opioid crisis. The state seeks to hold Johnson & Johnson responsible for opioid-related damages, questioning its role given its previous marketing of a fentanyl patch.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.915060"}], "overall_sentiment_score": -0.571033, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.708059", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.615240", "ticker_sentiment_score": "-0.414073", "ticker_sentiment_label": "Bearish"}]}, {"title": "LifeScan deal challenges Abbott, Dexcom for CGM market", "url": "https://www.medtechdive.com/news/lifescan-inks-deal-to-challenge-abbott-dexcom-for-cgm-market/555422/", "time_published": "20190523T001229", "authors": ["Nick Paul Taylor"], "summary": "LifeScan has partnered with Sanvita Medical to introduce a continuous glucose monitoring (CGM) system in North America and parts of Europe, aiming to enter a fast-growing market. This move positions LifeScan, previously a Johnson & Johnson unit, against established competitors like Abbott and Dexcom, which currently dominate the CGM market with significant sales growth. The company faces the challenge of differentiating its new device to compete effectively against these well-entrenched products.", "banner_image": null, "source": "MedTech Dive", "category_within_source": "General", "source_domain": "MedTech Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.923960"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.724720"}, {"topic": "technology", "relevance_score": "0.626629"}], "overall_sentiment_score": 0.026262, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DXCM", "relevance_score": "1.000000", "ticker_sentiment_score": "0.140801", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.810283", "ticker_sentiment_score": "0.128832", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.704650", "ticker_sentiment_score": "-0.244054", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "More Hacks Inevitable in Pharma Industry, Cybersecurity Expert Says", "url": "https://www.biospace.com/hacking-continues-to-be-a-concern-for-pharma-cybersecurity-expert-says", "time_published": "20190521T000636", "authors": ["Alex Keown"], "summary": "A cybersecurity expert warns that biotech and pharma companies are prime targets for cyberattacks due to valuable intellectual property and existing security gaps. The article highlights recent breaches at Charles River Laboratories and others, emphasizing the need for robust security protocols, including log-in management, 24-hour security services, and backup servers to combat evolving threats like ransomware.", "banner_image": null, "source": "BioSpace", "category_within_source": "General", "source_domain": "BioSpace", "topics": [{"topic": "life_sciences", "relevance_score": "0.906728"}, {"topic": "technology", "relevance_score": "0.821045"}], "overall_sentiment_score": -0.229377, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "CRL", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.234109", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRK", "relevance_score": "0.814200", "ticker_sentiment_score": "-0.274796", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.731752", "ticker_sentiment_score": "-0.217157", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Colgate-Palmolive tops Gartner\u2019s 2019 Supply Chain rankings", "url": "https://www.globalcosmeticsnews.com/colgate-palmolive-tops-gartners-2019-supply-chain-rankings/", "time_published": "20190521T000149", "authors": ["Georgina Caldwell"], "summary": "Colgate-Palmolive has secured the top position in Gartner\u2019s 2019 Supply Chain Top 25 rankings, moving up from fourth place in 2018 due to strong financial performance and focus on corporate social responsibility. Alibaba and Akzo Nobel also made their debut on the shortlist. Unilever joined the \"Masters\" category after consistently ranking in the top five for seven consecutive years, recognized for its advanced digital supply chain processes and use of emerging technologies.", "banner_image": null, "source": "Global Cosmetics News", "category_within_source": "General", "source_domain": "Global Cosmetics News", "topics": [{"topic": "manufacturing", "relevance_score": "0.914099"}, {"topic": "earnings", "relevance_score": "0.717501"}], "overall_sentiment_score": 0.44185, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CL", "relevance_score": "1.000000", "ticker_sentiment_score": "0.804587", "ticker_sentiment_label": "Bullish"}, {"ticker": "IT", "relevance_score": "0.721983", "ticker_sentiment_score": "0.314974", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.646923", "ticker_sentiment_score": "0.329378", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.596880", "ticker_sentiment_score": "0.332782", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.554594", "ticker_sentiment_score": "0.321420", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Boeing has a \u2018crisis of confidence.\u2019 It\u2019s time for the board to step up", "url": "https://www.cnn.com/2019/05/16/business/boeing-737-max-crisis-faa", "time_published": "20190516T102700", "authors": ["Matt Egan"], "summary": "Boeing is facing a profound crisis of confidence and reputation following two fatal 737 Max crashes, leading to calls for significant changes, including a shake-up of its board of directors and CEO's power. Corporate governance experts suggest the company needs to rebuild trust by openly addressing the issues, potentially hiring an outsider to investigate, and prioritizing safety over profits. The article highlights the contrast between Boeing's response and successful crisis management by other companies like Johnson & Johnson and General Motors.", "banner_image": null, "source": "CNN", "category_within_source": "General", "source_domain": "CNN", "topics": [{"topic": "manufacturing", "relevance_score": "0.933046"}, {"topic": "energy_transportation", "relevance_score": "0.802690"}, {"topic": "finance", "relevance_score": "0.725288"}], "overall_sentiment_score": -0.297793, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "BA", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.611980", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.641195", "ticker_sentiment_score": "0.238087", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.641143", "ticker_sentiment_score": "-0.406800", "ticker_sentiment_label": "Bearish"}]}, {"title": "Cytomegalovirus (CMV) Infection Treatment and Diagnosis", "url": "https://www.openpr.com/news/1861588/cytomegalovirus-cmv-infection-treatment-and-diagnosis", "time_published": "20190511T145300", "authors": [], "summary": "This press release details a market research report on Cytomegalovirus (CMV) Infection Treatment and Diagnosis, evaluating historical and current market trends to forecast future growth from 2019 to 2026. The report analyzes key players including Merck & Co. Inc. and Abbott Laboratories, covering market opinions, trends, and growth opportunities. It provides a comprehensive industry chain survey and market forecasts by product, application, and region, aiming to assist investors in making informed decisions.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.943686"}, {"topic": "finance", "relevance_score": "0.720025"}], "overall_sentiment_score": 0.24316, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMRX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.216576", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.937694", "ticker_sentiment_score": "0.201318", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.861059", "ticker_sentiment_score": "0.234196", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDX", "relevance_score": "0.707537", "ticker_sentiment_score": "0.214089", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.612385", "ticker_sentiment_score": "0.214956", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson to settle metal-hip lawsuits for about $1 billion, sources say", "url": "https://www.latimes.com/business/la-fi-johnson-johnson-settle-pinnacle-metal-hip-implant-20190507-story.html", "time_published": "20190507T094500", "authors": ["Jef Feeley"], "summary": "Johnson & Johnson has agreed to pay approximately $1 billion to resolve the majority of lawsuits claiming its metal-on-metal hips were defective and required removal. This settlement addresses over 95% of 6,000 cases involving the Pinnacle implants, including an earlier $400 million settlement, as the company continues to face other legal challenges, such as opioid and talcum powder lawsuits.", "banner_image": null, "source": "Los Angeles Times", "category_within_source": "General", "source_domain": "Los Angeles Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.907243"}, {"topic": "finance", "relevance_score": "0.745864"}], "overall_sentiment_score": -0.429525, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.400335", "ticker_sentiment_label": "Bearish"}]}, {"title": "Knee Implants Market 2019 | Revenue Opportunies by Players", "url": "https://www.openpr.com/news/1765423/knee-implants-market-2019-revenue-opportunies-by-players-zimmer-stryker-smith-nephew-plc-johnson-johnson-djo-global-inc-exactech-inc-zimmer-biomet-holdings-inc-b-braun-melsungen-ag-microport-scientific-corporation-depuy-synthes-and.html", "time_published": "20190506T123000", "authors": [], "summary": "This article forecasts revenue opportunities in the knee implants market for 2019, highlighting key players such as Zimmer, Stryker, and Johnson & Johnson. It discusses market drivers like the increasing prevalence of arthritis and obesity, along with demographic trends in North America, Europe, and Asia Pacific. The report emphasizes the growing demand for knee replacement surgeries and the impact of these factors on market growth.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.332326, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ZBH", "relevance_score": "1.000000", "ticker_sentiment_score": "0.419885", "ticker_sentiment_label": "Bullish"}, {"ticker": "SYK", "relevance_score": "0.919334", "ticker_sentiment_score": "0.301086", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.813353", "ticker_sentiment_score": "0.323263", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAX", "relevance_score": "0.749189", "ticker_sentiment_score": "0.301024", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.612279", "ticker_sentiment_score": "0.338348", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stryker strives for market share in orthopedic surgery robots", "url": "https://www.therobotreport.com/stryker-leads-orthopedic-surgery-robots/", "time_published": "20190506T012630", "authors": ["Chris Newmarker"], "summary": "Stryker is a leader in orthopedic surgery robots, with over 650 Mako robots placed globally, enhancing knee and hip replacement procedures. The company credits robotics for significant market share gains, notably through its \"Trojan horse\" strategy of linking robot use to its proprietary knee implants. Competitors like Johnson & Johnson, Zimmer Biomet, and Smith & Nephew are also entering the orthopedic robotics market, with varying approaches to cost and system size.", "banner_image": null, "source": "The Robot Report", "category_within_source": "General", "source_domain": "The Robot Report", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "technology", "relevance_score": "0.937779"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.835796"}, {"topic": "manufacturing", "relevance_score": "0.614265"}], "overall_sentiment_score": 0.217396, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SYK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.474408", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.731835", "ticker_sentiment_score": "0.145198", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.609861", "ticker_sentiment_score": "0.131165", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.571389", "ticker_sentiment_score": "0.144083", "ticker_sentiment_label": "Neutral"}]}, {"title": "NEWS: J&J Animas Exiting Insulin Pump Market", "url": "https://www.healthline.com/diabetesmine/133765", "time_published": "20190506T010701", "authors": ["Mike Hoskins"], "summary": "Johnson & Johnson's Animas insulin pump division is shutting down after nearly two decades, impacting 90,000 existing customers. This decision significantly reduces insulin pump choices for people with diabetes in the U.S. to just three major players. Medtronic will take over servicing existing Animas customers, while competitors Insulet and Tandem Diabetes Care are offering incentives to attract former Animas users.", "banner_image": null, "source": "Healthline", "category_within_source": "General", "source_domain": "Healthline", "topics": [{"topic": "life_sciences", "relevance_score": "0.944690"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.708374"}], "overall_sentiment_score": 0.264107, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PODD", "relevance_score": "0.997730", "ticker_sentiment_score": "0.426810", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.865851", "ticker_sentiment_score": "0.126281", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.845955", "ticker_sentiment_score": "0.323200", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.747667", "ticker_sentiment_score": "0.204820", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pfizer And Others Join Working Group To Use Blockchain Protocol For Supply Chain Management", "url": "https://www.forbes.com/sites/rachelwolfson/2019/05/02/pfizer-and-other-healthcare-companies-aim-to-bring-blockchain-based-chargeback-protocol-to-market/", "time_published": "20190502T070000", "authors": ["Rachel Wolfson"], "summary": "Pfizer Inc., McKesson Corporation, AmerisourceBergen Corporation, and Premier Inc. have joined a working group to use blockchain technology to improve chargeback processes in the pharmaceutical industry. The MediLedger Project initiative by Chronicled aims to create a blockchain-based protocol to resolve misalignments between contracting and chargebacks, which represent a significant deduction from gross sales for healthcare product companies. This approach intends to reduce costly errors, increase efficiency, and lower patient care costs by providing a shared, immutable \"source of truth\" for transactions while preserving data privacy.", "banner_image": null, "source": "Forbes", "category_within_source": "General", "source_domain": "Forbes", "topics": [{"topic": "blockchain", "relevance_score": "0.947252"}, {"topic": "life_sciences", "relevance_score": "0.844203"}, {"topic": "technology", "relevance_score": "0.733240"}, {"topic": "finance", "relevance_score": "0.611232"}], "overall_sentiment_score": 0.219423, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.976766", "ticker_sentiment_score": "0.258024", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.932717", "ticker_sentiment_score": "0.237128", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COR", "relevance_score": "0.891636", "ticker_sentiment_score": "0.247352", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.604360", "ticker_sentiment_score": "0.183156", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 innovative ways one company is helping rethink how we treat mental healthcare", "url": "https://www.jnj.com/innovation/how-johnson-johnson-is-helping-rethink-how-we-treat-mental-healthcare", "time_published": "20190501T004126", "authors": ["Lauren Bohn"], "summary": "Johnson & Johnson is addressing the global mental health crisis through three innovative approaches: improving access to mental healthcare in underserved regions, researching much-needed treatments for conditions like treatment-resistant depression and suicidal ideation, and advocating for workplace mental health. The company partners with governments and organizations to train healthcare workers, develop new therapies, and create mental health-friendly work environments.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.920615"}], "overall_sentiment_score": 0.433925, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.443637", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why investment giant Blackstone is funding huge drug trials for Novartis and others", "url": "https://www.inquirer.com/business/blackstone-drug-trials-genentech-novartis-johnson-life-science-20190426.html", "time_published": "20190426T165600", "authors": ["Rebecca Spalding"], "summary": "Investment giant Blackstone is aiming to become a major capital source for large pharmaceutical companies, funding drug trials through its new division, Blackstone Life Sciences. The firm acquired Clarus, an investment firm specializing in funding experimental medicines, and has already partnered with Novartis AG to launch Anthos Therapeutics Inc., focusing on developing a new kind of blood thinner. This strategy allows Blackstone to invest in high-growth industries like healthcare while addressing areas of medical research that pharmaceutical companies often overlook due to high costs and risks.", "banner_image": null, "source": "Inquirer.com", "category_within_source": "General", "source_domain": "Inquirer.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.917964"}, {"topic": "finance", "relevance_score": "0.713580"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.608035"}], "overall_sentiment_score": 0.303004, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.406524", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.709475", "ticker_sentiment_score": "0.252703", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.616845", "ticker_sentiment_score": "0.205907", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.559253", "ticker_sentiment_score": "0.240885", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "William Lyons III to be speaker at Elms\u2019 88th commencement exercises", "url": "https://iobserve.org/2019/04/25/william-lyons-iii-to-be-speaker-at-elms-88th-commencement-exercises/", "time_published": "20190425T010142", "authors": ["Staff report"], "summary": "William Lyons III, a healthcare entrepreneur and philanthropist, will be the commencement speaker at Elms College's 88th commencement exercises on May 18, where he will also receive an honorary degree. Lyons co-founded Blackstone Medical Inc., a successful spinal implant company, and is involved in numerous philanthropic efforts with his wife, particularly in education and medical research. Other honorary degree recipients this year include Savina Martin and Kathryn Buckley-Brawner, recognized for their significant societal contributions.", "banner_image": null, "source": "iObserve", "category_within_source": "General", "source_domain": "iObserve", "topics": [{"topic": "life_sciences", "relevance_score": "0.838870"}, {"topic": "finance", "relevance_score": "0.723632"}, {"topic": "manufacturing", "relevance_score": "0.621584"}], "overall_sentiment_score": 0.18073, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OFIX", "relevance_score": "0.736258", "ticker_sentiment_score": "0.306647", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZBH", "relevance_score": "0.640261", "ticker_sentiment_score": "0.118173", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.600486", "ticker_sentiment_score": "0.117393", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Subsidiary Janssen Partners With Sustained Drug Release Company UroGen", "url": "https://www.calcalistech.com/ctech/articles/0,7340,L-3760997,00.html", "time_published": "20190424T132500", "authors": [], "summary": "Johnson & Johnson's subsidiary Janssen Research & Development LLC has entered into a research agreement with Nasdaq-listed UroGen Pharma Ltd. The collaboration will focus on an early-stage feasibility evaluation in a mutually interesting therapeutic area. UroGen, an Israeli company, specializes in developing sustained drug release gels for urology.", "banner_image": "https://www.calcalistech.com/PicServer2/20122009/444747/shutterstock_1180026778_m.jpg", "source": "CTech", "category_within_source": "General", "source_domain": "CTech", "topics": [{"topic": "life_sciences", "relevance_score": "0.900507"}], "overall_sentiment_score": 0.147108, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "URGN", "relevance_score": "0.318543", "ticker_sentiment_score": "0.037208", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.986140", "ticker_sentiment_score": "0.292730", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.721495", "ticker_sentiment_score": "0.144528", "ticker_sentiment_label": "Neutral"}]}, {"title": "A vaccine for E. coli ? Meet a researcher hot on the trail", "url": "https://www.jnj.com/innovation/meet-janssen-researcher-working-on-human-e-coli-vaccine", "time_published": "20190424T004126", "authors": ["Jessica Brown"], "summary": "This article highlights the work of Jan Poolman, Ph.D., a Janssen researcher, on developing a vaccine for Extraintestinal Pathogenic Escherichia coli (ExPEC), a dangerous strain of E. coli primarily affecting adults over 60. The vaccine, co-developed with LimmaTech, aims to prevent life-threatening infections like bacteremia and sepsis, which are increasing due to antimicrobial resistance. Dr. Poolman discusses the vulnerability of older adults to ExPEC, the mechanism of the new bioconjugate vaccine, and the broader importance of senior vaccination to prevent bacterial diseases.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.932751"}], "overall_sentiment_score": 0.407508, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.414834", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson will pay $9.9 million for failing to disclose the risk of its surgical mesh devices", "url": "https://www.atg.wa.gov/news/news-releases/johnson-johnson-will-pay-99-million-failing-disclose-risk-its-surgical-mesh", "time_published": "20190422T004127", "authors": [], "summary": "Johnson & Johnson will pay $9.9 million to settle a lawsuit from Washington Attorney General Bob Ferguson for failing to disclose serious risks associated with its surgical mesh devices. The settlement avoids a trial and the funds will be used to assist women in Washington who were harmed by the devices. The company has also agreed to cease deceptive marketing practices and disclose any new risks associated with the mesh.", "banner_image": null, "source": "Washington State | Office of the Attorney General (.gov)", "category_within_source": "General", "source_domain": "Washington State | Office of the Attorney General (.gov)", "topics": [{"topic": "life_sciences", "relevance_score": "0.941049"}, {"topic": "finance", "relevance_score": "0.744733"}], "overall_sentiment_score": -0.494981, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.460478", "ticker_sentiment_label": "Bearish"}]}, {"title": "Sell in May, and Go Away? Maybe At Least Rotate? or Hedge\u2026", "url": "https://etfdb.com/leveraged-inverse-content-hub/sell-in-may-go-away-maybe-at-least-rotate-or-hedge/", "time_published": "20190418T045245", "authors": ["Direxion"], "summary": "This article discusses the \"Sell in May and go away\" adage for traders, exploring alternatives like rotating into less affected sectors or using inverse/leveraged inverse ETFs. It highlights potential opportunities in healthcare and technology stocks, citing specific companies and Direxion ETFs. The piece emphasizes that traders have choices to navigate seasonal market trends, whether by shifting focus or hedging against potential downturns.", "banner_image": "https://etfdb.com/media/W1siZiIsIjIwMjUvMDkvMDUvOGtkeXE2NzVwZl9MZXZlcmFnZWRfSW52ZXJzZV9EaXJleGlvbl9tYXN0aGVhZF9vdmVybGF5XzE2MDB4MTIxXzJ4LnBnIl1d/Leveraged_Inverse_Direxion_masthead_overlay_1600x121%402x.png", "source": "ETF Database", "category_within_source": "General", "source_domain": "ETF Database", "topics": [{"topic": "financial_markets", "relevance_score": "0.916475"}, {"topic": "life_sciences", "relevance_score": "0.747757"}, {"topic": "technology", "relevance_score": "0.825239"}, {"topic": "earnings", "relevance_score": "0.942160"}], "overall_sentiment_score": 0.280784, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPXT", "relevance_score": "0.812227", "ticker_sentiment_score": "0.022587", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.725980", "ticker_sentiment_score": "0.303824", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.702361", "ticker_sentiment_score": "0.421117", "ticker_sentiment_label": "Bullish"}, {"ticker": "MSFT", "relevance_score": "0.636877", "ticker_sentiment_score": "0.335029", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.613146", "ticker_sentiment_score": "0.236054", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson earnings: Drug sales in focus amid worry about generic competition", "url": "https://www.marketwatch.com/story/johnson-johnson-earnings-drug-sales-in-focus-amid-worry-about-generic-competition-2019-04-15?gaa_at=eafs&gaa_n=AWEtsqeEz2fm1UyX3nBicRHjdy0SBxV-J7uKnfH0lEPqSawL-sFvOTocHPF8&gaa_ts=6907fd74&gaa_sig=lYeny5PVn0OnBCXy0dCRHbwB5HlYF0Km9VuyZSLhSzEThKinyLeB-VR_twdbkRlq6YAXTgmQ3lIsWv-VltLuuw%3D%3D", "time_published": "20190415T142400", "authors": [], "summary": "Johnson & Johnson is slated to announce its first-quarter earnings, with a primary focus on drug sales given investor concerns about generic competition. The company's stock has underperformed the broader market, gaining 5.6% year-to-date compared to the Dow Jones Industrial's 13.2% and the S&P 500's 15.7% gains. Investors will be closely watching for insights into how J&J plans to address the impact of generic drugs on its pharmaceutical division.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "earnings", "relevance_score": "0.920977"}, {"topic": "life_sciences", "relevance_score": "0.847521"}, {"topic": "financial_markets", "relevance_score": "0.715313"}], "overall_sentiment_score": -0.212562, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.228017", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Bioengineered blood vessels may help vascular disease patients", "url": "https://yaledailynews.com/blog/2019/04/09/bioengineered-blood-vessels-may-help-vascular-disease-patients/", "time_published": "20190409T021300", "authors": ["Kyoung A Lee"], "summary": "Researchers at Yale and Humacyte have developed bioengineered blood vessels that evolve into living tissue in patients and demonstrate a higher success rate than traditional Teflon grafts. These vessels, called human acellular vessels, eliminate immune rejection risks by removing donor cells and are currently in Phase 3 clinical trials, with potential FDA approval offering a less invasive treatment for vascular disease patients. This innovation could significantly reduce complications and the need for frequent graft replacements.", "banner_image": null, "source": "Yale Daily News", "category_within_source": "General", "source_domain": "Yale Daily News", "topics": [{"topic": "life_sciences", "relevance_score": "0.917515"}], "overall_sentiment_score": 0.526167, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "HUMA", "relevance_score": "0.969972", "ticker_sentiment_score": "0.733238", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.559825", "ticker_sentiment_score": "0.324358", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The top 15 pharma companies by 2018 revenue", "url": "https://www.fiercepharma.com/special-report/top-15-pharma-companies-by-2018-revenue", "time_published": "20190408T004633", "authors": [], "summary": "This article lists the top 15 pharmaceutical companies based on their revenue in 2018. It provides a quick overview of the leading players in the pharma industry for that specific year.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "earnings", "relevance_score": "0.917141"}, {"topic": "life_sciences", "relevance_score": "0.805495"}], "overall_sentiment_score": 0.375496, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.919676", "ticker_sentiment_score": "0.395129", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.746138", "ticker_sentiment_score": "0.395415", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.708039", "ticker_sentiment_score": "0.396966", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRK", "relevance_score": "0.610223", "ticker_sentiment_score": "0.365428", "ticker_sentiment_label": "Bullish"}]}, {"title": "Coherus\u2019 Neulasta biosimilar surprises with strong early uptake", "url": "https://www.biopharmadive.com/news/coherus-neulasta-biosimilar-surprises-with-strong-early-uptake/552244/", "time_published": "20190408T000141", "authors": ["Ned Pagliarulo"], "summary": "Coherus BioSciences reported surprisingly strong preliminary net sales of $36 to $38 million for its Neulasta biosimilar, Udenyca, in the first quarter of 2019, significantly exceeding analyst expectations. This early uptake challenges the documented commercial struggles of other biosimilars in the U.S. market and suggests Udenyca could capture a substantial share of the Neulasta market.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "earnings", "relevance_score": "0.926247"}, {"topic": "life_sciences", "relevance_score": "0.903089"}], "overall_sentiment_score": 0.069881, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CHRS", "relevance_score": "1.000000", "ticker_sentiment_score": "0.432905", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.835092", "ticker_sentiment_score": "-0.232393", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.600641", "ticker_sentiment_score": "0.010563", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vascular Closure Device Market 2019 | Industry Insights by Top", "url": "https://www.openpr.com/news/1796781/vascular-closure-device-market-2019-industry-insights-by-top", "time_published": "20190407T151700", "authors": [], "summary": "The Vascular Closure Device market was valued at US$ 848.2 million in 2016 and is projected to experience a CAGR of 6.1% through 2025. This growth is driven by the increasing prevalence of cardiovascular diseases and regulatory approvals for new devices. Key players in this market include Abbott Laboratories, Medtronic Plc, and Terumo Corporation, with some companies successfully securing significant funding for expansion.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.935024"}], "overall_sentiment_score": 0.362839, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "0.932196", "ticker_sentiment_score": "0.304310", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.856816", "ticker_sentiment_score": "0.354570", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.899060", "ticker_sentiment_score": "0.355026", "ticker_sentiment_label": "Bullish"}, {"ticker": "ELV", "relevance_score": "0.635095", "ticker_sentiment_score": "0.315833", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.616949", "ticker_sentiment_score": "0.345354", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Completes Divestiture of Advanced Sterilization Products (ASP) to Fortive Corporation", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-completes-divestiture-of-advanced-sterilization-products-asp-to-fortive-corporation-300822090.html", "time_published": "20190401T163000", "authors": [], "summary": "Johnson & Johnson announced the completion of the divestiture of its Advanced Sterilization Products (ASP) business to Fortive Corporation for approximately $2.8 billion. ASP, a leader in infection prevention solutions with 2018 net revenue of about $800 million, provides capital, consumables, and software for sterilization and disinfection in healthcare facilities. Johnson & Johnson plans to discuss this transaction during its quarterly earnings call on April 16, 2019.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.923169"}, {"topic": "earnings", "relevance_score": "0.728436"}], "overall_sentiment_score": 0.313043, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.332521", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FTV", "relevance_score": "0.911536", "ticker_sentiment_score": "0.314241", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Announces Completion of Acquisition of Auris Health, Inc.", "url": "https://www.prnewswire.com/news-releases/johnson--johnson-announces-completion-of-acquisition-of-auris-health-inc-300822106.html", "time_published": "20190401T163000", "authors": [], "summary": "Johnson & Johnson announced the completion of its acquisition of Auris Health, Inc. for approximately $3.4 billion in cash, with potential additional contingent payments of up to $2.35 billion. This acquisition aims to enhance Johnson & Johnson's digital surgery portfolio, particularly in combatting lung cancer through Auris Health's robotic platform technology. The integration is expected to further Johnson & Johnson's commitment to connected, data-driven surgical solutions and improved patient outcomes.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.935532"}, {"topic": "technology", "relevance_score": "0.707755"}, {"topic": "earnings", "relevance_score": "0.612233"}], "overall_sentiment_score": 0.429716, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.429992", "ticker_sentiment_label": "Bullish"}]}, {"title": "A sweet pill to swallow", "url": "https://uq.edu.au/research/impact/stories/sweet-pill-to-swallow/", "time_published": "20190329T011112", "authors": ["Bronwyn Adams"], "summary": "UQ research has led to the spin-out company Protagonist Therapeutics, which is developing orally stable peptide drugs for inflammatory bowel disease and rare blood disorders like Beta thalassemia. These new treatments aim to offer safer and more convenient alternatives to existing injected therapies, with several drug candidates currently in clinical trials. The company's success, including its NASDAQ listing and partnerships, highlights the translation of academic research into significant medical advancements.", "banner_image": null, "source": "The University of Queensland", "category_within_source": "General", "source_domain": "The University of Queensland", "topics": [{"topic": "life_sciences", "relevance_score": "0.944469"}, {"topic": "ipo", "relevance_score": "0.631565"}], "overall_sentiment_score": 0.398844, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PTGX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.431822", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.744349", "ticker_sentiment_score": "0.313362", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Scientists Make Blood Vessels From Cadaver Tissues And Bring Them to Life in Patients", "url": "https://www.sciencealert.com/scientists-make-blood-vessels-from-cadaver-tissues-and-bring-them-to-life-in-patients", "time_published": "20190329T003224", "authors": ["Mike McRae"], "summary": "Humacyte, a US-based biotech company, has developed a radical new method for creating replacement blood vessels using tissues from deceased donors. This process involves stripping donor cells from a protein frame, creating a \"human acellular vessel\" (HAV) that the patient's own cells can populate without rejection. Clinical trials have shown these lab-grown vessels to be effective and offer a promising solution for patients with damaged blood vessels.", "banner_image": null, "source": "ScienceAlert", "category_within_source": "General", "source_domain": "ScienceAlert", "topics": [{"topic": "life_sciences", "relevance_score": "0.918813"}], "overall_sentiment_score": 0.40579, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "HUMA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.881455", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDX", "relevance_score": "0.680248", "ticker_sentiment_score": "0.339432", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.607607", "ticker_sentiment_score": "0.252657", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EW", "relevance_score": "0.596023", "ticker_sentiment_score": "0.217969", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Test tube blood vessels coming alive: Study", "url": "https://abcnews.go.com/Health/test-tube-blood-vessels-coming-alive-study/story?id=61995694", "time_published": "20190327T202600", "authors": ["Dr. Linda Drozdowicz"], "summary": "Scientists at Yale and Duke University, in coordination with Humacyte, have successfully grown complete blood vessels in a bioreactor from human cells. These lab-grown vessels, called Human Acellular Vessels (HAVs), were surgically implanted into hemodialysis patients and showed the ability to repopulate tissue and self-heal like native blood vessels. While promising for conditions like kidney failure, HAVs are still in the trial phase and require further testing and approval before mainstream medical use.", "banner_image": null, "source": "ABC News", "category_within_source": "General", "source_domain": "ABC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.940991"}], "overall_sentiment_score": 0.405998, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "HUMA", "relevance_score": "1.000000", "ticker_sentiment_score": "0.866370", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.601688", "ticker_sentiment_score": "0.207825", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.582809", "ticker_sentiment_score": "0.162921", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alcon will officially leave Novartis on April 9 after an 8-year run. What's next?", "url": "https://www.fiercepharma.com/pharma/after-8-year-run-alcon-to-officially-leave-novartis-april-9", "time_published": "20190322T124500", "authors": ["Angus Liu"], "summary": "Novartis is officially spinning off its eye care business, Alcon, on April 9 after an 8-year ownership, with Alcon shares listing on the Swiss and New York Stock Exchanges under \"ALC\". This move allows Novartis to focus capital and energy on its core medicines business, which includes 11 projected blockbuster launches by 2020. The separation concludes a tumultuous 11-year connection, with Alcon returning to growth in recent years and aiming for higher margins despite a competitive market.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.943997"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "earnings", "relevance_score": "0.834391"}, {"topic": "ipo", "relevance_score": "0.935310"}], "overall_sentiment_score": 0.107053, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.310615", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.607489", "ticker_sentiment_score": "-0.120982", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value", "url": "https://www.reuters.com/article/business/biogen-scraps-two-alzheimer-drug-trials-wipes-18-billion-from-market-value-idUSKCN1R21E2/", "time_published": "20190321T084700", "authors": ["Julie Steenhuysen and Takashi Umekawa"], "summary": "Biogen Inc. and Eisai Co. Ltd. halted two late-stage trials for their Alzheimer's drug aducanumab after a futility analysis suggested little hope of success, causing Biogen's market value to drop by over $18 billion. This setback highlights the ongoing challenges in Alzheimer's treatment development and raises concerns about Biogen's future growth prospects, prompting analysts to suggest acquisitions for pipeline expansion. The decision also casts doubt on the amyloid-targeting hypothesis for Alzheimer's, pushing research towards alternative approaches.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.903853"}, {"topic": "financial_markets", "relevance_score": "0.812569"}, {"topic": "earnings", "relevance_score": "0.728502"}], "overall_sentiment_score": -0.110666, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIIB", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.817281", "ticker_sentiment_label": "Bearish"}, {"ticker": "LLY", "relevance_score": "0.707772", "ticker_sentiment_score": "0.121539", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.610054", "ticker_sentiment_score": "0.133146", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.604126", "ticker_sentiment_score": "0.108359", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.643698", "ticker_sentiment_score": "0.147191", "ticker_sentiment_label": "Neutral"}]}, {"title": "Thermo Fisher expands biologics manufacturing at 3 sites", "url": "https://www.fiercepharma.com/manufacturing/thermo-fisher-expands-biologics-manufacturing-at-three-sites", "time_published": "20190320T101000", "authors": ["Eric Palmer"], "summary": "Thermo Fisher Scientific is investing $150 million to expand its biologics manufacturing capacity at three sites in North Carolina and Italy. This investment, driven by the increasing demand for biopharmaceuticals, will add aseptic filling lines and isolator technology for sterile liquid and lyophilized product development and commercial manufacturing. The expansion builds on Thermo Fisher's significant entry into the contract manufacturing organization (CDMO) market with its acquisition of Patheon.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "manufacturing", "relevance_score": "0.943786"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.849542"}], "overall_sentiment_score": 0.260347, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TMO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.429861", "ticker_sentiment_label": "Bullish"}, {"ticker": "CVS", "relevance_score": "0.712948", "ticker_sentiment_score": "0.219360", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.601928", "ticker_sentiment_score": "0.117872", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fluid-based lensmaker PowerVision acquired by Alcon for $285M", "url": "https://www.fiercebiotech.com/medtech/fluid-based-lensmaker-powervision-acquired-by-alcon-for-285m", "time_published": "20190318T101900", "authors": ["Conor Hale"], "summary": "Alcon has acquired PowerVision, a fluid-based lensmaker, for $285 million, aiming to accelerate the development of its innovative intraocular lens implant for cataract patients. PowerVision's technology allows for a shape-changing lens that reacts to eye muscle contractions, potentially offering spectacle independence. This acquisition highlights Alcon's commitment to new technologies in cataract surgery, with future milestone payments dependent on further development and clinical trials.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.928687"}, {"topic": "life_sciences", "relevance_score": "0.813593"}], "overall_sentiment_score": 0.222652, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.421891", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.637519", "ticker_sentiment_score": "0.109526", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.617773", "ticker_sentiment_score": "0.135264", "ticker_sentiment_label": "Neutral"}]}, {"title": "Restoration Robotics merging with Venus Concept", "url": "https://www.therobotreport.com/restoration-robotics-venus-concept/", "time_published": "20190315T013611", "authors": ["The Robot Report Staff"], "summary": "Restoration Robotics and Venus Concept have entered into a definitive merger agreement in an all-stock transaction, expected to close in Q3 2019. Restoration Robotics will own approximately 15% of the combined company, with Venus Concept owning the remaining 85%. The merger aims to create a leading player in minimally invasive hair restoration, leveraging Venus Concept's sales force and Restoration Robotics' ARTAS systems.", "banner_image": null, "source": "The Robot Report", "category_within_source": "General", "source_domain": "The Robot Report", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.942761"}, {"topic": "technology", "relevance_score": "0.848299"}, {"topic": "ipo", "relevance_score": "0.619012"}], "overall_sentiment_score": 0.228501, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VERO", "relevance_score": "0.344877", "ticker_sentiment_score": "0.040989", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.824464", "ticker_sentiment_score": "0.347386", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.703773", "ticker_sentiment_score": "0.305322", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MMM", "relevance_score": "0.605145", "ticker_sentiment_score": "0.304855", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "OrthoSpace joins Stryker surgical portfolio for sports medicine", "url": "https://www.therobotreport.com/orthospace-stryker-sports-medicine/", "time_published": "20190314T012630", "authors": ["Brad Perriello"], "summary": "Stryker Corp. announced its acquisition of OrthoSpace Ltd. for $220 million, integrating OrthoSpace's InSpace rotator cuff repair device into its sports medicine portfolio. The deal involves an initial cash payment of $110 million and potentially another $110 million based on milestones. This acquisition strengthens Stryker's presence in the surgical sports medicine market, complementing its existing portfolio and previous acquisitions like MAKO Surgical and K2M.", "banner_image": null, "source": "The Robot Report", "category_within_source": "General", "source_domain": "The Robot Report", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.905697"}, {"topic": "earnings", "relevance_score": "0.628085"}], "overall_sentiment_score": 0.217174, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SYK", "relevance_score": "1.000000", "ticker_sentiment_score": "0.447020", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.607714", "ticker_sentiment_score": "0.105653", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.635087", "ticker_sentiment_score": "0.145061", "ticker_sentiment_label": "Neutral"}]}, {"title": "Abivax's HIV Drug Shows Promise for Treating Ulcerative Colitis Patients", "url": "https://www.labiotech.eu/trends-news/ulcerative-colitis-abivax-hiv/", "time_published": "20190308T234134", "authors": ["Jonathan Smith"], "summary": "Abivax's HIV drug has shown promising results in treating moderate-to-severe ulcerative colitis patients, demonstrating sustained efficacy for over six months with no serious side effects. The drug works by altering messenger RNA assembly, interfering with HIV replication and increasing anti-inflammatory molecules, and is also being explored for other inflammatory diseases like Crohn's disease and rheumatoid arthritis. The company plans further clinical trials and follow-up studies to confirm the drug's long-term effects and potential in these areas.", "banner_image": null, "source": "Labiotech.eu", "category_within_source": "General", "source_domain": "Labiotech.eu", "topics": [{"topic": "life_sciences", "relevance_score": "0.931873"}], "overall_sentiment_score": 0.237493, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABVX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.502980", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABBV", "relevance_score": "0.647170", "ticker_sentiment_score": "0.144748", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.639397", "ticker_sentiment_score": "0.147118", "ticker_sentiment_label": "Neutral"}]}, {"title": "The top ten medical device companies by market share in 2018", "url": "https://www.medicaldevice-network.com/features/top-medical-device-companies/", "time_published": "20190307T235210", "authors": [], "summary": "This article identifies the top ten medical device companies by market share in 2018, detailing their revenues, key business segments, and significant acquisitions or divestitures for that year. Despite a fragmented industry, these ten companies collectively accounted for approximately 40% of the global medical device market, valued at $515.16 billion in 2018. Medtronic led the ranking with the largest market share.", "banner_image": null, "source": "Medical Device Network", "category_within_source": "General", "source_domain": "Medical Device Network", "topics": [{"topic": "earnings", "relevance_score": "0.908411"}, {"topic": "life_sciences", "relevance_score": "0.937253"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.838588"}], "overall_sentiment_score": 0.196718, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDX", "relevance_score": "0.860873", "ticker_sentiment_score": "0.271147", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAH", "relevance_score": "0.729119", "ticker_sentiment_score": "0.156151", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.795646", "ticker_sentiment_score": "0.246246", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GEHC", "relevance_score": "0.740231", "ticker_sentiment_score": "0.122939", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.735220", "ticker_sentiment_score": "0.080314", "ticker_sentiment_label": "Neutral"}]}, {"title": "Senate panel grills pharma CEO over executive bonuses and sales of AbbVie blockbuster drug Humira", "url": "https://www.cnbc.com/2019/02/26/senate-panel-grills-abbvie-ceo-over-bonuses-tied-to-sales-of-humira.html", "time_published": "20190227T060000", "authors": ["Berkeley Lovelace Jr."], "summary": "A Senate panel questioned AbbVie CEO Richard Gonzalez regarding executive bonuses tied to the blockbuster drug Humira's sales. Senator Ron Wyden expressed concern that linking sales to bonuses could disincentivize lowering drug prices. Gonzalez's 2017 compensation, which included a $4.3 million cash bonus, was significantly influenced by Humira's $18.3 billion sales, leading to accusations of aggressive patent protection to maintain exclusivity.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.932194"}, {"topic": "earnings", "relevance_score": "0.803740"}, {"topic": "economy_fiscal", "relevance_score": "0.743713"}], "overall_sentiment_score": -0.264585, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.406339", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.575630", "ticker_sentiment_score": "-0.228790", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.550978", "ticker_sentiment_score": "-0.233196", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BMY", "relevance_score": "0.566319", "ticker_sentiment_score": "-0.221959", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRK", "relevance_score": "0.550870", "ticker_sentiment_score": "-0.229347", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Intuitive Surgical receives FDA clearance for its lung cancer biopsy robot", "url": "https://www.fiercebiotech.com/medtech/fda-clears-intuitive-surgical-s-lung-cancer-biopsy-robot", "time_published": "20190220T100000", "authors": ["Conor Hale"], "summary": "Intuitive Surgical has received FDA clearance for its new endoluminal Ion platform, a minimally invasive lung cancer biopsy system. The system features a thin, articulating catheter designed to access difficult-to-reach lesions in the lung for tissue sampling. This move expands Intuitive Surgical's focus beyond traditional surgery and into diagnostic applications for early cancer detection.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "0.918493"}, {"topic": "technology", "relevance_score": "0.835593"}], "overall_sentiment_score": 0.265858, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.425660", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.739690", "ticker_sentiment_score": "0.147813", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ion lung biopsy system from Intuitive Surgical wins FDA approval", "url": "https://www.therobotreport.com/ion-lung-biopsy-intuitive-surgical-fda/", "time_published": "20190220T003700", "authors": ["Chris Newmarker"], "summary": "Intuitive Surgical Inc. announced that its Ion robotic endoluminal system for minimally invasive lung biopsies received FDA approval. The system features an articulating robotic catheter and integrates with existing imaging technologies, addressing the challenge of diagnosing small, difficult-to-access lung lesions. This approval positions Intuitive Surgical to expand its offerings beyond traditional surgery and compete in the growing surgical robotics market.", "banner_image": null, "source": "The Robot Report", "category_within_source": "General", "source_domain": "The Robot Report", "topics": [{"topic": "life_sciences", "relevance_score": "0.908080"}, {"topic": "technology", "relevance_score": "0.816229"}], "overall_sentiment_score": 0.231192, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.462236", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.741559", "ticker_sentiment_score": "0.149451", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.618205", "ticker_sentiment_score": "0.126870", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.564772", "ticker_sentiment_score": "0.134576", "ticker_sentiment_label": "Neutral"}]}, {"title": "GM, Bank of America and Johnson & Johnson earn top scores in new study of corporate gender equality", "url": "https://www.cnbc.com/2019/02/19/gm-tops-new-gender-equality-ranking-at-americas-largest-companies.html", "time_published": "20190219T104000", "authors": ["Harriet Taylor"], "summary": "A new study by Equileap analyzing gender equality at America's largest companies, specifically the S&P 100, awarded top scores to General Motors, Bank of America, and Johnson & Johnson. These companies were recognized for their performance across 19 criteria, including gender balance in leadership, pay equity, and parental leave policies. The study highlights the efforts these companies are making to close the gender gap and provides guidance for investors and consumers interested in supporting gender-equitable businesses.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "finance", "relevance_score": "0.845511"}], "overall_sentiment_score": 0.310115, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GM", "relevance_score": "1.000000", "ticker_sentiment_score": "0.435625", "ticker_sentiment_label": "Bullish"}, {"ticker": "BAC", "relevance_score": "0.921207", "ticker_sentiment_score": "0.334088", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.918503", "ticker_sentiment_score": "0.256383", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.745898", "ticker_sentiment_score": "0.323869", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.627273", "ticker_sentiment_score": "0.138864", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global Blood Cancer Drugs Market worth $55.6 billion by 2025:", "url": "https://www.openpr.com/news/1592149/global-blood-cancer-drugs-market-worth-55-6-billion-by-2025-major-key-players-johnson-johnson-inc-amgen-inc-bayer-ag-pfizer-inc-eli-lily-co-astrazeneca-abbvie-inc-and-other.html", "time_published": "20190215T124000", "authors": [], "summary": "The global blood cancer drugs market is projected to reach $55.6 billion by 2025, driven by increasing death incidences from blood cancer and continuous innovation in treatment development. Key market drivers include ongoing clinical trials and rising research in biological and targeted therapies, despite challenges from high drug prices and stringent government policies. North America is expected to dominate the market, while Asia-Pacific shows high growth potential due to increasing awareness and healthcare expenditure.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.904066"}, {"topic": "financial_markets", "relevance_score": "0.621182"}], "overall_sentiment_score": 0.278272, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.839204", "ticker_sentiment_score": "0.295299", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.744896", "ticker_sentiment_score": "0.232625", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.737407", "ticker_sentiment_score": "0.298403", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.602802", "ticker_sentiment_score": "0.218358", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "India a $50 billion market for energy storage: AES", "url": "https://www.pv-magazine-india.com/2019/02/14/india-a-50-billion-market-for-energy-storage-aes/", "time_published": "20190214T234156", "authors": ["Uma Gupta"], "summary": "India presents a potential investment opportunity of $50 billion in battery storage facilities, according to Andres Gluski, CEO of AES Corp, driven by its ambitious renewable energy targets and electric mobility push. The country's first 10 MW battery-storage system, built by AES and Mitsubishi Corp. for almost $9 million, was launched in New Delhi to support the grid. Energy storage is seen as crucial for integrating variable renewable energy, optimizing transmission and distribution investments, and addressing grid challenges.", "banner_image": null, "source": "pv magazine India", "category_within_source": "General", "source_domain": "pv magazine India", "topics": [{"topic": "energy_transportation", "relevance_score": "0.930845"}, {"topic": "economy_macro", "relevance_score": "0.824304"}], "overall_sentiment_score": 0.319966, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AES", "relevance_score": "1.000000", "ticker_sentiment_score": "0.604042", "ticker_sentiment_label": "Bullish"}, {"ticker": "GE", "relevance_score": "0.741759", "ticker_sentiment_score": "0.303182", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.628978", "ticker_sentiment_score": "0.208839", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MMM", "relevance_score": "0.635914", "ticker_sentiment_score": "0.218438", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.645642", "ticker_sentiment_score": "0.208585", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson to buy surgical robotics firm Auris for $3.4 billion", "url": "https://www.reuters.com/article/technology/johnson-johnson-to-buy-surgical-robotics-firm-auris-for-34-billion-idUSKCN1Q21QF/", "time_published": "20190213T173100", "authors": ["Manas Mishra"], "summary": "Johnson & Johnson announced its acquisition of Auris Health Inc for $3.4 billion in cash, marking its expansion into the rapidly growing healthcare robotics market. This strategic move aims to bolster J&J's medical device business and leverage Auris's surgical robotic scope used in respiratory procedures and lung cancer detection. The deal is expected to create a formidable competitor, particularly for current market leader Intuitive Surgical.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fwww.reuters.com%2Fresources%2Fr%2F%3Fm%3D02%26d%3D20190213%26t%3D2%26i%3D1356886616%26w%3D1280%26h%3D1280%26unrev%3D1%26rpc%3D426&auth=f2f01fbdc2ec68bd6c8137351659a852", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.932897"}, {"topic": "technology", "relevance_score": "0.819885"}], "overall_sentiment_score": 0.070924, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.206424", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.943236", "ticker_sentiment_score": "0.312628", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOGL", "relevance_score": "0.602205", "ticker_sentiment_score": "0.139201", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J (JNJ) Acquires Robotic-Surgery Firm Auris for $3.4 Billion", "url": "https://www.bloomberg.com/news/articles/2019-02-13/j-j-said-to-acquire-robotic-surgery-firm-auris-for-3-4-billion", "time_published": "20190213T135900", "authors": ["Cynthia Koons"], "summary": "Johnson & Johnson has agreed to acquire Auris Health Inc., a surgical robotics company, for approximately $3.4 billion in cash. This deal includes potential additional payments of up to $2.35 billion tied to milestones, giving J&J a new lung-cancer diagnostic and treatment tool. Auris, led by Fred Moll, specializes in robotic surgical scopes for identifying cancerous tumors in patients' lungs.", "banner_image": null, "source": "Bloomberg.com", "category_within_source": "General", "source_domain": "Bloomberg.com", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.900857"}], "overall_sentiment_score": 0.284449, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.617914", "ticker_sentiment_score": "0.127430", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.483498", "ticker_sentiment_label": "Bullish"}]}, {"title": "Edwards Lifesciences Enters Into Agreement To Acquire CASMED", "url": "https://www.prnewswire.com/news-releases/edwards-lifesciences-enters-into-agreement-to-acquire-casmed-300793643.html", "time_published": "20190212T083000", "authors": [], "summary": "Edwards Lifesciences announced its definitive merger agreement to acquire CAS Medical Systems, Inc. for approximately $100 million in an all-cash transaction at $2.45 per share. This acquisition aims to integrate CASMED's non-invasive cerebral oximetry technology with Edwards' hemodynamic monitoring platform, enhancing critical care monitoring with more comprehensive patient status insights. The transaction is expected to close in the second quarter of 2019, pending regulatory and stockholder approvals.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.917131"}], "overall_sentiment_score": 0.282584, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EW", "relevance_score": "1.000000", "ticker_sentiment_score": "0.417697", "ticker_sentiment_label": "Bullish"}, {"ticker": "BAX", "relevance_score": "0.573784", "ticker_sentiment_score": "0.282312", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.556712", "ticker_sentiment_score": "0.214012", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.553481", "ticker_sentiment_score": "0.176973", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.548904", "ticker_sentiment_score": "0.203877", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Catalyst Pharma sees net price of drug, once free, topping $300,000", "url": "https://www.macaubusiness.com/catalyst-pharma-sees-net-price-of-drug-once-free-topping-300000/", "time_published": "20190212T000629", "authors": ["Michael Erman and Caroline Humer"], "summary": "Catalyst Pharmaceuticals Inc. expects the net price of its drug, Firdapse, for the rare disease Lambert-Eaton Myasthenic Syndrome (LEMS), to exceed $300,000 annually, even with rebates. This comes after the drug, previously available for free through a compassionate use program, received U.S. approval. The pricing has drawn criticism, including from U.S. Senator Bernie Sanders and pharmacy benefit manager Express Scripts, who argue it exploits vulnerable patients despite the drug's orphan status.", "banner_image": null, "source": "Macau Business", "category_within_source": "General", "source_domain": "Macau Business", "topics": [{"topic": "life_sciences", "relevance_score": "0.917041"}, {"topic": "economy_fiscal", "relevance_score": "0.615721"}], "overall_sentiment_score": -0.082548, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CPRX", "relevance_score": "0.982406", "ticker_sentiment_score": "-0.334126", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CI", "relevance_score": "0.729618", "ticker_sentiment_score": "0.110034", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.622765", "ticker_sentiment_score": "0.087887", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tuberculosis survivors challenge Johnson & Johnson patent application in India", "url": "https://www.doctorswithoutborders.org/latest/tuberculosis-survivors-challenge-johnson-johnson-patent-application-india", "time_published": "20190207T004128", "authors": [], "summary": "Tuberculosis survivors, supported by Doctors Without Borders, have filed a patent challenge in India against Johnson & Johnson to prevent the extension of its monopoly on bedaquiline, a critical drug for drug-resistant TB. They argue that extending the patent from 2023 to 2027 would delay generic availability and affordability, making the safer and more effective treatment inaccessible to many who rely on toxic alternatives. The challenge aims to ensure bedaquiline is affordable and accessible globally, especially given its recommendation by the WHO and the high cure rates it offers.", "banner_image": null, "source": "Doctors Without Borders", "category_within_source": "General", "source_domain": "Doctors Without Borders", "topics": [{"topic": "life_sciences", "relevance_score": "0.940396"}, {"topic": "finance", "relevance_score": "0.643146"}], "overall_sentiment_score": -0.404873, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.410104", "ticker_sentiment_label": "Bearish"}]}, {"title": "Investors Eye the Growing Women\u2019s Health Market", "url": "https://www.fticonsulting.com/insights/fti-journal/investors-eye-growing-womens-health-market", "time_published": "20190129T001711", "authors": [], "summary": "The global women's health market is experiencing significant growth, attracting private equity and venture capital due to evolving demographic trends like an aging population and increased spending power. This surge is leading to new drugs, services, and technologies, particularly within the \"Femtech\" sector. Investors are encouraged to seize opportunities in this rapidly innovating market, which was valued at US$29 billion in 2015 and is projected to continue growing.", "banner_image": null, "source": "FTI Consulting", "category_within_source": "General", "source_domain": "FTI Consulting", "topics": [{"topic": "life_sciences", "relevance_score": "0.916486"}, {"topic": "finance", "relevance_score": "0.703940"}, {"topic": "technology", "relevance_score": "0.644451"}, {"topic": "economy_macro", "relevance_score": "0.622950"}], "overall_sentiment_score": 0.216912, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FCN", "relevance_score": "0.616562", "ticker_sentiment_score": "-0.100311", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.723320", "ticker_sentiment_score": "0.319549", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.726760", "ticker_sentiment_score": "0.333676", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.600463", "ticker_sentiment_score": "0.229713", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GEHC", "relevance_score": "0.638626", "ticker_sentiment_score": "0.247855", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Exclusive: Cisco poaches Juniper executive to lead new customer experience group", "url": "https://www.bizjournals.com/sanjose/news/2019/01/25/cisco-shakeup-cx-juniper-alvio-barrios-csco-jnpr.html", "time_published": "20190125T134900", "authors": ["Jennifer Elias"], "summary": "Cisco, undergoing a significant business model transformation, has recruited a high-level executive from rival Juniper to spearhead its new customer experience group. This move is part of Cisco's broader efforts to shake up its operations and leadership.", "banner_image": null, "source": "The Business Journals", "category_within_source": "General", "source_domain": "The Business Journals", "topics": [{"topic": "technology", "relevance_score": "0.915513"}], "overall_sentiment_score": 0.109184, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CSCO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.146720", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.710055", "ticker_sentiment_score": "0.149953", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novel same-day Type 2 diabetes treatment study launches in US", "url": "https://www.tmc.edu/news/2019/01/novel-same-day-type-2-diabetes-treatment-study-launches-in-us/", "time_published": "20190117T003125", "authors": ["Amy Laukka"], "summary": "A pilot study has been launched at The University of Texas Health Science Center at Houston (UTHealth) to investigate a same-day procedural therapy called The Revita\u2122 System for improving glucose control in Type 2 diabetes patients. This novel treatment, developed by Fractyl Laboratories Inc., involves duodenal mucosal resurfacing (DMR) to correct abnormal hormonal signaling and nutrient absorption without additional medications. The study aims to assess the safety and effectiveness of the device-based intervention, which targets insulin resistance and has the potential to prevent or even reverse disease progression.", "banner_image": null, "source": "TMC Houston", "category_within_source": "General", "source_domain": "TMC Houston", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.18436, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GUTS", "relevance_score": "1.000000", "ticker_sentiment_score": "0.412437", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.596159", "ticker_sentiment_score": "0.148266", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.567804", "ticker_sentiment_score": "0.126713", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.578174", "ticker_sentiment_score": "0.107423", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.579937", "ticker_sentiment_score": "0.143250", "ticker_sentiment_label": "Neutral"}]}, {"title": "JP Morgan's Dimon hosted a private dinner for pharma executives, and a major topic was Amazon", "url": "https://www.cnbc.com/2019/01/09/jp-morgan-ceo-jamie-dimon-talks-amazon-at-jpm-2019-private-dinner.html", "time_published": "20190109T132900", "authors": ["Christina Farr", "Angelica Peebles"], "summary": "Jamie Dimon hosted a private dinner for pharmaceutical executives, including those from Eli Lilly, Pfizer, and Johnson & Johnson, ahead of J.P. Morgan's health-care conference. A major topic of discussion was Amazon's ambitions in the health-care market and the J.P. Morgan-Amazon-Berkshire Hathaway health partnership. Dimon expressed the group's desire to lower health-care costs, a sentiment echoed by attending executives like Eli Lilly CEO Dave Ricks, who encouraged corporate America to take a more active role in employee health benefits.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.936645"}, {"topic": "retail_wholesale", "relevance_score": "0.726955"}, {"topic": "finance", "relevance_score": "0.649085"}, {"topic": "technology", "relevance_score": "0.626383"}], "overall_sentiment_score": -0.083322, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JPM", "relevance_score": "1.000000", "ticker_sentiment_score": "0.204123", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.911869", "ticker_sentiment_score": "0.101024", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.746949", "ticker_sentiment_score": "-0.214321", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.610262", "ticker_sentiment_score": "-0.222124", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.608101", "ticker_sentiment_score": "-0.221923", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "$Infusion Pumps Market Insights With Key Players ICU Medical,", "url": "https://www.openpr.com/news/1477816/infusion-pumps-market-insights-with-key-players-icu-medical-smiths-group-baxter-international-fresenius-kgaa-johnson-johnson-medtronic.html", "time_published": "20190108T075200", "authors": [], "summary": "The global infusion pumps market was valued at US$ 2,985.5 million in 2015 and is projected to grow at a CAGR of 6.0% during 2016-2024, driven by increasing applications and product advancements by key players like ICU Medical and Baxter. The market is segmented by product type, application, channel type, end user, and geography, with a focus on improving safety and reducing errors in medication delivery through innovations like smart pumps.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.814099"}], "overall_sentiment_score": 0.138133, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BAX", "relevance_score": "0.851027", "ticker_sentiment_score": "0.263578", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.701154", "ticker_sentiment_score": "0.136333", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.727555", "ticker_sentiment_score": "0.138340", "ticker_sentiment_label": "Neutral"}, {"ticker": "STE", "relevance_score": "0.652389", "ticker_sentiment_score": "0.144949", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie takes $4B hit on Rova-T failures", "url": "https://www.fiercebiotech.com/biotech/abbvie-takes-4b-hit-rova-t-failures", "time_published": "20190107T111800", "authors": ["Ben Adams"], "summary": "AbbVie will take an additional $4 billion impairment charge related to its Rova-T cancer drug, acquired in a $5.8 billion deal with Stemcentrx in 2016. This comes after the company stopped enrollment in a phase 3 trial due to worse survival rates in Rova-T patients and abandoned plans for accelerated FDA approval following weak phase 2 data. The estimated net impact of this impairment and related adjustments is approximately $4 billion, with AbbVie continuing to evaluate remaining intangible assets for further impairment.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "earnings", "relevance_score": "0.923454"}], "overall_sentiment_score": -0.440357, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.741987", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.550336", "ticker_sentiment_score": "-0.149653", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Global Baby Care Products Market is demanding globally with", "url": "https://www.openpr.com/news/1470844/why-global-baby-care-products-market-is-demanding-globally-with-top-key-players-such-as-procter-gamble-co-kimberly-clark-corp-johnson-and-johnson-unilever-plc-and-abbott-nutrition.html", "time_published": "20190104T091600", "authors": [], "summary": "The global baby care products market is experiencing significant demand, driven by increasing parental awareness of child safety, rising disposable incomes, and the growth of the working women population. Key players like Procter & Gamble, Kimberly Clark, and Johnson & Johnson are leading this market, which is projected to grow to over $110 billion by 2025 with a CAGR of 6%. North America currently holds the largest share due to high expenditure and progressive technology, though high costs and a lack of regulatory guidelines pose challenges to market growth.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.816704"}, {"topic": "finance", "relevance_score": "0.717008"}, {"topic": "life_sciences", "relevance_score": "0.604170"}, {"topic": "economy_macro", "relevance_score": "0.613577"}], "overall_sentiment_score": 0.248874, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KMB", "relevance_score": "0.949107", "ticker_sentiment_score": "0.347751", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.887861", "ticker_sentiment_score": "0.250684", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.842834", "ticker_sentiment_score": "0.206043", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.711278", "ticker_sentiment_score": "0.230620", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.595082", "ticker_sentiment_score": "0.102069", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bristol-Myers Squibb to Acquire Celgene for $74B", "url": "https://www.genengnews.com/topics/drug-discovery/bristol-myers-squibb-to-acquire-celgene-for-74b/", "time_published": "20190103T235637", "authors": ["Alex Philippidis"], "summary": "Bristol-Myers Squibb announced its plan to acquire Celgene for approximately $74 billion, aiming to create a powerhouse in immunology, inflammation, cardiovascular disease, and oncology. The deal is expected to generate over $15 billion annually from six late clinical-stage candidates and result in approximately $2.5 billion in cost synergies. Celgene shareholders will receive 1 BMS share and $50 cash, plus a Contingent Value Right for each Celgene share.", "banner_image": null, "source": "Genetic Engineering and Biotechnology News", "category_within_source": "General", "source_domain": "Genetic Engineering and Biotechnology News", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.904574"}, {"topic": "finance", "relevance_score": "0.745001"}], "overall_sentiment_score": 0.086385, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "0.984278", "ticker_sentiment_score": "0.332272", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.642756", "ticker_sentiment_score": "-0.265661", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.551953", "ticker_sentiment_score": "0.137328", "ticker_sentiment_label": "Neutral"}]}, {"title": "When Doctors Serve on Company Boards", "url": "https://www.nytimes.com/2018/12/31/health/cancer-centers-board-memberships-graphic.html", "time_published": "20181231T034119", "authors": ["Katie Thomas and Charles Ornstein"], "summary": "Cancer centers are re-evaluating the involvement of their doctors and researchers on corporate boards due to potential conflicts of interest. This article highlights several prominent hospital executives and cancer researchers who serve on the boards of publicly traded companies, detailing their affiliations and the significant compensation received. The financial figures underscore the dual roles these individuals play and the concerns these relationships may raise.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.921506"}], "overall_sentiment_score": -0.092652, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WAT", "relevance_score": "1.000000", "ticker_sentiment_score": "0.040132", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRL", "relevance_score": "0.816066", "ticker_sentiment_score": "-0.133103", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.803583", "ticker_sentiment_score": "-0.138132", "ticker_sentiment_label": "Neutral"}, {"ticker": "LH", "relevance_score": "0.749842", "ticker_sentiment_score": "-0.122858", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.716245", "ticker_sentiment_score": "-0.132543", "ticker_sentiment_label": "Neutral"}]}, {"title": "Infusion Pumps Market Growth by 2028 | Smiths Medical, MOOG Inc., Johnson & Johnson Private Ltd.", "url": "https://www.openpr.com/news/1462230/infusion-pumps-market-growth-by-2028-smiths-medical-moog-inc-johnson-johnson-private-ltd.html", "time_published": "20181227T160800", "authors": ["Future Market Insights"], "summary": "The infusion pumps market is projected to grow significantly by 2028, driven by technological advancements and increasing disease incidences. Key factors influencing growth include rapid progress in medical technology, the development of user-friendly and smart infusion pumps, and the rising demand for small and wearable devices. Despite challenges like regulatory recalls and safety concerns, manufacturers are focusing on design and R&D to enhance product quality and meet market demands, particularly for ambulatory, insulin, and PCA infusion pumps.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.943774"}], "overall_sentiment_score": 0.147325, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MOG-A", "relevance_score": "0.329104", "ticker_sentiment_score": "0.048960", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.863653", "ticker_sentiment_score": "0.201663", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAX", "relevance_score": "0.752232", "ticker_sentiment_score": "0.181492", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDX", "relevance_score": "0.734385", "ticker_sentiment_score": "0.199607", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.625727", "ticker_sentiment_score": "0.156812", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "ALS: New Center Aims to Change the Field", "url": "https://giving.massgeneral.org/stories/healey-gift-sparks-als-effort", "time_published": "20181220T014719", "authors": ["Terri Ogan Janos"], "summary": "Massachusetts General Hospital has opened a new center for ALS research and care, backed by a transformative $40 million gift from Sean Healey, executive chairman of Affiliated Managers Group, Inc. The Sean M. Healey and AMG Center for ALS aims to accelerate the discovery and testing of new therapies by bridging the gap between lab discoveries and patient treatments through innovative approaches like the master protocol trial. Dr. Merit Cudkowicz, chief of Neurology, emphasizes the center's goal to bring effective treatments to ALS patients faster by uniting the global research community.", "banner_image": null, "source": "Mass General Giving", "category_within_source": "General", "source_domain": "Mass General Giving", "topics": [{"topic": "life_sciences", "relevance_score": "0.918158"}], "overall_sentiment_score": 0.322427, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMG", "relevance_score": "1.000000", "ticker_sentiment_score": "0.475675", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABT", "relevance_score": "0.631659", "ticker_sentiment_score": "0.339942", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.633765", "ticker_sentiment_score": "0.286158", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.558709", "ticker_sentiment_score": "0.218635", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Advil and Panadol to MERGE: Will this affect the painkillers that YOU buy?", "url": "https://www.express.co.uk/life-style/health/1061027/Advil-Panadol-merge-affect-you-painkillers-glaxo-GSK-pfizer", "time_published": "20181219T082200", "authors": ["Georgina Laud"], "summary": "Pharmaceutical giants GlaxoSmithKline Plc and Pfizer Inc are forming a joint venture, merging their consumer healthcare divisions and creating the world's biggest supplier of over-the-counter medicines, including popular brands like Advil and Panadol. Glaxo will hold a 68 percent share in the new company, which will eventually separate into a pharmaceuticals/vaccines company and a new consumer healthcare company. The merger is expected to have an impact on staff, though details are still being worked out.", "banner_image": null, "source": "Daily Express", "category_within_source": "General", "source_domain": "Daily Express", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.943663"}, {"topic": "ipo", "relevance_score": "0.602788"}], "overall_sentiment_score": 0.240468, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.260958", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.752886", "ticker_sentiment_score": "0.237741", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.618988", "ticker_sentiment_score": "0.186849", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.589156", "ticker_sentiment_score": "0.189475", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Attorney behind Johnson & Johnson lawsuit speaks out", "url": "https://www.cnbc.com/video/2018/12/18/attorney-behind-johnson-johnson-lawsuit-speaks-out.html", "time_published": "20181218T084400", "authors": [], "summary": "Mark Lanier, the attorney representing women who won a lawsuit against Johnson & Johnson, discusses a Reuters report concerning the company's alleged knowledge of asbestos in its baby powder. The discussion relates to a July lawsuit where 22 women and their families prevailed against the company.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.916868"}], "overall_sentiment_score": 0.031712, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.303949", "ticker_sentiment_score": "0.008442", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson CEO: 'We unequivocally believe' our baby powder does not contain asbestos", "url": "https://www.cnbc.com/2018/12/17/johnson--johnson-ceo-denies-reports-about-asbestos-in-baby-powder.html", "time_published": "20181217T171700", "authors": ["Lizzy Gurdus"], "summary": "Johnson & Johnson CEO Alex Gorsky denied reports that the company's talc-based baby powder contains asbestos, citing numerous independent studies supporting their safety claim. This defense comes after reports from Reuters and The New York Times linked the company to knowledge of asbestos in its products, leading to a significant drop in Johnson & Johnson's stock value. Gorsky emphasized the totality of scientific evidence and the company's commitment to product safety.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.813163"}, {"topic": "finance", "relevance_score": "0.707866"}], "overall_sentiment_score": -0.314524, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.306453", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Johnson & Johnson reportedly knew about asbestos in baby powder, shares extend drop", "url": "https://www.foxbusiness.com/markets/johnson-johnson-reportedly-knew-about-asbestos-in-baby-powder-shares-plunge", "time_published": "20181217T100000", "authors": ["Megan Henney"], "summary": "Johnson & Johnson's shares dropped following a Reuters report alleging the company knew about asbestos in its baby powder for decades but failed to disclose it. J&J denied the report as \"one-sided, false and inflammatory,\" stating its baby powder is safe and asbestos-free. The company has faced numerous lawsuits regarding its talc products and continues to maintain their safety.", "banner_image": null, "source": "Fox Business", "category_within_source": "General", "source_domain": "Fox Business", "topics": [{"topic": "life_sciences", "relevance_score": "0.905456"}, {"topic": "financial_markets", "relevance_score": "0.818746"}], "overall_sentiment_score": 0.039628, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.346257", "ticker_sentiment_score": "0.027704", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson responds to recent news coverage on talc", "url": "https://www.jnj.com/our-company/johnson-johnson-responds-to-recent-news-coverage-on-talc", "time_published": "20181216T024213", "authors": [], "summary": "Johnson & Johnson issued a detailed response to a December 14, 2018 Reuters article regarding the safety of its talc products, asserting that Reuters misrepresented facts and omitted critical scientific information. J&J maintains that its talc is safe, does not cause cancer or asbestos-related diseases, and has consistently tested free of asbestos. The company highlights overwhelming scientific evidence, independent testing results, and its transparency with regulators to counter the claims made in the Reuters report.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.910257"}], "overall_sentiment_score": 0.029436, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.045703", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson\u2019s stock slammed after report it knew of asbestos in baby powder", "url": "https://www.marketwatch.com/story/johnson-johnson-stock-slammed-by-report-it-knew-of-asbestos-in-baby-powder-2018-12-14?gaa_at=eafs&gaa_n=AWEtsqctrTzSEdTeQdSA6hu4lzvJGxanFiWdPgneolVn2sXdJe50Q0zqULBQ&gaa_ts=690819b8&gaa_sig=qhH74Q_XHVVxMZ2kzTgw26B_miJa7fKl0mjQN1bFYXcxbkpN3KACpE52K2q94C6APp2RR1nkxK56AK0Q4lZlCw%3D%3D", "time_published": "20181214T163400", "authors": [], "summary": "Johnson & Johnson's stock experienced a significant drop following a Reuters report suggesting the company was aware for decades that its baby talcum powder was contaminated with asbestos. This news raises concerns about the company's legal liability, as asbestos is a known carcinogen alleged to have caused cancer in thousands of customers. The stock's performance on Friday marked its largest one-day percentage decline in 16 years.", "banner_image": null, "source": "MarketWatch", "category_within_source": "General", "source_domain": "MarketWatch", "topics": [{"topic": "life_sciences", "relevance_score": "0.945148"}, {"topic": "financial_markets", "relevance_score": "0.732052"}], "overall_sentiment_score": -0.628736, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.623632", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson loses $39.8 billion in market value in one day after report claims it knew about asbestos in its baby powder", "url": "https://www.cnbc.com/2018/12/14/jjs-market-value-plunged-afterreport-on-asbestos-in-its-baby-powder.html", "time_published": "20181214T162100", "authors": ["Angelica Peebles"], "summary": "Johnson & Johnson's market value plummeted by $39.8 billion in one day after a Reuters report alleged the company knew for decades that its baby powder contained asbestos. J&J denied the claims as \"false and inflammatory,\" while analysts described the stock sell-off as an \"over-reaction\" considering potential legal liabilities. The company suffered its worst trading day in over 15 years.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "financial_markets", "relevance_score": "0.924968"}, {"topic": "life_sciences", "relevance_score": "0.817978"}, {"topic": "earnings", "relevance_score": "0.744855"}], "overall_sentiment_score": -0.083065, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.433758", "ticker_sentiment_label": "Bearish"}, {"ticker": "WFC", "relevance_score": "0.627866", "ticker_sentiment_score": "0.133913", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.621380", "ticker_sentiment_score": "0.128734", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reuters stands by J&J report, says it was based 'entirely' on Johnson & Johnson documents", "url": "https://www.cnbc.com/2018/12/14/reuters-stands-by-johnson--johnson-report.html", "time_published": "20181214T153500", "authors": ["Michelle Fox"], "summary": "Reuters reporter Lisa Girion reaffirmed her report stating Johnson & Johnson knew for decades about asbestos in its baby powder, asserting the report was based \"entirely\" on J&J's own documents. Johnson & Johnson called the Reuters article \"one-sided, false and inflammatory,\" while Reuters highlighted internal company memos discussing asbestos. J&J's shares fell 9 percent, and the company faces numerous lawsuits regarding its talc baby powder.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.911948"}, {"topic": "finance", "relevance_score": "0.622453"}], "overall_sentiment_score": -0.443305, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.448771", "ticker_sentiment_label": "Bearish"}]}, {"title": "J&J knew for decades that asbestos lurked in its Baby Powder", "url": "https://www.reuters.com/investigates/special-report/johnsonandjohnson-cancer/", "time_published": "20181214T140000", "authors": ["LISA GIRION"], "summary": "A Reuters investigation revealed that Johnson & Johnson was aware for decades that its Baby Powder product sometimes contained carcinogenic asbestos. Despite facing thousands of lawsuits alleging a link between its talc and cancer, J&J has insisted on the product's safety. Internal documents show the company concealed this information from regulators and the public, while actively working to influence scientific research and regulatory efforts to limit asbestos in cosmetic talc.", "banner_image": null, "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.911763"}], "overall_sentiment_score": -0.838176, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.832048", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson knew products contained asbestos for decades, new report finds", "url": "https://www.today.com/health/johnson-johnson-knew-products-contained-asbestos-decades-new-report-finds-t145214", "time_published": "20181214T115300", "authors": ["Reuters"], "summary": "A new report reveals that Johnson & Johnson was aware of asbestos contamination in its talc products from at least 1971 into the early 2000s. The company faced internal concerns and external lawsuits alleging its talc caused cancer, with documents showing efforts to influence regulators and avoid disclosing test results. J&J continues to deny these claims, stating its products are safe and asbestos-free.", "banner_image": null, "source": "TODAY.com", "category_within_source": "General", "source_domain": "TODAY.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.906697"}], "overall_sentiment_score": -0.600865, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.633046", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson knew for decades that asbestos lurked in some of its baby powder", "url": "https://www.nbcnews.com/health/health-news/johnson-johnson-knew-decades-asbestos-lurked-its-baby-powder-n948016", "time_published": "20181214T113500", "authors": ["Reuters"], "summary": "Internal company documents, deposition, and trial testimony reveal that Johnson & Johnson's raw talc and finished powders sometimes tested positive for asbestos from at least 1971 to the early 2000s. The company allegedly withheld this information from regulators and the public, leading to numerous lawsuits from individuals claiming asbestos-tainted talc caused their cancers. J&J continues to deny the allegations, asserting its talc is safe and asbestos-free.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.937727"}], "overall_sentiment_score": -0.789537, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.776990", "ticker_sentiment_label": "Bearish"}]}, {"title": "J&J shares plunge 10% after report that the company knew for decades about asbestos in baby powder", "url": "https://www.cnbc.com/2018/12/14/johnson--johnson-shares-drop-on-reuters-report-that-the-company-knew-for-decades-of-asbestos-in-its-baby-powder.html", "time_published": "20181214T092900", "authors": ["Angelica Peebles"], "summary": "Johnson & Johnson shares plunged over 10% after a Reuters report alleged the company knew for decades about asbestos contamination in its baby powder but did not disclose it. J&J strongly denied the report, calling it \"one-sided, false and inflammatory\" and reiterating that its baby powder is safe and asbestos-free. Despite J&J's rebuttal, analysts suggest the talc legal risk will continue to impact the stock negatively.", "banner_image": null, "source": "CNBC", "category_within_source": "General", "source_domain": "CNBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.909457"}, {"topic": "financial_markets", "relevance_score": "0.808042"}], "overall_sentiment_score": -0.6231, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.615580", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson Knew of Asbestos in Baby Powder for Decades", "url": "https://www.asbestos.com/news/2018/12/14/johnson-johnson-asbestos-in-talc-for-decades/", "time_published": "20181214T024215", "authors": ["Tim Povtak", "Walter Pacheco"], "summary": "A Reuters investigation revealed that Johnson & Johnson was aware for decades that its baby powder products could contain asbestos but failed to warn the public or regulators, leading to a significant drop in its stock price. The company faces over 11,000 lawsuits, mostly regarding ovarian cancer, but also mesothelioma, with a surge in new cases expected in 2019. Despite maintaining that its products are safe, Johnson & Johnson has faced several large verdicts in asbestos-related talc lawsuits in 2018.", "banner_image": null, "source": "Mesothelioma Center", "category_within_source": "General", "source_domain": "Mesothelioma Center", "topics": [{"topic": "life_sciences", "relevance_score": "0.905763"}, {"topic": "financial_markets", "relevance_score": "0.806858"}], "overall_sentiment_score": -0.497545, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.453316", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson shares drop after asbestos report", "url": "https://www.bbc.com/news/business-46572536", "time_published": "20181214T024214", "authors": [], "summary": "Shares in Johnson & Johnson fell over 10% after a Reuters report alleged the company had known for decades about asbestos tainting its talcum powder. The pharmaceutical giant is facing thousands of lawsuits claiming its talc products caused cancer, with one recent ruling ordering a $4.7 billion payout to 22 women. J&J refutes the report, calling it \"one-sided, false and inflammatory\" and maintains its baby powder is safe and asbestos-free.", "banner_image": null, "source": "BBC", "category_within_source": "General", "source_domain": "BBC", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "financial_markets", "relevance_score": "0.826850"}], "overall_sentiment_score": 0.032102, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.335538", "ticker_sentiment_score": "0.049245", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson reportedly knew for decades that some tests found small amounts of asbestos in its baby powder", "url": "https://www.nbcnews.com/nightly-news/video/johnson-johnson-reportedly-knew-for-decades-that-some-tests-found-small-amounts-of-asbestos-in-its-baby-powder-1398460995936", "time_published": "20181214T014800", "authors": [], "summary": "Internal company documents reportedly reveal that Johnson & Johnson was aware for decades that some tests indicated small amounts of asbestos in its baby powder. The material in question is carcinogenic, and the company allegedly kept this information private. This revelation suggests a potential cover-up regarding a significant health concern associated with one of its prominent products.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.911139"}, {"topic": "finance", "relevance_score": "0.706222"}], "overall_sentiment_score": 0.004178, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.321289", "ticker_sentiment_score": "0.047679", "ticker_sentiment_label": "Neutral"}]}, {"title": "CEO Alex Gorsky Reflects on the Power of the Johnson & Johnson Credo", "url": "https://www.jnj.com/latest-news/johnson-johnson-ceo-alex-gorsky-reflects-on-the-power-of-the-companys-credo", "time_published": "20181213T024213", "authors": ["Johnson & Johnson"], "summary": "Johnson & Johnson CEO Alex Gorsky discusses the enduring power and evolution of the company's Credo, a guiding document since 1943. He explains how the Credo has adapted over time to reflect societal changes and employee feedback, emphasizing its role in fostering a purpose-driven, inclusive culture that prioritizes the health and well-being of humanity and employees. Gorsky highlights the importance of the Credo in guiding company decisions and driving innovation for future healthcare challenges.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.901500"}], "overall_sentiment_score": 0.493627, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.463485", "ticker_sentiment_label": "Bullish"}]}, {"title": "Honeywell plans to move world HQ out of N.J.", "url": "https://www.nj.com/news/2018/11/honeywell-plans-to-move-world-hq-out-of-nj.html", "time_published": "20181129T203600", "authors": ["The Associated Press"], "summary": "Honeywell International Inc. is moving its world headquarters from Morris Plains, New Jersey, to Charlotte, North Carolina, establishing 750 jobs there within six years. This move comes after New Jersey provided a $40 million tax credit to retain the company and North Carolina expanded tax breaks for high-paying jobs to attract the industrial conglomerate. Approximately 1,000 employees will remain in New Jersey across six Honeywell locations.", "banner_image": null, "source": "NJ.com", "category_within_source": "General", "source_domain": "NJ.com", "topics": [{"topic": "manufacturing", "relevance_score": "0.915825"}, {"topic": "economy_fiscal", "relevance_score": "0.944631"}], "overall_sentiment_score": 0.082538, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HON", "relevance_score": "1.000000", "ticker_sentiment_score": "0.264231", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.626086", "ticker_sentiment_score": "-0.141334", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lichen Sclerosus Treatment Market Size Expected to Surpass USD", "url": "https://www.openpr.com/news/1404709/lichen-sclerosus-treatment-market-size-expected-to-surpass-usd-150-million-with-eminent-key-players-astrazeneca-plc-bristol-myers-squibb-company-glaxosmithkline-plc-johnson-johnson-services-inc-merck-co-inc-pfizer-inc-sandoz-ag-by-2023.html", "time_published": "20181128T114300", "authors": [], "summary": "The Lichen Sclerosus Treatment Market is projected to reach USD 150 million by 2023, growing at a CAGR of 7.8% during the forecast period. Key drivers include the increasing prevalence of skin diseases and rising healthcare expenditure, despite challenges from a lack of specific treatments and awareness. Major players in the market include AstraZeneca, Bristol-Myers Squibb, and Pfizer.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.937814"}, {"topic": "finance", "relevance_score": "0.728053"}, {"topic": "economy_macro", "relevance_score": "0.645601"}], "overall_sentiment_score": 0.307497, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "0.925258", "ticker_sentiment_score": "0.341141", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.705285", "ticker_sentiment_score": "0.343218", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.741340", "ticker_sentiment_score": "0.336294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.739481", "ticker_sentiment_score": "0.321639", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "UNICEF and Johnson & Johnson: Teaming Up to Help Mothers and Children", "url": "https://www.unicefusa.org/stories/unicef-and-johnson-johnson-teaming-help-mothers-and-children", "time_published": "20181120T024215", "authors": ["Sarah Ferguson"], "summary": "UNICEF and Johnson & Johnson have partnered for over 30 years to improve the lives of children and families globally. J&J's new $10 million commitment will strengthen health systems, specifically focusing on training health workers and developing innovative tools to bridge health access and equity gaps. The article encourages readers to support children's rights on World Children's Day, November 20th, by going blue, signing a global petition, and shopping for blue-inspired gifts.", "banner_image": null, "source": "unicef usa", "category_within_source": "General", "source_domain": "unicef usa", "topics": [{"topic": "life_sciences", "relevance_score": "0.848090"}], "overall_sentiment_score": 0.412813, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.430355", "ticker_sentiment_label": "Bullish"}]}, {"title": "Top 10 Pharma Companies of 2018", "url": "https://www.genengnews.com/a-lists/top-10-pharma-companies-of-2018/", "time_published": "20181119T023638", "authors": ["Alex Philippidis"], "summary": "This article lists the top 10 pharmaceutical companies of 2018, ranked by market capitalization as of November 13, 2018. It discusses how pharma companies generally surpassed EPS expectations in Q3 despite a stock market downturn, and details the combined market cap growth of the top companies compared to previous years. The piece also highlights the reasons for Bristol-Myers Squibb and Bayer missing the top 10 list.", "banner_image": null, "source": "Genetic Engineering and Biotechnology News", "category_within_source": "General", "source_domain": "Genetic Engineering and Biotechnology News", "topics": [{"topic": "earnings", "relevance_score": "0.830828"}, {"topic": "financial_markets", "relevance_score": "0.923579"}, {"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.729458"}, {"topic": "economy_macro", "relevance_score": "0.630049"}], "overall_sentiment_score": 0.396902, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "IHE", "relevance_score": "1.000000", "ticker_sentiment_score": "0.288835", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.717563", "ticker_sentiment_score": "0.429827", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.737372", "ticker_sentiment_score": "0.442617", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRK", "relevance_score": "0.707480", "ticker_sentiment_score": "0.417142", "ticker_sentiment_label": "Bullish"}]}, {"title": "How Johnson & Johnson is pioneering in the fight against the world\u2019s #1 cancer killer", "url": "https://www.jnj.com/innovation/dr-avrum-spira-on-johnson-johnson-lung-cancer-initiative", "time_published": "20181113T024213", "authors": ["Sunny Sea Gold"], "summary": "Johnson & Johnson's new Lung Cancer Initiative aims to prevent, intercept, and cure early-stage lung cancer, led by Global Head Dr. Avrum Spira. The initiative focuses on early detection due to the disease's late-stage diagnosis and high mortality, leveraging J&J's diverse assets in pharmaceuticals, medical devices, and consumer products. The company also highlights the disproportionate impact of lung cancer in China, making it a key focus for global eradication efforts.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.949156"}], "overall_sentiment_score": 0.433307, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.431215", "ticker_sentiment_label": "Bullish"}]}, {"title": "Housing market for retiring baby boomers exploding in western Port St. Lucie", "url": "https://www.tcpalm.com/story/news/local/shaping-our-future/growth/2018/11/10/gl-homes-sees-demand-55-plus-communities-western-port-st-lucie/1824422002/", "time_published": "20181110T033147", "authors": ["George Andreassi"], "summary": "GL Homes, after a 12-year wait due to the Great Recession, is now developing several 55-and-up communities in western Port St. Lucie, with strong initial sales for Valencia Cay. Other major builders are also seeing high demand in this rapidly growing market for retiring baby boomers. This growth is driving a need for more medical facilities, benefiting businesses like Optimal Outcomes, and contributing to the development of vast residential and commercial spaces in Riverland and Tradition.", "banner_image": null, "source": "Treasure Coast News", "category_within_source": "General", "source_domain": "Treasure Coast News", "topics": [{"topic": "real_estate", "relevance_score": "0.928622"}, {"topic": "economy_macro", "relevance_score": "0.623997"}, {"topic": "life_sciences", "relevance_score": "0.637731"}], "overall_sentiment_score": 0.36426, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "TMHC", "relevance_score": "0.926503", "ticker_sentiment_score": "0.419127", "ticker_sentiment_label": "Bullish"}, {"ticker": "LEN", "relevance_score": "0.747395", "ticker_sentiment_score": "0.324745", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PHM", "relevance_score": "0.717164", "ticker_sentiment_score": "0.346066", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.629401", "ticker_sentiment_score": "0.326914", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Results from the Vascepa\u00ae (icosapent ethyl) cardiovascular outcomes REDUCE-IT\u2122", "url": "https://www.multivu.com/players/English/8431651-amarin-reduce-it-study-vascepa/", "time_published": "20181110T014724", "authors": [], "summary": "Amarin Corporation plc announced positive primary results from the REDUCE-IT\u2122 trial for Vascepa\u00ae (icosapent ethyl), demonstrating a 25% relative risk reduction in the primary composite endpoint of major adverse cardiovascular events. The study, presented at the American Heart Association Scientific Sessions, also showed significant reductions in cardiovascular death, heart attacks, and strokes, supporting Vascepa's role in addressing residual cardiovascular risk beyond cholesterol management. Amarin plans to submit an sNDA to the FDA in early 2019 to expand Vascepa's label based on these cardioprotective effects.", "banner_image": null, "source": "MultiVu", "category_within_source": "General", "source_domain": "MultiVu", "topics": [{"topic": "life_sciences", "relevance_score": "0.902514"}], "overall_sentiment_score": 0.310907, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMRN", "relevance_score": "1.000000", "ticker_sentiment_score": "0.875630", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.590384", "ticker_sentiment_score": "0.108437", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.585523", "ticker_sentiment_score": "0.110056", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.599035", "ticker_sentiment_score": "0.142186", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Chairman and CEO Alex Gorsky takes the #EmbracingSustainability challenge", "url": "https://www.jnj.com/latest-news/johnson-johnson-ceo-alex-gorsky-takes-the-embracingsustainability-challenge", "time_published": "20181107T024214", "authors": ["Johnson & Johnson"], "summary": "Johnson & Johnson Chairman and CEO Alex Gorsky accepted the #EmbracingSustainability Challenge launched by Business Roundtable. This initiative highlights how corporate leaders are working towards a more environmentally and economically sustainable future. Gorsky showcased Johnson & Johnson's commitment to sustainability, including their involvement with the UN 2030 Sustainable Development Goals and the New Plastics Economy Global Commitment.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.931468"}, {"topic": "finance", "relevance_score": "0.716214"}], "overall_sentiment_score": 0.387848, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.422363", "ticker_sentiment_label": "Bullish"}]}, {"title": "Wellness 360: 9 innovative Johnson & Johnson employee benefits for mind, body, and budget", "url": "https://www.jnj.com/health-and-wellness/innovative-employee-benefits-and-wellness-programs-from-johnson-johnson", "time_published": "20181107T024213", "authors": ["Michele Shapiro"], "summary": "Johnson & Johnson offers a comprehensive suite of innovative employee benefits focusing on mind, body, and budget. These unique programs include mental health support for families, resilience training, backup family care, health insurance discounts for healthy habits, financial coaching, student loan assistance, and affordable legal aid. The company aims to foster the world's healthiest workforce by continually enhancing its benefit offerings.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.910990"}, {"topic": "finance", "relevance_score": "0.714238"}], "overall_sentiment_score": 0.47986, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.476545", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson completes cloud migration with a boost from early adoption and its CIO", "url": "https://www.ciodive.com/news/johnson-johnson-CIO-cloud-migration-transformation/541395/", "time_published": "20181105T024214", "authors": ["Naomi Eide"], "summary": "Johnson & Johnson has successfully completed a five-year program to migrate nearly 90% of its computing workloads to a hybrid cloud, influenced by early adoption and CIO Stuart McGuigan's leadership. The company leveraged its extensive portfolio of over 200 operating companies and diverse ERP systems to become adept at transformation, customizing solutions to meet specific business needs across its pharmaceutical, medical devices, and consumer products divisions. This strategic move, initiated in 2012, positioned J&J ahead of the curve in cloud adoption and has allowed for agile changes, reduced operational rigidity, and increased focus on linking business strategy with analytical transformation.", "banner_image": null, "source": "CIO Dive", "category_within_source": "General", "source_domain": "CIO Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.946759"}, {"topic": "technology", "relevance_score": "0.822679"}], "overall_sentiment_score": 0.308779, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.347000", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson lands at Penn", "url": "https://penntoday.upenn.edu/news/johnson-johnson-lands-penn", "time_published": "20181101T024214", "authors": ["Lauren Hertzler"], "summary": "The University of Pennsylvania officially launched JPOD @ Philadelphia, a new partnership with Johnson & Johnson Innovation, on November 1, 2018. This networking hub at the Pennovation Center aims to leverage and boost Philadelphia's talent in health sciences, connecting regional innovators to the J&J Innovation and JLABS network. The initiative is expected to accelerate life-enhancing and life-saving work, as highlighted by leaders from Penn, Johnson & Johnson, and the City of Philadelphia.", "banner_image": null, "source": "Penn Today", "category_within_source": "General", "source_domain": "Penn Today", "topics": [{"topic": "life_sciences", "relevance_score": "0.914529"}, {"topic": "technology", "relevance_score": "0.808180"}, {"topic": "finance", "relevance_score": "0.602194"}], "overall_sentiment_score": 0.489778, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.842870", "ticker_sentiment_label": "Bullish"}, {"ticker": "QCOM", "relevance_score": "0.601988", "ticker_sentiment_score": "0.117806", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Pacemaker", "url": "https://www.irishamerica.com/2018/11/the-pacemaker/", "time_published": "20181101T020113", "authors": ["Patricia Harty", "Mark Donnelly"], "summary": "This article features an interview with Mike Mahoney, CEO of Boston Scientific, discussing his entrepreneurial journey, leadership philosophy, and the company's transformation into a global medical technology leader. Mahoney shares insights on the healthcare industry, the challenges Boston Scientific faced, and its strong connection to Ireland through manufacturing and R&D. He also offers advice on finding passion in one's career.", "banner_image": null, "source": "Irish America", "category_within_source": "General", "source_domain": "Irish America", "topics": [{"topic": "life_sciences", "relevance_score": "0.905644"}, {"topic": "finance", "relevance_score": "0.720782"}, {"topic": "manufacturing", "relevance_score": "0.603825"}, {"topic": "technology", "relevance_score": "0.613121"}], "overall_sentiment_score": 0.238825, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.512852", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.632826", "ticker_sentiment_score": "0.108637", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAX", "relevance_score": "0.558457", "ticker_sentiment_score": "0.103133", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson bags long-awaited cardiovascular nod for diabetes drug Invokana", "url": "https://www.fiercepharma.com/marketing/j-j-bags-long-awaited-cardiovascular-nod-for-diabetes-med-invokana", "time_published": "20181031T112200", "authors": ["Carly Helfand"], "summary": "Johnson & Johnson's diabetes drug Invokana has received FDA approval to reduce the risk of major cardiovascular problems in high-risk Type 2 diabetes patients, making it the only diabetes therapy with this specific indication. This approval comes after rival Jardiance had a similar nod for two years, and despite Invokana carrying a black box warning for lower extremity amputations, J&J hopes it will boost sales which have seen recent declines.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.928245"}], "overall_sentiment_score": 0.16538, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.154729", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.734826", "ticker_sentiment_score": "0.102478", "ticker_sentiment_label": "Neutral"}]}, {"title": "Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol", "url": "https://www.prnewswire.com/news-releases/grifols-demonstrates-a-significant-reduction-61-in-the-progression-of-moderate-alzheimers-disease-using-its-ambar-treatment-protocol-300738956.html", "time_published": "20181027T033000", "authors": [], "summary": "Grifols announced significant results from its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial, showing a 61% reduction in disease progression in moderate Alzheimer's disease patients. The treatment, which combines plasmapheresis with Albutein\u00ae, offers a promising new pathway for managing the illness. This breakthrough was presented at the \"Clinical Trials on Alzheimer's Disease\" congress in Barcelona.", "banner_image": null, "source": "PR Newswire", "category_within_source": "General", "source_domain": "PR Newswire", "topics": [{"topic": "life_sciences", "relevance_score": "0.937462"}], "overall_sentiment_score": 0.502695, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GRFS", "relevance_score": "1.000000", "ticker_sentiment_score": "0.868500", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.629760", "ticker_sentiment_score": "0.312701", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.583590", "ticker_sentiment_score": "0.298353", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson steps up vaccines R&D\u2014and prepares for launches\u2014with \u20ac72M plant", "url": "https://www.fiercepharma.com/vaccines/johnson-johnson-opens-eu72m-vaccine-plant-to-support-larger-clinical-trials-possible", "time_published": "20181025T102300", "authors": ["Eric Sagonowsky"], "summary": "Johnson & Johnson has opened a new \u20ac72 million vaccine plant in Leiden, the Netherlands, to support its expanding R&D pipeline and prepare for potential product launches. The facility, which took four years to complete, will produce clinical trial doses for viral vaccine candidates targeting diseases like HIV, RSV, Ebola, and Zika, and could also support early commercialization. This investment underscores J&J's commitment to addressing diseases where effective vaccines are currently unavailable or can be improved, building on its 2011 acquisition of Crucell.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}, {"topic": "manufacturing", "relevance_score": "0.831676"}], "overall_sentiment_score": 0.460186, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.471620", "ticker_sentiment_label": "Bullish"}]}, {"title": "Consumer deal fever hits Johnson & Johnson with $2.1B deal to buy out Japan's Ci:z", "url": "https://www.fiercepharma.com/pharma/johnson-johnson-offers-2-1b-to-buy-out-japan-s-ci-z-amid-consumer-deal-fever", "time_published": "20181023T112000", "authors": ["Angus Liu"], "summary": "Johnson & Johnson plans to acquire full control of Japanese cosmetics and skincare specialist Ci:z for $2.05 billion in cash. This acquisition, offering a 55% premium, aims to bolster J&J's skincare franchise in Asia, leveraging Ci:z's products like Dr.Ci:Labo and its direct-to-consumer skincare database. The deal reflects a broader trend of Big Pharma companies engaging in M&A within the consumer health sector.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "1.000000"}, {"topic": "life_sciences", "relevance_score": "0.940593"}, {"topic": "retail_wholesale", "relevance_score": "0.701051"}], "overall_sentiment_score": 0.255491, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.421353", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.728123", "ticker_sentiment_score": "0.114120", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Look into Johnson & Johnson\u2019s Diabetes Care Business", "url": "https://marketrealist.com/2018/10/a-look-into-johnson-johnsons-diabetes-care-business/", "time_published": "20181023T090200", "authors": ["Daniel Collins"], "summary": "Johnson & Johnson's Diabetes Care segment reported significant year-over-year revenue declines in both U.S. and international markets for the third quarter and the first nine months of 2018. This decline is attributed to the discontinuation of pumps and price decreases in blood glucose monitoring. In contrast, peers like Tandem Diabetes Care, Insulet, and DexCom showed strong year-over-year growth in their third-quarter revenues.", "banner_image": null, "source": "Market Realist", "category_within_source": "General", "source_domain": "Market Realist", "topics": [{"topic": "earnings", "relevance_score": "0.943035"}, {"topic": "life_sciences", "relevance_score": "0.816965"}], "overall_sentiment_score": 0.20514, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TNDM", "relevance_score": "0.914811", "ticker_sentiment_score": "0.396049", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.877255", "ticker_sentiment_score": "-0.309647", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DXCM", "relevance_score": "0.749867", "ticker_sentiment_score": "0.323190", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.702540", "ticker_sentiment_score": "0.329517", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Investing Insights: Jack Bogle and Earnings Results", "url": "https://www.morningstar.com/funds/investing-insights-jack-bogle-earnings-results", "time_published": "20181020T014702", "authors": ["Christine Benz", "Damien Conover", "Neil Macker", "Andrew Lange", "Susan Dziubinski", "Seth Goldstein"], "summary": "This article features an interview with Jack Bogle, founder of The Vanguard Group, discussing his outlook on market returns, the growth of indexing, and international investing. It also includes analysis on third-quarter earnings reports for Johnson & Johnson, Netflix, and IBM, and discusses dividend-paying ETFs and the bullish outlook for electric vehicle penetration.", "banner_image": null, "source": "Morningstar", "category_within_source": "General", "source_domain": "Morningstar", "topics": [{"topic": "earnings", "relevance_score": "0.900289"}, {"topic": "financial_markets", "relevance_score": "0.826823"}, {"topic": "technology", "relevance_score": "0.723903"}, {"topic": "life_sciences", "relevance_score": "0.624774"}, {"topic": "energy_transportation", "relevance_score": "0.647549"}], "overall_sentiment_score": 0.165961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALB", "relevance_score": "0.808577", "ticker_sentiment_score": "0.516144", "ticker_sentiment_label": "Bullish"}, {"ticker": "NFLX", "relevance_score": "0.802581", "ticker_sentiment_score": "-0.204203", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.818927", "ticker_sentiment_score": "0.267773", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IBM", "relevance_score": "0.822025", "ticker_sentiment_score": "-0.291485", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EIX", "relevance_score": "0.618533", "ticker_sentiment_score": "0.514613", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson takes $630M hit on RSV drug bought with Alios", "url": "https://www.fiercebiotech.com/biotech/j-j-takes-630m-hit-rsv-drug-bought-alios", "time_published": "20181018T081400", "authors": ["Phil Taylor"], "summary": "Johnson & Johnson has announced a $630 million impairment charge in the third quarter after its lead respiratory syncytial virus (RSV) drug, lumicitabine, which was acquired through the 2014 Alios BioPharma deal, was placed on clinical hold. The drug was a key driver of the $1.75 billion acquisition and was considered a front-runner among RSV candidates, a disease for which there are currently few approved therapies. This setback raises questions about the future of the orally active antiviral and its potential to become a blockbuster product.", "banner_image": null, "source": "Fierce Biotech", "category_within_source": "General", "source_domain": "Fierce Biotech", "topics": [{"topic": "life_sciences", "relevance_score": "0.917100"}, {"topic": "earnings", "relevance_score": "0.821126"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.741744"}], "overall_sentiment_score": -0.199706, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.254152", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.624449", "ticker_sentiment_score": "-0.144199", "ticker_sentiment_label": "Neutral"}]}, {"title": "MeiraGTx, Janssen Enter Research Collaboration", "url": "https://www.contractpharma.com/breaking-news/meiragtx-janssen-enter-research-collaboration/", "time_published": "20181018T025224", "authors": ["Betsy Louda"], "summary": "MeiraGTx has announced a research collaboration and evaluation agreement with Janssen Pharmaceuticals, facilitated by Johnson & Johnson Innovation. Under the agreement, MeiraGTx will utilize its proprietary riboswitch technology to engineer regulatable gene therapy constructs using Janssen's gene sequences. This collaboration aims to evaluate the utility of MeiraGTx's gene regulation platform for future product development, offering a mechanism to activate and deactivate gene therapies using a small molecule based on patient needs.", "banner_image": null, "source": "Contract Pharma", "category_within_source": "General", "source_domain": "Contract Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.927126"}], "overall_sentiment_score": 0.471894, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MGTX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.516564", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.878329", "ticker_sentiment_score": "0.410197", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why Philly made sense for Johnson & Johnson\u2019s first innovation office", "url": "https://technical.ly/startups/johnson-johnson-jpod/", "time_published": "20181016T024215", "authors": ["Roberto Torres"], "summary": "Johnson & Johnson has established its first innovation office, JPOD Philadelphia, within Pennovation to foster life sciences entrepreneurship. The office will provide mentorship, networking, and access to J&J's global resources without taking equity from startups. Philadelphia was chosen due to its strong existing life sciences sector.", "banner_image": null, "source": "Technical.ly", "category_within_source": "General", "source_domain": "Technical.ly", "topics": [{"topic": "life_sciences", "relevance_score": "0.918372"}, {"topic": "technology", "relevance_score": "0.734936"}], "overall_sentiment_score": 0.40042, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.437328", "ticker_sentiment_label": "Bullish"}]}, {"title": "Prescription Drugs Power Johnson & Johnson Results", "url": "https://www.wsj.com/articles/johnson-johnson-raises-profit-outlook-following-higher-sales-1539690522?gaa_at=eafs&gaa_n=AWEtsqfXkYWXKNUAYOpYPGxmnRYceiP7IOoBYMcOrTrIYuerlq4gEbGh2eqq&gaa_ts=690819b2&gaa_sig=CvOK7gtLmAwM8cj76Mg6MVXcN4RRFhsbhqDegeSZ8Afj9rX_ssFucX86i7-KQJ1c05jZZbmB3WE_HNLB90Zn1w%3D%3D", "time_published": "20181016T024214", "authors": ["Peter Loftus", "Kimberly Chin"], "summary": "Johnson & Johnson reported increased revenue and profit for the third quarter, largely driven by strong pharmaceutical sales, which helped offset a weaker performance in its medical-device sector. The company's cancer drugs saw significant growth, contributing to a 6.7% rise in sales for its pharmaceutical unit. Following these results, J&J raised its full-year forecast.", "banner_image": null, "source": "The Wall Street Journal", "category_within_source": "General", "source_domain": "The Wall Street Journal", "topics": [{"topic": "earnings", "relevance_score": "0.908598"}, {"topic": "life_sciences", "relevance_score": "0.808226"}], "overall_sentiment_score": 0.520394, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.506325", "ticker_sentiment_label": "Bullish"}]}, {"title": "Case Study: Jazz Pharmaceuticals v. Amneal Pharmaceuticals", "url": "https://www.fdli.org/2018/10/jazz-pharmaceuticals-v-amneal-pharmaceuticals/", "time_published": "20181010T014724", "authors": ["Frederick R. Ball and Carolyn Alenci"], "summary": "This case study details the Federal Circuit's decision in Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, affirming that certain patent claims for Xyrem's risk-management system were invalid due to obviousness in light of prior art. The court determined that FDA Advisory Committee materials were publicly accessible and thus constituted prior art, regardless of explicit indexing or searchability. The decision emphasizes that companies must carefully consider information shared with the FDA before a patent's priority date, as such materials can be deemed publicly available and used as prior art.", "banner_image": null, "source": "Food and Drug Law Institute (FDLI)", "category_within_source": "General", "source_domain": "Food and Drug Law Institute (FDLI)", "topics": [{"topic": "life_sciences", "relevance_score": "0.943710"}, {"topic": "finance", "relevance_score": "0.617963"}], "overall_sentiment_score": -0.607135, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "AMRX", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.616235", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.916619", "ticker_sentiment_score": "-0.602596", "ticker_sentiment_label": "Bearish"}]}, {"title": "See, snap and fund: Johnson & Johnson Vision push for eye health to donate to charity for shared photos", "url": "https://www.fiercepharma.com/marketing/see-snap-and-fund-j-j-vision-campaign-for-eye-health-awareness-to-donate-to-charity-for", "time_published": "20181008T103000", "authors": ["Beth Snyder Bulik"], "summary": "Johnson & Johnson Vision is launching a global campaign called #spotlightsight to raise awareness for eye health, coinciding with World Sight Day on Oct. 11. The campaign utilizes a \"Donate a Photo\" app, where J&J Vision will contribute $1 per shared photo to the Himalayan Cataract Project and Sight for Kids, committing to fund 1,000 cataract procedures and 100,000 children's vision screenings. This initiative is part of J&J's broader push into eye health, fueled by recent acquisitions and a focus on preventable blindness worldwide.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.921344"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.618560"}], "overall_sentiment_score": 0.330128, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.334603", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Healthy Trucking: The importance of engaging drivers in the National Diabetes Prevention Program", "url": "https://unidosus.org/blog/2018/10/05/healthy-trucking-national-diabetes-prevention-program/", "time_published": "20181005T030637", "authors": ["Stephanie Presch"], "summary": "This article highlights the importance of engaging truck drivers in the National Diabetes Prevention Program (National DPP) to combat the high risk of type 2 diabetes due to their occupation. Organizations like the Healthy Trucking Association of America (HTAA) and Russell Transport, Inc. are actively promoting digital versions of the program and culturally relevant orientations to reach this population. The effort aims to improve driver health, productivity, and retention by addressing challenges inherent in their demanding work environment.", "banner_image": null, "source": "UnidosUS", "category_within_source": "General", "source_domain": "UnidosUS", "topics": [{"topic": "life_sciences", "relevance_score": "0.910630"}], "overall_sentiment_score": 0.281745, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OMDA", "relevance_score": "0.877684", "ticker_sentiment_score": "0.406608", "ticker_sentiment_label": "Bullish"}, {"ticker": "UNH", "relevance_score": "0.677609", "ticker_sentiment_score": "0.295399", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.550479", "ticker_sentiment_score": "0.138774", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J bets billions on RNA interference", "url": "https://www.biopharmadive.com/news/jj-bets-billions-on-rna-interference/538908/", "time_published": "20181004T015124", "authors": ["Jacob Bell"], "summary": "Janssen, a unit of Johnson & Johnson, has finalized a licensing deal worth up to $3.75 billion with Arrowhead Pharmaceuticals for rights to up to four RNA interference therapies, including an investigational hepatitis B treatment. Arrowhead is set to receive $250 million upfront and could earn an additional $3.5 billion in milestone payments, plus royalties. The deal highlights the growing interest in RNAi therapies following the FDA's first approval in this class.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.925693"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.800917"}], "overall_sentiment_score": 0.100431, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ARWR", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.122501", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.912328", "ticker_sentiment_score": "0.300783", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Planes, trains ... robots and drones? Meet the man who's taking Johnson & Johnson's supply chain into the future", "url": "https://www.jnj.com/innovation/meet-the-man-whos-taking-johnson-johnson-supply-chain-into-the-future", "time_published": "20181001T024213", "authors": ["Michael Strong", "as told to Nicole Frehsee Mazur"], "summary": "Michael Strong, Worldwide Director of Engineering and Packaging for Global Distribution Operations at Johnson & Johnson Supply Chain, is spearheading innovation to modernize the company's delivery of products. He's implementing cutting-edge technologies like \"The Hulk\" collaborative robot for heavy lifting, augmented reality for faster product picking, and exploring autonomous vehicles and drones for inventory management and urgent deliveries in remote areas. Strong's work aims to enhance efficiency, safety, and customer satisfaction by adopting advanced solutions from factory floor to global distribution.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.942746"}, {"topic": "retail_wholesale", "relevance_score": "0.815478"}, {"topic": "technology", "relevance_score": "0.837222"}, {"topic": "manufacturing", "relevance_score": "0.700726"}], "overall_sentiment_score": 0.184695, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.483954", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMZN", "relevance_score": "0.603486", "ticker_sentiment_score": "0.131288", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBY", "relevance_score": "0.568385", "ticker_sentiment_score": "0.110399", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.589513", "ticker_sentiment_score": "0.136517", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOW", "relevance_score": "0.595317", "ticker_sentiment_score": "0.143614", "ticker_sentiment_label": "Neutral"}]}, {"title": "I was on the ground during the HIV epidemic\": Meet the scientist who's sharing the spotlight with celebs at the Global Citizen Festival", "url": "https://www.jnj.com/latest-news/interview-paul-stoffels-global-citizen-festival", "time_published": "20180929T024215", "authors": ["Camille Chatterjee"], "summary": "Dr. Paul Stoffels, Johnson & Johnson's Chief Scientific Officer, discusses the company's commitment to global public health, including efforts to prevent HIV infections through an investigational vaccine. He highlights J&J's participation in the Global Citizen Festival and the collaboration with various partners to address global health challenges like HIV and multidrug-resistant TB. Stoffels emphasizes the importance of a vaccine to eradicate HIV and touches on the significant progress made in HIV treatment since the early epidemic.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.417996, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.444107", "ticker_sentiment_label": "Bullish"}]}, {"title": "Enteral Feeding Formulas Market Analysis 2018 | Forecasts", "url": "https://www.openpr.com/news/1268402/enteral-feeding-formulas-market-analysis-2018-forecasts-players-like-nestl-abbott-b-braun-group-cr-bard-hormel-foods-halyard-health-fresenius-kabi-danone-mead-johnson-nutrition-shepherd-center-hormel-foods-aveanna-healthcare-victus-inc.html", "time_published": "20180928T062600", "authors": [], "summary": "This article forecasts the global Enteral Feeding Formulas market, projecting it to reach USD 10.32 billion by 2025 with a CAGR of 7.8% from 2018 to 2025. It details market segmentation by product, application, end users, stage, and geography, identifying key players like Nestl\u00e9, Abbott, and Danone. The report also highlights major market drivers such as increasing healthcare expenditure and rising geriatric populations.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.945436"}, {"topic": "financial_markets", "relevance_score": "0.807682"}, {"topic": "economy_macro", "relevance_score": "0.636080"}], "overall_sentiment_score": 0.312652, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AVAH", "relevance_score": "0.800140", "ticker_sentiment_score": "0.335328", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.731664", "ticker_sentiment_score": "0.301870", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HRL", "relevance_score": "0.704321", "ticker_sentiment_score": "0.313929", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.624592", "ticker_sentiment_score": "0.312367", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.617339", "ticker_sentiment_score": "0.304365", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Jabil, Johnson & Johnson strike \u2018transformational\u2019 deal", "url": "https://stpetecatalyst.com/jabil-johnson-johnson-strike-transformational-deal/", "time_published": "20180925T000000", "authors": ["Margie Manning"], "summary": "Jabil Inc. announced a \"transformational\" deal to acquire 14 sites from Johnson & Johnson Medical Devices Companies, significantly expanding their 12-year partnership. This strategic collaboration is expected to generate over $1 billion in annual revenue for Jabil and is part of its initiative to diversify revenue streams. Jabil aims to add $2 billion in new business in the coming year, with a focus on healthcare, cloud services, 5G, and automotive sectors.", "banner_image": null, "source": "St Pete Catalyst", "category_within_source": "General", "source_domain": "St Pete Catalyst", "topics": [{"topic": "mergers_and_acquisitions", "relevance_score": "0.917199"}, {"topic": "earnings", "relevance_score": "0.818947"}, {"topic": "life_sciences", "relevance_score": "0.721335"}, {"topic": "manufacturing", "relevance_score": "0.701841"}, {"topic": "technology", "relevance_score": "0.628727"}], "overall_sentiment_score": 0.259794, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JBL", "relevance_score": "1.000000", "ticker_sentiment_score": "0.326203", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.910335", "ticker_sentiment_score": "0.311652", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.744868", "ticker_sentiment_score": "0.141696", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharma\u2019s slow embrace of continuous manufacturing", "url": "https://www.biopharmadive.com/news/pharmas-slow-embrace-of-continuous-manufacturing/532811/", "time_published": "20180924T034103", "authors": ["Ned Pagliarulo"], "summary": "The pharmaceutical industry is slowly adopting continuous manufacturing, a method common in other sectors, despite its benefits like faster production and increased flexibility compared to traditional batch processing. While the FDA encourages its use and companies like Vertex, Johnson & Johnson, and Eli Lilly have implemented it for some products, widespread adoption is hindered by the high cost of overhauling existing manufacturing networks, regulatory uncertainties given the global nature of pharma, and a historical focus on manufacturing as a cost-center rather than a value-adder. However, a shift in mindset valuing innovation in manufacturing, particularly with the rise of complex biologics and cell/gene therapies, suggests continuous manufacturing may be approaching a tipping point.", "banner_image": null, "source": "BioPharma Dive", "category_within_source": "General", "source_domain": "BioPharma Dive", "topics": [{"topic": "life_sciences", "relevance_score": "0.905983"}, {"topic": "manufacturing", "relevance_score": "0.916756"}], "overall_sentiment_score": 0.218719, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.293984", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.865681", "ticker_sentiment_score": "0.203018", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.793378", "ticker_sentiment_score": "0.204854", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Lichen Sclerosus Treatment Market to Grow at a CAGR of 7.8%", "url": "https://www.openpr.com/news/1243273/lichen-sclerosus-treatment-market-to-grow-at-a-cagr-of-7-8-by-market-share-trend-analysis-with-astrazeneca-plc-bristol-myers-squibb-company-glaxosmithkline-plc-johnson-johnson-services-inc-merck-co-inc-pfizer-inc-till-2023.html", "time_published": "20180917T162200", "authors": [], "summary": "The global Lichen Sclerosus Treatment Market is projected to grow at a CAGR of 7.8% to reach USD 150 million by 2023. Key drivers include the increasing prevalence of skin diseases and rising healthcare expenditure, while challenges include a lack of specific treatments and awareness. Major players in the market include AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., and Pfizer Inc.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.928359"}, {"topic": "finance", "relevance_score": "0.718077"}, {"topic": "financial_markets", "relevance_score": "0.635206"}, {"topic": "economy_macro", "relevance_score": "0.613302"}], "overall_sentiment_score": 0.214219, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "0.940711", "ticker_sentiment_score": "0.206302", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.734916", "ticker_sentiment_score": "0.230902", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.725521", "ticker_sentiment_score": "0.231658", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRK", "relevance_score": "0.738732", "ticker_sentiment_score": "0.209634", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Perrigo's OTC Version of Diarrhea Drug Imodium Gets FDA Nod", "url": "https://finance.yahoo.com/news/perrigo-apos-otc-version-diarrhea-133601573.html", "time_published": "20180910T031124", "authors": ["Zacks Equity Research"], "summary": "Perrigo received FDA approval for its store brand over-the-counter equivalent of Johnson & Johnson's Imodium Multi-Symptom Relief tablet, which treats diarrhea symptoms. This approval aligns with Perrigo's strategy to expand its branded OTC opportunities in the U.S. and is expected to benefit the company following its decision to divest the RX segment due to declining sales.", "banner_image": null, "source": "Yahoo Finance", "category_within_source": "General", "source_domain": "Yahoo Finance", "topics": [{"topic": "life_sciences", "relevance_score": "0.932559"}, {"topic": "earnings", "relevance_score": "0.840053"}], "overall_sentiment_score": 0.158496, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PRGO", "relevance_score": "1.000000", "ticker_sentiment_score": "0.289154", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.702045", "ticker_sentiment_score": "0.117527", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.649565", "ticker_sentiment_score": "0.100904", "ticker_sentiment_label": "Neutral"}]}, {"title": "Molecular Imaging Products & Solutions", "url": "https://www.gehealthcare.com/products/molecular-imaging", "time_published": "20180910T022720", "authors": [], "summary": "GE HealthCare's Molecular Imaging platform offers products and solutions designed for personalized care, aiming to generate insightful images. The company is committed to integrating diagnostics and therapeutics through its Theranostics approach, connecting drug discovery, disease diagnosis, and treatment monitoring. They also provide a Smart Subscription service for continuous updates to MI applications.", "banner_image": null, "source": "GE HealthCare", "category_within_source": "General", "source_domain": "GE HealthCare", "topics": [{"topic": "life_sciences", "relevance_score": "0.927160"}, {"topic": "technology", "relevance_score": "0.732175"}], "overall_sentiment_score": 0.298451, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GEHC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.436386", "ticker_sentiment_label": "Bullish"}, {"ticker": "TMO", "relevance_score": "0.738177", "ticker_sentiment_score": "0.337548", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAX", "relevance_score": "0.624934", "ticker_sentiment_score": "0.202204", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.632826", "ticker_sentiment_score": "0.207063", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aetna agrees to pay for Abbott pain control device", "url": "https://www.startribune.com/aetna-agrees-to-pay-for-abbott-pain-control-device/492426911", "time_published": "20180905T013600", "authors": ["Joe Carlson"], "summary": "Aetna has agreed to provide national coverage for Abbott's Proclaim DRG neurostimulator, expanding access to this non-opioid pain therapy for approximately 22 million Aetna members. This device, originally from St. Jude Medical, treats neuropathic pain by sending electrical stimulation to dorsal root ganglia and was approved by the FDA in 2016 for certain chronic pain conditions. The move supports efforts to offer alternatives to opioid-based pain management amidst the opioid crisis.", "banner_image": null, "source": "Star Tribune", "category_within_source": "General", "source_domain": "Star Tribune", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.170253, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.981927", "ticker_sentiment_score": "0.319736", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.719738", "ticker_sentiment_score": "0.139874", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.640709", "ticker_sentiment_score": "0.139163", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.577781", "ticker_sentiment_score": "0.114836", "ticker_sentiment_label": "Neutral"}]}, {"title": "New Versius robot surgery system coming to NHS", "url": "https://www.bbc.co.uk/news/health-45370642", "time_published": "20180903T024141", "authors": ["Fergus Walsh"], "summary": "A British company, CMR Surgical, has unveiled a new robotic surgery system called Versius, expected to operate on patients next year. This system is designed to be smaller, more flexible, and versatile than the American da Vinci system, aiming to perform a wider range of operations at a more cost-effective rate for NHS hospitals. The Versius robot has independent modular arms and is quicker to set up and easier to learn, potentially expanding the benefits of keyhole surgery to more patients.", "banner_image": "https://ichef.bbc.co.uk/news/976/cpsprodpb/11A9F/production/_103233897_gettyimages-152431713.jpg", "source": "BBC", "category_within_source": "General", "source_domain": "BBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.918844"}, {"topic": "technology", "relevance_score": "0.813062"}], "overall_sentiment_score": 0.119097, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.933616", "ticker_sentiment_score": "0.146866", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.649633", "ticker_sentiment_score": "0.124225", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.711935", "ticker_sentiment_score": "0.106911", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA warns of flesh-eating genital infection linked to diabetes drug", "url": "https://www.drugdeliverybusiness.com/fda-warns-of-flesh-eating-genital-infection-linked-to-diabetes-drug/", "time_published": "20180831T015647", "authors": ["Fink Densford"], "summary": "The FDA issued a warning about a serious flesh-eating bacterial infection, Fournier\u2019s gangrene, linked to SGLT2 inhibitors used for type 2 diabetes. Between March 2013 and May 2018, 12 cases were reported, resulting in one death and multiple disfiguring surgeries for patients. The federal watchdog is requiring drug manufacturers, including Johnson & Johnson, Eli Lilly, Bristol-Myers Squibb, Astra Zeneca, Merck, and Pfizer, to add a new warning to their drug labels.", "banner_image": null, "source": "Drug Delivery Business", "category_within_source": "General", "source_domain": "Drug Delivery Business", "topics": [{"topic": "life_sciences", "relevance_score": "0.917036"}, {"topic": "finance", "relevance_score": "0.641074"}], "overall_sentiment_score": -0.403427, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "0.833063", "ticker_sentiment_score": "-0.404083", "ticker_sentiment_label": "Bearish"}, {"ticker": "JNJ", "relevance_score": "0.700061", "ticker_sentiment_score": "-0.418921", "ticker_sentiment_label": "Bearish"}, {"ticker": "LLY", "relevance_score": "0.744548", "ticker_sentiment_score": "-0.384442", "ticker_sentiment_label": "Bearish"}, {"ticker": "MRK", "relevance_score": "0.621825", "ticker_sentiment_score": "-0.424010", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.636286", "ticker_sentiment_score": "-0.416331", "ticker_sentiment_label": "Bearish"}]}, {"title": "Ureteral Stents Market Grows with Boston Scientific Co, Cook", "url": "https://www.openpr.com/news/1204858/ureteral-stents-market-grows-with-boston-scientific-co-cook-medical-inc-c-r-bard-inc-medline-industries-inc-teleflex-etc-during-2018-2023.html", "time_published": "20180828T081600", "authors": [], "summary": "The global Ureteral Stents Market is projected to grow at a CAGR of 8% between 2017 and 2023, driven by increasing cases of kidney stones, prostate cancers, and other urological conditions. Key players include Boston Scientific Corporation, Cook Medical, Inc., and C.R. Bard, Inc. The market is segmented by type, material, and application, with North America and Europe expected to see significant expansion.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.935257"}, {"topic": "finance", "relevance_score": "0.712469"}], "overall_sentiment_score": 0.410806, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "TFX", "relevance_score": "0.833230", "ticker_sentiment_score": "0.439722", "ticker_sentiment_label": "Bullish"}, {"ticker": "BSX", "relevance_score": "1.000000", "ticker_sentiment_score": "0.403373", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABT", "relevance_score": "0.744519", "ticker_sentiment_score": "0.410912", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.732764", "ticker_sentiment_score": "0.431232", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.622874", "ticker_sentiment_score": "0.412533", "ticker_sentiment_label": "Bullish"}]}, {"title": "ESC: Johnson & Johnson hunts for silver lining as Xarelto bombs blood clot, heart failure studies", "url": "https://www.fiercepharma.com/marketing/esc-johnson-johnson-admits-double-xarelto-flop-blood-clot-heart-failure-studies", "time_published": "20180827T105000", "authors": ["Carly Helfand"], "summary": "Johnson & Johnson's anticoagulant drug Xarelto failed in two separate studies presented at the European Society of Cardiology annual meeting, showing no improvement over a placebo in preventing blood clots or reducing cardiovascular events in heart failure patients. Despite these setbacks and previous trial failures, J&J's Janssen unit believes future studies and combined data could still lead to new approvals for Xarelto, which faces strong competition from Pfizer and Bristol-Myers Squibb's Eliquis.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.945808"}, {"topic": "earnings", "relevance_score": "0.619979"}], "overall_sentiment_score": -0.099444, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.385775", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.623119", "ticker_sentiment_score": "0.125659", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.645789", "ticker_sentiment_score": "0.124149", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRK", "relevance_score": "0.577313", "ticker_sentiment_score": "-0.141864", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sweden & GE Healthcare Open Testa Center", "url": "https://www.contractpharma.com/video/sweden-ge-healthcare-open-testa-center/", "time_published": "20180823T022720", "authors": ["Betsy Louda"], "summary": "The Swedish government and GE Healthcare have opened Testa Center, a 27,000 sq. ft. innovation center in Uppsala, Sweden, with a joint investment of approximately \u20ac15 million. This center aims to boost commercialization of new technologies and support manufacturing capabilities in the life sciences sector, particularly for biopharmaceuticals. BioLamina, a Swedish biotechnology company, is the first to utilize the facility for scaling up its production of protein-based reagents used in cell therapy development.", "banner_image": null, "source": "Contract Pharma", "category_within_source": "General", "source_domain": "Contract Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.903482"}, {"topic": "manufacturing", "relevance_score": "0.848607"}, {"topic": "finance", "relevance_score": "0.622428"}, {"topic": "technology", "relevance_score": "0.625081"}, {"topic": "economy_fiscal", "relevance_score": "0.630057"}], "overall_sentiment_score": 0.289247, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GEHC", "relevance_score": "1.000000", "ticker_sentiment_score": "0.414010", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.611075", "ticker_sentiment_score": "0.235786", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.627802", "ticker_sentiment_score": "0.244510", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.607477", "ticker_sentiment_score": "0.218917", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clinical Nutrition Products Market Is Booming Worldwide | Abbott Nutrition, Groupe Danone, Nestle HealthCare Nutrition", "url": "https://www.openpr.com/news/1193530/clinical-nutrition-products-market-is-booming-worldwide-abbott-nutrition-groupe-danone-nestle-healthcare-nutrition.html", "time_published": "20180822T114600", "authors": [], "summary": "A new study by HTF MI provides an in-depth overview of the Global Clinical Nutrition Products Market, forecasting its status to 2023. Key players in this growing market include Abbott Nutrition, Groupe Danone, and Nestle HealthCare Nutrition, among others. The report segments the market by type (Parenteral Nutrition & Enteral Nutrition), application (Postoperative Patients & Postpartum Women), and region, also offering competitive analysis and financial data for major companies.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.904017"}, {"topic": "finance", "relevance_score": "0.737438"}], "overall_sentiment_score": 0.231052, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SCL", "relevance_score": "0.802472", "ticker_sentiment_score": "0.275099", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.965897", "ticker_sentiment_score": "0.311020", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAX", "relevance_score": "0.861437", "ticker_sentiment_score": "0.292108", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MMM", "relevance_score": "0.639615", "ticker_sentiment_score": "0.123719", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.706729", "ticker_sentiment_score": "0.209594", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Exact Sciences signs national agreement with Pfizer to market Cologuard tests to physicians", "url": "https://www.jsonline.com/story/money/business/health-care/2018/08/22/exact-sciences-signs-agreement-pfizer-market-cologuard-tests/1062292002/", "time_published": "20180822T030725", "authors": ["Guy Boulton"], "summary": "Exact Sciences has signed a national agreement with Pfizer to market its Cologuard non-invasive colorectal cancer screening test to physicians and health systems. Pfizer sales representatives will join Exact Sciences' sales force and commit to at least 625,000 sales calls annually, alongside an additional $138 million in marketing spending through 2021. This partnership aims to significantly expand the reach and adoption of Cologuard, leveraging Pfizer's marketing capabilities and relationships within the healthcare industry.", "banner_image": null, "source": "Milwaukee Journal Sentinel", "category_within_source": "General", "source_domain": "Milwaukee Journal Sentinel", "topics": [{"topic": "life_sciences", "relevance_score": "0.912604"}, {"topic": "earnings", "relevance_score": "0.849437"}], "overall_sentiment_score": 0.227314, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.985906", "ticker_sentiment_score": "0.317867", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DGX", "relevance_score": "0.680991", "ticker_sentiment_score": "0.264240", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.588155", "ticker_sentiment_score": "0.141723", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson makes Fortune's 2018 Change the World list", "url": "https://www.jnj.com/latest-news/johnson-johnson-earns-spot-on-fortune-2018-change-the-world-list", "time_published": "20180820T024213", "authors": ["Johnson & Johnson"], "summary": "Johnson & Johnson has been recognized on Fortune's 2018 Change the World list for its global efforts in training healthcare professionals. The company's initiatives include the Johnson & Johnson Institute, which trains over 125,000 surgeons, doctors, and nurses annually, and the \"Institute on Wheels\" mobile training center serving India. Additionally, the Medical and Surgical Skills Institute in Ghana has trained over 27,000 healthcare professionals in West Africa, impacting millions of patients.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.925940"}, {"topic": "finance", "relevance_score": "0.600126"}], "overall_sentiment_score": 0.439295, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.446904", "ticker_sentiment_label": "Bullish"}]}, {"title": "Saudi Arabia Medical Devices Market 2018 Professional Industry", "url": "https://www.openpr.com/news/1186642/saudi-arabia-medical-devices-market-2018-professional-industry-survey-by-top-brands-johnson-johnson-general-electric-medtronic-baxter-international-forecast-to-2023.html", "time_published": "20180818T103300", "authors": [], "summary": "This article provides an analysis of the Saudi Arabia Medical Devices Market in 2018, highlighting its reliance on imports, particularly from U.S. and European suppliers. Key players like Johnson & Johnson and Medtronic are mentioned, along with market segmentation by product types, therapeutic applications, and end-users. The report also discusses market drivers such as rising public healthcare expenditure and technology advancements, alongside constraints like regulatory frameworks and connectivity issues.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.942030"}], "overall_sentiment_score": 0.279255, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAX", "relevance_score": "0.866715", "ticker_sentiment_score": "0.291596", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.717272", "ticker_sentiment_score": "0.263599", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GEHC", "relevance_score": "0.679080", "ticker_sentiment_score": "0.258553", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.681652", "ticker_sentiment_score": "0.290879", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAH", "relevance_score": "0.604059", "ticker_sentiment_score": "0.280324", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Boston Scientific expands heart implant TV campaign, treading on anticoagulants' turf", "url": "https://www.fiercepharma.com/marketing/boston-sci-takes-device-tv-ad-national-challenging-blood-thinner-drugs-home-field", "time_published": "20180815T092000", "authors": ["Beth Snyder Bulik"], "summary": "Boston Scientific has expanded its TV advertising campaign for the Watchman heart implant device after successful local market testing. This move puts the device in direct competition with blood-thinning drugmakers, who frequently use TV ads for their products like Xarelto and Eliquis. The campaign aims to educate patients and physicians about Watchman as an alternative to long-term anticoagulant use.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.910726"}], "overall_sentiment_score": 0.080262, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "0.966999", "ticker_sentiment_score": "0.259157", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.735242", "ticker_sentiment_score": "0.067561", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.718609", "ticker_sentiment_score": "0.061218", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.663858", "ticker_sentiment_score": "0.099579", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.574672", "ticker_sentiment_score": "-0.053063", "ticker_sentiment_label": "Neutral"}]}, {"title": "7 questions for Alex Gorsky about Johnson & Johnson's groundbreaking work in South Africa", "url": "https://www.jnj.com/latest-news/ceo-alex-gorsky-on-johnson-johnson-work-in-south-africa", "time_published": "20180813T024213", "authors": ["Johnson & Johnson"], "summary": "Alex Gorsky, Johnson & Johnson Chairman and CEO, discusses the company's extensive work and commitment in South Africa, covering over 100 partnerships and programs addressing HIV, TB, mental health, and maternal/child health. He highlights the company's historical presence, future growth plans, and efforts to empower the next generation of healthcare leaders in the region.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "0.907203"}], "overall_sentiment_score": 0.809377, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.810400", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson CEO Alex Gorsky dines with Trump as president promises \u2018substantial\u2019 drug price cuts", "url": "https://www.fiercepharma.com/pharma/johnson-johnson-ceo-alex-gorsky-dines-trump-could-substantial-price-cuts-come-next", "time_published": "20180808T121800", "authors": ["Angus Liu"], "summary": "Johnson & Johnson CEO Alex Gorsky dined with President Trump, who promised \"substantially\" lower drug prices would be announced soon. This marks Gorsky's potential second dinner with Trump in a month, and comes as the administration continues to pressure pharmaceutical companies on drug costs. Gorsky emphasized drug innovation's value and the need for careful consideration to avoid unintended consequences in healthcare pricing policy.", "banner_image": null, "source": "Fierce Pharma", "category_within_source": "General", "source_domain": "Fierce Pharma", "topics": [{"topic": "life_sciences", "relevance_score": "0.923250"}, {"topic": "economy_fiscal", "relevance_score": "0.710238"}], "overall_sentiment_score": -0.289316, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.979893", "ticker_sentiment_score": "-0.276315", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pepsi's Indra Nooyi latest high-profile female CEO to exit", "url": "https://www.syracuse.com/business-news/2018/08/pepsi_ceo_nooyi_steps_down.html", "time_published": "20180807T113900", "authors": ["The Associated Press"], "summary": "Indra Nooyi, a prominent female and minority CEO in the Fortune 500, is stepping down as PepsiCo's chief executive after 12 years. She led PepsiCo during a period of changing consumer tastes, emphasizing \"good for you\" options while retaining traditional products. Ramon Laguarta, a PepsiCo veteran, will succeed her as CEO in October, with Nooyi remaining as chairwoman until early next year.", "banner_image": null, "source": "Syracuse.com", "category_within_source": "General", "source_domain": "Syracuse.com", "topics": [{"topic": "retail_wholesale", "relevance_score": "0.813437"}, {"topic": "finance", "relevance_score": "0.738850"}, {"topic": "mergers_and_acquisitions", "relevance_score": "0.617594"}], "overall_sentiment_score": 0.004145, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PEP", "relevance_score": "1.000000", "ticker_sentiment_score": "0.034350", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.647466", "ticker_sentiment_score": "0.019570", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPB", "relevance_score": "0.604682", "ticker_sentiment_score": "0.026847", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDLZ", "relevance_score": "0.646254", "ticker_sentiment_score": "0.020572", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.640954", "ticker_sentiment_score": "0.010639", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alan H. Auerbach", "url": "https://labusinessjournal.com/news/alan-auerbach/", "time_published": "20180730T030707", "authors": ["staff-author"], "summary": "Alan H. Auerbach is the Chairman, CEO, and President of Puma Biotechnology, a biopharmaceutical company he founded in 2011, focusing on cancer treatments. Previously, he founded Cougar Biotechnology, which he sold to Johnson & Johnson for approximately $1 billion in 2009. Auerbach also held positions at Wells Fargo Securities as a senior research analyst and at Diagnostic Products Corporation.", "banner_image": null, "source": "Los Angeles Business Journal", "category_within_source": "General", "source_domain": "Los Angeles Business Journal", "topics": [{"topic": "life_sciences", "relevance_score": "0.922558"}], "overall_sentiment_score": 0.24272, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PBYI", "relevance_score": "1.000000", "ticker_sentiment_score": "0.314814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.603703", "ticker_sentiment_score": "0.149507", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intracranial Pressure (ICP) Monitoring Market Analysis 2018:", "url": "https://www.openpr.com/news/1146878/intracranial-pressure-icp-monitoring-market-analysis-2018-global-industry-top-players-including-philips-healthcare-ge-healthcare-siemens-healthcare-medtronic-inc-and-many.html", "time_published": "20180726T093400", "authors": [], "summary": "This article analyzes the Intracranial Pressure (ICP) Monitoring Market in 2018, segmenting it by method, market, instrument, applications, and end-users. Key players like Philips Healthcare, GE Healthcare, and Medtronic Inc. are identified, with growth driven by increasing neurological disorders and technological advancements, while high costs and reimbursement policies act as restraints. The regional analysis highlights North America's dominance and Asia's rapid growth.", "banner_image": null, "source": "openPR.com", "category_within_source": "General", "source_domain": "openPR.com", "topics": [{"topic": "life_sciences", "relevance_score": "0.943672"}, {"topic": "finance", "relevance_score": "0.838869"}], "overall_sentiment_score": 0.271448, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GEHC", "relevance_score": "0.913404", "ticker_sentiment_score": "0.319967", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDT", "relevance_score": "0.824036", "ticker_sentiment_score": "0.294446", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.623279", "ticker_sentiment_score": "0.234573", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MMM", "relevance_score": "0.635765", "ticker_sentiment_score": "0.248869", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.570194", "ticker_sentiment_score": "0.199692", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Meet a Johnson & Johnson researcher poised to crack the HIV vaccine code", "url": "https://www.jnj.com/innovation/meet-a-johnson-johnson-researcher-working-to-create-an-hiv-vaccine", "time_published": "20180722T024215", "authors": ["Sheila Weller"], "summary": "This article profiles Hanneke Schuitemaker, Ph.D., a Johnson & Johnson researcher dedicated to developing an HIV vaccine. It details her career trajectory, motivations rooted in patient experiences, and the significant progress her team has made, including promising trial results for an investigational HIV vaccine regimen. The article highlights her personal and professional journey, underscoring her commitment to finding a preventive solution for HIV.", "banner_image": null, "source": "Johnson & Johnson", "category_within_source": "General", "source_domain": "Johnson & Johnson", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": 0.808157, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "0.839116", "ticker_sentiment_label": "Bullish"}]}, {"title": "Women who sued Johnson & Johnson declare victory after $4.69 billion talc verdict", "url": "https://www.reuters.com/article/world/women-who-sued-johnson-johnson-declare-victory-after-469-billion-talc-verdic-idUSKBN1KA02E/", "time_published": "20180720T010900", "authors": ["Tina Bellon"], "summary": "Women who sued Johnson & Johnson for allegedly causing ovarian cancer with their talc-based products declared victory after a St. Louis jury awarded them $4.69 billion in damages. Despite J&J's claims of innocence and intent to appeal, the women believe they have brought awareness to the public. J&J faces approximately 9,000 talc product liability cases and maintains their products are safe and free of asbestos.", "banner_image": "https://www.reuters.com/resizer/v2/https%3A%2F%2Fwww.reuters.com%2Fresources%2Fr%2F%3Fm%3D02%26d%3D20180720%26t%3D2%26i%3D1293393278%26w%3D1280%26h%3D1280%26un-resized%3Dtrue&w=800&h=800&auth=e1cf80ad8bb5817cdd1e2373fb8959f2", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.921462"}, {"topic": "finance", "relevance_score": "0.720328"}], "overall_sentiment_score": -0.82092, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.822318", "ticker_sentiment_label": "Bearish"}]}, {"title": "Jury orders J&J to pay $4.7 billion in Missouri asbestos cancer case", "url": "https://www.reuters.com/article/business/jury-orders-jj-to-pay-47-billion-in-missouri-asbestos-cancer-case-idUSKBN1K234U/", "time_published": "20180713T120500", "authors": ["Tina Bellon"], "summary": "A Missouri jury ordered Johnson & Johnson to pay $4.69 billion to 22 women who alleged that the company's talc-based products, including baby powder, contained asbestos and caused their ovarian cancer. This verdict is the largest J&J has faced related to talc allegations, despite the company's denial of asbestos presence or cancer links and its plans to appeal the decision. J&J shares fell 1% in after-hours trading following the punitive damages award.", "banner_image": "https://www.reuters.com/article/business/jury-orders-jj-to-pay-47-billion-in-missouri-asbestos-cancer-case-idUSKBN1K234U/", "source": "Reuters", "category_within_source": "General", "source_domain": "Reuters", "topics": [{"topic": "life_sciences", "relevance_score": "0.931932"}, {"topic": "financial_markets", "relevance_score": "0.600193"}], "overall_sentiment_score": -0.460177, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.458086", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson told to pay $4.7 billion in baby powder case", "url": "https://www.nbcnews.com/health/health-news/johnson-johnson-told-pay-4-7-billion-baby-powder-case-n891111", "time_published": "20180713T093100", "authors": ["Reuters"], "summary": "A Missouri jury has ordered Johnson & Johnson to pay a record $4.69 billion to 22 women who alleged the company's talc-based products, including its baby powder, contained asbestos and caused them to develop ovarian cancer. J&J denies the allegations, calling the trial \"fundamentally unfair\" and plans to appeal the decision, having successfully overturned previous talc verdicts. Mark Lanier, the lawyer for the women, urged J&J to remove its talc products from the market or add a serious warning.", "banner_image": null, "source": "NBC News", "category_within_source": "General", "source_domain": "NBC News", "topics": [{"topic": "life_sciences", "relevance_score": "0.914347"}], "overall_sentiment_score": -0.635339, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.629748", "ticker_sentiment_label": "Bearish"}]}, {"title": "Jury Awards $4.7 Billion To Women In Johnson & Johnson Talcum Powder Suit", "url": "https://www.npr.org/2018/07/13/628684038/jury-awards-4-7-billion-to-women-in-johnson-johnson-talcum-powder-suit", "time_published": "20180713T044000", "authors": ["Scott Neuman"], "summary": "A St. Louis Circuit Court jury has ordered Johnson & Johnson to pay nearly $4.7 billion in damages to 22 women and their families who claim asbestos in the company's talcum powder caused ovarian cancer. The verdict includes $4.14 billion in punitive damages and $550 million in compensatory damages, making it the largest single verdict in such cases so far. Johnson & Johnson has stated it is \"deeply disappointed\" and plans to appeal the decision, maintaining its products are safe and asbestos-free.", "banner_image": null, "source": "NPR", "category_within_source": "General", "source_domain": "NPR", "topics": [{"topic": "life_sciences", "relevance_score": "0.940231"}, {"topic": "finance", "relevance_score": "0.745514"}], "overall_sentiment_score": -0.635633, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.608977", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson ordered to pay $4.7bn over talc cancer claims", "url": "https://www.theguardian.com/business/2018/jul/13/johnson-johnson-ordered-to-pay-47bn-in-talc-powder-claim", "time_published": "20180713T043300", "authors": ["Sarah Butler"], "summary": "Johnson & Johnson has been ordered to pay $4.7bn in damages to 22 women who claim its talcum powder caused their ovarian cancer. The jury's decision came after a six-week trial where evidence of asbestos in the company's products for over 40 years was presented. Johnson & Johnson plans to appeal the verdict, maintaining that its products are safe and do not cause ovarian cancer.", "banner_image": null, "source": "The Guardian", "category_within_source": "General", "source_domain": "The Guardian", "topics": [{"topic": "life_sciences", "relevance_score": "0.922440"}, {"topic": "retail_wholesale", "relevance_score": "0.713394"}], "overall_sentiment_score": -0.421054, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.441714", "ticker_sentiment_label": "Bearish"}]}, {"title": "Jury slams Johnson & Johnson with almost $4.7B tab in talcum powder suit", "url": "https://www.cbsnews.com/news/jury-slams-johnson-johnson-almost-4-7b-tab-in-talcum-powder-suit-asbestos-baby-powder/", "time_published": "20180713T041600", "authors": ["CBS/AP"], "summary": "A St. Louis jury ordered Johnson & Johnson to pay nearly $4.7 billion in damages to 22 women and their families who claimed the company's talcum powder caused ovarian cancer due to asbestos contamination. This was the first case focusing on asbestos in the powder, with plaintiffs' lawyers alleging Johnson & Johnson covered up evidence for decades. The company plans to appeal, maintaining its products are asbestos-free and do not cause ovarian cancer.", "banner_image": null, "source": "CBS News", "category_within_source": "General", "source_domain": "CBS News", "topics": [{"topic": "life_sciences", "relevance_score": "1.000000"}], "overall_sentiment_score": -0.804604, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.844455", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson to pay $4.7bn damages in talc cancer case", "url": "https://www.bbc.com/news/business-44816805", "time_published": "20180713T024215", "authors": [], "summary": "Johnson & Johnson has been ordered to pay $4.7bn in damages to 22 women in a Missouri court who alleged its talc products caused their ovarian cancer. The pharmaceutical giant, which faces 9,000 similar lawsuits, plans to appeal the verdict, insisting its products are safe and free of asbestos. The case highlights ongoing debate about the link between talc and ovarian cancer, with the scientific evidence not being conclusive.", "banner_image": "https://ichef.bbc.co.uk/news/976/cpsprodpb/175C3/production/_102558669_gettyimages-1002599026.jpg", "source": "BBC", "category_within_source": "General", "source_domain": "BBC", "topics": [{"topic": "life_sciences", "relevance_score": "0.929099"}, {"topic": "finance", "relevance_score": "0.706817"}], "overall_sentiment_score": -0.429792, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.427953", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson Must Pay $4.7 Billion in Talc Cancer Case", "url": "https://time.com/5337841/johnson-johnson-damages-talc-powder-cancer/", "time_published": "20180712T221900", "authors": ["Tim Bross", "Margaret Cronin Fisk", "Jef Feeley"], "summary": "A jury ordered Johnson & Johnson to pay $4.69 billion ($4.14 billion in punitive damages and $550 million in compensatory damages) to 22 women who claimed asbestos in the company\u2019s talc products caused them to develop ovarian cancer. This marks the largest jury award in the U.S. in 2018 for a product-defect claim. J&J plans to appeal the verdict, asserting its products do not contain asbestos and do not cause ovarian cancer, while the plaintiffs' lawyer argued the company suppressed evidence of asbestos contamination.", "banner_image": null, "source": "Time Magazine", "category_within_source": "General", "source_domain": "Time Magazine", "topics": [{"topic": "life_sciences", "relevance_score": "0.934019"}, {"topic": "finance", "relevance_score": "0.741575"}], "overall_sentiment_score": 0.042831, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.346688", "ticker_sentiment_score": "0.033660", "ticker_sentiment_label": "Neutral"}]}, {"title": "BREAKING UPDATE: $4.69 Billion Verdict Pounds Johnson & Johnson in 22-Plaintiff, Talc-Cancer Trial", "url": "https://blog.cvn.com/breaking-550m-verdict-punitives-tbd-smacks-johnson-johnson-in-22-plaintiff-talc-cancer-trial", "time_published": "20180712T162302", "authors": ["Arlin Crisco"], "summary": "A Missouri jury slammed Johnson & Johnson with a $4.69 billion verdict, including $4.14 billion in punitive damages, in a trial involving 22 women who developed ovarian cancer after using the company's talc-based products. The verdict is the largest to date in the ongoing talc litigation. J&J plans to appeal, reiterating its stance that its talc is asbestos-free and that previous verdicts in this court have been reversed on appeal.", "banner_image": "NULL", "source": "CVN News", "category_within_source": "General", "source_domain": "CVN News", "topics": [{"topic": "life_sciences", "relevance_score": "0.925059"}, {"topic": "finance", "relevance_score": "0.731573"}], "overall_sentiment_score": -0.603737, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.641687", "ticker_sentiment_label": "Bearish"}]}, {"title": "Johnson & Johnson Told to Pay $4.7 Billion in Baby Powder Lawsuit (Published 2018)", "url": "https://www.nytimes.com/2018/07/12/business/johnson-johnson-talcum-powder.html", "time_published": "20180712T024213", "authors": ["Tiffany Hsu"], "summary": "Johnson & Johnson was ordered to pay $4.69 billion to 22 women and their families who claimed asbestos in the company's talcum powder caused ovarian cancer. A Missouri jury awarded $4.14 billion in punitive damages and $550 million in compensatory damages. Johnson & Johnson plans to appeal the verdict and faces over 9,000 similar lawsuits.", "banner_image": null, "source": "The New York Times", "category_within_source": "General", "source_domain": "The New York Times", "topics": [{"topic": "life_sciences", "relevance_score": "0.919366"}, {"topic": "finance", "relevance_score": "0.708220"}], "overall_sentiment_score": -0.433649, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "1.000000", "ticker_sentiment_score": "-0.400675", "ticker_sentiment_label": "Bearish"}]}]